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Montag, 4. Oktober 2010
Eröffnung (Audimax/ Tentomax)
Mikrosysteme für partikuläre Life Science Produkte 
(PK 4.7)
Plenarvorträge
16:00 ‐ 16:45
13:00 ‐ 13:30
16:50 ‐ 17:50
Plenarvortrag
From Systems Biology to Personalized Medicine ‐ Vision, wishful thinking or just a hype? 
(Audimax/ Tentomax)
13:30 ‐ 14:15
Ausstellung (Kubus)/ Posterpräsentation (Foyer)/ Kaffeepause (Kubus & Foyer)14:15 ‐ 16:00
ab 19:30
17:50 ‐ 18:15 Kaffeepause (Foyer & Kubus)
Keynotes Kurzvorträge
Hormone (SN 19.4)
Phytopharmaka (SN 19.3)
Biologisch aktive Naturstoffe (SN 19.3)
Arzneimittelfälschungen und Arzneimittelsicherheit                                       
(SN 19.2)
18:15 ‐ 19:15
Keynotes Kurzvorträge
19:00 ‐ 20:00
Regulatory RNAs ‐ from identification to therapeutic 
application (PK 4.3)
Klinische Pharmazie (SN 19.4)
Computational Drug Design (PK 4.3)
Podiumsdiskussion
The practice of metabonomics/ metabolomics 
in the search for biomarkers (SN 19.1)
Ausgeträumt ‐ Infektionskrankheiten, ihr 
Verschwinden und ihre Rückkehr im 20. 
Jahrhundert (PK 2.2)
Begrüßungsabend (Foyer & Kubus)
Mikrosysteme für partikuläre Life Science Produkte 
(PK 4.7)
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Montag, 4. Oktober 2010 
Plenarvorträge 
 
 
13:30  Balling, R. 
FROM SYSTEMS BIOLOGY TO PERSONALIZED MEDICINE – VISION, 
WISHFUL THINKING OR JUST A HYPE? 
(Audimax/ Tentomax)  
Moderation: Christel C. Müller‐Goymann, Technische Universität Braunschweig 
 
16:00  Wilson, I.D. 
THE PRACTICE OF METABONOMICS/METABOLOMICS IN THE SEARCH FOR 
BIOMARKERS 
(SN 19.1)  
Moderation: Hermann Wätzig, Technische Universität Braunschweig 
 
16:00  Gradmann, C. 
AUSGETRÄUMT – INFEKTIONSKRANKHEITEN, IHR VERSCHWINDEN UND 
IHRE RÜCKKEHR IM 20. JAHRHUNDERT 
(PK 2.2) 
Moderation: Bettina Wahrig, Technische Universität Braunschweig 
 
 
 
Podiumsdiskussion 
       
19:00  Fink, E.; Bejeuhr, G.; Cramer, M.; Holzgrabe, U. 
WIE ERKENNE ICH EINE ARZNEIMITTELFÄLSCHUNG? 
(SN 19.2) 
Pl‐01
Pl‐02
Pl‐03
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Montag, 4. Oktober 2010 
Keynotes 
 
Mikrosysteme für partikuläre Life Science Produkte (PK 4.7) 
Moderation: Claus‐Peter Klages, Technische Universität Braunschweig 
 
16:50  Kwade, A.; Büttgenbach, S.; Klages, C.P.; Krull, R.; Franco‐Lara, E.; Müller‐Goymann, C.C.; 
Bunjes, H.; Radespiel, R.; Kähler, C.J.; Augustin, W.; Scholl, S.; Kampen, I. 
MICRO SYSTEMS FOR FORMULATION‐ AND PROCESS‐ PARAMETER‐SCREENING 
17:20          Krull, R.; Edlich, A.; Demming, S.; Zadeh, S.; Radespiel, R.; Büttgenbach, S.; Franco‐Lara, E. 
MICROBIOREACTORS – A SCREENING‐TOOL FOR BIOLOGICAL PROCESSES 
17:35  Bunjes, H.; Fehr, S.; Finke, J.H.; Schur, J.; Müller‐Goymann, C.C.; Lesche, C.; Büttgenbach, 
S.; Gothsch, T.; Kwade, A.; Jasch, K.; Huzhalska, V.; Kulik, A.; Augustin, W.; Scholl, S. 
PREPARATION OF LIPID NANOPARTICLES IN MICRO‐STRUCTURED SYSTEMS 
 
Regulatory RNAs ‐ from identification to therapeutic application (PK 4.3) 
Moderation: Roland K. Hartmann, Philipps‐Universität Marburg 
 
16:50  Jäschke, A.; Samanta, A.; Strauß, B.; Winz, M. 
CHEMICAL RNOMICS ‐ THE SEARCH FOR NEW REGULATORY RNAS 
17:10  Helm, M.; Hirsch, M. 
FLUORESCENCE SPECTROSCOPY BASED ANALYSIS OF SMALL INTERFERING RNA 
INTEGRITY DURING FORMULATION, TRANSFECION, AND INTRACELLULAR DISTRIBUTION 
17:30  Hartmann, R.K.; Thomas, M.; Lange‐Grünweller, K.; Weirauch, U.; Gutsch, D.; Aigner, A.; 
Grünweller, A. 
REPRESSION OF THE PROTO‐ONCOGENE PIM‐1 BY MIR‐33A 
 
Computational Drug Design (PK 4.3) 
Moderation: Knut Baumann, Technische Universität Braunschweig 
 
18:15  Meier, R.; Pippel, M.; Baldauf, C.; Sippl, W. 
PARADOCKS ‐ A FRAMEWORK FOR MOLECULAR DOCKING WITH POPULATION‐BASED 
METAHEURISTICS 
18:35  Scheiber, J. 
SEEING THE WOOD, NOT ONLY THE TREES ‐ SYSTEMS CHEMICAL BIOLOGY   
18:55  Wolber, G. 
PHARMACOPHORE‐BASED VIRTUAL SCREENING: AN EFFICIENT TOOL FOR BIO‐ACTIVITY 
PROFILING AND AFFINITY PREDICTION 
   
Key2‐1
Key2‐2
Key2‐3
Key3‐1
Key3‐3
Key3‐2
Key1‐1
Key1‐2
Key1‐3
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Montag, 4. Oktober 2010 
Kurzvorträge 
 
Klinische Pharmazie (SN 19.4) 
Moderation: Ralf Benndorf, Technische Universität Braunschweig 
 
16:50  Fiß, T.; Dreier, A.; van den Berg, N.; Ritter, C.A.; Hoffmann, W. 
PREVALENCE AND DETERMINANTS FOR THE INTAKE OF INAPPROPRIATE DRUGS IN 
PRIMARY HEALTH CARE 
17:05  Niemann, D.; Ewen, A.L.; Oelsner, S.; Köpf, E.; Traiser, C.; Seebald, K.; Henhapl, T.; 
Meyburg, J.; Ruef, P.; Schmitt, C.P.; Bertsche, A.; Haefeli, W.E.; Bertsche, T. 
PROSPECTIVE MULTI‐STEP INTERVENTION STUDY TO PREVENT DRUG ADMINISTRATION 
ERRORS IN PAEDIATRIC SETTINGS 
17:20  Niebecker, R.; Kuester, K.; Kunz, U.; Kloft, C. 
COMPARISON OF BODY SIZE DESCRIPTORS AS INFLUENTIAL FACTORS IN SIBROTUZUMAB 
POPULATION PHARMACOKINETICS 
17:35  Birkle, S.; Schlager, H.; Dörje, F.; Lee, G.; Richter, W. 
CARDIOVASCULAR RISK SCREENING AND PREVENTION CARE FOR 50 ‐ 70 YEAR OLD 
PEOPLE IN COMMUNITY PHARMACIES 
 
Phytopharmaka (SN 19.3) 
Moderation: Christian Fleck, Friedrich‐Schiller‐Universität Jena 
 
16:50  Abdel‐Aziz, H.; Wadie, W.; Kelber, O.; Weiser, D.; Khayyal, M.T. 
EVIDENCE FOR THE EFFECTIVENESS OF STW5 (IBEROGAST) IN AN EXPERIMENTAL MODEL 
OF ULCERATIVE COLITIS. 
17:05  Klein, K.; Merkel, K.; Jandaghi, D.; Kelber, O.; Vinson, B.R.; Weiser, D.; Klessen, C.; 
Rammensee, H.G.; Heinle, H. 
LOCALISATION AND PHARMACOLOGY OF HISTAMINE‐INDUCED FREE RADICAL 
PRODUCTION IN SMALL AND LARGE INTESTINE 
17:20  Kelber, O.; Bonaterra, G.A.; Zügel, S.; Hildebrandt, W.; Weiser, D.; Kinscherf, R. 
ANTI‐PROLIFERATIVE EFFECTS OF THE ANTIDYSPEPTIC DRUG STW 5 IN COMPARISON 
WITH NSAIDS 
17:35  Unger, M.; Völker, M.; Schaeflein, L.; Frank, A. 
INHIBITION OF PRODRUG ACTIVATION BY HERBAL EXTRACTS AND SECONDARY PLANT 
METABOLITES 
 
Biologisch aktive Naturstoffe (SN 19.3) 
Moderation: Ludger Beerhues, Technische Universität Braunschweig 
 
18:15  Mundt, S.; Bui, H.; Le, T.; Zainuddin, E.; Jansen, R.; Nimtz, M.; Wray, V.;  
Preisitsch, M. 
NEW ANTIBIOTICS FROM CYANOBACTERIA 
 
P1‐1
P1‐2
P1‐3
P1‐4
B1‐1
K1‐1
K1‐2
K1‐3
K1‐4
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Montag, 4. Oktober 2010 
18:30  Probst, K.; Bechthold, A. 
CHANGING A MUTANT’S MIND 
18:45  Kaufmann, D.; Kaur Dogra, A.; Tahrani, A.; Herrmann, F.; Wink, M. 
TRADITIONAL CHINESE MEDICAL PLANTS INHIBIT ACETYL‐CHOLINESTERASE, A KNOWN 
ALZHEIMER TARGET 
19:00  Belkheir, A.; Hänsch, R.; Beerhues, L. 
IMMUNOFLUORESCENCE LOCALIZATION OF POLYKETIDE SYNTHASES IN THE MEDICINAL 
PLANT HYPERICUM PERFORATUM 
 
Hormone (SN 19.4) 
Moderation: Klaus Mohr, Rheinische Friedrich‐Wilhelm‐Universität Bonn 
 
18:15  Hatlapatka, K.; Matz, M.; Baumann, K.; Rustenbeck, I. 
HOW DOES THE INSULIN GRANULE BEHAVE BEFORE ITS RELEASE? ‐ TIRF MICROSCOPY 
ANALYSIS 
18:30  Matz, M.; Hatlapatka, K.; Rustenbeck, I.; Baumann, K. 
TOWARDS FULLY AUTOMATED TIRF MICROSCOPY IMAGE DATA ANALYSIS 
18:45  Dehm, F.; Pergola, C.; Jazzar, B.; Rossi, A.; Laufer, S.; Sautebin, L.; Werz, O. 
SEX BIAS IN LEUKOTRIENE GENERATION CAUSES GENDER‐SPECIFIC EFFICACY OF 
LEUKOTRIENE SYNTHESIS INHIBITORS 
19:00  Rogge, A.; Pergola, C.; Werz, O. 
INFLUENCE OF PREGNANCY ON LEUKOTRIENE FORMATION: A PRIME EXAMPLE FOR 
PERSONALIZED MEDICINE 
 
Mikrosysteme für partikuläre Life Science Produkte (PK 4.7) 
Moderation: Rolf Schubert, Albert‐Ludwigs‐Universität Freiburg 
 
18:15  Lesche, C.; Holle, A.; Finke, J.H.; Müller‐Goymann, C.C.; Büttgenbach, S. 
EMULSIFICATION (O/W) IN MICROCHANNEL GEOMETRIES FOR PHARMACEUTICAL 
SCREENING APPLICATIONS 
18:30  Schoenitz, M.; Jasch, K.; Augustin, W.; Huzhalska, V.; Kulik, A.; Fehr, S.; Bunjes, H.; Finke, 
J.H.; Müller‐Goymann, C.C.; Scholl, S. 
USING MICRO HEAT EXCHANGERS FOR PHARMACEUTICAL APPLICATIONS 
18:45  Kähler, C.J.; Cierpka, C.; Segura, R.; Rossi, M. 
3D FLOW FIELD MEASUREMENTS IN COMPLEX MICROSYSTEMS 
19:00  Schmolke, H.; Finke, J.H.; Müller‐Goymann, C.C.; Klages, C.P. 
ADHESION OF SOLID LIPID NANOPARTICLES ON POLYELECTROLYTE MULTILAYER COATED 
SURFACES 
 
 
 
B1‐2
B1‐3
B1‐4
P2‐1
P2‐2
P2‐3
P2‐4
T1‐1
T1‐2
T1‐3
T1‐4
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Dienstag, 5. Oktober 2010
Plenarvorträge
Kurzvorträge
Bacterial infections at atomic resolutions      
(PK 2.2)
Keynotes
09:00 ‐ 09:45
09:50 ‐ 10:50
Möglichkeiten und Grenzen individualisierter 
Medizin (SN 19.1)
Biotechnology of bioactive compounds from plants 
(SN 19.4) Nanopartikel (PK 4.7)
Wirkstoffsynthese (PK 4.3)
Pharmakokinetik (SN 19.3)
Biochemie/Molekularbiologie (SN 19.7)
Colloids as vaccine delivery systems ‐ Kolloide 
als Impfstoffträger (PK 2.2)
Therapieindividualisierung in der Onkologie: Klinische 
Anwendungen und Trends in der Forschung (SN 19.2)
The genome as a tool for clinical pharmacy     
(SN 19.1)
Gesellschaftsabend begleitet von Jazz Appeal (Mensa II)
Polymere für die Implantation (PK 4.7)
Enzyme in der Wirkstofffindung (SN 19.2) Analytik (PK 4.3)
Signaltransduktion (SN 19.3)
Antitumorwirkstoffe (SN 19.7)
Entwicklung neuer antitumoraler 
Metallkomplexe (SN 19.1)
Kaffeepause (Foyer & Kubus)
Plenarvorträge
Keynotes
Kaffeepause (Foyer & Kubus)
Hyperforin ‐ From the herb to the molecule 
and target (PK 2.2)
Kurzvorträge
Mittagspause/ VdPPHI‐Sitzung (SN 19.2)
Plenarvorträge
Ausstellung (Kubus)/ Posterpräsentation (Foyer)/ Kaffeepause (Kubus & Foyer)
Plenarvorträge
Die Bedeutung von Stammzellen für die 
Diabetes‐Therapie (SN 19.1)
Pharmacological inhibitors of cyclin‐
dependent protein kinases relevant to cancer 
(PK 2.2)
17:00 ‐ 17:15
17:15 ‐ 18:15
ab 19:30
10:50 ‐ 11:15
11:15 ‐ 12:00
12:00 ‐ 13:30
13:30 ‐ 14:15
14:15 ‐ 16:15
16:15 ‐ 17:00
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Dienstag, 5. Oktober 2010 
Plenarvorträge 
 
 
09:00  Heinz, D.W. 
BACTERIAL INFECTIONS AT ATOMIC RESOLUTION 
(PK 2.2) 
Moderation: Ute Wittstock, Technische Universität Braunschweig 
 
09:00  Kroemer, H.K. 
MÖGLICHKEITEN UND GRENZEN INDIVIDUALISIERTER MEDIZIN 
(SN 19.1) 
Moderation: Ralf Benndorf, Technische Universität Braunschweig 
 
11:15  Rades, T. 
COLLOIDS AS VACCINE DELIVERY SYSTEMS ‐ KOLLOIDE ALS 
IMPFSTOFFTRAEGER 
(PK 2.2) 
Moderation: Heike Bunjes, Technische Universität Braunschweig 
 
11:15  McLeod, H.L. 
THE GENOME AS A TOOL FOR CLINICAL PHARMACY 
  (SN 19.1) 
  Moderation: Conrad Kunick, Technische Universität Braunschweig 
 
13:30  Seufert, J. 
DIE BEDEUTUNG VON STAMMZELLEN FÜR DIE DIABETES‐THERAPIE 
(SN 19.1) 
Moderation: Ingo Rustenbeck, Technische Universität Braunschweig 
 
13:30  Meijer, L. 
PHARMACOLOGICAL INHIBITORS OF CYCLIN‐DEPENDENT PROTEIN 
KINASES RELEVANT TO CANCER 
(PK 2.2) 
Moderation: Conrad Kunick, Technische Universität Braunschweig 
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16:15  Müller, W.E.; Leuner, K. 
HYPERFORIN – FROM THE HERB TO THE MOLECULE AND TARGET 
(PK 2.2) 
Moderation: Ludger Beerhues, Technische Universität Braunschweig 
 
16:15  Keppler, B.K. 
ENTWICKLUNG NEUER ANTITUMORALER METALLKOMPLEXE 
(SN 19.1) 
Moderation: Ingo Ott, Technische Universität Braunschweig 
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Keynotes 
 
Biotechnology of bioactive compounds from plants (SN 19.4) 
Moderation: Ute Wittstock, Technische Universität Braunschweig 
 
09:50  Halkier, B.A. 
BIOENGINEERING OF GLUCORAPHANIN FROM BROCCOLI 
10:20  Liu, B.Y.; Wang, H.; Du, Z.G.; Li, G.F.; Ye, H.C. 
ENGINEERING ARTEMISIA ANNUA FOR ARTEMISININ PRODUCTION 
10:35  Heckenmüller, H.; Selge, T.; Wilke, S.; Schütte, K.; Gorr, G. 
LONG‐TERM STORAGE OF UNDIFFERENTIATED PLANT CELLS FOR PRODUCTION OF HIGH 
VALUE SUBSTANCES 
 
Therapieindividualisierung in der Onkologie: Klinische Anwendungen und Trends in der 
Forschung (SN 19.2) 
Moderation: Ralf Benndorf, Technische Universität Braunschweig 
 
09:50  Hempel, G. 
INDIVIDUALIZATION OF ANTICANCER DRUG DOSING BASED ON PHARMACOKINETIC 
PRINCIPLES 
10:10  Ritter, C.A. 
INDIVIDUALIZATION OF ANTICANCER DRUG TREATEMENT BASED ON 
PHARMACOGENETIC FACTORS 
10:30  Jaehde, U. 
INDIVIDUALIZATION OF ANTICANCER DRUG THERAPY USING BIOMARKERS 
 
Enzyme in der Wirkstofffindung (SN 19.2) 
Moderation: Christa E. Müller, Rheinische Friedrich‐Wilhelm‐Universität Bonn  
 
17:15  Rauh, D. 
STABILIZING INACTIVE KINASE CONFORMATIONS WITH SMALL ORGANIC MOLECULES 
17:35  Beerhues, L. 
PLANT POLYKETIDE SYNTHASES IN THE BIOSYNTHESIS OF ACTIVE CONSTITUENTS 
17:55  Müller, M. 
CHEMOENZYMATISCHE WIRKSTOFF‐SYNTHESE 
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Kurzvorträge 
 
Biochemie/Molekularbiologie (SN 19.7) 
Moderation: Joachim José, Heinrich‐Heine Universität Düsseldorf 
 
09:50  Erdmann, N.; Folz, M.; Dobner, B.; Langner, A. 
CELLCULTURE STUDIES OF NOVEL CATIONIC LIPOSOMES USED AS NON‐VIRAL VECTORS 
FOR GENE DELIVERY 
10:05  Giera, M.; de Vlieger, J.; Falck, D.; Lingeman, H.; Kool, J.; Irth, H.; Niessen, W.M.A. 
HYPHENATED BIOAFFINITY SCREENING ‐ THE INTEGRATED SCREENING OF COMPLEX 
MIXTURES 
10:20  Hartung, A.; Schlesinger, M.; Massing, U.; Bendas, G. 
LIPID‐BASED GENE VECTORS FOR VCAM‐1 – KNOCKDOWN IN ENDOTHELIAL CELLS 
10:35  Oehmigen, K.; Hähnel, M.; Hoder, T.; Wilke, C.; Weltmann, K.D.; von Woedtke, T. 
PLASMA‐LIQUID‐INTERACTIONS: CHEMISTRY AND ANTIMICROBIAL EFFECTS 
 
Nanopartikel (PK 4.7) 
Moderation: Klaus Langer, Westfälische Wilhelms‐Universität Münster 
 
09:50  Müller, A.; Ni, Z.; Heßler, N.; Kralisch, D.; Fischer, D. 
BACTERIAL NANOCELLULOSE: INFLUENCE OF FREEZE‐DRYING ON THE DELIVERY OF 
DRUGS 
10:05  Möschwitzer, J. 
DRUG NANOPARTICLES PREPARED BY NOVEL COMBINATIVE PARTICLE SIZE REDUCTION 
TECHNIQUES 
10:20  Hozsa, C.; Breunig, M.; Göpferich, A. 
SHEDDING LIGHT ON THE INTRACELLULAR PROCESSING OF REDUCTION SENSITIVE 
POLY(ETHYLENE IMINE) GENE CARRIERS 
10:35  Nawroth, T.; Wurster, E.C.; Peters, T.; Buch, K.; Huehn, E.; Langguth, P.; Decker, H.; 
Pairet, B.; Meesters, C.; Grunewald, C.; Hampel, G.; Frey, H.; Hofmann, A.M.; 
Schmidberger, H.; Saenger, M.; Alexiou, C. 
MODULAR TARGET NANOPARTICLES – DRUG CARRIERS FOR RADIATION THERAPY OF 
CANCER 
 
Pharmakokinetik (SN 19.3) 
Moderation: Thilo Bertsche, UniversitätsKlinikum Heidelberg 
 
09:50  Oswald, S.; Meyer zu Schwabedissen, H.; Nassif, A.; Modess, C.; Lütjohann, D.; Desta, Z.; 
Kroemer, H.K.; Siegmund, W. 
IMPACT OF EFAVIRENZ ON INTESTINAL AND HEPATIC METABOLISM AND TRANSPORT: 
INTERACTION STUDY WITH EZETIMIBE IN HEALTHY VOLUNTEERS 
P3‐1
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10:05  Peters, J.; Oswald, S.; Haenisch, S.; Ludwig, K.; Bernhardt, J.; Saljé, K.; Modess, C.; 
Cascorbi, I.; Siegmund, W. 
INFLUENCE OF ROUX‐EN‐Y GASTRIC BYPASS SURGERY ON THE PHARMACOKINETICS OF 
PARACETAMOL, TALINOLOL AND AMOXICILLIN IN OBESE PATIENTS 
10:20  Parr, M.K.; Diel, P.; Schänzer, W. 
THE SARM‐LIKE ACTIVITY OF SUPPLEMENT INGREDIENT NOR‐ANDROSTENEDIONE 
DEPENDS ON ROUTE OF ADMINISTRATION 
10:35  Weindl, G.; Klipper, W.; Bätz, F.M.; Schäfer‐Korting, M. 
COMPARATIVE ANALYSIS OF ESTERASE ACTIVITY IN RECONSTRUCTED HUMAN SKIN 
MODELS AND EXCISED HUMAN SKIN 
 
Wirkstoffsynthese (PK 4.3) 
Moderation: Peter Gmeiner, Friedrich‐Alexander‐Universität Erlangen‐Nürnberg 
 
09:50  Bracher, F.; Huber, K.; Knapp, S. 
4‐CYANO‐1‐OXO‐β‐CARBOLINES AS INHIBITORS OF PIM KINASES 
10:05  Behrendt, C.T.; Eisenreich, W.; Fischer, M.; Maes, L.; Kurz, T. 
SYNTHESIS AND ANTIPLASMODIAL ACTIVITY OF REVERSE FOSMIDOMYCIN ANALOGS 
10:20  Dosa, S.; Stirnberg, M.; Klaß, V.; Häußler, D.; Maurer, E.; Gütschow, M. 
SULFAMOYL BENZAMIDINES AS ARGININE MIMETICS: INHIBITION OF TRYPSIN‐LIKE 
SERINE PROTEASES AND ACTIVE‐SITE MAPPING 
10:35  Meyer, C.; Wünsch, B. 
SPIROCYCLIC σ RECEPTOR LIGANDS: EXPLORING HYDROPHOBIC POCKETS BY ARLYATION 
OF ANNULATED THIOPHENES 
 
Analytik (PK 4.3) 
Moderation: Thomas Jira, Ernst‐Moritz‐Arndt Universität Greifswald 
 
17:15  Alban, S.; Schiemann, S.; Lühn, S.; Schneider, T. 
COMPREHENSIVE QUALITIY CONTROL OF HEPARINS BY A SIMPLE MICROPLATE ASSAY 
PROCEDURE 
17:30  Lalk, M.; Dörries, K.; Gierok, P.; Liebeke, M.; Meyer, H.; Wunder, A. 
A METABOLOMICS VIEW ON STAPHYLOCOCCUS AUREUS 
17:45  Bertram, N.; Ostermeyer, M.; Gottsleben, F. 
NEW INSIGHTS WITH 'OLD' METHODS? HIGH PRECISION POLARIMETRY AND 
REFRACTOMETRY: FROM KAISER'S GELATINE TO DETECTING BIOLOGICAL WARFARE 
AGENTS 
18:00  Pettelkau, J.; Ihling, C.; Schröder, T.; Olausson, B.; Lange, C.; Sinz, A. 
INTERACTION STUDIES BETWEEN PEPTIDES DERIVED FROM PHOTORECEPTOR GUANYLYL 
CYCLASE AND GCAP‐2 
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Antitumorwirkstoffe (SN 19.7) 
Moderation: Sigurd Elz, Universität Regensburg 
 
17:15  Krieger, M.L.; Schneider, V.; Kalayda, G.V.; Jaehde, U.; Bendas, G. 
CISPLATIN‐CONTAINING LIPOSOMES TO INVESTIGATE THE MECHANISMS OF 
CHEMORESISTANCE IN TUMOUR CELLS 
17:30  Oster, A.; Hinsberger, S.; Werth, R.; Marchais‐Oberwinkler, S.; Frotscher, M.; Hartmann, 
R.W. 
NEW DESIGN CONCEPT FOR THE DEVELOPMENT OF 17β‐HSD1 INHIBITORS: PROMISING 
DRUG CANDIDATES FOR THE TREATMENT OF ESTROGEN DEPENDENT DISEASES 
17:45  Westendorf, A.F.; Zerzankova, L.; Grünert, R.; Sadler, P.J.; Brabec, V.; Bednarski, P.J. 
LIGHT‐ACTIVATABLE TRANS‐DIAZIDO PT(IV): BIOLOGICAL ACTIVITY AND THE INFLUENCE 
OF AMINO LIGANDS 
18:00  Tolle, N.; Dunkel, U.; Müller, C.; Preu, L.; Oehninger, L.; Rubbiani, R.; Meyer, A.; Ott, I.; 
Haase, T.; Behrends, S.; Totzke, F.; Schächtele, C.; Kubbutat, M.H.G.; Kunick, C. 
NOVEL FLUORESCENT PROTEIN KINASE INHIBITORS 
 
Polymere für die Implantation (PK 4.7) 
Moderation: Dagmar Fischer, Friedrich‐Schiller‐Universität Jena 
 
17:15  Asmus, L.R.; Gurny, R.; Möller, M. 
A POLYMER AS SOLVENT AND SUSTAINED RELEASE EXCIPIENT FOR LIPOPHILIC DRUGS – 
HEXYLSUBSTITUTED POLY(LACTIDE) 
17:30  Dempwolf, W.; Pfaffenroth, C.; Sluszniak, M.; Lorenz, C.; Hoffmann, A.; Winkel, A.; 
Stiesch, M.; Windhagen, H.; Menzel, H. 
DESIGNING POLYMER INTERLAYERS TO IMPROVE IMPLANT SURFACES 
17:45  Nowak, C.; Metz, H.; Mäder, K.; Hacker, M.; Schulz‐Siegmund, M. 
VEGF RELEASE FROM CA‐/ZN‐ALGINATE GELS AND THEIR PHYSICO CHEMICAL 
PROPERTIES 
18:00  Teßmar, J.; Reintjes, T.; Göpferich, A. 
OPTIMIZED DEGRADATION AND MECHANICAL PROPERTIES OF POLYMER FILMS FOR 
SURGICAL ADHESION PREVENTION 
 
Signaltransduktion (SN 19.3) 
Moderation: Angelika M. Vollmar, Ludwig‐Maximilians‐Universität München 
 
17:15  Janßen, N.; Kebig, A.; Kostenis, E.; Mohr, K. 
THE Gq‐COUPLED MUSCARINIC M3 RECEPTOR GAINS Gi SIGNALING COMPETENCE 
UNDER CONDITIONS OF ENHANCED cAMP 
17:30  Bock, A.; Holzgrabe, U.; De Amici, M.; Mohr, K. 
LINKER LENGTH IS PIVOTAL FOR POTENCY OF DUALSTERIC AGONISTS AT MUSCARINIC 
M2 RECEPTORS 
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17:45  Michaelis, M.; Paulus, C.; Löschmann, N.; Dauth, S.; Stange, E.; Doerr, H.W.; Nevels, M.; 
Cinatl, J. 
THE MULTI‐TARGETED KINASE INHIBITOR SORAFENIB INHIBITS HUMAN 
CYTOMEGALOVIRUS REPLICATION 
P4‐3
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Mittwoch, 6. Oktober 2010
Stimulators and activators of soluble 
guanylate cyclase: from bench to bedside      
(SN 19.1)
Polymers for the control of cell material 
interactions on the micro‐ and nanoscale      
(PK 2.2)
10:05 ‐ 11:05
11:05 ‐ 11:30 Kaffeepause (Foyer & Kubus)
Keynotes Kurzvorträge
Plenarvorträge
09:15 ‐ 10:00
Herz‐Kreislauf (SN 19.3)
Analytik (PK 4.3)
Computerunterstützte Wirkstofffindung (SN 19.4)
Dermale Therapie (PK 4.7)
Feste Arzneiformen (SN 19.7)
Pharmakologische Wirkstoffoptimierung durch 
Polymerkonjugation (SN 19.2)
Plenarvortrag
11.30 ‐ 12:15
Preisverleihungen, Ehrungen (Audimax/ Tentomax)12:15 ‐ 13:00
Evidence‐based complementary medicine ‐ a contradiction in terms?                        
(Audimax/ Tentomax)
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Plenarvorträge 
 
 
09:15  Stasch, J.P. 
STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE: 
FROM BENCH TO BEDSIDE 
(SN 19.1) 
Moderation: Soenke Behrends, Technische Universität Braunschweig 
 
09:15  Brandl, F.; Teßmar, J.; Breunig, M.; Göpferich, A. 
POLYMERS FOR THE CONTROL OF CELL MATERIAL INTERACTIONS ON THE 
MICRO‐ AND NANOSCALE 
(PK 2.2) 
Moderation: Christel C. Müller‐Goymann, Technische Universität Braunschweig 
 
11:30  Ernst, E. 
EVIDENCE‐BASED COMPLEMENTARY MEDICINE – A CONTRADICTION IN 
TERMS? 
(Audimax/ Tentomax) 
Moderation: Ingo Rustenbeck, Technische Universität Braunschweig 
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Keynotes 
 
Pharmakologische Wirkstoffoptimierung durch Polymerkonjugation (SN 19.2) 
Moderation: Roland Frank, Helmholz Zentrum für Infektionsforschung Braunschweig 
 
10:05  Vorstheim, P. 
BIG IS BEAUTIFUL – HESylation® AS AN EXAMPLE FOR DRUG‐POLYMER CONJUGATES 
10:35  Kontermann, R. 
NEUE STRATEGIEN ZUR VERLÄNGERUNG DER HALBWERTSZEIT REKOMBINANTER 
PROTEINE 
10:50  Apeler, H. 
NEXT GENERATION SITE‐SPECIFICALLY PEGYLATED FVIII FOR THE TREATMENT OF 
HEMOPHILIA A 
 
   
Key7‐1
Key7‐2
Key7‐3
http://www.digibib.tu-bs.de/?docid=00038117 24/02/2011
Mittwoch, 6. Oktober 2010 
Kurzvorträge 
 
Analytik (PK 4.3) 
Moderation: Ulrike Holzgrabe, Julius‐Maximilians‐Universität Würzburg 
 
10:05  Sproß, J.; Sinz, A. 
IMMOBILIZED MONOLITHIC TRYPSIN REACTOR FOR APPLICATION IN PHARMACEUTICS 
AND PROTEOMICS 
10:20  Kammerer, B.; Kahlich, R.; Laufer, S. 
ACHIRAL–CHIRAL LC/LC–MS/MS COUPLING FOR DETERMINATION OF CHIRAL 
DISCRIMINATION EFFECTS IN DRUG METABOLISM 
10:35  Telsnig, D.; Kassarnig, V.; Kalcher, K.; Ortner, A. 
OPTIMIZATION AND APPLICATION OF PEA SEEDLING AMINE OXIDASE MODIFIED 
BIOSENSORS 
10:50  Tawab, M.; Werz, O.; Schubert‐Zsilavecz, M. 
FILLING THE GAP BETWEEN PHARMACOLOGICAL TESTING AND IN VIVO FINDING ON THE 
EXAMPLE OF BOSWELLIA SERRATA 
 
Computerunterstütze Wirkstofffindung (SN 19.4) 
Moderation: Gerhard Wolber, Freie Universität Berlin 
 
10:05  Schiedel, A.C.; Seibt, B.F.; Sherbiny, F.F.; Maaß, A.; Müller, C.E. 
ROLE OF THE SECOND EXTRACELLULAR LOOP OF THE ADENOSINE A2B RECEPTOR IN 
RECEPTOR ACTIVATION 
10:20  Strasser, A.; Wittmann, H.J. 
IN SILICO ANALYSIS OF THE HISTAPRODIFEN INDUCED ACTIVATION PATHWAY OF THE 
GUINEA‐PIG H1‐RECEPTOR 
10:35  Negri, M.; Recanatini, M.; Hartmann, R.W. 
DYNAMIC MOTION INVESTIGATION OF 17β‐HSD1 PROVIDES INSIGHTS IN ITS ENZYME 
KINETICS AND LIGAND BINDING 
 
Dermale Therapie (PK 4.7) 
Moderation: Rolf Daniels, Eberhard‐Karls Universität Tübingen 
 
10:05  Keck, C.M. 
THE SILVER ‐ NANOLIPID ‐ COMPLEX (sNLC): IN VIVO EFFICACY 
10:20  Hahn, T.; Nägel, A.; Heisig, M.; Kostka, K.H.; Hansen, S.; Neumann, D.; Lehr, C.M.; Schäfer, 
U.F. 
FINITE DOSE SKIN PENETRATION ‐ EXPERIMENT AND SIMULATION 
10:35  Lusiana; Müller‐Goymann, C.C. 
THE PERMEATION STUDY OF TERBINAFINE HCl FROM POLOXAMER 407 BASED 
THERMOGELLING FORMULATIONS ACROSS ISOLATED HUMAN STRATUM CORNEUM 
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10:50  Michaelis, M.; Leopold, C.S. 
INFLUENCE OF IBUPROFEN CONTENT ON THE RHEOLOGICAL AND THERMAL BEHAVIOR 
OF AN ACRYLIC PRESSURE SENSITIVE ADHESIVE 
 
Feste Arzneiformen (SN 19.7) 
Moderation: Jörg Breitkreutz, Heinrich‐Heine‐Universität Düsseldorf 
 
10:05  Kleinebudde, P.; Knop, K.; Müller, J. 
END POINT CONTROL OF AN ACTIVE COATING PROCESS BY RAMAN SPECTROSCOPY 
10:20  Reitz, E.; Thommes, M. 
HOT MELT EXTRUSION OF LOW MOLECULAR WEIGHT CRYSTALLINE MATERIALS 
10:35  Metzger, P.O.J.; Wahl, M.A. 
POROUS CARRIERS AS A TARGET FOR DRUG LOADING BY SUPERCRITICAL FLUID 
TECHNOLOGY USING AN OPEN OR ENVIRONMENT FRIENDLY CLOSED LOOP SYSTEM 
10:50  Taupitz, T.; Klein, S. 
VARIOUS FORMULATION APPROACHES TO IMPROVE DRUG RELEASE FROM A FIXED 
DOSE COMBINATION PRODUCT 
 
Herz‐Kreislauf (SN 19.3) 
Moderation: Christoph Ritter, Ernst‐Moritz‐Arndt‐Universität Greifswald 
 
10:05  Khayyal, M.T.; Abdel‐Aziz, H.; El‐Awady, S.; Ammar, R. 
STUDIES ON THE MECHANISM OF ANTIHYPERTENSIVE ACTION OF SOLANUM INDICUM 
SSP. DISTICHUM 
10:20  Krähling, J.R.; Busker, M.; Haase, N.; Haase, T.; Linnenbaum, M.; Oberle, S.; Behrends, S. 
ANALYSIS OF REQUIREMENTS FOR DIMERIZATION OF NITIRIC OXIDE SENSITIVE 
GUANYLYL CYCLASE 
10:35  Liebl, J.; Weitensteiner, S.B.; Vereb, G.; Takacs, L.; Fürst, R.; Vollmar, A.M.; Zahler, S. 
CYCLIN DEPENDENT KINASE 5 (CDK5) REGULATES ENDOTHELIAL CELL MIGRATION AND 
ANGIOGENESIS 
10:50  Fürst, R.; Schmerwitz, U.K.; Sass, G.; Khandoga, A.G.; Joore, J.; Totzke, F.; Krombach, F.; 
Tiegs, G.; Zahler, S.; Vollmar, A.M. 
FLAVOPIRIDOL PROTECTS AGAINST INFLAMMATION BY INHIBITION OF CDK9 
 
P5‐1
P5‐2
P5‐3
P5‐4
T4‐4
T5‐1
T5‐2
T5‐3
T5‐4
http://www.digibib.tu-bs.de/?docid=00038117 24/02/2011
Pharmaziehistorische Veranstaltung
http://www.digibib.tu-bs.de/?docid=00038117 24/02/2011
Pharmaziehistorische Veranstaltung 
Pharmazie in Braunschweig:  
Historische und aktuelle Aspekte 
(SN 19.4) 
 
Montag, 04. Oktober, 2010 
 
09:00  Begrüßung und Einführung 
Dilg, P.  
09:15  Beisswanger, G.; Wacker, G.                
HOF – STADT – LAND. APOTHEKEN IM HERZOGTUM  
BRAUNSCHWEIG‐WOLFENBÜTTEL 
10:00  Wahrig, B.                   
UNIVERSITÄTSPHARMAZIE IN BRAUNSCHWEIG VON 1835 BIS  
HEUTE 
10:45  Pause 
11:15  Pohl, U.                   
FRIEDRICH JULIUS OTTO ZWISCHEN UNIVERSITÄT UND GEWERBE     
12:00  Wulle, S.                    
DAS DFG‐SONDERSAMMELGEBIET PHARMAZIE DER UB  
BRAUNSCHWEIG 
12:45  Ende der Veranstaltung 
H‐1 (n.v.) 
H‐2 (n.v.) 
H‐3 (n.v.) 
H‐4 (n.v.) 
http://www.digibib.tu-bs.de/?docid=00038117 24/02/2011
Fachgruppensymposien
http://www.digibib.tu-bs.de/?docid=00038117 24/02/2011
Fachsymposium Allgemeinpharmazie 
Pharmazeutische Betreuung und  
Arzneimittelsicherheit 
(SN 19.2) 
 
Mittwoch, 06. Oktober, 2010 
 
14:30  Themeneinführung und Vorstellung der Referenten 
  Hannig, M.; Kresser, J. 
14:45  Aly, A.F. 
FÖRDERUNG DER KOOPERATION VON ARZT UND APOTHEKER ALS 
THEMA/ MAßNAHME DES NEUEN AKTIONSPLANS DES 
BUNDESMINISTERIUMS FÜR GESUNDHEIT ZUR VERBESSERUNG DER 
ARZNEIMITTELTHERAPIESICHERHEIT (AMTS) 
15:20  Schwenzer, S. 
ZUKUNFT eMEDIKATION. WIE IT DIE PHARMAZEUTISCHE BETREUUNG 
UNTERSTÜTZEN KANN 
15:55  Schäfer, M. 
ERSCHLIEßUNG VON SICHERHEITS‐ UND WIRTSCHAFTLICHKEITSRESERVEN 
DURCH DIE DOKUMENTATION ARZNEIMITTELBEZOGENER PROBLEME 
16:30  Podiumsdiskussion AMTS/ Pharmazeutische Betreuung/ Praxis und 
Zukunft 
Schäfer, M.; Holzgrabe, U.; Aly, A.F.; Schwenzer, S.; Kresser, J.; Hannig, M. 
17:30  Mitgliederversammlung der Fachgruppe Allgemeinpharmazie   
‐ Bericht des Vorstands Dr. M. Hannig 
‐ Neue Kommunikationswege der Fachgruppe 
‐ Fachsymposium 2011 
‐ Verschiedenes 
   
 
F1‐1
F1‐2
F1‐3
http://www.digibib.tu-bs.de/?docid=00038117 24/02/2011
Fachsymposium Arzneimittelkontrolle/ Pharmazeutische Analytik 
Ein facettenreiches Spektrum:  
Pharmazeutische Analytik an Universitäten 
 (PK 4.3) 
 
Mittwoch, 06. Oktober, 2010 
 
14:30  Begrüßung  
14:45  Parr, M.K. 
TRACING CHEATERS IN SPORTS – MASS SPECTROMETRY IN ANTI‐DOPING 
RESEARCH 
15:15  Holzgrabe, U. 
  DAS ARZNEIBUCH UND ORTHOGONALE METHODEN   
15:45  Sproß, J.; Sinz, A. 
PREPARATION OF MONOLITHIC COLUMNS FOR LC‐MS/MS ANALYSIS OF 
PROTEINS AND DRUGS 
16:15  Pause 
16:45  Scriba, G.K.E. 
CE IN PHARMACEUTICAL ANALYSIS – APPLICATION TO DRUG IMPURITY 
PROFILING 
17:15  Jose, J.; Gratz, A.; Götz, C. 
CAPILLARY ELECTROPHORESIS (CE) AND FRET AS TOOLS FOR TESTING 
INHIBITORS OF HUMAN PROTEINKINASE CK2 
17:45  Jung, M. 
  AKTIVITÄTSASSAYS FÜR HISTON‐MODIFIZIERENDE ENZYME IN  
  WIRKSTOFFSUCHE UND BIOANALYTIK 
18:15  Pause 
18:30  Heilmann, J. 
  NACHWEIS UND BESTIMMUNG VON PRENYLIERTEN CHALCONEN  
  (XANTHOHUMOL)UND IHREN METABOLITEN IN ZELLKULTUREN,  
  PLASMA UND GEWEBEN 
19:00  Speikamp, Feußner, Jäckel, Wätzig 
  INDUSTRIEFORUM ANALYTIK: AKTUELLE AUSBILDUNGSINHALTE FÜR 
  ZUKUNFTSWEISENDE KONZEPTE 
20:00  Gesellschaftsabend in der Braunschweiger Traditionskneipe „Mephisto“ 
 
F2‐1
F2‐3
F2‐4
F2‐5
F2‐2(n.v.)
F2‐6(n.v.)
F2‐7(n.v.)
F2‐8(n.v.)
http://www.digibib.tu-bs.de/?docid=00038117 24/02/2011
Fachsymposium Arzneimittelkontrolle/ Pharmazeutische Analytik 
Physikalische und pharmazeutisch‐technologische 
Methoden: State of the Art 
 (PK 4.3) 
 
Donnerstag, 07. Oktober, 2010 
 
08:45  Begrüßung  
09:00  Vielle, C. 
  OVERVIEW ABOUT THE DEVELOPMENTS IN THE EUROPEAN PHARMACOPEIA  
  IN TERMS OF PHYSICOCHEMICAL AND PHARMACEUTICAL TECHNICAL  
  METHODS 
09:30  Langguth, P. 
  BESTIMMUNG DER WIRKSTOFFFREISETZUNG IN‐VITRO: METHODEN IM  
  SPAGAT ZWISCHEN QUALITÄTSKONTROLLE UND BIORELEVANZ 
10:15  Roßricker, T. 
  UNTERSUCHUNGSMETHODEN ZUR QUALITÄTSKONTROLLE VON 
AEROSOLEN 
10:45  Pause 
11:15  Wundrack, A. 
  PH‐MESSUNG IN KOMPLEXEN MATRICES 
11:45  Petrich, M. 
  ANALYSE VON SPURENELEMENTEN IN PHARMAZEUTIKA MIT AAS, ICP‐OES 
UND ICP‐MS 
12:15  Raith, K. 
  GALENISCHE UND PHYSIKALISCHE METHODEN IN DER AMTLICHEN 
  ARZNEIMITTELUNTERSUCHUNG 
12:45  Abschlussdiskussion 
 
F3‐1(n.v.)
F3‐2(n.v.)
F3‐3(n.v.)
F3‐4(n.v.)
F3‐5(n.v.)
F3‐6(n.v.)
http://www.digibib.tu-bs.de/?docid=00038117 24/02/2011
Fachsymposium Klinische Pharmazie 
Arzneimittelsicherheit –  
Chancen für die Klinische Pharmazie 
 (SN 19.3) 
 
Sonntag, 03. Oktober, 2010 
 
14:00  Keiner, D. 
A YEAR CPOE ‐ PRACTICAL EXPERIENCES AND PERSPECTIVES FROM A 
CLINICAL PHARMACIST 
14:45  Nowak, K. 
SAFETY OF PHARMACOTHERAPY ON THE INTERFACE BETWEEN 
OUTPATIENT AND INPATIENT TREATMENT 
15:30  Pause 
15:50  Bertsche, T. 
CLINICAL‐PHARMACEUTICAL INTERVENTION STUDIES TO OPTIMISE 
PATIENT SAFETY IN DRUG THERAPY IN HOSPITAL SETTINGS 
16:35  Mahler, C. 
MEDICATION SAFETY – HOW DO NURSES CONTRIBUTE? 
17:20  Mitgliederversammlung der Fachgruppe Klinische Pharmazie 
   
F4‐2
F4‐1
F4‐3
F4‐4
http://www.digibib.tu-bs.de/?docid=00038117 24/02/2011
Fachsymposium Klinische Pharmazie 
Arzneimittelsicherheit –  
Chancen für die Klinische Pharmazie 
 (SN 19.3) 
 
Montag, 04. Oktober, 2010 
 
08:30  Jaehde, U.; Hanke, F. 
MEDICATION SAFETY OF ELDERLY PATIENTS IN NURSING HOMES 
09:15  Dreischulte, T. 
DATA DRIVEN QUALITY IMPROVEMENT IN PRIMARY CARE (DQIP): USING 
ROUTINE DATA TO IMPROVE THE QUALITY AND SAFETY OF PRESCRIBING 
IN PRIMARY CARE 
10:00  Pause 
10:20  Eickhoff, C. 
 ARZNEIMITTELTHERAPIESICHERHEIT IN DER SELBSTMEDIKATION 
11:05  Schwalbe, O.; Braun, C.; Simons, S.; Jaehde, U. 
MORE THAN GOOD PRICES ‐ PATIENT SAFETY IN DRUG THERAPY WITHIN 
A LARGE COLLABORATION OF COMMUNITY PHARMACIES 
11:50  Schrappe, M. 
  ERKENNTNISINTERESSE UND INSTRUMENTE ‐ WICHTIGE 
  METHODISCHE FRAGESTELLUNGEN IN DER  
  ARZNEIMITTELTHERAPIESICHERHEIT 
 
F5‐1
F5‐2
F5‐4
F5‐3(n.v.)
F5‐5(n.v.)
http://www.digibib.tu-bs.de/?docid=00038117 24/02/2011
Fachsymposium Pharmakologie und Toxikologie 
In Vitro Hautmodelle Als Alternative  
Pharmakologische Testsysteme 
(SN 19.4) 
 
Mittwoch, 06. Oktober, 2010 
 
14:30  Begrüßung und Einführung 
  Weindl, G. 
14:45  Hennies, H.C.; Torres, S.; Casper, R.; Weindl, G.; Ackermann, K.; Küchler, 
S.; Oji, V.; Traupe, H.; Schäfer‐Korting, M.; Eckl, K.M. 
IN‐VITRO MODELS FOR CONGENITAL KERATINIZATION DISORDERS 
15:20  Küchler, S.; Wolf, N.; Schäfer‐Korting, M. 
IN VITRO WOUND HEALING MODELS 
15:55  Pause 
16:15  Merk, H. 
  HAUTTUMORMODELLE 
16:50  Weindl, G. 
IN VITRO INFECTION MODELS OF LOCALIZED CANDIDA INFECTIONS 
17:25  Abschlussdiskussion 
 
F6‐1
F6‐2
F6‐4
F6‐3(n.v.)
http://www.digibib.tu-bs.de/?docid=00038117 24/02/2011
Fachsymposium Pharmazeutische Biologie 
Pflanzenextrakte im Spannungsfeld zwischen Rationaler 
Phytotherapie und Lebensmitteln bzw. Kosmetika 
(SN 19.3) 
               
Mittwoch, 06. Oktober, 2010 
 
14:30  Begrüßung und Einführung 
  Knöss, W. 
14:45  Steffen, C. 
  KLINISCHE PRÜFUNGEN IM ABGRENZUNGSBEREICH 
15:20  Riedel, F. 
  STOFFLISTE 
15:55  Pause 
16:15  Schraitle, R. 
  VERKEHRSMÖGLICHKEITEN/VERTRIEBSOPTIONEN 
16:50  Stein, J. 
  SEKUNDÄRE PFLANZENINHALTSSTOFFE ALS NUTRACEUTICALS – HYPE OR 
HOPE? 
17:25  Lohmüller, E.M. 
  KOSMETIKA 
18:00  Abschlussdiskussion 
 
F7‐1(n.v.)
F7‐2(n.v.)
F7‐3(n.v.)
F7‐4(n.v.)
F7‐5(n.v.)
http://www.digibib.tu-bs.de/?docid=00038117 24/02/2011
Fachsymposium Pharmazeutische/Medizinische Chemie 
Mitgliederversammlung 
 
(SN 19.4) 
               
Mittwoch, 06. Oktober, 2010 
 
13:15  Mitgliederversammlung 
 
http://www.digibib.tu-bs.de/?docid=00038117 24/02/2011
Fachsymposium Pharmazeutische Technologie 
Dermale Therapie 
 
(PK 4.7) 
 
Mittwoch, 06. Oktober, 2010 
 
14:15  Begrüßung und Einführung 
  Müller‐Goymann, C.C. 
14:25  Neubert, R.H.H. 
NEUE ERKENNTNISSE ZUR MOLEKULAREN UND MORPHOLOGISCHEN 
STRUKTUR DES STRATUM CORNEUM 
15:05  Schäfer, U.F. 
IN‐VITRO METHODS TO DETERMINE THE DERMAL ABSORPTION. WHAT 
THEY CAN – WHERE ARE THEIR LIMITS? 
15:45  Lademann, J.; Richter, H.; Sterry, W.; Patzelt, A. 
PENETRATION AND STORAGE OF NANOPARTICLES IN THE SKIN 
16:25  Pause 
16:45  Daniels, R. 
DERMATOLOGICAL VEHICLES – CLASSICAL AND INNOVATIVE 
FORMULATION CONCEPTS 
17:25  Müller‐Goymann, C.C.; Grüning, N.; van Hemelrijck, C. 
FORMULATION FOR THE TREATMENT OF SOLAR DAMAGES 
18:05  Abschlussdiskussion und Mitgliederversammlung der Fachgruppe 
Pharmazeutische Technologie 
 
F8‐1
F8‐2
F8‐3
F8‐4
F8‐5
http://www.digibib.tu-bs.de/?docid=00038117 24/02/2011
Posterliste
http://www.digibib.tu-bs.de/?docid=00038117 24/02/2011
Posterbeiträge 
Pharmazeutische Technologie 
Polymere 
T001  Bauhuber, S.; Göpferich, A.; Breunig, M. 
REDUCTIVELY DEGRADABLE LINEAR POLY(ETHYLENE GLYCOL)‐POLY(ETHYLENE IMINE)‐COPOLYMERS 
FOR THE DELIVERY OF NUCLEIC ACIDS 
T002  Bertz, A.; Wöhl‐Bruhn, S.; Bunjes, H.; Menzel, H. 
DRUG DELIVERY SYSTEMS BASED ON MODIFIED HYDROXYETHYL STARCH 
T003  Heller, A.; Brockhoff, G.; Göpferich, A. 
INFLUENCE OF BIOMATERIALS ON MITOCHONDRIAL FUSION IN VITRO 
T004  Hoffmann, S.; Schädlich, A.; Mäder, K. 
PLASMA VOLUME EXPANDERS AS POTENTIAL DRUG DELIVERY SYSTEMS – AN IN VIVO STUDY 
UTILISING NONINVASIVE NEAR INFRARED FLUORESCENCE OPTICAL IMAGING 
T005  Kamoun , E.A.; Winkel, A.; Stiesch, M.; Menzel, H. 
A NEW VISIBLE‐LIGHT PHOTOINITIATING SYSTEM FOR BIOMEDICAL APPLICATIONS: SYNTHESIS AND 
CHARACTERIZATION 
T006  Luschmann, C.; Strauß, O.; Teßmar, J.; Luschmann, K.; Göpferich, A. 
DEVELOPMENT OF OPHTHALMIC FORMULATIONS FOR POORLY WATER‐SOLUBLE DRUGS: USING 
POLYETHYLENGLYCOLES 
T007  Strasdat, B.; Laabs, F.; Bunjes, H. 
PREPARATION OF SMALL HYDROGEL MICROPARTICLES AS ACCEPTOR COMPARTMENTS FOR DRUG 
TRANSFER STUDIES 
T008  Wöhl‐Bruhn, S.; Heim, E.; Bertz, A.; Menzel, H.; Ludwig, F.; Schilling, M.; Bunjes, H. 
RELEASE PROPERTIES OF HYDROGEL DRUG CARRIER SYSTEMS CHARACTERIZED BY 
MAGNETORELAXOMETRY 
T009  Kühn, N.; Kaminski, L.; Wätzig, H.; Reichl, S. 
SYNTHESIS OF POLY‐L‐CYSTEINE AND ITS EFFECT ON PARA‐CELLULAR DRUG TRANSPORT ACROSS 
CORNEAL EPITHELIUM 
 
Polymere Nanopartikel 
T010  Buch, K.; Nawroth, T.; Langguth, P. 
CHARACTERIZATION OF POLY(LACTIC‐CO‐GLYCOLIC ACID) NANOPARTICLES CONTAINING 
LANTHANIDES 
T011  Engel, A.; Plöger, M.; von Storp, B.; Langer, K. 
SOLVENT DISPLACEMENT METHOD FOR THE PREPARATION OF HSA‐NANOPARTICLES 
T012  Ferstl, M.; Drechsler, M.; Rischer, M.; Göpferich, A. 
CHARACTERIZATION OF NANOSTRUCTURED POLY‐ELECTROLYTE PEPTIDE COMPLEXES 
T013  Fütterer, S.; Andreasen, H.; Jahn, M.; Nawroth, T.; Jørgensen, S.L.; Kolb, U.; Hofmeister, W.; 
Langguth, P. 
COMPARISON OF NANOPARTICULAR IRON FORMULATIONS FOR PARENTERAL USE – ARE THEY 
SIMILAR AND READILY EXCHANGEABLE? 
 
http://www.digibib.tu-bs.de/?docid=00038117 24/02/2011
Posterbeiträge 
T014  Probst, S.; Blunk, T.; Göpferich, A. 
ENZYME‐RESPONSIVE NANOPARTICLES FOR CARTILAGE TARGETING 
T015  Schädlich, A.; Rose, C.; Kuntsche, J.; Caysa, H.; Müller, T.; Göpferich, A.; Mäder, K. 
IN VIVO AND EX VIVO STUDIES OF PEG ‐ PLA BLOCK COPOLYMER NANOPARTICLES FOR TUMOR 
VISUALISATION AND TREATMENT 
 
Nanopartikel / Emulsionen 
T016  Acar, S.; Müller, R.H.; Keck, C.M. 
ROLE OF α‐MODIFICATION ON PHYSICAL STABILITY OF LIPID NANOPARTICLES 
T017  Hommoss, A.; Shegokar, R.; Müller, R.H. 
DEVELOPMENT OF PRESERVED HIGHLY‐LOADED ARGAN OIL NANOSTRUCTURED LIPID CARRIERS 
(NLC) 
T018  Horst, J.C.; Bunjes, H. 
IMPACT OF SALTS ON THE PARTICLE SIZE OF DISPERSED CUBIC PHASES 
T019  Kuntsche, J.; Sänger, S.; Mengersen, F.; Bunjes, H. 
ANALYSIS OF SUPERCOOLED SMECTIC NANOPARTICLES BY ASYMMETRICAL FLOW FIELD‐FLOW 
FRACTIONATION 
T020  Mell, N.A.; Lehr, C.M.; Collnot, E.M. 
NANOPARTICLES FOR THE ORAL DELIVERY OF IL‐10 TO THE INFLAMED INTESTINE 
T021  Gurung, S.; Schubert, R. 
COMPARISION OF NANOEMULSION PREPARED BY HIGH PRESSURE HOMOGENIZATION AND 
ULTRASONICATION 
T022  Harden, D.; Müller, R.H.; Keck, C.M. 
HIGHLY CONCENTRATED 40% I.V. NANOEMULSIONS FOR DRUG DELIVERY 
T023  Kumpugdee‐Vollrath, M.; Tong, L.; Krause, J.P. 
PRODUCTION AND CHARACTERIZATION OF O/W CONCENTRATED EMULSIONS STABILIZED BY PLANT 
PROTEIN 
T024  Mayenfels, F.; Flögel, U.; Schrader, J.; Schubert, R. 
DEVELOPMENT OF STABLE PERFLUOROCARBON‐CONTAINING NANOEMULSIONS FOR THE USE IN 
1H/19F MRI 
T025  Mengersen, F.; Bunjes, H. 
INVESTIGATION OF THE CHEMICAL STABILITY OF SUPERCOOLED SMECTIC NANOPARTICLES 
T026  Noack, A.; Mäder, K. 
SOLID LIPID NANOPARTICLES (SLN) AS A TOOL FOR THE ENHANCEMENT OF THE BIOAVAILABILITY OF 
CURCUMIN 
T027  Steinbach, A.; Süss, R. 
QUANTITATIVE IMAGING – A NEW APPROACH TO QUANTIFY NUCLEAR IMPORT OF LIPOPLEX‐
DELIVERED pDNA 
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Posterbeiträge 
Mikrosysteme für partikuläre Life Science Produkte 
T028  Fehr, S.; Schmolke, H.; Klages, C.P.; Bunjes, H. 
PREPARATION OF EMULSIONS AND SOLID LIPID PARTICLES BY DIRECT MEMBRANE EMULSIFICATION 
T029  Finke, J.H.; Schuldt, A.; Schur, J.; Gothsch, T.; Lesche, C.; Büttgenbach, S.; Kwade, A.; Müller‐
Goymann, C.C. 
UTILIZATION OF CUSTOMIZED MICROCHANNEL GEOMETRIES FOR SOLID LIPID NANOPARTICLE 
PRODUCTION 
T030  Gothsch, T.; Beinert, S.; Lesche, C.; Büttgenbach, S.; Kwade, A. 
CHARACTERISATION OF HIGH PRESSURE DISPERSION PROCESSES IN DIFFERENT MICRO CHANNEL 
GEOMETRIES 
T031  Demming, S.; Vila‐Planas, J.; Sommer, B.; Edlich, A.; Lopez‐Martinez, M.J.; Verpoorte, E.; Krull, R.; 
Franco‐Lara, E.; Llobera, A.; Büttgenbach, S. 
DISPOSABLE PDMS MICROBIOREACTORS WITH INTEGRATED ONLINE ANALYTICS FOR 
BIOTECHNOLOGICAL SCREENING 
 
Liposomen 
T032  Bilek, H.; Tong, L.; Perlich, J.; Vainio, U.; Kumpugdee‐Vollrath, M. 
DETERMINATION OF LIPOSOMES WITH DIFFERENT DRUGS 
T033  Böhm, K.; Süss, R. 
OPTIMIZING SHELF LIFE OF DOXORUBICIN LOADED LIPOSOMES BY LYOPHILIZATION 
T034  Burghardt, A.; Schaffran, T.; Gabel, D.; Süss, R.; Schubert, R. 
BORON‐LIPIDS IN LIPOSOMES: LIPOSOME/CELL INTERACTION AND LIPID EXCHANGE 
T035  Decker, C.; Fahr, A.; Kuntsche, J. 
ASYMMETRICAL FLOW FIELD‐FLOW FRACTIONATION FOR THE CHARACTERIZATION OF LIPOSOMES 
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FROM SYSTEMS BIOLOGY TO PERSONALIZED MEDICINE – 
VISION, WISHFUL THINKING OR JUST A HYPE? 
Balling, R. 
Luxembourg Centre for Systems Biomedicine (LCSB), Univ. of Luxembourg  
New technologies to analyse genome wide DNA-sequence variations and the 
ability to carry out high-throughput measurements of RNA, protein expression or 
metabolite concentrations in blood and other tissues is changing biomedical 
research. The tremendous amount of data obtained during the course of disease 
progression or in response to drug treatments provide a basis for a mathematical 
description and the development of mathematical models of disease pathogenesis. 
Instead of looking at individual components, we can now focus our attention on the 
interaction between the various components and the dynamics of biological 
systems. A network representation and analysis of the physiology and 
pathophysiology of biological systems and diseases is an effective way to study 
their complex behavior. Genetic, chemical or other environmental influences can 
trigger cascades of failures, which lead to the fragility and malfunctioning of 
cellular networks and to specific diseases.  
Systems level approaches have a great potential to yield new insights into the 
molecular basis of drug action and to guide the improvement of drug safety and 
efficacy. The hopes and challenges associated with the application of systems 
biology and the development of a personalized medicine will be discussed. 
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THE PRACTICE OF METABONOMICS/METABOLOMICS IN THE 
SEARCH FOR BIOMARKERS  
Wilson, I.D. 
Dept. of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, 
AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, 
UK.
One of the aspirations of clinical innovation in the 21st century is contained in the 
concept of “personalised medicine“ where the aim is to optimise the treatment 
regimen such that the right drug is given to the right patient at the correct dose.
Central to the delivery of this concept is the assumption that patients can be 
profiled in some way, either via genetic data, or through phenotypes based on 
protein or metabolite signatures (proteomics/metabonomics) to derive specific 
biomarkes (or patterns of biomarkers). In the area of global metabolite profiling 
(metabonomics/metabolomics) this has resulted in the development of the idea of 
pharmacometabonomics where, by analogy to pharmacogenomics, predose 
metabolic phenotypes can be used to predict drug response.   
The production of global metabolite profiles from biofluids and tissues as a means 
of studying the metabolic response of humans or other organisms to a toxic insult, 
or the development of disease, represents a major analytical challenge. Currently 
the bulk of the investigations in this field have used high field NMR spectroscopy 
or (increasingly) a separation technique combined with mass spectrometry (MS) 
(most often HPLC-MS and UPLC-MS, but also GC-MS, GCxGCMS and CE-MS). 
Validation and quality control in this type of work are essential, but by no means 
trivial, if useable data are to be obtained. Following profiling the data must then be 
interrogated using multivariate statistics so as to discover the potential biomarkers 
hiding in the forest of other metabolites, and then these must be identified and then 
investigated using sensitive, specific and fully validated, methods to confirm their 
utility.
The use of HP and UPLC-MS methods for biomarker discover and validation in 
metabonomic studies of disease models and in the investigation of nephro- and 
hepatotoxicity in rodents will be discussed in detail, and a road map for this type of 
study will be provided. 
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AUSGETRÄUMT – INFEKTIONSKRANKHEITEN, IHR 
VERSCHWINDEN UND IHRE RÜCKKEHR IM 20. JAHRHUNDERT 
Gradmann, C 
University of Oslo, Section for Medical Anthropology and Medical History 
Zu den wichtigsten Entwicklungen in der europäischen Medizingeschichte des 20. 
Jahrhunderts gehört die Veränderung der Bedeutung von Infektionskrankheiten. 
Bis zum 1. Weltkrieg bildeten Krankheiten wie Tuberkulose, Cholera oder Typhus, 
verstanden als Volksseuchen, den Dreh- und Angelpunkt des öffentlichen 
Gesundheitswesens. Allerdings ging bereits seit dem Ende des 19. Jahrhunderts 
ihre epidemiologische Bedeutung zurück. Dieser Prozess hatte seinen Ursprung in 
einer allgemeinen Verbesserung der Lebensverhältnisse, welche durch 
medizinische Innovationen wie Serumtherapie, Schutzimpfungen und allmählich 
auch durch spezifische Therapien gefördert wurde. Mit der Verfügbarkeit von 
Sulfonamiden und fungalen Antibiotika kam insofern nach dem 2. Weltkrieg ein 
historischer Wandel zum Abschluss. An dessen Ende hatten chronische 
Erkrankungen des Herz-Kreislaufssystems, Diabetes und anderes mehr den Platz 
der klassischen Volksseuchen im öffentlichen Gesundheitswesen aber auch im 
Bewusstsein ihrer Zeitgenossen übernommen. In den 1980er Jahren verdichtete 
sich eine ganze Reihe von teilweise schon vorgängigen Veränderungen in ein 
neues Bedrohungsszenario, in dem Infektionskrankheiten nun wieder einen 
prominenten Platz einnahmen. Als wichtige Stichworte seien AIDS, 
Antibiotikaresistenzen, die Neudefinition chronischer Krankheiten als ansteckende 
und schließlich die Karriere von neuen ‚Volksseuchen‘ wie der Grippe genannt. 
Wahrnehmung und Wirklichkeit sind jedoch zweierlei: Waren die 
Infektionskrankheiten jemals wirklich unter Kontrolle, inwiefern lassen sich die 
neuen und die alten Volksseuchen vergleichen, wie haben sich die Strategien ihrer 
Kontrolle im Laufe der Zeit verändert? Ausgehend von solchen und anderen 
Fragen möchte ich in meinem Vortrag dazu einladen, dass 20. Jahrhundert in seiner 
Gesamtheit als eine Epoche der Medizingeschichte zu begreifen. 
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BACTERIAL INFECTIONS AT ATOMIC RESOLUTION 
Heinz, D.W.1, Klink, B.U.1, Niemann, H.H.2, Ferraris, D.M.1
1Department of Molecular Structural Biology, Helmholtz Centre for Infection 
Research, Braunschweig, Germany. 
2Department of Chemistry, Bielefeld University, Bielefeld, Germany. 
Molecular mimicry is a common hallmark of the various strategies employed by 
pathogenic microorganisms during the infection of the human host. The skillful 
subversion of host cell processes by emulation can, for instance, allow adhesion 
and invasion into the host cell that are crucial steps during infection. We have been 
studying the mechanism of host cell invasion by the food-borne human pathogen 
Listeria monocytogenes, the causative agent of listeriosis. Using X-ray 
crystallography we have solved the structures of the so-called internalins, of which 
internalins A (InlA) and B (InlB) represent the two major listerial invasion 
proteins. While InlA directly interacts with human E-cadherin, promoting specific 
invasion into human epithelial cells, InlB recognizes and activates the receptor 
tyrosine kinase Met, the natural receptor for hepatocyte growth factor (HGF) 
allowing bacterial entry into a much wider spectrum of host cells. The structure of 
InlB in complex with human Met revealed InlB, which is structurally unrelated to 
HGF, perfectly mimics the function of the growth factor by activating its receptor 
by induced dimerization. To confirm the critical role of dimeric InlB in this process 
we used cross-linking experiments in which InlB-molecules were linked via
disulfide bridges to form covalent InlB-dimers that showed enhanced Met 
activation surpassing that of HGF. We anticipate a potential pharmaceutical use of 
cross-linked InlB in wound-healing processes that rely on Met activation based cell 
scattering.
In a second example we present structural information on a new class of proteins 
from Shigella sp., the cause of bacillary dysentery. These proteins act as perfect 
molecular mimics of guanosine nucleotide exchange factors involved in actin 
cytoskeleton dynamics, a central host cell process manipulated during bacterial 
invasion. 
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MÖGLICHKEITEN UND GRENZEN INDIVIDUALISIERTER MEDIZIN 
Kroemer H.K. 1
1Abteilung Allgemeine Pharmakologie, Zentrum für Pharmakologie und 
Experimentelle Therapie, Ernst Moritz Arndt Universität Greifswald.  
Das Gesundheitssystem der Bundesrepublik Deutschland steht vor großen 
Herausforderungen. Die rasch alternde Bevölkerung mit höherer 
Krankheitsprävalenz, zunehmender Multimorbidität und immer 
komplexeren Behandlungsmöglichkeiten erfordert eine konsequente 
Qualitätsentwicklung und die Optimierung des Ressourceneinsatzes. Als 
eine Option wird international die Individualisierte Medizin (Synonym 
„Personalisierte Medizin“) diskutiert. Mit ihr wird angestrebt, unter 
Zuhilfenahme modernster Diagnostik und durch Einsatz neuer, individuell 
auf die Bedürfnisse des Patienten ausgerichteter Therapieverfahren die 
Effektivität der Behandlung zu steigern, unerwünschte Effekte zu 
vermeiden, somit die Effizienz zu erhöhen und vermeidbare Kosten zu 
reduzieren. 
Insbesondere im Bereich einer Individualisierung der Therapie mit 
Arzneimitteln hat es in jüngster Zeit erhebliche Fortschritte gegeben. So 
konnte gezeigt werden, dass Patientinnen mit Brustkrebs, die einen 
genetischen Defekt in der CYP2D6 vermittelten Bioaktivierung von 
Tamoxifen haben, eine signifikant schlechtere Prognose aufweisen. 
Gleiches gilt für solche Patientinnen, die zusätzlich zu Tamoxifen mit 
Antidepressiva behandelt wurden, die ebenfalls dazu führen können, dass 
die Giftung von Tamoxifen nicht funktioniert. 
Eine Umsetzung personalisierter Medizin in die tägliche Praxis erscheint 
deswegen machbar, weil die dafür notwendigen Techniken für einen 
breiten Einsatz verfügbar sind. Die Lagerung von biologischen Proben 
großer Patientenkollektive erfolgt in automatisierten Biobanken. Die 
analytischen Verfahren zur Diagnostik dieser Proben (Genetik oder 
Proteindiagnostik) erfolgt mit Hochdurchsatzmethoden. Analysen des 
humanen Genoms zeigen, dass neben Umweltfaktoren die genetische 
Variabilität über Veränderungen im Proteom und Metabolom entscheidend 
zum individuellen Erscheinungsbild multifaktorieller Erkrankungen beiträgt.  
Im Kontext der Etablierung der personalisierten Medizin verändern sich 
auch konzeptionelle und theoretische Grundlagen der Medizin. Es 
entstehen neue Fragen der Probanden-/Patientenethik.
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COLLOIDS AS VACCINE DELIVERY SYSTEMS - KOLLOIDE ALS 
IMPFSTOFFTRAEGER  
Rades, T.1
1 The New Zealand National School of Pharmacy, University of Otago, PO Box 
913, Dunedin, New Zealand; thomas.rades@stonebow.otago.ac.nz ; Tel.: +64 3 
479 5410, Fax.: +64 3 479 7034 
With current gene and protein technology it is now possible to identify specific 
regions of some whole organisms or cells which are likely to be recognized by the 
immune system, and to reproduce them synthetically as subunit vaccines. These so 
called epitopes are very safe because they are non-living but they also tend to be 
only poorly immune stimulating.  
To improve the immunogenicity of a poorly immunogenic antigen, our approach is 
to use colloids as delivery systems.  Liposomal delivery systems and related lipidic 
particles are thought to enhance the immune response by more closely mimicking a 
virus or microorganism due to the possibility of multimeric antigen presentation 
and their larger size compared to subunit antigens.  
Our group has developed and characterised a range of colloidal delivery systems 
for the delivery of subunit vaccines:  
 Mannosylated liposomes  
 Adjuvant (Quil A) containing liposomes,  
 Immune stimulating complexes (ISCOMs),  
 Cationic ISCOMs (termed Pluscoms),  
 ISCOM implants,  
 Cubosomes.  
In this presentation an overview will be presented about the various colloidal 
delivery systems our group has developed for the delivery of subunit vaccines. 
New results in this field, both on physico-chemical characterisation and 
immunological activity of these colloidal carriers, will be presented.  
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THE GENOME AS A TOOL FOR CLINICAL PHARMACY 
Prof.  Howard L. McLeod, PharmD
UNC Institute for Pharmacogenomics and Individualized Therapy, Schools of 
Pharmacy and Medicine, University of North Carolina-Chapel Hill, Chapel Hill, 
NC, USA.  hmcleod@unc.edu 
The field of pharmacogenomics has seen some exciting advances in the recent past. 
The Human Genome Project and International HapMap projects have uncovered a 
wealth of information for researchers. This has lead to the discovery of clinically 
predictive germline genotypes (e.g. UGT1A1*28-irinotecan, TYMS TSER-
fluoropyrimidines, CYP2D6-tamoxifen), germline haplotypes (e.g. VKORC1 
Haplotype A-warfarin) and somatic mutations (e.g. epidermal growth factor 
receptor-gefitinib/erlotinib, KRas-cetuximab/panitumumab).  The introduction of 
FDA approved pharmacogenetic tests and the initiation of genotype-guided clinical 
trials to treat cancer and heart disease have provided the first steps towards the 
integration of pharmacogenomics into clinical practice.  It is also clear that there 
are many barriers to clinical application.  These include expanding the science to 
understanding the pathways of genes that regulate a drug’s activity.  This 
information can be used as potential clinical biomarkers for selecting which drug 
or dosage is more likely to provide benefit to a patient.  Genetic approaches are 
currently being used to assess the number of apparent genes/pathways involved in 
the cytotoxicity of a novel compound.  Genomic tools can also be used to 
illuminate the mechanism(s) of action of compounds that behave in a pattern that is 
unique amongst existing drugs.  There are also critical non-science issues, such as 
integration of new tests into health systems, changing old habits to allow 
application of new data, and the reality that the cost of both testing and the 
therapeutic options are a key driver in health care.  As the scientific evidence 
matures, we must think beyond our favorite aspect of translational science if we are 
to overcome the many obstacles to delivering more careful selection of cancer 
therapy.    
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DIE BEDEUTUNG VON STAMMZELLEN FÜR DIE DIABETES-
THERAPIE  
Seufert, J.1
1Abteilung Endokrinologie und Diabetologie, Universitätsklinikum Freiburg 
Für die Stammzelltherapie des Diabetes mellitus und anderer Erkrankungen 
stehen prinzipiell verschiedene Stammzell-Reservoirs mit jeweils spezifischen 
Vor- und Nachteilen zur Verfügung. Humane embryonale Stammzellen sind 
einfach zu isolieren und zu vermehren und können in insulinproduzierende Zellen 
differenzieren. Im Hinblick auf die ethische Problematik bei der Gewinnung von 
Stammzellen aus menschlichen Embryonen brachte der Nachweis, dass adulte 
somatische Körperzellen durch gezielte Manipulation in pluripotente Zellen mit 
embryonalen Charakter zurückgeführt werden können, einen entscheidenden 
Durchbruch, sogenannte induzierte pluripotente Stammzellen (IPS). Nach wie 
vor steht dem klinischen Einsatz aber das erhebliche tumorigene Potenzial dieser 
Zellen entgegen. Die gezielte Differenzierung adulter mesenchymaler 
Knochenmarksstammzellen ist technisch anspruchsvoller als die embryonaler 
Stammzellen, dafür können sie einfach und ethisch unproblematisch gewonnen 
werden. Erst seit kurzem weiß man, dass in den meisten Geweben kleine Menge 
adulter gewebsspezifischer Stammzellen vorhanden sind, deren Identifizierung 
und Isolierung sich aber schwierig gestaltet. Aus dem Pankreas wurden bislang 
duktale Stammzellen (aus dem Epithel der Pankreasgänge) und insuläre 
Stammzellen gewonnen, und es wurde gezeigt, dass aus humanen duktalen 
Stammzellen insulinproduzierende Zellen differenzieren können. Diese können 
aber derzeit in noch nicht ausreichender Menge für den klinischen Einsatz in vitro
hergestellt werden. Ein interessanter Aspekt ergibt sich aus der Beobachtung, dass 
das GLP-1 als Wachstumsfaktor für duktale Vorläuferzellen und für Betazellen 
fungiert. Damit können humanes GLP-1 und dessen Analoga zur Expansion von 
pankreasspezifischen adulten Stammzellen genutzt werden. Zumindest im 
Tierversuch konnte mit Exenatide auch schon eine Zunahme der Betazellmasse 
und eine Verbesserung der Diabeteseinstellung erzielt werden. 
Wir sind zusammenfassend aktuell an einem Punkt angekommen, an dem man 
mit Bestimmtheit davon ausgehen kann, dass in der Zukunft Strategien entwickelt 
werden können, um voll funktionelle insulinproduzierende Betazellen, aus 
welcher Quelle auch immer, für den therapeutischen Einsatz bei Patienten mit 
Diabetes mellitus zu generieren. 
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PHARMACOLOGICAL INHIBITORS OF CYCLIN-DEPENDENT 
PROTEIN KINASES RELEVANT TO CANCER. 
Meijer, Laurent 
C.N.R.S., Protein Phosphorylation & Human Disease Group, Station Biologique, 
29682 Roscoff, FRANCE (<meijer@sb-roscoff.fr>) 
Phosphorylation of serine, threonine and tyrosine residues represents one of the 
most common post-translational mechanisms used by cells to regulate their 
enzymatic and structural proteins. Alterations in the phosphorylation of proteins 
represent a frequent feature associated with human disease. This is the reason for 
an exponentially growing investment in the discovery, optimization and therapeutic 
evaluation of small molecular weight, pharmacological inhibitors of protein 
kinases. It is estimated that 30-35% of drug discovery programs in the 
pharmaceutical industry currently target a protein kinase! Presently, over 130 
kinase inhibitors are undergoing clinical evaluation against diseases such as 
cancers, inflammation, diabetes, and neurodegeneration. 
Among the 518 human kinases, our laboratory has focused its efforts on several 
families of serine/threonine kinases: cyclin-dependent kinases (CDKs), glycogen
synthase kinase -3 (GSK-3 and its Plasmodium ortholog PfGSK-3), casein kinases 
1 (CK1) and dual-specificity tyrosine phosphorylation regulated kinases (DYRKs). 
In particular, CDKs have attracted considerable interest because of their numerous 
key physiological functions such as regulation of cell division cycle, apoptosis, 
multiple neuronal activities, pain signaling, insulin release, transcription, RNA 
splicing, etc... Their involvement in human diseases such as cancers & leukemias, 
chronic & acute neurodegenerative disease (Alzheimer’s and Parkinson’s diseases, 
stroke), kidney diseases (glomerulonephritis, polycystic kidney disease), 
inflammation, type 2 diabetes, viral infections, unicellular parasites has been 
widely investigated and will be summarized. 
To illustrate the potential of pharmacological inhibitors of these kinases, we will 
describe a selection of CDK inhibitors derived from the clinical phase 2 drug 
roscovitine. The selectivity and intracellular mechanism of action of these 
compounds, their chemical synthesis and their pharmacological properties have 
been extensively studied and will be presented as representative examples of the 
multiple effects of kinase inhibitors in cells, tissues and organisms, and their 
therapeutic potential against selected cancers. The key role of the survival factor 
Mcl-1 and the transcription factor Myc in the action of CDK inhibitors will be 
highlighted. 
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HYPERFORIN – FROM THE HERB TO THE MOLECULE AND TARGET 
Müller, W.E.1, Leuner K.1
1Department of Pharmacology, Biocenter, Goethe University Frankfurt 
More than ten years ago we got interested in the antidepressant mechanism of 
Hypericum extract. We soon found out that similar to other antidepressants 
hypericum extract inhibits the neuronal uptake of serotonin, norepinephrine, and 
dopamine and that hyperforin is the responsible constituent. However, hyperforin 
was not an inhibitor of the respective transporters but inhibited neuronal uptake by 
elevating free intracellular Na+, thereby decreasing the sodium gradient over the 
neuronal membrane, the driving force for the amine transporter. In a next step we 
identified TRPC6 channels as the specific targets of hyperforin not only mediating 
Na+ but also Ca2+ influx. By breaking down the pharmacophor of hyperforin to 
simple substituted phloroglycinol derivatives we could demonstrate that the 
compounds share its target at the TRPC6 channel probably with its physiological 
activator diacylglycerol. Since antidepressant activity has recently been linked with 
neuroplasticity and TRPC6 channels are relevant for neuroplasticity phenomena 
our findings of substantial effects of hyperforin on neuritic outgrowth would 
suggest that it works as antidepressant not only by enhancing the extracellular 
levels of monoamines but also by directly activating neuronal plasticity. Again, 
these effects are only seen for hyperforin but not for other constituents of 
hypericum extract. TRPC6 channels not only promote neuronal differentiation but 
also reduce keratinocyte proliferation and promote their final differentiation. Our 
findings that hyperforin stimulates keratinocyte differentiation by activating 
TRPC6 channels are finally suggesting that its use in dermatological diseases e.g. 
atopic dermatitis might also be explained by activation of the same target as for its 
use as an antidepressant drug. 
Singer A, et al. (1999) J Pharmacol Exp Ther 290:1363-1368. 
Wonnemann M, et al. (2000) Neuropsychopharmacol 23:188-197 
Treiber K, et al. (2005) Br J Pharmacol 145:75-83 
Leuner K, et al. (2007) FASEB J 21:4101-4111 
Leuner K, et al. (2010) Mol Pharmacol 77:368-377 
Müller M, et al. (2008) J Biol Chem 283:33942-33954 
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ENTWICKLUNG NEUER ANTITUMORALER METALLKOMPLEXE 
Keppler, B. K.1
1Institut für Anorganische Chemie, Universität Wien 
Die chemische Diversität der Metallverbindungen eröffnet eine Fülle an Möglichkeiten 
für die Entwicklung antitumoraler Wirkstoffe. Derzeit werden u. a. Verbindungen von 
Ruthenium, Gallium und Lanthan in präklinischen und teilweise bereits in klinischen 
Studien untersucht.  Vor allem die Rutheniumverbindung NKP1339 hat bereits bei 
terminalen Tumorpatienten therapeutische Aktivität gezeigt. Die Wirkmechanismen 
sind vermutlich ebenso unterschiedlich wie das chemische Verhalten der 
Metallelemente (v. a. hinsichtlich Koordination- und Redoxchemie), die zytotoxischen 
Potenzen dieser Verbindungen korrelieren jedoch nicht notwendigerweise mit der 
Aktivität in vivo. 
Im Falle der heterozyklischen Rutheniumkomplexe wurden lange Zeit vor allem 
Interaktionen mit Serumproteinen und DNA untersucht, doch blieb v. a. die Relevanz 
der letzteren fraglich. Derzeit wird an der Identifizierung anderer, möglicherweise 
ausschlaggebender Targets gearbeitet. Weiters wurde die Aktivität im Tiermodell 
erhärtet, und die klinischen Studien wurden wieder aufgenommen. 
Der oral bioverfügbare Galliumkomplex KP46 erwies sich als besonders wirksam in 
der Primärzellkultur des malignen Melanoms, und eine erste klinische Studie erbrachte 
Hinweise auf eine Aktivität im Nierenzellkarzinom. Die lipophile Ligandensphäre 
dieser Verbindung hat nicht nur Auswirkungen auf die Biodistribution, sondern 
möglicherweise auch auf den Wirkmechanismus, der von anderen 
Galliumverbindungen abzuweichen scheint. 
Das antitumorale Potential der Lanthaniden wurde bis vor kurzem kaum untersucht. 
Die Lanthanverbindung KP772 wurde jedoch in vivo als wirksam erkannt, und 
multidrug-resistente Zellmodelle erwiesen sich als hypersensitiv gegenüber dieser 
Verbindung. Durch Langzeit-Behandlung lässt sich ein Verlust des MRP-1 und eine 
Resensitivierung gegenüber organischen Chemotherapeutika erreichen, was völlig neue 
Perspektiven für die Resistenz-Überwindung eröffnet. 
Auch auf dem Gebiet der Platinverbindungen können neue Fortschritte berichtet 
werden. So ergaben zuvor nicht untersuchte Struktur-Wirkungs-Beziehungen rund um 
die Oxaliplatin-Struktur Aufschlüsse für die Entwicklung wirksamer Derivate, 
während pH-sensitive Platin-Komplexe sowie Platin–Oxim-Komplexe mit aktiven 
trans-Isomeren als weitere vielversprechende Innovationen untersucht werden.
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STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE 
CYCLASE: FROM BENCH TO BEDSIDE 
Stasch, J.-P. 
Cardiovascular Research, Bayer Schering Pharma, Aprather Weg 18a, D-42096 
Wuppertal, Germany 
The soluble guanylate cyclase (sGC) is a key signal-transduction enzyme in the 
cardiovascular system and activated by NO. It became apparent that many 
cardiovascular diseases are associated with a dysfunction of the NO/sGC system. 
Importantly, two different forms of sGC exist in vivo, the native and heme-free 
sGC. sGC activators, such as cinaciguat (BAY 58-2667) are capable of selectively 
activating the haem-free enzyme via binding to the enzyme's haem pocket. These 
new compounds selectively target the dysfunctional sGC that is prevalent under 
disease conditions. Cinaciguat has demonstrated efficacy in patients with acute 
decompensated heart failure (ADHF), reducing pre- and afterload and increasing 
cardiac output. A clinical IIb study for the indication of ADHF is currently 
underway. sGC stimulators, such as BAY 41-2272 and riociguat (BAY 63-2521), 
show a dual mode of action: they sensitize sGC to the body's own NO while also 
directly stimulating sGC independently of NO. They may be beneficial in the 
treatment of a range of cardiovascular and non-cardiovascular disorders. Riociguat 
had beneficial effects on pulmonary haemodynamics, right heart hypertrophy, and 
remodeling of the pulmonary vasculature in animal models of pulmonary 
hypertension (PH). Riociguat has demonstrated efficacy in patients with PH, 
reducing pulmonary vascular resistance and increasing cardiac output. A clinical 
phase II study shows that riociguat significantly improves exercise capacity, 
hemodynamic and symptoms in patients with pulmonary arterial hypertension and, 
remarkably, also in patients with chronic thromboembolic pulmonary hypertension. 
Based upon the promising results, global phase III trials of riociguat in patients 
with different forms of PH are underway. 
Pl-12
POLYMERS FOR THE CONTROL OF CELL MATERIAL INTERAC-
TIONS ON THE MICRO- AND NANOSCALE 
Brandl, F.1, Tessmar, J.1, Breunig, M.1, Göpferich A.1
1Pharmazeutische Technologie, Universität Regensburg 
Numerous biomedical applications depend critically on the controlled interaction 
of cells with materials. Cellular responses upon material contact are in tissue engi-
neering and regenerative medicine applications of utmost significance since they 
decide over cell proliferation and differentiation. A strategy towards the control of 
these processes that was developed rather successfully in recent years is a biomi-
metic approach that relies on mimicking natural interaction mechanisms. For such 
applications, polymers have been developed that mimic macromolecular compo-
nents of the extracellular environment1. They bind to cell surface receptors that 
allow for cell signalling thus giving us the opportunity to control basic cellular 
processes. In these cases we provide cells with a microscopic environment that is 
larger than the cellular dimensions. Polymers play a similarly prominent role for 
the development of nanoscopic drug delivery carriers the dimensions of which are 
substantially smaller than that of a cell. Especially the search for novel materials 
that allow for specific cell entry has been intensified recently2. Such materials need 
to host substances like nucleic acids and have concomitantly to allow for specific 
interactions with cells. 
The requirements that applications on the micro- as well as on the nanoscale pose 
have tremendous implications for a polymer. While we have mastered to imple-
ment most basic requirements, like the ability to degrade, we are still trying to de-
sign polymers with a maximum degree of functionality. This is not a trivial task 
since we need to outfit them with almost mutually exclusive properties. On the one 
hand the polymers need to possess a certain degree of camouflage to avoid intrinsic 
unspecific interactions with cells especially off-target cells. Yet on the other hand 
they must be visible to their target with a maximum degree of selectivity and affin-
ity. This apparent paradox can only be resolved when we implement spatial and 
temporal variability into the structure of polymers. Along these design criteria a 
number of materials have been developed in recent years for sophisticated applica-
tions that will be reviewed during the presentation. 
[1] S. Drotleff et al., Europ. J. Pharm. Biopharm. 58 (2004) 385–407. 
[2] W. Hild et al., PNAS, 107 (2010) 10667-10672. 
Pl-13
EVIDENCE-BASED COMPLEMENTARY MEDICINE – A 
CONTRADICTION IN TERMS? 
E Ernst, Director, Complementary Medicine 
Peninsula Medical School, Universities of Exeter & Plymouth, UK 
Complementary medicine is popular. This is particularly true of Germany where 
about two thirds of population use such treatments each year. This level of 
popularity means that we should have good evidence about the effectiveness and 
risks of complementary medicine, and that we need to act according to this 
evidence. Summarizing the current knowledge, we observe the following: 
 Only few therapies are demonstrably effective. 
 Some seem to be demonstrably ineffective. 
 For many treatments, the effectiveness is unknown. 
 The risks are frequently under-researched. 
It follows that, in this area, more research is urgently needed. Evidence-based 
complementary medicine must not remain a contradiction in terms. As in all of 
medicine, only those methods should be employed that demonstrably generate 
more good than harm. 
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MICRO SYSTEMS FOR FORMULATION- AND PROCESS- 
PARAMETER-SCREENING 
Kwade, A.1, Büttgenbach, S.2, Klages, C.-P.3, Krull, R.4, Franco-Lara, E.4,
Kampen, I.1, Müller-Goymann, C.5, Bunjes, H.5, Radespiel, R.6, Kähler, C.7,
Augustin, W. 8, Scholl, S. 8
1Partikeltechnik, TU Braunschweig 2Mikrotechnik, TU Braunschweig 
3Oberflächentechnik, TU Braunschweig 4Bioverfahrenstechnik, TU 
Braunschweig, 5Pharmazeutische Technologie, TU Braunschweig 
6Strömungsmechanik, TU Braunschweig 7Strömungsmechanik und Aerodynamik, 
Universität der Bundeswehr München  8Chemische und Thermische 
Verfahrenstechnik, TU Braunschweig 
Micro systems feature many advantages like very effective mass and heat transfer, 
fast mixing, narrow residence time distributions, small educt and system volumes, 
very small product losses as well as small cleaning expenditure. The DFG research 
group „Micro Systems for particular Life-Science-Products“ develops and 
investigates micro systems for two different screening applications: On one side a 
micro system for the processing and formulation of nano scaled drug delivery 
systems (lipid nano particles) including their loading and on the other side micro 
bio reactor systems for the determination of advantageous conditions for cells 
cultivation. Key aspects of the research are the development and design of 
geometries and surfaces of micro systems for these two applications, the specific 
adjustment of stresses, mass and heat transport (e.g. oxygen and substrate 
delivery), the minimization of wear and adhered particles as well as securing 
Cleaning in Place (CIP). Moreover, experimental and numerical methods are 
developed with which the micro systems can be characterised and evaluated 
regarding fluid flow, particle stressing, wear, fouling and cleaning.  
The capability of the micro systems will be presented by discussing results of 
dispersing nano particles and emulsification of lipids in different high pressure 
micro channels as well as of the cultivation of yeast cells in micro bio reactors. The 
different high pressure geometries show different properties and advantages 
depending on the kind of process, dispersing or emulsification. Beside the process 
investigations the fluid flow in the different micro systems was investigated 
experimentally by Micro-Particle Image Velocimetry (μPIV) and numerically by 
CFD-simulations. Moreover, the micro systems were characterised regarding wear 
applying different surface coatings as well as adhesion of particles and micro 
organisms.
Key1-1
MICROBIOREACTORS – A SCREENING-TOOL FOR BIOLOGICAL 
PROCESSES
Krull, R.1, Edlich, A.1, Demming, S.2, Zadeh, S. A.3, Radespiel, R.3, 
Buettgenbach, S.2, Franco-Lara, E.1 
1Institute of Biochemical Engineering, 2 Institute for Microtechnology, 3 
Institute of Fluid Mechanics, Technische Universität Braunschweig 
 
In the last years the well-established usage of conventional microtiterplates is 
fundamentally refined by the introduction of micro-scale bioreactors as suitable 
tool for a wide range of interesting applications. A diffusion based microbioreactor 
(MBR) system operated with a reaction volume of 8 L is developed and 
characterized to intensify the process understanding in microscale cultivations. The 
device is composed of a glass bottom and a microstructured top layer made of gas 
permeable poly(dimethylsiloxane) (PDMS) using UV-depth and soft lithography. 
The potential of the MBR as screening tool for biological processes is evaluated. 
The advantage of the designed MBR is the use for the continuous cultivation mode 
by integrating online measurement technique for dissolved oxygen (DO) and 
optical density (OD) to measure biomass growth. The bioreactor geometry was 
chosen to achieve homogeneous flow during continuous process operation. CFD 
simulation data used for geometry design were verified via micro-particle-image 
velocimetry (PIV). In the used MBR geometry no concentration gradients 
occurred along the entire reaction volume because of rapid diffusive mixing. A 
homogeneous medium flow inside the growth chamber of the MBR can be 
realized. Undesirable bubble formation before and during operation was reduced 
by using degassed medium as well as moistened and moderate incident air flow 
above the PDMS-membrane. Due to this a passive oxygen supply of the culture 
medium in the device is ensured by diffusion through the PDMS-membrane. The 
oxygen supply itself was monitored online via integrated DO sensors based on a 
fluorescent dye complex. An adequate overall volumetric oxygen transfer 
coefficient as well as the mechanical stability of the device has been accomplished 
for a membrane thickness of 300 m. Experimental investigations consider 
measurements of DO and OD (online) for the biomass growth and the 
concentration of glucose and ethanol (offline) via HPLC in a modified Verduyn 
growth medium. The used model organism Saccharomyces cerevisiae DSM 2155 
tended to strong reactor wall growth. The reaction kinetics of the model organism 
estimated in the MBR were compared with data of a conventional 1L-stirred tank 
bioreactor system. 
Key1-2
PREPARATION OF LIPID NANOPARTICLES IN MICRO-
STRUCTURED SYSTEMS 
Bunjes, H.1, Fehr, S.1, Finke, J. H.1, Schur, J.1, Müller-Goymann, C. C.1,
Lesche, C.2, Büttgenbach, S.2, Gothsch, T.3, Kwade, A.3, Jasch, K.4,
Huzhalska, V.4, Kulik, A.4, Augustin, W.4, Scholl, S.4
1Institut für Pharmazeutische Technologie, 2Institut für Mikrotechnik, 3Institut für 
Partikeltechnik, 4Institut für Chemische und Thermische Verfahrenstechnik, 
TU Braunschweig 
Lipid nanoparticles are promising carrier systems for the delivery of lipophilic 
drugs. Their potential benefits in delivering insoluble substances such as sun 
protection pigments or water soluble biomacromolecules like proteins are also 
being explored. The most common way of preparing such particles is by high-
pressure homogenization of a coarse, premixed emulsion using the melted matrix 
materials if solid lipids are to be processed. This manufacturing method can easily 
be scaled up but the preparation of very small quantities, as would be beneficial for 
formulation screening, is currently not established. It was thus our aim to explore 
the use of microsystems for the small-scale preparation of lipid nanoparticles with 
at least similar product quality as high-pressure homogenized dispersions. 
Different types of microsystems were used instead of conventional homo-
genization valves to disperse the particles into the colloidal state. One approach 
employed different types of customized silicon microchannels in which the lipid 
phase is dispersed by different types of flow. The emulsification efficiency highly 
depended on the geometry of the channels as well as on the pressure applied. With 
multiple passes, mean particle sizes in the range of 100-200 nm could be prepared. 
Alternatively, the lipid phase was dispersed by extrusion of the coarse premix 
through nanoporous filters. Also with this method, particles with a mean size 
around 120 nm could be obtained depending on the pore size, extrusion conditions 
and the composition used. In optimized cases, extrusion resulted in very narrow 
particle size distributions after multiple passes. Very small batch sizes (1 ml) 
could be prepared when a handheld extruder was used but this method was more 
sensitive to sample composition than larger-scale extrusion. For the crystallization 
step, that is required for the preparation of solid lipid nanoparticles, the use of a 
micro heat exchanger, allowing very high cooling rates, was established. While the 
continuous crystallization of different triglyceride-based compositions was easily 
possible, a wax-based dispersion led to plugging of the heat exchanger channels 
during the crystallization process.  
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CHEMICAL RNOMICS - THE SEARCH FOR NEW REGULATORY 
RNAS 
Jäschke, A., Samanta, A., Strauß, B., Winz, M.
Institut für Pharmazie und Molekulare Biotechnologie, Ruprecht-Karls- 
Universität Heidelberg
Riboswitches are RNA sequences that directly sense – without the help of proteins 
– metabolite concentrations and thereby induce changes in gene expression. To 
date, there exists no biochemical screening method for isolating naturally occurring 
unknown riboswitches from biological samples.  
We are establishing a direct and unbiased experimental approach for the isolation 
of unknown riboswitches. This approach combines methods developed in 
functional proteomics and experimental RNomics and will allow isolating 
functional RNAs solely by their ability to bind a metabolite, without any prior 
knowledge about primary sequence or higher-order structure. The basis of this 
strategy is photoaffinity tagging. Metabolites are, by chemical derivatization, 
converted into photoaffinity probes that contain a photoreactive group and an 
affinity tag (e.g., biotin). After binding to their target RNAs, the probes will be 
photocrosslinked by UV irradiation, thereby creating a covalent linkage between 
RNA and affinity tag. After affinity chromatography, the isolated RNAs are 
amplified by a combination of adapter ligations and tailing methods. Adapter 
sequences are designed for direct use in next generation sequencing. Isolated 
metabolite-binding RNAs will be characterized biochemically. 
Key2-1
FLUORESCENCE SPECTROSCOPY BASED ANALYSIS OF SMALL 
INTERFERING RNA INTEGRITY DURING FORMULATION, 
TRANSFECION, AND INTRACELLULAR DISTRIBUTION 
Helm, M.1, Hirsch, M.1
1Pharmazeutische Chemie, Johannes Gutenberg Universität Mainz  
The field of therapeutic oligonucleotides has rebounded due to the development of 
small interfering RNAs (siRNAs). An upsurge is taking place in industry and 
academia alike, owing to the fact that applications of siRNA in life science 
research are of outstanding importance in their own right. A key feature of siRNAs 
is the reprogramming of a complex cellular mechanism, originally evolved to 
control gene expression. Reprogramming by siRNA includes redirecting catalytic 
RNase activity to a target mRNA of choice. Despite impressive advances in 
pharmaceutical chemistry, biology, and technology, the efficiency of different 
siRNAs, once delivered into the cell, is still variable. Moreover, most of the 
delivered siRNA material does not reach its final destination in the catalytic 
complex intact. Conjugation of siRNA to dyes that form donor-acceptor pairs in 
fluorescence resonance energy transfer (FRET), allows tracing the distribution of 
intact siRNA during nanoscale formulation and across the various subcellular 
compartments. Intact siRNAs performs a movement into the nucleus and out again, 
before being subject to degradation, which leads to perinuclear accumulation of 
siRNA debris. We are currently characterizing differential distribution patterns of 
siRNAs from different formulations, with various chemical modifications, and of 
distinct biological activity. 
Key2-2
REPRESSION OF THE PROTO-ONCOGENE PIM-1 BY MIR-33A 
Hartmann, R.K. 1, Thomas, M.1, Lange-Grünweller, K.1, Weirauch, U.2, Gutsch, 
D.2, Aigner, A.2, Grünweller, A.1
1Pharmazeutische Chemie, Philipps-Univ. Marburg  
2 Institut für Pharmakologie, Medizinische Fakultät, Philipps-Univ. Marburg, 
The constitutively active serine/threonine kinase Pim-1 is upregulated in several 
cancer types, mainly based on the action of several interleukines and growth 
factors at the transcriptional level. In contrast, a regulation of Pim-1 by miRNAs, 
which may well add to the differential expression in tumor versus normal cells, has 
not been reported so far. Tumor relevant miRNAs may either act as oncogenic 
miRNAs or exert tumor suppressor activity. Here we newly establish miR-33a as a 
miRNA with tumor suppressor activity, and demonstrate that it acts through 
inhibition of the oncogenic kinase Pim-1 as a natural miR-33a target. A screen for 
miRNA expression in K562 lymphoma and LS174T colon carcinoma cells 
revealed only low endogenous miR-33a levels relative to other miRNAs, such as 
the oncogenic miR-17-5p or miR-20a. Transfection of the two cell lines with miR-
33a mimics reduced Pim-1 levels. In contrast, another kinase involved in cell cycle 
regulation and predicted by TargetScan 5.1 with an even higher score, Cdk6, was 
found to be no target for miR-33a regulation. Seed mutagenesis of the Pim-1 3'-
UTR in a luciferase reporter construct demonstrated the specificity of the miR-33a-
dependent downregulation. The transfection of K562 and LS174T cells with a 
miR-33a mimic decelerated proliferation without inductin of apoptosis. The 
persistence of this effect was comparable to that of an siRNA-mediated knockdown 
of Pim-1. We further provide evidence for a role of Pim-1 in promoting cell cycle 
progression at G1- to S-phase and G2- to M-phase transitions. In conclusion, we 
demonstrate the potential of miR-33a to act as a tumor suppressor miRNA and 
identify an underlying mechanism based on deceleration of cell cycle progression 
upon downregulation of Pim-1, which suggests miR-33a replacement therapy 
through forced expression as a novel therapeutic strategy. 
Key2-3
PARADOCKS - A FRAMEWORK FOR MOLECULAR DOCKING WITH 
POPULATION-BASED METAHEURISTICS 
Meier, R.1, Pippel, M.2, Baldauf, C.3, Sippl, W. 2
1Institut für Biochemie, Universität Leipzig 2Pharmazeutische Chemie und 
Klinische Pharmazie, MLU Halle-Wittenberg 2 Theory Department, Fritz-Haber-
Institut der MPG 
Molecular docking is a simulation technique that aims to predict the binding pose 
between a ligand and a receptor. The resulting multi-dimensional continuous 
optimization problem is practically unsolvable in an exact way. One possible 
approach is the combination of an optimization algorithm and an objective function 
that describes the interaction. The software is designed to hold different 
optimization algorithms and objective functions. At the current stage, an adapted 
particle-swarm optimizer (PSO) is implemented. Available objective functions are: 
(i) the empirical objective function p-Score, and (ii) an adapted version of the 
knowledge-based potential PMF04. We tested the docking accuracy in terms of 
reproducing known crystal structures from the PDBbind core set. For 73 % of the 
test instances the native binding mode was found with an rmsd below 2 Å. The 
virtual screening efﬁciency was tested with a subset of 13 targets and the respective 
ligands and decoys from the directory of useful decoys (DUD). ParaDockS with 
PMF04 shows a superior early enrichment. The here presented approach can be 
employed for molecular docking experiments and virtual screenings of large 
compound libraries in academia as well as in industrial research and development.  
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SEEING THE WOOD, NOT ONLY THE TREES - SYSTEMS CHEMICAL 
BIOLOGY 
Scheiber, J.1
1Disease & Translational Informatics, Roche Diagnostics GmbH, Penzberg 
The vast majority of virtual screening approaches aims to identify compounds that 
are active against a particular target. Such a reductionist approach usually does not 
consider both the interaction of targets within biological systems and possible 
polypharmacological activities of compounds.  
This talk will give a general overview of these concepts and recent successes in 
applying them.  
Key3-2
PHARMACOPHORE-BASED VIRTUAL SCREENING: AN EFFICIENT 
TOOL FOR BIO-ACTIVITY PROFILING AND AFFINITY PREDICTION 
Wolber, G.1
1Pharmazeutische Chemie, FU Berlin, Institut f. Pharmazie, Königin-Luisestr. 
2+4, 14195 Berlin 
Virtual screening using three-dimensional arrangements of chemical features (3D 
pharmacophores) has become an important method in computer-aided drug design. 
Although frequently used, considerable differences exist in the interpretation of 
these chemical features and their corresponding 3D overlay algorithms. We have 
recently developed an efficient and accurate 3D alignment algorithm based on a 
pattern recognition technique [1]. In the presented work, we extend this algorithm 
to be used for high-performance virtual database screening and investigate, 
whether applying this geometrically more accurate 3D alignment algorithm 
improves virtual screening results over conventional incremental n-point distance 
matching approaches. Additionally, the application of pharmacophore-based virtual 
screening algorithms for drug-repurposing and activity profiling will be discussed. 
[1] G. Wolber, A. Dornhofer, and T. Langer. Efficient overlay of small molecules 
using 3-D pharmacophores. J. Comput.-Aided Mol. Design, 20(12): 773-788 
(2006) 
Key3-3
BIOENGINEERING OF GLUCORAPHANIN FROM BROCCOLI 
Halkier, Barbara Ann
Department of Plant Biology and Biotechnology, Faculty of Life Sciences, 
University of Copenhagen 
Epidemiological studies have demonstrated reduced risk of developing cancer upon 
consumption of diets rich in cruciferous vegetables. Key players in this 
chemoprevention are the natural products glucosinolates, in particular the 
methionine-derived glucoraphanin which is highly abundant in broccoli. Improved 
nutrition by functional foods or health-promoting dietary supplements is an 
attractive means for prevention of lifestyle-based diseases. Towards this goal, we 
have transferred the entire glucoraphanin biosynthetic pathway consisting of 
thirteen genes from Arabidopsis into the non-cruciferous tobacco by transient 
expression. The engineering involves the chloroplast-localized chain elongation 
machinery (5 genes) that converts methionine to dihomomethionine, and the 
cytosolic, ER-anchored core structure pathway ((8 genes) that converts 
dihomomethionine to the glucoraphanin. Transport engineering is important to 
ensure efficient channeling of intermediates between compartments and proper 
storage of end product to prevent feedback inhibition, but not much attention has 
so far been given to this aspect of engineering. Our progress in development of a 
technology platform for transport engineering will be discussed, as will our 
technology platform for engineering plant pathways into yeast.  
1) Mikkelsen et al. (2010) Reconstitution of the glucoraphanin biosynthetic 
pathway. Molecular Plant (in press)  
Key4-1
ENGINEERING ARTEMISIA ANNUA FOR ARTEMISININ 
PRODUCTION 
Liu, B.Y.1,2, Wang, H.1, Du, Z.G.1, Li, G.F.1, Ye, H.C.1
1Key Laboratory of Photosynthesis and Environmental Molecular Physiology, 
Institute of Botany, The Chinese Academy of Sciences.  
2Pharmazeutische Biologie, TU Braunschweig 
Artemisinin (also called qinghaosu) is a sesquiterpene lactone with an unusual 
1,2,4-trioxane ring structure. It was isolated from the herb Artemisia annua L. by 
Chinese scientists in an effort of searching for novel antimalarial drugs in the 
1970s. Artemisinin derivatives have provided the basis for the most effective 
treatments of multi-drug resistant and cerebral malaria, particularly in the form of 
artemisinin-based combination therapies (ACTs) which are advocated by the WHO 
in order to reduce the odds of resistance development. Artemisinin derivatives 
inactivate or kill gametocytes of Plasmodium spp. by inhibition of the 
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) after activation by iron ions. 
Besides the antimalarial activity, artemisinins have been reported to possess 
antiviral, anticancer and antischistosomal activities.  
A. annua is the only plant species known to synthesize and accumulate artemisinin. 
Since the detection of antimalarial activity of artemisinin, a lot of efforts including 
chemical synthesis, plant cell cultures, hairy roots and fermentation of engineered 
microorganism etc. have been made to increase the production of this compound. 
However, none of them are competitive and the A. annua plant is still the only 
commercial source of artemisinin. The low content of artemisinin in A. annua,
ranging from 0.1to 1% of dry weight, makes artemisinin relatively expensive. In 
addition, it is hard to meet the demand of over 100 million courses of ACTs per 
year. Therefore, one of the most promising approaches to reduce the price of ACTs 
is metabolic engineering of the A. annua plant to obtain higher artemisinin content 
in the transgenic lines. In the past decade, we have established an Agrobacterium-
mediated transformation system of A. annua and successfully transferred a number 
of genes related to artemisinin biosynthesis into the plant. Various aspects of these 
efforts will be presented. 
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LONG-TERM STORAGE OF UNDIFFERENTIATED PLANT CELLS 
FOR PRODUCTION OF HIGH VALUE SUBSTANCES 
Heckenmüller, H.1, Selge, T.1 Wilke, S.1 Schütte, K.1 Gorr, G.1
1Phyton Biotech GmbH, Alter Postweg 1, 22926 Ahrensburg 
Medicinal plants have been always considered a healthy source of life and today 
numerous pharmaceutically active substances are at least based on chemical 
structures which have been isolated from plants. Due to the huge chemical 
complexity of the substances of interest in many cases the biosynthetic pathway 
requires subsequent chemical modifications which are catalysed by specific 
enzymes. Therefore the specific plant cells which comprise these sets of enzymes 
are the best resources for the supply of the natural substance as seen for paclitaxel - 
a secondary metabolite isolated from Taxus sp..
Moreover it has been shown that the production of secondary metabolites with 
plant cell fermentation – e.g. the production of paclitaxel - not only is valuable but 
at the same time allows the supply of the substance of interest at high quality. 
For a robust and reliable industrial scale production process consistency and 
stability of the used cell material is required. In case of undifferentiated plant cells 
it has been shown that long-term storage of the material can be performed by 
cryopreservation. This well known technology is a method to conserve living cells 
but it allows to secure cells at a defined status and to recover this status even many 
years later, too. As a consequence every new production cycle can be started from 
plant material which has been recovered from cryopreserved cells thus allowing for 
a high batch-to-batch consistency. This procedure has been applied successfully for 
the paclitaxel production since 1997 and is still ongoing. 
Although long-term storage of plant material is feasible for many plant species – 
our cell bank comprises cryopreserved material from hundreds of different plant 
species - the substance profiles prior and post freezing have to be investigated 
seriously case by case. 
Stability tests performed at Phyton indicate that cryopreserved cell banks are a 
valuable source for the production of natural-based actives to be used in the 
pharmaceutical and health care industry.  
Key4-3
INDIVIDUALIZATION OF ANTICANCER DRUG DOSING BASED ON 
PHARMACOKINETIC PRINCIPLES 
Hempel, Georg
Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, 
Universität Münster 
It is generally believed that for anticancer drugs the maximal tolerable dose is also 
the most effective dose, although this postulate is not necessarily true for all drugs. 
In oncology, many drugs are administered in doses very close to the maximum 
tolerated dose and, therefore, display a narrow therapeutic range. 
In clinical practise, dosing of cytostatic drugs is based on body surface area (BSA). 
The rationale for this procedure is that the metabolic rate of the body as well as the 
volume of the extracellular space correlates well with BSA. Thus, as metabolic rate 
often correlates with the drugs` clearance and extracellular volume correlates with 
the volume of distribution of not too lipophilic drugs, BSA can be used to achieve 
comparable AUC`s as well as maximum concentrations (Cmax) for most of the 
patients. Although this practise has been questioned in general, in heterogeneous 
populations BSA-dosing is the method of choice today as long as other approaches 
are not tested and validated. As an alternative, allometric scaling was suggested for 
children as a general approach of size-adjusted dosing. 
For drugs being excreted mainly by glomerular filtration, formulae for dosing 
based on glomerular filtration rate were developed and evaluated. For carboplatin, 
the method of defining a target AUC and calculating the dose based on renal 
function is now established in clinical routine.  
However, for many situations drug monitoring is recommended. For example, it is 
mandatory to adjust the administration of the leucovorin rescue after high-dose 
methotrexate (Mtx) therapy according to Mtx plasma concentration measurements. 
In leukaemia patients, asparaginase activity has to be controlled due to possible 
formation of inactivating antibodies. Dose individualisation of Busulfan based on 
plasma concentration measurements is done in some clinical centres. For patients 
receiving high-dose therapy before bone marrow transplantation, it would be 
desirable to have plasma concentrations of the cytostatic drugs in order to improve 
safety of these very risky treatment regimens. However, it is an analytical and 
logistic challenge to monitor drugs like cyclophosphamide and their highly 
unstable active metabolites in clinical routine. 
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INDIVIDUALIZATION OF ANTICANCER DRUG TREATEMENT 
BASED ON PHARMACOGENETIC FACTORS 
Ritter, Christoph A
Institute of Pharmacy, Clinical Pharmacy, Ernst-Moritz-Arndt-University of 
Greifswald 
Genetic alterations are pivotal events in the development of neoplastic diseases. 
With the advent of extremely sensitive and broad high throughput gene analysing 
techniques such as fine tiling comparative genomic hybridization (CGH) and deep 
sequencing methods the tumor genome is now readily accessible. The 
identification of genetic aberrations and the characterization of their functional 
consequences have created marked improvements for cancer diagnostics, treatment 
stratification, and have even resulted in new and specifically targeted therapies. 
One of the great milestones in this respect was the development of the Bcr-abl-
kinase inhibitor imatinib (Gleevec®) which is now an irreplaceable drug in the 
treatment of several types of Philadelphia chromosome-positive leukemia as well 
as subsets of gastrointestinal stromal tumors. On the other hand genetic alterations 
also affect genes that are involved in the metabolism and excretion of anticancer 
drugs. For instance, nucleoside analogs such as mercaptopurine or thioguanine 
which are mainstays for treatment of acute leukemias are heavily metabolized to 
active and inactive compounds. Genes involved in these processes include, most 
notably, thiopurine S-methyltransferase (TPMT), but other genes, i.e the drug 
transporter ABCC4 seem to be involved in thiopurine disposition as well. Genetic 
variation in these genes results in either toxicity or treatment failure. Taking all this 
into account, successful cancer treatment relies on a good knowledge of the genetic 
driving forces of progression of the individual tumor as well as the genetic 
variability of genes that affect disposition of the individually selected drugs at the 
tumor site. Considering the need for individual tumor testing, only few genetic 
diagnostic tools are available for routine use and mandatory or recommended by 
drug regulation authorities. And even those do not entirely reflect the genotype-
phenotype correlation as has recently been shown for the TPMT testing, which 
denotes the complexity of these processes. The possibility of whole tumor genome 
sequencing will certainly propel individualization of tumor treatment, but for a 
whole understanding genetic testing ultimately needs to be combined with miRNA 
pattern analysis, tumor epigenetics and the identification of treatment guiding 
biomarkers.  
Key5-2
INDIVIDUALIZATION OF ANTICANCER DRUG THERAPY USING 
BIOMARKERS 
Jaehde, U.
Institute of Pharmacy, Clinical Pharmacy, Universität Bonn 
Pharmacokinetic/pharmacodynamic principles are increasingly applied in order to 
to define and optimise dosage regimens. In oncology, this methodology has not 
been used widely due to the lack of pharmacodynamic markers that can be 
frequently measured. In contrast to the classical cytotoxic drugs, for most targeted 
drugs biomarkers are available of which some are easily measurable in the 
patients´ plasma.  
This approach seems to be particularly promising for drugs with antiangiogenic 
properties which have been shown to influence blood pressure and plasma 
concentrations of various proteins (VEGF-A, soluble VEGFR-2 and VEGFR-3) 
The response to these biomarkers has been associated with clinical outcome, 
particularly in renal cell carcinoma patients. Therefore, it seems promising to 
integrate biomarker concentrations as pharmacodynamic markers into PK/PD 
models.   
We conducted an explorative study in healthy subjects to investigate the 
concentration-effect relationship for sunitinib and its active metabolite SU12662. 
Based on drug and biomarker measurements, we developed semi-mechanistic 
pharmacokinetic/pharmacodynamic (PK/PD) models using NONMEM (Lindauer 
et al. 2010). Recently we have shown that these models can also be used to predict 
drug and metabolite concentrations as well as biomarker response in patients with 
metastatic colorectal cancer patients (see Kanefendt et al., this conference). The 
drug, metabolite and biomarker concentration-time profiles simulated by using the 
final PK/PD models will then be analyzed for correlations with clinical effects of 
the drug (response, toxicity). In the next step, clinical data, e.g. tumor size, can be 
incorporated in order to develop integrated ‘PK/PD/outcome models’. 
In conclusion, the development of semi-mechanistic PK/PD models based on 
biomarker data is feasible for targeted anticancer drugs. Future studies will reveal 
the potential to individualize therapy, e.g. by defining an optimal dosage regimen 
for each individual patient. 
Reference: 
Lindauer A et al. Clin Pharmacol Ther 2010;87:601-608
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STABILIZING INACTIVE KINASE CONFORMATIONS WITH SMALL 
ORGANIC MOLECULES 
Rauh, D.1
1Chemical Genomics Centre of the Max Planck Society, Max Planck Institute 
Dortmund 
The complexity of kinase biology is controlled by layers of regulatory mechanisms 
involving different combinations of post-translational modifications, 
intramolecular contacts, and intermolecular interactions. Ultimately, these 
mechanisms achieve their effect by favoring particular conformations that promote 
or prevent the kinase domain from catalyzing protein phosphorylation. A more 
detailed understanding of the structural principles that regulate protein kinase 
activity allowed us to develop a novel fluorescence-based binding assay (FLiK) for 
the identification and optimization of inhibitors that stabilize enzymatically 
incompetent kinase conformations. 
Key6-1
PLANT POLYKETIDE SYNTHASES IN THE BIOSYNTHESIS OF 
ACTIVE CONSTITUENTS 
Beerhues, L.
Pharmazeutische Biologie, TU Braunschweig 
Plants produce a huge array of natural products which display a range of biological 
activities. Plant constituents have long been exploited by humans as sources of 
drugs and continue to play an important role in drug discovery, either as the actual 
drug substances, semisynthetic derivatives or synthetic analogues. A major group 
of plant-derived natural products are polyketides which are formed by a family of 
homodimeric enzymes, called type III polyketide synthases (PKSs). A rare starter 
substrate for PKSs is benzoic acid. We detected and expressed in E. coli two plant 
type III PKSs that condense benzoyl-CoA with three malonyl-CoAs to form either 
a benzophenone or a biphenyl, thus referred to as benzophenone synthase and 
biphenyl synthase, respectively. Benzophenone metabolism, e.g. in Hypericum
species, involves a number of active polyprenylated polycyclic compounds and 
biphenyl derivatives are defence metabolites of apple. 
Reprogramming of biosynthetic pathways is an attractive approach of 
modifying the structures of natural products. Enzymes can be engineered to accept 
altered substrates and/or to produce new types of products. Enzymatic steps can be 
added or blocked. These metabolic engineering strategies have been successful in 
microorganisms but have not been widely explored to yield unnatural natural 
products from complex, lengthy plant pathways. Heterologous production of plant 
constituents in recombinant microorganisms is still often limited by the paucity of 
cloned genes involved. 
We subjected benzophenone synthase to site-directed mutagenesis. The enzyme 
was converted by a single amino acid substitution in the active site cavity 
(Thr135Leu) into a functional phenylpyrone synthase, a novel type III PKS variant.
The dramatic change in both product and substrate specificities was rationalized by 
homology modeling. A new pocket may be opened by the point mutation. Two 
isoenzymes of biphenyl synthase were found to prefer salicoyl-CoA as a starter 
substrate, leading to formation of 4-hydroxycoumarin, a precursor of dicoumarol. 
These findings provide the chance of generating new natural products in transgenic 
plants and derived tissue cultures that express engineered enzymes. 
J. Biol. Chem. 2009, 284, 30957; Plant Mol. Biol. 2009, 72, 17 
Key6-2
CHEMOENZYMATISCHE WIRKSTOFF-SYNTHESE  
Müller, M. 
Institut für Pharmazeutische Wissenschaften, Albert-Ludwigs Universität 
Freiburg
Naturstoffe bieten als privilegierte Strukturen einen erfolgversprechenden Einstieg 
in die Wirkstofffindung. Wir nutzen die durch die Biosynthese vorgezeigten 
Produktionsrouten in Kombination mit Diversitäts-orientierter Synthese zur 
Darstellung neuer potentieller Wirkstoffe.
Natur-
stoffe
Wirkstoffe Biosynthese
Biokatalyse
Die Vielfalt der Naturstoffstrukturen stellt einen der Gründe für deren Eigenschaft 
als ‚privilegierte’ Strukturen dar. Gleichzeitig ist dies aber auch von Nachteil bei 
dem Versuch ‚biomimetische’ Syntheserouten hin zu definierten Zielmolekülen zu 
etablieren. Während die Natur auf oftmals rasch wechselnde Bedingungen flexible 
Antworten finden musste, dient die zielorientierte Synthese der selektiven 
Darstellung eines Produktes mit optimierten Eigenschaften für eine bestimmte 
Anwendung. 
Von uns wird eine biomimetische Synthesestrategie basierend auf methodischen 
Untersuchungen der Biosynthese propagiert. Dies resultiert in einer chemo-
enzymatischen Synthese einer Vielfalt von Produkten unter Verwendung biokata-
lytischer in-vitro und in-vivo Transformationen in Kombination mit selektiven 
nicht-enzymatischen Syntheseschritten.  
Hiermit werden die Vorteile enzymatischer Synthesen, hohe katalytische Aktivität, 
ausgeprägte Selektivität und mögliche Übertragbarkeit in Ganzzell-Produktions-
prozesse, mit denen der nicht-enzymatischen Methoden, breite Substrattoleranz 
und Produktvielfalt, in hervorragender Weise kombiniert. Im Endeffekt resultiert 
dies in einem Zugang zu einer Naturstoff-ähnlichen Strukturvielfalt mit einer 
hohen Wahrscheinlichkeit für biologische Aktivität. 
Key6-3
BIG IS BEAUTIFUL – HESylation® AS AN EXAMPLE FOR DRUG-
POLYMER CONJUGATES 
Vorstheim, P. 
BU HESylation Technology, Kabi Innovation Centre, Fresenius Kabi Deutschland 
GmbH, Bad Homburg  
Drug delivery systems play a crucial role in optimising drug properties. Within the 
last decade polymers conjugated to pharmaceutically active molecules have 
emerged as one of the preferred tools in modern pharmaceutical development 
enabling the scientist to tailor the properties of the drug. Due to polymer 
conjugation the increase of the molar mass leads to reduced kidney excretion and 
results in a prolonged plasma half life of the drug. Furthermore, the shielding of the 
drug with the polymer may reduce the recognition of the immune system and its 
consequential clearance from the body. These effects have been demonstrated for 
several macromolecule classes, the most frequently used being poly ethylene 
glycol (PEG), albumin and poly carbohydrates like hydroxyethyl starch (HES). 
HES products have been widely used as plasma volume expander in clinical 
practice for decades. They show an unprecedented safety record with daily 
administration exceeding 200g for adults. Their biodegradability is well known and 
there are no negative effects on the inflammatory system. Even after repeated 
infusions, HES in not accumulated in the blood plasma. Allergic reactions were 
found at 0.06% of patients and its immunogenicity was reported to be neglectible. 
The HESylation® Technology platform is based on the extensive expertise in the 
field of HES: a drug delivery technology linking HES derivatives to drug 
substances has been established by Fresenius Kabi, the world’s largest producer of 
pharmaceutical grade HES.  
Like PEGylation Fresenius´ HESylation® Technology allows the targeted 
modification of drugs by site-specific coupling. Besides plasma half life, HES-
coupling frequently improves key parameters such as bioavailability, solubility, 
stability and safety parameters of the respective drug. A broad portfolio of process 
variants, coupling chemistries and specific chemical linkers have been developed 
to allow for a wide range of customised HES drug conjugates. At present, the most 
important application for the HESylation® Technology is seen in the area of 
biopharmaceuticals.  
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NEUE STRATEGIEN ZUR VERLÄNGERUNG DER HALBWERTSZEIT 
REKOMBINANTER PROTEINE
Kontermann, Roland
Institut für Zellbiologie und Immunologie, Universität Stuttgart, Allmandring 31, 
70569 Stuttgart 
Die therapeutische Anwendung von kleinen Proteintherapeutika ist oft durch die 
kurze Halbwertszeit limitiert. Strategien zur Verlängerung der Halbwertszeit 
rücken deshalb zunehmend in das Interesse der pharmazeutischen Forschung und 
Entwicklung. Dies beinhalten Strategien zur Vergrößerung des hydrodynamischen 
Radius, z.B. durch Konjugation hydrophiler Polymere und Kohlenhydrate, aber 
auch die Fusion an Plasmaproteine, wie z.B. Albumin, bzw. albuminbindende 
Strukturen. Neben einer Größenzunahme kann hierdurch auch ein Recycling über 
den neonatalen Fc-Rezeptor implementiert werden. Die Grundlagen als auch die 
Auswirkungen auf die Halbwertszeit verschiedener Strategien (PEGylierung, N-
Glycosylierung, Fusion an humanes Serumalbumin, Fusion an eine 
Albuminbindedomäne von Protein G) werden anhand eines rekombinanten 
bispezifischen Antikörpermoleküls vergleichend dargestellt.   
Key7-2
NEXT GENERATION SITE-SPECIFICALLY PEGYLATED FVIII FOR 
THE TREATMENT OF HEMOPHILIA A 
Apeler, H. 
Global Biologics - Cell & Protein Sciences, Bayer Schering Pharma AG, 
Wuppertal
Hemophilia A is caused by deficiencies in coagulation factor VIII (FVIII) and is 
the most common hereditary coagulation disorder. FVIII circulates as a 
heterodimer composed of a heavy chain of approximately 200 kDa and a light 
chain of 80 kDa. It consists of the structural domains A1-A2-B-A3-C1-C2. 
The current treatment for hemophilia A involves intravenous injection of 
recombinant (rFVIII) or plasma-derived human FVIII. Injections of FVIII are 
either given on demand in response to a bleeding event or as a prophylactic therapy 
that is administered 2 to 4 times a week. The requirement for frequent injections is 
primarily due to the short circulating FVIII half-life of 12 to 14 hours in patients. 
In order to improve the therapeutic properties of FVIII for hemophilia patients, 
recombinant B-domain deleted human FVIII (FVIII-BDD) was modified at various 
positions by site specific PEGylation. The resulting PEGylated BDD muteins were 
evaluated for FVIII activity and plasma half-life. Activity assays showed that FVIII 
activity was retained following PEGylation. In vitro characterization was 
consistent with PEGylation occurring at the intended locations. Pharmacokinetic 
studies identified muteins with an increased plasma half-life. In bleeding models of 
hemophilic mice, PEGylated FVIII-BDD not only exhibited prolonged efficacy 
that is consistent with the improved pharmacokinetics but also showed efficacy in 
stopping acute bleeds comparable with that of unmodified rFVIII. In summary site-
specifically PEGylated FVIII has the potential to be a long-acting prophylactic 
treatment while being fully efficacious for on-demand treatment for patients with 
hemophilia A. 
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EMULSIFICATION (O/W) IN MICROCHANNEL GEOMETRIES FOR 
PHARMACEUTICAL SCREENING APPLICATIONS 
Lesche, C.1, Holle, A.1, Finke, J. H.2, Müller-Goymann, C.2, Büttgenbach, S.1 
1Institut für Mikrotechnik, TU Braunschweig 
2Pharmazeutische Technologie, TU Braunschweig 
In pharmaceutical industry, emulsification processes are of high relevance for the 
handling of active ingredients. Typically very valuable agents are applied. These 
are on the one hand very expensive and on the other hand only exist in small 
quantities. To reduce both, expenditure of cost and time for the development of 
such pharmaceuticals during agent and formulation screening, a handling 
procedure has to be provided for these small quantities. Microsystem technologies 
offer several advantages concerning this aspect, such as small fluid volumes and 
precise control of process conditions. In the framework of the DFG research unit 
856 mikroPART a microsystem for O/W emulsification was developed. The used 
formulation is Miglyol® 812 as dispersed phase and distilled water as continuous 
phase. To keep the droplets stable, 3 % Solutol® HS 15 is added to the continuous 
phase. The microsystem consists of one inlet for the disperse phase, at least one 
inlet for the continuous phase, a droplet formation zone in the middle and one 
outlet for the obtained emulsion. It consists of a structured top base made of 
poly(dimethlysiloxane) (PDMS) which is bonded to a glass bottom to attain a 
closed microfluidic device. This material combination allows microscopic 
observation during emulsification process because of the given transparency of 
both materials. The influence of the channel geometry on the droplet formation was 
analyzed according to the two known principles: T-junction and flow-focusing. For 
both cases the design and size of the droplet formation zone was modified: the inlet 
of the disperse phase at the T-junction and the nozzle geometry of the flow-
focusing systems. For the later design the angle between the inlets of the two 
phases was varied. In general, acute angles lead to larger droplets. Besides the 
geometrical influence, the dependence between the volume flow ratio 
Qcontinuous/Qdispers and the resulting droplet size was analyzed. With increased 
volume flow ratios, a decrease in droplet size can be attained. The presented 
microsystems generate well controllable, monodispersed emulsions. Depending on 
the volume flow and the microchannel geometry, oil droplets were generated with 
minimal diameters of 30 m. 
T1-1
USING MICRO HEAT EXCHANGERS FOR PHARMACEUTICAL 
APPLICATIONS  
Schoenitz, M.1, Jasch, K.1, Augustin, W.1, Huzhalska, V.1, Kulik, A.1, Fehr, S.2,
Bunjes, H.2, Finke, J.H.2, Müller-Goymann, C.2, Scholl, S.1
1Institut für Chemische und Thermische Verfahrenstechnik, TU Braunschweig 
2Institut für Pharmazeutische Technologie, TU Braunschweig 
Micro-structured systems offer many advantages compared to macro-scale systems 
among which process intensification is the major one. Process intensification in 
heat transfer processes leads to the possibility of moving from batch to continuous 
processing mainly due to high heat and mass transfer coefficients. This effect is 
mainly caused by the very high surface to volume ratio. Another advantage for 
sensitive products is the low shear stress in the laminar regime and the short 
residence time. Additionally the hold-up of the apparatus is in the range of some 
milliliters. 
A model batch process of crystallization of drug carrier lipid nanoparticles is used 
here to demonstrate some benefits and application possibilities of micro heat 
exchangers. Currently the crystallization of solid lipid nanoparticles is usually 
performed in a batchwise process under poorly defined cooling conditions, without 
much regard to the aspects of heat transfer and precise process control. In addition, 
these setups often only allow the application of low cooling rates. The use of high, 
well-defined cooling rates could offer very interesting new possibilities for the 
production of such drug carrier systems1.
Using a micro heat exchanger device, high and well-defined cooling rates can be 
achieved for the continuous melt crystallization of solid lipid nanoparticles. During 
the crystallization of various solid lipid nanoparticle formulations it was found that 
some formulations lead to particle deposition and blocking of small passages in the 
micro heat exchanger. Obviously, specific interactions between the lipid 
nanoparticles and the surfaces of the device may occur and need to be considered 
in the design of the process as well as of the equipment. For formulations without 
deposition tendencies, reproducible experiments show that the continuous 
microfluidic process is applicable to produce solid lipid nanoparticles with constant 
product properties, like particle size and polymorphic form. 
1 Jasch, K., N. Barth, S. Fehr, H. Bunjes, W. Augustin and S. Scholl, A Microfluidic 
Approach for a Continuous Crystallization of Drug Carrier Nanoparticles, Chemical 
Engineering & Technology 32 (2009), 11, pp. 1806-1814 
T1-2
3D FLOW FIELD MEASUREMENTS IN COMPLEX MICROSYSTEMS 
Kähler, C. J. 1, Cierpka, C.1, Segura, R.1, Rossi, M.1,
1 Institut für Strömungsmechanik und Aerodynamik 
Universität der Bundeswehr München
State-of-the-art Microsystems for pharmaceutical applications have complex 
geometries which induce complex fluid motion. To validate the efficiency of these 
microsystems, the challenge of measuring the 3D flow field has to be overcome. 
Moreover, it is essential to characterize the mixing of different pharmaceutical 
components in Microsystems in order to validate their effectiveness. To solve both 
issues, a novel measurement technique to locate and track the motion of individual 
particles in a fluid volume (3D) has been developed at the UniBw München. This 
method has the capability of instantaneously determining the three-dimensional 
positions of tracer microparticles inside the flow when their image is captured by a 
digital camera. The basic principle of the technique consists of breaking the axis-
symmetry of the optical system, introducing astigmatism to the digital recordings. 
This optical distortion gives the particle images an elliptical shape whose 
dimensions change as a function of their depth position. The astigmatism effect is 
introduced to the optical system by a cylindrical lens mounted directly in front of 
the camera’s sensor, which is coupled to the output port of a state-of-the-art 
inverted microscope. 
The accurate identification of the three-dimensional locations of tracer particles in 
a volume at consecutive instants of time, allows for the calculation of all three 
components of the flow velocity. The simplicity of this measurement technique 
makes it stand out over other known approaches that attempt to measure similar 
flow conditions. This innovative flow diagnostics method only requires one 
camera, takes advantage of the illuminated volume in its entirety, and has been 
validated with benchmark flows to prove its robustness and reliability.  
On the other hand, the potential to instantaneously identify the three-dimensional 
position of tracer particles in a fluid volume allows for the reconstruction of the 
physical state of the seeded flow at a specific time. This is of particular importance 
when attempting to characterize the interaction between two fluids, as they would 
inside micro structures designed for efficient mixing of several species. By seeding 
one of the fluids to be mixed, which allows for the reconstruction of the volume 
that it occupies in the micro mixer, the interface with its non-seeded counterpart 
can be characterized precisely. 
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ADHESION OF SOLID LIPID NANOPARTICLES ON 
POLYELECTROLYTE MULTILAYER COATED SURFACES 
Schmolke, H.1, Finke, J. H.2 , Müller-Goymann2, C. C., Klages, C.-P.1
1Institut für Oberflächentechnik, TU Braunschweig, 2Institut für pharmazeutische 
Technologie, TU Braunschweig 
In the production of nanoparticulate drug carriers in microsystems, the adhesion of 
particles to the surface causes a loss of active pharmaceutical ingredients (APIs) 
and affects the product quality (due to changes in flow and heat transfer conditions 
or due to cross-contamination). Being able to control particle adhesion and 
cleanability by adjusting the surface properties in such devices is therefore a 
crucial point.  
Polyelectrolyte multilayers (PEMs) represent a versatile tool for surface 
modification. They can be assembled practically independent of the chemical 
nature of the substrate by adsorption from aqueous solution in a layer-by-layer 
dipping process and - by using a dynamic flow-through principle - even in capped 
microsystems.  
In this study, the adhesion of solid lipid nanoparticles on PEM-coated stainless 
steel was investigated. The type of PEM and its surface charge were varied. Using 
PEM as a baselayer, poly(ethylene glycol) (PEG) was additionally incorporated by 
subsequent adsorption of a custom-made Poly(acrylic acid)-graft-PEG
(PAA-g-PEG) copolymer from water.  
Three nanoparticulate suspensions were tested: two consisting of a mixed matrix of 
hard fat and phospholipid (native and hydrated) stabilized by 1 % Macrogol-15-
stearate and one consisting of a mixed matrix of carnauba wax and decyl oleate 
stabilized by 1 % Polysorbate 80.  
The relative amount of adsorbed particles was investigated by highly sensitive 
Fourier transform infrared spectroscopy in attenuated total reflection mode (FTIR-
ATR) in dependence on the environmental conditions at adsorption (room 
temperature / elevated temperature / temperature ramp).  
Both enhancement and reduction of particle adhesion could be observed for PEM 
compared to bare stainless steel. In general, the PEGylated PEM showed least 
adhesion of particles. The cleanability of PEM and PEM/PAA-g-PEG coated 
stainless steel was examined using a cleaning procedure with ethanol. It was found 
to be highly effective for hard fat particles but ineffective for wax particles. 
T1-4
BACTERIAL NANOCELLULOSE: INFLUENCE OF FREEZE-DRYING 
ON THE DELIVERY OF DRUGS 
Müller, A.1, Ni, Z.2, Heßler, N.3, Kralisch, D.3, Fischer, D.1
1Lehrstuhl für Pharmazeutische Technologie, Universität Jena; 2College of  
Pharmacy, Wuhan University, Wuhan, China; 3Institut für Technische Chemie 
und Umweltchemie, Universität Jena 
Bacterial nanocellulose (BNC) is a hydrogel, which provides numerous advantages 
for the use as drug delivery system. Because of its biocompatibility and remarkable 
material properties it has already been described as well suited for various medical 
applications [1].  
In the present study, freeze-drying of BNC hydrogels as a method to accomplish 
long-term storage and easy application was investigated with regard to influence on 
the loading and release of the model drug bovine serum albumin (BSA). 
Comparative in vitro release experiments between never-dried and freeze-dried 
BNC samples were performed. Effects of protein concentration, incubation time, 
temperature, type of release medium, pH and pre-swelling on loading and release 
of BSA were investigated. Protein quantification was carried out by UV 
spectroscopy. Loading and release of BSA could be controlled by all varied 
parameters. Steady-state conditions of the release could be observed for all tested 
BNC gels after 24-48 hours. However, freeze-dried samples loaded and released a 
lower amount of BSA (70-80%) compared to never-dried samples which could be 
correlated to the changes in the three-dimensional network structure after freeze-
drying. Nearly comparable release results for initial never-dried and freeze-dried 
samples were obtained by freeze-drying after BSA loading. In conclusion, freeze-
drying is a suitable method to improve handling as well as storage stability of 
protein loaded BNC gels in pharmaceutical applications. 
[1] Klemm, D., et al. (2009) Macromol. Symp. 280: 60-71  
T2-1
DRUG NANOPARTICLES PREPARED BY NOVEL COMBINATIVE 
PARTICLE SIZE REDUCTION TECHNIQUES 
Möschwitzer, J. 1,2 
1 Institut für Pharmazie, Abteilung Pharmaceutics, Biopharmaceutics and 
NutriCosmetics, Freie Universität Berlin, Germany 
2 Pharmaceutical Development. Abbott Healthcare Products (formerly Solvay 
Pharmaceuticals), Weesp, The Netherlands 
The majority of new chemical entities (NCEs) suffer from undesirable physico-
chemical and biopharmaceutical properties, leading to erratic drug absorption, food 
effects and low oral bioavailability. Particle size reduction is a practical approach 
to enhance the oral exposure of these poorly soluble drug molecules, particularly 
for those molecules with a dissolution rate dependent bioavailability. Top-down 
technologies as wet ball milling (WBM) or high pressure homogenization (HPH) 
are currently the most advanced technologies with several commercial products on 
the market. Both technologies utilize mostly micronized APIs in order to prevent a 
clogging of the machines. The particle size is further reduced by means of 
mechanical comminution caused by shear forces, impaction forces or cavitation 
forces. Long milling times, abrasion of milling beads and wearing of the machines 
are disadvantages of the standard top-down techniques.  
A relatively new and smart way to produce nanosuspensions is the combination of 
two particles size reduction principles to improve the process effectiveness. In a 
first step the coarse starting material is modified using one bottom-up step and 
further processed into nanosuspensions by applying a top-down technique. 
Currently different combinative technologies are employed. The first one is known 
as H42 process and can be described as combination of spray-drying (bottom up 
step) and high pressure homogenization. Another combinative technology is known 
as H96 process. This technology combines the modification of the starting material 
by means of freeze drying (bottom up step) with different top town technologies, 
such as WBM or HPH. Besides these two principles other combinative 
technologies exist, e.g. combinations of precipitation and HPH as well as 
combinations of WBM with HPH.  
The work presented here gives a detailed overview of different novel combinative 
particle size reduction technologies. It will discuss the reasons for the improved 
particle size reduction effectiveness and how to optimize the particle size reduction 
effectiveness by selecting an appropriate technology and process conditions. 
T2-2
SHEDDING LIGHT ON THE INTRACELLULAR PROCESSING OF RE-
DUCTION SENSITIVE POLY(ETHYLENE IMINE) GENE CARRIERS 
Hozsa C., Breunig M., Göpferich A. 
Department of Pharmaceutical Technology, University of Regensburg 
Linear, low molecular weight (MW) poly(ethylene imines) (PEIs) crosslinked with 
reduction sensitive disulfides to high MW branched derivatives are highly efficient 
delivery agents for DNA as well as for small interfering RNA (siRNA). They do 
not share the cytotoxicity of their non-cleavably branched counterparts as they are 
intracellularly degraded into small less toxic fragments by cellular thiols like gluta-
thione.1 The exact location and time point of this reduction process are important 
as they determine if the nucleic acid reaches its destination before the carrier is 
degraded. Prematurely released nucleic acids would most likely have a signify-
cantly lower effect on target cells. So far, however, this process is poorly under-
stood.2
To gain a better understanding of those events we linked the reduction sensitive 
fluorescent probe BODIPY FL L-cystine to linear PEI (lPEI) and cystine cross-
linked PEI (bPEI). In a reductive environment BODIPY FL L-cystine is cleaved 
(as well as bPEI) into two highly fluorescent monomers making it the ideal tool for 
fluorescence based method like flow cytometry. In preliminary experiments we 
investigated the degradation of our PEI/nucleic acid complexes by glutathione 
using fluorescence spectroscopy. We observed significant differences in the 
cleavage behavior depending on the polymer and the nucleic acid used. Linear PEI 
seems to form much stronger complexes with DNA than with siRNA preventing 
the disulfide cleavage or possibly the DNA release. For polyplexes made with 
branched PEI however siRNA behaves like DNA leading us to the conclusion that 
polyplex cleavage and nucleic acid release might not necessarily be associated. We 
also evaluated the intracellular processing of DNA polyplexes by flow cytometry. 
By influencing the cellular trafficking and disulfide cleavage of our model nano-
complexes with agents like chloroquine or N-ethylmaleimide we provide evidence 
that polyplexes based on linear PEI are differently processed in vitro than poly-
plexes made of branched PEI. 
We conclude that our findings underline the importance of custom designed 
carriers for gene therapeutics depending on the nucleic acid to be delivered. 
[1] Lungwitz U., et al., Eur. J. Pharm. Biopharm. 60, 247-266 (2005) [2] Bauhuber 
S., et al., Adv. Mater. 21, 3286- 3306 (2009) 
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MODULAR TARGET NANOPARTICLES – DRUG CARRIERS FOR 
RADIATION THERAPY OF CANCER 
Nawroth, T.1a, Wurster, E.C.1a, Peters, T1a, Buch, K1a, Huehn, E.1a, Langguth, P.1a,
Decker, H.1b, Pairet, B.1b, Meesters, Ch.1b, Grunewald, C.1c, Hampel, G.1c,
Frey, H.1c, Hofmann, A.M.1c, Schmidberger, H.2, Saenger, M.2 Alexiou, Ch.3
1aPharmazeutische Technologie und Biopharmazie; 1bMolekulare Biophysik; 
1cOrganische Chemie; Gutenberg-Universität, Mainz;  
2Klinik für Radioonkologie und Radiotherapie, Universitätsmedizin, Mainz 
3Nanomedizin; Hals-, Nasen- Ohren-Klinik, Universitätsklinik, Erlangen 
Target Nanoparticles can enforce radio- and chemotherapy of cancer in two ways: 
concentration of the drug in particles, and targeted localization of therapeutic mate-
rial in the tumor. A further advantage is the selective uptake and delivery at cellular 
level by endocytosis. For radiotherapy the drug is an enhancer, which enforces the 
radiation induced cell inactivation with respect to untreated or healthy cells lacking 
the uptake. In chemotherapy and combined radio-chemotherapy this inactivates the 
malign cells by bio-chemical interaction, leading to a tumor growth stop.  
Our therapeutic nanoparticles for enhanced radiotherapy are combined from lipids, 
stabilizing polymers and magnetic iron oxides. The particles of ~100 nm size carry 
an enhancer load of lanthanide chelates or boron as radiation absorption target and 
chemotherapeutics, e.g. cis-Platin, as proliferation inhibitors. A major object are 
target liposomes bearing modular surface signals for cellular uptake, and the drug 
load. A premature uptake of the therapeutic target nanoparticles is avoided by 
novel stealth lipids bearing a polyglycerol head. Other nanoparticles contain 
polymers and poly-ferrofluids for magnetic drug targeting MDT and release.The 
particles are characterized by spectroscopy, dynamic light scattering DLS, electron 
microscopy, neutron and synchrotron X-ray scattering and imaging, and magnetic 
characterization. The drug release from target nanoparticles is observed by nano-
dissolution experiments. This reveals the drug release at body temperature after 
administration, and the formulation stability during preparation and storage. The 
biocompatibility and possible toxicity is investigated with cancer cell cultures of 
several lines of brain, lung, liver, colon and kidney cancer. In our kinetic EPN test 
cell cultures are used as tumor models.  This distinguishes between toxic or radio-
toxic action and the favorate cancer cell proliferation inhibition, which is equiva-
lent to a tumor growth stop. As radiation sources for neutron capture therapy NCT 
we use the reactors TRIGA Mainz, and ILL Grenoble, for photon therapy tests the 
accelerators at radiooncology clinics Mainz, and the ESRF synchrotron Grenoble.  
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A POLYMER AS SOLVENT AND SUSTAINED RELEASE EXCIPIENT 
FOR LIPOPHILIC DRUGS – HEXYLSUBSTITUTED POLY(LACTIDE) 
Asmus, L., Gurny, R., Möller, M.
School of Pharmaceutical Sciences, Group of Pharmaceutics,  
University of Geneva, University of Lausanne, Switzerland 
Hexylsubstituted poly(lactide) (hexPLA) is, like poly(lactide) (PLA) an entirely 
degradable polyester. While the in vivo degradability and good biocompatibility 
allow PLA to be widely used in the medical field for various applications, the 
pronounced burst-release and the solid aggregate state limit its use for parenteral 
release applications. These PLA formulations are not injectable on their own 
without the addition of plasticizers or the use of sophisticated application systems.  
In contrast, hexPLA is a viscous liquid at room temperature, allowing the direct 
incorporation of APIs and facilitating the injectability of the excipient without the 
need for additional organic solvents. The degradation and release profile of 
hexPLA can be modified by using different molecular weights.  
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Furthermore, hexPLA shows solvent characteristics towards lipophilic drugs, as it 
was illustrated with the dye Sudan III and the antipsychotic drug Haloperidol. 
Quantification by UV-spectroscopy of saturated solutions showed that the 
incorporation capacity of both substances was higher, the lower the molecular 
weight of the polymer was. Thus, formulations could be prepared with the same 
concentration of the API, but with different ratios of dissolved to suspended drug.  
A release study revealed, that the solution to suspension ratio had high influence on 
the burst-release characteristic. By using a drug solution, the initial burst can be 
avoided, which is of advantage for APIs with a narrow therapeutic window, as is 
Haloperidol. In conclusion, hexPLA can be used as a solvent and sustained release 
excipient for lipophilic drugs. 
T3-1
DESIGNING POLYMER INTERLAYERS TO IMPROVE IMPLANT 
SURFACES 
Dempwolf, W.1, Pfaffenroth, C.1, Sluszniak, M.1, Lorenz, C.1, Hoffmann, A.2,
Winkel, A.3, Stiesch, M.3, Windhagen, H.4, Menzel, H.1
1Institut für Technische Chemie, TU Braunschweig 
2Klinik für Unfallchirurgie, 3Zahnärztliche Prothetik und Biomedizinische 
Werkstoffkunde, 4Orthopädische Klinik, Medizinische Hochschule Hannover 
Titanium and its alloys are widely used as implant materials due to their good 
biocompatibility and mechanical properties. With the help of polymeric coatings 
the implant surfaces can be adjusted in their properties according to the needs of 
application. Two different applications of this concept are highlighted here: Firstly, 
attaching signalling proteins like Bone Morphogenetic Proteins (BMP) to the 
surface employing a polymer interlayer aims at an improved osseointegration of 
the implant. Secondly the installation of antimicrobial polymers to the surface is 
targeted to prevent or at least retard adhesion of bacteria and the formation of 
biofilms. To address these issues we covalently attach polymers onto titanium 
oxide surfaces via photochemical grafting onto (1) or utilizing the surface activity 
of phosphonates (2), respectively. The coating results in ultra thin polymer films at 
the nanometer scale.  For the covalent binding of BMP2 e.g. poly (4-vinylbenzyl) 
phosphonic acid diethylester-co-glycidyl methacrylate has been designed showing 
a high ability to bind the protein as determined by using an immunoassay. This 
immobilized protein retains some biological activity as tested by a cellular 
signaling system. Starting point of creating antimicrobial surfaces is the synthesis 
of copolymers e.g. poly (vinylbenzylphosphonate-co-hexylpyridinium) (3) 
combining the biocompatibility of phosphate groups with the antimicrobial effect 
of quarternized poly(4-vinylpyridinium).  
Acknowledgement: This work was supported by the DFG as part of the SFB 599. 
(1) Griep-Raming, N., Karger, M., Menzel, H., Langmuir, 201, 11811, 2004.  
(2) Adden, N., Gamble, L. J., Castner, D. G., Hoffmann, A., Gross, G., Menzel, H. 
Biomacromolecules, 7, 2552, 2006.  
(3) Heuer, W., Winkel, A., Kohorst, P., Lutzke, A., Pfaffenroth, C., Menzel, H., 
Bach, Fr.-W., Volk, J., Leyhausen, G., Stiesch, M.  Advanced Biomaterials 2010, 
accepted. 
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VEGF RELEASE FROM CA-/ZN-ALGINATE GELS AND THEIR 
PHYSICO CHEMICAL PROPERTIES  
Nowak, C.1, Metz H. 2, Mäder K. 2, Hacker, M. 1 , Schulz-Siegmund, M.1 
1Pharmazeutische Technologie, Universität Leipzig 2Pharmazeutische 
Technologie,  MLU Halle-Wittenberg 
 
The aim of this study was to develop an injectable drug delivery system for vas-
cular endothelial growth factor (VEGF), based on alginate and in situ gelation. The 
desired route of administration requires the application of an ionotropic internal 
gelation method. CaCO3 and/or [ZnCO3]2·[Zn(OH)2]3 represented the cross-linking 
salt, from which Ca2+ and Zn2+ are liberated by glucono--lactone (GDL), to cross-
link the alginate. Final pH value within the gel has to be considered carefully for 
reasons of biocompatibility and the influence on release kinetics of charged VEGF 
from alginate gel. pH value within the gel was determined by VIS spectroscopy 
after addition of phenol red and bromcresol green to the alginate solution prior to 
gelation. Results were verified by ESR spectroscopy. The obtained gels were found 
to be slightly acidic. To determine the influence of the gel structure on VEGF 
release, gels were neutralized after solidification. To identify the effect of cross-
linking salt and alginate composition (guluronic (G) or mannuronic acid (M) 
content), these parameters were systematically varied and VEGF release 
determined by ELISA. In addition, alginate gels were characterized rheologically. 
Gels cross-linked only by Ca2+ showed strong burst release of VEGF.  An 
increased Zn2+ content reduced the burst release. Gels cross-linked with more than 
50 % Zn2+ showed a sustained VEGF release. Zn2+, however, decreased the total 
amount of released VEGF. An increasing M content of the alginate, resulted in an 
reduced amount of VEGF release, whereas the shape of the release profile was 
maintained. In high G gels, even small Zn2+ contents considerably modified release 
profiles, whereas VEGF release from high M gels was less affected. Rheological 
properties were obtained by oscillating rheometry. Gels cross-linked by Ca2+ 
showed higher storage moduli and viscosities than gels cross-linked by Zn2+. 
Mixture of Ca2+and Zn2+ showed an intermediate storage modulus, observed for 
high G and high M gels. By selecting suitable combinations of cross-linking salts 
and types of alginate, VEGF release profiles can be adjusted to different needs.  
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OPTIMIZED DEGRADATION AND MECHANICAL PROPERTIES OF 
POLYMER FILMS FOR SURGICAL ADHESION PREVENTION 
Teßmar, J.1, Reintjes, T.1, Göpferich, A.1
1Lehrstuhl für Pharmazeutische Technologie, Universität Regensburg 
Thin polymeric films made from biodegradable polymers are a well established 
tool for the prevention of tissue adhesions after trauma or larger surgical 
procedures. They can be used after gynecological surgery as well as after heart 
surgery or to treat injuries of tendons by minimizing the undesirable growth of scar 
tissue within neighboring tissues. For all these application degradable polymer 
films made from poly(lactic acid) [PLA] have proven to be well suited, however, 
an improvement with respect to their in-vivo degradation and an easier surgical 
applicability is highly desirable. 
In order to achieve this goal the ultrathin polymeric films were modified in 
different ways using excipients or copolymerization. In order to speed up the 
degradation dilactide - yielding lactic acid in water - and poly(ethylene glycol) 
[PEG] - enhancing the uptake of water - were added to the solvent cast polymer 
films. Both substances only provided a faster degradation (indicted by gel 
permeation chromatography) and softening (indicated by the glass transition) for a 
limited time (few weeks), since both excipients were lost due to their excellent 
solubility in the degradation medium. The alternative copolymerizations with PEG 
led to polymer films with increased wettability indicated by smaller water contact 
angles, and also an enhanced uptake of water during degradation. Copolymers were 
synthesized from PEGs with different molecular weights (1k to 20k Da) and with 
different geometries (4 arm and 8 arm) [1], resulting in ABA triblock copolymers 
in case of the linear PEGs or star-shaped polymers for the respective star PEGs 
with attached multiple PLA chains. The release of water soluble PEG was 
significantly reduced due to the copolymerization, leading to a longer persistence 
in the polymer films with all its beneficial effects on water uptake and film 
softness. During the degradation the enhanced water uptake as mediated by PEG 
lead to a faster film breakdown (< 4 weeks) with softer breakdown products due to 
the remaining softening effect of the PEG components. 
It was successfully demonstrated that copolymerization of PLA with PEG can be 
used to prepare surgical adhesion barriers with faster degradability and softer 
degradation products, which are hopefully less harmful to the surrounding tissue. 
References: 
1. Lucke A, Teßmar J, Schnell E, Schmeer G and Göpferich A (2000) Biomaterials 21:2361-2370. 
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THE SILVER - NANOLIPID - COMPLEX (sNLC): IN VIVO EFFICACY 
C.M. Keck1,2 
1Fachhochschule Kaiserslautern, University of Applied Sciences, Department of 
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10-16, 66953 Pirmasens, Germany 
2Laboratory of Molecular Biomedicine, Institute of Bioscience, Universiti Putra 
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The silver-nanolipid-complex (sNLC) is a combination of microsilver particles 
(10μm) and nanostructured lipid carriers (NLC). At the end of 2008, by chance, it 
was found that this combination can be active against light to servere medium 
atopic dermatits. Until now the mechanism of action remains not clear and is thus 
aspect of many research activities. The proposed mechanism of action is the release 
of positively charged silver ions from the silver microparticles, which absorb onto 
the surface of the negatively charged nanoparticles forming silver ion coated NLC 
(sNLC). NLC are known to poccess increased adhesiveness, therefore in theory the 
retention time of the silver ions bound to the NLC is longer at the desired site of 
action (e.g. skin or bacteria surfaces), leading to an improved activity than silver 
ions allone.  
The adsorption of silver ions onto the surface of the NLC could be shown by 
applying Asymmetric-Flow Field Flow Fractionation coupled with Multi Angle 
Light Scattering (AF4-MALS). Other frequently applied techniques e.g. dynamic 
light scattering were not suitable to prove this. The in vivo efficacy was 
investigated by studying a) the antibacterial activity (e.g. using the well  agar  
diffusion  method and broth  dilution  method), b) the anti-inflammatory activity 
and c) the erythema score in a atopic dermatitis mouse model. In all studies not 
only an additional, but synergistic effect was found, when silver was combined 
with NLC. The data suggest that sNLC might be a novel and effective therapy 
concept for the treatment of atopic dermatitis without adverse side effects. Further 
studies are ongoing. 
T4-1
FINITE DOSE SKIN PENETRATION - EXPERIMENT AND 
SIMULATION
Hahn, T.1, Naegel, A.2, Heisig, M.2, Kostka, K.-H.3, Hansen, S.1,4, Neumann, D.5,
Lehr, C.-M.1,4 Schaefer, U. F.1
1Biopharmaceutics and Pharm. Technology, Saarland University, Saarbrücken 
2Goethe Center for Scientific Computing, Goethe University, Frankfurt 
3Department of Plastic and Hand Surgery, Caritaskrankenhaus, Lebach 
4Dep. of Drug Deliv., Helmholtz Inst. for Pharm. Res. Saarland, Saarbrücken 
5Scientific Consilience, Saarland University, Saarbrücken 
By definition, for finite dose skin absorption experiments a dose of less than 
10 μl/cm² or 10 mg/cm² is applied to the skin surface 1. In this study in vitro finite 
dose skin penetration experiments were established and the results were compared 
to simulations of a 2D diffusion model in order to show, whether this model 
developed for infinite dose can correctly predict finite dose skin absorption.  
The experiments were performed using human abdominal full-thickness skin in a 
Franz diffusion cell. A finite volume of 5-8 μl/cm² of the model drug flufenamic 
acid in aqueous solution was applied.
For simulating the experiments, we extended the functionality of a previously 
established 2D diffusion model, which had been developed and validated for 
infinite dosing 2,3. The model is based on the anatomical structure of the skin and 
uses only physicochemical input parameters. 
Simulated and experimental concentration-depth profiles for the SC and the deeper 
skin layers using the same physicochemical input values as in the infinite dose 
experiments correlated reasonably.  
As expected, for finite dose experiments, the drug amount in the donor decreased 
both in the simulation and the experiment. However, this effect was more 
pronounced for the experimental data set resulting in high drug amounts in the SC 
already after 15 minutes. This finding does not correlate well with the simulation. 
One reason might be that the outer, loosely packed corneocyte layer of the SC, the 
stratum disjunctum, does not exhibit a strong barrier function and might have 
quickly soaked up the donor solution. Future work comprises the inclusion of this 
mechanism in the model framework. 
1. OECD.  (2004) Guidance document for the conduct of skin absorption studies. OECD series on testing and 
assessment. Number 28. 
2. Hansen S, Henning A, Naegel A, Heisig M, Wittum G, Neumann D, Kostka K-H, Zbytovska J, Lehr C-M, Schaefer 
UF.  (2008) European Journal of Pharmaceutics and Biopharmaceutics. 68:352-367. 
3. Naegel A, Hansen S, Neumann D, Lehr C-M, Schaefer UF, Wittum G, Heisig M.  (2008)  European Journal of 
Pharmaceutics and Biopharmaceutics. 68:368-379.
T4-2
THE PERMEATION STUDY OF TERBINAFINE HCL FROM 
POLOXAMER 407 BASED THERMOGELLING FORMULATIONS 
ACROSS ISOLATED HUMAN STRATUM CORNEUM 
Lusiana, Müller-Goymann, C.C.
Institut für Pharmazeutische Technologie, TU Braunschweig 
The permeation of drug across skin is determined by two main steps, i.e. the 
interaction of vehicle with the stratum corneum and the drug thermodynamic 
activity within the formulation. The vehicle can control the drug release and in 
some extent modifies the barrier properties of the stratum corneum.  
In this study, 1% terbinafine HCl, a lipophilic antifungal drug with log P 3.3 and 
aqueous solubility of 0.7% was incorporated into semisolid poloxamer 407 based 
thermogelling formulations and the permeations across isolated human stratum 
corneum were examined. The formulation was composed of the mixtures of 
poloxamer 407: middle chain triglycerides Miglyol® 812N (4:1), isopropyl alcohol: 
dimethyl isosorbide (1:1) and water. The mixture of poloxamer 407: Miglyol®
812N was employed from 25-50%, meanwhile the mixture of isopropyl alcohol: 
dimethyl isosorbide (penetration enhancers) was from 12-40%. The formulation 
was manufactured using Cito unguator 2000 Konietzko GmbH at the speed of 1450 
rpm for 1.5 min. The marketed product Lamisil® Creme and a 20% poloxamer 
hydrogel containing 1% drug were tested as well. The complex viscosities of the 
formulations were measured using a controlled stress rheometer CVO 50 from 
Bohlin.
The results showed that high contents of poloxamer and water were responsible for 
the high viscosity of the formulations; meanwhile the penetration enhancers 
decreased the viscosity. There was a good agreement between the complex 
viscosity and the reciprocal drug flux and this was also the case for the drug 
accumulated amount in the stratum corneum after 48 h of permeation. The apparent 
flux increase along with the increase in enhancers contents was rather due to the 
decrease in the viscosity of the formulation. All flux values were higher compared 
to those from Lamisil® Creme, except for the formulation with more than 40% 
poloxamer content. The formulations with viscosities about the same magnitude 
showed about equal flux values, showing that variation in compositions was not 
affecting the amount of permeated drug across the skin. Furthermore, viscosity 
could be a predictive tool in estimating the drug flux from this formulation. 
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INFLUENCE OF IBUPROFEN CONTENT ON THE RHEOLOGICAL 
AND THERMAL BEHAVIOR OF AN ACRYLIC PRESSURE SENSITIVE 
ADHESIVE 
M. Michaelis1, C. S. Leopold1 
1Institute of Pharmacy, Dept. of Pharmaceutical Technology, University of 
Hamburg, Germany 
 
Adhesion of transdermal systems to the skin is a critical factor directly related to 
cutaneous drug penetration and thus therapeutic effect. It is well known that the 
viscoelastic behavior plays a critical role in the performance of pressure sensitive 
adhesive (PSA) products and bonds. In the present study the change of the 
adhesion properties of DuroTak®-387-2051 (Henkel), a solvent-based acrylic PSA, 
is compared to the rheological and thermal behavior at increasing ibuprofen 
content. 
Samples of DuroTak®-387-2051 with increasing ibuprofen content were prepared 
for rheological analysis by lamination multiple layers of 0.2 mm dry adhesive film 
to achieve a final thickness of about 1 mm. The samples were cut into discs of     
25 mm diameter each. Temperature sweep and frequency sweep experiments were 
performed on a Rheometrics Dynamic Analyzer II (Rheometrics) equipped with a 
25 mm parallel plate geometry and a convection oven. A frequency sweep was run 
at +32 °C followed by a combined temperature frequency sweep from -60 to    
+200 ºC (5 °C steps) at 0.1 to 100 rad/s. Linear viscoelastic behavior was 
confirmed by strain test at 100 rad/s. DSC measurements were done using a DSC7 
(Perkin Elmer) with a heating rate of 10 K/min in a temperature range between -
100 and 130 °C. 
Tan  curves were obtained from frequency-sweeps as well as combined 
temperature-frequency-sweeps. The latter were displayed in 3D plots showing a 
decrease of the dynamic glass transition temperature (Tg) with increasing drug 
content at all investigated frequencies. The minimum of the tan  curves of samples 
with increasing drug content was found to be shifted to higher values.  
Frequency sweep measurements of drug loaded samples at 32 °C also showed an 
increase in tan  for all investigated frequencies. This indicates that the addition of 
ibuprofen to DuroTak®-387-2051 results in a loss of shear resistance and an 
increase in tack. The decrease in Tg and thus plasticization could be confirmed by 
DSC measurements. 
 
T4-4
END POINT CONTROL OF AN ACTIVE COATING PROCESS BY 
RAMAN SPECTROSCOPY  
Kleinebudde, P., Knop, K., Müller, J.
Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-University 
Universitaetsstr. 1, 40225 Duesseldorf, Germany 
In the formulation of solid dosage forms film coating represents an important unit 
operation which can provide different functions like taste masking, product 
identification and protective layering. Active coating is a specific application 
where the active ingredient is comprised in the coating layer. Active coating is a 
challenging operation regarding the achievement of desired amount of coating and 
coating uniformity. In order to guarantee the quality of such dosage forms it is 
desirable to develop tools that are able to monitor the coating operation and to 
determine the end point and the coating uniformity, respectively. 
The model drug diprophylline was coated on placebo tablets and a multivariate 
quantitative calibration was developed using tablets collected at different stages of 
coating and increasing amount of API from a small-scale pan coater. The Raman 
spectral measurements were correlated with the amount of coated active ingredient 
at each time point by using PLS. Afterwards the developed model was validated in 
agreement with ICH guideline Q2 whereby the focus was the transfer to real time 
monitoring in order to demonstrate the suitability of Raman spectroscopy as PAT 
tool for in-line quantitative monitoring of active coating. 
Typical validation characteristics for assay procedures like accuracy, specificity, 
precision, range, and linearity were examined. Additionally the detection limit and 
quantitation limit were included in the investigation in order to assign the area in 
which quantitative inline monitoring of active coating is possible. Furthermore, the 
repeatability should be assessed using samples, which cover the specified range for 
the procedure.
After validation the developed model was used successfully to monitor the 
progress of coating in a laboratory film coater BFC 5 by the inline measurements 
and to determine the end point of active coating. Finally the model developed on 
the lab scale pan coater with a batch size of 3.5 kg could be transferred in a scale 
up experiment to a pilot scale coater with a batch size of 30 kg. 
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HOT MELT EXTRUSION OF LOW MOLECULAR WEIGHT 
CRYSTALLINE MATERIALS 
Reitz, E., Thommes, M. 
Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-University, 
Duesseldorf, Germany 
Hot melt extrusion is a well established technology which is mainly used for 
amorphous compounds. The melt viscosities of low molecular weight crystalline 
materials are frequently too low to produce mechanically stable extrudates from the 
extrusion die. In order to overcome this issue, a new technology was proposed in 
which the extrudate crystallized rapidly at the extrusion die. 
In this study, a new extrusion die was developed and validated to extrude melts of 
low molecular substances, such as mannitol, using a lab scale extruder (Leistritz, 
Mikro GL27-28D). The main problem which had to be mitigated was a 
temperature gradient across the die which led to crystallization within the die and 
subsequent clogging.  
The extrusion die was varied systematically by insulating it as well as by adding 
multiple heating devices to various positions on the die. The temperature gradient 
across the die and temperature fluctuation were monitored by temperature gauges 
added to critical parts of the die. Finally, the temperature gradient was decreased 
from 21 to 7°C while the temperature fluctuations were reduced from 14 to 1.5°C. 
Using this optimized die configuration, it was possible to extrude a powder mixture 
of 90 % mannitol and 10 % griseofulvin. The extrudate had an adequate shape, and 
the drug and the excipient were in the crystalline state. The dissolution rate of the 
drug from the extrudates was much higher than from the physical mixture.  
In conclusion, the extrusion of crystalline materials is possible using a twin screw 
extruder with a modified die. Since the end product is crystalline, the stability 
issues common to amorphous systems can be avoided.  
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POROUS CARRIERS AS A TARGET FOR DRUG LOADING BY 
SUPERCRITICAL FLUID TECHNOLOGY USING AN OPEN OR 
ENVIRONMENT FRIENDLY CLOSED LOOP SYSTEM  
Metzger, P.O.J., Wahl, M.A. 
Pharmazeutische Technologie und Biopharmazie, Pharmazeutisches Institut, 
Eberhard-Karls-Universität Tübingen 
Purpose:
Development of a system to load sparingly soluble drugs into preformulated 
carriers with tailored dissolution properties by the use of environment-friendly 
supercritical fluid technology. 
Methods:
Loading of a model drug (cumarin) was performed using controlled particle 
deposition from a supercritical solution. In a 2.1 l loading chamber 3.0 g cumarin 
was incubated with supercritical CO2 for 3.5 h (15 MPa; 40 °C; 2 h / 30 MPa; 
60 °C; 1,5 h). Afterwards the system was relaxed adiabatically without falling 
below the critical temperature, either in a closed loop system with recycling of the 
CO2 and drug or in an open system without recycling. 
Porous carriers with different dissolution properties were formed from 
Avicel PH 102®, ethylcellulose, Eudragit RS PO® and corn starch. Glass frits and 
cylindric lump sugar were used for comparison.  The carrier porosity was 
determined (gas-comparison-pyknometry) before loading and the drug content 
(UV-VIS at 280nm) and dissolution (Stricker model, pH7.4) after loading. Drug 
particle distribution was observed by fluorescence microscopy (350/420nm). 
Results:
The porosity of the carriers varied according to the carrier composition between 
32.37±2.22 and 71.22±2.05 (%±SD,n=5-20). Fluorescence microscopy showed 
homogenous allocation of small deposited particles across the tablet. Due to the 
different loading conditions (i.e. variations of T, p, t) the drug content varied 
depending on the tablet porosity, material and working conditions. Dissolution 
showed modulated release properties according to the carrier system used. 
Conclusion:
With the controlled particle deposition method (CPD) employing supercritical 
CO2, we successfully loaded monolithic porous carriers with a model drug. Our 
closed loop technology presented here enables the recycling of both, CO2 and the 
used drug, offering an interesting way to handle highly potent or toxic drugs. The 
final products show modified drug dissolution properties, as intended. 
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VARIOUS FORMULATION APPROACHES TO IMPROVE DRUG 
RELEASE FROM A FIXED DOSE COMBINATION PRODUCT  
Taupitz, T.1, Klein, S.2
1Institut für Pharmazeutische Technologie, Goethe Universität Frankfurt, 2Institut 
für Pharmazie, EMAU Greifswald 
In the present study we wanted to improve the dissolution behaviour of two 
BCS class II compounds, glimepiride, a weakly acidic drug and 
pioglitazone, a weak base, in a fixed dose combination product. Two 
different formulation approaches were used for this purpose. The first 
approach was an inclusion complex of each of the drugs with hydroxy-
propyl-ß-cyclodextrin (HP-ß-CD) and the other one was a mixture of solid 
dispersions of each compound with Soluplus®, a recently marketed 
copolymer. The main objective was to obtain formulations that show a 
dissolution behaviour superior to that of each of the pure drugs and also to a 
marketed fixed dose combination. 
A freeze drying procedure was used to prepare the inclusion complexes of 
both compounds and HP-ß-CD as well as the solid dispersions with 
Soluplus®. Formulations were then subject to thermal analysis, solubility 
and dissolution tests. To elucidate, if the dissolution performance of our 
new formulations is superior to that of the marketed product, solubility- and 
dissolution tests were performed in two test fluids simulating conditions in 
the stomach and the upper small intestine.
DSC spectra of the complex formulations indicated that true inclusion 
complexes and amorphous solid dispersions were obtained. Results of the 
solubility experiments showed a significant increase of glimepiride and 
pioglitazone aqueous solubility. Dissolution performance of both fixed dose 
combination formulations was superior to that of the pure drugs and the 
marketed formulation under gastric and small intestinal conditions. 
Based on their in vitro performance, we assume that the in vivo behaviour of 
our formulations might be superior to that of the marketed formulation. This 
assumption and the applicability of these formulation approaches to other 
combinations of weakly basic and a weakly acidic BCS class II drugs needs 
will be proved in future experiments.
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NEW ANTIBIOTICS FROM CYANOBACTERIA 
Mundt, S.1, Bui, H.1, Le, T.1, Zainuddin, E.1, Jansen, R.2, Nimtz, M.2, Wray, V.2,
Preisitsch, M.1
1Pharmaceutical Biology, Ernst-Moritz-Arndt-University, Greifswald,  
2Helmholtz Centre for Infection Research, Braunschweig, 
In the last decades screening programs revealed that cyanobacteria are rich sources 
of new active structures with potential as new pharmaceuticals or lead structures, 
nevertheless the rich resources of German lakes, the Baltic Sea and Asian countries 
are hardly screened so far. Due to recent development in bacterial resistance and 
the increasing incidence of MRSA-strains worldwide we focused on screening of 
antibiotic activity of such hardly tested cyanobacterial strains and isolation and 
structural elucidation of the active substances. 
Laboratory cultures were established and biomass as well as cultivation medium 
was extracted with solvents of different polarity. Extracts have been tested in agar-
plate diffusion assay for antibacterial and antifungal activity. Bioassay-guided 
isolation of the active compounds was done by column chromatography including 
HPLC. Structure was elucidated by analysis of ESI-MS-MS, ESI-TOF-MS, 1D (1H
and 13C) and 2D (COSY, TOCSY, ROESY, NOESY, HMQC and HMBC) NMR 
spectra and amino acid analyses. 
Separation of the n-hexane extract of Limnothrix redekei HUB 051 (Müggelsee, 
Germany) resulted in the identification of three unsaturated fatty acids, -linolenic 
acid, coriolic acid and -dimorphecolic acid showing antimicrobial activity in 
vitro. Separation of the methanol extract of the freshwater strain Lyngbya sp.
resulted in the identification of four novel antibacterial active undecapeptins, 
lyngbyazothrins A-D. From methanol extracts of different filamentous 
cyanobacterial strains collected from lakes or acidic soils of rice, cotton and coffee 
fields in Vietnam several compounds with antibacterial activity have been isolated 
e.g. daklakapeptin, fluorensadiol, hapalindols, ambiguine isonitrils as well as 
carbamidocyclophanes, variably chlorinated paracyclophanes presented MIC 
values between 0.04 to 0.1 μmol against Staphylococcus aureus.
Our first results show that so far hardly investigated cyanobacteria from the Baltic 
Sea, German lakes and from Asian countries are sources of structural new active 
compounds with potential therapeutically value. Culture optimization to enhance 
the yields of the active compounds is in progress.  
B1-1
CHANGING A MUTANT’S MIND 
Probst, K., Bechthold, A.  
Pharmazeutische Biologie, Albert-Ludwigs-Universität Freiburg  
In 1998 Mensacarcin, a cytostactic substance with activity against many tumor cell 
lines, was isolated from Streptomyces sp. Gö C4/4. The anticancer potency of this new 
drug is similar to that of the clinically used doxorubicin1. The presence of two epoxy 
moieties in the molecule makes further investigations on the biosynthesis interesting, 
since these moieties are scarce in secondary metabolites of Streptomycetes. 
 Mensacarcin     Didesmethylmensacarcin 
A gene cluster for the biosynthesis was identified, cloned and sequenced. The 
heterologous expression of this cluster in Streptomyces albus (S. albus) led to the 
production of the non-methylated derivative Didesmethylmensacarcin2.
To elucidate the biosynthetic pathway of Didesmethylmensacarcin five oxygenases and 
four genes with currently unknown functions were investigated by Red/ET-mediated 
deletion and subsequent heterologous expression in S. albus. Unfortunately, the 
amounts of the new intermediates produced by these strains were very low. 
By overexpression of the pathway specific regulatory gene mnsR1 in the mutated 
strains the amount of the produced intermediates was drastically increased.  
The chemical structure of these new compounds will be elucidated. 
References: 
[1] M. Arnold, PhD thesis, University of Göttingen, 2002
[2] A. Linnenbrink, PhD thesis, University of Freiburg, 2008 
B1-2
TRADITIONAL CHINESE MEDICAL PLANTS INHIBIT ACETYL-
CHOLINESTERASE, A KNOWN ALZHEIMER TARGET 
Kaufmann, D.1, Kaur Dogra, A.2, Tahrani, A.1, Herrmann, F.1, Wink, M.1
1Ruprecht-Karls-Universitaet Heidelberg, Institute for Pharmacy and Molecular 
Biotechnology, Department of Biology, Im Neuenheimer Feld 364, 69120 
Heidelberg, Germany 
2Centre for Pharmacognosy and Phytotherapy, The School of Pharmacy, 
University of London, 29-39 Brunswick Square, London, WC1N 1AX, UK 
Inhibition of acetylcholinesterase (AChE) is a common treatment for early stages 
of the most general form of dementia, Alzheimer’s Disease (AD). When AChE is 
inhibited, more acetylcholine is available resulting in an improvement of cognitive 
function. Although the therapy with AChE inhibitors (AChEI) is considered to be 
only symptomatic, these medications are still the first choice for treating AD 
patients in early stages of the disease. 
In this study, methanolic, dichloromethane and aqueous crude extracts from 84 
Traditional Chinese Medical (TCM) plants were tested for in vitro anti-
acetylcholinesterase activity based on Ellman’s colorimetric assay. Identity of the 
plants was assured by DNA barcoding. Thin Layer Chromatography (TLC) and 
mass spectrometry (MS) were performed to gain a first insight into the chemical 
compounds of the TCM plant extracts used.  
Five TCM plants showed a notable inhibitory activity of AChE. Extracts from 
Coptis spp., Capsella bursa-pastoris, Mahonia bealei, Phellodendron spp., and 
Polygonum multiflorum exhibited a distinctive AChE inhibition with Mahonia
bealei and Phellodendron spp. featuring this inhibitory activity in all three extracts. 
Two of these TCM extracts showed a stronger AchE inhibition than the already 
known AChEI galanthamine (EC50 = 4.33 μg/ml) with EC50 values ranging from 
0.031 μg/ml (methanolic extract of Coptis spp.) to 2.5 μg/ml (aqueous extract of
Coptis spp.).
These findings suggest that Traditional Chinese Medical plants represent an 
important source of natural compounds that affect the activity of AChE, which 
might be interesting drug candidates to slow down the progression of AD.
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IMMUNOFLUORESCENCE LOCALIZATION OF POLYKETIDE 
SYNTHASES IN THE MEDICINAL PLANT HYPERICUM PERFORATUM
Belkheir, A1 2, Hänsch, R.3 ,Beerhues, L.2
1Faculty of Pharmacy, Al-Arab Medical University Benghazi, Libya 
2Pharmazeutische Biologie, TU Braunschweig 3 Plant Biology, TU Braunschweig 
Extracts from Hypericum perforatum (St. John’s wort; Clusiaceae) are widely used 
as antidepressants for the treatment of mild to moderate episodes. The medicinal 
plant is characterized by the presence of different types of secretory tissue 
including translucent glands, black nodules and secretory canals. Hypericum 
species are attractive experimental systems for studying the biosynthesis of a 
diversity of aromatic polyketides. Two type III polyketide synthases (PKSs) 
involved are benzophenone synthase (BPS) and chalcone synthase (CHS), for 
which cDNAs had been cloned and characterized. The enzymes were subjected to 
immunochemical studies and their distribution in H. perforatum was analyzed 
using immunofluorescence localization. Both enzymes were heterologously 
expressed in E. coli as His6-tagged proteins and GST-fusion proteins. Polyclonal 
antibodies were raised against the His6-tagged PKSs in rabbits and the IgG 
fractions were isolated. The specificity of the antibodies was examined using 
immunoblotting and immunotitration techniques. Protein extracts from various H.
perforatum organs were subjected to SDS-PAGE and immunoblotting. BPS was 
mainly immunodetected in middle-aged fruits. CHS was detected in young leaves 
and flower buds. The tissue-specific localization of BPS and CHS was studied with 
H. perforatum organs using the immunofluorescence technique and confocal laser 
scanning microscopy. BPS was expressed to a low extent in mesophyll cells of 
young leaves and strongly expressed in the glandular cells of large translucent 
glands present inside the leaves. In roots, BPS was located in the cortex cells. In 
floral parts, as far as studied, BPS was found in the secretory tissue of sepals of 
young buds and in middle-aged fruits. In addition, seeds present in the middle-aged 
fruits contained BPS. CHS was strongly expressed in the mesophyll cells of young 
leaves and was not present in glands. Nor was the enzyme observed in roots. In 
floral parts, as far as studied, CHS is located in the mesophyll of sepals of young 
buds.
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4-CYANO-1-OXO--CARBOLINES AS INHIBITORS OF PIM KINASES  
Bracher, F.1, Huber, K.1, Knapp, S.2 
1Department Pharmazie - Zentrum für Pharmaforschung, Ludwig-Maximilians-
Universität München 
 2Structural Genomics Consortium, University of Oxford 
 
The 1-oxo--carboline alkaloid bauerine C (1) having some unique structural 
elements (dichlorophenyl moiety, N-methyl indole) was isolated from the blue-
green alga Dichotrix baueriana showed antiviral and cytotoxic activities in 
preliminary screenings.  
We worked out the first total synthesis of this alkaloid and found that bauerine C as 
and its dihydro derivative 2 have inhibitory activity against a broad range of 
kinases. 
 
In order to improve the solubility properties and the selectivity against kinases, 
polar substituents were introduced into the molecule. For this purpose we worked 
out a new method for anellation of the lactam ring bearing a cyano group at C-4, as 
well as variable substituents (including spiro rings) at C-3. 
 
Spiropiperidine analgues  3 of bauerine C showed potent and selective inhibition of 
PIM kinases and cytotoxic effects in screenings on tumor cell lines. 
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C1-1
SYNTHESIS AND ANTIPLASMODIAL ACTIVITY OF REVERSE 
FOSMIDOMYCIN ANALOGS 
Behrendt, C. T.,1 Eisenreich, W.,2 Fischer, M.,3 Maes, L.4, Kurz, T.1
1Institut für Pharmazeutische und Medizinische Chemie, HHU Düsseldorf; 
2Center for Integrated Protein Science, TU München; 3Institut für 
Lebensmittelchemie, Universität Hamburg; 4Laboratory for Microbiology, 
Parasitoloy and Hygiene (LMPH), University of Aantwerp. 
Inhibition of enzymes involved in the non-mevalonate pathway of isoprenoid 
biosynthesis represents a promising strategy for the development of novel 
antimalarials [1-3]. A series of reverse hydroxamate-based Fosmidomycin analogs 
was synthesized and evaluated for their inhibitory activity against the recombinant 
DXRs of E. coli and P. falciparum as well as for their antiplasmodial activity and 
cytotoxicity. The most active derivative inhibits the target enzyme 1-deoxy-D-
xylulose 5-phosphate reductoisomerase (DXR) in the low nanomolar range and is 
devoid of cytotoxic effects on human MRC-5 cells.  
[1] Jomaa, H. et al., Science 1999, 285, 1573. [2] Kurz, T.; Geffken, D.; 
Kaula, U. (BioAgency AG), DE 10356410 and WO 2005048715, 2005. [3] 
Ruangweerayut, R. et al., Malaria J. 2008, 7, 225.
C1-2
SULFAMOYL BENZAMIDINES AS ARGININE MIMETICS: INHIBITION 
OF TRYPSIN-LIKE SERINE PROTEASES AND ACTIVE-SITE MAPPING 
Dosa, S.; Stirnberg, M.; Klaß, V.; Häußler, D.; Maurer, E.; Gütschow, M. 
Pharmazeutisches Institut, Universität Bonn, D-53121 Bonn, Germany 
 
The substrate specificity of trypsin-like serine proteases is largely determined by an 
aspartate pointing to a cleavage specificity for arginine at P1 position. Substances 
with the benzamidine functionality as arginine mimetic are expected as potential 
inhibitors.[1] We prepared an extended series of meta- and para-sulfamoyl benz-
amidines and investigated the scope and the limitations in terms of the inhibition of 
trypsin, thrombin and the typ II transmembrane serine protease matriptase-2.[2,3] 
Matriptase-2 suppresses the transcription of the Hamp gene encoding hepcidin and 
is thus thought to play an important role in iron homeostasis.[4, 5]  
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[1] Peterlin-Maši, L. Curr. Med. Chem. 2006, 13, 3627. [2] Velasco et al. J. Biol. 
Chem. 2002, 277, 37637. [3] Stirnberg, M. et al. Biochem. J. in press. [4] Silvestri 
et al. Cell Metab. 2008, 8, 502. [5] Finberg et al. Nat. Genet. 2008, 40, 569. 
 bovine trypsin Ki (M) 
human thrombin 
Ki (M) 
human matriptase-2 
Ki (M) 
1-16 >30 >70 >80 
17-32 4-40 >7 >50 
33-44 7-60 7-200 >7 
45-56 >20 >20 >5 
57-70 0.1-9 0.5-40 8-40 
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SPIROCYCLIC  RECEPTOR LIGANDS: EXPLORING HYDROPHOBIC 
POCKETS BY ARLYATION OF ANNULATED THIOPHENES 
Meyer, C. , Wünsch, B. 
Institut für Pharmazeutische und Medizinische Chemie, WWU Münster  
 
 Receptors are well established as a receptor family with its own binding profile 
and a characteristic distribution in the CNS as well as in endocrine, immune and 
some peripheral tissues. Today at least two  receptor subtypes have been 
identified which are termed 1 and 2 receptor. Modulation of 1 receptor activity 
offers some potential for the treatment of acute and chronic neurological disorders. 
Furthermore, some human tumor cell lines are able to express a large number of 1 
and/or 2 receptors. Consequently 1 (and 2) receptor ligands may be used for 
diagnosis and therapy of cancer. 
Our aim is to develop novel compounds with high 1 receptor affinity and high 
selectivity over the 2 subtype as well as other relevant receptors in the CNS. 
Recently we have shown that the substituent in position 1 of spirocyclic pyrazoles 
1 influences considerably the 1 affinity. The spirocyclic pyrazole 1b with a phenyl 
moiety in position 1 (R = Ph, Ki = 1.5 nM) is almost 15-fold more active than the 
corresponding methyl derivative 1a (R = CH3, Ki = 21 nM) [1]. Replacement of the 
pyrazole ring by a thiophene ring led to the very potent 1 ligand 2a (Ar = H, Ki = 
0.22 nM). So the idea came up to combine the high affinity thiophene substructure 
with an additional aryl substituent in position 1 (2), 2 (3) or 3 (3). 
In the talk we report on the synthesis and the pharmacological properties of the 
arylated thiophene derivatives. The non-activated spirocyclic thiophenes 2 and 3 
were regioselectively arylated in - or -position in presence of Pd-catalysts [2]. 
Finally the 1 and 2 receptor affinities of the synthesized  receptor ligands were 
investigated in competitive binding assays with radioligands. 
 
 
 
 
 
 
 
[1] Schläger, T.; Dissertation 2008, Münster [2] Yanagisawa, S.; Ueda, K.;  
Sekizawa, H.; Itami, K., J.Am.Chem.Soc. 2009, 131, 14622-14623  
Financial support by the IRTG Münster/Nagoya (DFG) is gratefully acknowledged. 
C1-4
CELLCULTURE STUDIES OF NOVEL CATIONIC LIPOSOMES USED 
AS NON-VIRAL VECTORS FOR GENE DELIVERY 
Erdmann, N., Folz, M., Dobner, B., Langner, A. 
Martin Luther University Halle Wittenberg, Institute of Pharmacy 
 
Gene therapy provides novel strategies for the treatment of acquired and inherited 
diseases, e.g. severe combined immune deficiency, cystic fibrosis and Parkinson’s 
disease and it presents an alternative method to traditional chemotherapy against 
cancer. The principle of gene therapy is based on substitution, inhibition or 
addition of gene functions.  
For application of genetic material it requires efficient vectors that protect nucleic 
acid against degradation and deliver it to target cells. These vehicles can be 
generally divided into two categories, viral and non-viral ones. Non-viral gene 
vectors such as cationic liposomes have several advantages compared with their 
viral counterparts, including low immune response, the ability to transfer large 
DNA molecules and they are easy to produce in large scale of similar quality. 
However, the low gene transfection efficiency is still the major disadvantage of 
these gene delivery systems.  
Novel cationic lipids based on -branched fatty acids have been synthesized in our 
group. To observe the structure-activity relationship the substances were modified, 
e.g. different chain length of the backbone or spacer and altered positive charged 
head group. We had combined them with diverse neutral helper lipids to form 
stable liposomes able to bind the chosen plasmid DNA encoding pCMV Sport -
Gal to form the lipoplex. 
Cellular uptake and toxicity of these formulations were tested on different cell lines 
with serum-containing and serum-free medium. To get information about the 
transfection efficiency the -galactosidase activity was measured using an ONPG 
assay. Cell viability was determined using a MTT assay.  
 
C2-1
HYPHENATED BIOAFFINITY SCREENING – THE INTEGRATED 
SCREENING OF COMPLEX MIXTURES 
Giera, M.1, de Vlieger J.1, Falck D.1, Lingeman H.1, Kool J.1, Irth H.1, Niessen 
W.M.A.1
1Department of Chemistry, Biomolecular Analysis Group, VU university, De 
Boelelaan 1083, 1081 HV Amsterdam, The Netherlands 
In today’s drug discovery processes new approaches like metabolic conversions 
with biologically modified enzymes, or combinatorial chemistry approaches 
become more and more important to discover the chemical space around lead 
substances. The so generated substance mixtures require sophisticated separation 
and bioaffinity screening protocols in order to identify active substances within the 
generated mixtures. One possibility to face this challenge are so called high 
resolution screening systems (HRS), combining separation sciences, bioaffinity 
screening and mass spectrometry in a single platform. This combination leads to 
the simultaneous separation, bioaffinity determination and identification of active 
substances from crude mixtures. In this lecture we will discuss the principle of 
HRS, its benefits and drawbacks on basis of the successful development and 
implication of different target examples, including the estrogen receptors alpha and 
beta, the p38 MAP Kinase, as well as a screening approach for antibacterial 
substances. The development of an online HRS assay for the drug target MAP 
Kinase p38 alpha based on fluorescence enhancement and its application to screen 
for bioactive compounds generated by means of metabolic or chemical 
modifications will be discussed in detail. 
C2-2
LIPID-BASED GENE VECTORS FOR VCAM-1 – KNOCKDOWN IN 
ENDOTHELIAL CELLS 
Hartung, A.1, Schlesinger, M. 1, Massing, U.2, Bendas, G.1 
1Pharmazeutische Chemie II, Universität Bonn, 2Klinik für Tumorbiologie, 
Universität Freiburg 
 
Besides its function in blood pressure regulation or hemostasis the vascular endo-
thelium plays a crucial role in inflammatory reactions. Activated endothelial cells 
express inflammatory specific surface receptors like vascular cell adhesion 
molecule-1 (VCAM-1) which initiates binding and subsequent migration of leuko-
cytes into the tissue and thus promotes inflammatory processes. Therefore, the re-
striction of VCAM-1 function could be a possibility in the therapy of autoimmune 
diseases. As one option the transfection of endothelial cells with -VCAM-directed 
shRNA could lead to post-transcriptional downregulation of VCAM-1. 
 
The aim of this work was to combine vascular targeting and gene manipulation 
using lipid-based gene vectors as an antiinflammatory approach. 
We could show that the transfection of -VCAM-shRNA into bEnd.3 endothelial 
cells induced an approx. 50% reduction of VCAM-1 expression levels compared to 
wild-type cells after stimulation with TNF-. As a functional consequence reduced 
adhesion of VCAM-1 binding B16F10 melanoma cells to transfected bEnd.3 was 
determined applying a microscopic cell binding assay under flow conditions. 
Based on these results we encapsulated -VCAM-shRNA into liposomes which 
were applicable for systemic administration. Dual asymmetric centrifugation [1] 
provided small homogeneous liposomes with high DNA entrapment rates. Al-
though the DNA remained intact during manufacturing procedure no down-
regulation could be observed after incubation of liposomes to bEnd.3 cells. 
Alternatively, we investigated stabilized lipid-based particles (SPLP) as gene 
vectors which consist of a lipid-complexed single plasmid entrapped within a lipid 
bilayer [2]. The preparation by detergent-dialysis resulted in serum-stable vesicles 
of small and well-defined size and yielded high DNA encapsulation rates. Pre-
liminary transfection experiments applying a GFP-encoding plasmid revealed 
SPLP to be a promising approach for vascular gene therapy. 
 
[1] Hirsch M et al. (2009) J Control Release 135(1), 80-88 
[2] Wheeler JJ et al. (1999) Gene Ther 6, 271-281 
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PLASMA-LIQUID-INTERACTIONS: CHEMISTRY AND 
ANTIMICROBIAL EFFECTS 
Oehmigen, K., Hähnel, M., Hoder, T., Wilke, Ch., Weltmann, K.-D., von 
Woedtke, Th.
Leibniz Institute for Plasma Science and Technology e. V. (INP Greifswald), 
Felix-Hausdorff-Str. 2, D-17489 Greifswald, Germany;  
E-mail: oehmigen@inp-greifswald.de 
Biomedical application of physical plasma is a growing field of research and 
development. Generally, biological plasma effects are mediated by liquid 
environments. Physical plasma treatment of liquid by a dielectric barrier discharge 
(DBD) under atmospheric air conditions resulted in microorganism inactivation 
accompanied by acidification as well as generation of nitrate (NO3-), nitrite (NO2-)
and hydrogen peroxide (H2O2). These detected compounds resulted of complex 
plasma-liquid-interactions on the plasma/gas-liquid-interface and diffused from 
this interface into deeper layers of the liquid. To clarify possible mechanisms of 
reactive species generation as well as of microorganism inactivation in plasma-
treated liquid, the interface between plasma and liquid phase was analyzed by 
Fourier transformed infrared spectroscopy (FT-IR) and optical emission 
spectroscopy (OES). Neither UV radiation nor cytotoxic nitric oxide (NO) or 
hydroxyl radicals (HO), but nitrous oxide (N2O) and ozone (O3) were measured. 
Possible reactions of these gaseous molecules with the aqueous liquid could result 
in acidification and generation of NO3-, NO2- and H2O2. Furthermore, these species, 
detected in the gas as well as liquid phases, could serve as reaction partners to 
generate NO, HO, nitrogen dioxide (NO2), pernitro acid (ONOOH) and 
hydroperoxy radicals (HOO) in the liquid which could be responsible for 
antimicrobial effects. Concluding, the possible applications of physical plasma in 
pharmaceutical fields are discussed. 
C2-4
COMPREHENSIVE QUALITIY CONTROL OF HEPARINS BY A 
SIMPLE MICROPLATE ASSAY PROCEDURE 
Alban, S., Schiemann, S., Lühn, S., Schneider, T. 
Abt. Pharmazeutische Biologie, Pharmazeutisches Institut, Christian-Albrechts-
Universität, Kiel 
 
In 2008, hundreds of serious adverse events demonstrated the health risk by 
counterfeit heparin and initiated a comprehensive revision of the Pharmacopoia 
monographs for the quality control of heparin. So far, the proposed purity tests 
include 1H-NMR-spectroscopy, SAX-HPLC and the Lowry assay, which are 
sophisticated, expensive and time-consuming, respectively. Here, we present an 
assay procedure allowing both the simultaneous detection of a wide range of 
potential heparin falsifications and natural contaminants, whereby this purity 
testing is directly combined with the determination of the potency of heparin. 
Samples of pure reference heparin (HR) and heparin spiked (HS) with varying 
contents of contaminants were examined. The contaminants included falsifications, 
e.g. OSCS, other heparin imitating sulfated glycans (SG), the FXa inhibitor 
rivaroxaban (DXI), the thrombin inhibitor argatroban (DTI) as well as the natural 
contaminant dermatan sulfate (DermS) and BSA as a protein. The assay procedure 
was performed as follows: A sample of the heparin to be tested (HT) and of a 
heparin reference (HR) (100 g/ml) were incubated with 2.5 IU/ml heparinase I for 
100 min. Then, the incubated and the non-incubated samples were measured in a 
novel fluorescence assay using the heparin sensor Polymer-H (FA) and 
chromogenic anti-FXa- (aXa) and anti-thrombin (aIIa) assays.  
The assay procedure provides information on both the purity and the potency of a 
heparin sample. By the FA, OSCS (LOD 0.5%) and other SG as well as proteins 
(LOD 0.1 %) are detected in incubated HS by increased fluorescence intensity 
compared to HR. By the potency assays aXa- and the aIIa-assay, the aXa-and aIIa-
activities (aXa-IU/mg and aIIa-IU/mg) of the non-incubated HS (IU/mg) are deter-
mined. Remaining aXa- or aIIa-activity of the incubated HS indicates again 
contamination with any SG (LOD 0.3 %), but additionally with any DXI or DTI 
(e.g. LOD 0.07 %), resp.. Finally, by using heparin cofactor II instead of 
antithrombin as reagent in the aIIa-assay, the content of DermS is quantified (LOD 
1.0 %). In conclusion, the combination of the classical potency assays, i.e. aXa- 
and aIIa-assay, with an enzymatic degradation step and a fluorescence measurement 
using the sensor Polymer-H allows a rapid, simple and comprehensive examination 
of the quality of heparin just requiring a microplate reader. 
C3-1
A METABOLOMICS VIEW ON STAPHYLOCOCCUS AUREUS 
Lalk, M., Dörries, K., Gierok, P., Liebeke, M., Meyer, H., Wunder, A. 
Pharmazeutische Biologie, Ernst-Moritz-Arndt-University Greifswald, Germany 
Staphylococcus aureus is a versatile pathogenic bacterium responsible for a wide 
range of nosocomial infections found in humans and animals. As a commensally 
microorganism S. aureus is resting on mucosa and skin. Most severe forms of 
staphylococcal infections are endocarditis, osteomyelitis, sepsis and forms of the 
toxic shock syndrome. Many S. aureus strains are able to express a large number of 
virulence factors like cell-surface exposed proteins, enzymes and toxins supporting 
invasion into tissues and cells. For survival within the host, several regulatory 
strategies, defined structural and functional features of virulence factors and the 
interaction with the core cell metabolism are responsible. These interactions 
between the eukaryotic and bacterial cells caused e.g. by nutritional limitation, 
anaerobic life or antibiotic stresses result in an adaption of the microbial virulence 
factor expression and metabolism to survive within the host environment. There is 
also an urgent need for new antimicrobial drugs especially against S. aureus and its 
Methicillin and Vancomycin resistant strains (MRSA & VRSA). To find new 
antibiotic targets or to evaluate the connection between virulence and metabolism 
in S. aureus, we have to understand the physiology of this versatile pathogen and it 
is therefore of crucial importance to decipher its metabolome. Approaches to 
understand the metabolic adaption of S. aureus towards environmental stresses 
represent a main focus of our research. In combination with proteomics, the 
metabolomics approach allows a global view and a better understanding of 
regulatory systems, dynamic ranges and the control of metabolic pathways of 
pathogens like Staphylococcus aureus. The talk will give an introduction into the 
life of S. aureus and presents recent results of the investigation of its metabolism.  
References:
1) A protocol for the investigation of the intracellular Staphylococcus aureus
metabolome. H. Meyer, M. Liebeke, M. Lalk. Anal. Biochem. 2010, 401, 250-259. 
2) Role of the (p)ppGpp synthase RSH, a RelA/SpoT homolog, in stringent 
response and virulence of Staphylococcus aureus. T. Geiger, C. Goerke, M. Fritz, 
T. Schäfer, K. Ohlsen, M. Liebeke, M. Lalk, C. Wolz. Infect. Immun. 2010, 78, 
1873-1883. 
3) A metabolomic view of Staphylococcus aureus and its eukaryotic-like 
serine/threonine kinase and phosphatase deletion mutants. M. Liebeke, H. Meyer, 
S. Donat, K. Ohlsen, M. Lalk. Chem. Biol. 2010, accepted. 
C3-2
NEW INSIGHTS WITH 'OLD' METHODS? HIGH PRECISION 
POLARIMETRY AND REFRACTOMETRY: FROM KAISER'S 
GELATINE TO DETECTING BIOLOGICAL WARFARE AGENTS. 
Bertram, N.1, Ostermeyer, M. 1, Gottsleben, F. 1
1Anton Paar OptoTec GmbH, D – 30926 Seelze-Letter, Germany 
Determining refractive indices and optical rotation are well-established in charac-
terising substances. These properties are macroscopic and conveniently measurable 
with optical methods [1]. Current pharmaceutical research, to the contrary, is faced 
with questions on the intricately accessible nano-scale. However, several nano-
effects manifest themselves in easily measurable optical properties. It is therefore 
interesting to see how high precision refractometry and polarimetry can contribute 
to current pharmaceutical research, also in combination with other methods: 
Polarimetric studies have been carried out to shed light onto phase transitions in 
gelatine (e.g. sol-gel transitions) [2]. In order to ensure effective drug delivery, the 
interaction of gelatine with agent substances has been studied e.g. for amphiphilic 
substances and diclofenac [3]. In the class of agent nano-particles, the measure-
ment of size-distributions by laser diffractometry has been shown to be highly 
sensitive to the refractive index as an input parameter [4], thus emphasising the 
urgent need for highly accurate refractometry in order to obtain reliable results. 
Polarimetric techniques are frequently employed in the context of measuring enan-
tiomeric excess in agent synthesis. Furthermore, polarisation-sensitive HPLC has 
been utilised to detect optically active samples e.g. concentrations of a nerve agent 
in blood samples [5]. Optical measurements are fast, non-destructive, and, in case 
of polarimetry, selective for optically active substances. New generation refracto-
meters and polarimeters ensure high accuracy and reproducibility, ease of use and 
stability in order to deliver a valuable contribution to pharmaceutical research. 
[1] WHO Pharmacopoeia: http://apps.who.int/phint/en/p/docf/   
[2] M. Philipp, U. Müller, R. Sanctuary, J. Baller, J. K. Krüger, New Journal  
of Physics 10 093028, 15 (2008). 
[3] T. Rades, W. Schuetze, R. Hirsch, C.C. Mueller-Goymann 
Pharmazie 49, 294-295 (1994); T. Rades, W. Schuetze, C.C. Mueller-
Goymann, Pharmazie 48, 425-432 (1993);  A. Schneeweis, I. Papantoniou, 
C.C. Mueller-Goymann, Pharm. Pharmacol. Lett. 7, 42-44 (1997);  
[4] C. M. Keck, R. H. Müller, International Journal of Pharmaceutics 355, 
150–163 (2008); J. C. Horst, H. Bunjes, private communication (2010).  
[5] G. Reiter, J. Mikler, I. Hill, K. Weatherby, H. Thiermann, F. Woreka,?
Journal of Chromatography B, 873, 86–94 (2008). 
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INTERACTION STUDIES BETWEEN PEPTIDES DERIVED FROM 
PHOTORECEPTOR GUANYLYL CYCLASE AND GCAP-2 
Pettelkau, J.1, Ihling, C.1, Schröder, T.2, Olausson, B.3, Lange, C.2, Sinz, A.1
1Pharmaceutical Chemistry and Bioanalytics, Institute of Pharmacy, 2Technical
Biochemistry; 3Structural Biology of Membrane Proteins, Institute of Biochemistry 
and Biotechnology, Martin Luther University Halle-Wittenberg 
We conducted interaction studies between peptides derived from photoreceptor 
guanylyl cyclase (ROS-GC) and the guanylyl cyclase-activating protein 2 (GCAP-
2) using a combination of chemical cross-linking and high-resolution mass 
spectrometry. ROS-GC is a membrane protein, which increases the concentration 
of cGMP and regulates the adaptation of the retina in response to light. The activity 
of the enzyme is Ca2+-dependently regulated by GCAP-1, GCAP-2, and ATP. 
GCAP is an N-terminally myristoylated Ca2+-binding protein containing four EF-
hand motifs. It is known that a malfunctioning ROS-GC/GCAP interaction may 
lead to degenerative retinopathies underlining the importance to understand these 
interactions in detail. Cross-linking reactions between ROS-GC peptides, that 
represent potential GCAP binding sites (amino acids 503-522 (GC-peptide 1) and 
965-981 (GC-peptide 2) of the full-length protein), and GCAP-2 were performed 
with and without Ca2+ using the homobifunctional amine-reactive, isotope-labeled 
(D0 and D4) cross-linker bis(sulfosuccinimidyl)glutarate (BS2G). Matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) 
was used to analyze the intact cross-linked complexes. Cross-linking reaction 
mixtures were separated by one-dimensional gel electrophoresis (SDS-PAGE). For 
a detailed structure analysis of the complexes, gel bands of interest were excised 
and digested with trypsin and Glu-C. The peptide mixtures were analyzed by nano-
HPLC/MALDI-TOF/TOF-MS and nano-HPLC/nano-electrospray ionization (ESI)-
linear ion trap (LTQ)-Orbitrap-MS. A number of intramolecular cross-links and 
several cross-linker-modified lysines were identified in GCAP-2. Intriguingly, 
several cross-links pointed to an interaction between the N-terminus of GC peptide 
2 and different lysines of GCAP-2. In the excised gel bands, GC-peptides 1 and 2 
were identified confirming the proposed interaction between both GC-peptides and 
GCAP-2. Based on the cross-links between the GC-peptides and GCAP-2, we are 
currently creating models of the GCAP-2/GC-peptide complexes. Preliminary 
docking experiments gave a first hint on the orientation of GC-peptide 2 in the 
GCAP-2/peptide complex. The final aim of this study is to create a structural 
model of the functional complex between ROS-GC and GCAP-2 in the membrane. 
C3-4
CISPLATIN-CONTAINING LIPOSOMES TO INVESTIGATE THE 
MECHANISMS OF CHEMORESISTANCE IN TUMOUR CELLS
Krieger, M.L., Schneider, V.,  Kalayda G.V., Jaehde U., Bendas, G.
Pharmaceutical Department, University of Bonn, D-53121 Bonn, Germany 
Cisplatin is one of the most widely used drugs in therapy of advanced ovarian 
cancer. Resistance of tumour cells against anticancer chemotherapy is a major 
problem limiting its therapeutic potential. The most frequently observed 
mechanisms leads to a reduction of intracellular platinum levels, and a diminished 
cytotoxicity. 
Liposomal cellular entry via endocytosis appears a promising approach to 
circumvent accumulation defects in resistant cells. In this study the potential of 
cisplatin liposomes to overcome chemoresistance was investigated. A2780 
cisplatin-sensitive and -resistant ovarian cancer cells were incubated with 
holotransferrin-targeted cisplatin-containing liposomes. Cytotoxicity (MTT and 
ATP assays) and cellular platinum accumulation (flameless AAS) were compared 
to those of the free drug. For better insights in intracellular processing of liposomal 
vs. free cisplatin, confocal laser scanning microscopy was applied. 
In comparison to the free drug, the liposomal uptake of cisplatin is increased in the 
resistant cells and decreased in the sensitive cells. Interestingly, the uptake of 
liposomal cisplatin was nearly identical in both cell lines. The platinum 
accumulation in both cell lines was correlated with cytotoxicity. Liposomes 
displayed a higher cytotoxicity in the resistant cells in comparison to the free drug. 
The measurements of the intracellular ATP levels suggest a modified intracellular 
trafficking of liposomal cisplatin after endocytotic uptake. Furthermore, despite of 
their higher cytotoxicity, liposomes may be restricted in the intracellular drug 
release [1]. This issue deserves further investigation. 
With respect to the established benefit of passive liposome targeting to tumour 
tissues, these findings suggest liposomes as promising tools to gain further insight 
into the mechanisms of chemoresistance and to potentially overcome it. 
[1] Krieger, M.L. et al., Overcoming cisplatin resistance of ovarian cancer cells by 
targeted liposomes in vitro. Int J Pharm., 2010;   389: 10-17 
C4-1
NEW DESIGN CONCEPT FOR THE DEVELOPMENT OF 17-HSD1
INHIBITORS: PROMISING DRUG CANDIDATES FOR THE 
TREATMENT OF ESTROGEN DEPENDENT DISEASES 
Oster A, Hinsberger S, Werth R, Marchais-Oberwinkler S, Frotscher M and 
Hartmann RW
Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2.3, D-
66123 Saarbrücken, Germany & Helmholtz Institute for Pharmaceutical Research 
Saarland (HIPS), Campus C2.3, D-66123 Saarbrücken, Germany.  
Estradiol (E2), the most important estrogen in humans, is involved in the initiation 
and progression of estrogen-dependent diseases like breast cancer and 
endometriosis. Its intracellular concentration is regulated by 17-hydroxysteroid 
dehydrogenase type 1 (17-HSD1) which catalyzes the reduction of the less active 
estrone (E1). Because of its expression in the diseased tissues, inhibition of 17-
HSD1 is considered as new promising therapy for the treatment of estrogen-
dependent diseases. Although several classes of highly potent steroidal and 
nonsteroidal inhibitors as well as in vivo proof of concept for the indication breast 
cancer are already described, no 17-HSD1 inhibitor has entered the clinical 
development so far. For the design of novel potential inhibitors, a new strategy was 
applied by considering selected amino acids in three areas within the substrate 
binding site as potential interacting partners. Besides the catalytic tetrade and the 
C-terminal region (well known as interacting areas of the natural substrate) a rather 
hydrophobic subpocket located under the catalytic center was chosen as third area. 
The applied design concept resulted in a new highly potent and selective class of 
17-HSD1 inhibitors. Its development and structural variations led to interesting 
structure-activity relationships.The developed inhibitors were further evaluated 
with regard to their selectivity toward 17-HSD2. This enzyme catalyzes the 
oxidation of E2 into E1 and thus represents a biological counterpart of the type 1 
enzyme. According to the therapeutic concept, relative binding affinity for estrogen 
receptors  and  (ER, ER) should be as low as possible to avoid any intrinsic 
estrogenic effects. In contrast to some other inhibitor classes, the intracellular 
activity (in T47D cells, a breast cancer cell line expressing 17-HSD1 and 17-
HSD2) of these inhibitors was evaluated and revealed IC50-values in the low 
nanomolar range. All data obtained make these inhibitors interesting candidates for 
further preclinical evaluation.  
C4-2
LIGHT-ACTIVATABLE TRANS-DIAZIDO PT(IV): BIOLOGICAL 
ACTIVITY AND THE INFLUENCE OF AMINO LIGANDS 
Westendorf A.F.a, Zerzankova L.b, Grünert R.a, Sadler P.J.c, Brabec V.b,
Bednarski P.J.a
a Institute of Pharmacy, University of Greifswald. b Institute of Biophysics, 
Academy of Sciences Czech Republic. c Department of Chemistry, University of 
Warwick, UK. 
Light-sensitive Pt(IV) complexes are a new approach to lower adverse 
drug reactions, increase the selectivity and therefore enhance the efficacy of 
platinum-based anticancer treatment. They can be used in the photodynamic 
therapy for the treatment of localized tumors accessible for irradiation.Here we 
report on the influence of the amino ligand towards the biological activity of three 
trans-diazido platinum(IV)-complexes.  
The complexes trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] (1) and 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(pyridine)] (2) were first described by 
Sadler. We have now synthesized the piperidine analogue trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(piperidine)] (3) and studied its photobiological properties. To 
analyze the cell growth inhibitory potential, an in vitro microtiter method with 
various human cancer cell lines was used. Least active complex was 1, while 2 and 
3 showed similar antiproliferative activity. No cross resistance to oxoplatin was 
found for 2 and 3. DNA is considered to be the main target of platinum-based 
anticancer drugs, thus we studied the interaction of the light activated complexes 2
and 3 with DNA. The binding to calf thymus DNA was studied by a square wave 
voltammetry assay. After irradiation of 2 and 3 the binding to DNA of was almost 
completed by 10 min (cisplatin 50% after 180 min). Importantly, high chloride 
concentrations (100 mM) inhibited the platination of DNA. The decrease in 
ethidium bromide (EtBr) DNA intercalation was investigated next. For 2 and 3 a 
greater decrease in EtBr fluorescence was detected compared to cisplatin, 
indicating the formation of more bifunctional DNA adducts. Unwinding of closed 
circular supercoiled pUC19 plasmid DNA was analyzed by an agarose gel mobility 
shift assay. The levels of interstrand cross-linking by 2, 3 and cisplatin in linear 
DNA were measured by using the pUC19; the cross-linking efficiency for both 
complexes is comparable to cisplatin. In conclusion, the introduction of a more 
bulky ligand increased the cytotoxic potency compared to an ammine ligand, but 
there was no difference in the photobiological properties between complexes with a 
cyclic aliphatic amine (piperidine) and a heterocyclic amine ligand (pyridine). 
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NOVEL FLUORESCENT PROTEIN KINASE INHIBITORS  
Tolle, N.1, Dunkel, U.1, Müller, C.1, Preu, L.1, Oehninger, L.1, Rubbiani, R.1,
Meyer, A.1, Ott, I.1, Haase, T.2, Behrends, S.2, Totzke, F.3, Schächtele, C.3,
Kubbutat, M. H. G.3, Kunick, C.1
1 Technische Universität Braunschweig, Institut für Pharmazeutische Chemie, 
Beethovenstraße 55, 38106 Braunschweig, Germany; 2 Technische Universität 
Braunschweig, Institut für Pharmakologie, Toxikologie und Klinische Pharmazie, 
Mendelssohnstraße 1, 38106 Braunschweig, Germany; 3 ProQinase GmbH, 
Breisacher Straße 117, 79106 Freiburg, Germany 
Fluorescent tags are feasible structure ele-
ments for visualization of the intracellular 
localization of drug molecules. However, 
these tags may change both the biological 
activity and the cellular distribution of the 
original molecular entity. We here report a 
novel class of protein kinase inhibitors 
which shows fluorescence based on the core 
structure of the molecules and not because 
of an added fluorescent tag. These novel 
compounds are (4Z)-4-{[N-(difluoroboryl)-
anilino]methylene}-3,4-dihydro-1H-1-benz-
azepine-2,5-diones (1) which are chemically 
related to the paullones, a family of 
inhibitors of glycogen synthase kinase-3 (GSK-3) and of cyclin-dependent kinases 
(CDKs). Compared to the paullones, 1 shows a modified kinase inhibition profile. 
The synthesis, the spectroscopic properties and the chemical stability of 1 will be 
discussed in the presentation. It will be demonstrated that both the stability and the 
kinase inhibitory activity of the new compound class is strongly influenced by the 
nature of the substituent R2. The inhibition profile in an array of 16 cancer-related 
protein kinases will be presented as well as the antiproliferative activity for HT-29 
human colon carcinoma cells. It was proven by confocal laser scanning microscopy 
that the novel fluorescent protein kinase inhibitors enter the cytosol, but not the 
nucleus of HT-29 cells.
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IMMOBILIZED MONOLITHIC TRYPSIN REACTOR FOR 
APPLICATION IN PHARMACEUTICS AND PROTEOMICS
Sproß, Jens, Sinz, Andrea 
Abteilung Pharmazeutische Chemie und Bioanalytik, Institut für Pharmazie, 
Martin-Luther-Universität Halle-Wittenberg, Wolfgang-Langenbeck-Str.4, D-
06120 Halle/Saale 
 
The use of monolithic supports for a wide variety of applications has rapidly 
expanded during the past few years. The greatest advantages of monoliths 
comprise their high chromatographic performance even at high flow rates, long 
life-time of the columns and the possibility of down-scaling, which opens novel 
applications in the field of microfluidics. Classical reversed phase (RP) or ion-
exchange separation media are applied for a broad variety of analytes - small 
molecules or proteins - while monolithic supports can also be employed for more 
specialized analytical challenges owing to their ease of modification, which 
includes almost all known coupling techniques. As such, an affinity enrichment of 
analytes and separation of enantiomers have been described. 
In this work, a monolithic trypsin reactor (MTR) was prepared with the aim of 
identifying and characterizing proteins. The employed monolithic support was 
prepared from glycidyl methacrylate, acrylamide, and ethylene glycol 
dimethacrylate by free radical polymerization and trypsin was coupled to the 
support using the glutaraldehyde technique. The enzymatic activity of immobilized 
trypsin was determined using the prototype substrate N-benzoyl-L-arginine ethyl 
ester. Using cytochrome c and bovine serum albumin (BSA) as model proteins 
digestion parameters, i.e., protein concentration, chaotropic agent, digestion 
temperature, were optimized. The digests were collected and analyzed by matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-
TOF/TOF-MS). Moreover, an automated HPLC/MS system allowing an integrated 
digestion of proteins, separation of the resulting peptides, and a subsequent 
identification of the poteins by mass spectrometry was established. Finally, the 
MTR was used for analyzing a protein mixture. Four proteins (310 to 800 ng/mL) 
were digested in the presence of a 1,000-fold molar excess of BSA. The digest was 
separated by nano-HPLC and analyzed by MALDI-TOF/TOF-MS/MS resulting in 
the identification of all four low abundant proteins. 
The high efficiency of the MTR combined with a low back pressure and digestion 
times within a few minutes demonstrate the great potential for high-throughput 
protein identification and characterization. 
C5-1
ACHIRAL–CHIRAL LC/LC–MS/MS COUPLING FOR 
DETERMINATION OF CHIRAL DISCRIMINATION EFFECTS IN 
DRUG METABOLISM 
Kammerer, B.1,2, Kahlich, R. 1, Laufer, S.1
1 Pharmazeutisches Institut, Universität Tübingen and  2Zentrum für 
Biosystemanalyse, Universität Freiburg 
Many physiological processes show a high degree of stereoselectivity, including 
the metabolism of xenobiotics as catalyzed by cytochrome P450 enzymes. An 
analysis of these chiral discrimination effects in drug metabolism is essential for an 
in-depth understanding of metabolic pathways that differ between enantiomers of a 
given chiral drug or metabolite thereof. Achiral chromatographic separation and 
structural identification followed by chiral analysis of metabolites from blood 
specimens usually requires a time-consuming multistage analytical technique.  
In an effort to optimize such a complicated analytical scheme, a novel two-
dimensional online achiral–chiral liquid chromatography–tandem mass 
spectrometry (LC/LC–MS/MS) coupling method was developed by using a peak 
parking technique in combination with a makeup flow system. Metabolites were 
separated in the first dimension using a C18 reversed-phase system. A makeup 
eluent of water/methanol (95/5) was split into the flow before storing the 
metabolites separately on chiral cartridges. Subsequently, the metabolite 
enantiomers were eluted backward onto the analytical chiral column and separated, 
and the ratio of enantiomers was determined. The method was successfully 
validated with respect to limit of detection, linearity, intra- and interday accuracy, 
and precision. In the course of a human volunteer study investigating the influence 
of CYP (cytochrome) 2C9 genetic polymorphism on phenprocoumon (PPC) 
metabolism, we used this new two-dimensional online analytical technique for the 
analysis of PPC metabolites in plasma. The enantiomeric forms of 4-, 6-, and 7-
hydroxy-PPC metabolites as well as two novel metabolites were identified, and the 
ratio of the enantiomers was calculated. We found that the enantiomeric ratio for 
the different metabolites in the plasma sample of each measured individual differs 
markedly from a nearly 100% chiral discrimination for the two new putative 
metabolites. 
This new analytical coupling method possesses general utility in the analysis of 
chiral discrimination effects, particularly as it relates to pharmacokinetics and 
dynamics, a scientific field that is rapidly becoming an area of concern and interest. 
C5-2
OPTIMIZATION AND APPLICATION OF PEA SEEDLING AMINE 
OXIDASE MODIFIED BIOSENSORS 
Telsnig, D.1, Kassarnig, V1. Kalcher, K2, Ortner, A.1
1Institute of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, 
Karl-Franzens-University Graz, Austria 
 e-mail: dietlind.telsnig@uni-graz.at 
2Institute of Chemistry, Department of Analytical Chemistry, Karl-Franzens-
University Graz, Austria 
Pea seedling amine oxidase (PSAO) is a Cu-TOPA enzyme catalyzing the 
oxidative deamination of biogenic amines in the presence of oxygen and water as 
shown in the following reaction equation [1]. 
R-CH2-NH2 + O2 + H2O  R-CHO + NH3 + H2O2 
A rapid and simple method for the determination of biogenic amines based on 
carbon paste biosensors modified with manganese dioxide [2] and PSAO has been 
developed. This amperometric detector for hydrogen peroxide has been 
investigated in flow injection analysis (FIA) with an operating potential of +0,4 V 
vs. Ag/AgCl.  Sorensen phosphate buffer 0,1 M; pH 7,5 has been used as media.   
Immobilization of enzyme has been performed by entrapping DAO in Nafion®
films. This method provides good fixation of the enzyme as well as low impact on 
enzyme activity. The analytical parameters have been investigated and the sensor 
was used to estimate the biogenic amines content in food samples. 
References 
[1] McGrath A.P., Hilmer K.M., Collyer C.A., Shepard E.M., Elmore B.O., Brown 
D.E., Dooley, D.M., Guss J.M. Biochemistry 48, 9810-9822 (2009)  
[2] Schlachl K,. Alemu H., Kalcher K., Jezkova J., Svancara I., Vytras K., 
Analytical Letters 30(15), 2655-2673 (1997) 
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FILLING THE GAP BETWEEN PHARMACOLOGICAL TESTING AND 
IN VIVO FINDING ON THE EXAMPLE OF BOSWELLIA SERRATA
Tawab, M.,1 Werz, O.,2 Schubert-Zsilavecz, M.1,3
1Central Laboratory of German Pharmacists, Eschborn, 2Pharmaceutical 
Analytics, University Tübingen, 3Pharmaceutical Chemistry / ZAFES, Goethe-
University  
Very often, especially in case of herbal remedies, pharmacological data are 
not found in line with in vivo findings in human. In many cases this may be 
attributed to the poor bioavailability of the respective pharmacologically 
active substances in vitro. On the example of Boswellia serrata, a promising 
anti-inflammatory alternative that was assigned an orphan drug by the EMA 
for treating peritumoral edema, it is shown how this gap may be filled. 
Until recently, the pharmacological effects of Boswellia serrata were 
mainly attributed to suppression of leukotriene (LT) formation via inhibition 
of 5-lipoxygenase (5-LO) by 11-keto--boswellic acid (KBA) and acetyl-
11-keto--boswellic acid (AKBA). These two BAs have been also chosen in 
the monograph of Indian frankincense in the European Pharmacopoiea 6.0 
as markers to ensure the quality of the air-dried gum-resin exudate of B. 
serrata.
However KBA and AKBA failed to inhibit LT formation in human whole 
blood and pharmacokinetic data revealed concentrations of AKBA and 
KBA in plasma below the pharmacologically effective concentration in
vitro, putting the hitherto assumed mechanism of action into question. In 
view of this apparent gap between in vitro and in vivo data, the Caco-2 
model was used to evaluate the contribution of individual boswellic acids to 
the observed effects. A close look at the clinical indications of BSE and the 
underlying results of clinical trials as well as the experimental data from in
vitro studies, and all available pharmacokinetic and metabolic data of BAs, 
resulted finally in a new mechanism of action for Boswellia serrata, which 
is worth to be investigated in further clinical trials and pharmacological 
studies.
C5-4
ROLE OF THE SECOND EXTRACELLULAR LOOP OF THE 
ADENOSINE A2B RECEPTOR IN RECEPTOR ACTIVATION 
Schiedel, A.C.1, Seibt, B.F.1,  Sherbiny, F.2, Maaß, A.2, Müller, C.E.1
1PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I,  
University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany. 2Fraunhofer 
Institute SCAI, Schloss Birlinghoven, 53754 Sankt Augustin, Germany. 
The human adenosine A2B receptor, which belongs to the familiy of G protein-
coupled receptors (GPCRs), plays an important pathophysiological role in 
inflammatory processes, especially in respiratory diseases, where it appears to have 
a proinflammatory role. In contrast to the closely related A2A receptor subtype, 
which mediates antiinflammatory and immunosuppressive effects at low, 
nanomolar adenosine concentrations, the A2B receptor is typically only activated by 
much higher, micromolar concentrations of adenosine. The second extracellular 
loop (ECL2) is known to participate in ligand binding in many GPCRs. The ECL2 
of the A2B receptor is several amino acids longer then the ECL2 of the other 
adenosine receptor subtypes. 
In the present study we combine homology modeling, loop simulation and 
mutagenesis in order to gain deeper insights into the structure and function of the 
human A2B receptor. The complete ECL2 of the A2B receptor was replaced by the 
ECL2 of the A2A receptor by overlap extension mutagenesis and selected single 
amino acid residues were exchanged for alanine by site-directed mutagenesis. The 
resulting receptor mutants were stably expressed in CHO cells using a retroviral 
expression system, and characterized by radioligand binding and functional assays.  
All agonists investigated showed increased efficacy at the loop-exchange mutant as 
compared to the wildtype A2B receptor, while most single mutants did not show 
any effect. In contrast to the wild type A2B receptor, the loop-exchange mutant 
could be activated by the A2A-selective agonist CGS21680 at micromolar 
concentrations.
The second extracellular loops of the adenosine A2 receptors appear to play an 
important role in receptor activation. 
C6-1
IN SILICO ANALYSIS OF THE HISTAPRODIFEN INDUCED 
ACTIVATION PATHWAY OF THE GUINEA-PIG H1-RECEPTOR 
Strasser, A.1, Wittmann, H.-J.2
1Pharmazeutische Chemie, Universiät Regensburg 2Fakultät Chemie/Pharmazie, 
Universität Regensburg 
The histamine H1-receptor (H1R) belongs to the rhodopsin-like G protein-coupled 
receptors. Several studies suggest that the binding of (partial) agonists into the 
binding pocket of biogenic amine receptors induces a conformational change from 
the inactive to the active state of the receptors. Meanwhile several crystal structures 
of inactive and active states of opsin or biogenic amine receptors are known. 
However, there is only little knowledge about the binding (or unbinding) pathways 
of ligands into the binding pocket of biogenic amine receptors on molecular level. 
So far, it was not possible with molecular dynamic simulations to observe the 
ligand binding and receptor activation. Furthermore, there is nearly nothing known, 
in which state of ligand binding the receptor gets activated. Thus, the aim was to 
get more detailed insights into the process of ligand binding and receptor 
activation. With the recently developed LigPath algorithm, we scanned the 
potential energy surface of the binding process of dimeric histaprodifen, a partial 
agonist at the gpH1R, into the binding pocket of the gpH1R, taking also into 
account the receptor activation [1]. The calculations exhibited large conformational 
changes of Trp6.48 and Phe6.55 during ligand binding and receptor activation. 
Additionally, conformational changes were also observed for Phe6.52, Tyr6.51 and 
Phe6.44. Conformational changes of Trp6.48 and Phe6.52 are discussed in literature as 
rotamer toggle switch in context of receptor activation. Additionally, the 
systematic scan of the potential energy surface allows to predict favored binding 
pathways. The calculations indicate that the binding of dimeric histaprodifen, 
accompanied by receptor activation is energetically preferred. In general, this study 
gives new insights onto ligand binding and receptor activation on molecular level.  
[1] Strasser A, Wittmann HJ (2010) In silico analysis of the histaprodifen induced 
activation pathway of the guinea-pig histamine H1-receptor; J comput aided mol 
des, in press 
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DYNAMIC MOTION INVESTIGATION OF 17-HSD1 PROVIDES 
INSIGHTS IN ITS ENZYME KINETICS AND LIGAND BINDING 
Negri M 1, Recanatini M 2 and Hartmann RW1 
1 Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2.3, D-
66123 Saarbrücken, Germany & Helmholtz Institute for Pharmaceutical Research 
Saarland (HIPS), Campus C2.3, D-66123 Saarbrücken, Germany.  
2 Department of Pharmaceutical Sciences, University of Bologna, Via Belmeloro, 
6, I-40126 Bologna, Italy 
 
Bisubstrate enzymes, such as 17-hydroxysteroid dehydrogenase type 1 (17-
HSD1), exist in solution as an ensemble of conformations. 17-HSD1 catalyzes the 
last step of the biosynthesis of estradiol and, thus, it is a potentially attractive target 
for breast cancer treatment. Based on a structural analysis of the available crystal 
structures, different enzyme conformations were assigned to the putative five steps 
of the random bi-bi kinetic cycle of 17-HSD1. Moreover, in order to validate the 
designed catalytic cycle all-atom molecular dynamic simulations were performed 
using the four 3D-structures best describing apoform, opened, occluded and closed 
state of 17-HSD1 as starting structures. With three of them binary and ternary 
complexes were built with NADPH and NADPH-estrone, respectively, while two 
were investigated as apoform. Free energy calculations followed up with the aim to 
judge more accurately which of the MD complexes describes a specific kinetic 
step. The analysis of these eight long range MDs revealed an essential role played 
by backbone and side chain motions, especially of the FG’-loop, in cofactor and 
substrate binding. Thus, a selected-fit mechanism is suggested for 17-HSD1, 
where ligand-binding induced concerted motions of the FG-segment and the C-
terminal part guide the enzyme along its preferred catalytic pathway. 
The elucidation of the kinetic mechanism and of the peculiar role of the flexible 
FG‘-loop laid the basis for the identification of a novel binding mode for the 
bis(hydroxyphenyl)arene derivatives, highly potent inhibitors of 17-HSD1. In 
particular, docking studies using an opened enzyme conformer, supported by an 
exhaustive molecular electrostatic potential investigation, led to the discovery of a 
novel binding mode for this class of inhibitors. They seem to bind in a synergic 
manner to the nicotinamide moiety of NADPH via 	-	 stacking and h-bond 
formation, hence freezing the enzyme in a „half-switching“ state and inducing a 
dynamic disruption of the enzyme‘s kinetics. This binding mode was then 
confirmed by a multiple-trajectory MD approach supported by free binding energy 
calculations.  
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PREVALENCE AND DETERMINANTS FOR THE INTAKE OF 
INAPPROPRIATE DRUGS IN PRIMARY HEALTH CARE  
Fiss, T.1,3, Dreier, A.1, van den Berg, N.1, Ritter, CA.2, Hoffmann, W.1,3
1Institute for Community Medicine, University Greifswald 2Institute of Pharmacy, 
University Greifswald 3German Centre for neurodegenerative diseases, 
Greifswald/ Rostock 
Objectives: Drug intake is associated with a risk of drug related problems, e.g. the 
intake of potentially inappropriate drugs (PIM). The proportion of PIM taken by 
elderly people in the AGnES-studies (dtsch. Arzt-entlastende Gemeinde-nahe E-
Health-gestützte Systemische Intervention) was analysed. Methods: 744 patients 
aged >65 years and regular drug intake received a standardized IT-supported, 
comprehensive home medication review (HMR) conducted by specially qualified 
AGnES-practice assistants in a community-based, prospective cohort study in the 
ambulatory health care sector. Out of these patients, 373 received a pharmaceutical 
intervention by the local pharmacist and a follow-up HMR. The updated Beers’-list 
was used to detect PIM for patients >65 years as well as drug-condition 
interactions. GP’s diagnoses were extracted from patients’ health records. Results:
18% (n=134) of the patients received in total n=163 inappropriate drugs during the 
baseline data collection. Out of these drugs, most prevalent PIM were 
benzodiazepine derivates (n=45) and non-selective monoamine reuptake inhibitors 
(n=29). A total of n=25 drug-condition interactions (e.g. Amitriptyline and COPD) 
were identified. The intake of PIM was associated with self reported falls (phi-
value: 0.1074; p=0.0244). Multivariate binary logistic regression showed that the 
number of taken active substances (OR=1.176; 95%-CI 1.121-1.234, p<0.001) is a 
determinant for taking at least one PIM. In patients’ follow-up data we found an 
insignificant reduction of the proportion of patients taking PIM from 18.5% (n=69) 
to 15.3% after pharmaceutical intervention (n=57; p=0.0704; McNemar test). 
Conclusions: In a community based setting a high proportion of patients taking 
PIM was investigated. Statistical associations with self-reported falls were found. 
A limited reduction of intake of PIM over the follow up period may have been 
caused by insufficient knowledge of PIM by pharmacist and GP, respectively. 
Since study procedures did not focus on PIM, confounding may influence data. A 
more significant reduction of PIM-intake should be aimed in the future. Further 
research should employ controlled designs. 
K1-1
PROSPECTIVE MULTI-STEP INTERVENTION STUDY TO PREVENT 
DRUG ADMINISTRATION ERRORS IN PAEDIATRIC SETTINGS 
Niemann, D.1, Ewen, A.L.1, Oelsner, S.1, Köpf, E.1, Traiser, C.1, Seebald, K.2,
Henhapl, T.2, Meyburg, J.2, Ruef, P.2, Schmitt, C.P.2, Bertsche, A.2, Haefeli, 
W.E.1, Bertsche, T.1
1Dep. of Clinical Pharmacology and Pharmacoepidemiology, Cooperation Unit 
Clinical Pharmacy, 2University Children’s Hospital, University of Heidelberg 
Introduction Particular pharmaceutical knowledge is required in administering 
drugs which are often not approved for children. In routine care, drug 
administration errors are alarmingly frequent in children. Therefore, we conducted 
a study investigating a monitoring and teaching concept to prevent those errors.
Participants and Methods A multi-step study was approved by the local Ethics 
Committee and conducted in a general paediatric ward (GPW) and paediatric 
intensive care unit (PICU). (i) Clinical pharmacists observed the nurses to identify 
errors in routine drug administration. (ii) An expert panel developed a 
questionnaire to identify knowledge deficits (KDs) and (iii) presented the answers 
(1st intervention) followed by (iv) another monitoring. (v) Errors were classified in 
a decision-matrix for a teaching course (2nd intervention) followed by (vi) another 
monitoring. Fisher’s-Exact-Test and Mann-Whitney-U-Test were used for 
statistical analysis (significant with p<0.05).
Results The monitoring in GPW assessed 767/1161 processes (66%) with at least 
one administration error. The error prevalence was 1053/1161 (91%) which 
decreased to 263/400 (66%, p<0.001) after the 1st and to 254/645 (39%, p<0.001) 
after the 2nd intervention. Concerning IV drugs in 38/326 processes (12%) the 
wrong kind of solvent, in 94/326 (29%) the wrong amount of solvent were used. 
The error prevalence in the wrong kind of solvent decreased to 3/167 (2%, 
p<0.001; RRR 83%) by the teaching course and in the amount of solvent to 13/87 
(15%, p<0.001, RRR 48%) by the questionnaire. The overall prevalence of KDs 
(response rate 60% vs.64%) was similar in GPW and PICU (20% vs.22%, p>0.05) 
whereas the prevalence of KDs in subcategories varied between the GPW and the 
PICU (IV drugs 43% vs.31%, p=0.013, oral drugs 2%vs.19%, p<0.001).  
Conclusion Monitoring was an appropriate strategy to identify unexpected high 
error prevalence in routine drug administration. A multi-step intervention strategy 
tailored to the prevalence, potential severity, and causes of the errors prevented a 
high fraction of those identified errors.
K1-2
COMPARISON OF BODY SIZE DESCRIPTORS AS INFLUENTIAL 
FACTORS IN SIBROTUZUMAB POPULATION PHARMACOKINETICS 
Niebecker, R.1,2, Kuester, K.1, Kunz, U.3 Kloft, C.1
1Department of Clinical Pharmacy, Martin-Luther-Universitaet Halle-Wittenberg 
2Graduate Research Training program PharMetrX 3Boehringer Ingelheim Pharma 
GmbH & Co. KG, Biberach 
Background: Several monoclonal antibodies including sibrotuzumab have been 
shown to exhibit body size-dependent pharmacokinetics (PK) [1]. The objective of 
this analysis was to compare the suitability of different body size descriptors 
(BSD) as patient specific factors (covariates) in a population PK model, to 
determine the optimal BSD and to investigate the impact of differences in body 
size on sibrotuzumab exposure. 
Methods: Sibrotuzumab PK has best been described by a two-compartment model 
with both linear and nonlinear elimination from the central compartment. Body 
weight (BW) was incorporated as a covariate on 4 structural model parameters [2]. 
Nonlinear mixed-effect modelling with NONMEMTM was applied to estimate 
model parameters for the baseline model without BSD covariates and for the 
models including the following body size descriptors: BW, patient height, body 
mass index (BMI), body surface area, fat-free mass, ideal body weight, lean-body 
mass. 
Results: (1) Compared to the baseline model, incorporation of body size 
significantly improved the model performance by reducing unexplained variability. 
(2) The different BSDs performed similar, with the exception of BMI, being 
inferior. (3) Covariate relations in patients with median and “extreme“ (0.05 and 
0.95 percentile) BSD values indicated considerable influence of body size. (4) This 
influence was confirmed by deterministic simulations of a 12 week treatment 
period with weekly dosing of 100 mg sibrotuzumab. Minimum Css in patients with 
“extremely low” body size even exceeded maximum Css of patients with 
“extremely high” body size. 
Conclusion: Body size does have an impact on sibrotuzumab PK. Based on the 
analyses, no single BSD appears to be superior. Stochastic simulation will be 
implemented to further evaluate this hypothesis and may ultimately contribute to 
optimised dosing regimens. 
References: [1]. D.R. Mould, B. Green. BioDrugs 24: 23 (2010). [2]. C. Kloft et al. 
Invest New Drugs 22: 39 (2004). 
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CARDIOVASCULAR RISK SCREENING AND PREVENTION CARE 
FOR 50 - 70 YEAR OLD PEOPLE IN COMMUNITY PHARMACIES 
Birkle, S.1, Schlager, H.1, Dörje, F.2, Lee, G.3, Richter, W.4
1WIPIG, München, 2Apotheke, UK Erlangen, 3Lehrstuhl für Pharmazeutische 
Technologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, 4Institut für 
Fettstoffwechsel und Hämorheologie, Windach 
Coronary heart disease is much more frequent in the Northeast of Bavaria, 
Germany, than in other regions of Bavaria. The aim of this project is, 1st, to 
evaluate the presence of risk factors for coronary heart disease in this high-risk 
region and, 2nd, to contribute to cardiovascular risk reduction by preventive 
Pharmaceutical Care. For this purpose a new screening method is used: People 
between the age of 50 and 70 years are invited to have their blood pressure, body 
mass index and other data measured in a community pharmacy. In addition a small 
blood sample from the finger pad is taken and sent to a specialized laboratory to 
detect alterations of metabolism. Besides routinely determined parameters as total 
cholesterol, HDL cholesterol and LDL cholesterol, other lipid values like small 
dense LDL and VLDL-composition are measured. For people with increased 
cardiovascular risk Prevention Care Services are offered for twelve months, e.g. 
Diet Counseling in community pharmacies. Afterwards all participants are tested 
again.
Thirteen community pharmacies are involved in this project. After 5 months of 
recruiting (February till June 2010), 1521 participants have already been included. 
85 % of them are showing severe cardiovascular risk factors which were mainly 
caused by unhealthy lifestyle. Therefore cardiovascular risk factors in this region 
may be reduced by improving lifestyle habits. Within this project community 
pharmacists offer support to subjects at risk to modify their lifestyle. At the end of 
the follow-up we will evaluate the effect of the Prevention Care Services on the 
assessed risk factors for coronary heart disease. If it could be shown, that those 
pharmaceutical interventions are successful, we aim to expand this project to other 
community pharmacies. 
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EVIDENCE FOR THE EFFECTIVENESS OF STW5 (IBEROGAST) IN 
AN EXPERIMENTAL MODEL OF ULCERATIVE COLITIS. 
Abdel-Aziz, H.1, Wadie, W.2, Kelber, O.3, Weiser, D.3, Khayyal, M. T2.  
1Faculty of Pharmacy, Heliopolis University, 2Faculty of Pharmacy, Cairo 
University, 3Scientific Department, Steigerwald Arzneimittelwerk GmbH
 
Our earlier studies with the successful use of STW5 in Trinitrobenzene sulfonic 
acid –induced colitis as an experimental model of Crohn‘s disease has prompted us 
to investigate the potential use of the drug in Dextran Sodium Sulfate (DSS) 
induced colitis as an experimental model reflecting more closely ulcerative colitis 
in man. 
Colitis was induced in rats by feeding them with DSS (5%) in drinking water for 
one week. STW 5 (Iberogast), a multicomponent herbal preparation of established 
efficacy in functional dyspepsia and irritable bowel syndrome, was tested in dose 
levels of 2 ml/kg and 5 ml/kg alongside with sulfasalazine (300 mg/kg) as a 
reference standard. The drugs were given orally daily for 1 week before initiation 
of colitis induction and continued during the week of DSS feeding. At the end of 
the experimental period, animals were sacrificed, the colons examined, and blood 
samples taken for measurement of relevant parameters. 
DSS induced a sharp decrease in body weight which was more effectively 
normalized by STW 5 than by sulfasalazine. It also led to shortening of colon 
length and an increase in colon mass index, effects that were reversed by treatment 
with either drug. Changes in myeloperoxidase, reduced glutathione, glutathione 
peroxidase, and TNF induced by DSS were also reversed by STW5 and by 
sulfasalazine almost to the same extent.  
The present findings emphasize the antioxidant and antiinflammatory effects of 
STW 5 and point to the potential usefulness of STW 5 in the clinical setting of 
ulcerative colitis. 
P1-1
LOCALISATION AND PHARMACOLOGY OF HISTAMINE-INDUCED 
FREE RADICAL PRODUCTION IN SMALL AND LARGE INTESTINE 
Klein K.1, Merkel K.1, Jandaghi D1, Kelber O.2, Vinson B.R.2, Weiser D.2,
Klessen C.3, Rammensee H.G.4, Heinle H.1
1Physiology, University of Tübingen, Tübingen, 2Scientific Department, 
Steigerwald Arzneimittelwerk GmbH, Darmstadt, 3Anatomy, 4Biology, 
University of Tübingen, Tübingen, Germany 
Oxidative stress is a hallmark of the inflammatory reaction and is also involved in 
many acute and chronic diseases of the intestine. As the generation of oxygen free 
radicals by intestinal preparations can be stimulated by histamine, we aimed to 
characterize this effect in different preparations from small and large intestine 
from brown standard mice (SV1297) and to describe the influence of 
pharmacological agents, so studying pathogenic mechanisms involved in 
inflammation and allergy in the gastrointestinal tract.  
After excision of the gut, three layers of the wall were prepared and separated into 
mucosa, tela submucosa and muscularis. The preparations of the gut were studied 
histologically. Free radical production of the tissue was detected by luminol-
enhanced chemiluminescence.  
As histology showed, different types of leukocytes are located mainly in mucosal 
and submucosal layers. Radical production could be stimulated by histamine in a 
concentration range from 5 to 100 μmol/L, mainly in segments of proximal and 
distal small intestine, less in colon, and only in the tela submucosa. Neither the 
intact wall of the gut, nor the pure mucosa or the muscularis could be stimulated 
by histamine. The effect could be blocked specifically by the H3-antagonist 
clobenpropit with an IC50 of approx. 0.1 μmol/L; blockers of H1 and H2 receptors 
exerted inhibitory effects only at concentrations more than 10-100fold higher. 
Similar to the antioxidant trolox, herbal extracts from peppermint and chamomile, 
as well as STW 5 (Iberogast®), a herbal combination preparation with 
antiinflammatory properties and containing these extracts, had significant 
inhibitory effects even in dilutions down to 0.1 μl/ml. 
It can be concluded, that submucosal tissue, especially in the small intestine, 
represents a source of free radicals. This source of free radicals could 
be important in inflammatory and allergic intestinal diseases, as well as in 
irritable bowel syndrome, a disease often involving subclinical inflammations, 
and might be a target for pharmacotherapeutic interventions. 
P1-2
ANTI-PROLIFERATIVE EFFECTS OF THE ANTIDYSPEPTIC DRUG 
STW 5 IN COMPARISON WITH NSAIDS  
Kelber, O.1, Bonaterra, GA.2,3, Zügel, S.3, Hildebrandt, W.3, Weiser, D.1, 
Kinscherf, R.3 
1Scientific Department, Steigerwald Arzneimittelwerk GmbH 2Section 
Macroscopic Anatomy, Medical Faculty Mannheim, University of Heidelberg 
3Department of Medical Cell Biology, University Marburg 
 
STW 5 (Iberogast®) consist of a combination of nine plant extracts and is widely 
used in the treatment of functional gastrointestinal disorders, including functional 
dyspepsia and irritable bowel syndrome. Our objective was to determine anti-
proliferative effects of STW 5 on colon adenocarcinoma cells (HT-29) in 
comparison with non steroidal anti-inflammatory drugs (NSAIDs) like aspirin 
(ASA) or diclofenac (Diclo), which both have been shown to reduce of colon 
carcinoma risk in clinical and epidemiological trials. 
HT-29 cells were treated with Diclo (0.025-0.1 mM), ASA (0.2-2.5 mM), STW 5 
(3-300 g/ml) or its components STW 6 (Iberis amara totalis; 12.5 g/ml), STW 
5-K II (peppermint leaves; 50 g/ml), STW 5-K VII (milk thistle fruit; 50 g/ml) 
or STW 5-K VIII (lemon balm leaves; 25 g/ml). The anti-proliferative effects 
were measured with Sulforhodamine. Apoptosis was identified by YO-PRO-1® 
staining. The expressions of the apoptosis-relevant factors p53, Bcl2, BAX , 
Caspase-3 and the transcription factors subunits of nuclear factor-kappa B (NF-
B)-p65 (RELA), -p50 mRNA were quantified by Real-Time PCR. Treatment with 
either Diclo (0.1 mM), ASA (2.5 mM), STW 5 (100 g/ml) or its components 
STW 6 (12.5 g/ml), STW 5-K II (50 g/ml), STW K VII (100 g/ml) or STW 5-
K VIII (25 g/ml) inhibited proliferation by ca. 50-60 % (ASA or Diclofenac 45-
50%) in comparison with untreated cells (control). STW 5 (as well as ASA or 
Diclo) induced a 3 to 4- fold increase in apoptosis. Moreover, 100 g/ml STW 5 
showed a 20% or 30% induction of Caspase-3 or BAX expression, whereas ASA 
or Diclo revealed inhibitory effects. Furthermore, 100 g/ml STW 5 inhibited the 
Bcl2 and p53 mRNA expression compared to 25 g/ml. 100 μg/ml STW 5 
increased the expression of NF-B subunits compared with ASA and Diclo. Our 
data suggest that STW 5 and some of its components show anti-proliferative 
effects on HT-29 adenocarcinoma cells in vitro, possibly due to an induction of 
apoptosis cascade via caspase-3 activation, an influence on mitochondrial stability 
and the activation of the NF-B pathway. The STW 5 -induced pathway may be 
different from the pathway initiated by ASA or Diclo. 
P1-3
Kurzvorträge - Pharmakologie & Toxikologie
Kurzvo träge
http://www.digibib.tu-bs.de/?docid=00038117 24/02/2011
INHIBITION OF PRODRUG ACTIVATION BY HERBAL EXTRACTS 
AND SECONDARY PLANT METABOLITES 
Unger, M., Völker, M., Schaeflein, L., Frank A.
Institute of Pharmacy and Food Chemistry, University of Würzburg, Germany; 
The bioactivation of pharmacologically inactive prodrugs by drug metabolizing 
enzymes e.g. esterases, phosphatases or cytochrome P450 (CYP) enzymes is a 
pivotal prerequisite for their pharmacological action. Examples for prodrugs which 
are bioactivated by CYP enzymes are irinotecan, cyclophosphamide, desogestrel 
and the ADP induced platelet aggregation inhibitors ticlopidine and clopidogrel. 
Recently, the bioactivation of clopidogrel attracted much interest because the 
concomitant use of clopidogrel and proton-pump inhibitors attenuates the benefit 
of antiplatelet therapy. In this case it was speculated that the main reason for the 
impaired clopidogrel bioactivation is the inhibition of CYP2C19 by the proton 
pump inhibitor omeprazole. Here we describe herbal extracts and secondary plant 
metabolites which have the potential to interfere with prodrug bioactivation 
because they inhibit CYP enzymes or esterases. For example, the inhibition of the 
bioactivation of cyclophosphamide to aldophosphamide was studied using a 
LC/LC/MS-based screening method. Herbal extracts and natural products were 
incubated with cyclophosphamide and human liver microsomes or recombinant 
CYP2B6 and aldophosphamide was quantified with LC/LC/MS in the positive 
electrospray ionisation mode after derivatisation with O-(pentafluorobenzyl)-
hydroxylamine. Also, the inhibition of the bioactivation of clopidogrel by herbal 
extracts was studied using an LC/LC/MS-based CYP2C19 inhibition assay. Since 
many prodrugs such as irinotecan or methylphenidate are activated by esterases, 
we also studied the inhibition of esterases in a human liver S9 fraction with p-
nitrophenyl acetate as substrate. Among the herbal extracts and natural products 
with inhibitory activity are peppermint, hawthorne and quercetine, respectively. 
The obtained data suggest that the bioactivation of prodrugs by CYP enzymes or 
esterases can be strongly inhibited by herbal extracts or secondary plant 
metabolites. This implies a risk for drug interactions if natural products with a high 
inhibitory activity are bioavailable or applied in quantities that exceed the 
therapeutical relevant doses. Thus, care should be taken if prodrugs are used 
concomitantly with herbal extracts. 
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HOW DOES THE INSULIN GRANULE BEHAVE BEFORE ITS 
RELEASE? - TIRF MICROSCOPY ANALYSIS   
Hatlapatka, K.1, Matz, M.2, Baumann, K.2 and Rustenbeck, I.1
1Institute of Pharmacology, Toxicology and Clinical Pharmacy and 2Institute of 
Medicinal Chemistry, University of Braunschweig, Germany  
Background: The release of a pool of membrane-adjacent secretory granules 
which are in a primed and docked state and await one final trigger, a 
depolarization-induced influx of Ca2+, is held responsible for the first phase of 
glucose-induced insulin secretion.  Recently, we observed that 15 mM K+ led to a 
20 mV depolarization  and to a lasting increase of the cytosolic Ca2+ concentration 
([Ca2+]i), but only to a modest transient increase in secretion, suggesting that the 
effect of depolarization on insulin secretion is only incompletely understood. 
Methods: Insulin secretion was measured by perifusion of mouse islets and MIN6 
pseudoislets and ELISA of the effluate. The [Ca2+]i of islets and MIN6 cells was 
measured with the Fura technique. Submembrane granules were visualized by 
transfection of MIN6 cells with an insulin-EGFP fusion protein and imaging by 
TIRF microscopy at 37°C. The images were evaluated by a purpose-made program 
written in MatLab to achieve a complete observer-independent quantitation.  
Results: Islets perifused with 5 mM glucose showed only a transient increase in 
secretion when K+ was raised to 15 mM. A subsequent elevation to 40 mM K+
resulted in a prompt overshooting increase in secretion which remained increased 
as long as 40 mM K+ was present. In contrast, [Ca2+]i was continuously elevated by 
15 mM K+ and increased further when K+ was raised to 40 mM. The same 
secretion and [Ca2+]i pattern could be observed with MIN6 pseudoislets. MIN6 
cells transfected with insulin-EGFP were therefore used to analyze the behavior of 
submembrane granules by TIRF microscopy at 5 time points: beginning, prior to 
high K+, one each during 15 and 40 mM K+ and one after washout of high K+. At 
each time point a sequence of 100 images was acquired within 12 s. Resident time, 
number of arriving and departing granules (i.e. return or release), and the total and 
net distance covered by the submembrane granules were evaluated as mentioned. 
Conclusion: 40 mM K+ affects arrival, departure and residence time of insulin 
granules, but not movement parallel to the membrane. 15 mM K+ is moderately 
effective, which concurs with dynamic secretion measurements. Currently there is 
no indication that long-term resident granules are preferentially departing during 
stimulation.  
P2-1
TOWARDS FULLY AUTOMATED TIRF MICROSCOPY IMAGE DATA 
ANALYSIS 
Matz, M.1, Hatlapatka, K.2, Rustenbeck, I.2, Baumann, K.1
1Institute of Pharmaceutical Chemistry, TU Braunschweig 2Institute of 
Pharmakology and Toxicology, TU Braunschweig 
Recently, total internal reflection fluorescence microscopy (TIRF-M) was 
established as a standard method for observing molecular processes occurring close 
to the cell membrane. The so obtained image data and sequences of image data (i.e. 
movies) are usually evaluated with commercial software packages, which 
determine count statistics of the labeled cell components or tracking of single 
objects.
The goal of this continuing work is to develop a simple and fast software solution 
that analyzes the images and movies with special focus on simultaneously tracking 
all detectable objects in TIRF microscopic images. To guarantee robustness and 
unbiased analysis, the data analysis shall be almost parameter-free (i.e. ideally 
needs no expert input). 
The current data analysis algorithm comprises the following steps: First, the 
images and image sequences are preprocessed. Next, the fluorescing cell parts of 
interest are automatically detected and tracked from picture to picture over time. 
During tracking, all detected objects are characterized by seven different 
parameters such as the x- and y-coordinates, ground area, peak height, and the peak 
integral. The analysis was developed and tested on real-time, live cell imaging 
TIRF sequences. The results will be presented in the talk.  
P2-2
SEX BIAS IN LEUKOTRIENE GENERATION CAUSES GENDER-
SPECIFIC EFFICACY OF LEUKOTRIENE SYNTHESIS INHIBITORS 
Dehm, F.1, Pergola, C.1, Jazzar, B.1, Rossi, A.2, Laufer, S.3, Sautebin, L.2, Werz, 
O.1 
1Department of Pharmaceutical Analytics, 4Department of Medicinal Chemistry, 
Pharmaceutical Institute, University Tuebingen, 72076 Tuebingen, Germany  
2Department of Experimental Pharmacology, University of Naples Federico II, 
80131 Naples, Italy 
 
Leukotrienes (LTs) are powerful lipid mediators of immune and inflammatory 
responses derived from phospholipase(PL)A2–released arachidonic acid by the 
enzyme 5-lipoxygenase (5-LO), aided by the 5-LO-activating protein (FLAP). 
Prominent diseases (e.g. asthma, allergic rhinitis, rheumatoid arthritis) that are 
related to LTs are more common in females and gender-disparities in LT 
biosynthesis exist due to down-regulation by androgens [1]. Here we show that 
FLAP inhibitors are more efficient in females than in males, and that androgens are 
responsible for these gender differences in vitro and in vivo. In human blood from 
females, FLAP inhibitors (MK886, Bay-X1005 and licofelone) suppressed 5-LO 
product formation more efficiently than in blood from males, and this difference 
was abolished by supplementation of female blood with 5-dihydrotestosterone. 
Instead, direct 5-LO inhibitors reduced 5-LO product formation in males and 
females equally well. MK-886 effectively reduced LTB4 pleural levels in female 
but not in male rats treated with carrageenan, and MK886 increased survival only 
of female mice in a model of PAF-induced lethal shock. Administration of 
testosterone abolished the protective effects of MK886. In view of the current 
active development of FLAP inhibitors as therapeutics in respiratory and 
cardiovascular diseases, our data suggests to call for “gender-tailored therapy” in 
LT-related diseases and prompt for consideration of gender issues in the 
development and use of drugs modifying LT biosynthesis, in order to optimize 
medical therapy both for men and women. 
References 
[1] Pergola, C. et al., ERK-mediated regulation of leukotriene biosynthesis by 
androgens: a molecular basis for gender differences in inflammation and asthma. 
Proc Natl Acad Sci U S A. 105(50):19881-6 (2008) 
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INFLUENCE OF PREGNANCY ON LEUKOTRIENE FORMATION:          
A PRIME EXAMPLE FOR PERSONALIZED MEDICINE 
Rogge, A.1, Pergola, C.1, Werz, O.1       
1Department of Pharmaceutical Analytics, Pharmaceutical Institute, University of 
Tübingen, Germany  
Pregnancy is considered as the most fundamental sex difference and is 
accompanied by major changes of the immune system which are necessary for a 
successful outcome of gestation. Pregnancy is characterized by downregulation of 
cell-mediated immunity and upregulation of humoral immunity as well as of 
certain components of the innate immune system. Leukotrienes (LT) and other 
lipoxygenase (LO) products are powerful lipid mediators with major roles in 
inflammation and innate immunity. Although it is known that the course and 
characteristics of LT-related diseases (like asthma and allergic rhinitis) change 
during pregnancy, the regulation of LT biosynthesis has not been investigated 
under theses conditions. Here, we show that LT synthesis in blood and isolated 
neutrophils strongly differs during pregnancy from non-pregnant females. Thus, 5-
LO product formation in stimulated (Ca-ionophore A23187 or 
lipopolysacharide/fMLP) whole blood from pregnant donors is significantly higher 
(1.8-fold) than in blood from female controls. Although increased neutrophil 
numbers may explain the increased LT formation in blood of pregnants, isolated 
neutrophils from pregnant donors have significant lower capacities (1.5-fold) for 5-
LO product synthesis. Interestingly, plasma from pregnant donors upregulates 5-
LO product formation (1.4-fold) in neutrophils from control females. Taking 
together, complex mechanisms (neutrophilia, upregulating effects of plasma, 
downregulation of LT synthetic capacity in neutrophils) are involved in regulation 
of 5-LO product formation during pregnancy resulting in higher LT-biosynthesis in 
blood from pregnant donors. This higher LT formation in blood from pregnant 
donors might explain the higher incidence of asthma and allergic rhinitis during 
pregnancy and represents a prime example for the importance of research in the 
field of personalized medicine.  
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IMPACT OF EFAVIRENZ ON INTESTINAL AND HEPATIC 
METABOLISM AND TRANSPORT: INTERACTION STUDY WITH 
EZETIMIBE IN HEALTHY VOLUNTEERS  
Oswald S.1, Meyer zu Schwabedissen H.1, Nassif A.1, Modess C.1, Lütjohann D.2,
Desta Z.3, Kroemer H.K.1, Siegmund W.1
1Department of Pharmacology, University of Greifswald, Germany; 2Department
of Clinical Pharmacology, University of Bonn, Germany; 3Indiana University 
School of Medicine, Indianapolis, USA   
Background: Hypercholesterolemia frequently occurs in HIV-infected patients 
treated with antiretroviral drugs as efavirenz (EFA). These patients may benefit 
from combination with the cholesterol absorption inhibitor ezetimibe (EZE). 
Disposition and lipid-lowering effects of EZE are dependent on intestinal ABCB1, 
ABCC2 and UGT1A1. These genes are known targets of the nuclear receptors 
CAR and PXR. EFA was shown to be a potent activator of CAR. In this study, we 
determined the influence of EFA on disposition and effects of EZE.  
Methods: Steady state pharmacokinetics of EZE (10 mg, po) alone and after 
multiple doses of EFA (400 mg, po) was studied in 12 healthy male subjects. 
Genome wide expression analysis was performed in duodenal biopsies before and 
after EFA treatment (8 d). Subsequently, mRNA levels were verified for known 
CAR targets in intestinal tissue and peripheral blood mononuclear cells (PBMCs). 
Serum cholesterol and plant sterols were measured to conclude on EZE effects. 4-
ßOH-cholesterol and serum bilirubin were determined as surrogates for hepatic 
CYP3A4 and UGT1A1 activity. Results: Intestinal expression of several CAR 
target genes such as ABCB1, CYP3A4, CYP2B6 and UGT1A1 was not affected 
by chronic EFA treatment. In well agreement to this, EFA treatment had no effect 
on the serum levels of EZE but significantly decreased the GLUC exposure 
(325±152 vs. 466±223ng×h/ml, p=0.005) as caused by inhibition of UGT1A1 (in 
vitro data). Sterol-lowering effects of EZE were not altered by EFA. On the 
contrary, serum levels of 4-ßOH-cholesterol were significantly increased 
(100±33.8 vs. 64.0±24.2 ng/ml, p<0.05). Moreover, chronic treatment with EFA 
significantly up-regulated ABCB1 (p=0.0007) and CYP2B6 (p=0.0158) in PBMCs 
of our subjects. Conclusions: Chronic treatment with EFA did not influence 
intestinal genes of metabolism and transport but up-regulated hepatic CYP3A4 as 
well as ABCB1 and CYP2B6 in PBMCs. The observed influence of EFA on 
disposition of EZE as obviously caused by modulation of intestinal glucuronidation 
of EZE seems not to be of clinical relevance.   
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INFLUENCE OF ROUX-EN-Y GASTRIC BYPASS SURGERY ON THE 
PHARMACOKINETICS OF PARACETAMOL, TALINOLOL AND 
AMOXICILLIN IN OBESE PATIENTS  
Peters J.1, Oswald S.1, Haenisch S.2, Ludwig K.3, Bernhardt J.3, Saljé K.1, Modess 
C.1, Cascorbi I.2, Siegmund W.1
1Department of Pharmacology, University of Greifswald, Germany; 2Institute for 
Experimental and Clinical Pharmacology, University of Kiel, Germany ; 3Klinik
für Chirurgie, Klinikum Südstadt, Rostock, Germany 
Background: Roux-en-Y gastric bypass, whereby the stomach, the duodenum and 
the jejunum are circumvented, is an accepted procedure in weight loss surgery. 
Despite its frequent application and the well documented risk of nutritional 
deficiencies, only little is known about the pharmacokinetic consequences in these 
patients. Therefore, this study aims to evaluate the influence of this bariatric 
surgery on pharmacokinetics of paracetamol (well absorbed along the gut), 
talinolol (ABCB1 substrate) and amoxicillin (PEPT1 substrate). We hypothesized 
that absorption of talinolol and amoxicillin is decreased after surgery because of 
the regional intestinal expression of ABCB1 and PEPT1. 
Methods: Disposition of paracetamol (200 mg, po), talinolol (50 mg, po) and 
amoxicillin (250 mg, po) was studied in a three-period, cross-over study in 8 obese 
patients (7 females, 1 male, age 22-53 years, body mass index 44.3-61.9) before 
and after Roux-en-Y gastric bypass surgery. Serum concentrations of paracetamol, 
talinolol and amoxicillin were quantified using validated HPLC-UV and LC-
MS/MS methods. Tissue specimens were taken from the duodenum and the jejunal 
anastomosis, respectively, before, during and one year after surgery. 
Results: Bariatric surgery did not significantly affect Cmax (2.63±1.07 μg/ml vs. 
2.00±0.69 μg/ml), AUC0-24h (6.11±1.56 μg×h/ml vs. 5.94±3.90 μg×h/ml) and half-
life (4.35±2.89 h vs. 3.97±2.47 h) of paracetamol. Cmax and AUC0-24h of talinolol 
(36.5±17.3 ng/ml vs. 42.7±17.2 ng/ml; 350±115 ng×h/ml vs. 403±155 ng×h/ml) 
and amoxicillin (2.57±1.51 μg/ml vs. 3.84±1.45 μg/ml, p=0.036; 7.47±4.58 
μg×h/ml vs. 8.23±1.65 μg×h/ml) tended to be decreased. The differences in 
disposition were most prominent during the absorption period of talinolol (AUC0-
6h, 98.4±23.8 ng×h/ml vs. 142±57 ng×h/ml, p=0.075) and amoxicillin (AUC0-3h,
5.02±2.88 μg×h/ml vs. 6.14±1.66 μg×h/ml).  
Conclusions: Roux-en-Y gastric surgery may result in reduced oral absorption of 
talinolol and amoxicillin by bypassing the respective ABCB1- and PEPT1-
mediated absorption windows for both compounds in the proximal intestine. 
P3-2
THE SARM-LIKE ACTIVITY OF SUPPLEMENT INGREDIENT NOR-
ANDROSTENEDIONE DEPENDS ON ROUTE OF ADMINISTRATION 
Parr, MK., Diel, P., Schänzer, W. 
Center for Preventive Doping Research, German Sport University Cologne  
 
19-Norandrostenedione (estr-4-ene-3,17-dione, NOR, structure in fig. 1) represents 
one of the first prohormones that were marketed as dietary supplements. During 
metabolism it is converted to the active hormone 19-nortestosterone (nandrolone, 
17-hydroxyestr-4-en-3-one, NT, structure in fig. 1). To characterize its tissue 
specific androgenic and anabolic potency after s.c. and p.o. administration and to 
identify potential adverse effects Nor was studied in a hershberger assay. 
Orchiectomized rats were treated with NOR for 12 days either s.c. (1 mg/kg 
BW/day) or orally (0.1, 1 and 10 mg/kg BW/day). The tissue weights of the levator 
ani, the seminal vesicle and the prostate were analyzed to determine the anabolic 
and androgenic activity. Heart and liver wet weights were examined to identify 
side effects. Serum concentrations of NOR and its metabolite NT were determined. 
After s.c. administration NOR stimulates skeletal muscle growth in a highly 
selective manner but exhibits only weak androgenic activity in rats. In contrast, 
after oral administration of NOR neither stimulation of the prostate nor the levator 
ani could be observed in the doses administered in this study. 
Interestingly, and in contrast to s.c. treatment, oral administration of NOR resulted 
in a dose-dependent decrease of body weight. GC-MC analysis revealed that free 
and glucuronidated NOR and NT were detectable in the serum after oral and s.c. 
administration and that NOR was converted to NT in comparable amounts 
independent of the route of administration. 
In summary, oral administration of NOR as in “dietary supplements”, at least in the 
rat, seems to be a very ineffective strategy to increase  skeletal muscle mass  but 
seems to be associated with side effects. 
 
O
O
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O
NOR NT  
Fig. 1: Chemical structures of Norandrostenedione (NOR) and Nandrolone (NT) 
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COMPARATIVE ANALYSIS OF ESTERASE ACTIVITY IN 
RECONSTRUCTED HUMAN SKIN MODELS AND EXCISED HUMAN 
SKIN
Weindl, G.1, Klipper, W.1, Bätz, F.M.1, Schäfer-Korting, M.1
1Institut für Pharmazie (Pharmakologie und Toxikologie), Freie Universität Berlin 
Reconstructed 3D models of human skin and epidermis have mainly been 
characterized regarding their barrier function and validated for the use in in vitro
tests for skin corrosion and skin irritation. A great deal less is known about their 
metabolic capacity concerning activation of prodrugs and toxification or 
detoxification of chemicals and drugs. In this study, we aimed to compare the 
esterase activity in commercially available reconstructed human skin and epidermis 
models and excised human skin. Metabolite profiling of the double ester 
prednicarbate by HPLC-UV and determination of enzyme kinetic parameters Vmax
and KM using fluorescein diacetate as a model substrate was performed in parallel. 
After 24 hours prednicarbate exposure, prednisolone was detected as the main 
metabolite, however, the relative amount ranked as: full-thickness (epidermis and 
dermis) skin model ~ epidermis model > excised human skin. The similar results 
for full-thickness and epidermis models can be explained by the higher esterase 
activity in human keratinocytes as compared to fibroblasts which contribute very 
little to the total activity. The formation rates of fluorescein fitted the Michaelis-
Menten model. In accordance with prednicarbate metabolism, Vmax of fluorescein 
diacetate cleavage was highest in full-thickness skin models and lowest in excised 
human skin. KM values did not markedly differ between the test matrices. In 
conclusion, our results indicate that reconstructed human skin models may be 
useful to quantitatively address esterase activity of native human skin, although an 
increased activity compared to normal human skin should be taken into account. 
P3-4
THE Gq-COUPLED MUSCARINIC M3 RECEPTOR GAINS Gi 
SIGNALING COMPETENCE UNDER CONDITIONS OF ENHANCED 
cAMP 
Janßen, N.1, Kebig, A.1, Kostenis, E.2, Mohr, K.1 
1Pharmacology and Toxicology Section, Institute of Pharmacy, University of Bonn; 
2Section Molecular-, Cellular-, and Pharmacobiology, Institute of Pharmaceutical 
Biology, University of Bonn 
 
Signaling pathway activation was investigated in CHO cells using an optical 
biosensor technique to measure cellular dynamic mass redistribution (DMR; Epic® 
system). CHO cells were stably transfected either with the cDNA of the human 
muscarinic M2 receptor, preferentially coupling to Gi, the human adrenergic 2 
receptor, preferentially coupling to Gs or the human muscarinic M3 receptor, 
preferentially coupling to Gq. Agonists used for receptor stimulation were a 
dualsteric agonist with M2-preference and Gi-selectivity (ref. 1), orciprenaline as a 
2 activator and acetylcholine to stimulate the M3 receptor. To dissect signaling 
events that underlie the whole cell DMR response, G proteins were targeted with 
selective toxins. To inhibit Gi, cells were pretreated with pertussis toxin (PTX, 
100 ng/ml) overnight. This toxin ADP-ribosylates the undissociated Gi protein 
and results in an inactivated heterotrimer. To mask a Gs dependent DMR response, 
cholera toxin (CTX, 100 ng/ml, overnight) was used. It maximally activates the Gs 
pathway by ADP-ribosylating the activated -subunit of Gs-coupled receptors. As 
expected DMR signals were eliminated by pertussis toxin in case of hM2 activation 
and by cholera toxin in case of h2 activation. In case of hM3, the signal was not 
sensitive to PTX but instead augmented after CTX pretreatment. Surprisingly, the 
M3 signal of CTX pretreated cells was partially sensitive to pertussis toxin. To 
check whether an intracellular cAMP elevation may cause the unexpected Gi 
component, the direct adenylylcyclase stimulant forskolin (10 μM, 2.5 hours) was 
applied and again the cellular response to acetylcholine included a PTX-sensitive 
component. These findings suggest that the human muscarinic M3 receptor is 
capable of coupling to Gi proteins under conditions of elevated intracellular cAMP. 
In conclusion the G protein selectivity of the muscarinic M3 receptor depends on 
the functional context in CHO cells. 
[1] Antony et al. (2009) FASEB J. 23: 442-450. We are grateful to Prof. Dr. Ulrike 
Holzgrabe (University of Würzburg, Germany) and Prof. Dr. Marco De Amici (University 
of Milan, Italy) for the design and synthesis of “hybrid 1”. We thank Corning Life Sciences 
for their support on the Epic® system. E.K. and K.M. are supported by the DFG. 
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LINKER LENGTH IS PIVOTAL FOR POTENCY OF DUALSTERIC 
AGONISTS AT MUSCARINIC M2 RECEPTORS 
Bock, A.1, Holzgrabe, U.2, De Amici, M.3, Mohr, K.1 
1Pharmacology and Toxicology Section, Institute of Pharmacy, University of 
Bonn, 2Institute of Pharmaceutical Chemistry, University of Würzburg, 
3Department of Pharmaceutical Sciences, University of Milan, Italy 
 
Seven-transmembrane receptors (7TMRs), also known as G protein-coupled 
receptors (GPCRs), constitute the largest class of cell membrane-bound receptors. 
Many 7TMRs contain at least one allosteric binding site which is topographically 
distinct from the orthosteric site recognized by the respective endogenous 
messenger compound. The muscarinic M2 acetylcholine receptor is an excellent 
model to study allosteric/orthosteric interactions as the core region of the allosteric 
binding site is well characterised. Recently, bisquaternary allosteric/orthosteric 
hybrid compounds were designed consisting of an allosteric antagonist fragment 
(from either naphmethonium or W84) linked via an aliphatic hexamethylene 
middle chain with an orthosteric high affinity agonist. Most interestingly, these 
dualsteric agonists showed subtype-selectivity for the M2 receptor and biased 
agonism by exclusively activating the Gi pathway [1]. However, the potency of 
these hybrids was considerably lower than that of the orthosteric building block. 
Here we investigated the role of middle-chain length in affecting the potency of 
dualsteric agonists. In addition, the allosteric and the orthosteric building blocks 
were systematically varied. M2 receptor-mediated G protein activation was 
measured by [35S]GTP
S binding in membranes of Flp-InTM CHO cells stably 
expressing the human muscarinic M2 receptor. Summing up, the findings show that 
middle-chain elongation considerably increases the potency of dualsteric agonists.  
 
[1] Antony J et al. (2009). Dualsteric GPCR targeting: a novel route to binding and 
signaling pathway selectivity. FASEB J 23: 442-450 
 
Support by the DFG is gratefully acknowledged (HO 1368/12-1, MO 821/2-1). 
  
 
P4-2
THE MULTI-TARGETED KINASE INHIBITOR SORAFENIB INHIBITS 
HUMAN CYTOMEGALOVIRUS REPLICATION 
Michaelis, M.1, Paulus, C.2, Löschmann, N.1, Dauth, S.1, Stange, E.1, Doerr, 
H.W.1, Nevels, M.2, Cinatl, J jr.1
1Institut für Medizinische Virologie, Klinikum der Goethe-Universität, Frankfurt 
am Main 2Institut für Medizinische Mikrobiologie und Hygiene, Universität 
Regensburg
Human cytomegalovirus (HCMV) is a major pathogen in immuno-compromised 
individuals. Here, non-toxic concentrations of the anti-cancer kinase inhibitor 
sorafenib were shown to inhibit replication of different HCMV strains (including a 
ganciclovir-resistant strain) in different cell types. In contrast to established anti-
HCMV drugs, sorafenib inhibited HCMV major immediate early promoter activity 
and HCMV immediate early antigen (IEA) expression. Sorafenib is known to 
inhibit Raf. Comparison of sorafenib with the MEK inhibitor U0126 suggested that 
sorafenib inhibits HCMV IEA expression through inhibition of Raf but 
independently of signalling through the Raf downstream kinase MEK 1/2. In 
concordance, siRNA-mediated depletion of Raf but not of MEK reduced IEA 
expression. In conclusion, sorafenib diminished HCMV replication in clinically 
relevant concentrations and inhibited HCMV IEA expression, a 
pathophysiologically relevant event that is not affected by established anti-HCMV 
drugs. Moreover, we demonstrated for the first time that Raf activation is involved 
in HCMV IEA expression. 
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STUDIES ON THE MECHANISM OF ANTIHYPERTENSIVE ACTION 
OF SOLANUM INDICUM SSP. DISTICHUM. 
Khayyal, M. T.1, Abdel-Aziz, H.2, El-Awady, S.3, Ammar, R. 4
1Faculty of Pharmacy, Cairo University, 2Faculty of Pharmacy, Heliopolis 
University, 3Faculty of Pharmacy, Suez Canal University, 4Faculty of Pharmacy, 
Sinai University. 
Oral treatment of L-NAME hypertensive rats with S. distichum (30mg/kg) for one 
week after induction of hypertension showed a significant reduction in the elevated 
SBP and resulted in an 
increased diuretic activity manifested by increased renal excretion of water and 
electrolytes (Na+ and K+), raised NO levels in the sera of treated rats and a 
reduction of MDA levels in the sera of rats. 
The extract further protected against the deleterious effects of hypertension on the 
kidneys, heart and vascular smooth muscle. 
The results obtained confirmed that S. distichum extract has a definite 
antihypertensive activity in this model. This antihypertensive effect could be due to 
a variety of factors acting simultaneously, namely, a) preservation of NO 
vasorelaxant properties by increasing its level in sera of hypertensive rats, 
b)maintenance of the cellular antioxidant capacity, c) enhancement of pressure 
natriuresis and d) protection against hypertension-induced organ damage. 
The ethyl acetate and methanol (50%) fractions of the extract showed highest 
activity, indicating that polyphenolic compounds, which are highly soluble in the 
ethyl acetate and methanol, may have been responsible for the antihypertensive 
activity of the extract. 
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ANALYSIS OF REQUIREMENTS FOR DIMERIZATION OF NITIRIC 
OXIDE SENSITIVE GUANYLYL CYCLASE  
Kraehling, J. R., Busker, M., Haase, N., Haase, T., Linnenbaum, M., Oberle, S., 
Behrends, S. 
Pharmakologie, Toxikologie und Klinische Pharmazie, TU Braunschweig  
 
Nitric oxide sensitive guanylyl cyclase is the physiological receptor for nitric oxide 
(NO) and nitric oxide releasing drugs. Its second messenger cyclic GMP is crucial 
for vasodilatation, penile erection, platelet disaggregation and neurotransmission. 
The heterodimeric enzyme is formed by a 1-subunit and either an 1- or an 2-
subunit. Dimerization of the enzyme is a prerequisite for its catalytic activity. 
There is conflicting evidence which parts of the subunits are mandatory for 
heterodimerization. Wagner et al. (J Biol Chem 2005; 280:17687-17693) show that 
amino acids 61-128 of the 1 subunit are mandatory for quantitative 
heterodimerization.  
 
In the current study we purified the 1-subunit after co-expressing different 1 
deletion mutants using an analogous strategy to the study of Wagner et al. 2005. 
We found preserved quantitative dimerization with 1 despite truncation of 259 or 
364 amino acids of the 1-subunit. Analogous amino-terminal truncation of the 1 
subunit (1NH-NOX) also led to preserved heterodimerization. In addition we used 
fluorescence resonance energy transfer (FRET) based on fluorescence lifetime 
imaging using fusion proteins of the 1 subunit with EYFP and the 1-subunit and 
its deletion mutants with ECFP. Analysis of the respective combinations in HEK-
293 cells showed that the fluorescence lifetime was significantly shorter for 1/1, 
1N258/1 and 1N363/1 than the negative control. We conclude that the amino-
termini of the 1- and the 1-subunit are dispensable for quantitative dimerization.  
 
Next we asked whether dimerization depends on chaperone systems or cellular 
organelles. Using a cell free expression system based on eukaryotic Sf9 cells 
(EasyXpress®, Qiagen), we successfully co-expressed the  and  subunits as 
detected by Western blot analysis. In contrast to co-expression in intact Sf9 cells, 
no catalytic activity could be detected in the cell free Sf9-system. This indicates 
that chaperones systems or cellular organelles present in intact Sf9 cells, but absent 
in the cell free Sf9-system are vital for formation of an intact heterodimeric 
enzyme.  
 
P5-2
CYCLIN DEPENDENT KINASE 5 (CDK5) REGULATES ENDOTHELIAL 
CELL MIGRATION AND ANGIOGENESIS
Liebl, J.1, Weitensteiner, S.B.1, Vereb, G.2 Takacs, L.3, Fürst, R.1, Vollmar, A.M.1,
Zahler, S.1
1Center for Drug Research, Pharmaceutical Biology, Ludwig-Maximilians-
University, 81377 Munich, Germany  
2Medical and Health Science Center, Department of Biophysics and Cell Biology, 
University of Debrecen, H-4032 Debrecen, Hungary 
3Medical and Health Science Center, Department of Ophthalmology, University 
of Debrecen, H-4032 Debrecen, Hungary 
Angiogenesis contributes to various pathological conditions including arthritis, 
psoriasis, diabetic retinopathy, macula degeneration, and cancer. During recent 
years, the search for anti-angiogenic compounds and their molecular targets has 
been intensified, focusing on the inhibition of vascular endothelial growth factor 
(VEGF) signalling. Due to the resistance against existing anti-angiogenic therapy 
an urgent need exists to understand the molecular basis of vessel growth and to 
identify new targets for anti-angiogenic therapy.  
Here we show that Cdk5, an important modulator of neuronal processes, regulates 
endothelial cell migration and angiogenesis, suggesting Cdk5 as a novel target for 
anti-angiogenic therapy. Inhibition or knockdown of Cdk5 reduce endothelial cell 
motility and block angiogenesis in vitro and in vivo. We elucidate a specific 
signalling of endothelial Cdk5. In contrast to neuronal cells, the motile defects 
upon inhibition of Cdk5 are not caused by an impaired function of focal adhesions 
or microtubules, but by a modulation of the actin cytoskeleton. In the endothelium, 
Cdk5 regulates the formation of lamellipodia, actin-based protrusions at the leading 
edge of migrating cells that represent a prerequisite for cell motility. The effect of 
Cdk5 seems to be mediated by the small GTPase Rac1. Inhibition of Cdk5 
decreases the activity of Rac1 at the leading edge, indicating Rac1 as a novel 
downstream effector of Cdk5. 
Our work elucidates Cdk5 as a crucial new regulator of endothelial cell migration. 
It suggests Cdk5 as a novel, pharmacologically accessible target for anti-
angiogenic therapy and provides the basis for a new therapeutic application of 
Cdk5 inhibitors as anti-angiogenic agents. 
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FLAVOPIRIDOL PROTECTS AGAINST INFLAMMATION BY 
INHIBITION OF CDK9 
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The Netherlands 5ProQinase GmbH, Freiburg 
 
Flavopiridol (FP), a natural compound-derived pan-CDK inhibitor, is used in 
clinical studies for the treatment of different types of malignancies. We 
hypothesized that FP possesses anti-inflammatory properties. Hence, we 
investigated the impact of FP on inflammatory processes in vivo and in vitro and 
studied the underlying mechanisms of action in detail. 
In vivo, FP effectively protected against concanavalin A-induced inflammatory 
liver injury in mice as it inhibited the rise in serum levels of transaminases (AST, 
ALT), reduced necrosis, and lowered infiltration of neutrophils. Studying 
leukocyte-endothelial cell interactions in vivo in venules of the mouse cremaster 
muscle, we found that FP reduces the TNF-evoked leukocyte adherence and 
transmigration. Neutrophil adhesion to endothelial cells was also reduced in vitro. 
This is due to an inhibition of endothelial cell adhesion molecule (E-selectin, 
ICAM-1) protein and mRNA expression, both in vitro and in vivo. Mechanistically, 
FP decreased TNF-induced NF-B reporter gene expression, but did not influence 
NF-B DNA-binding activity, p65 translocation, degradation of IB, and IKK 
activity. In order to elucidate the basis of these surprising results, we performed a 
cellular kinome profiling (PepChip microarray). FP inhibited the kinases LIMK1, 
JNK1, CK2, and PKC-. However, by gene silencing or pharmacological inhibition 
of these kinases, we found that none of them is significantly involved in ICAM-1 
regulation. We then tested FP for its inhibitory profile in a recombinant kinase 
panel: FP (100 nM) inhibited CDK4, 6, 8, and 9 more potently than other (cell 
cycle-related) CDKs. By using shRNA and a specific inhibitor, we identified 
CDK9 as the kinase responsible for the effect on ICAM-1. 
In summary, we revealed FP as a potent anti-inflammatory compound in vivo. FP 
effectively blocked the interaction of leukocytes and endothelial cells by inhibition 
of endothelial cell adhesion molecule expression. Mechanistically, FP potently 
reduced NF-B-driven transcription, but does not interfere with NF-B activation. 
This effect is related to the inhibition of the transcription-associated kinase CDK9. 
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REDUCTIVELY DEGRADABLE LINEAR POLY(ETHYLENE 
GLYCOL)-POLY(ETHYLENE IMINE)–COPOLYMERS FOR THE 
DELIVERY OF NUCLEIC ACIDS 
Bauhuber, S., Göpferich, A., Breunig, M.
Lehrstuhl für Pharmazeutische Technologie, Universität Regensburg  
* This work was supported by the DFG (Deutsche 
Forschungsgemeinschaft), grant BR 3566/1-1.  
The delivery of nucleic acids with polymers has become a promising tool for the 
modulation of gene expression inside cells. Branched poly(ethylene imine) (bPEI) 
is still the gold standard, but also shows a significant toxicity to cells. In order to 
overcome this problem derivatives of this polymer were proposed, especially block 
copolymers from linear PEIs of low molecular weight and poly(ethylene glycol) 
(PEG). While all other approaches created branched, graft copolymers, we propose 
strictly linear, redox-sensitive PEG-PEI block copolymers. We hypothesize that 
this strategy is more favourable for the formation of well-defined and better 
shielded nanocarriers because the sterically isolated PEG does not interfere with 
the interaction between PEI and the nucleic acid. We are sure that the polyplexes 
(complexes of nucleic acids and polymers) obtained from these copolymers will 
also show excellent stability and good diffusion in extracellular matrices. 
Furthermore, these polyplexes are reductively degradable inside cells which will 
decrease their cytotoxicity. To proof our hypothesis we synthesized redox-
sensitive, linear PEG-PEI copolymers and tested their complexation ability of 
nucleic acids. Additionally, we investigated their diffusion in the extracellular 
matrix of a 3D-tumour model. 
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DRUG DELIVERY SYSTEMS BASED ON MODIFIED 
HYDROXYETHYL STARCH 
Bertz, A.1, Wöhl-Bruhn, S.2 Bunjes, H.2, Menzel H.1 
1 Institut für Technische Chemie, TU Braunschweig 
2 Institut für Pharmazeutische Technologie, TU Braunschweig 
 
Protein - based pharmaceuticals are of increasing importance for the treatment of 
various diseases like cancer or inflammatory disorders. Since such therapeutic 
proteins often show fast degradation in the human body, a protecting carrier system 
that releases the protein in a controlled way is needed to maintain the therapeutic 
concentration over a certain period of time. Hydrogel microspheres seem to be a 
promising drug delivery system fulfilling this function. Previously described 
microspheres based on hydroxyethyl starch (HES) modified with hydroxyethyl 
methacrylate (HEMA) showed an undesired strong initial burst release and 
insufficient polymer solubility. Therefore, polyethylene glycol methacrylate 
(P(EG)nMA) was used as new crosslinkable substituent to solve these problems. 
The hydrophilicity can be tailored by simple variation of reagent ratios, reaction 
time and length of the polyethylene glycol spacer. The modified HES can be 
crosslinked within 15 min. by photopolymerisation using the photoinitiator 
Irgacure® 2959 at 366 nm (3.5 mW/cm2). The resulting transparent hydrogels were 
characterized by swelling measurements in phosphate buffer (pH 7.4) and 
oscillation rheology and show good mechanical properties. Storage moduli from 
200 - 7500 Pa (stress: 1 - 40 Pa, frequency: 1 - 100 Hz) were achieved and the 
swelling ratio can be varied in a wide range. By increasing the polymer 
concentration from 10 wt% to 20 wt% a distinct increase in mechanical strength 
can be obtained. A variation of the initiator concentration (0.015 - 0.1 wt%) or 
irradiation time (10 - 30 min) seems to barely influence the gel stability. However, 
at high initiator concentrations and long irradiation times the resulting hydrogels 
become more fragile. First degradation studies confirm the enzymatic degradation 
of the HES- P(EG)nMA backbone by -amylase and the long - time swelling 
experiments show degradation of the polymer network by hydrolysis. 
HES- P(EG)nMA was also used for the preparation of microspheres via a water-in-
water emulsion. After purification and lyophilization microspheres with a size of 
~ 10 μm were obtained which showed high encapsulation efficiency for FITC-
dextran 70 kDa of > 70 %. Release studies with this FITC-dextran demonstrated 
almost no burst release but a steady release over months.  
T002
INFLUENCE OF BIOMATERIALS ON MITOCHONDRIAL FUSION IN 
VITRO 
Heller, A.1, Brockhoff, G.2, Göpferich, A.1
1Department of Pharmaceutical Technology, University of Regensburg 
2Clinic of Gynecology and Obstetrics, Caritas-Hospital St. Josef, University of 
Regensburg
Mitochondrial fusion is an event, which occurs continuously in cells to form large 
networks. It is the result of a cell´s effort to adapt and response to various 
metabolic and environmental stimuli with the ability to redistribute impaired and 
not impaired proteins as well as mutated and wild-type mtDNA. This process is 
highly important to maintain mitochondrial function.  
Mitochondrial fragmentation on the other hand can be the cause or consequence of 
mitochondrial dysfunction. The enhancement of mitochondrial fusion could 
therefore be an important tool to normalize the distribution of mutated and  
wild-type mtDNA and is hence a desired therapeutic approach in the field of 
mitochondrial medicine. 
Our overall goal was to explore if we can make use of mitochondrial drug targeting 
strategies and enhance mitochondrial fusion with the help of bio- or nanomaterials. 
In this study we investigated the influence of biomaterials on mitochondrial fusion 
in vitro using a PEG-derivative and isolated mitochondria from mammalian cells 
which were either transfected with a green or red fluorescent protein (GFP or 
RFP).
Mitochondrial fusion of green and red fluorescent mitochondria was analyzed by 
flow cytometry as well as confocal microscopy. Fusion efficiency was quantified 
by the flow cytometry results. 
The analysis revealed a higher percentage of green and red fluorescent double 
positive events, that means fused mitochondria, in PEG-treated samples compared 
to a usual fusion strategy of mitochondria in vitro. 
We thus could show that it is possible to enhance mitochondrial fusion in vitro 
using biomaterials, such as PEG-derivatives which can be a promising step towards 
the enhancement of mitochondrial fusion in cells as well. 
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PLASMA VOLUME EXPANDERS AS POTENTIAL DRUG DELIVERY 
SYSTEMS – AN IN VIVO STUDY UTILISING NONINVASIVE NEAR 
INFRARED FLUORESCENCE OPTICAL IMAGING 
Hoffmann, S.,  Schädlich, A. and Mäder, K.
Pharmazeutische Technologie und Biopharmazie, MLU Halle-Wittenberg 
Hydroxyethyl starches (HES) and Dextrans (DEX) are biodegradable polymers that 
are commonly used as plasma volume expanders (PVE). As they are biocompatible 
and nontoxic they could be used as drug delivery systems with prolonged 
circulation time. Three different PVE’s were used in this study: HES 200K, HES 
450K and Dextran 500K. Aim of this study was to investigate the body fate of 
these polymers. For that purpose noninvasive near infrared fluorescence optical 
imaging was utilised. 
The polymers have been modified to introduce an amine function that enables a 
stable amid linkage with carboxyl function carrying fluorescent molecules. 
Substitution degree was determined utilising H1-NMR (Gemini 2000, 400 MHz). 
The polymers were labelled with an IR fluorescent dye (800CW from LI-COR). In 
vivo imaging studies were performed with a fluorescence imaging system 
(Maestro, Cambridge Research & Instrumentation) in nude mice (SKH1) from 
Charles River Lab (n=4). 50 μl isotonic solution of the polymers were 
intravenously injected into the tail vein of nude mice. The experiments with 
HES 450K and DEX 500K are still running and will be presented on the poster. 
For HES 200K the IR fluorescent signal was detectable in the total body. 
Immediately after injection an accumulation of HES could be found in the bladder, 
indicating that a fraction of HES molecules has a molecular weight below renal 
excretion barrier. The bladder signal became weaker after 5 hours due to emiction 
but was still predominant after 24 hours compared to the total body signal. The 
urine was intensively fluorescent even after 24 hours. After 150 minutes an artefact 
in the area of the gallbladder and a large fluorescence signal in the intestinal loops 
could be observed indicating hepatic clearance (figure). HES could be also found 
in the excrement, which was collected during 24 hours. The distribution of HES in  
mouse body could be observed for 72 hours. We expect 
even longer circulation for HES 450 and DEX 500. 
Left: Distribution of HES 200 in a nude mouse after 330 
minutes (colour inverted). High concentrations are dark. 
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A NEW VISIBLE-LIGHT PHOTOINITIATING SYSTEM FOR 
BIOMEDICAL APPLICATIONS: SYNTHESIS AND 
CHARACTERIZATION 
Kamoun, E.A.1, Winkel, A.2, Eisenburger, M.2, Stiesch, M.2, Menzel, H.1 
1 Institut für Technische Chemie, TU Braunschweig 
2 Klinik für Zahnärztliche Prothetik und Biomedizinische Werkstoffkunde, 
Medizinische Hochschule Hannover  
  
This study presents the synthesis and characterization of a new visible-light 
photoinitiating system for crosslinking of hydroxyethyl starch modified with 
hydroxyethyl methacrylate (HES-HEMA). This polymer can be crosslinked and 
can give biocompatible and biodegradable hydrogels which are suitable as drug 
delivery systems.  
Light-activated dental composites are widely used in clinical restorative dentistry. 
Photopolymerization in this application is commonly carried out using an initiator 
system comprising an -diketone, such as camphorquinone (CQ), together with an 
amine reducing agent (coinitiator). For preparation of hydrogels by photocross-
linking CQ is disadvantageous because of its poor solubility in water. Additionally, 
biocompatibility and toxicity of the coinitiators and its solvents are potential 
concerns. Thus attempts have been made to replace the simple amine coinitiators as 
e.g. dimethylaminoethyl methacrylate by less toxic alternatives. For example N-
phenylglycine and L-arginine have been used as alternative new coinitiators, which 
are less toxic.   
To overcome the solubility problems carboxylated camphorquinone CQ-COOH 
was synthesized as a new water soluble photosensitizer. The chemical structure of 
CQ-COOH has been proven using different characterization methods e.g. NMR, 
MS, FT-IR, and UV-VIS spectroscopy. CQ-COOH is completely soluble in water 
and absorbs visible light between 400-490 nm with an absorption maximum at 
max = 457 nm.  
In combination with amine coinitiators such as L-arginine CQ-COOH shows a 
higher photo-reactivity than CQ for photocrosslinking of HES-HEMA. The 
resulting hydrogels show better mechanical properties and smaller mesh sizes in 
the network. Cytotoxicity testing has been conducted for all ingredients of the new 
photoinitiating system by investigating cell viability by MTT-assays. It can be 
noted that, both CQ-COOH as photosensitizer and L-arginine as coinitiator alone 
only show minor cytotoxicity towards human gingival fibroblasts cells (HGFib).  
T005
DEVELOPMENT OF OPHTHALMIC FORMULATIONS FOR POORLY 
WATER-SOLUBLE DRUGS: USING POLYETHYLENGLYCOLES 
Luschmann C.1, Strauß O.3, Teßmar J.1, Luschmann K. 2, Goepferich A.1
1 Department of Pharmaceutical Technology, University of Regensburg; 2 Pharma Stulln 
GmbH, Stulln; 3 Klinik und Poliklinik für Augenheilkunde, Klinikum der Universität 
Regensburg; 
Drugs like Cyclosporine A or a number of corticoids are known to be efficient 
tools in the therapy of prevalent ophthalmic diseases like the keratokonjunctivitis 
sicca. They could help to move from a palliative to a causal therapy. Unfortunately, 
these potent drugs suffer from low solubility in water and can, therefore, not be 
administered via aqueous solutions. Oily eye drops would be an alternative, 
however, their administration leads to irritations on the eye surface. 
Liquid polyethylenglycoles (PEGs) would be potent solvents since they are non-
aqueous, unlimited water miscible and combine qualities of hydrophilic and 
lipophilic solvents. 
Therefore, we hypothesized that it would be possible to create in situ precipitating 
systems for Cyclosporine A with PEGs as solvents. Upon contact of the PEG 
formulation with the tear fluid the rapid increase of the water content induces a 
precipitation of the drug. 
For our investigations we selected two different types of PEG, a polyethylenglycol-
monomethylether and a polyethylenglycoldimethylether, both with an average 
molecular mass of 500 Da. To have further influence on the precipitation, with 
respect to the point of precipitation (PoP) and the resulting particle sizes, we used 
Solutol® HS15 (BASF), a Macrogol-15-hydroxystearate as an amphiphilic 
additive.
Using high performance liquid chromatography we observed an outstanding 
solubility of Cyclosporine A in both PEGs. With a high throughput method for 
turbidimetric analysis of drug precipitation, we showed that with decreasing 
concentrations of drug the amounts of water which are necessary to induce a 
precipitation, increased. In the presence of Solutol® these levels could be increased 
further.
Using dynamic light scattering and light microscopy we could show that particle 
size and particle size distributions at the PoP decreased and were generally more 
stable with increasing levels of Solutol®.  
We could thus show that PEGs can be effective carriers for poorly water-soluble 
drugs and a promising approach for their ophthalmic application. 
T006
PREPARATION OF SMALL HYDROGEL MICROPARTICLES AS 
ACCEPTOR COMPARTMENTS FOR DRUG TRANSFER STUDIES 
Strasdat, B., Laabs, F., Bunjes, H.
Institut für Pharmazeutische Technologie, TU Braunschweig 
Lipid nanoparticles are being investigated as intravenous drug delivery systems, in 
particular for lipophilic drugs. It is, however, difficult to analyze the release 
behavior of such substances from colloidal carriers under realistic conditions. As a 
new approach to overcome this difficulty, a release setup based on the transfer of 
the lipophilic drug into a colloidal lipophilic acceptor system incorporated into Ca-
alginate microbeads was suggested [1]. The microgel particles were formed by 
electrostatic droplet generation and hardened in a CaCl2-solution. They had particle 
sizes of about 330 to 1350 μm, depending on the diameter of the needle applied for 
droplet generation. Tyloxapol-stabilized trimyristin nanoparticles were 
incorporated into the hydrogel particles as lipophilic acceptors. The donor system 
also consisted of these nanoparticles and contained the lipophilic dye Nile red as 
drug model. In transfer experiments with water-diluted, nanoparticle-containing 
acceptor microbeads and a donor-acceptor lipid mass ratio of 1 + 25 dye transfer 
was not completed within one hour regardless of microbead size. Presumably, this 
slow transfer was caused by the relatively large size of the microbeads. 
In the present study, smaller microgel particles were prepared to verify this 
assumption and to obtain a lower diffusion barrier as an approach to create more 
in vivo-like release conditions. Smaller alginate particles could be prepared by 
spraying a mixture of lipid nanoparticle dispersion and low viscosity Na-alginate 
(1 %) into a CaCl2-solution (5 % w/w) using the two-fluid spray nozzle (diameter: 
0.7 mm) of a BÜCHI Mini Spray Dryer B-191. After hardening, the microbeads 
were washed with ultrapure water and filtered off via a paper filter. A median 
particle size of about 45 μm (d10 = 15 μm, d90 = 110 μm) was determined by laser 
diffraction. Transfer studies with these small particles revealed a considerably 
faster transfer of Nile red than with larger microbeads. It was already completed 
after a few minutes. 
In conclusion, smaller Ca-alginate microbeads lead to a very fast transfer. The 
transfer system with the small microbeads is now closer to in vivo-like release 
conditions and is an interesting approach to investigate the transfer of lipophilic 
drugs also to other lipophilic systems. 
[1] Strasdat, B., Bunjes, H., Poster presented at the DPhG annual meeting, Jena, 2009
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RELEASE PROPERTIES OF HYDROGEL DRUG CARRIER SYSTEMS 
CHARACTERIZED BY MAGNETORELAXOMETRY 
Wöhl-Bruhn, S.1, Heim, E.2, Bertz, A.3, Menzel, H.3, Ludwig, F.2, Schilling, M.2,
Bunjes, H.1
1Institut für Pharmazeutische Technologie, 2Institut für Elektrische Messtechnik 
und Grundlagen der Elektrotechnik, 3Institut für Technische Chemie; TU 
Braunschweig 
Hydrogels and hydrogel microparticles are under investigation as new delivery 
systems for bioactive molecules, e.g. proteins. With their ability to incorporate a 
huge amount of water or buffer, they offer optimal conditions for a long in vivo
stability of proteins. The release of proteins occurs by diffusion and hydrogel 
degradation. In this study, we used polymers based on hydroxyethyl starch (HES) 
modified either with hydroxyethyl methacrylate (HEMA) or polyethylene glycol 
methacrylate (P(EG)6MA) as cross-linkable substituents for the production of 
hydrogels and hydrogel microparticles. In order to study the release properties of 
the HES-HEMA and HES-P(EG)6MA hydrogels, superparamagnetic nanoparticles 
(MNP) were incorporated into the gels to mimic biomacromolecules . By analyzing 
the magnetic relaxation behavior of the MNPs, the fractions of physically 
entrapped (immobilized) and mobile nanoparticles can be determined. The 
hydrogels were produced with various UV irradiation times to investigate the 
optimal cross-linking conditions for the different polymers and the influence on the 
release profile. Furthermore, MNPs were incorporated into HES-P(EG)6MA
microparticles during the water-in-water emulsion preparation process. Buffered 
aqueous polyethylene glycol (MW = 12,000) and HES-P(EG)6MA solutions were 
gently vortexed, the latter containing the photoinitiator and the magnetic 
nanoparticle suspension. The resulting emulsion was exposed to UV light for 
cross-linking of the HES-P(EG)6MA containing droplets. After multiple washing 
steps, the microsphere emulsion was used to study the release profile of MNPs 
emerging from the hydrogel microspheres over several weeks. -amylase was 
added to all systems to accelerate the degradation process.  
This work was financially supported by the DFG via SFB 578. 
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SYNTHESIS OF POLY-L-CYSTEINE AND ITS EFFECT ON PARA-
CELLULAR DRUG TRANSPORT ACROSS CORNEAL EPITHELIUM 
Kühn N.1, Kaminski L.2, Wätzig H.2, Reichl S.1
1 Institut für Pharmazeutische Technologie, Technische Universität Carolo-
Wilhelmina zu Braunschweig, Mendelssohnstraße 1, 38106 Braunschweig;        
2 Institut für Pharmazeutische Chemie, Technische Universität Carolo-Wilhelmina 
zu Braunschweig, Beethovenstraße 55, 38106 Braunschweig 
The limiting factor for the bioavailability of many hydrophilic drugs is their 
insufficient paracellular absorption. The absorption barrier is represented by 
epithelial cell membranes which are interconnected by tight junctions. The 
formation of tight junctions is supposedly controlled by protein tyrosine kinase 
which is influenced by the presence of reduced glutathion (GSH). Thiolated 
polymers, so-called thiomers, show a permeation enhancing effect by affecting the 
GSH/GSSG equilibrium via their thiol groups and are regarded as a promising 
approach to improve drug uptake [1]. This study describes the synthesis of poly-L-
cysteine (PLC), a homopolymer of L-cysteine, as a novel thiomer. Furthermore, the 
influence of PLC on corneal cell viability and drug permeability was studied.  
PLC was synthesized from Tmob-protected L-cysteine by formation of cyclic 
cysteine N-carboxyanhydride and subsequent polymerization initiated by n-
hexylamine. The product was water-soluble up to a concentration of 30 g/L and its 
molecular weight ranged between 36-38 kDa as determined by SEC. The amount 
of free thiol groups determined via Ellman's reagent was 1.7 μmol thiol groups per 
gram poly-L-cysteine in average.  
The influence of PLC on the cell viability was tested using the different in vitro 
assays CellTiter-Blue® (conversion of resazurin), CytoTox-ONE™ (LDH release) 
and CellTiter Glo® (ATP presence). PLC showed only a minor or no ill-effect on 
the survival of corneal epithelial cells (cell viability more than 80%). Permeation 
studies were performed in vitro using human corneal epithelial cells (HCE-T) 
grown on a polycarbonate filter forming tight cell layers. Transport experiments 
were carried out with the model compound sodium fluorescein (SF) as paracellular 
marker. The application of PLC resulted in a 25fold increase of the SF permeation 
coefficient (8.5·10-6 cm/s in the presence of PLC; 3.4·10-7 cm/s in control 
experiment).  
[1] Bernkop-Schnürch et al. (2004) Thiomers: potential excipients for non-invasive peptide delivery systems. 
Eur J Pharm Biopharm 58:253-63. 
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CHARACTERIZATION OF POLY(LACTIC-CO-GLYCOLIC ACID) 
NANOPARTICLES CONTAINING LANTHANIDES 
Buch, K.1, Nawroth, T.1 Langguth, P.1
1Pharmaceutical Technology and Biopharmaceutics, Johannes Gutenberg-
University Mainz 
Poly(lactic-co-glycolic acid) is a copolymer which is used in a host of FDA-
approved therapeutic devices, owing to its biocompatibility and biodegradability. 
Depending on the monomers’ ratio used for the polymerization, different forms of 
PLGA with different properties can be obtained. In this study, Resomer® RG 502H 
with a ratio of 50:50 lactide to glycolide was used. 
A method for preparation of nanoparticles containing different lanthanides by 
adaptation of a published protocol was developed, based on a solvent-evaporation-
method[1]. Structural investigation of these particles was done by dynamic light 
scattering (DLS), transmission electron microscopy (TEM) and small angle 
neutron scattering (SANS) to investigate particle size and particle shape. The 
particles typically depict a size range from 80 up to 500 nm with a mean diameter 
of 200 nm. Target load in the case of erbium as heavy metal was determined by 
UV-spectroscopy after complete dissolution of the particles in DMSO.  
Biocompatibility and toxicity of the particles was tested in cell culture. A549 cells, 
a human lung carcinoma cell line, were incubated with different concentrations of 
drug-containing polymer for different time periods, cell viability was tested 
afterwards via 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT)-assay, adapted from literature[2]. The amount of purple formazan built by 
reduction of MTT was measured spectro-photometrically by dissolving the dye in 
DMSO. No specific toxic effects of our particles were found in comparison to 
empty particles. 
Different applications for our system can be foreseen, i.e. imaging purposes and 
others are likely to follow. 
1. Gaumet, M., R. Gurny, and F. Delie, Fluorescent biodegradable PLGA particles with 
narrow size distributions: Preparation by means of selective centrifugation. Int J Pharm, 
2007.
2. Mosmann, T., Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assays. J Immunol Methods, 1983. 65(1-2): p. 55-63.
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SOLVENT DISPLACEMENT METHOD FOR THE PREPARATION OF 
HSA-NANOPARTICLES 
Engel, A., Ploeger, M., von Storp, B., Langer, K. 
Institut für Pharmazeutische Technologie und Biopharmazie, WWU Münster 
Nanoparticles prepared of human serum albumin (HSA) represent promising 
carriers for drug delivery. Protein-based particles can be obtained by several 
methods. The objective of the present study was the establishment of a solvent 
displacement method for the preparation of HSA-nanoparticles. Therefore the 
influence of different organic solvents, stirring speed, and needle diameter on 
particle size and size distribution of the produced nanoparticles was investigated. 
The experimental approaches focused on the organic solvents ethanol, acetone, and 
isopropanol in different concentrations and one experimental set with a 
combination consisting of methanol and ethanol. Further the influence of different 
stirring speeds between 200 and 1000 rpm and needle diameters between 0.7 mm 
and 1.8 mm were tested. Size and size distribution measurements were performed 
by PCS. 
Large particles with a broad size distribution were received when using high 
concentrated ethanol, acetone and isopropanol as organic solvent. After reducing 
the concentration of the organic solvent, nanoparticles of a decreased size could be 
achieved. The combination of methanol and ethanol led to the smallest particles of 
the study with a particle diameter below 50 nm and a monomodal size distribution. 
The investigation of the needle diameter pointed out that the resulting particles 
became smaller with increasing diameter, whereas the variation of the stirring 
speed showed no significant influence on the particle preparation. 
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CHARACTERIZATION OF NANOSTRUCTURED POLY-
ELECTROLYTE PEPTIDE COMPLEXES 
Ferstl, M.1, Drechsler, M.2, Rischer, M.3, Göpferich, A.1
1Department of Pharmaceutical Technology, University of Regensburg 
2Macromolecular Chemistry II, University of Bayreuth 
3Pharmaceutical Development, Zentaris GmbH, Frankfurt am Main 
Self assembly is ubiquitous in chemistry, materials science and biology. It is a 
widely used term that describes the phenomena of self-organization. According to 
the literature it is well known that polyelectrolyte-surfactant systems self assemble 
[1]. In our work we investigated the interaction between oppositely charged 
polyelectrolytes and small peptides and their ability to undergo similar 
complexation. Different anionic polylectrolytes (sodium hyaluronate, sodium 
carboxymethylcellulose and xanthan gum) which differ in their chemical 
composition and their charge density were examined in order to determine their 
influence on the structural composition of the aggregates. A positively charged 
decapeptide was used as counterpart. The nature of the polylelectrolyte-peptide 
complexes was investigated in dilute solutions as well as in solid state.
Cryogenic-temperature transmission electron microscopy (cryo-TEM) revealed 
that the interaction between the anionic polyelectrolytes and the oppositely charged 
peptide led to the formation of nanofibers. Our investigations showed that their 
diameter, length and shape varied with the used polyelectrolyte. The interaction of 
the peptide with the polyelectrolyte caused a complete change of conformation, 
which was analyzed by circular dichroism (CD). Light microscopy pictures of the 
solid state of the complexes provided further morphological information. 
In conclusion, we successfully developed nanofibers by the self assembly of 
polyelectrolyte-peptide complexes. On the one hand the self assembly is based on 
electrostatic interactions between oppositely charged molecules. On the other hand 
the hydrophobic interactions between the peptide molecules play an important role 
in structural organization. By using polyelectrolytes with different properties the 
length, shape and diameter of the nanofibers can be adjusted. These nanofibers 
may have a potential application as a controlled release system 
[1] Kötz, J. (2001) Prog. Polym. Sci. 26: 1199-1232 
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COMPARISON OF NANOPARTICULAR IRON FORMULATIONS FOR 
PARENTERAL USE – ARE THEY SIMILAR AND READILY 
EXCHANGEABLE? 
Fütterer S.1, Andreasen H.2, Jahn M.1, Nawroth T.1, Jørgensen S.L.2, Kolb U.3, 
Hofmeister W.4, Langguth P.1 
1Pharmaceutical Technology and Biopharmaceutics, J. Gutenberg-University 
Mainz 2Pharmacosmos A/S, Holbaek, Denmark, 3Physical Chemistry, J. 
Gutenberg-University Mainz 4Geosciences, J. Gutenberg-University Mainz 
 
Parenteral iron is today widely used for the treatment of iron deficient anaemia. 
From initial widespread use in nephrology the use has in recent years spread to 
other disease areas such as gastroenterology, cardiology, oncology, pre/post 
operatively, obstetrics and gynaecology. Historically, the first parenteral iron 
preparations were toxic, being administered as an iron oxyhydroxide complex. The 
problem was circumvented with the introduction of compounds where iron was 
surrounded by a carbohydrate. The currently marketed parenteral iron preparations 
are considered equally efficacious but vary in molecular size of the nanoparticle, 
pharmacokinetics, and adverse reaction profiles.  
In the present study, the available intravenous iron agents low molecular weight 
iron dextran (Cosmofer®, Infed®) sodium ferric gluconate (Ferrlecit®), iron sucrose 
(Venofer®), iron carboxymaltose (Ferinject®), ferumoxytol (Feraheme®) and iron 
isomaltoside (Monofer®) were compared with respect to particle size (GPC, DLS, 
TEM), structure (XRD), free iron content (dialysis), acid soluble iron and in vitro 
liberation of iron in plasma (Ferrozine method). 
The particle size varied depending on the principle of the determination method 
(e.g. core vs. hydrodynamic diameter) but increased in the following order (TEM): 
sodium ferric gluconate < iron sucrose < LMW iron dextran < ferumoxytol  iron 
isomaltoside. In case of iron carboxymaltose the cores tend to cluster and single 
cores are not definable. With respect to acid soluble iron the formulations showed 
clear differences in which sodium ferric gluconate and iron sucrose were the most 
labile complexes and ferumoxytol was the most stable followed by iron 
isomaltoside  iron carboxymaltose  iron dextran. A negative correlation between 
half life of iron liberation and surface to volume ratio of the complexes was 
observed. The liberation of iron into plasma demonstrated differences in the 
stability of the iron complexes in biological media and in principle but not in each 
case followed the rank order of acid soluble iron. In conclusion it can be shown 
that nanoparticular parenteral iron formulations differ which may in part explain 
their dosing recommendations and adverse reaction profiles. 
T013
ENZYME-RESPONSIVE NANOPARTICLES FOR CARTILAGE 
TARGETING 
Probst, S.1, Blunk, T.2, Göpferich, A.1
1Pharmazeutische Technologie, Universität Regensburg 2Klinik für 
Unfallchirurgie, Universitätsklinikum Würzburg 
Inflammatory processes in synovial joints are characterized by upregulation of 
matrix degrading enzymes. Thereby, matrix metalloproteinases (MMPs) have 
predominant roles in both rheumatoid arthritis and osteoarthritis. Nanoparticles 
would be promising carriers for drug delivery into joints and even cartilage, since 
the dense cartilage matrix restricts access of larger vehicles [1]. Unfortunately the 
synovial fluid undergoes a continuous turnover so that even microparticles are 
rapidly cleared from the joint space within hours [2]. 
Here, we introduce an approach to use MMPs to specifically target and immobilize 
nanoparticles at such inflamed sites and show nanoparticle development and 
characterization. A PEG-coating protects our nanoparticles from unspecific tissue 
interaction and protein binding until the PEG-chains are cleaved by MMPs. Upon 
cleavage the surface characteristics of the particles change and allow them to bind 
to cartilage tissue by electrostatic interactions. As model particles gold 
nanoparticles were chosen. We synthesized collagenase-sensitive PEG-ligands by 
liquid phase peptide synthesis that allow for the attachment to gold via thiol-gold 
bonds. In order to achieve a compromise between protection and accessibility for 
the enzyme a mixed surface layer of cleavable and stable chains of different length 
was developed. As a surrogate for matrix degrading enzymes we used collagenase 
from Clostridium histolyticum. The sensitivity of the enzyme-responsive PEG-
polymers was demonstrated. To further prove the feasibility of our approach we 
monitored the cleavage of the PEG-ligands by collagenase from a solid gold 
surface by surface plasmon resonance (SPR)-measurements. Enzymatic activation 
of PEG-coated nanoparticles could be observed by dynamic light scattering (DLS) 
experiments which revealed a decrease of the hydrodynamic diameter and a change 
of the zeta potentials. In contrast, the nanoparticles remained unchanged in the 
presence of the collagenase inhibitor EDTA. After the successfully demonstrated 
nanoparticle development, ongoing studies include interactions of the particles 
with cartilage tissue in vitro and the application in an in vivo rodent model. 
[1]D.A.Rothenfluh et al, Nature Materials, 7, 248-254 (2008). [2]N.Gerwin et al, 
Advanced Drug Delivery Reviews, 58, 226-242 (2006) 
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IN VIVO AND EX VIVO STUDIES OF PEG - PLA BLOCK COPOLYMER 
NANOPARTICLES FOR TUMOR VISUALISATION AND TREATMENT 
Schädlich, A.1, Rose, C.2, Kuntsche, J.1, Caysa, H.3, Mueller, T.3, Göpferich, A.2,
Mäder, K.1
1Pharmazeutische Technologie, Martin-Luther-Universität Halle-Wittenberg;  
2Pharmazeutische Technologie, Universität Regensburg;  
3Klinik für Innere Medizin IV, Martin-Luther-Universität Halle-Wittenberg 
Nanoparticles (NP) have the potential to overcome multiple biological barriers and 
to deliver drugs selectively to tumor cells, but also for the application in tumor 
imaging for cancer diagnosis. It is known that the NP matrix (e.g. the polymer) and 
surface properties play an important role. It is reported that PEG can improve the 
in vivo behaviour. But also particle size variations are a critical factor concerning 
the in vivo fate caused by a rapid clearance of circulating NPs during systemic 
delivery thus avoiding undesirable accumulation in the body. In this study, the fate 
of different PEG2-PLAx block copolymer NPs was explored after i.v. adminis-
tration. The near infrared dye DiR (invitrogen) was incorporated. This allows to 
measure the fate of the NPs through the whole body by non invasive multispectral 
in vivo fluorescence imaging [1]. Furthermore the HT29 and A2780 xenograft 
tumor models were used to explore the in vivo tumor accumulation of the NPs. 
In vitro characterisations (A4F/MALLS, PCS and TEM) indicate narrow particle 
size distributions with the mean diameters in the lower nanometer range. Results of 
toxicity tests revealed that the NPs show no distinctive toxicity thus allowing 
injection to the mice. Detailed in vivo studies were performed to identify 
differences in distribution, accumulation and elimination behavior of different 
polymer ratios and particle sizes. The circulating NPs were detectable in the blood 
stream for over 4 hours. An accumulation in liver and spleen was detectable 
in vivo. High concentrations of the NPs in the HT29 and A2780 carcinoma tissues 
were observable already 6 h after injection. The intensity increased within the first 
24 h. Different tests with these two carcinoma cell lines and also ex vivo tissues 
with confocal microscopy confirmed these results. Ex vivo studies were done to 
measure the maxima and total fluorescence intensities of different organs. This 
allows to identify possible excretion pathways by detecting slight accumulations in 
kidneys and intestine, which were not visible in vivo. Studies are ongoing in order 
to detect metastases by fluorescence imaging. 
[1] Y. Jiang et al.: In-vivo studies on intraperitoneally administrated poly(vinyl 
alcohol), J. of Biomedical Materials Research Part B: Applied Biomaterials, 2010 
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ROLE OF -MODIFICATION ON PHYSICAL STABILITY OF LIPID 
NANOPARTICLES 
Acar, S.1, Müller, R. H. 1, Keck, C. M.1, 2, 3  
1Freie Universität Berlin, Institute of Pharmacy, Department of Pharmaceutics, 
Biopharmaceutics & NutriCosmetics, Kelchstr. 31, 12169 Berlin, Germany. 
2Fachhochschule Kaiserslautern - University of Applied Sciences, Applied 
Logistics- and Polymer Sciences, Pirmasens, Carl-Schurz-Str. 10-16, 66953 
Pirmasens, Germany 
3Laboratory of Molecular Biomedicine, Institute of Bioscience, University Putra 
Malaysia, Malaysia 
 
Introduction: The major aims in formulation development of lipid nanoparticles 
are a high drug loading capacity, physical long term stability and the ability to 
identify suitable formulations at an early stage of the development.  
Experimental methods: A main reason of physical instability is the expulsion of 
drug over the time of storage. In this study differential scanning calorimetry (DSC) 
was used to compare the thermograms of drug loaded and non-loaded solid lipid 
nanoparticles (SLN, lipid matrix consist of one solid lipid), nanostructured lipid 
carriers (NLC, lipid matrix consists of a blend of a solid lipid and a liquid lipid) 
and their physical mixtures (i.e. non-homogenized lipid matrices of each system).  
Results: The thermograms of homogenized and non-homogenized samples 
(physical mixtures) were not always similar. Thus only the homogenized samples 
(SLN and NLC with and without drug) could be used for analysis. For NLC only 
one melting point for the lipid was detected. This corresponded to the stable ß-
modification. No changes over time were observed. In contrast to this in all SLN 
thermograms an additional lower melting point, corresponding to the -
modification of the lipid, was detected at the day of production. Over the time of 
storage (1 year) the amount of -modification decreased. In parallel, for the SLN, 
drug expulsion was clearly detectable using light microscopy. No expulsion was 
observed for NLC. The results provide the first evidence, that a) the transformation 
of -modification to -modification causes drug expulsion, b) addition of liquid 
lipid can prevent the crystallization of the instable -modification, c) DCS-
thermograms of the physical mixtures cannot be used to screen for suitable lipid 
mixtures.  
Conclusion: Drug expulsion during storage can be prevented if the lipid re-
crystallizes without -modification. This can be obtained if liquid lipid is added to 
a solid lipid matrix. 
T016
DEVELOPMENT OF PRESERVED HIGHLY-LOADED ARGAN OIL 
NANOSTRUCTURED LIPID CARRIERS (NLC) 
Hommoss, A. 1, Shegokar, R. 2, Müller, R. H. 2
1Arab International University (AIU), Faculty of Pharmacy, Ghabaghib, 
Daraa, Syrian Arab Republic. 2Freie Universität Berlin, Institut für Pharmazie, 
Pharmazeutische Technologie, Biopharmazie und Kosmetik, Kelchstraße 31, 
12169 Berlin 
Nanostructured lipid carriers (NLC) are used in many dermal cosmetic 
formulations, but are also in development for pharmaceutical products. In cosmetic 
industry, the cosmetic companies buy the NLC as concentrated suspensions from 
manufacturers of cosmetic excipients and actives, e.g. Dr. Rimpler GmbH/ 
Germany. The NLC concentrates are admixed to the finished products. For micro-
bial safety reasons, these concentrates need to be preserved, but at the same time 
the preservatives can impair their physical stability. Therefore the compatibility 
with each formulation needs to be investigated, a systematic screening for 
preservatives performed. This was done in this study for Argan oil loaded NLC. 
The consumer prefers preservative-free products. Therefore in this study 
substances were used, which do not need to be declared as preservative, but have 
preservation action. Several preservative systems were admixed to the developed 
formulation and the physical stability was monitored. In addition, the loading with 
Argan oil should be as high as possible, but the NLC still solid at body 
temperature. Therefore a screening of blends of argan oil with high melting lipids 
was performed to identify the blend with highest possible oil content (40% oil and 
60% solid lipid in the blend). 
Upon admixing ethanol 20% to the formulation, immediately particle aggregation 
could be detected using laser diffractometry (LD diameter 99% about 140 μm). 
The samples gelled after 24 hrs. On the other hand samples preserved with 10% 
propylene glycol did not show any change in particle size in comparison to the 
non-preserved formulation, measured after one day and 3 months storage. The 
mean particle size was about 230 nm (PCS) and the LD diameter 99% about 0.6 
μm. Samples preserved with 5% pentylene glycol proved also stable after 3 months 
and did not show any change in particle size.  
In this study it was shown that NLC with high Argan oil load can be produced. 
They were preserved successfully without affecting the physical stability of the 
suspension.
T017
IMPACT OF SALTS ON THE PARTICLE SIZE OF DISPERSED CUBIC 
PHASES 
Horst, J.C., Bunjes, H. 
Institut für Pharmazeutische Technologie, TU Braunschweig 
Dispersed cubic phases, as they e.g. form in the system monoolein/poloxamer 407/ 
water after homogenization, are considered as potential drug carriers. Autoclaving 
is often performed after homogenization to improve the structure of the dispersions 
with regard to homogeneity and complete formation of the cubic phase [1]. In 
literature, the properties of poloxamer 407 are mentioned as potentially important 
factor for the temperature dependent formation of the cubic phase nanoparticles 
[2]. Since this point has previously not been studied in detail experimentally, this 
study aimed at elucidating the underlying mechanisms. Dispersions containing 
different concentrations of poloxamer 407 and monoolein, and in some cases 2.5 % 
glycerol for isotonization and/or 0.01 % thiomersal for preservation, were prepared 
from pre-equilibrated crude dispersions by high pressure homogenization, followed 
by autoclaving. Particles with a P-type cubic structure were detected within the 
resulting dispersions as expected. The presence of thiomersal, a surface active 
sodium salt, increased the particle size but did not change the cubic phase of the 
nanoparticles. In a system containing only poloxamer 407, glycerol and water, the 
addition of thiomersal lowered the cloud point of poloxamer 407. According to 
earlier investigations with similar systems, a comparable reduction of the cloud 
point can be achieved by the addition of salts [3]. This could be confirmed for the 
solution described above. With regard to the dispersions, there is a correlation 
between a reduction of the cloud point caused by thiomersal and a larger particle 
size after heat treatment. This can be attributed to a longer exposure of the 
dispersions to temperatures above the cloud point in comparison to the thiomersal-
free dispersions, since only temperatures distinctly above the cloud point allow a 
fast and uniform particle growth. A very pronounced cloud point reduction by a 
high amount of salt like e.g. NaCl led to a collapse of the system. In conclusion, 
alterations of the cloud point of poloxamer due to the addition of excipients seem 
to have pronounced effects on the structural behavior of the considered dispersions. 
Clarification of these effects may help to better understand the formation of the 
cubic particles and to control the properties of the dispersions in the future. 
[1] Wörle, G. et al. (2006), Eur. J. Pharm. Sci., 27, 44-53                                         
[2] Barauskas, J. et al. (2005), Langmuir, 21, 2569-2577                                        
[3] Pandit, N. et al. (1999), J. Colloid Interface Sci., 222, 213-220
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ANALYSIS OF SUPERCOOLED SMECTIC NANOPARTICLES BY 
ASYMMETRICAL FLOW FIELD-FLOW FRACTIONATION 
Kuntsche, J.1, Sänger, S.1, Mengersen, F.2, Bunjes, H.2
1Pharmazeutische Technologie und Biopharmazie, MLU Halle-Wittenberg 
2Pharmazeutische Technologie, TU Braunschweig 
Supercooled smectic nanoparticles have been introduced as carrier system for 
poorly water soluble drugs, particularly with respect to parenteral administration 
[1]. These nanoparticles are based on a strongly supercooled smectic phase of 
cholesterol ester(s). The liquid crystalline state may offer advantages over the 
liquid and the crystalline state of the lipid nanoparticle matrix. However, these 
dispersions are rather complex with regard to the colloidal structures involved: In 
addition to colloidal structures formed by the excess of stabilizer(s) (e.g., micelles, 
vesicles), two co-existing types of supercooled smectic nanoparticles have been 
observed in dispersions stabilized for example on the basis of phospholipids [1]. 
Asymmetrical flow field-flow fractionation (A4F) combined with multi-angle laser 
light scattering (MALLS) is a promising method for the analysis of such complex 
formulations due to its versatility, broad separation range (a few nm up to about 
1 μm [2, 3]) and the possibility to obtain homogeneous sample fractions. 
In a first approach, different formulations of supercooled smectic nanoparticles 
were analyzed by A4F/MALLS. In addition to size analysis, a homogeneous 
sample of supercooled smectic nanoparticles – where the majority of excess 
stabilizer has been removed – could be obtained by semi-preparative A4F and 
subsequent concentration by ultrafiltration and centrifugation. This purified sample 
was used to study the interaction of DSPE-mPEG-micelles with the lipid 
nanoparticles in order to obtain information about the possibility and efficiency of 
the preparation of PEGylated supercooled smectic lipid nanoparticles by a post-
insertion process as described for lipid emulsions in the literature [4]. Our first 
results, however, indicate that post-insertion of DSPE-mPEG into smectic 
nanoparticles is not possible (or at least highly inefficient) by just mixing the lipid 
nanoparticles with the micelles. 
References 
[1] J. Kuntsche, K. Westesen, M. Drechsler, M.H.J. Koch, H. Bunjes, Pharm. Res. 21 (2004) 1834. 
[2] W. Fraunhofer, G. Winter, Eur. J. Pharm. Biopharm. 58 (2004) 369. 
[3] J. Kuntsche, K. Klaus, F. Steiniger, J. Biomed. Nanotech. 5 (2009) 384. 
[4] J. Rossi, S. Giasson, M.N. Khalid, P. Delmas et al., Eur. J. Pharm. Biopharm. 67 (2007) 329. 
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NANOPARTICLES FOR THE ORAL DELIVERY OF IL-10 TO THE 
INFLAMED INTESTINE 
Mell, N. A.1, Lehr C.-M.1,2, Collnot, E.-M.1,2 
1Biopharmaceutics and Pharm. Technology, Saarland University, Saarbrücken 
2Dep. of Drug Deliv., Helmholtz Inst. for Pharm. Res. Saarland, Saarbrücken
Interleukin-10 (IL-10) is a regulatory cytokine which has pleiotropic effects in 
immunoregulation and inflammation. It has been proposed as a potent anti-
inflammatory therapy in inflammatory bowel diseases (IBD). So far, the clinical 
results of systemic recombinant IL-10 therapy in IBD were disappointing because 
of lack of efficacy at low doses and adverse effects at high doses. It is assumed that 
daily systemic application does not allow for efficient delivery to the sites of 
inflammation due to the short serum half life of about 1-3 hours. Thus, a local and 
sustained delivery to the inflamed intestinal mucosa appears to be a more 
promising approach, resulting in high local concentrations and avoiding systemic 
side effects. Drug delivery systems on the basis of nanoparticles may be promising 
as they selectively accumulate in the inflamed intestinal mucosa and have a longer 
transition time in the intestine compared to larger particles. 
In this study nanoparticulate carrier systems for oral application and local release 
of IL-10 in the terminal ileum and the large intestine were prepared and 
characterised. In first studies bovine serum albumin (BSA) and fluorescein 
isothiocyanate-labelled bovine serum albumin (FITC-BSA) were used as model 
proteins. 
T020
COMPARISION OF NANOEMULSION PREPARED BY HIGH PRESSURE 
HOMOGENIZATION AND ULTRASONICATION 
Gurung, S.1, Schubert, R.1
1Institut für Pharmazeutische Wissenschaften, Lehrstuhl für Pharmazeutische 
Technologie und Biopharmazie, Universität Freiburg 
Nanoemulsions are a type of emulsion with monodisperse droplets typically in the 
range of 20-200 nm. The smaller droplet size makes them transparent or 
translucent. They are not thermodynamically but are kinetically stable1. Being non-
equilibrium systems, they cannot be formed spontaneously instead requires high 
energy input, which can be achieved by using high-shear stirrers, high pressure 
homogenizers or ultrasound generators. The high energy input leads to deforming 
forces that are able to break the droplets into smaller ones, provided the Laplace 
pressure is overcome. High energy emulsification method has several advantages 
over low energy emulsification method. Those advantages included flexible control 
of droplet size and size distribution2. The mechanism for the formation of 
nanoemulsion using both the two energy sources involves the formation and 
collapse of cavitation bubbles filled with steam or gas. As a result of this 
cavitation, the dispersed droplets are disrupted following the formation of new 
droplets3. O/W emulsions intended for parenteral administration are designed for 
the incorporation of lipophilic drugs which exhibit poor aqueous solubility4. The 
size of nanoemulsion is affected by formulation and composition variables as well 
as by mechanical mixing condiitons1.
The main objective of this study is to prepare nanoemulsion by using two 
different types of high energy input, namely high pressure homogenizer and 
ultrasound generator and compare their characteristic features on the basis of 
droplet size, zeta potential and stability. In future, the surface of nanoemulsions 
will be modified using different ligands or antibodies so as to study the cellular 
uptake of nanoemulsions by different cell lines. After successful uptake of drug 
loaded nanoemulsions, they will be finally targeted to the cells of interest, i.e., 
immune cells or tumour cells to study the anticancer activity of the loaded drug.  
1 Forgiarini A., Esquena J., González C. and Solans C., Langmuir, 17, 2076-2083 (2001) 
2 Morales D., Gutiérrez J. M., García-Celma M. J. and Solans C., Langmuir, 19, 7196-7200 (2003) 
3 Hansrani P. K., Davis S. S. and Groves M. J., J Parent Sci Techn., 37, 145-150 (1983) 
4 Prankerd R. J., Frank S. G. and Stella V. J., J. Parenter. Sci. Technol., 42, 76-81 (1990) 
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HIGHLY CONCENTRATED 40% I.V. NANOEMULSIONS FOR DRUG 
DELIVERY
Harden, D.1, Müller, R.H.1, Keck, C.M.2,3
1 Pharmaceutical Technology, Department of Pharmaceutics, Biopharmaceutics 
  and NutriCosmetics, Freie Universität Berlin 
2 University of Applied Sciences Kaiserslautern, Fachhochschule Kaiserslautern 
3 Laboratory of Molecular Biomedicine, Institute of Bioscience, University Putra  
  Malaysia 
Poorly water soluble, lipophilic or amphiphilic drugs (e.g. amphotericin B) can be 
i.v. administered as o/w emulsions. These emulsions are on the basis of emulsions 
for parenteral nutrition, typically 10% or 20% oil content. However for some 
drugs this would still lead to an uncomfortable high injection or infusion volume. 
Therefore the production of ideally 40% i.v. emulsions is of interest and was 
investigated. The influence of production parameters (pressure, cycle number) on 
the resulting particle size and content of larger particles (tailing of size 
distribution) was studied. 
The emulsions were produced by homogenization at 500, 800 and 1500 bar up to 
5 cycles (Micron LAB 40). The particle size analysis was performed by laser 
diffractometry (LD) using a Mastersizer 2000 and photon correlation 
spectroscopy (PCS) using a Zetasizer Nano ZS (both Malvern Instruments, 
Malvern, UK). 
Two cycles at 800 bar were sufficient to reach a size small as about 250 nm, 
polydispersity index 0.09 (PCS) for 30% emulsions. This is in the range of the 
size of emulsions for parenteral nutrition, i.e. acceptable. Applying only 500 bar 
production pressure required 5 cycles for a similar size. To make the production 
cost-effective, 800 bar is optimal. Increasing the pressure to 1,500 bar decreased 
the size only by 20 nm, that means it was not possible to reduce the number of 
cycles to one cycle by pressure increase. Increasing the oil concentration to 40% 
required 3 production cycles for reaching the same size range. No difference in 
size was found between 800 bar and 1,500 bar at 3 cycles for 40% emulsions, in 
addition no further size reduction could be achieved from 3 to 5 homogenization 
cycles. This can be explained by the loss of homogenization efficiency in the 
more viscous emulsions system – despite the same power density. The LD 
diameter 99% as measure for large droplets was about 0.6 μm for all emulsions. 
In summary, 40% i.v. emulsions are feasible by a cost-effective production 
(800 bar, 3 cycles) still being of low viscosity due to the small droplet size. 
T022
PRODUCTION AND CHARACTERIZATION OF O/W 
CONCENTRATED EMULSIONS STABILIZED BY PLANT PROTEIN  
Kumpugdee-Vollrath, M.1, Tong, L.1, Krause J-P.1
1Beuth Hochschule für Technik Berlin, Fachbereich II: Mathematik-Physik-
Chemie, Luxemburger Straße 10, D-13353 Berlin 
Concentrated emulsion contains a very large amount of dispersed phase, thus it can 
significantly enhance the entrapment of pharmaceutical drug substances or other 
active agents. The aim of this work is to produce and characterize a concentrated 
emulsion, which is stabilized by soybean protein. The stability and particle size 
distribution for the concentrated emulsion were determined by a light scattering 
method. In order to prepare the concentrated emulsion, 100 grams of original 
emulsions (or pre-emulsion) with 30% w/w of Miglyol 812 and 70% w/w 
phosphate buffer were prepared separately using an ultrasonic probe (UP 75) and a 
high pressure homogenizer (Emulsi Flex®-C5). Soybean protein at the level of 1%, 
2% and 3% w/w was applied as a stabilizer. It is important to control a pre-
emulsion with the soluble soybean protein at pH=8, in order to get smaller droplets 
with stable interface protein films. The homogenizing time by the ultrasonic probe 
was 2 min. If the high pressure homogenizer was used the emulsion was pressed 
five times through the machine in order to produce the pre-emulsion. The pre-
emulsion was centrifuged by a high speed centrifugation machine at 5400 min-1 for 
30 min in order to receive the concentrated emulsion. The particle size distribution 
of the concentrated emulsion was determined by a Malvern Mastersizer-S. The 
concentrated emulsion was diluted with 10% w/w sodium dodecyl sulfate (SDS) 
and during the measurement with a light scattering method 5% w/w SDS was used 
instead of deionized water as the background to avoid the agglomeration between 
the drops. The size distribution of the concentrated emulsion produced by an 
ultrasonic probe is monomodal with a size-average of about 1.8 μm. In contrast, 
the concentrated emulsions prepared by a high pressure homogenizer show many 
peaks with the size-average of 2.1 μm which means that they have a broad size 
distribution.      
Reference: 
[1] Paruta-Tuarez E., Fersadou H., Sadtler V., Marchal P., Choplin L., Baravian C.,  
Castel C. (2010) Highly concentrated emulsions: 1. Average drop size by analysis 
of incoherent polarized steady light transport. J. Colloid Interface Sci., 346(1), 136-
142.       
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DEVELOPMENT OF STABLE PERFLUOROCARBON-CONTAINING 
NANOEMULSIONS FOR THE USE IN 1H/19F MRI  
Mayenfels, F.1, Flögel, U.2, Schrader, J.2, Schubert, R.1
1Dept. of Pharm.Technology and Biopharmacie, University of Freiburg, Germany 
2Dept. of cardiovascular Physiology, University of Düsseldorf, Germany 
A new approach for the in-vivo detection of inflammatory processes by 1H/ 19F-
magnetic resonance imaging (MRI) using emulsified perfluorocarbons (PFCs) was 
established in two separate models of local inflammation in animal experiments. 
Due to the lack of any natural 19F background in human or animal organisms, PFCs 
can serve as a positive contrast agent in 1H/19F MRI for the visualization of 
inflammatory processes1. Within these studies the monocyte-macrophage-system 
was identified as main carrier system taking the preparations to the injured tissues.
Next investigations deal with the development of homogeneous and stable 
nanoemulsions. Ostwald ripening is a well known phenomenon which occurs 
especially in inhomogeneous preparations and results in destabilization. To obtain 
nanoemulsions of definite sizes and narrow size distributions, after the high 
pressure homogenization a subsequent particle sizing by preparative size exclusion 
chromatography (SEC) was performed.  
Further studies were conducted to decrease the side signals in MRI by increasing 
the specifity of uptake by the monocyte-macrophage system. It is well known that 
phagocytosis of particles depends on their size and charge.  Therefore, the size and 
charge dependent phagocytosis was investigated using flow cytometry 
Another approach to increase the specifity of the uptake is the coupling of specific 
ligands to the surface of the emulsion droplets. A well established coupling 
procedure for active targeting of liposomes is the sterol-based-post insertion 
technique (SPIT)2. For this purpose a conjugate of a specific ligand (e.g. 
antibodies, antibody-fragments) and an activated sterol-PEG1300 anchor were 
prepared and inserted into the lipid monolayer. The targeting efficiency was 
observed in in-vitro studies using flow cytometry. 
1 Flögel U., Ding Z., Hardung H., Jander S., Reichmann G., Jacoby C., Schubert 
R., Schrader J., In vivo monitoring of inflammation after cardiac and cerebral 
ischemia by 19F magnetic resonance imaging, Circulation 118: 140-8 (2008) 
2 Gantert M., Lewrick F., Adrian J.E., Rössler J., Steenpaß T., Schubert R., Süss 
R., Receptor-Specific Targeting with Liposomes In Vitro Based on Sterol-PEG1300
Anchors, Pharm Res 26: 529-38 (2009)
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INVESTIGATION OF THE CHEMICAL STABILITY OF 
SUPERCOOLED SMECTIC NANOPARTICLES 
Mengersen, F., Bunjes, H. 
Pharmazeutische Technologie, TU Braunschweig 
Supercooled smectic cholesterol ester nanoparticles are under investigation as a 
new carrier system for lipophilic drugs [1]. The thermotropic liquid crystalline 
state of the matrix lipid combines a high viscosity with a certain mobility on the 
molecular level. This is expected to lead to advantages with respect to physico-
chemical stability and drug loading capacity. Such nanoparticles can be prepared 
by high-pressure melt homogenization in the presence of emulsifiers. The 
nanoparticle surface can be modified by incorporating surface modifying agents 
into the aqueous phase before the homogenization process, e.g. PEGylated 
phospholipids to achieve steric stabilization. These PEGylated nanoparticles are a 
promising formulation with respect to small particle size, long-term stability 
against recrystallization and stability upon autoclaving [2]. Since previous studies 
showed an increase of the negative zeta potential and a decrease of the pH value in 
the dispersions during storage, the aim of this work was to investigate the chemical 
stability of the dispersions. As the systems are based on cholesterol esters and 
stabilized with phospholipids which are both susceptible to oxidation and 
hydrolysis, their stability was studied directly after preparation and during storage. 
Qualitative analysis of the phospholipids and the cholesterol ester was performed 
by HPTLC. In addition, HPLC was applied to quantify the cholesterol ester 
concentration. The influence of the chemical processes on the physical properties 
of the systems was observed by particle size and zeta potential measurements. 
Extensive hydrolysis during storage was observed in the dispersions solely 
stabilized with phospholipids, leading to a pronounced decrease in pH. In the 
systems additionally containing sodium glycocholate degradation occurred only to 
a very minor extent. The phospholipid hydrolysis could be reduced by adding TRIS 
buffer (10 mM, pH 7.4) into the aqueous phase before the preparation process. 
Extensive phospholipid hydrolysis seems to promote the degradation of cholesteryl 
myristate, as detected in several dispersions during storage. 
References 
[1] J. Kuntsche, K. Westesen, M. Drechsler, M.H.J. Koch, H. Bunjes, Pharm. Res. 21 (2004) 1834. 
[2] F. Mengersen, H. Bunjes, Poster presented at the 7th World Meeting on PBP, Malta 2010. 
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SOLID LIPID NANOPARTICLES (SLN) AS A TOOL FOR THE 
ENHANCEMENT OF THE BIOAVAILABILITY OF CURCUMIN  
Noack, A.1, Mäder, K.1
1Pharmazeutische Technologie, MLU Halle-Wittenberg
Dried and powdered rhizoma of turmeric, Curcuma longa, is a major ingredient of 
curry powder. This spice finds widespread use in South Asia. The characteristic 
yellow colour of turmeric is caused from phenolic compounds, so called 
curcuminoids. The principal curcuminoid is curcumin (Diferuloylmethan). 
Numerous scientific articles have reported about the beneficial effects of curcumin 
(1,2). One point of particular interest is its anticancer activity. However the main 
problem that limits the application of curcumin as a pharmaceutical is its low oral 
bioavailability (2). One possible pathway to increase bioavailability is the 
development and application of nanoparticles. In the present work curcumin was 
incorporated in solid lipid nanoparticles (SLN) and nanoemulsions.  
The mixture for the SLN and nanoemulsion contained 10% (w/w) lipid 
(glyceroltrimyristate, glyceroltristearate, castor oil), 2.5% emulsifier Poloxamer 
188 (w/w), and 87.5% (w/w) of distilled water. The components were mixed at 
room temperature and heated up to 80-85 °C. After the lipid was melted an 
emulsion was formed using an ultra-turrax (IKA, Staufen, Germany) for 5 min at 
14000 rpm.  The hot premix was processed through a Stansted high-pressure 
homogenizer (Stansted Fluid Power Ltd., Stansted, UK). The starting pressure was 
set at 50 MPa and was increased every three cycles up to 100 MPa. The 
nanodispersions were cooled down slowly to room temperature, filled into glass 
vessels and stored either at 22 °C or at 8 °C. In further experiments curcumin in the 
range of 20-75 mg was embedded into the lipid phases and processed as described 
above. The mean particle size of the SLN preparations was at 150 nm whereas the 
nanoemulsion showed a mean particle size of 300 nm. The shape of the particles 
was investigated by transmission electron microscopy (TEM). The particles 
showed an anisometric shape. An in vitro prediction of the biofate of the particles 
and curcumin was gained by carrying out a pancreatin-assay. The stability of the 
incorporated curcumin was tested by incubating the preparation over several days 
under different conditions. 
Our experiments show that high-pressure homogenization is a valuable method for
the production of nanoparticles. It was possible to produce stable particle 
dispersions and to incorporate curcumin. Furthermore characterization of the 
particles using e.g. DSC, XRD, EPR, a4F and NMR is ongoing.
1. Anand, P., Sundaram, C. et al., Cancer Letters, 267, 1, 133-164 
2. Anand, P., Kunnumakkara, A. B. et al., Molecular Pharmaceutics, 4, 6, 807-818 
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QUANTITATIVE IMAGING – A NEW APPROACH TO QUANTIFY 
NUCLEAR IMPORT OF LIPOPLEX-DELIVERED pDNA
Steinbach, A., Süss, R.
Department of Pharmaceutical Technology and Biopharmacy, University of 
Freiburg, Germany 
Cationic lipids spontaneously bind, condense and coat DNA resulting in the 
formation of lipid/DNA complexes, so-called lipoplexes [1]. These complexes 
transduce plasmids into cells causing expression of the genes (transfection). Low 
levels of transfection circumvent therapeutical efficacy of non-viral strategies, 
whereby nuclear accumulation of the plasmid DNA is among the major obstacles 
of these non-viral delivery systems [2]. 
This project aims to analyse nuclear transport of lipoplex-released pDNA as a 
potential transfection barrier in two cellular models, A-10 SMC and MDCK II. 
A novel strategy called “quantitative imaging” is applied to study nuclear import of 
lipoplex-delivered pDNA, implying a combination of confocal laser scanning 
microscopy and image-based computer analysis using the open source software 
CellProfiler [3]. This strategy has already been used in former work to quantify the 
intracellular dissociation of lipid/DNA complexes followed by FRET analysis [4]. 
Here, this technique enables to track cy3-labeled complex DNA inside the cell and 
to quantify the amount of nuclear-accumulated complex released pDNA.  
These studies reveal nuclear entry of the pDNA to represent a decisive transfection 
barrier in MDCK II cells. The investigated cellular models differ strongly in the 
amount of nuclear-accumulated complex DNA: nuclear transport is by far more 
efficient in A-10 compared to MDCK II cells. 
References: 
[1] Felgner et al., Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl 
Acad Sci USA 1987; 84(21): 7413-7 
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PREPARATION OF EMULSIONS AND SOLID LIPID PARTICLES BY 
DIRECT MEMBRANE EMULSIFICATION 
Fehr, S.1, Schmolke, H.2, Klages, C.-P.2, Bunjes, H.1
1Institut für Pharmazeutische Technologie, 2Intitut für Oberflächentechnik,  
TU Braunschweig 
Aqueous lipid emulsions and solid lipid particles with particle sizes in the nano- 
and micrometer range are being investigated intensively as drug delivery systems. 
They are usually prepared by high energy dispersion techniques like high-
pressure homogenization. Homogenization generates high shear forces and may 
thus not be suitable for the processing of sensitive substances, like e.g. proteins. 
Therefore, this study investigates the possibility to prepare dispersions of lipid 
particles by direct membrane emulsification as an alternative low energy and low 
shear method. Direct membrane emulsification is an established technique for the 
preparation of monodisperse microparticulate emulsions. In this process, the liquid 
lipid phase is forced by low pressures through the pores of a membrane into the 
aqueous continuous phase, which is recirculated, e.g. by agitation with a stirrer, to 
facilitate droplet detachment. The lipid droplets grow at the pore openings of the 
membrane surface and are stabilized by emulsifiers present in the continuous 
phase. When the droplets reach a certain size they detach from the membrane. 
Solid lipid particles are usually processed above the melting point of the lipid and 
subsequently solidified by cooling below the recrystallization temperature. In the 
present study, the influence of the emulsifier (sodium dodecyl sulfate, polysorbate 
20, sorbitan monooleate), the type of the lipid phase (medium chain triglycerides, 
soybean oil, trimyristin) and the pore size of the SPG (Shirasu porous glass) 
membrane on the particle size of the resulting dispersions was investigated. The 
particle size distribution was measured by submicron enhanced laser diffractometry 
and additionally with polarization microscopy. The particle size was primarily 
controlled by the pore size of the membrane. Typical ratios of mean pore size to 
mean particle size were in the range of 1:3 to 1:4.The influence of the surface 
properties of the glass membrane and the additional use of ultrasound were also 
under investigation. Hydrophilization of the membrane by plasma treatment and 
sonication during emulsification both reduced the comparatively long production 
time, which is a main disadvantage of direct membrane emulsification. Also the 
pressure required for droplet formation was lowered. This might be an advantage 
for the preparation of nanoscaled systems, because an increasing pressure was 
required and the production times increased with decreasing pore size.
T028
UTILIZATION OF CUSTOMIZED MICROCHANNEL GEOMETRIES 
FOR SOLID LIPID NANOPARTICLE PRODUCTION 
Finke, J. H.1, Schuldt, A.1, Schur, J.1, Gothsch, T.2, Lesche, C.3, Büttgenbach, S.3,
Kwade, A.2, Müller-Goymann, C. C.1
1Inst. f. Pharmazeutische Technologie, TU Braunschweig, 2Inst. f. Partikeltechnik, 
TU Braunschweig, 3Inst. f. Mikrotechnik 
Solid lipid nanoparticles (SLN) are commonly produced by means of high pressure 
homogenization of a dispersion of molten lipids in a continuous aqueous phase. To 
achieve adequately small particle sizes and a narrow distribution of these, multiple 
passes through the homogenization valve are necessary. Thus homogenization is a 
discontinuous batch process. This holds for all other essential process steps: pre-
emulsification, dissolving or dispersing APIs in the lipid matrix or aqueous phase, 
and crystallization. To establish all these process steps in one overall micro system, 
a continuously passed through setup is required. This facilitates low dead volume 
and small production scale, as desired for formulation screening. However, 
homogenization by a single passage poses a major challenge to the microchannel 
geometries. High efficiency in droplet break-up is required. 
Customized micro structures were at first manufactured in silicone by wet-
chemical etching. Different flow regimes (shear, elongational and turbulent flow) 
were applied by generally differing design approaches. Minor geometric changes 
within these design groups were carried out to elucidate their influence on product 
qualities. These were preliminary demonstrated using an emulsion (5 % 
Miglyol®812, 3 % Solutol® HS 15 in water). Orifice-like micro channel structures, 
applying high elongational stress to the product flow, were identified superior by 
producing small particle sizes (down to about 450 nm for one passage at 300 bar) 
and showing comparably low volume flow rates. 
The manufacture of solid lipid nanoparticles necessitates higher pressures up to 
1500 bar for single-pass production and elevated temperatures. The micro 
component substrate was changed to steel structured by μ-EDM (electrical 
discharge machining) to overcome these obstacles (silicone micro components 
rupture above 400 bar). SLN [1] with a median particle size of about 120 nm were 
produced by one single passage using an 80 μm orifice with a length of 600 μm. 
[1] M. A. Schubert et al., Eur J Pharm Sci, 27, pp. 226-236, 2006  
The authors gratefully acknowledge the DFG for financial support of the DFG research group 856 
“Mikrosysteme für partikuläre Life-Science-Produkte“ ( ).
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CHARACTERISATION OF HIGH PRESSURE DISPERSION 
PROCESSES IN DIFFERENT MICRO CHANNEL GEOMETRIES 
Gothsch, T.1, Beinert, S.1, Lesche. C.2, Büttgenbach, S.2, Kwade, A.1
1Institute for Particle Technology, TU Braunschweig 2Institute for 
Microtechnology, TU Braunschweig 
High pressure dispersion in micro channels has several characteristics which 
recommend this method especially for pharmaceutical applications, e.g. a narrow 
residence time distribution, the possibility to use small educt batches and a 
relatively accurate adjustment of the induced stresses with a good reproducibility. 
Due to the small dimensions and the corresponding small volumes the micro 
systems have a low inertia which enables the application as screening instruments 
for the processing of valuable active pharmaceutical ingredients. Nevertheless 
abrasion of the micro channels and depositions, which can lead to blockages or 
contamination of the product, pose big challenges. 
Two types of micro channels have been analyzed: silicon micro channels covered 
with a glass plate enabling an optical access for the flow measurements (μPIV) up 
to an entrance pressure of 500 bar and stainless steel micro systems enabling a 
pressure drop of up to 2300 bar. In order to characterize the high pressure 
dispersion process, flow analysis by means of “Computational Fluid Dynamics” 
simulations (CFD) in combination with “Micro Particle Image Velocimetry” 
(μPIV) and dispersion experiments with inorganic nanoparticles were carried out. 
Four channel geometry types, straight, Z-, Y- and orifice channels were analyzed. 
Dispersion experiments exposed a clear hierarchy regarding the dispersion 
efficiency of the different geometry types at constant pressure drops. The results 
show that the geometries as well as the dimensions of the micro channels influence 
the dispersion efficiency, the appearance of blockages and the amount of abrasion. 
With CFD-simulations and flow measurements (μPIV) areas of low velocities or of 
backflow connected with the risk of depositions and the occurrence of cavitation 
were identified. The CFD simulations are also conducted to get a better 
understanding of the stress field by solving the turbulent flow fields of the different 
micro channels and using these for a stationary particle tracking. Based on these 
particle pathes the elongational, shear and turbulent stresses were calculated. 
The authors gratefully acknowledge the DFG for financial support within the DFG 
research group 856 “Mikrosysteme für partikuläre Life-Science-Produkte“ 
(mikroPART). 
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DISPOSABLE PDMS MICROBIOREACTORS WITH INTEGRATED 
ONLINE ANALYTICS FOR BIOTECHNOLOGICAL SCREENING 
Demming, S.1, Vila-Planas, J.2, Sommer, B.3, Edlich, A.3,  Lopez-Martinez, M.J.4,
Verpoorte, E.4, Krull, R.3, Franco-Lara, E.3, Llobera2, A., Büttgenbach, S.1
1Institut für Mikrotechnik, TU Braunschweig, Germany; 2Centro Nacional de 
Microelectronica-CSIC, Barcelona, Spain; 3Institut für Bioverfahrenstechnik, 
TU Braunschweig, Germany; 4Pharmaceutical Analysis, Department of 
Pharmacy, University of Groningen, The Netherlands  
Considering both the high quantity of existing - but still unknown - 
microorganisms and the rapid progress of genome sequencing techniques, the 
development of cultivation platforms aiming at reliable high-throughput screening 
for bioprocess development is still a challenge. Small volume cultures offer the 
advantageous combination of a global reduction in experimental costs and time 
with simultaneous process enhancement. The latter is related to the fact that 
microenvironments allow precise control of procedural conditions in combination 
with an increased flexibility of parameter screening. With regard to high-speed 
drug screening, in vivo- or in vitro-like microenvironments for cells also play an 
important role because novel drug formulations are often limited in volume. 
During screening, online monitoring of different physical, chemical or biological 
parameters is indispensable in these microenvironments, since elaborate offline 
analytics are often limited due to small available sample volumes in rapidly 
changing microcultures. Using microtechnologies, innovative screening tools can 
be fabricated that simultaneously allow the integration of fluidic structures with 
electrochemical and optical elements for culture control and monitoring. By use of 
soft lithographic techniques in combination with poly(dimethylsiloxane) (PDMS), 
inexpensive disposable microchips can be produced with transparent and 
biocompatible characteristics. The microbioreactors (MBR) presented here are 
based on glass substrates (optionally structured with metallic electrodes) that are 
covalently bonded to a PDMS layer. This PDMS layer features the desired reactor 
design and structures for different optical interrogation approaches. All the MBRs 
include different types of online analytics to monitor retention time, dissolved 
oxygen concentration, pH, cell morphology or optical density. Cultivations of yeast 
cells (S. cerevisiae), spores (A. ochraceus) and primary human endothelial cells 
demonstrate the successful performance (such as proven scalability when 
compared to laboratory-scale bioreactors) of these highly integrated 
biomicrodevices for versatile application as disposable screening tools. 
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DETERMINATION OF LIPOSOMES WITH DIFFERENT DRUGS 
Bilek, H.1, Tong, L.1, Perlich, J.2, Vainio, U.2, Kumpugdee-Vollrath, M.1
1Beuth Hochschule für Technik Berlin, Fachbereich II: Mathematik-Physik-
Chemie, Luxemburger Straße 10, D-13353 Berlin 2Deutsches Elektronen-
Synchrotron (DESY/HASYLAB), Notkestr. 85, D-22607 Hamburg
Liposomes have been widely used in pharmaceutical field as transdermal and 
parenteral application. Liposomes are an alternative system for reducing the 
toxicity associated with drug.  
The aim of this research work was to study the new formulation based on 
liposomes with different drugs which can be used as nano drug delivery systems. 
In our project the liposomes were prepared by lipid film hydration technique. A 
lipid film of different Phospholipon-types was prepared in a vial by dissolving the 
lipid in a mixture of chloroform and methanol (2:1, v/v) followed by removal of 
the organic solvent by a vacuum drying cabinet at 40°C for 24 h. Prior to the 
measurement by X-ray scattering, the lipid films were dissolved in sterile pure 
water at different concentrations of a model drug. In order to determine some 
properties of liposomes, e.g. shape, diameter and repeat distance (long spacing and 
water layer) the X-ray and light scattering as well as electron microscopy were 
applied. X-ray scattering based on synchrotron radiation allows a high resolution 
surface or interface sensitive structure analysis. Therefore the X-ray scattering 
technique from the synchrotron source at the beamline BW4 and B1 at HASYLAB, 
DESY, Hamburg was applied to determine the significant peaks of the scattering 
pattern, which can give information about the different formulations. The 
information about the nanostructure of the different formulations by various 
measuring techniques will allow us to formulate the better drug delivery system 
and to understand the mechanism of action of different composition inside the 
formulation. 
References: 
[1] Weidenauer U., Mäder K. (2010) Innovative Arzneiformen. Wissenschaftliche 
Verlagsgesellschaft GmbH, Stuttgart, 149-163. 
[2] Tong L., Bilek H., Roth S.V., Perlich J., Gramdorf S., Kumpugdee-Vollrath M. 
(2010) Determination of different drug delivery systems by GISAXS from a 
synchrotron source. 7th World Meeting on Pharmaceutics, Biopharmaceutics and 
Pharmaceutical Technology, Malta, 8th to 11th March. 
T032
OPTIMIZING SHELF LIFE OF DOXORUBICIN LOADED LIPOSOMES            
BY LYOPHILIZATION 
Böhm, K.; Süss, R. 
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The stability of aqueous liposome preparations is influenced by hydrolysis of the 
phospholipids being part of the formulation [1]. One possibility to circumvent this 
problem is the storage of liposomes in the dry state. Freeze drying of a liposome 
dispersion can be applied to achieve a porose lyophilisation cake which can be 
easily reconstituted when needed [2]. The removal of water affects the liposome 
integrity because of its spacer-function between the vesicles, resulting in size 
changes and leakage of the encapsulated compound [2]. Therefore, lyoprotectants 
like disaccharides can be added to protect liposomes against freezing and thawing 
stress [2]. 
HSPC (hydrated soy phosphatidylcholine)/cholesterol liposomes were prepared by 
the lipid film method and subsequently loaded with doxorubicin (DXR) using the 
remote loading method. The encapsulation efficiency (EE) of DXR was detected 
fluorimetrically on the LS 50B, Perkin Elmer. 
For the freeze drying process half of the samples were frozen in the -80°C deep 
freezer whereas the other half was cooled down in the freeze dryer using an 
Alpha 2-4 (Martin Christ, Osterode, Germany). After complete freezing the 
samples were united in the freeze dryer and the primary drying lasted 72h with a 
starting temperature of -35 °C followed by the secondary drying for 6 h at 30 °C. 
The lyophilized products were stored at 4 °C and characterized regarding EE and 
size changes. Depending on the amount of sucrose the EE varied showing the best 
results with higher concentrations of sucrose. Regarding size changes before and 
after freeze drying the nontreated liposomes seem to be more stable. 
References: 
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BORON-LIPIDS IN LIPOSOMES:  
LIPOSOME/CELL INTERACTION AND LIPID EXCHANGE 
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In Boron Neutron Capture Therapy (BNCT) of tumours, 10B-containing molecules 
within the tumour are subjected to neutron rays. The resulting - and 7Li-particles 
act as damaging agents to the adjacent tumour cells. Liposomes might be helpful in 
transporting the molecules to the tumour site. 
In this study, SAINT-like lipids which contain negatively charged closo-
dodecaborate clusters as polar head groups and feature varieties in alkyl chain 
lengths as well as linker moieties to the boron cluster [1] are used as main 
components in the formulation of liposomes. The cellular association of the 
liposomes and the exchange of lipids between membranes (e.g. liposomes) is of 
particulate interest in this project. 
For cell association studies, Kelly cells were incubated (37 °C or 4 °C) with 
liposomes consisting of SPC (soy phosphatidylcholine), cholesterol and the 
respective boron-lipid in equimolar amounts along with Rhodamine-PE as 
fluorescence label and optionally 5 % DSPE-PEG-2000 (PEGylated distearoyl-
phosphatidylethanolamine). Flow cytometry analysis showed cellular association 
of the boron-liposomes in the range of 30 to 80 % at 37 °C, and below 20 % when 
incubation was performed at 4 °C. This indicates that an active internalization of 
the liposomes takes place. For lipid alkyl chain lengths of C14 and C16 a decrease in 
association can be observed for preparations containing DSPE-PEG-2000. 
Boron-lipid exchange might occur with tissue membranes (e.g. blood vessel 
endothelium) before arrival of the liposomes at the designated target tissue. 
Therefore, the analysis of the exchange of lipids between liposomal bilayers was 
performed by means of free-flow electrophoresis [2]. First results indicate a 
correlation of exchange rate and diminishing chain length when using similar 
lipids. 
_________________________ 
[1] Schaffran T, Burghardt A, Barnert S, Peschka-Süss R, Schubert R, Winterhalter M, Gabel D. Pyridinium lipids with the 
dodecaborate cluster as polar headgroup: Synthesis, characterization of the physical-chemical behavior and toxicity in cell 
culture. Bioconjugate Chem 2009, 20, 2190-2198  
[2] Holzer M, Momm J, Schubert R. Lipid transfer mediated by a recombinant pro-sterol carrier protein 2 for the accurate 
preparation of asymmetrical membrane vesicles requires a narrow vesicle size distribution: A free-flow electrophoresis 
study. Langmuir 2010, 26 (6), 4142-415 
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ASYMMETRICAL FLOW FIELD-FLOW FRACTIONATION FOR THE 
CHARACTERIZATION OF LIPOSOMES 
Decker, C.1, Fahr, A.1, Kuntsche, J.2
1Pharmaceutical Technology, FSU Jena 2Pharmaceutical Technology and 
Biopharmaceutics, MLU Halle/Saale 
In asymmetrical flow field-flow fractionation (A4F) a laminar flow and a lateral 
cross flow is applied in a channel for sample fractionation in contrast to 
conventional chromatographic methods using a stationary and a mobile phase. By 
combining the A4F system with a multi-angle light scattering detector (MALLS) 
size determination of colloids at each elution time becomes possible and accurate 
determination of size distributions can be achieved. Asymmetrical flow field-flow 
fractionation is thus a promising method for size determinations of colloidal drug 
carrier systems like liposomes, as one of the most important parameter is carrier 
size and size distribution which affects circulation time in-vivo as well as 
biodistribution and targeting abilities. 
In the present study, liposomes composed of DPPC/DPPG (9:1 w/w) were 
analyzed by A4F/MALLS. Drug-free liposomes and liposomes loaded with 
different lipophilic drugs were prepared in 5 % glucose solution by extrusion. The 
influence of the osmolarity of the carrier liquid (pure water, sodium chloride 
solutions (25, 50, and 100 mM) and an isotonic glycerol/water mixture) on the size 
of the liposomes was evaluated. To obtain information about liposome and drug 
recovery different radioactive markers (either 3H or 14C) were incorporated into the 
liposomes.  
Reproducible results were obtained under all fractionation conditions. Vesicle size 
was, however, affected by the carrier liquid with largest sizes measured in pure 
water. Nevertheless, no indication of vesicle destabilization or disturbed elution 
behavior was observed. Interestingly, liposomes loaded with temoporfin (a water-
insoluble, highly hydrophobic photosensitizer) were less sensitive to osmotic 
swelling than the drug-free liposomes. Whereas liposome recovery (lipid marker) 
was close to 100 %, recovery of incorporated drugs was less in all cases and 
strongly dependent on the partition coefficient of the drug. Recovery of temoporfin 
(logP ~ 9.597) for example was about 80 % whereas recovery of corticosterone 
(logP ~ 1.758) was only 2 %. 
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IMPROVEMENT OF PHOTODYNAMIC ANTIBACTERIAL THERAPY 
Fahr, A.1, Rüger, R.1, Gitter, B.2, Albrecht, V. 2, Wieland, G.D. 2, Yang, K.W.1
1 Lehrstuhl für Pharmazeutische Technologie, Friedrich-Schiller-Universität Jena, 
Lessingstraße 8, 07743 Jena, Germany 2Biolitec AG, Jena, Winzerlaer Straße 2, 
07745 Jena, Germany  
Abstract: 
Recently, photodynamic antimicrobial therapy (PACT) attracted a lot of attention 
as a promising treatment modality to eradicate bacteria, especially against 
antibiotic-resistant species. In this study, a generation II photosensitizer, 
temoporfin, was incorporated into liposomes to increase its solubility, and the 
liposomal surface was modified with a lectin, wheat germ agglutinin (WGA), 
aiming to improve the targeting delivery of Temoporfin to bacteria. In use of a 
functional phospholipid, DSPE-PEG2000-NHS, WGA was successfully and 
conveniently conjugated to liposomes, proved by gel electrophoresis. Methicillin-
resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa were used 
as the model of gram-positive and gram-negative bacteria, respectively. The 
delivery of temoporfin to bacteria was confirmed using fluorescence microscopy, 
while the delivery efficiency of different formulations was compared using flow-
cytometry, proving that the WGA modified liposomes delivered more temoporfin 
to MRSA and Pseudomonas aeruginosa compared to unmodified liposomes. In the 
photodynamic inactivation test, the WGA modified liposomes eradicated all MRSA 
and increased the bactericidal efficacy significantly against Pseudomonas 
aeruginosa, showing obvious improvement of PACT. Therefore, the WGA bearing 
liposome is a potential modality for PACT against antibiotic-resistant bacteria, 
particularly of great importance for local microbial infections.  
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GRAPHITE FURNACE AAS AS A QUANTITATIVE ANALYTIC 
METHOD FOR DETERMINATION OF INTRALIPOSOMAL ARSENIC 
TRIOXIDE 
Müller, I.1, Schubert, R.1
1Institut für Pharmazeutischen Technologie und Biopharmazie, 
 Universität Freiburg 
The aim of the PhD project is the effective encapsulation of arsenic trioxide (ATO) 
as an antineoplastic drug1 into liposomes combined with an active targeting against 
GD2, as a specific marker for neuroblastoma cells. The first critical challenge for 
the determination of the intraliposomal arsenic trioxide amount is to establish a 
suitable quantitative analytic method within a range of 5-10 μg/l. According to 
results of Chen et al. 20062, ATO could be effectively encapsulated via a remote 
loading mechanism. Previously encapsulated nickel acetate forms an unsoluble 
precipitate with ATO resulting in high encapsulation efficiency (98%). 
         A quantitative analytic method for arsenic trioxide was affected by a complex 
matrix including liposomes, NiIIAc and isotonic HEPES buffer. Graphite furnace 
atomic absorption spectroscopy (GF-AAS) is a suitable quantitative analytic 
method with regard to high sensivity level even with an elevated salt burden. In 
GF-AAS, a single drop (20μl) of sample to be analyzed is positioned on the 
platform of a graphite tube. In a multi-step temperature program, the drop
evaporates, matrix is then removed through pyrolysis, molecules are atomized and 
absorption of these atoms is detected. Following optimization of length and 
temperature of the evaporation, pyrolysis and atomization phase, the detection and 
quantification limit was determined via the calibration line method. Within a range 
of 2.5-25 μg/l a sixfold measurement was performed, and results analyzed 
concerning relative standard deviation and linearity. It could be shown that a 
concentration of 5 μg/l could be securely determined with a RSD less 5% and 
linearity over the entire range. Different lipid compositions were tested in order to 
find the optimal mixture for highest encapsulation efficiency. 
1 Ferrara et al. : Acute promyelocytic leukemia: what are the treatment options?  
     Expert Opin Pharmacother. 2010 Mar;11(4):587-96.
2 Chen et al. : Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer  
   drug release, J. Am. Chem. Soc., 2006, 128 (41), 13348-13349 
.    
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Introduction
Oral drug administration is mainly regulated by the step of intestinal absorption. 
For various substances uptake is strongly superimposed by an active efflux back 
into the lumen via ATP-driven pumps like the P-glycoprotein (P-gp), significantly 
decreasing their bioavailability. 
P-gp inhibitory effects can be determined via in-vitro transport studies and the 
calcein accumulation assay (CAA) using CaCo2, as well as MDCKII-mdr1 cells. 
Former results indicate that particular synthetic phospholipids (PL) display a P-gp 
inhibitory potential.  
The aim of this study is to identify further potent PL species and to investigate their 
mechanism of inhibition by varying diverse experimental parameters. 
Experimental Methods 
Cell culture: CaCo2 and MDCKII-mdr1 cells were routinely maintained in 
supplemented DMEM. Cells were grown for either 21 days in Transwell® plates in 
case of transport studies, or for 8, resp. 4 days (MDCKII-mdr1) in 96-well plates in 
case of CAA.  
Lipid formulations: PL were applied as micellar or liposomal formulations. 
Transport studies: CaCo2 cell layers were pre-incubated with lipid and digoxin 
(3H-labeled) was added apically for absorptive or basolaterally for secretory 
studies, respectively. Monolayer integrity was determined via transepithelial 
electrical resistance (TEER) measurements and the ratio of the apparent 
permeability coefficients (Papp) of both directions displayed P-gp effects. 
Calcein Accumulation Assay: After pre-incubation with lipid or Verapamil as a 
positive control the intracellular accumulation of the fluorescent dye calcein 
indicated P-gp inhibition. 
Results 
C12-phosphatidylglycerol, C6-phsophatidylserine and various unsaturated 
symmetric and asymmetric phosphatidylcholines (PC) induced a significant, 
concentration-dependent enhancement of net drug absorption in the CaCo2-
transport studies. Using CAA C10-PC displayed a higher P-gp inhibiton than 
Verapamil depending on the pre-incubation time, whereas cis-22:6-PC showed a 
pronounced transporter selectivity. 
T038
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Drug nanocrystals are an approach for the formulation of poorly soluble drugs, 
including parenteral injections (i.v., i.m.) [1]. For injectables, aseptic production is 
typically required because terminal sterilization is in many cases not feasible. The 
aseptic process requires equipment suitable for aseptic processing. In lab scale, 
high pressure homogenizers are more convenient than bead mills. Previously an 
aseptic production line was established based on an APV Gaulin LAB 40 with a 
batch size of about 40ml. However, even when producing a low concentrated 1% 
nanosuspension, this requires 0.4g material per batch. This is far too much for very 
expensive drugs, and new chemical entities of very limited availability, esp. in a 
systematic screening. Therefore the scale down ability was investigated by using 
an Avestin B3 with about 3ml batch size, reducing the amount of drug needed by a 
factor >10. The aims of the study were to assess a) how efficient the B3 is 
compared to the LAB 40, and b) if comparable results can be achieved with both 
homogenizers, i.e. if previous experiences can be used for the B3. Several actives 
with antioxidative capacity, and with potential use in supportive cancer treatment 
(curcumin, hesperetin, hesperidin), were used to produce nanosuspensions with 
both homogenizers. Production was performed applying a pre-milling with 
increasing pressure, and 20 homogenization cycles at 1,500 bar. Size was analyzed 
as a function of cycle number by photon correlation spectroscopy (Zetasizer Nano 
ZS) and laser diffractometry (Malvern 2000, both Malvern Instr., UK). The result 
depended very much on the type of active. For hesperedin, a similar PCS size was 
obtained (about 280 nm), hesperetin and curcumin were distinctly larger when 
using the B3 (about 546 nm versus 378 nm respectively 925 nm versus 633 nm 
with LAB 40). In some productions a small size identical to the LAB 40 was 
obtained, but production reproducibility was insufficient (hesperedin). This is 
attributed to the lack of precise pressure control, whereas reproducibility with the 
LAB 40 was good. In addition, often the size decayed slower with increasing 
cycles. In summary: for nanocrystals the B3 appears suitable for first feasibility 
runs, but – in contrast to nanoemulsions - not optimal for screening of production 
parameters. 
1. Keck C.M. and Müller R.H., Eur J Pharm Biopharm, 2006. 62(1): 3-16. 
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The rapid introduction of an aqueous buffered protein solution in which carrier 
material is dissolved into a water-miscible organic solvent such as propan-2-ol or 
2-methyl-2,4-pentanediol leads to the formation of protein-coated microcrystals 
(PCMCs). Due to the immediate removal of the water no crystal growth can occur 
after nucleation for kinetic reasons. Hence, the protein as well as other components 
dissolved in the aqueous phase precipitate as fine particles in the amorphous form. 
After the precipitation process the resulting PCMC suspension can be concentrated 
and finally be dried via supercritical fluid extraction (SFE) using supercritical 
carbondioxide. The PCMCs can either be utilized as fine and well flowing powder 
or be resuspended in another nonsolvent system [1]. 
A precedent study had focused on a formulation screening to assess the 
applicability of this technology to a non-glycosylated cytokine [2]. One very 
promising formulation was chosen to investigate in depth bioactivity and protein 
structure of the cytokine. The analytical focus was placed on a cytopathic effect 
assay as bioactivity test as well as on the characterization of the protein structure 
via fluorescence, 2nd derivative UV and FT-IR spectroscopy. 
Overall, the cytokine´s bioactivity was entirely preserved after the PCMC 
precipitation process. In this respect, the choice of the reconstitution medium 
turned out to have a tremendous effect concerning ionic strength and pH. The 
reconstitution media that combined an acidic pH and a low ionic strength led to 
optimal recovery of bioactivity. Bioactivity of cytokine formulated as PCMC were 
equivalent to standard lyophilized formulation. Furthermore, no structural changes 
of the protein could be detected by the spectroscopic methods comparing the 
starting material prior to precipitation and the PCMC powder after reconstitution. 
Thus, the PCMC precipitation process had no deleterious effect on the very 
cytokine and was successfully applied whilst preserving bioactivity and protein 
conformation. 
[1] König, C. Thesis 2010, [2] Berkenhoff, K., et al. Poster 7th PBP World 
Meeting, Malta, 2010 
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THE USE OF DOE TO OPTIMIZE PROCESS PARAMETERS FOR A 
NOVEL PRODUCTION METHOD FOR NANOSUSPENSIONS 
Heinzerling, O. 1; Salazar, J. 2; Müller, R.H. 2 ; Möschwitzer, J. 1,2 
1 Pharmaceutical Development. Abbott Healthcare Products (formerly Solvay 
Pharmaceuticals), Weesp, The Netherlands 
2 Institut für Pharmazie, Abteilung “Pharmaceutics, Biopharmaceutics and 
NutriCosmetics”, Freie Universität Berlin, Germany 
Modern active pharmaceutical ingredients (APIs) show in most of the cases poor 
water solubility, which causes an inadequate dissolution rate and therefore a low 
oral bioavailability. Particle size reduction (PSR) with high pressure 
homogenization (HPH) is a suitable method to enhance the bioavailability of these 
APIs. The achievable particle size is depending on certain compound properties, 
such as crystallinity, hardness and morphology. In some cases it is difficult to 
obtain small particles. To solve this problem a combinational PSR method (FD-
HPH) was developed, which is a combination of freeze drying (FD) (bottom-up) 
with HPH (top-down). The FD step modifies the drug structure and the HPH 
nanosizes the particles. First experiments have shown a relation between the FD 
conditions and the final particle size. Both the API concentrations as well as the 
organic solvent composition influence the porosity and the crystallinity of the drug 
during lyophilization. To properly analyse the influence of these parameters studies 
were conducted according to design of experiments principles. The model 
compound glibenclamide was dissolved in organic solvents (mixtures of DMSO 
and TBA) within different concentrations. The obtained API solutions were snap-
frozen with liquid nitrogen and freeze dried. The outputs were characterized using 
SEM, DSC and XRPD and subsequently homogenized at high pressure using a 
Micron LAB 40 (APV-Gaulin) homogenizer. The nanosuspensions were 
characterized using PCS and LD for average particle size and distribution. 
Significantly smaller drug nanoparticles could be produced by using optimized 
process conditions. After 20 homogenization cycles with the modified API (high 
TBA content and low API concentration during FD, amorphous structure) the 
particle size was very small: 187 nm (PCS z-ave) and 0.146 μm (LD 50%). On the 
contrary, with unmodified API the results were 772 nm (PCS z-ave) and 0.520 μm 
(LDV 50%). It was shown, that the structure modification of the drug by means of 
FD can significantly improve the particle size reduction effectiveness of HPH. The 
solvent and the drug concentration used for the FD need to be selected carefully. 
For this purpose design of experiments (DoE) is a very useful tool. 
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INJECTABLE EXTENDED RELEASE LIDOCAINE SMARTCYSTALS 
FOR DERMAL APPLICATION 
Müller, R. H., Al Shaal, L., Shegokar, R. 
Freie Universität Berlin, Institut für Pharmazie, Pharmazeutische Technologie, 
Kelchstraße 31, 12169 Berlin 
Water soluble anesthetics (e.g. lidocaine HCL) are rapidly cleared from the 
application/injection site by diffusion. To obtain an extended release formulation 
for dermal and later on injectable use, the poorly water soluble lidocaine base was 
formulated as nanocrystal suspension (nanosuspension). Crystals provide a 
prolonged release. Sufficiently high drug levels can be generated by adjusting the 
surface (size) of the nanocrystals as one of the dissolution controlling factors. 
Lidocaine base nanosuspension 5% (w/w), stabilized with 1% Plantacare 2000 UP, 
was tried to be produced by high pressure homogenization (HPH). This resulted in 
a suspension with relatively large crystals showing pronounced sedimentation and 
caking tendency. Obviously the high energy milling process was not suitable for 
this formulation composition. 
Therefore, as alternative a low energy smartCrystal production process was used, 
the combination technology (CT) of pearl milling followed by low pressure HPH. 
Lidocaine was produced using a PML 2 pearl mill (Bühler AG, Switzerland) for 3 
hours followed by high pressure homogenization at a low pressure of 300 bar. The 
produced smartCrystals were characterized by photon correlation spectroscopy 
(PCS, Zetasizer Nano ZS (Malvern Instruments, UK)), laser diffractometry, (LD, 
Mastersizer 2000 (Malvern Instruments)), and light microscopy (Orthoplan, 
Germany) to check for presence of aggregates. 
Particle size reduction was observed as function of milling time in the small size 
milling chamber. The smallest achieved mean particle size for the lidocaine 
smartCrystals was 244 nm with a polydispersity index of 0.173. LD and light 
microscopy confirmed absence of aggregates and showed uniform distribution of 
crystals. From this, the low energy CT process is suitable, and Plantacare 2000 UP 
efficient in stabilizing the nanocrystals and preventing aggregation. The 
nanosuspension had a homogenous, nice, uniform looking appearance. Exchanging 
the Plantacare against GRAS accepted stabilizer for injection (e.g. lecithin, Tween 
80) opens the perspective for an injectable prolonged release formulation, of 
interest e.g. after surgery. 
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PREDICTION OF PARTICLE FORMATION AFTER STIR STRESS OF 
AN IGG1 SOLUTION 
Spalthoff, V., Winter, G. 
Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, 
Ludwig-Maximilian-University  
The discussion about protein aggregation is becoming more and more important in 
the field of biologicals which need to be administered parenterally. With reference 
to this it is interesting to evaluate whether aggregation and particle formation can 
be described and predicted by fitting data to a theoretical model.  
One typical stress factor for biopharmaceuticals during manufacture storage and 
handling is mechnical stress. We studied stirring stress, as upscaling of stirring 
processes is a challenging task and on the other hand provides an excellent 
opportunity to apply mathematical modelling. Factors to be considered are: stirring 
speed, vessel size, formulation. 
Using computational fluid dynamic simulations software (STAR-CCM+; CD 
Adapco, Nuremberg) the stirring process at three different stirring speeds in 
injection bottles using a magnetic stir bar was simulated to get information about 
the applied stresses in the liquid phase. In parallel, lab experiments were carried 
out: IgG1 solutions were stressed by stirring and measured afterwards using light 
obscuration to determine the particle count in size classes >1μm.  
Stressing with other stirring speeds than used within the simulation experiment, the 
particle counts were found to properly fit into the simulated maximal stress tensor 
magnitudes.
We found that, keeping all conditions the same except stirring speed, the count of 
particles >1μm and >2μm can be well predicted. However, count of particles 
>10μm and >25μm as tested according to USP <788> can not be predicted using 
the applied software model.  
Such results raise the question whether new pharmacopoeial specifications 
regarding particle counts in biotec-parenterals are needed to cover particles in the 
range 1-10μm, as they are obviously behaving different than particles >10μm and 
>25μm.  
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INVESTIGATIONS ON LABELING OF AL(OH)3-GEL FOR MAGNETIC 
RESONANCE TRACKING 
Thom, K.1, Aurich, K.2, Kühn, J.-P.3, Glöckl, G.1, Weitschies, W.1
1Institute of Pharmacy, University of Greifswald 
2Institute of Immunology and Transfusion Medicine, University of Greifswald 
3Institute of Diagnostic Radiology and Neuroradiology, University of Greifswald
As early as in 1926 Glenny et al. reported the use of aluminium compounds as 
adjuvants in vaccines. Since that time aluminium hydroxide (Al(OH)3) and 
aluminium phosphate (AlPO4) have most commonly been used[1]. Nevertheless, 
the mode of action could not be ascertained in detail up to date. For a long time a 
depot effect was accepted as an explanation, but in recent years it became clear that 
this is not the sole cause [2]. A novel method to investigate the fate of Al(OH)3 in
vivo could be magnetic resonance imaging (MRI). As Al(OH)3 is not directly 
visible in MRI, labeling with superparamagnetic iron oxide particles might be 
feasible. Here we used ferucarbotran particles (Resovist®, Bayer Schering Pharma 
AG, Germany) for the generation of complexes with Al(OH)3. Resovist® is a 
commercially available MRI contrast agent for imaging of liver lesions consisting 
of carboxydextran coated iron oxide nanoparticles as an injectable solution. Since 
it is a FDA-approved contrast agent, the potential for clinical trials is given. 
For labeling a colloidal suspension of Al(OH)3 (Alhydrogel®, Sigma-Aldrich, 
Germany) was merged with ferucarbotran particles in varying ratios of iron and 
aluminium. The formed complexes were characterized regarding their size by 
dynamic light scattering and laser diffraction measurements. Their zeta potential 
was determined by electrophoretic light scattering measurements. To investigate 
the stability of the aggregation the complexes were centrifuged after one, three and 
five days of incubation in different media. The pellet and the supernatant were 
analyzed concerning iron content using atomic absorption spectrometry. When
adding excessive adjuvant Resovist® was completely bound. The adsorption was 
stable for at least five days. 
The first investigations showed that Al(OH)3 was labeled with Resovist® simply by 
mixing. The adsorption probably resulted from electrostatic interactions due to 
opposing zeta potential of both components. The results of stability investigations 
are encouraging. The identification of suitable MRI parameters is ongoing. 
[1] Baylor, N. W. et al. Vaccine 20 (2002), 18-23; 
[2] Marrack, P. et al. Nat Rev Immunol 9 (2009), 287-293; 
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SKIN DELIVERY OF FERULIC ACID FROM DIFFERENT LIPID 
VESICULAR SYSTEMS 
Ming Chena, Xiangli Liua and Alfred Fahra 
a Department of Pharmaceutical Technology, Friedrich-Schiller-University Jena 
The aim of the present research is to evaluate the skin delivery capabilities of 
different lipid vesicular systems, including conventional liposomes (CL), Tween 
80-based deformable liposomes (DL), invasomes (INS) and ethosomes bearing 
ferulic acid (FA) being an antioxidant exhibiting a wide range of therapeutic effects 
against various diseases. All of the test formulations were characterized for particle 
size distribution, -potential, vesicular shape and surface morphology, in vitro 
human skin permeation and skin deposition. Dynamic Light Scattering (DLS) and 
Transmission Electron Microscopy (TEM) defined that all of liposomal vesicles 
were almost spherical, displaying unilamellar structures with low polydispersity 
(PDI<0.2) and nanometric size range (z-average no more than 150nm). In addition, 
all the vesicular systems except conventional liposomes were negatively charged to 
a certain extent. In vitro skin permeation and skin deposition experiments 
demonstrated that the permeation profile of ferulic acid through human stratum 
corneum epidermis membrane (SCE) and the drug deposition in skin were both 
improved significantly using these vesicular liposomal systems.  Permeation and 
skin deposition enhancing effect was highlighted by the ethosomal system 
containing 18.0 mg/ml of ferulic acid with an significantly (P<0.01) enhanced skin 
flux (267.8±16.77 μg/cm2/h) and skin drug deposition (51.67±1.94μg/cm2), which 
was 75 times and 7.3 times higher than those of ferulic acid from saturated PBS 
(pH 7.4) solution, respectively. This study demonstrated that ethosomes are 
promising vesicular carriers for delivering ferulic acid into or across the skin. 
 
T045
CHARACTERIZATION OF SEMISOLID SLN-DISPERSIONS BASED ON 
PHOSPHOLIPON 90H 
Dahl, K., Müller-Goymann, C.C. 
Institut für Pharmazeutische Technologie, TU Braunschweig 
The aim of the present study was the preparation and physico-chemical 
characterization of semisolid nanoparticular dispersions based on hard fat and 
Phospholipon	 90 H (P90H), a completely hydrogenated phospholipid. The 
lecithin-hard fat mixtures - hereinafter referred to as lipid matrices (LM) - served 
as basis for the production of semi-solid nanoparticular systems. The considered 
formulations contained - in addition to the lipid matrix (with 10% P90H) - a non-
ionic emulsifier for the stabilization (Macrogol-15-Hydroxystearate, Solutol	
HS15), thimerosal as a preservative and water as external phase. The lipid matrix 
content was 10, 12.5 and 15 %, respectively. The systems were prepared by hot 
pressure homogenization using different homogenizers (EmulsiFlex-C5 from 
Avestin and Panda from Niro Soavi). The “Avestin systems” were collected in a 
single vial, the “Niro systems” were filled into several vials due to a bigger sample 
volume. The partical size distribution for all SLN dispersions was almost 
monomodal, the z-averages of the dispersions were below 500 nm as far as systems 
with P90H contents of 10% were concerned. Over a storage period of 6 weeks at 
room temperature, the dispersions remained stable in relation to their particle sizes 
and distributions. The use of different homogenizers did not affect particle size and 
particle size distribution either. Using oscillation measurements, viscous and elastic 
properties of the formulations could be determined. In addition, consistencies and 
product stability of the systems could be classified. The linear viscoelastic area, 
storage and loss modulus, phase angle and the complex viscosity are important 
parameters to characterize the rheological properties of a given system. The storage 
and the way of manufacturing the systems seemed to have a significant influence 
on the rheological properties. One week after production the “Avestin systems” 
offered a higher consistency and stability compared to the corresponding “Niro 
systems”. Over a storage period of six weeks a decrease in consistency of the 
systems was generally observed. Furthermore the Niro systems dominated the 
Avestin systems in terms of consistencies and stabilities that were related to the 
kind of filling and sampling. Taking a sample at different time points from the 
same vial had a critical influence on the sample’s microstructure. 
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INVESTIGATION OF THE MECHANISM OF EMULSION 
STABILIZATION WITH A TRITERPENE EXTRACT FROM THE OUTER 
BARK OF BIRCH 
Grysko, M.1, Jäger, S.2, Daniels, R.1
1Lehrstuhl für Pharmazeutische Technologie, Universität Tübingen 
2Carl Gustav Carus-Institut, Am Eichhof 30, 75223 Niefern-Öschelbronn 
A w/o emulsion system stabilized by a triterpene dry extract from the outer bark of 
birch (TE) was the subject of the present study. 
The primary aim was the characterisation of the TE’s influence on the interfacial 
tension between the lipophilic phase and the aqueous phase. Furthermore, oil 
solubility of the TE and its distribution in emulsions were investigated. 
Water-in-oil emulsions were prepared by adding water to a lipophilic phase that 
consisted of TE finely dispersed in oil by means of an Ultra-Turrax®. Surface 
tension was measured using the axisymmetric drop shape analysis (ADSA) 
method. The structure of TE stabilized emulsions was investigated with a confocal 
Raman microscope (CRM). The oil solubility of the main constituents of the TE 
was quantified by gas-chromatography. 
As a result, it was found that the TE was completely soluble in the oil phase at 
concentrations < 2.3 mg/ml. Close to its saturation concentration, the TE reduced 
the interfacial tension between the oil and water by only 5 mN/m.  
The total amount of dissolved triterpenes in the oil could be further increased when 
the added amount of TE exceeded the saturation limit. The supernatant of TE 
suspensions containing 60 mg/ml revealed a total concentration of triterpenes of 
3.3 mg/ml and an interfacial tension of 18.8 mN/m. However, it could be 
demonstrated, that this supernatant does not form stable o/w emulsions. 
Obviously, the presence of suspended TE particles is a necessary prerequisite for 
the emulsion stabilizing effect of the TE. Accordingly, CRM showed that TE 
particles covered the water droplets and additionally formed a network in the 
lipophilic phase.  
Thus we conclude from these results, that TE stabilized emulsions are Pickering 
emulsions. The stability is mainly given by the adsorption of solid particles to the 
oil-water interface. The surface activity of dissolved triterpenes plays only a minor 
role.
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INVESTIGATION OF THE STABILITY OF O/W PICKERING 
EMULSIONS STABILIZED WITH COATED AND UNCOATED 
CALCIUM CARBONATE  
Horst A., Daniels R. 
Pharmazeutische Technologie, Universität Tübingen  
Solid stabilized emulsions (Pickering emulsions) have several advantages 
compared to classical emulsions. They are surfactant free and thus are attractive for 
dermal and oral use where classical emulsifiers are sometimes not well tolerated. 
The aim of this study was to evaluate the suitability of uncoated CaCO3
nanoparticles and their mixtures with stearic acid coated CaCO3 for an o/w 
emulsion stabilization. Moreover, the effect of particle concentration on emulsion 
stability was investigated. 
Wettability of CaCO3 nanoparticles was characterized by a modified Wilhelmy 
plate method measuring the advancing contact angles with water. 
CaCO3 stabilized Pickering emulsions consisted of CaCO3/ MCT/water 
(5% / 20% / 75%). The CaCO3 was either pure uncoated CaCO3 or mixtures 
consisting of 3 parts of uncoated and 1 part of coated particles (mixture 3+1), and 
equal amounts of coated and uncoated particles (mixture 1+1), respectively.  
The effect of the particle concentration was investigated with emulsions containing 
3, 4, 5 or 6 g CaCO3.
Physical stability of emulsions was characterized by droplet size measurement on 
emulsion samples stored for 4 weeks at 23 °C and 40 °C.  
It was shown that the contact angle of particulate emulsifiers with water can be 
used to characterize their polarity. The wettability of particle mixtures was shown 
to be additive and increases with the amount of hydrophobically coated particles. 
Stability tests of the emulsions clearly indicate a synergistic effect of particle 
mixtures. Compared to the emulsion stabilized with pure uncoated CaCO3
emulsions stabilized with the mixtures do not show substantial coalescence or at 
least reach a stable plateau value within the first days of storage. Furthermore, their 
terminal droplet size is smaller. This indicates that the particle mixtures are able to 
stabilize a larger interfacial area than the singular uncoated particles. It could also 
be demonstrated that increasing amounts of particulate emulsifiers lead to smaller 
droplet sizes and avoid the risk of droplet coalescence. Thus it can be concluded 
that stable Pickering emulsions can be formulated successfully using optimized 
mixtures of hydrophilic and hydrophobic nanoparticles. 
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FORMULATION, PHYSICAL STABILITY AND CRYSTALLINE STATUS 
OF POLYHYDROXY SURFACTANT BASED SLN AND NLC  
Kovacevic, A.1, Savic, S.1, Milic, J.1, Müller, RH.2, Keck, CM.2 
1Pharmaceutical Technology and Cosmetology, University of Belgrade, Serbia  
2Pharmazeutische Technologie, Freie Universität Berlin 
 
A pre-requisite to apply lipid nanoparticles on sensitive or irritated skin is to use 
non-ionic surfactants at low concentrations. They should be low irritant to the skin 
(often refered as „skin friendly”) and should not contain ethylene oxyde groups. 
Polyhydroxy surfactants may fullfill these requirements. At present no data are 
available for the use of these stabilizers for lipid nanoparticles (SLN and NLC). A 
number of different surfactants from the mentioned group were evaluated in the 
preformulation study. Their wetting ability onto the lipid matrix of nanoparticles 
were assessed by contact angle measurements to identify suitable candidates for 
further investigations. From this, polyglycerol 6-distearate (PD) and alkyl (C8-C14) 
polyglucoside (AG) were identified as the most suitable candidates. SLN and NLC 
were produced by hot high-pressure homogenization and analysed in regard to 
physical stability by dynamic light scattering. The solid state of the particles was 
assessed by differential scanning calorimetry. In all experiments, the total amount 
of lipid was kept constant (10% (w/w)). Both surfactants in the conc. of 1% (w/w) 
led to almost same nanoparticles with a mean diameter between 150 and 200 nm 
and polydispersity index below 0.15. Measured zeta potential (in distilled water) 
for both SLN and NLC were higher than |30mV|. All systems were physically 
stable over the investigated period of 3 month. AG based SLN had a lower 
crystallinity index and melting enthalpy than PD based one. NLC stabilized with 
PD showed a melting event, whereas NLC stabilized with AG did not. The results 
indicate that polyhydroxy surfactants: a) interact with the lipid matrix and b) can 
either prevent or accelerate the crystallisation. A possible explanation is that long 
saturated alkyl chains of PD contribute to the overal solid lipid content inside SLN 
and NLC, whereas short alkyl chains of AG prevent crystallization.  
In conclusion: Polyhydroxy surfactants are suitable stabilizers for both SLN and 
NLC. However, depending on the molecular structure they interact differently with 
the lipid matrix of the particles and thus may change their structure. This 
observation will be a subject of further investigations.  
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COMPOUNDING OF SUSPENSION-TYPE OINTMENTS WITH 
DIFFERENT HOMOGENIZERS - A COMPARATIVE STUDY 
Leopold, C.S., Michler, V.A. 
Institute of Pharmacy, Dept. of Pharmaceutical Technology, University of 
Hamburg 
 
Suspension-type ointments were compounded with two commercially available 
mixing systems and with three roll mills. The systems were compared with regard 
to the quality of the manufactured ointments. 
Suspension-type ointments with 10% salicylic acid and the bases macrogol oint-
ment, wool fat ointment, and white ointment were compounded either with the 
Cito-Unguator®-e and TOPITEC® mixing systems or with three roll mills (Exakt 
50, 50EC, 80E) of different gap size. The manufacturing process was evaluated 
with regard to the time required for ointment preparation and ointment tempera-
ture. The quality of the ointments was examined with respect to homogeneity, par-
ticle size distribution, rheological properties and stability. 
The homogeneity of the ointments was best with the three roll mills and the 
TOPITEC® mixing system. Particle size distribution was also best with the three 
roll mills leading to a particle size between 10 and 40 m using the smallest gap 
size. The Cito-Unguator®-e and the TOPITEC® systems led to broader particle 
size distributions and particles were larger. The rheological properties differed 
significantly between the ointments prepared with the three roll mills and the two 
mixing systems. With three roll mills a soft consistency of the ointments accompa-
nied by a low flow limit was obtained, whereas with ointments prepared with the 
two mixing systems ointment consistency was hard and flow limits were high. This 
phenomenon may be explained by the significant temperature increase of the oint-
ments during manufacture with the two mixing systems. Time required for prepa-
ration of the ointments was not significantly more with the three roll mills. 
However, some product loss has to be expected. 
With three roll mills a better quality of suspension-type ointments may be obtained 
in comparison to the Cito-Unguator®-e and the TOPITEC® mixing systems: Par-
ticle size is smaller, particle size distribution is narrow, ointment stability is better, 
the temperature of the processed ointments does not increase significantly and the 
rheological properties are most favorable. Moreover, preparation of ointments with 
three roll mills allows quality control measures during the manufacturing process 
before transfer of the ointments into jars or tubes. 
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FILM FORMING SEMISOLID FORMULATIONS FOR DERMAL 
APPLICATION
Lunter, D., Daniels, R. 
Pharmazeutische Technologie, Eberhard Karls Universität Tübingen  
 
Generally, formulations for dermal application can be divided into two groups: 
liquid/semisolid formulations such as creams and ointments and adhesive patches. 
Whilst semisolid formulations can be applied to large areas of the (diseased) skin, 
retardation of drug release is more easily achieved by adhesive patches. As some 
diseases require formulations that exhibit prolonged drug release and can be 
applied to large areas, a film forming semisolid formulation for dermal application 
was developed and investigated. The formulations under investigation consisted of 
an O/W emulsion, containing a thickener, Eudragit NE 30D and/or 
Eudragit RS 30D as film forming polymers. The influence of different thickeners 
(HPMC, PVP and PVA) on the stability of Eudragit dispersions was investigated. 
Free films were prepared from emulsions containing varying compositions of 
Eudragit NE and RS 30D. The influence of Eudragit composition on the 
mechanical properties (adhesion and elongation) and the water resistance of free 
films was investigated. High adhesion, elongation of  30 % and high water 
resistance were required. It was found, that the addition of HPMC or PVP to 
Eudragit NE 30D leads to sedimentation of the Eudragit nanoparticles. PVA did 
not decrease the stability of Eudragit dispersions and was therefore used for 
emulsion preparation. Elongation was found to increase with increasing 
Eudragit NE 30D fraction. Adhesion to glass was expected to increase with 
increasing Eudragit RS 30D fraction. Interestingly, films containing either 
Eudragit NE 30D or Eudragit RS30D showed equally low adhesion whilst films 
containing mixtures of Eudragit NE 30D and Eudragit RS 30D showed an even and 
high force of adhesion to glass. Adhesion to polycarbonate was found to be 
generally higher than to glass. As expected, the adhesion to polycarbonate did 
increase with increasing amounts of NE up to 40 parts NE. At higher amounts of 
NE, films were destroyed during the measurement because adhesion to the 
polycarbonate surface was higher than cohesion of the films. Water resistance was 
found to be enhanced by increasing amounts of Eudragit RS 30D. Desired 
properties were obtained from formulations containing 60-100 parts of RS. 
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REDUCED TRANSDERMAL PERMEATION OF TRETINOIN BY 
NANOENCAPSULATION. 
Melero, A.1, Meyers, P.1, Pohlmann, A.R.2, Guterres, S.P.2, Beck, R.2,3, Ourique, 
A.3, Lehr, C.M.1 and Schaefer, U.F.1.
1Institute of Biopharmaceutics and Pharmaceutical Technology, Saarland 
University. Saarbrücken, Germany. 2Instituto de Química, Universidade Federal  
do Rio Grande do Sul,  Porto Alegre, RS, Brazil. 3Faculdade de Farmácia, 
Universidade Federal  de Santa Maria, Santa Maria,  RS, Brazil. 
The aim of this work was to encapsulate tretinoin (TTN) in poly-(epsilon)-
caprolactone nanocapsules (TTN-nc) to reduce the topical absorption of the drug 
and avoid its important side effects.  
Four formulations were assayed: A free TTN-solution, a TTN-nc suspension 
(0.5%) and two hydrogels. TTN-nc suspensions were prepared by the interfacial 
deposition method developed by Fessi, H. et al (1988)1. Hydrogels (0.5%) were 
prepared by dispersing 0.5 % Ultrez Carbopol ® either in the TTN-nc suspensions 
or in the TTN-solution. TTN diffusion has been evaluated by means of static Franz 
diffusion cells. The four formulations were applied by infinite dosing into the 
donor compartment. The acceptor compartment was filled with EtOH:PBS (pH 
7.4) (50:50, V/V) solution. Human heat separated Epidermis was used as diffusion 
membrane. Sampling was performed every 2 h for 32 h. At least five replicates 
were assayed for each condition.  
Formulating TTN in a gel (Kp=0.7±0.1*10-6 cm/s), reduced significantly TTN 
diffusion compared to the solution (Kp=1.8±0.2*10-6 cm/s).  Encapsulated TTN 
showed, no difference when applied in form of solution or gel (Kp=0.3±0.1*10-6 
cm/s), but showed a significantly lower permeation compared to the free drug 
solution.
TTN transdermal diffusion can be strongly reduced by nanoencapsulation of drug 
independently of the topical formulation selected as vehicle for the nanocapsules. 
1. Fessi, H., Puisieux, F., Devissaguet, J.P., 1988. Procede de préparation dês 
systèmes coloïdaux d’une substance sous forme de nanocapsules. 
European Patent 0274961 A1.    
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COLLOIDAL CARRIER SYSTEMS FOR ENHANCED CUTANEOUS 
DELIVERY OF HYDROPHILIC DRUGS 
Naumann, S., Mrestani, Y. Neubert, R.
Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Halle/Saale, 
Germany
Background The long term treatment of severe Psoriasis with classical systemic 
therapeutics such as Ciclosporin is accompanied by a high risk of serious side-effects, 
due to the high dosages necessary to reach the target organ, the skin1.
Objective The aim of the presented work is to develop a drug delivery system for a 
potent drug which can be applied topically instead of the oral therapy with its serious 
side-effects. Thus, a higher concentration at the pharmacological relevant location, the 
skin can be achieved. Another advantage is the lower exposure for the organism. 
Consequently, the selected drug needs to be surveyed for a possible dermal application. 
Methods First, the physicochemical properties of the substance were determined. The 
saturation solubility in different lipophilic and hydrophilic mediums was investigated 
using the method of precipitation. According to Lützhoff et al.2 the partion coefficients 
between octanol and buffer with varying pH was evaluated. Further, for quantification 
we optimized a HPLC method. The isoelectric point (IEP) was also established with 
the aid of capillary electrophoresis (CE) using UV detection. 
Results Solubility of the substance: In lipophilic mediums, like Tegosoft DEC®, IPM®
or IPP® and in hydrophilic mediums, like water the model-substance was “practically 
insoluble”3. By adding Transcutol P to the lipophilic mediums the solubility could be 
increased to “very slightly soluble”3. In contrast, in water the solubility could be 
increased to the same range by addition of Propylenglycol or even better by 
Pentylenglycol. PH values between 5 and 9 improve the solubility behavior of the 
solution as well. The IEP was evaluated to approx. 3.3. 
Conclusion The used model-substance does not possess the optimal properties and 
requirements for a dermal application. The drug is hydrophilic, practically insoluble 
and it has also a low permeability4. Therefore, it is necessary to develop a colloidal 
vehicle system, which has the ability to increase the bioavailability of the substance 
within the skin. Further investigations such as skin penetration of the selected drug 
incorporated in a colloidal vehicle system have to be performed. 
Literature [1] Ludwig-Peitsch,W.K., Kemmler, N. et al. (2006). Akt Dermatol(32): 190-200. 
[2] Lutzhoft, H. C., W. H. Vaes, et al. (2000). Chemosphere 40(7): 711-4. 
[3] Classification according to European Pharmacopoeia 6.8 
[4] Wu, C. Y. and L. Z. Benet (2005). Pharm Res 22(1): 11-23. 
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ALKYLPOLYGLYCOSIDE STABILIZED NLC: INFLUENCE OF 
SURFACTANT CONCENTRATION ON PARTICLE SIZE & STABILITY  
Peters, D.1, Keck, C.M.2
1Freie Universität Berlin, Department of Pharmaceutics, Biopharmaceutics and 
NutriCosmetics, Kelchstrasse 31, 12169, Berlin, Germany 
2Fachhochschule Kaiserslautern, University of Applied Sciences, Department of 
Applied Logistics- and Polymer Sciences, Campus Pirmasens, Carl-Schurz-Straße 
10-16, 66953 Pirmasens, Germany 
Introduction: Alkylpolyglycosides (APGs) have been developed by Emile Fischer 
in the early 1900s. However, large scale production and thus commercial 
recognition only started about 20 years ago. Thus APGs are often referred to be 
novel. APGs are nonionic surfactants with interesting properties. They are 
produced from renewable resources only and are fully biodegradable. After dermal 
application they are extremely skin friendly and nonirritant. Therefore they are also 
candidates for the production of skin friendly nanostructured lipid?carriers.  
Experimental Methods: In this study two APGs with different alkyl chain lengths 
(C8-C16 and C8-C10 fatty alcohol glucosides, Plantacare 818 and 810 
respectively) were used. Nanostructered Lipid Carrier (NLC) (10% lipid phase) 
were produced by hot high pressure homogenization with surfactant concentrations 
of 2, 4, 6 and 8% (w/w) respectively. The particle size was investigated by Photon 
Correlation Spectroscopy (PCS) and Laser Diffractometry (LD). The zeta potential 
was measured in distilled water with a conductivity of 50 μS/cm and pH 5.8
Results and discussion: The influence of the surfactant concentration on the 
particle size, surface charge and physical stability of NLC was investigated. All 
samples produced led to small sizes and narrow particle size distributions (PI < 
0.2) during a period of 3 months at room temperature, indicating that APGs possess 
a very effective stabilization mechanism for NLC. The smallest particles 
(Plantacare 818 <100nm) were achieved with surfactant concentrations of 6%.
Zeta potentials increased from 2%- 6%. More surfactant did not yield a higher zeta 
potential, indicating that 6% fully cover the surface of the particles. 
Conclusion: APGs are suitable stabilizers for the production of skin friendly and 
physically stable NLCs. APGs follow the rule that smallest particles are obtained if 
the ratio of surfactant to lipid is equal to 0.6. Therefore, NLC formulations with 
10% lipid phase will obtain the best results with 6% surfactant. 
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ASSESSMENT OF EMULSIFYING PROPERTIES OF ALGAL 
EXTRACTS 
Petersen, K., Steckel, H.
Christian Albrecht University Kiel, Department of Pharmaceutics & 
Biopharmaceutics, Gutenbergstrasse 76, 24118 Kiel, Germany 
Semisolid preparations are very important dosage forms to deliver drugs to the skin 
or to offer nutritional attributes.  
They are often composed of a hydrophilic and a hydrophobic phase and, therefore, 
need to be stabilized by surface-active substances. For this matter low molecular 
surfactants can be used which often show adverse side effects, like irritation of the 
skin, allergic reactions or an unwanted penetration-enhancement of substances that 
can damage the skin [1]. 
Other substances with higher molecular weight - without the above mentioned 
drawbacks - can stabilize emulsions by forming a film at the phase boundary layer 
and by increasing the viscosity of the coherent phase. Known polymeric 
emulsifiers are for example hydrophobically derivatized carbomers or substituted 
cellulose ethers. 
In this work, algal extracts as renewable primary products were analysed for their 
potential emulsifying properties that have the previously described advantages and 
do not need further processing. The examined products were freeze-dried aqueous 
extracts from different algae (Saccharina latissima, Ulva lactuca, Palmaria 
palmata, Undaria pinnatifida, Ascophyllum nodosum). 
The extracts were dissolved in water, mixed with a range of lipophilic phases and 
homogenized by Ultra-Turrax®. Homogenization parameters and composition of 
the emulsions were varied and their influence on the stability was determined. 
HPMC-stabilized emulsions as described by [2] were prepared for comparative 
purposes. The stability of the resulting emulsions was determined by dynamic light 
backscattering, microscopy, centrifugation and thermal stress tests. 
The pure algal extracts at the used solid contents were not able to stabilize the 
emulsions. However, it was possible to produce stable semisolid formulations 
when the viscosity of the coherent phase was increased by the addition of 
polyacrylic acid, while the negative controls (use of polyacrylic acid alone) led to 
rapid phase separation.
[1] Wilhelm, K.-P. et al., JAAD 30 (1994) 944-949 
[2] Wollenweber, C. et al., Colloids Surf. Anal. 172 (2000) 91-101 
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FINITE DOSE SKIN PENETRATION EXPERIMENTS IN VITRO: THE 
ROLE OF THE LATERAL COMPARTMENT 
Selzer, D.1, Hahn, T.1, Neumann, D.2, Lehr C.-M.1,3, Schäfer, U. F.1
1Biopharmaceutics and Pharm. Technology, Saarland University, Saarbrücken 
2Scientific Consilience, Saarland University, Saarbrücken
3Dep. of Drug Deliv., Helmholtz Inst. for Pharm. Res. Saarland, Saarbrücken
Franz diffusion cell penetration experiments are widely used to study in vitro skin 
absorption of topically applied substances. For the detailed examination of full-
thickness skin, tape stripping of the stratum corneum (SC) and cryosectioning of 
the deeper skin layers (DSL) is typically applied1 and the amount of drug in each 
compartment is determined.  
An important issue especially when performing finite dose experiments is the drug 
amount in the “lateral” part of the skin. This part of the skin is not in direct contact 
with the donor solution during incubation and is typically discarded when 
performing infinite dose diffusion experiments. 
However, for finite dose studies a substance flux into the lateral part may lead to 
considerable difficulties in interpreting and modeling finite dose substance flux due 
to a rapid depletion of diffusant in the donor compartment.  
In this study the role of the lateral compartment and the impact of the experimental 
methodology1 (skin stretching before tape stripping and the usage of a smaller 
punch to separate the deeper skin layers) was examined with the help of 
computational pharmacokinetic compartment models. The time-dependent flux 
between the different compartments of the skin (SC, DSL and lateral part) was 
assumed to follow first-order kinetics. The resulting set of ordinary differential 
equations was integrated numerically and fitted to experimental data using a multi-
dimensional non-linear least-squares and weighted least-squares approach. 
The model showed that due to the experimental setup, scaling of the measured 
masses inside the different compartments is crucial to avoid the creation of 
“pseudo-lateral” parts that might falsify the total mass recovery results. 
Furthermore, there is evidence for a non-negligible lateral flux beyond the 
boundary of the incubated area that should be taken into account when studying 
and modeling in vitro finite dose dermal absorption.  
1 Heike Wagner, N. Z., Claus-Michael Lehr, Ulrich Schäfer. in Cell Culture 
Models of Biological Barriers (ed Claus-Michael Lehr) Ch. 17, 289-309 
(Taylor & Francis, 2002). 
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INVESTIGATION OF THE INHALED FRACTION AND PARTICLE 
SIZE DISTRIBUTION OF A NEBULIZED ORPHAN DRUG  
Cordts, E.1, Buske, S.1, Wagenseil, L.1, Kuhli, M.1, Pietschmann, H.2, Fischer, B.2,
Steckel, H.1
1 Institut für Pharmazeutische Technologie, Christian-Albrechts-Universität Kiel  
2Apeptico Forschung und Entwicklung GmbH, Wien 
AP301 is a synthetic peptide which consists of 17 amino acids and corresponds to a 
structural motif of the human Tumour Necrosis Factor alpha. AP301 peptide 
activates lung fluid clearance and protects both endothelial and epithelial lung 
tissue from microbial toxin- and reactive oxygen species-induced hyper-
permeability. It is being developed by Apeptico in various pulmonary indications, 
such as treatment of the pulmonary oedema in Acute Lung Injury (ALI) and Acute 
Respiratory Distress Syndrome (ARDS), prevention and treatment of Ischemia 
Reperfusion Injury during lung transplantation and prevention and treatment of 
hyper-permeability upon microbial and/or viral infection of the lower respiratory 
tract and has received Orphan Drug Designation both in Europe and USA. 
In order to apply this orphan drug to the lungs, its solution is nebulized using an 
active membrane nebulizer (Aeroneb Solo, Aerogen Ltd., Galway, Ireland). 
The aim of experiments was to investigate the feasibility of inhalational 
administration of this drug to the lungs. Therefore, it was aimed to gather 
information about the particle size distribution of the produced aerosol and the 
output rate of AP301. Three different concentrations (1, 5, 25 mg/ mL) of protein 
were nebulized. Each concentration was measured three times. 
To determine the inhalable fraction of the produced aerosol, a modified Pari 
Compas breath simulator (Pari GmbH, Starnberg) set-up with 5 different stages 
was used. After each run, the different parts were washed out with a water-
methanol-mixture and the amount of API for each fraction was determined via UV 
spectroscopy. 
As a next step, information about particle size distribution of the produced aerosol 
was obtained using a precooled Next Generation Pharmaceutical Impactor (NGI, 
Copley Scientific, Nottingham, UK) at a flow rate of 15 L/min. The residue of each 
stage was again analysed via UV spectroscopy.  
In addition, the gained results were compared to those of laser diffraction testing 
(Sympatec HELOS Inhaler module, Sympatec GmbH, Clausthal-Zellerfeld). 
Regarding the fine particle fraction and inhaled fraction, the results show a good 
feasibility of nebulization for an aqueous solution of AP301.
T057
SYSTEMIC DELIVERY OF LYOPHILIZED PROTEINS VIA 
INHALATION
Pfeffer, J. F. and Steckel, H. 
Christian Albrecht University Kiel, Department of Pharmaceutics and 
Biopharmaceutics, Grasweg 9a, D-24118 Kiel, Germany 
Since proteins and peptides are poorly absorbed in the gastrointestinal tract, the 
lungs are a promising target for administering these types of substances because of 
their large inner surface area, thin epithelium, and relatively low protease activity 
[1]. Insulin as model protein was lyophilized with L-glutamic acid and polysorbate 
80 as stabilizers forming low-density, stable but easily dispersible cakes. An active 
inhalation device, based on dispersion by means of air impact, was developed 
warranting fine dispersion of cakes suitable for lung delivery. Aerosol 
characteristics of lyophilisates were determined using in-vitro cascade impaction 
(Next Generation Pharmaceutical Impactor, NGI).  
In this study, device parameters dispersing pressure and dispersing time were 
evaluated regarding their influence on resulting fine particle fraction (FPF), which 
is a measure for the mass of API deposited in deeper lung regions [2]. A design of 
experiment was set up, varying dispersion pressure between 1 and 3 at and 
dispersion time between 0.1 and 1 s. Results, calculated with Design-Expert® 8 
software, show a significant influence of dispersing time, even though it is a weak 
one. The resulting FPF values fluctuate around 30%, wherein the highest values are 
achieved with minimum parameter settings. The delivered doses found in the NGI 
decrease with increasing parameter settings, whereas the vial and device retention 
are relatively stable. The study has shown that direct aerosolization of lyophilized 
proteins is possible and has some potential for systemic delivery of drug products. 
Future research will target an elevation of both fine particle fraction and delivered 
dose.
[1] Okamoto et al., Dry Powders for Pulmonary Delivery of Peptides and Proteins, 
KONA No.20 (2002) 
[2] Mendes et al., A non-dimensional functional relationship for the fine particle 
fraction produced by dry powder inhalers, J. Aerosol Sci. 38, 6 (2007) 
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DEVELOPMENT OF A DRY POWDER NASAL VACCINE 
FORMULATION 
Trows, S. and Westmeier, R.
Christian Albrecht University Kiel, Department of Pharmaceutics and 
Biopharmaceutics, Grasweg 9a, D-24118 Kiel, Germany 
Mucosal vaccination via the nasal route is a promising alternative to the systemic 
application of vaccines as the nasal tissue is well equipped with immunocompetent 
cells and is easily accessible. In contrast to soluble antigens, particulate antigens do 
not only elicit a local but also a systemic immune response [1]. Hence a particulate 
dry powder formulation comprising good stability is favorable. 
In this study, primary particles containing BSA (bovine serum albumin) as model 
antigen and chitosan as mucoadhesive and stabilizing excipient were produced by 
spray-drying (SD) and powder blends were prepared using 2, 5 and 10% of the 
spray-dried microparticles and four different coarse carriers: microcrystalline 
cellulose, trehalose, crystalline and spray-dried mannitol (fraction 45-90 μm). 
Particle size distribution, uniformity of delivered dose, stability of the protein and 
nasal deposition of the powder mixtures were determined. For the in-vitro 
deposition experiments a nasal cast model [2] which is based on a computer 
tomography scan of a human nose, and a nasal dry powder device (PowderJet) 
were used. Deposition studies of the pure microparticles showed that about 40% of 
the protein was not deposited in the nasal cavity because the particles were too 
small (~ 3 μm). The particle size of the formulation should be in the range of 10 to 
100 μm in order to avoid inhalation. Accordingly, the inhalable fraction was 
significantly reduced to about 5% by the introduction of powder mixtures. In this 
case, the microparticles are co-deposited with the coarser carrier in the nasal 
cavity. In contrast to the pure microparticles the powder mixtures could also be 
readily dispersed by means of the PowderJet and showed an excellent uniformity 
of the delivered dose. In conclusion, the preparation of interactive powder blends 
was found to be an easy and effective way of delivering SD-stabilized antigens to 
the nasal cavity. 
[1] Davis SS. Nasal Vaccines. Adv Drug Del Rev 51 (2001), 21-42. 
[2] Egen, M., Heyder, K., Kohler, D., Kranz, Y., Müller, C., Schiewe, J. and 
Schönbrodt, T., Method development for deposition studies in a nasal cast, 
Respiratory Drug Delivery 2010, Orlando, Florida (2010) 
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NOVEL DRUG-CARRIERS FOR PULMONARY ADMINISTRATION 
UTILIZING A TEMPLATE-ASSISTED APPROACH 
Tscheka, C.1, Kohler D.1, Schneider, M.1
1Pharmaceutical Nanotechnology, Saarland University, Saarbrücken 
Treating pulmonary diseases today requires the frequent administration of drugs. 
Currently no system for prolonged release is available, which results in a weak 
adherence to medication for chronic pulmonary diseases.  
Recent scientific publications indicate a high importance of shape concerning the 
internalization of particles by alveolar macrophages. Surprisingly, the local 
morphology at the point of contact with the phagocyte is profoundly dominating 
the fate of the particle and size is only of relevance, if the volume exceeds the 
capacity of the macrophage. The possible geometries in order to prevent ingestion 
are numerous and include cylindrical forms such as tubes, rods and fibers. 
Learning from the hazardous consequences of asbestos exposition, it was 
discovered that microfibers easily reach the deep lung and cannot be cleared. 
Therefore the geometry of a fiber is ideal shape for a progressive pulmonary drug-
carrier system. 
Utilizing these finding we are aiming at the preparation of cylinders that can not be 
readily phagocytosed. We selected a template-assisted approach to from the 
cylindrical shapes in the confined space of a membrane. The sacrificial membrane 
is subsequently dissolved in order to liberate the cylinders. 
T060
IN VITRO INVESTIGATIONS FOR MAGNETIC LUNG DRUG TARGETING: 
INFLUENCE OF AEROSOL FLOW VELOCITY ON THE DEFLECTION IN 
MAGNETIC FIELDS 
Baumann, R., Glöckl, G., Wentzlaff, M., Nagel, S., Weitschies, W.
Pharmaceutical Technology, Ernst-Moritz-Arndt-University Greifswald 
For magnetic drug targeting to the lung a suspension of magnetic nanoparticles in 
water (ferrofluid) containing cytostatic drug is atomized and the magnetizable aerosol 
droplets are inhaled. A magnetic field is arranged close to the lung in the region of lung 
cancer. The aerosol droplets are deposited in the diseased lung due to the magnetic 
field. It may be possible to achieve therapeutic drug concentrations at the tumor site. 
The ferrofluid was atomized by two different nebulizers (eFlow and Pari Boy) in order 
to vary the median mass diameter of the droplets which was determined by laser 
diffraction. The deflection of magnetic droplets was investigated in the magnetic field 
of two opposing circular disc permanent magnets (r = 25 mm, l = 15 mm) with a 
magnetic remanence of 1450 mT at a distance of 20 or 40 mm between the magnetic 
poles and in an electromagnetic field (r = 22 mm, I = 1 A, 3 A and 5 A) with a distance 
of 40 mm between the two opposing north poles. About 50 mg iron were sprayed into a 
square tube (5 x 2 cm) which was placed centrally between the two opposing magnets. 
The walls to the magnets were covered with paper. A reproducible aerosol flow 
velocity was generated by using a vacuum pump. We investigated the degree of aerosol 
deposition at 4 and 8 l/min. The paper with the deposited nanoparticles was 
decomposed and the iron content was quantified by flame atomic absorption 
spectrometry. 
The eFlow generated aerosols with a droplet size of 4 to 6 μm and the Pari Boy of 
about 3 μm. The size decreased with increasing ferrofluid concentration. The strongest 
magnetic field gradients were generated at the edges of the opposing circular disc 
magnets. The gradients near the pole surface were up to 120 T/m. At a distance of 2 cm 
between the two opposing magnets a nearly homogeneous gradient of 15 to 20 T/m 
was achieved. The gradients decreased with increasing distance. Atomic absorption 
spectrometry showed that up to 63% of iron were intercepted onto the paper. The best 
deposition was achieved by eFlow. This was caused by the large droplet size of up to 
5.16 μm that is generated by the vibrating membrane. Large droplets contain more 
magnetite nanoparticles and are deflected more easily. But this high deposition with 
large aerosol droplets is not applicable for magnetic drug targeting. Aerosol droplets of 
such a size only reach the upper airways and lead to adverse reactions due to high 
deposition in mouth and trachea.
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COMPARISON OF POROSITY FROM GRANULES AND SLUGS MADE 
BY DRY GRANULATION 
Huber, N.1, Lammens, R.F.2, Steffens, K.-J.1
1Department of Pharmaceutical Technology, University Bonn  
2TSC Lammens, Heymannstrasse 50, 51373 Leverkusen 
Porosity is regarded as an important factor for the compactability of granules, 
produced either by wet or dry granulation. For granules obtained from roller 
compaction, in many cases the porosity is estimated by measuring the ribbon. 
This work shows first results of comparing mercury porosimetry data from 
granules and the slugs from which they are gained by milling. Therefore slugs of 
plain Microcrystalline Cellulose (MCC) as well as binary mixtures from MCC with 
Calcium Phosphate (Di-Cafos PA) and MCC with Eudragit RS PO were produced 
by briquetting. 
The briquetting was accomplished by a Flexitab® (Röltgen, Solingen), a pneumo-
hydraulic-single punch press using 10 mm biplan punches. 
10 tablets of each batch were reserved for measuring the porosity, the remaining 
tablets were milled by a KitchenAid® with grain mill Attachment to produce the 
granules.
The porosity was measured with a Pascal 140/440- System with Win-Pascal1.05 
Software (Thermo Fisher Scientifics, Waltham, USA). The data of the granules 
were treated as already published at APV-Congress on Malta, March 2010. 
The results indicate that for slugs of plain Avicel with a high porosity the 
difference to the granule porosity is high, too. By decreasing slug porosity with 
higher compaction pressure, results get closer to the values for the granules. 
This behaviour is changing for the powder blends. According to the compaction 
behaviour of the powder the difference in porosity decreases with a higher 
fragmentation tendency. 
Referring to those results it seems to be incorrect using data from slug 
measurements for describing granule porosity. 
T062
THE USE OF HYDROPHILIC RELEASE MODIFIERS FOR SOLID 
LIPID EXTRUSION 
Güre, S., Kleinebudde, P. 
Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-University of 
Düsseldorf 
 
Solid lipid extrusion is a technique which makes it possible to process a wide range 
of excipients and APIs together with solid fats to extrudates of defined properties. 
By variation of the solid fat type or more effectively by adding a hydrophilic 
release modifier it is possible to change the release behaviour. Polyethylene glycol 
(PEG) as an example has been used in preliminary studies as such a hydrophilic 
agent. Beside PEGs further excipients are available to enhance the dissolution from 
solid lipid extrudates. The aim of this study was to compare the effectiveness of 
different groups of release enhancers, having different chemical and physical 
properties. Extrudates consisting of 55 % diprophylline and 45 % tristearin 
(reference extrudate) and 50% diprophylline, 45 % tristearin and 5 % release 
enhancer were manufactured. Conventional super disintegrants (Kollidon® CL and 
CL-SF, Ac-Di-Sol®, Primojel® and L-HPC) made the first group of release 
enhancers. Among the various disintegrant types differences could be detected. Ac-
Di-Sol® and Primojel® had the strongest influence on the release rate reaching 80 
% released drug after less than 30 minutes compared to the reference extrudate, 
which took 300 minutes to reach the same amount of released drug. The influence 
of Kollidon® CL and CL-SF was quite different. The CL-type enhanced the release 
rate much stronger than the CL-SF-type since its mean particle size is higher than 
that of the CL-SF type. The second group of excipients consisted of hydrocolloids 
(Tylose® H 20 and H 30000 and Metolose® 65 SH 50 and 4000), which form gel 
structures. Hydrocolloids of high viscosity levels led to higher release rates than 
those of lower viscosity levels. Readily water soluble excipients made the third 
group of release modifiers (Polyglykol® 10000, sodium chloride and mannitol) and 
very probably leave pores in the lipid matrix during dissolution out of which the 
API can be released. Polyglykol® 10000 played an extraordinary role since its 
release enhancing effect was the strongest. Sodium chloride and mannitol instead 
did not influence the release rate as PEG did. The extrudates were physically 
characterized by differential scanning calorimetry (DSC) and scanning electron 
microscopy (SEM). In summary this study showed that it is easily possible to 
manufacture extrudates with different release characteristics by integrating an 
appropriate release modifier to the matrix. 
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HOT-MELT EXTRUSION - A NEW PRODUCTION TECHNIQUE FOR 
ORAL APPLICABLE FILMS? 
Koester, M., Thommes, M.  
Pharmazeutische Technologie und Biopharmazie, Heinrich-Heine-Universität, 
Düsseldorf
In the last few years, mucoadhesive oral films have become important in the 
individual therapy of children as well as adults. Hot-Melt extrusion (HME) is a 
common technology used to produce films in the plastics industry. Since HME 
has been established in pharmaceutics for many years, this technology was a 
natural choice for use in film formation.  
This study dealt with the screening of different polymer substances in production 
of mucoadhesive films. A Coperion ZSK18MC and a BBA CompactContiCooler 
40/40 were used to produce endless films of about 25mm width and about 200μm 
thickness. For each formulation, the extrusion parameters (screw speed, barrel 
temperatures, feed rate) as well as the roller cooler parameters (roll temperatures, 
speed) were optimized in order to obtain a film of adequate shape and size. In a 
new approach, the strand was plastically deformed into a thin film and cooled at 
the same time. 
The sugar alcohols (Mannitol, Xylitol) were investigated based on their high 
chemical stability. Both substances result in a brittle extrudate which could not be 
plastically deformed into thin films. This was attributed to the rapid 
crystallization. The sugar ethers Hydroxypropylmethylcellulose and 
Hydroxypropylcellulose degrade during the extrusion. Polyethylene glycol (PEG) 
of different molecular weights (10k - 4000k) showed an excellent extrusion 
behavior. While the low molecular weight PEG were quite soft, the high 
molecular weight was hard and sturdy.  
Soluplus had an excellent film formation behavior, however brittle films were 
obtained. A combination of 10% PEG 20k and Soluplus resulted in films of 
adequate mechanical properties.   
In conclusion, a film formulation was found which could be processed with HME.  
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HOT MELT EXTRUSION OF ISOMALT AS HYDROPHILIC CARRIER 
FOR POORLY SOLUBLE SUBSTANCES 
Paulsen, K., Steckel, H. 
Christian Albrecht University, Kiel, Department of Pharmaceutics & 
Biopharmaceutics, Gutenbergstrasse 76, 24118 Kiel, Germany 
Hot melt extrusion is a process of rising interest to increase the dissolution, the 
solubility and the bioavailability of poorly soluble drugs [Lit.1]. Typically, 
hydrophilic, water-soluble polymers are used to produce solid solutions or solid 
dispersions of the drug. But there are also some interesting approaches to use sugar 
alcohols, such as sorbitol, mannitol or isomalt, as a carrier for such poorly soluble 
substances. In this case, the hydrophilic carrier increases the wettability of the drug 
and may enhance its dissolution. Isomalt is a disaccharide alcohol which is 
composed of two stereoisomers: 1-O--D-glucopyranosyl-D-mannitol dihydrate 
(1,1-GPM dihydrate) and 6-O--D-glucopyranosyl- D-sorbitol (1,6-GPS). 
In this study, the influence of different extrusion temperature programs on the 
morphology of the extrudates was investigated. For a rapid dissolution, it is 
necessary to develop the process to obtain an amorphous extrudate which shows 
acceptable long term stability. As a surrogate for the stability, the re-crystallisation 
behaviour was investigated with Differential Scanning Calorimetry (DSC) and X-
ray Powder Diffractometry (XRPD). Additionally the influence of the storage 
conditions of the extrudate on the re-crystalisation behaviour was investigated. To 
investigate the influence of the isomalt quality on the stability of the extrudate in 
the amorphous form, two different isomalt grades were used: galenIQTM 720 with 
an equimolecular amount of both stereoisomers and galenIQTM 721 with a 
stereoisomer ratio 3:1 (GPS:GPM).  
The results show, that the temperature program of the extrusion process as well as 
the isomalt grade influences the glass transition temperature (Tg) of the extrudate. 
Also the re-crystallisation is strongly influenced.  
Acknowledgements: Thanks to Beneo-Palatinit for the kind donation of galenIQTM
and to Gabler GmbH for allocating an extruder for these experiments. 
Reference:  
[1] J. Breitenbach, Melt extrusion from process to drug delivery technology, Eur. J. 
Pharm. Biopharm. 54(2002) 107-117 
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DEVELOPMENT OF LOZENGES BASED ON EXTRUDED STARCH 
Kipping, T, Rein, H 
Pharmazeutische Technologie, Universität Bonn 
During the past four decades there has been intensive research on modified- and 
controlled-release drug delivery systems. The most common way to produce 
controlled-release tablets is by applying wet granulation or direct compression 
techniques. Both occasion high costs. Hot-melt extrusion shows many benefits 
compared to ordinary manufacturing techniques. The continuous mode of 
operation and the potential to save production costs are the main advantages. 
The aim of this work is the development of lozenges for buccal use.  
An important aspect was to characterize the suitability of different starches for 
extrusion. Extrudates made of five different types of starch (corn starch, 
Eurylon®5, pea starch, potato starch and Waxilys®200) were produced by using a 
Brabender single screw extruder (type 811201) fitted with a slit die (length: 3 mm, 
width: 8 mm,. height: 2,5 mm), A cork borer (diameter: 8 mm) was used for 
shaping biplanar lozenges.
Three different batches were compared: Placebo- menthol- and clove oil-lozenges.  
All samples were stored in a climatic exposure test cabinet (climatic zone 2 
according to ICH Q1F Guideline). Glass transition temperatures were determined 
by differential scanning calorimetry. Water contents of the extrudates were 
measured by thermogravimetry. It could be shown, that an increase of moisture 
content leads to a decrease of glass transition temperature. For investigating the 
hardness of the extrudates a tablet hardness distribution tester was used. Hardness 
of the extrudates rapidly increased during the first two weeks of storage time, then 
remained static. The degree of hardness could be linked to the type of starch used 
for extrusion. Crystallinity of the extrudates was determined by x-ray 
diffractometry. According to the x-ray data, for nearly all samples extrusion led to 
a complete amorphisation of the starch. Scanning electron microscopy proofed the 
results of the x-ray diffractometry. Organoleptic features of the lozenges were 
evaluated by questionnaires. Sufficient dissolving times in mouth of more than 30 
minutes could be observed. Drug release rates could be related to the ratio of 
amylopectin and amylose of the used starch. Waxylis®200 showed strongest 
cooling intensities, whereas lowest cooling intensities were obtained for 
Eurylon®5.  
T067
NIR-CHEMICAL IMAGING FOR THE EVALUATION OF DRUG 
DISTRIBUTION IN SOLID MATRICES 
Hoffmann, E.M.1, Wening, K.1, Breitkreutz, J.1
1Institut für Pharmazeutische Technologie und Biopharmazie, Heinrich-Heine-
Universität Düsseldorf 
Near infrared chemical imaging (NIR-CI) is a versatile analytical technique that 
combines conventional imaging and spectroscopy. Spatial and spectral information 
is simultaneously obtained. This rapid and non-destructive method is employed to 
investigate the distribution of ingredients in pharmaceutical products. 
Aim of this study was to investigate the suitability of NIR-CI for evaluating the 
distribution in solid matrices like melt extrudates. The extrudates contained 20 %
metoprolol tartrate (Microsin, Bucharest) as active ingredient (API), mannitol 
(Pearlitol® 160C, Roquette, Lestrem) and poloxamer 188 (Lutrol® F 68, BASF, 
Ludwigshafen) as excipients. The matrices are delivered by a solid dosage pen, a 
novel dosage system for personalised medicine, which cuts the extrudates into 
tablet-like slices for individual dosinga. The homogeneity of the extrudates and the 
uniformity of the individual parts were evaluated with NIR-CI (NIR-CI 2450, 
Malvern Instruments, Worcestershire). Spectra (1200-2400 nm) of the API and the 
excipients were recorded and compared with the spectra of the native extrudates or 
slices containing individual doses. Multivariate data analysis was employed to 
investigate the distribution of the API and the excipients.  
Although calculation and visualization of the distribution was possible, the 
interpretation of the data however is difficult. In comparison with the reference 
spectra of the pure substances, a spectrum of an extrudate area with a calculated 
high concentration is a hybrid of all three ingredients. The differences between the 
spectra of calculated high and low concentrations are very small, indicating a 
homogenous distribution of the ingredient.  
For the evaluation of slices´ uniformity, more than 900 spectra of an individual 
slice were averaged and compared to the mean spectra of different extrudate parts. 
The mean spectra were very similar indicating the uniformity of the slices. This 
could be confirmed by determination of content via UV-spectroscopy.  
In conclusion NIR-CI is suitable for the evaluation of the dose uniformity, but for 
the distribution of individual ingredients, data should be carfully evaluated.  
a K. Wening, J. Breitkreutz. doi: 10.1016/j.ijpharm.2010.05.036 
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STARCH-BASED PELLETS PREPARED BY HOT MELT EXTRUSION 
AND DIE-FACE PELLETIZATION
Bialleck, S., Rein, H.
Department of pharmaceutical technology, University of Bonn 
Aim of the work was to develop a solid solution or dispersion of drugs with 
different starches via hot melt extrusion which is directly pelletized with a die face 
micropelletizer. The influence of the different starches, drugs and additives on the 
extrusion process, the physicochemical properties and the release profile of the 
resulting pellets was investigated. The extrudates were produced on a twin screw 
extruder (ZSE 18 HPPH 40D, Leistritz; Germany) fitted with varying dies. The 
strand was immediately pelletized using a die face Micropelletizer (LM P18 PH, 
Leistritz; Germany).  
Different drugs (Ibuprofen, Paracetamol, Phenazon and Tramadol-HCl), additives 
and starches were mixed with a tumble blender and filled into the gravimetric 
dosing unit (K-PH-CL-24-KT20, K-Tron; Switzerland) of the twin screw extruder. 
The powder was fed into the extruder simultaneously mixed with water and 
extruded using temperatures between gelatinisation temperature and 100 °C. With 
scanning electron microscopy the morphology of the resulting pellets was 
examined. The cristallinity of the pellets was analyzed by X-ray diffractometry.  
Phenazon and Tramadol*HCl form a solid solution whereas Paracetamol and 
Ibuprofen can only be dispersed in the starch-matrix with the used extrusion 
parameters. The gas pycnometric density of the pellets was determined using a 
helium pycnometer (Ultrapycnometer 1000T, Quantachrome; Germany). The 
apparent density was measured with a mercury porosimeter (Pascal 140, Thermo 
Fisher Scientific Inc.; US). Specific surface area analysis was performed using 
Nova 3000-Series BET, (Quantachrome Corporation; Germany). 
Particle size distributions were measured by laser diffraction (Laserdiffractometer 
HELOS, Sympatec GmbH; Germany). Dissolution studies show that the release 
profile is conditioned by the used starch, additive and active ingredient. 
Mathematical modelling of the drug release data indicates that the drug release is 
mainly based on swelling and diffusion and can be altered by the additives and 
active ingredients. 
According to the available data, die face pelletization of hot melt extruded starch is 
an interesting innovative way to produce drug containing pellets with nearly 
monodisperse particle size distribution, very low porosity and surface area, the 
desired shape and release characteristics. 
T069
ENTERIC COATING OF PELLETS PREPARED BY POWDER VS. 
SOLUTION LAYERING TECHNIQUE USING FLUID BED EQUIPMENT 
Cwik, M., Schubert, Rolf
Department of Pharmaceutical Technology and Biopharmacy, University of 
Freiburg, Germany 
Drug loaded pellets are usually prepared by solution or suspension layering 
technique (SL) when using fluid bed processor. Former investigations have proved 
that drug powder layered (PL) pellets can successfully be prepared using a 
modified fluid bed processor Ventilus 25 (Innojet Herbert Hüttlin, Germany), too. 
In this study pellets prepared by both layering techniques were subsequently coated 
with an enteric polymer and products were compared regarding coating efficiency, 
coating level and drug release profile. Additionally, the coating results for three PL 
batches are compared to each other to show reproducibility. 
All pellets were prepared with the same water soluble model drug using either SL 
or PL technique. Eudragit L 30 D - 55 (Evonik Röhm GmbH, Germany) was 
chosen as enteric coating polymer and applied using the Ventilus 2.5. The 
dissolution of the coated dosage forms was measured corresponding to Ph Eur. 
When the enteric coating layer is thick enough no drug substance is released at a 
pH value below 5.5. In these experiments pellets were coated with a preferably thin 
functional film to quantify and compare required coating levels. When the applied 
coating level is barely sufficient to form a continuous film, small differences in 
coating thickness lead to differing drug release profiles. Therefore drug release 
profiles were compared when drug release was 6 - 10 % after 120 min. 
PL pellets provided a better process performance because pellets were less 
electrostatic. Furthermore PL pellets could be as efficiently coated as SL pellets 
and coating efficiency was reproducible for the three PL pellet batches.  
Drug release profiles of the three coated PL batches were equal. As soon as the 
enteric layer was disrupted PL pellets released the drug moderately faster than SL 
pellets. This effect can be explained by their larger surface area due to cavities 
within the drug layer and may be advantageous to improve the solubility of poorly 
soluble drugs. 
At this point of process development PL pellets require a significantly higher 
coating level to result in a drug release profile comparable to SL pellets. Therefore 
further investigations focus on the improvement of surface area properties of PL 
pellets by adapting the process parameters. 
T070
COLON TARGETING: THE APPLICATION OF ENTERIC COATINGS 
TO PROTECT CHITOSAN COATED TABLETS IN THE GIT  
Drechsler, M., Schubert, R. 
Department of Pharmaceutical Technology and Biopharmacy, University of 
Freiburg, Germany 
Colon targeting refers to the specific release of oral medications in the colon. It is 
suitable for peptide and protein drugs which may be absorbed in the colon, but 
have to be protected against low pH in the stomach and enzymes in the small 
intestine. Furthermore, colon targeting is also important for the local therapy of 
colonic diseases, e.g. ulcerative colitis or colon cancer. To achieve this goal, solid 
dosage forms containing the drug are coated with a polymer film, which is 
designed to be specifically degraded in the colon by the enzymes present in its 
microflora. 
In our studies the polymer chitosan, which is known to be enzymatically 
degradable, was used. Tablets were coated in the Innnojet Air Coater 025 fluidized 
bed apparatus (Innojet Technologies, Steinen, Germany). Different types and film 
thicknesses of chitosan were chosen to investigate their influence on drug release. 
Dissolution studies were carried out using an USP type I method (Paddle method, 
100 rpm, 37 °C). The simulated intestinal fluid (SIF) was a phosphate buffer 
(pH 6.8) representing the conditions in the small intestine and the physiological 
large intestine. Because of the solubility of chitosan in the stomach, different 
additional enteric coatings were investigated to protect the chitosan film coating. 
Disintegration studies with and without an additional enteric coating were carried 
out as described in Ph. Eur. for enteric coatings in HCl (0.1 N) at 37 °C and 
compared to each other.  
It could be shown that the drug release of chitosan-coated tablets could be reduced 
to below 16.0 % for the first 180 minutes, presenting the early drug release in the 
small intestine. Afterwards, the film coatings were intact for over 20 hours under 
physiological conditions. The type of chitosan did not influence the drug release. 
The disintegration time of chitosan-coated tablets increases with higher amounts of 
applied chitosan in 0.1 N HCl. Enteric coatings can inhibit tablet disintegration for 
more than 120 minutes. Afterwards the drug release in pH 6.8 is similar to tablets 
without enteric coating or even reduced. These characteristics would be beneficial 
in the possible application of chitosan coated tablets for colon targeting. Enzymatic 
degradation studies with these batches and conditions are under progress. 
T071
DEVELOPMENT AND CHARACTERISATION OF LIPID SHELL 
ANTHOCYANIN MICROCAPSULES 
Oidtmann, J1., Gedrich, S1., Syrowatka, F.2, Mäder, K.1
1Pharmazeutische Technologie und Biopharmazie, MLU Halle-Wittenberg; 
2Interdisziplinäres Zentrum für Materialwissenschaften, MLU Halle-Wittenberg 
Anthocyanins are secondary plant ingredients which are responsible for the red 
colour of fruits e.g. in bilberrys (Vaccinum Myrtillus L.). Amongst others they are 
used in the prevention of colon cancer due to their antioxidative capacity [1]. The 
aim of this work was to microencapsulate these polyphenolic compounds to protect 
them against early degradation. Because of their intended use as a dietary 
supplement we selected only excipients which are accepted as food ingredients. 
For the characterisation of the particles ESEM and light microscopic pictures were 
taken. For the ESEM pictures the particles were treated with a razor blade to reveal 
their inner structure. It is evident that the particles have more than one core. In 
comparison with the light microscopic pictures the existence of multi cores is 
approved. The dark red zones are cores filled with the acidic extract solution. 
ESEM analysis shows a broad particle size distribution. These results were 
confirmed by laser diffraction. Mean Particle diameter (d50) was about 177 μm 
(n=4). The use of an Ultra-Turrax® for particle preparation causes a decrease of the 
incorporation rate and did not result in a narrower particle size distribution. 
The release of the incorporated anthocyanins was tested using UV-spectroscopic 
pH-differential method [2]. During 120 minutes incubation in SGF (without 
enzyme) only 12 % of the incorporated anthocyanins were released. In phosphate 
buffer pH 6.8 release was faster. During 120 minutes 22 % of the incorporated 
anthocyanins were released. Stability tests showed that the Particles are stable over 
a period of at least four weeks at room temperature (in the dark). Particle size 
distribution did not change during the observation period. Also the flowability 
remains constant. 
It was shown, that stable microparticles were developed. A lipid shell coated 
hydrophilic cores. Release studies showed, that the capsules are able to save the 
incorporated anthocyanins from early degradation. 
The authors would like to thank the DFG (MA 1648/6-1) and the DFG/AiF-Cluster 
“Bioaktive Inhaltsstoffe aus mikrostrukturierten Multikapselsystemen” for 
financial support. 
[1] Woodward, G. et al. Journal of Agricultural and Food Chemistry (2009) 
[2] Giusti, M. M. Current Protocols in Food Analytical Chemistry (2001) 
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ELECTROSTATIC CHARGING IN A FEED FRAME OF A TABLET 
PRESS 
Knop, K., Fokscha, M.
Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-University 
Universitaetsstr. 1, 40225 Duesseldorf, Germany 
Electrostatic charging may be a problem in the process of tableting especially when 
high speed rotary tablet presses are used. Powder flow through the hopper can be 
hindered or tablets can stick together or to parts of the tablet press. The electro-
static charge occurs when particles come into contact and are separated afterwards. 
This can be the case for the powder flow in the hopper, the feeder, the dies or 
during movement of the tablets on the turret or other parts of the tablet press. 
In this study the influence of material and operating conditions of a feed frame 
with paddles on the electrostatic charging of pharmaceutically used powders was 
evaluated. A mixer consisting of a cylindrical bowl and a paddle mixer was used as 
a model for the feeder. The electrostatic potential was measured by an electrostatic 
sensor which was positioned above the mixing bowl. 
The influence of the material of the mixing vessel and the paddle as well as the 
rotating speed of the stirrer was investigated in a 23 full factorial design with 2 
replicates under controlled environmental conditions. Paracetamol was chosen as 
model drug, because it is known for its ability to electrostatic charging. The 
material of the stirrer (metal or plastic) showed a significant influence on the 
electrostatic charge whereas the material of the mixer bowl and the rotating speed 
had no significant influence. The measured differences of the electrostatic potential 
were in the order of several kV. 
In a second experimental set other powders and powder mixtures used in tableting 
were evaluated. The conducting and grounded metal stirrer was superior over the 
insulating glass or plastic stirrer in the model. For the construction of feeders in 
tablet presses the usage of insulated feed frame paddles should be avoided and all 
machine parts should be well grounded. 
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QUANTIFICATION OF STICKING TO THE PUNCH SURFACES 
DURING TABLET MANUFACTURE – A COMPARATIVE STUDY 
Saniocki, I., Sakmann, A., Leopold, C.S.
Institute of Pharmacy, Department of Pharmaceutical Technology, University of 
Hamburg 
Sticking is a common problem observed during tablet manufacture. In the present 
study material adhering to both, the upper punch and the lower punch, is quantified 
using HPLC. Ibuprofen is chosen as model drug because of its high tendency of 
sticking to punch surfaces. The content of ibuprofen in the formulations is varied 
from 10 % to 90 % (w/w) using either Ludipress® or Microcelac® 100 as direct 
compression excipient. Tableting is performed with an instrumented rotary die 
tablet press equipped with flat-faced punches of 10 mm diameter. The compaction 
forces are 7, 10 and 13 kN, respectively. Following each compaction run the upper 
punch is removed from the machine and the punch surface is cleaned from 
ibuprofen using 5 ml of methanol for the quantification via HPLC. The amount of 
residual powder from the lower punch is determined with a swab method using a 
Q-tip soaked with methanol. Subsequently, the Q-tip is immersed in 5 ml of 
methanol. Quantification is carried out after an extraction period of at least 24 h.  
Sticking to the upper punch as well as to the lower punch is decreased with 
increasing compaction force. Higher compaction forces increase the cohesivity 
within the tablet. Furthermore, electrostatic interactions between the chrome-plated 
punch surface and the powder particles are reduced leading to reduced adhesion 
forces. Sticking to the upper punch is observed with all formulations. However, the 
amount adhering to the punch surface with the Microcelac® formulation containing 
10 % of ibuprofen is found to be below the detection limit of the HPLC method. 
Sticking of ibuprofen to the lower punch surface could neither be observed with the 
Microcelac® formulations containing up to 20 % ibuprofen nor with the Ludipress®
formulation with 10 % drug content. However, compaction of tablets with higher 
drug contents lead to a residue in the center of the lower punch. The punch is 
completely covered with residue at drug contents of 50 % with both, the 
Microcelac® and the Ludipress® formulation. Furthermore, the amount of 
ibuprofen adhering to the upper punch is considerably higher than that sticking to 
the lower punch. The extent of sticking is assumed to be affected by the 
mechanism of detachment of the punches from the tablet: The upper punch is 
separated from the tablet in vertical direction. In contrast, the tablet detachment 
from the lower punch occurs by tangential shear forces induced by the take-off bar. 
T074
ORALLY DISINTEGRATING MINI-TABLETS WITH 
HYDROCHLOROTHIAZIDE - A NOVEL DOSAGE FORM FOR 
PAEDIATRIC USE 
Stoltenberg, I., Breitkreutz, J.
Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-University, 
Düsseldorf
Orally disintegrating mini-tablets (ODMTs) are a new concept for paediatric drug 
delivery. These tablets with a diameter smaller than 3 mm are intended to 
disintegrate in the oral cavity in less than 30 seconds. This novel dosage form is 
particularly suitable for younger children, infants and toddlers, and could be 
manufactured with conventional tabletting facilities.  
The aim of this study was to investigate the feasibility of various ready-to-use 
excipients for direct compression of stable and child-appropriate ODMTs with 
hydrochlorothiazide. 
Ludiflash® (BASF, Germany), Parteck® ODT (Merck, Germany), Pearlitol® Flash 
(Roquette, France), Pharmaburst® 500 (SPI Pharma, USA) and Prosolv® ODT were 
used as directly compressible tableting excipients. Sodium stearyl fumarate (Pruv®,
JRS Pharma, Germany) was used as lubricant and hydrochlorothiazide from 
Unichem (India) served as model-drug. 
Biconvex mini-tablets with 2 mm diameter were directly compressed with a rotary 
tablet press (IMA Kilian, Germany) by using a 19-tip mini-tableting tool (Ritter, 
Germany). Varying compression forces were applied. 
Crushing strength (Texture Analyzer, Stable Micro Systems, UK), friability and the 
time required for complete wetting of an ODMT (simulated wetting test-time, 
SWT), as well as uniformity of dosage units were determined.  
All formulations compressed with 5kN and 8kN indicated a sufficient friability 
below 1%. The crushing strength of these ODMTs ranged between 2.64N and 
17.6N. These major differences depend on varieties in compactability of the 
excipients. The ODMTs showed SWT-times between 3.1s and 25.2s. Further 
“uniformity of dosage units” was demonstrated, according to Ph.Eur. monograph 
2.9.40. 
All excipients are suitable for preparation of ODMTs with hydrochlorothiazide. 
Orally disintegrating mini-tablets are supposed to be very useful formulations for 
the treatment of young children and may be considered as a new technology 
platform for paediatrics. 
T075
ENHANCEMENT OF GRISEOFULVIN RELEASE FROM LIQUISOLID 
COMPACTS AND OPTIMIZATION THEREOF 
Hentzschel, C.M., Sakmann, A., Leopold, C.S.
Institute of Pharmacy, Department of Pharmaceutical Technology, University of 
Hamburg 
The potential of liquisolid systems to improve the release of poorly soluble drugs 
was investigated using griseofulvin as model drug. The in vitro release rates of this 
drug, formulated as directly compressed tablets with crystalline griseofulvin and as 
liquisolid compacts, respectively, were studied. 
The new formulation technique of liquisolid compacts was used to convert liquid 
drug medications into acceptably flowing and compactable powders. Several 
liquisolid tablet formulations were prepared using a mathematical model to 
calculate the appropriate quantities of powder and liquid ingredients. 
Therefore, solutions and suspensions of griseofulvin in the non-volatile liquid 
vehicle PEG 300 were mixed with selected powder excipients. In the present study 
the powder excipients typically used for the liquisolid technique (Avicel® PH200 
and Aerosil® 200 in a ratio of 20:1) were compared to Neusilin® US2, an 
amorphous magnesium aluminometasilicate with an extremely high specific 
surface area. 
The liquisolid formulation containing a drug solution showed a significantly higher 
drug release rate than the directly compressed formulation containing micronized 
griseofulvin. This may be explained by the fact that the drug in the liquisolid 
system is already dissolved.  
Moreover, it has been shown that with compacts containing drug suspensions the 
release rate increases with decreasing amounts of undissolved drug in the liquid 
vehicle. However, a decrease of suspended drug in the liquid vehicle at a given 
drug amount requires a higher volume of liquid. Because the powder excipients can 
only adsorb limited amounts of liquid while maintaining good flow and tableting 
properties this results in an increase in tablet weight.  
Neusilin® US2 with its extremely high liquid adsorption capacity allows the 
production of liquisolid formulations with lower tablet weights than formulations 
with Avicel® PH200 and Aerosil® 200. 
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DEVELOPMENT OF A GASTRO-RETENTIVE EXTENDED RELEASE 
FORMULATION OF FUROSEMIDE 
Glöckl, G.1,2, Lukas, R.2, Garbacz, G.1,2, Weitschies, W.2
1Center of Drug Absorption and Transport, University of Greifswald 
2Institute of Pharmacy, University of Greifswald 
Furosemide is a very potent loop diuretic. The clinical application is restricted to 
emergency medication due to its rapid elimination. Extended release formulations 
fail due to the fact that absorption is limited to the upper small intestine. To 
overcome this problem a gastro-retentive formulation is designed. The prolonged 
residence in the stomach is accomplished by intense swelling of the tablet matrix. 
Erosion is prevented by means of a highly flexible protective coating. The drug 
release is controlled solely by diffusion.  
Varying matrices and pore forming excipients were tested to achieve a swelling 
independent of pH and ionic strength of the dissolution media. When replacing the 
gelling agent CMC-Na against agar, the matrix showed a more viscous behavior. 
The dissolution rate of the BCS class IV drug was accelerated by means of 
coprecipitation with PVP K-25 from methanolic solution.  
Drug release was tested in a standard paddle apparatus (900 mL, 37 °C, 50 rpm) in 
media with pH 5.8, 4.5 and 1.7 to simulate the varying conditions of the stomach in 
the fasted and fed state. Furthermore, the impact of mechanical forces on the drug 
dissolution was investigated using a novel dissolution stress test apparatus. The 
applied testing regime allows the generation of pressure waves at predetermined 
intervals to simulate gastric motility in the pylorus region in the fasted state.  
The swelling of uncoated matrices was nearly unaffected by pH. Water influx was 
susceptible to the plasticizer used. Drug release was also dependent on the kind of 
pore former employed. Dissolution profiles applying the standard test were nearly 
linear. In the case of the dissolution stress test an increase in dissolution rate was 
observed directly after applying the pressure waves. However, the stress equivalent 
to maximum motility in the fasted stomach did not result in a complete burst of the 
dosage form. 
Unfortunately, the drug release decreased markedly with increasing acidity of the 
dissolution media. This was most likely due to the restricted solubility of 
furosemide in the applied media. To overcome this issue, the integration of buffer 
substances into the tablet matrix will be examined in further studies.  
Financial support granted by the German federal ministry of education and 
research (FKZ: 03IP612) is gratefully acknowledged. 
T077
QUALITY CONTROL OF ALUMINIUM BLISTER FOILS: 
QUANTITATIVE ANALYSIS OF HEAT SEAL LACQUERS   
Mühlfeld L. 1 , Langguth P. 1 , Häusler H. 2, Hagels H. 2
1Pharmaceutical Technology and Biopharmaceutics, J. Gutenberg-University 
Mainz 2Boehringer Ingelheim Pharma GmbH & Co. KG 
According to GMP Guidelines the quality control of the pharmaceutical industries 
comprises not only “Inprocess controls” and controls of bulk and drug products but 
also the control of all starting materials. In addition to analysis of active substances 
and excipients, the control of packaging materials is obligatory. A compound of 
many packages used for drug products, especially blisters are aluminium foils. To 
achieve a sealability of the aluminium material against polymer foils, e.g. the 
formable foils of blister packaging, the aluminium usually is coated with a 5 to 9 
g/m² layer of heat seal lacquer. As the heat-sealed joint is the most critical 
compound of blisters related to mechanical stability and impermeability against 
outside influences it must be assured, that the heat seal lacquer is of reproducible 
quality. Therefore it is analyzed concerning identity, firmness of sealing joint and 
grammage (mass per unit area). Currently the generally applied method for 
determination of grammage is a gravimetric method which requires a removal of 
the lacquer. Using this method as reference, several instrumental methods for 
determination of the heat seal lacquer grammage were developed and compared to 
each other concerning parameters required for validation of analytical procedures 
in the ICH guidelines Q2(R1). Interferometric, IRRAS and beta backscatter 
techniques were well suitable for the measurements. Using these techniques novel 
procedures applicable for routine quality control of pharmaceutical packaging 
materials are suggested. 
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EXPRESSION ANALYSIS OF DRUG TRANSPORTER PROTEINS IN 
EXCISED HUMAN NASAL MUCOSA AND CELL LINE RPMI 2650 
Dolberg, A.M., Reichl, S.
Institut für Pharmazeutische Technologie, Technische Universität Carolo-
Wilhelmina zu Braunschweig, Mendelssohnstraße 1, 38106 Braunschweig 
The nasal mucosa is an interesting site for systemic application of drugs, since it 
has a number of advantages as a delivery route for drugs with systemic action, 
including easy accessibility, extensive vascular supply and avoidance of first-pass-
metabolism. In the development of drugs for nasal application, identification and 
characterisation of different efflux and uptake systems are necessary. P-
glycoprotein (P-gp) and multidrug resistance-associated proteins (MRP) are 
classified as ATP-binding cassette (ABC) transporters based on their sequences, 
organisation of the ATP-binding domains and efflux function. ABC proteins 
represent a large family of integral membrane transporters that utilize the energy of 
ATP hydrolysis to carry specific substrates across membranes. The solute-carrier 
gene (SLC) superfamily encodes another large family of membrane-bound 
transporters, located in almost every cellular and organelle membranes. Proteins of 
the SLC family include passive transporters, ion-coupled transporters and 
exchangers.
A comparison was performed between excised human nasal mucosa from 
turbinectomy surgeries and our in-vitro model based on immortalised human nasal 
epithelial cells (RPMI 2650) concerning the mRNA expression of different efflux 
and uptake transporter proteins. To profile the mRNA expression of eight ATP-
binding cassette transporter (P-gp, MRP 1 till 5, BCRP and CFTR), two 
oligopeptide transporter (PEPT1 and 2) as well as four organic cation transporter 
(OCT 1 and 3, OCTN1 and 2) the Reverse Transcriptase Polymerase Chain 
Reaction (RT-PCR) was applied. All bands for the DNA amplification products of 
selected ABC and SLC proteins (except for OCT3) were detected in both samples 
and located at positions with the expected sizes. However, a difference in signal 
strength was observed. First permeation studies using specific P-gp substrate 
Rhodamine 123 in the presence and absence of verapamil as inhibitor of this 
transporter were performed in both apical to basolateral (ab) as well as basolateral 
to apical (ba) directions with the in-vitro model. No significant difference in the 
permeation coefficients of Rhodamine-123 between ab and ba direction was 
detected and no influence of verapamil could be observed, suggesting the absence 
of P-glycoprotein in the RPMI 2650 model.  
T080
EXAMINING THE SUITABILITY OF RIBOFLAVIN/UVA-TREATMENT 
FOR TISSUE ENGINEERING APPLICATIONS 
Grobe G. M., Reichl S. 
Institut für Pharmazeutische Technologie, Technische Universität Carolo-
Wilhelmina zu Braunschweig, Mendelssohnstraße 1, 38106 Braunschweig 
To improve the mechanical stability of a tissue engineered human cornea construct, 
which is used as an in vitro model for drug absorption studies, the collagen matrix 
of this construct is to be strengthened by collagen cross-linking. A suitable method 
to induce photooxidative cross-linking of collagen fibrils is UVA irradiation 
combined with riboflavin as a photosensitizer.  
After riboflavin/UVA-treatment, the viscoelastic properties of the collagen matrix 
and the molecular weight of its proteins, as well as cell viability of the human 
corneal keratocytes (HCK) incorporated in the stromal matrix, were analyzed 
depending on the dose of irradiation using oscillation rheology, gel electrophoresis 
and the MTT assay, respectively. In addition, the cell damage to the HCKs after 
riboflavin/UVA-treatment was also analyzed in monolayer cultures. Various 
luminescent cell assays were performed to clarify whether the decrease in cell 
viability was a consequence of apoptosis or necrosis. Furthermore, fluorescent 
double staining was carried out using an apoptotic/necrotic cells detection kit. 
The improvement of mechanical properties was low, whereas resultant cell damage 
was considerable and dose-dependent. When lower doses of irradiation were used, 
the reduction of cell viability was triggered by apoptosis while necrosis supervened 
for increased doses of irradiation. 
We conclude that in contrast to clinical applications, the riboflavin/UVA-treatment 
does not seem to be a suitable method to obtain a sufficiently firm stromal matrix 
including vital keratocytes to build a tissue engineered human cornea construct to 
be used as an in vitro model for drug absorption studies. 
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CHARACTERISATION OF A CORNEA CONSTRUCT FOR DRUG 
ABSORPTION STUDIES AND COMPARISON WITH EXCISED TISSUE 
Hahne, M., Reichl, S. 
Technische Universität Carolo-Wilhelmina zu Braunschweig, Institut für 
Pharmazeutische Technologie, Mendelssohnstr. 1, D-38106 Braunschweig 
 
The increased use of ophthalmic products over the past decades has lead to an 
enlarged demand of transcorneal drug absorption studies in vitro and in vivo. Due 
to the lack of alternatives animal experiments are widely-used for such studies as 
well as ocular cytotoxicity tests. Models of the human cornea based on tissue 
engineering could avoid several disadvantages of animal experiments such as 
ethical concerns and poor standardisation. Despite these numerous disadvantages 
so far no available in vitro model is generally accepted. In the context of 
prevalidating a human cornea construct (HCC) for in vitro drug absorption 
experiments, this study describes the analysis of its barrier characteristics and 
compares it with that of excised rabbit and porcine cornea.  
Human cornea constructs were cultivated under serum free conditions on 
permeable polycarbonate filters (Transwells®, Costar) using SV 40 immortalised 
human keratocytes (HCK-Ca) and immortalised human epithelial cells (HCE-T). 
Briefly, using Keratinocyte Growth Medium (KGM, Lonza, USA) and an 
advanced cultivation schedule the HCC showed a suitable barrier. Its equivalence 
to native tissue was analysed by comparative absorption experiments with isolated 
rabbit and porcine cornea. For this purpose model substances with a wide range of 
molecule characteristics were used, including hydrophilic dye sodium fluorescein, 
lipophilic dye rhodamine B, macromolecule FITC labeled dextran (FD-4), 
-blocker timolol, steroid hormone dexamethasone, prostaglandin analogue 
bimatoprost and antiviral drug aciclovir. Diffusion experiments with HCCs were 
performed in Transwells® according to a standardised protocol, while permeation 
studies with excised corneas were accomplished in the vertical Ussing chamber 
system (Havard Apparatus). To investigate the intra-laboratory repeatability the 
construct cultivation as well as the permeation studies were performed 
independently by different experimenters.  
Reconstructed human cornea constructs exhibited a barrier in the same range as 
excised corneas. Resulting from the standardised cultivation procedure HCCs 
showed high reproducibility and lower standard deviation than excised tissue. 
Therefore the HCC could turn out to be a promising in vitro alternative to the use 
of ex vivo tissue. 
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INLUENCE OF INLB 321 CD ON IMMORTALIZED HUMAN DERMAL 
KERATINOCYTES AND INTACT ORGANOTYPIC CO-CULTURE 
Kolditz, F.1, Krausze, J.2, Heinz, D. W.2, Niemann, H.3, Müller-Goymann, C. C.1
1Institut für Pharmazeutische Technologie, TU Braunschweig; 2Division of 
Structural Biology, Helmholtz Centre for Infection Research (HZI); 3Departement 
of Chemistry, Bielefeld University 
Internalin B (InlB) is an invasion protein of Listeria which facilitates its uptake into 
the host cells via activation of the receptor tyrosine kinase c-Met. It was proposed 
that receptor dimerization, which is essential for activation, is mediated through an 
InlB dimer. The variant InlB 321 CD¹ (crystal dimer), i. e. a dimerized fragment of 
Internalin B, was designed to stabilize the InlB dimer in solution and study the 
effects on c-Met activation. In previous studies, recombinant InlB 321 CD 
produced in E. coli was used in binding studies and in in vitro scatter assays¹. It 
was shown, that InlB 321 CD is a stronger agonist than both monomeric InlB 321 
and Internalin B. In human skin the c-Met receptor is mainly expressed on 
keratinocytes where it leads among other effects to proliferation. Therefore, the 
present project aims at the influence of dimeric as well as monomeric InlB 321 on 
re-epithelialization of dermis with keratinocytes. Subsequent to studying the 
potency of InlB 321 CD on the HaCaT cell line (human dermal immortalized 
keratinocytes), the effects of InlB 321 CD on bioengineered skin of a keratinocyte-
fibroblast co-culture as a human skin equivalent were studied to test whether the 
morphology of the bioengineered skin as a model of intact skin was affected..
Methods: A viability assay via MTT was carried out on HaCaT monolayer, after 
incubation with InlB 321 CD in a range of 0.01 nM – 0.5 nM; 30 nM HGF (a 
physiological c-Met receptor agonist) served as positive control. Intact organotypic 
co-cultures were determined in the same manner using MTT test. The histological 
analysis of morphology was performed of treated and untreated constructs by 
polymer-embedding and haematoxylin and eosin staining.  
Results: Within a range from 0.05 nM to 0.5 nM InlB 321 CD showed a 
significant increase in viability of HaCaT monolayers compared to medium and 
monomeric InlB 321 of the equivalent concentrations whereas neither morphology 
nor viability of intact organotypic co-cultures were affected.  
1Ferraris, D.M. et al., Ligand-Mediated Dimerization of the Met Receptor Tyrosine Kinase 
by the Bacterial Invasion Protein InlB, J. Mol. Biol. (2009), doi:10.1016/j.jmb.2009.10.074 
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mRNA EXPRESSION OF METABOLIC ENZYMES IN HUMAN 
CORNEA, CORNEAL CELL LINES AND CORNEA CONSTRUCT 
Kölln, C., Reichl, S.
Institut für Pharmazeutische Technologie, Technische Universität 
Carolo-Wilhelmina zu Braunschweig, Mendelssohnstraße 1, 38106 Braunschweig 
Drugs from ophthalmic formulations are mainly absorbed into the eye via corneal 
route. However, few is known about drug metabolism during transcorneal passage. 
The objective of this study was to determine the mRNA expression of phase I and 
II isoenzymes in human corneal tissue, corneal cell lines as well as human cornea 
construct as in vitro model for drug absorption studies. 
The polymerase chain reaction was used to profile the mRNA expression of 10 
cytochrome P450 enzymes and 7 phase II enzymes in three human corneal cell 
lines HCE-T (epithelial), HCK-Ca (stromal) and HENC (endothelial cells) as well 
as in tissue engineered cornea equivalent. Furthermore, the human colon 
adenocarcinoma cell line Caco-2, human corneal epithelium obtained from donor 
corneas and human liver tissue were investigated. 
The immortalized human corneal epithelial cell line (HCE-T) showed marginal 
mRNA expression of the P450 enzymes 2A6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4 and 
3A5. Signals for CYP1A2 and CYP2B6 were absent. The tested phase II enzymes 
GSTA4-4, GSTO1-1, GSTP1-1, NAT1, NAT2, SULT1A1 and UGT1A1 could be 
detected in HCE-T. In the case of phase II enzymes higher expression levels of 
mRNA were observed in comparison to CYP 450 enzymes. The mRNA expression 
in the immortalized human corneal keratocytes cell line (HCK-Ca) was quite 
similar to HCE-T. However, the P450 enzymes 2A6, 2C9 and 3A5 as well as the 
phase II enzyme NAT2 were not discovered. The human corneal endothelial cell 
line (HENC) showed the same mRNA pattern like HCK-Ca cells. PCR for the 
cornea construct shows similar result as obtained for the cell lines HCE-T and 
HCK-Ca, whereas CYP2C19 and NAT2 were not detected. 
Overall, the mRNA expression of tested phase I and phase II enzymes in the three 
corneal cell lines and the cornea equivalent correlated well with the expression 
pattern found in human cornea epithelium in vivo. 
T084
GENE EXPRESSION OF NOGGIN AND CHORDIN IN PRE-
OSTEOBLASTS IN RESPONSE TO BMP-2  
Schneider, Hellen1, Naumann, Andreas2 , Manja Kamprad3, Hacker, Michael1 ,
Schulz-Siegmund, Michaela1
1Pharmazeutische Technologie, Universität Leipzig,  
2Fraunhofer-Institut für Zelltherapie und Immunologie IZI, Leipzig,  
3Institut für Klinische Immunologie und Transfusionsmedizin, Leipzig 
Non healing bone defects can be successfully treated with high dosages of Bone 
morphogenetic protein 2 (BMP-2) to recruit and differentiate stem cells as has 
been shown with Infuse
. But therapies involving potent growth factors also bear 
a risk for severe side effects. BMP-2 is a highly regulated osteogenic protein. 
There are internal antagonists for BMP-2, e.g. noggin and chordin. A gene 
silencing strategy for these internal BMP-2 antagonists may allow for a reduction 
of effective BMP-2 dosing. The aims of this study are: 1) to determine gene 
expression of noggin and chordin in rat bone marrow derived mesenchymal stem 
cells (rMSC) and human adipose tissue derived stem cells (hADSC) during 
osteogenic supplementation with and without BMP-2; 2) to show siRNA 
transfection of both cell types with a control siRNA and 3) to investigate the 
effect of siRNA against both BMP-2 antagonists. Results: Osteogenic 
differentiation protocols for both hADSCs and rMSCs were applied successfully. 
Expression profiles of noggin and chordin were examined by total RNA-
extraction with Trizol and reversed phase PCR / gel electorphoresis / GelRed 
staining. rMSCs showed reliable noggin expression already during the first days 
of osteogenic differentiation with and without supplementation with BMP-2. 
Chordin mRNA, on the other hand, was expressed in very low amounts and was 
only detectable in some samples on days 3 to 6. For hADSCs the situation was 
found to be different. In all hADSC groups chordin was expressed particularly 
strong between days 5 and 14, while noggin expression was weak. BMP-2 
supplementation enhanced noggin expression in hADSCs but the levels found for 
chordin were not reached. Transfection of rMSCs with fluorescent labelled 
siRNA using HighPerfect (Qiagen) and Lipofectamine™ RNAiMAX (Invitrogen) 
showed 97 % fluorescent cells in flow cytometry. Cell death assay, an assay used 
to prove successful transfection by gene silencing of vital proteins, on the other 
hand, was only successful for hADSCs, particularly in combination with 
Lipofectamine™ RNAiMAX. Finally, we examined the effects of siRNA against 
noggin. First results showed down-regulation of noggin between days 2 and 4. 
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COMPARISON AND EVALUATION OF ABC TRANSPORTER 
EXPRESSION IN DIFFERENT CORNEA MODELS AND A CACO2 
CELL LINE 
Verstraelen J., Reichl S. 
Institut für Pharmazeutische Technologie, Technische Universität Carolo-
Wilhelmina zu Braunschweig, Mendelssohnstraße 1, 38106 Braunschweig 
The aim of most drugs for eye treatment is reaching the inner space of the eye 
indicating that these substances need to pass the cornea. Up to now parameters like 
transcorneal permeation rate and toxicity of ophthalmic drugs, needed for 
registration and approval of human medicines, are mostly tested and analyzed on 
research animals. This led to a great need to replace animal test systems by in vitro 
cell culture models. In this context the identification and characterisation of the 
different substance uptake systems in the cornea is of interest. Besides the presence 
of tight junctions, the permeation through the corneal epithelium could be strongly 
influenced by the presence of several efflux transporter systems. The expression at 
mRNA and protein level of ABC transporters in different corneal models was 
investigated. A comparison between a monolayer of immortalised human corneal 
epithelial cells submerged and air-liquid-interface cultivated, previously 
established human cornea construct, excised human and animal cornea, concerning 
the mRNA expression of efflux transporters was performed using reverse 
transcriptase PCR. The presence of protein expression was analyzed using Western 
blot and immunohistochemistry, whereas the level of activity was determined using 
a bidirectional permeation assay with specific substrates and inhibitors for each 
transporter.  The mRNA expression of nine efflux transporters (MDR1, MRP1-6, 
CFTR and BCRP) was examined and a similar pattern was obtained between the 
epithelial corneal cell line, the constructs, human and rabbit cornea. However, 
mRNA expression of MDR1, MRP4 and CFTR was not detectable in porcine 
cornea cells. The permeation studies with rhodamine 123 and verapamil showed an 
absence of MDR1 in all models except in the Caco2 cell line (positive control) and 
rabbit cornea, where the permeation with [H3]Erythromycin and MK571 on the 
other hand showed the expression of MRP2 in the epithelial corneal cell line. The 
confocal images and Western blot confirmed the previous results.  
In conclusion, two discrepancies were pointed out in this study, showing not only a 
difference in the expression of efflux transporters at mRNA and protein level, but 
also between the three investigated species. 
T086
EVALUATION OF CULTURE CONDITIONS OF TWO HUMAN 
CORNEAL CELL LINES EMPLOYED FOR THE ESTABLISHMENT OF 
A NEW CORNEAL MODEL TO ASSAY DRUG PERMEABILITY  
Haltner, E; G.A. Guzman Castro 
Across Barriers GmbH, Saarbrücken 
Objective: The main purpose of the joint research project study was to establish an 
in vitro corneal permeability model using two immortalized cell lines as well as 
ensure the reproducibility between three different laboratories. Within the joint 
research project “Prevalidation of an serum free Cornea Construct for Drug 
Diffusion Studies” the cell culture conditions of the two used cell types were 
evaluated to set for the three dimensional hemi cornea constructs.  
Methods: Seeding density was varied from 450,000 cells to 100,000 cells per flask 
(75cm2) for HCK-Ca cells, 450,000 to 300,000 for HCE-T cells. After 7 days the 
HCK-Ca and HCE-T cell lines were seeded onto membranes of Polycarbonate and 
with two different pore size (3.0 μm and 0.4μm) and polyester filters (pore size 0.4 
μm; Transwell-ClearTM). The TEER was determined and permeability of 
Fluorescein and Propranolol.  
Results: The optimum number of cells (8 mio) harvested from 75 cm² flasks after 
7 days for HCK-Ca cells than a seeding density of 1.0e5 cells was used; for HCE-T 
cells (8 mio) 3.0e5. The vitality was always above 90%. Higher densities decreased 
the number of harvested cell down to 50%. The TEER values varied from 970 to 
1560 .cm². Monolayer grown on Transwell ClearTM (Polyester, pore size 0.4 μm) 
has developed higher TEER values compared to polycarbonate Transwells (pore 
size 3.0 and 0.4 μm). The TEER of cells grown in polycarbonate filters with 0.4 
and 3.0 μm pore size were similar. No difference were observed between 
permeability coefficients (Papp, 10-6 cm*s-1) for FLU 0.28±0.030 and PRO 
13.2±0.58, 11.8±0.55 for polycarbonate membrane. FLU permeability (0.20 cm*s-
1) was similar for cells grown on polyester Transwells, the permeability PRO 
permeability (8.95 cm*s-1) was lower compared to the permeability measured with 
cells grown on polycarbonate Transwells. 
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ISOLATION AND CHARACTERISATION OF HUMAN ELASTIN 
Jung, M.C.1, Heinz, A.1, Wohlrab, J.2, Heyroth, F.3, Neubert, R.H.H.1,
Schmelzer, C.E.H.1
1Institute of Pharmacy; 2Department of Dermatology and Venereology; 3IWZ of 
Material Sciences, Martin Luther University Halle-Wittenberg, Halle (Saale) 
Elastin is one of the most abundant proteins of the extracellular matrix (ECM). 
Depending on the anatomical requirements of vital tissue, elastin forms different 
types of structures with a characteristic organisation of highly cross-linked elastic 
fibres inside the ECM. Damaged fibres, which may occur as a consequence of 
processes such as enzyme dysregulation, pathological conditions and aging, result 
in a loss of elasticity. To understand the structural changes of elastin during these 
processes, it is necessary to gain insight into the morphological and molecular 
constitution of the native protein. Such studies may aid in the development of new, 
adequate therapies to conserve and to reconstitute the elasticity and the 
functionality of the ECM. 
An isolation method of Daamen et al. (1) was adapted and the experimental 
conditions were optimised to obtain highly purified and intact elastin fibres out of 
the ECM of vital human tissue using single biopsies. The morphological 
constitution of elastin isolated from skin, aorta and cartilage was investigated by 
scanning electron microscopy (SEM). Furthermore, elastin was digested with 
different elastases and the released peptides were analysed by HPLC coupled to 
tandem mass spectrometry (LC/MS/MS). Through the identification of the 
cleavage products, the primary structure of different elastins, including the splice 
variants of tropoelastin and post-translational modifications, was investigated.  
With this novel experimental approach, it is not only possible to visualise the 
structure of mature elastic fibres, but also to characterise elastin on the molecular 
level to allow comparison between different human tissues. Moreover, it is possible 
to identify potential changes and modifications of elastin, for instance in aged or 
UV-exposed skin or in tissues affected by diseases such as aneurysm or cancer 
development. Furthermore, intact mature elastin and its precursor tropoelastin are 
important substrates to investigate the elastinolytic abilities of proteases (2).  
(1) Daamen, W. F. et al., Isolation of intact elastin fibers devoid of microfibrils. 
Tissue Eng 2005, 11, 7-8, 1168-1176. 
(2) Heinz, A. et al., Degradation of tropoelastin by matrix metalloproteinases. 
FEBS J. 2010, 277 (8), 1939-1956. 
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LYNGBYAZOTHRINS A-D, NOVEL ANTIMICROBIAL AND 
CYTOTOXIC CYCLIC UNDECAPEPTIDES FROM LYNGBYA SP.
Preisitsch, M.1, Zainuddin, E.1, Puhlmann, E.1, Wende, K.1, Jansen, R.2, Nimtz, 
M.2, Wray, V.2, Mundt, S.1
1Pharmaceutical Biology, Ernst-Moritz-Arndt-University, Greifswald 
2Helmholtz Centre for Infection Research, Braunschweig, 
Infectious diseases belong to the most frequent causes of death in the world. 
Although there are meanwhile more than 90 drugs in clinical use, the therapeutic 
efficiency is strongly influenced by the increasing number of resistant pathogens. 
On account of this the search for innovative and more effective compounds has 
become crucial importance. Cyanobacteria are known as a useful source of 
bioactive secondary metabolites to fill the pipelines for novel active 
pharmaceutical leads. Especially the genus Lyngbya exhibits a large number of 
natural metabolites including antibiotic, anticancer, cytotoxic, antifungal and 
antiviral activities. Among other bioactive products such as pyrroles, amides, 
alkaloids, lactones, derivatives of fatty acids and cyclic peptides and lipopetides of 
mixed polyketide synthase/nonribosomal peptide synthetase origin represent the 
largest part. Here we present four novel cyclic undecapeptides, lyngbyazothrins A 
(1), B (2), C (3) and D (4), which were isolated by bioassay-guided fractionation of 
a crude methanol/water extract from the cultured, filamentous cyanobacterium 
Lyngbya sp. 36.91 as binary mixtures (1/2 and 3/4). Their structures were 
elucidated by analysis of 1D and 2D NMR spectra, ESIMSMS, ESITOFMS and 
amino acid analysis. Three unusual amino acids were present and identified as 4-
methoxyhomophenylalanine in 1 and 3, homophenylalanine in 2 and 4 and 3-
amino-2,5,7,8-tetrahydroxy-10-methylundecanoic acid (Aound) in all compounds. 
Only 3 and 4 had an additional N-acetyl-N-methyltyrosine unit whose carboxyl 
group is bound to the 5-hydroxyl group of the Aound residue. The mixture of 
lyngbyazothrins A (1) and B (2) showed only low antimicrobial activity against 
Micrococcus flavus, whereas the mixture of lyngbyazothrins C (3) and D(4) was 
active against Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa,
Serratia marcescens and Candida maltosa. Further investigations of the cytotoxic 
activity revealed that only the mixture of 3 and 4 as well as purified 3 showed an 
intense cytotoxic effect against a human urinary bladder cancer cell line, whereas 
an effect could not be seen for 1 and 2. First insights in the structure-response 
relationships by chemical degradation suggest that the acyl residue at C-5 of the 
Aound unit plays an important role in antimicrobial activity. 
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CHEMICAL AND BIOLOGICAL INVESTIGATIONS OF MANUKA 
HONEY 
Bäcker, C.1, Wende, K.1, Meyer, U.2, Lindequist, U.1
1Institut der Pharmazie, Pharmazeutische Biologie, 
 Ernst Moritz Arndt Universität Greifswald
2WALA GmbH, Bad Boll/Eckwälden 
Manuka honey is mainly gained from New Zealands endemic Myrtaceae 
Leptospermum scoparium J.R. et G.Forst. Its increasing clinical use in wound 
management originates from its special antimicrobial effects. Recent work 
identified 1,2-dicarbonyl methylglyoxal (MGO) as a major antibacterial 
compound [1] which appears in Manuka honey in high levels and is formed from 
dihydroxyacetone during storage [2]. In this study several Manuka honeys were 
investigated for antibacterial activity, MGO content and phenolic compounds. 
Antibacterial testing was done by agar diffusion assay as well as in the epidermis 
model ´cow udder teat´ [3]. Aqueous dilutions of Manuka honeys were able to 
inhibit growth of multi-resistant strains of Staphylococcus aureus, Staphylococcus 
epidermidis, Escherichia coli and Pseudomonas aeruginosa. In these honeys, 
MGO amounts ranging from 400 to over 1000 mg/kg were found. However, no 
hydrogen peroxide was detected in Manuka honeys. In comparison: a rape honey 
contained only 3 mg/kg MGO but high amounts of hydrogen peroxide. It showed 
inhibiting effects on both Staphylococcus strains. If MGO was added to a non 
Manuka honey the resulting bacterial inhibition was the same as for a Manuka 
honey with comparable MGO amount. Detected and quantified phenolic 
compounds such as phenyllactic acid or methyl syringate did not exert 
antimicrobial activity on the tested strains. Osmotic effects did not contribute to 
inhibiting effect. Therefore, it appears likely that clinical benefits of Manuka 
honeys are proportional to its 1,2-dicarbonyl methylglyoxal content. 
References: 1. Mavric, E et al. (2008) Mol. Nutr. Food Res. 52:483-489.  2. 
Adams, CJ et al. (2009) Carbohydrate Research 343:1050-1053. 3. Lukowski, G. et 
al. (2008) Skin Pharmacol Physiol 21: 98-105   
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THE INTERACTION BETWEEN THYMOL AND EDTA AGAINST 
MULTIRESISTANT BACTERIA 
Hamoud, R.1, Reichling, J1. Wink, M.1  
1 Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, 
Heidelberg, Germany 
 
Ethylenediaminetetraacetic acid (EDTA) is a known chelating agent of Ca+2 and 
Mg+2  ions. The bi-valent metal ions are responsible of many chemical and 
biochemical reactions, which promote food destruction. Furthermore their basic 
role in the protection of bacterial cell wall especially of gram-negative bacteria. 
EDTA has been used as a food preservative and antimicrobial agent. The 
interaction between EDTA and several antibiotics against different strains of 
bacteria including multiresistant strains has been studied and many combinations 
such as the combination between EDTA and carbenicillin, oxytetracycline and 
others showed synergistic effects. 
Thymol is a monoterpene and major component  of the essential oil of Thymus 
species (Lamiaceae). It shows strong antimicrobial properties. 
The aim of this study was to investigate the interaction between EDTA and 
Thymol against multiresistant bacteria. Two methods were performed to evaluate 
the activity of several combinations against Methicillin-resistant Staphylococcus 
aureus (MRSA ATCC 10442), Vancomycine resistant Enterococcus (VRE ATCC 
31299) and Klebsiella pneumonia (ATCC 700306) namely Checkerboard dilution 
and time-kill curve methods. Synergism is defined as an FIC index ‹ 0.5 by 
checkerboard dilution method and as a 100-fold or 2-log10 decrease in colony 
count after 24 h by the combination compared with that by the most active single 
agent by time- kill curve method.  
The results obtained in Checkerboard dilution method indicate additive and 
indifferent effect against Gram-positive and Gram-negative bacteria with an FIC 
index between 0.7 and 2. A synergistic effect was recorded only against Klebsiella 
pneumonia as an FIC ‹ 0.5.  
EDTA was found to enhance the bactericidal activity of thymol in time-kill curve; 
strong bactericidal activity was achieved with some combinations, whereas the two 
substances alone did not show the same degree of bactericidal activity after 24h. 
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BIPHENYL FORMATION IN FIRE BLIGHT-INFECTED  
MALUS DOMESTICA CULTIVARS 
Hüttner, C.1, Beuerle, T.1, Flachowsky, H.2, Richter, K.3, Beerhues, L.1
1Institute of Pharmaceutical Biology, TU Braunschweig, Braunschweig, Germany 
2Julius Kühn Institute, Federal Research Centre for Cultivated Plants, 
Institute for Breeding Research on Horticultural and Fruit Crops, Dresden, 
Germany
3Julius Kühn Institute, Federal Research Centre for Cultivated Plants, 
Institute for Resistance Research and Stress Tolerance, Quedlinburg, Germany 
Fire blight is the most dangerous bacterial disease of the Pyrinae. This Rosaceous 
subfamily includes economically important fruit trees, such as apple (Malus 
domestica) and pear (Pyrus communis). Fire blight is caused by the pathogen 
Erwinia amylovora and can lead to the death of the infested plant. After pathogen 
attack, the plants produce biphenyls and the structurally related dibenzofurans as 
phytoalexins. The precursor of these defence compounds, 3,5-dihydroxybiphenyl, 
results from the condensation of benzoyl-CoA with three molecules of malonyl-
CoA, catalyzed by biphenyl synthase (BIS). A series of Malus species and M.
domestica cultivars was investigated after inoculation with E. amylovora. In M.
domestica cv. ‘Holsteiner Cox’, the formation of biphenyls and dibenzofurans was 
detected in the stem. This cultivar is being used as a model system for studying the 
regulation and localization of the biosynthesis of biphenyl and dibenzofuran 
phytoalexins.  
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BIOCHEMISTRY OF GLUCOSINOLATE HYDROLYSIS: ANALYSIS OF 
THE INTERACTION BETWEEN MYROSINASE AND SPECIFIER 
PROTEINS 
Gumz, F.1, Wittstock, U.1
1Pharmazeutische Biologie, TU Braunschweig  
Specifier proteins are part of the glucosinolate-myrosinase system present in the 
Brassicaceae, including nutritionally valuable vegetables and spices (e.g. broccoli 
and mustard). For the plant, glucosinolates are defense compounds. For humans, 
they are of note because they may have beneficial health effects. For example, 
regular consumption of broccoli is associated with a reduced incidence of certain 
cancers. This effect is mainly attributed to isothiocyanates which are the common 
products of the myrosinase-catalyzed hydrolysis of glucosinolates upon tissue 
damage. In the presence of specifier proteins, the hydrolysis is redirected to other 
products, e.g. nitriles or epithionitriles, and a lower proportion of isothiocyanates 
is produced. Specifier proteins have no enzymatic activity on glucosinolates, but 
likely act on the aglyca released by myrosinase. Experiments have shown that if 
epithospecifier protein (ESP) and myrosinase are separated spatially, 
isothiocyanates are formed in vitro. Thus, it seems that the ESP needs to interact 
with myrosinase. However, it has also been shown that there is no stable 
interaction between ESP and myrosinase. 
In order to detect the presumably transient interaction between myrosinase and 
specifier proteins, we used a label transfer method with a trifunctional crosslinker 
Mts-Atf-Biotin (Pierce). First, the purified myrosinase from Sinapis alba was 
biotin-labeled over the Mts moiety of the linker by disulfide bonds. After an 
initial incubation with a purified recombinant nitrile-specifier protein 
(Arabidopsis thaliana NSP3) and allylglucosinolate, the Atf moiety was activated 
by UV light. This allows the transfer of the biotin label to proteins in a distance of 
11.1 Å expected only for specific protein-protein-interaction. After the disulfide 
bonds had been reduced, the label transfer was analyzed by immunoblotting. As a 
result, we were able to detect the biotin label on NSP3 but not on carbonic 
anhydrase used as a negative control. Thus, NSP3 and myrosinase interacted in 
our in vitro assay. The next step is to characterize the interaction in more detail 
and to determine the site of interaction in NSP3 and myrosinase.  
B093
EVOLUTION OF SPECIFIER PROTEINS IN THE BRASSICALES 
Kuchernig, J.-C.1, Burow, M.1, Wittstock, U.1
1Pharmazeutische Biologie, TU Braunschweig  
Glucosinolates are secondary metabolites found predominantly in the order 
Brassicales including nutritionally valuable vegetables and spices like broccoli, 
rucola, horseradish, and mustard. Health benefits associated with consumption of 
these foods are attributed to the isothiocyanates released when glucosinolates are 
hydrolysed by co-occuring myrosinases upon tissue disruption. For the plants, 
isothiocyanates are defence compounds toxic to insects, nematodes and 
microorganisms. Depending on the glucosinolate side-chain structure, the presence 
of specifier proteins results in the formation of alternative products, e.g. nitriles, 
epithionitriles and organic thiocyanates, with divergent biological activities. These 
products appear to lack the positive health effects and to be less effective in direct 
plant defence. Because of the high variability in the composition of the about 120 
known glucosinolates and the varying occurence of specifier proteins with different 
specificities in different species, but also in different organs and developmental 
stages of a single plant, we wanted to get a better insight into the evolution of this 
protein family. Our approach was to identify and characterise specifier proteins 
from glucosinolate-containing plants from different families of the Brassicales and 
to subject their amino acid sequences to phylogenetic analyses. 
Species that produce non-isothiocyanate products upon glucosinolate hydrolysis 
were selected based on a phytochemical screening among 28 species belonging to 
six families. GC-MS analysis of autolysates of seeds, and if available, seedlings, 
leaves and flowers, showed that non-isothiocyanates products were only formed in 
15 species belonging to the Brassicaceae. Based on known amino acid sequences 
of nine specifier proteins from Arabidopsis, broccoli, and garden cress, we 
designed degenerate primers to identify cDNAs encoding specifier proteins. After 
cloning of twelve full-length cDNAs from six additional species, we characterised 
the corresponding proteins by heterologous expression in E. coli and constructed 
phylogenetic trees using different algorithms. 
In conclusion, amino acid sequence similarity does not appear to be a sufficient 
parameter to predict catalytic activity of specifier proteins. Phylogenetic analyses 
propose a common ancestor of all specifier proteins and at least two independent 
origins of thiocyanate-forming activity from epithiospecifier-activity.  
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CLONING, EXPRESSION AND MODELLING OF P5R-LIKE ENONE 
REDUCTASES FROM VARIOUS ANGIOSPERMS 
Bauer, P.1, Brydziun, M.1, Müller-Uri, F.1, Kreis, W.1 
1Pharmazeutische Biologie, Universität Erlangen 
 
5-configured cardenolides are still of great medicinal and economical importance 
in the treatment of cardiac insuffiency in humans. As far as their biosynthesis is 
concerned the stereospecific reduction of progesterone to 5-pregane-3,20-dion is 
often referred to as one key step, because here the characteristic cis configuration 
between ring A and B is formed. The reaction is catalysed by the enzyme 
progesterone 5-reductase (P5R), which has been cloned from several members 
of the genus Digitalis and functionally expressed in E. coli [1]. The crystal 
structure of Digitalis lanata P5R has been solved revealing a novel class of short 
chain dehydrogenases/reductases (SDRs), with only two of the typical catalytic 
residues (K147 and Y179) being conserved [2]. An orthologous gene (VEP1) has 
also been cloned from the model plant Arabidopsis thaliana, which does not 
produce cardenolides. The respective recombinant enzyme was also capable of 
reducing progesterone stereo-selectively in vitro [3]. Both enzymes were capable 
of reducing other steroidal, cyclic or non-cyclic enone substrates [4].   
In this work we report the cloning of orthologous genes from various cardenolide-
containing and cardenolide-free medicinal important angiosperms including 
Mentha piperita, Gomphocarpus fruticosus, Atropa belladonna, Plantago major, 
Nerium oleander Erysimum crepidifolium and Erysimum rhaeticum. With the 
exception of the A.belladonna protein we succeded in the heterologous expression 
in E. coli. The functionality was shown using TLC, GC-MS and HPLC. As the 
proteins share 67 to 96 percent sequence identity on amino acid level with the D. 
lanata 5-POR we used this structure (PDB 2v6g) as a template for modelling. We 
included the substrate progesterone into the 3D models and compared the binding-
sites of the functional active enzymes. In addition to the expected catalytic Y179 
and K147 residues another five amino acids could be identified within the 
substrate-binding pocket, namely W106, G145, F153, M215 and F343  being 
conserved in all enzymes. The residues seem to cluster around the proximal part of 
the substrate and may be involved in the positioning of the enone-structure-
element. The importance of the structurally conservation of these residues will now 
be investigated using site-directed mutagenesis.  
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BENZALDEHYDE DEHYDROGENASE INVOLVED IN BENZOIC ACID 
FORMATION  
Gaid, M.M., Beerhues, L. 
Pharmazeutische Biologie, TU Braunschweig 
Despite its simple structure, the biosynthesis of benzoic acid is poorly understood. 
Cell suspension cultures of Sorbus aucuparia (Rosaceous subtribe Pyrinae, 
formerly subfamily Maloideae) respond to elicitor treatment with biphenyl and 
dibenzofuran accumulation. These two classes of phytoalexins are benzoic acid-
derived polyketides. The formation of benzoic acid proceeds via benzaldehyde as 
an intermediate. Benzaldehyde dehydrogenase (BD) catalyzes the last reaction of 
benzoic acid biosynthesis by converting benzaldehyde to benzoic acid, which is 
finally activated by a CoA ligase to give benzoyl-CoA. Biphenyl synthase (BIS) 
then condenses benzoyl-CoA with three molecules of malonyl-CoA, leading to 
formation of the carbon skeleton of the inducible defence compounds. Detection 
and characterization of BD in elicitor-treated S. aucuparia cell cultures was 
suggestive of benzoic acid biosynthesis via a non--oxidative pathway. The 
preferred substrate for BD was benzaldehyde (Km = 49 μM). Cinnamaldehyde and 
hydroxybenzaldehydes were relatively poor substrates. BD activity was dependent 
on the presence of NAD+ as a cofactor (Km = 67 μM). 
A cDNA encoding aldehyde dehydrogenase (putative BD) was cloned from 
elicitor-treated cells. The ORF encodes a 54.8 kDa protein. No N-terminal targeting 
signal was identified by analysis of the amino acid sequence. The transcriptional 
level of the putative BD gene was significantly higher than that of the BIS gene, 
which is in agreement with the changes in the specific BD and BIS activities after 
elicitor treatment. These results provide first insight into benzoic acid metabolism 
in the economically valuable subtribe Pyrinae. 
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HYPERFORIN BIOSYNTHESIS: CDNA CLONING OF 
ISOBUTYROPHENONE SYNTHASE 
Belhadj, I. , Gaid, M.M. , Beerhues, L. 
Institut für Pharmazeutische Biologie, Technische Universität Braunschweig, 
Mendelssohnstr. 1, 38106 Braunschweig, Germany 
Hyperforin is an important antidepressant constituent of Hypericum perforatum 
(St. John´s wort, Clusiaceae) [1]. Cell cultures of the related species H. calycinum 
were found to contain the homologue adhyperforin and to a low extent hyperforin, 
when grown in BDS medium in the dark. Cell-free extracts from the cell cultures 
contained isobutyrophenone synthase (BUS) activity catalyzing the stepwise 
condensation of isobutyryl-CoA with three molecules of malonyl-CoA to give 
phlorisobutyrophenone, the hyperforin skeleton [2]. BUS is likely to be a type III 
polyketide synthase (PKS). The aim of the present work was cDNA cloning of 
BUS. H. perforatum plants and H. calycinum cell cultures were used for the 
isolation and reverse transcription of poly (A+) mRNA pools. Degenerate primers 
that matched conserved motives of known PKS sequences were designed. PCR 
with combinations of these primers led to the amplification of a new cDNA 
fragment that was extended by 3´ and 5´ RACE techniques to give the full-length 
clone. The resulting sequence shared 88% identity with other PKSs and is a 
promising candidate to encode BUS. Heterologous expression of the open-reading 
frame in E. coli for functional analysis is in progress. 
1. Beerhues L (2006) Phytochemistry 67: 2201-2207 
2. Klingauf P, Beuerle T, Mellenthin A, El-Moghazy S, Boubakir Z, 
Beerhues L (2005) Phytochemistry 66: 139-145  
B097
BENZOPHENONE  SYNTHASE FROM HYPERICUM CALYCINUM
CELL CULTURES: CDNA CLONING AND FUNCTIONAL EXPRESSION     
Zodi R, Beuerle T, Beerhues L 
Institut für Pharmazeutische Biologie, Technische Universität Braunschweig, 
Mendelssohnstr. 1, D-38106 Braunschweig, Germany 
Hypericum is a medicinally important genus (Clusiaceae). H. perforatum (St. 
John’s wort) is the best-known member of the genus and widely used as an 
antidepressant agent. Cell suspension cultures of the related species, H. calycinum,
form 1,3,6,7-tetrahydroxy-8-prenylxanthone upon elicitation with yeast extract. 
Xanthones thus appear to serve as phytoalexins in Hypericum species, as reported 
previously. In addition, they exhibit antitumour, anti-HIV, and antimicrobial 
activities [1].
O
OH
OHOH
OH O
1,3,6,7-tetrahydroxy-8-prenylxanthone 
The carbon skeleton of xanthones is formed by benzophenone synthase (BPS), 
which catalyses the condensation of benzoyl-CoA and three molecules of malonyl-
CoA followed by intramolecular cyclization. Time-course changes in BPS activity 
and xanthone formation were studied. Maximum product formation and enzyme 
activity were found at 12 and 9 h, respectively, after addition of the elicitor. The 
BPS cDNA was cloned using primers derived from H. androsaemum cDNA [2] 
and the open-reading frame was functionally expressed in E. coli as 6xHis-tagged 
protein. The enzymatic product after incubation with benzoyl-CoA and malonyl-
CoA was identified as 2,4,6-trihydroxybenzophenone. Characterization of the 
recombinant enzyme is underway. 
References: 1. Beerhues L, Liu B (2009) Phytochemistry 70: 1719-1727. 2. Liu B et al. (2003) Plant J. 34: 847-
855.
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ARABINOGALACTAN-PROTEINS FROM CELL SUSPENSION 
CULTURES OF PELARGONIUM SIDOIDES DC
Duchow, S., Blaschek, W., Classen, B. 
Pharmaceutical Institute, Dept of Pharmaceutical Biology, University of Kiel, 
Gutenbergstraße 76, 24118 Kiel, Germany 
Arabinogalactan-proteins (AGPs), secreted by suspension cultured cells of 
Pelargonium sidoides grown in different plant growth regulator-containing media 
were investigated quantitatively and qualitatively. Suspension cultures of 
Pelargonium sidoides have been established in MS media supplemented with 2,4-
dichlorphenoxyacetc acid (2,4-D) or 2,4-D plus kinetin. The cell-free medium was 
used to isolate the AGPs by precipitation with -glucosyl Yariv reagent. The pure 
AGPs have been structurally characterized with regard to the polysaccharide part. 
Quantification of neutral sugars by acetylation pointed out arabinose (Ara) and 
galactose (Gal) as dominating monosaccharide residues in a ratio of 1 : 2. 
Colourimetric determination of uronic acids revealed an amount of 5-8%. Linkage 
type analysis showed that the main components are 1,3,6-Gal(p), 1,3-Gal(p) and 1-
Ara(f) as well as minor amounts of 1,6-Gal(p), 1,4-Gal(p),1-Gal(p), 1,5-Ara(f) and 
1,2-Ara(f). Molecular weight of AGPs has been determined by size exclusion 
chromatography with laser light scattering detection and found to range between 80 
and 85 kDa.  
B099
XANTHINE OXIDASE INHIBITION BY DIFFERENT SAPONIN 
GLYCOSIDES FROM HYACINTHACEAE SPECIES 
Arjune, S. and Klar, F. 
Division of Natural Product Research, Flurepha, Gelsenkirchen 
The use of various Hyacinthaceae species especially these of genus Eucomis for 
medical applications has a longstanding tradition in the South African native 
population. Prepared decoctions from shaved bulbs and leafs in boiled water have 
been used for several indications in order to treat inflammation and pain. 
Previous studies showed enrichment of pharmacological active metabolites in 
outlasting parts however in leaf extracts a highly decreased content was found [1]. 
Several human metabolic diseases e.g. gout and hyperuricemia are associated with 
elevated uric acid (UA), catalyzed by xanthine oxidase (XO) [2]. Hence therapy 
can be achieved by XO inhibition in order to block UA formation from 
hypoxanthine and xanthine, we determined inhibition of XO by Hyacinhaceae’s 
saponin-glycosides. Allopurinol, a known substrate analogon of hypoxanthine and 
potent inhibitor of XO, has been frequently used for treatment of gout and 
hyperuricemia. Due to life-threatening side-effects of Allopurinol e.g. progressive 
renal failure or hepatitis, screening for novel non-purine derived XO inhibitors is 
an essential goal future pharmaceutical approach [3]. 
Extractions of bulbous parts from Chionodoxa luciliae Boiss., Drimiopsis maculata
Lindl., Eucomis bicolor Bak., E. pole-evansii N.E.Br., Ornithogalum dubium
Houtt. and O. saundersiae Bak. were separated and saponine-rich fractions were 
tested for inhibitory effects on XO activity.
[1] M. Ipek and F. Klar, Z. Phytother. 30 (2009) S24. 
[2] V. Massey, et al; J. Biol. Chem. 244 (1969) 3999. 
[3] P. Valentao et al; J. Agric. Food Chem. 49 (2001) 3476. 
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EFFECTS OF SPIROCYCLIC NORTRITERPENOIDS FROM EUCOMIS 
COMOSA ON PEROXIDATION IN INFLAMMATORY PROCESSES 
Klar, F.
Division of Natural Product Research, Flurepha, Gelsenkirchen 
The bulbous Hyacinthaceae Eucomis comosa (Houtt.) Wehrh. is known to be rich 
in homoisoflavones, chromanones and nortriterpenoids. In previous studies anti-
inflammatory effects, especially the inhibition of cyclooxidases, have been 
described for substances and extracts of several Eucomis species [1]. The aim of 
our work was to investigate effects of isolated spirocyclic nortriterpenoids from 
bulbs of E. comosa on different inflammation parameters. 
Inflammatory cells produce differentiation cytokines, which possess the ability to 
generate reactive oxygen species (ROS). ROS can damage cellular molecules 
which in turn augment the state of inflammation [2]. We tested inhibitory activity 
of E. comosa’s nortriterpenoids on lipid peroxidation in erythrocytes from rabbit 
whole blood using the TBA in vitro assay. Furthermore inhibitory effects on the 
myeloperoxidase (MPO) from rabbit leukocytes were investigated. MPO serves as 
an essential enzyme for anti-bacterial responses in contaminated leukocytes [3]. As 
MPO levels are often increased in inflammatory processes, MPO contributes to the 
pathogenesis of chronic inflammatory diseases. Hence MPO inhibition would be 
beneficial in future anti-inflammatory therapies. 
[1] M. Ipek and F. Klar, Z. Phytother. 30 (2009) S24. 
[2] C.G. Cochrane, Am. J. Med. 91 (1991) S23-S30. 
[3] K. Suzuki et al., Anal. Biochem. 132 (1983) 345-352. 
B101
SULFATED POLYSACCHARIDES OF THE RED ALGAE DELESSERIA
SANGUINEA: “PROCESS DEFINES THE PRODUCT”
Grimm, J., Grünewald, N., Alban, S.
Abt. Pharmazeutische Biologie, Pharmazeutisches Institut, Christian-Albrechts-
Universität, Kiel 
To increase the local fishery resources, a large-scale artificial reef was established 
in the Baltic Sea close to Nienhagen in 2003. Since the reef structures turned out to 
be abundantly colonized by the red macroalga Delesseria sanguinea (Hudson) 
Lamouroux (D.s.), a project was initiated to evaluate its economic applicability. 
D.s. was shown to contain substantial amounts of sulfated polysaccharides (D.s.-
SP) exhibiting anti-inflammatory activity and anti-skin aging effects. Meanwhile 
more than 150 D.s.-SP batches were isolated from D.s. harvested over the period of 
5 years, analyzed and tested. The D.s.-SP consist of a homogenous fraction of 
branched sulfated xylogalactans (gal : xyl = ~6.6), which can be isolated in 
reproducible, high quality by a standardized procedure. Depending on the harvest 
time of D.s., the D.s.-SP however may contain up to 23% glucose mainly 
representing starch. Although the latter does not influence the activities, it is 
regarded as an impurity. Therefore, the standard procedure was further modified to 
reduce the co-extracted starch as well as to generally increase the yield of D.s.-SP. 
According to the standard procedure, D.s. is extracted with demineralised water for 
8h at 80°C yielding season-dependently 11.9% D.s.-SP (6.1-17.9%). As revealed 
by repeated 8h-extraction (EX), the D.s.-SP EX is not complete. Therefore, D.s. 
was extracted 2x for 4h and 4x for 2h, respectively. The 1st EX yielded 9.9% in 
both cases, by the 2nd EX the yields increased to 13.3% and 15.0%, resp. being 
higher than that by a single 8h-EX. The 4x2h-EX finally led to 17.9%, so that a 2x 
EX seems sufficient. The 2x2h EX is not only the shortest, but also results in the 
lowest glucose content (2x2h: 8.9%, 2x4h: 10.9%, 1st 8h: 14.4%, 2nd 8h: 25.1%). 
The use of 70% (v/v) ethanol or CaCl2 solution instead of 90% (v/v) ethanol to 
precipitate the extracted D.s.-SP showed to be further measures to reduce the 
glucose content without significantly reducing the yield. The yield can be much 
increased by extracting dried and milled D.s. instead of fresh alga (e.g. 25.5% vs. 
12.0%). In conclusion, the presented data on the isolation of D.s.-SP exemplary 
demonstrate the thesis “the process defines the product” claimed for plant extracts. 
Small changes of the procedure showed to significantly improve the quality of the 
D.s.-SP and to additionally increase their yield. 
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A NEW HYALURONIDASE ASSAY: INLFUENCE OF VARIOUS ASSAY 
PARAMETERS ON THE INHIBITORY ACTIVITY 
Arpe, N.; Alban, S. 
Abt. Pharmazeutische Biologie, Pharmazeutisches Institut, Christian-Albrechts-
Universität, Kiel 
Hydrolysis of connective tissue by enzymes such as hyaluronidase is a 
characteristic step during inflammation and tumor metastasis as well as during skin 
ageing. Accordingly, hyaluronidase represents an interesting target for the 
development of anti-inflammatory-, anti-metastatic-, and anti-ageing agents. The 
aim of the present study was to develop a convenient assay to screed potential 
hyaluronidase inhibitors. 
The established “all in one microplate” assay consists of the following steps: (1) 
Incubation of hyaluronan, hyaluronidase and the test compound (hyaluronan 
degradation). (2) Cleavage of the terminal N-acetyl-glucosamine (GlcNAc) units 
from the resulting hyaluronan oligosaccharides by potassium tetraborate buffer, pH 
10.0 (3) Incubation of the GlcNAc units with 4-dimethylaminobenzaldehyde 
(Morgan Elson reaction) (4) Measurement of the optical density at 570 nm. In the 
context of the assay development, the impact of following parameters was 
evaluated: (1) origin and salt form of the hyaluronan substrate, (2) composition of 
the buffer, (3) pH value of the buffer, (4) ion-concentration of the buffer. As 
exemplary hyaluronidase inhibitors unfractionated heparin (UFH), the 
semisynthetic glucan sulfate PS3, and the sulfated polysaccharide fraction from the 
red alga Delesseria sanguinea (D.s. SP) were used.  
Ad (1): The extent of degradation turned out to depend on the origin of hyaluronan 
and increased in the order: human umbilical cord < bacterial fermentation < cock´s 
combs, whereas the respective inhibitory potency of test substances inversely 
improves, i.e. cock´s combs < bacterial fermentation < human umbilical cord. At 
pH 5.0, sodium hyaluronan showed to represent a slightly better substrate than 
potassium hyaluronan. This was confirmed (ad (2)) by performing the assay with 
potassium phosphate instead of sodium phosphate buffer. Ad (3): The inhibitory 
activities were found to be clearly dependent on the pH and increased in the order 
7.0 < 6.5 < 5.5 < 5.0. Ad (4): As expected, high ion-concentrations of the buffer 
were associated with reduced inhibitory activities of the used test compounds. 
In conclusion, the “all in one microplate” hyaluronidase assay is a useful tool for 
screening of potential inhibitors. To ensure its reproducibility, each parameter, 
especially the type of the hyaluronan, has to be standardized. 
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COMPARISON OF THREE METHODS FOR THE DETERMINATION 
OF OSCS IN FALSIFIED HEPARIN 
Schiemann, S.1, Lühn, S.1, Beyer, T.2, Holzgrabe, U.2, Alban, S.1 
1Abt. Pharmazeutische Biologie, Pharmazeutisches Institut, Christian-Albrechts-
Universität, Kiel 
2Abt. Pharmazeutische und Medizinische Chemie, Institut für Pharmazie und 
Lebensmittelchemie, Julius-Maximilians-Universität, Würzburg 
 
A novel challenge in the quality control is the detection of counterfeit heparins. For 
that, we developed both a fluorescence assay (FA) and an anti-FXa assay-based 
method (aXa-A). After provisional revision of the Ph.Eur. monograph on heparin, 
the currently mandatory test for pharmaceutical industry is 1H-nuclear magnetic 
resonance spectroscopy (NMR). The aim of this study was to compare our two 
methods with NMR. 
A number of 150 samples of both pure and contaminated heparin batches (SH) 
were provided by the BfArM. Their OSCS content was determined using 3 
methods. 1. FA: After enzymatic degradation of the heparin in the SH, the 
fluorescence intensity increase of Polymer-H by OSCS is measured as described 
earlier (Lühn, Alban, JPBA 2010). 2. aXa-A: The aXa-A determines OSCS by its 
heparinase-I (hep-I) inhibitory potency. After incubation of the SH with hep-I, the 
remaining heparin is measured in a chromogenic aXa-A. At both FA and aXa-A, 
OSCS is quantified by calibration curves with OSCS-spiked heparin. 3. NMR: 
NMR-spectra of the SH were recorded according to Beyer et al. (JPBA 2008). 
All three methods matched concerning the categorisation of the 150 SH in non-, 
low-, middle- or high-contaminated samples. The correlation function of FA vs. 
NMR was y = 0.9952x + 0.6567 with a coefficient of determination R= 0.9954. In 
the aXa-A, saturation was observed in SH containing >10% OSCS. For SH with 
10% OSCS, the correlation function was y = 1.0844x + 0.1072 with R = 0.9934. 
Further, some practical advantages of both FA and aXa-A compared to NMR 
became obvious: the required SH amount (< 30g) is 1000 times lower, 30 SH are 
examined in the same time as 1 with NMR and has a much easier valid 
quantification procedure. 
The study demonstrates that both the FA and aXa-A are as sensitive and reliable as 
NMR, but much less expensive. Thus, these two novel assays represent rapid and 
simple options for the detection of counterfeit heparins.
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SENSITIVE DETECTION OF HEPARIN MIMETICS BY MODIFI- 
CATION OF THE SENSOR MOLECULE-BASED POLYMER-H-ASSAY 
Lühn, S., Schiemann, S., Alban, S. 
Abt. Pharmazeutische Biologie, Pharmazeutisches Institut, Christian-Albrechts-
Universität, Kiel 

In 2008, unfractionated heparin (UFH) contaminated with the heparin mimetic 
oversulfated chondroitin sulfate (OSCS, up to 35%) penetrated the worldwide 
market and was associated with severe adverse reactions. Also batches of the 
LMWH enoxaparin contained up to 7% OSCS. Therefore, feasible and reliable 
methods to test heparins for falsification are urgently needed. We intended to 
elaborate a simple and rapid approach, which is based on a recently developed 
assay (Lühn, Alban, JPBA 2010) for direct quantification of heparins.  
1. Basic microplate assay: Serial dilutions of UFH, enoxaparin, contaminated 
heparin, OSCS as an exemplary heparin mimetic and OSCS-spiked heparins, were 
mixed with a solution of the heparin sensor Polymer-H. After 10 min at room 
temperature, the fluorescence intensity (FI) was measured ((em) 330 nm, (ex) 
510 nm). 2. Pre-treatment step: Incubation of the samples with heparinase I (hep-I). 
For complete degradation, several parameters (e.g. temperature, time, UFH-, hep-I 
conc.) were tested. 
Like heparins, OSCS concentration dependently increased the FI of Polymer-H. 
Thus, it can be quantified, but not in the presence of heparins. Therefore, the 
heparin in OSCS-heparin mixtures has to be eliminated first. Enzymatic 
degradation with hep-I turned out to be most suitable. After optimization, the LOD 
was 0.4% / 0.5% OSCS in UFH / enoxaparin, and the LOQ 1.1% / 0.9%. The 
detected OSCS concentration was 0.01 g/ml and so 50 times lower than expected. 
The reason is that OSCS concentration dependently inhibits hep-I resulting in 
incomplete heparin degradation. Thus the FI increase caused by OSCS itself is 
amplified by the remaining heparin. 
This novel 2-step microplate fluorescence assay represents a sensitive, rapid and 
simple method to detect OSCS and other heparin mimetics in heparins. In contrast 
to 1H-NMR spectroscopy, it requires neither expensive equipment nor much 
experience. Therefore, it could also be used in clinical practice, to check the 
applied heparin preparation when a patient suffered any adverse event. 
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CHARACTERIZATION OF PHENOLIC COMPOUNDS BY HPLC-DAD/-
ESI-MS2 IN FLAVONOID ENRICHED EXTRACTS OF CURLY KALE 
Schwanck, B., Blaschek, W.
Pharmaceutical Institute, Dept of Pharmaceutical Biology, University of Kiel, 
Gutenbergstraße 76, 24118 Kiel, Germany 
Curly kale contains high amounts of ascorbic acid and other constitutional 
components like polyphenols. Especially flavonoids are known for antioxidative 
capacitiy and other beneficial effects to human health. Since type 2 diabetes 
belongs to the main diseases of the industrialized countries, the main concern of 
this project is to find flavonoids as potential inhibitors of the sodium glucose co-
transporter (SGLT1) to reduce the intestinal uptake of glucose thereby avoiding 
increased postprandial blood glucose concentrations.  
The flavonoid composition of curly kale (Brassica oleracea L. var. sabellica L.) 
and its extracts has been analyzed by HPLC-DAD/ESI-MS2. Thereby, a large 
number of kaempferol and quercetin glycosides and their acylated derivatives 
could be found, furthermore structures of the flavonoid glycosides could be 
approved after specific cleavage of the ester linkage. Depending on the starting 
plant material three flavonoid aglycones could be quantified after acidic hydrolysis: 
kaempferol as the main aglycone, followed by quercetin and isorhamnetin.  
The total flavonoid concentration in various sources of kale ranged from 1550 – 
5000 ppm of fresh weight. In order to produce a final product with high flavonoid 
content an aqueous kale juice was prepared and concentrated using an adsorber 
resin (AMBERLITE™ FPX66). The identification of apigenin, rhamnetin and 
dihydrokaempferol (in traces) in such flavonoid enriched kale extracts with LC-ESI 
(+) MS has not been reported previously. Different enriched extracts of curly kale 
were tested for their inhibition of SGLT1 in Xenopus oocytes with two electrode 
voltage clamp technique. The inward current evoked by 1mM of the hSGLT1 
substrate  –methyl-D-glucopyranoside was potently reduced. 
Acknowledgements: We thank the Federal Ministry of Education and Research for 
financial support, Project-No. 315371E. 
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AUTODISPLAY OF NADH-OXIDASE YIELDS A CONVENIENT 
SYSTEM FOR COFACTOR REGENERATION 
Kranen, E., Völker, T. Maas, R., Jose, J. 
Institut für Pharmazeutische und Medizinische Chemie, Bioanalytik, Heinrich-
Heine- Universität Düsseldorf 
Surface display of active proteins on living cells provides several advantages for 
biotechnological applications. Among other display systems in bacteria and yeast, 
autodisplay was developed based on the secretion mechanism of the 
autotransporter family of proteins and represents a very elegant way to express a 
recombinant protein on the surface of Escherichia coli. Using such cells as whole 
cell biocatalysts, a substrate to be processed does not need to cross a membrane 
barrier but has free access. Moreover, being connected to a carrier (the cell as a 
biological matrix), the surface displayed protein can be purified, stabilized and 
applied to industrial processes much more convenient than a free molecule.  
Since the application of dehydrogenases in stereochemical synthesis is of growing 
interest, the simple supply of cofactors like NAD+ becomes more and more 
important. One opportunity to regenerate NAD+ from NADH is employing a 
NADH-Oxidase. These group of enzymes catalyses the oxidation of NADH with 
concomitant reduction of oxygen. The primary aim of the present study was to 
combine the advantages of autodisplay with the attractive features of a NADH-
Oxidase from Lactobacillus brevis.
This enzyme in particular recycles NAD+- cofactor by transferring 4 electrons and 
simply forming H2O as a convenient by-product. NADH-Oxidase (NOX) was 
surface displayed on E. coli. Surface display was examined by its accessibility to 
proteases added to whole cells. NADH-concentrations in the presence of cells 
could be measured by the absorption at 340 nm. Testing parameters and enzymatic 
activity were optimized regarding an industrial application of the system. 
The capability of the whole cell biocatalyst for cofactor regeneration in terms of 
stability was investigated. Cells stored at -20°C and -70°C turned out to be stable 
with no loss in activity for about seven weeks. To test its capacity for cofactor 
regeneration, the NOX-biocatalyst was combined with an aldehyde dehydrogenase 
using acetaldehyde as the substrate. In this combined assay, NAD+ could 
successfully be regenerated by the whole cell biocatalyst. Our results show an 
economic and convenient way to regenerate cofactors by simply employing the 
whole cells. 
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AUTODISPLAY OF COMBINATORIAL ANTIBODY LIBRARIES IN 
E.COLI
Thömmes S1, Blasshofer F1, Jose J1
1Institut für Pharmazeutische und Medizinische Chemie, HHU Düsseldorf  
Antibodies offer a high significance in therapy, as antitoxins or for diagnostical 
purposes. Thereby developing new antibody structures establish new applications 
and therapy strategies. One approach for developing new antibodies is to screen 
antibody libraries against a selected target structure. Such libraries consisting of 
variable antibody fragments are constructed by the autodisplay system. The 
autodisplay system is an established tool for expression of recombinant proteins at 
the cell surface of gram-negative bacteria. It is based on the autotransporter 
secretion mechanism, a mechanism naturally evolved for surface translocation of 
toxins or pathogenic factors. [1] Using this system, combinatorial antibody libraries 
of variable antibody fragments were expressed and displayed at the surface of 
E.coli. These antibody libraries were constructed by site-directed mutagenesis of 
the high variable complementary determining region 3 (CDR 3) of a mouse 
monoclonal antibody fragment. In order to gain higher variability, the CDR 3 
sequence of the light chain and the heavy chain were mutated separately. 
Afterwards they were combined in one strain in order to co-express both variable 
regions without being connected via an internal peptidic spacer. The free motility 
within the outer membrane, a unique feature of autodisplay, enabled the formation 
of functional heterodimers. [2] The antibody library was screened against a 
selected target structure by fluorescence activated cell sorting. Binding to this 
target structure, a new antibody structure could be detected and was reanalysed by 
flow cytometer analysis.  
References: 
[1] Jose J, Meyer TF, Microbiol Mol Biol R 2007, 71: 600-19 
[2] Jose J, Park M, Pyun JC (2010), Biosens Bioelectron , 25:1225-1228. 
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AUTODISPLAY OF CYP106A2 AND CYP3A4 IN ESCHERICHIA COLI 
Schumacher, S.1, Hannemann, F.2 Bernhardt, R.2 Jose, J.1
1Pharmazeutische und Medizinische Chemie, HHU Düsseldorf 2Institut für 
Biochemie, Universität des Saarlandes 
Cytochrome P450 enzymes are diverse oxygenation catalysts which can be found 
throughout nature. Even though most of the pharmaceutical industries interest has 
focused on drug development and biotransformation studies, these enzymes can 
also play an important role in the development of other useful chemicals  [1]. At 
the moment there are two different ways to use these enzymes for synthetic 
purposes. They are either purified after recombinant expression and reconstituted 
with an artificial membrane system, or they are expressed and used in a whole cell 
context. Both ways have their limitations. Reconstituted membrane vesicles with 
P450 enzymes are laborious to produce and they are absolutely not suited for 
industrial applications. Using whole cells with intrinsic P450s limits the set of 
substrates to be converted to those which are able to cross membranes [2]. To 
circumvent these obstacles, CYP106A2 and CYP3A4 were expressed on the 
surface of E. coli cells by the use of Autodisplay, an efficient surface display 
system, developed in our group [3]. Cellular surface display allows the use of 
whole E.coli cells with the benefit that no purification or preparation steps of the 
target proteins are needed. The aim of the present project is to investigate whether 
it is possible to express a functional P450 enzyme on the surface of E.coli and in a 
later step conduct whole cell substrate converions . 
For this purpose the genes of both enzymes were amplified by PCR and inserted 
into a plasmid encoding the domains needed for Autodisplay. Cellular surface 
display was prooved by fluorescence microscopy and fluorescence activated cell 
sorting (FACS).  To investigate the functionality of the enzymes conversion assays 
were performed followed by a high performance liquid chromatography analysis. 
Our results indicate, that Autodisplay enables a functional surface display of P450 
enzymes in E. coli. 
[1] F.P. Guengerich, Nat Rev Drug Discov 2002, 1: 359-66 
[2] Y. Li, D.A. Drummond, A.M. Sawayama, C.D. Snow, J.D. Bloom, 
 F.H.Arnold, Nat Biotechnol 2007, 9: 1051-1056.  
[3]  J.Jose, T.F. Meyer, Microbiol Mol Biol Rev 2007, 71: 600-19
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AUTODISPLAY OF 60 KDA/ROSS-A AND DEVELOPMENT OF A 
SURFACE DISPLAY ELISA FOR SLE PATIENT SERA SCREENING 
Braukmann, A.1, Petermann, K.1, Vordenbäumen, S.2, Bleck, E.2, Schneider, M.2,
Jose, J.1
1Pharmazeutische und Medizinische Chemie, HHU Düsseldorf 
2Abteilung für Endokrinologie, Diabetologie und Rheumathologie, HHU 
Düsseldorf
To test human sera on an antibody reaction against a specific antigen enzyme 
linked immunosorbent assay (ELISA) is a common tool. Human 60 kDa Ro/SS-A 
is a well characterized nuclear antigen for autoantibodies which can be found in 
connective tissue diseases such as systemic lupus erythematosus (SLE). As in the 
case of human 60 kDa Ro/SS-A, antigens used in ELISAs are recombinantly 
expressed in E. coli. This means that cells have to be lysed and purification steps 
are needed in order to get the desired protein to set up the corresponding ELISA. 
To avoid these disadvantages human 60 kDa Ro/SS-A was expressed on the 
surface of E. coli using Autodisplay. Autodisplay is an efficient surface display 
system for gram-negative bacteria and is based on the autotransporter secretion 
pathway [1]. The cell surface exposure of 60 kDa Ro/SS-A was verified by 
immunolabeling of whole cells with a polyclonal serum against 60 kDa Ro/SS-A. 
Cells displaying the 60 kDa Ro/SS-A antigen on the surface were used to coat a 96 
well microplate. 60 sera (30 patients and 30 control sera) were screened on a 60 
kDa Ro/SS-A antibody reaction. In order to eliminate antibodies against native E.
coli, human sera were preabsorbed with E. coli cells which were displaying a 
control peptide instead of 60 kDa Ro/SS-A prior to the assay. It turned out that 25 
of the 30 control sera were negative, while 26 of the 30 patient sera showed a 
positive reaction. The new ELISA using E. coli with autodisplayed antigen showed 
a sensitivity of 86.67% and a specificity of 83.33% by a cut-off value of 0.28. 
These values are in the same range as those obtained with a commercially available 
ELISA using purified 60 kDa Ro/SS-A antigen. Our results show that Autodisplay 
provides a simple, rapid and cheap access to human antigens for an accelerated 
development of ELISAs in order to screen human sera against specific antibody 
reactions [2]. 
[1] J. Jose, T.F. Meyer, Microbiol Mol Biol Rev 2007, 71: 600-19 
[2] K. Petermann, S. Vordenbäumen, A. Braukmann, E. Bleck, M. Schneider, 
J. Jose, Anal. Biochem, in press 
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THE NEWLY DISCOVERED MOLYBDENUM ENZYME MARC IS 
INVOLVED IN THE REDUCTION OF N-HYDROXYLATED DNA BASES 
Krompholz, N.1, Havemeyer, A.1, Wahl, B.2, Bittner, F.2, Mendel, R.R.2, Clement, 
B.1
1Pharmazeutisches Institut, Christian-Albrechts-Universität zu Kiel 2Institut für 
Pflanzenbiologie, TU Braunschweig  
The mitochondrial Amidoxime Reducing Component mARC is a newly discovered 
molybdenum containing protein in eukaryotes. The human and plant genome codes 
for two mARC proteins. These 35 kDa proteins form the catalytic part of an
enzyme system consisting of NADH cytochrom b5 reductase, cytochrom b5 and 
mARC. 
The mARC-containing enzyme system is able to reduce the model substrate 
benzamidoxime and several N-hydroxylated prodrugs, like the N-
hydroxypentamidine, N-hydroxymelagatran or guanoxabenz. Furthermore mARC 
is also involved in the detoxification of aromatic hydroxylamines formed as 
metabolites from the antimicrobial agents sulfamethoxazole and dapsone. 
By cellular metabolism or the action of chemical and physical factors N-
hydroxylated base analogues can be produced. In this report, the reduction of the 
toxic and mutagenic N-hydroxylated base analog N-hydroxy-cytosine to the 
corresponding amine cytosine is demonstrated. The activity of the reduction is 
compared with the model substrate benzamidoxime. We found also a high 
extrahepatic reductase activity in pig mitochondria from different organs like 
kidney or thyroid. The detoxification of base analogues could be a first hint on the 
physiological role of the mammalian mARC proteins.
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A NEWLY DISCOVERED HUMAN MOLYBDENUM ENZYME MARC 
- INVOLVED IN DRUG METABOLISM - 
Havemeyer, A.1, Krischkowski, C.1, Plitzko, B. 1, Reichmann, D.2, Bittner, F2,
Mendel, R.R.2, Clement, B.1
1Pharmazeutisches Institut, Christian-Albrechts-Universität zu Kiel 2Institut für 
Pflanzenbiologie, TU Braunschweig  
mARC1 and mARC2 (mitochondrial amidoxime reducing component 1 and 2) are 
newly discovered mammalian molybdenum containing proteins, characterized by a 
so-called MOSC domain. These 35-kDa proteins represent a novel group of 
molybdenum proteins in eukaryotes as they form the catalytic part of a three-
component enzyme system together with the electron transport proteins 
cytochrome b5 and its reductase. In mammals this N-reductive enzyme system is 
located in the outer mitochondrial membrane and it was already shown that it is 
responsible for the reductive activation of several N-hydroxylated prodrugs. Thus 
mARC plays a major role in drug metabolism though its physiological relevance is 
not still clear.
Unusual for drug metabolizing enzymes, we found unexpected high extrahepatic 
mARC-expression and activity levels, for example in kidney and thyroid. The 
determined reductase activities exceed even the hepatic activities, depending on the 
tissue investigated.
In continuation of our drug metabolism studies we show, that probably only the 
mitochondrial and not the microsomal isoform of cytochrom b5 is involved in 
described three component enzyme system. Furthermore the optimal stoichiometry 
of the recombinant enzymes cytochrom b5, its reductase and mARC was 
determined. By this an optimal reconstitution assay was developed which is now in 
routine use. Using this in vitro assay, we can predict if a new prodrug would be 
reduced in vivo.
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BENZAMIDOXIME METABOLISM IN FIVE GENETIC VARIANTS OF 
MITOCHONDRIAL AMIDOXIME REDUCING COMPONENT  
Sierck, G.1, Havemeyer, A.1, Reichmann D.2, Remmler, C.3, Bittner, F.2, Cascorbi, 
I.3, Mendel, RR. 2, Clement, B.1
1Pharmazeutisches Institut, Abt. Pharmazeutische und Medizinische Chemie, 
Christian-Albrechts-Universität zu Kiel 2Institut für Pflanzenbiologie, TU 
Braunschweig  3Institut für experimentelle und klinische Pharmakologie, UK-SH, 
Campus Kiel 
The oral bioavailability of amidines is limited. Therefore, amidoximes were 
introduced as prodrugs to increase bioavailability. They are less basic and not 
protonated under physiological conditions. This results in a sufficient oral 
absorption.
While studying N-reduction of these amidoxime structures, mARC (mitochondrial 
amidoxime reducing component) was recently found in our laboratory. It is the 
fourth human molybdenum containing enzyme and part of a mitochondrial enzyme 
system consisting of mARC, cytochrome b5 and NADH cytochrome b5 reductase. 
This enzyme system is capable of reducing N-hydroxylated compounds.  
The human genome encodes two homologes of mARC, mARC-1 and mARC-2. 
Single nucleotide polymorphisms (SNPs) are known for both variants, but there is 
no data about their functional relevance.  
We investigated four nonsynonymous SNPs in mARC-1 (c.493A>G, c.560T>A, 
c.736T>A and c.739G>C) and one in mARC-2 (c.730G>A) resulting in alterations 
of the encoded amino acid sequence. To determine the frequency of these SNPs 
they have been genotyped by pyrosequencing in a cohort of 334 healthy Caucasian 
individuals. Recombinant enzymes and variants have been expressed in E. coli, and 
N-reduction of benzamidoxime, a model compound for amidoxime prodrugs, has 
been used as activity assay for analyzing possible changes in substrate kinetics. 
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A PHENOTYPIC YEAST ASSAY FOR THE SCREENING OF 
POTENTIAL AQUAPORIN INHIBITORS 
Krenc, D.1, Wu, B.1 Beitz, E.1
1Pharmazeutische Chemie, CAU Kiel  
Aquaporins are membrane proteins that facilitate the diffusion of small uncharged 
solutes across biological membranes. Their selectivity ranges from strict water-
selectivity to permeation by larger molecules such as glycerol. They are found in 
nearly all organisms. In humans, they enable rapid fluid homeostasis throughout 
the body, a prominent example of dysregulation being Diabetes insipidus, in which 
the trafficking of aquaporin 2 is affected. 
The determination of the three dimensional structures of some aquaporins has 
allowed the in silico high-throughput screening of molecules to find potential 
inhibitors. 
We use a phenotypic yeast assay to test the activity of potential aquaporin 
inhibitors. A yeast strain unable to grow on ammonium salts as the sole nitrogen 
source will do so if it is made to express an ammonia-permeable aquaporin. An 
inhibitor is expected to reduce yeast growth. An aquaporin-independent nitrogen 
source, such as an amino acid, serves as a control. Liquid yeast cultures are 
incubated inside microtiter plates and their growth recorded turbidimetrically. 
So far we have tested a small number of potential inhibitors of Plasmodium 
falciparum aquaporin, with no “hit” as yet. Further candidates as well as potential 
inhibitors of human aquaporin 9 will be tested. 
“A yeast-based phenotypic screen for aquaporin inhibitors” 
  B. Wu, K. Altmann, I. Barzel, S. Krehan, E. Beitz; Eur J Physiol 456, 717-720 (2007).  
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DEVELOPMENT OF A CE BASED ASSAY FOR DETERMINATION OF 
HUMAN MYT1 KINASE ACTIVITY 
Alexander Rohe1, Claudia Philipp1, Petar Balgarov1, Christiane Göllner1, Ghassab 
Al-Mazaideh1, Frank Erdmann2, Wolfgang Sippl1, Hans-Hermann Rüttinger3,
Matthias Schmidt1
1 Department of Medicinal Chemistry, Martin-Luther-University Halle-Wittenberg, 
W.-Langenbeck-Str.4, 06120 Halle, Germany 
2 Max Planck Research Unit for Enzymology of Protein Folding, Weinbergweg 22, 
06120 Halle/Saale, Germany 
3 Department of Pharmaceutical Chemistry and Bioanalytics, Martin-Luther-
University Halle-Wittenberg, W.-Langenbeck-Str.4, 06120 Halle, Germany 
The human Myt1 kinase (Myt1hu) is an enzyme that catalyzes the phosphorylation 
of threonine 14 and tyrosine 15 of Cdc2 kinase by transferring the -phosphate 
group from ATP to the hydroxyl group of the threonine, or tyrosine residue of the 
target protein. The inhibitory phosphorylation of Cdc2 is important for timing the 
entry into mitosis (M phase). The transition from G2 to M phase requires the 
activity of M-phase-promoting factor (MPF), which consists of Cdc2 and B-type 
cyclins (cyclin B1). Inhibition of Myt1 kinase is known to cause premature 
activation of Cdc2. Since inhibitors of Myt1 kinase are supposed to kill rapidly 
proliferating cells and interfere with cell cycle checkpoints, such inhibitors are 
potential new targets for drug development and could represent a valuable addition 
to conventional chemotherapy in order to help overcoming resistances. Therefore,
determination of the kinase activity requires development of new methods in 
biochemical research as well as in drug development. Here we describe a CE based 
kinase assay for human Myt1 using a fluorescence detection method for 
determination of phosphorylation status of the amino acids tyrosine and threonine 
in a specific peptide fragment of Cdc2. Under the CE conditions used, the different 
phosphorylated forms of the peptide were rapidly separated within 15 min. The 
quantification of the phospho-peptides enables us to characterize the human Myt1 
kinase activity and also allows conclusions about kinetic parameters. We prepared 
a fluorophore-labeled substrate QKIGEGTYGVVYKC peptide which is a 
fragment of Cdc2 as well as the mono- and bis-phosphorylated forms as references. 
The results were quantified by the areas of the fluorescence peaks and highlight the 
feasibility of this CE method, which is a simple and reliable technique for 
determining and characterizing various enzyme reactions particularly kinase 
enzymes.
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IN VITRO INVESTIGATIONS OF NEW BRANCHED LIPIDS FOR 
LIPOSOMAL GEN TRANSFER 
Kreideweiß P., Folz M., Wölk C., Heinze M., Dobner B., Langner B.
Institute of Pharmacy; Martin Luther University, Wolfgang Langenbeck Straße 4, 
06120 Halle/Saale, Germany 
Three major aspects can characterize an ideal way of delivering DNA into cells. At 
first the transgene should be protected against the degradation through cell 
nucleases. Additionally the gene material has to be transported high efficiently 
through biological membranes and other cytosolic compartments with no or less 
noxious effects. These aspects have been investigated intensively over the past few 
years demonstrating that the finishing line to find the perfect gene transfer method 
could not be already crossed. Two different methods have been taking shape. 
Vector-mediated transfer by liposomes, polysomes and virus particles and the non 
vector-mediated gene delivery by microinjection, biolistic transfection or 
electroporation, which can be summarized as physical and mechanical methods, are 
only few examples for these two different groups. Despite of simplicity of use and 
lack of toxicity non vector-mediated transfer systems suffering from less satisfying 
results for gene expression based on fast DNA degeneration and the restriction of 
application for certain tissues new usefull alternative vector-mediated transfer 
systems had to be developed.  
There are two different vector-mediated delivery systems. Viral vectors are 
characterized by high efficiency for gene delivery but also by the possibility of 
causing strong immune responses and the limitation of transgene-size. Non-viral 
gene transfer with cationic liposomes provides the delivery of genetic material with 
low toxicity and high DNA-loading capacity and reproduceability. 
We use new synthesized cationic lipids with different head and backbone groups 
combined with different helper lipids like DOPE or cholesterol to form lipoplexes 
able to surpass LipofectAmine™, used as reference.Transfection efficieny and 
cytotoxicity were analyzed in serum-free and serum-containing medium with MTT, 
detecting the cell viability, and the ONPG.-assay measuring the galactosidase 
activity after incorpoation of the Lac-Z-gene containing plasmid DNA. 
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SYNTHESIS OF NOVEL CATIONIC LIPIDS WITH MALONIC 
DIAMIDE BACKBONE AND LYSINE CONTAINING HEADGROUP 
Wölk, C., Heinze, M., Kreideweiß, P., Dobner, B., Langner, A. 
Martin-Luther-University Halle-Wittenberg, Institute of Pharmacy, Wolfgang-
Langenbeck-Str. 4, 06120 Halle (Saale), Germany 
Gene therapy based on the introduction of genetic material into cells in order to 
obtain a therapeutic benefit is a promising method for the treatment of genetic 
disorders but also for cancer, cardiovascular, and neurologic diseases. To realise 
the gene transfer special delivery systems (vectors) are used. At present viral gene 
delivery systems dominate in clinical trials. But due to the drawbacks using viral 
vectors which are not negligible the development of non viral gene delivery 
systems is a promising alternative. Non viral vectors are less immunogenic than the 
viral ones and they do not induce cancer. However, the toxicity and the low 
transfection efficiency of these systems are still problematical and require new 
developments and new substances in this field. 
One promising field of non viral gene transfer is the lipofection. Following the 
potent lipids with malonic diamide structure, designed in our research group, we 
synthesized new compounds with an enlarged cationic headgroup structure. It was 
realised by the coupling of the basic amino acid lysine via tris(aminoethyl)amine 
spacer to the malonic acid amide backbone. Furthermore, we varied the length and 
degree of saturation of the alkyl chains attached to the malonic acid structure 
establishing structure-function relationships. The new compounds were tested in 
cell culture systems (LLCPK1 and A549) to investigate the in-vitro transfection 
efficacy and toxicity properties compared to a commercially available transfection 
reagent.
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PREDICTED INTESTINAL PERMEABILITIES VS. IN-VIVO 
AVAILABILITIES OF PEG 400 OLIGOMERS 
Scheicher, B., Spahn-Langguth, H. 
Institute of Pharmaceutical Sciences, Karl-Franzens-University Graz, Austria  
Polyethylene glycols are polymers prepared by polymerization of ethyleneoxide. 
They are of importance as cosolvents in drug preparations. PEG 400 represents a 
mixture of different oligomers with an average molecular weight of 400 and most 
abundant oligomers between mol. wt. 238 and 643. PEG 370 and PEG 414 
oligomers are the major components (19.83 and 19.44 %, respectively). PEGs 
present in the organism, however, appear to exhibit a smaller influence on 
disposition processes than surfactants, such as Tween 80 and Cremophor EL, 
although, e.g., P-gp mediated transport and verapamil metabolism were affected to 
some extent.    
Because of the wide range of molecular sizes it is anticipated that effective 
intestinal permeabilities (Peff) are different and so should be oral absorption. 
Effective permeabilities were estimated for man and rat along with logP values 
employing Gastroplus/ADMET Predictor. In-vivo absolute bioavailabilities are 
based on rat data, where PEG 400 (0.5 ml/kg = 575 mg/kg) was dosed 
intravenously and perorally, respectively, and where no interconversion was 
assumed.   
In-silico Peff ‘s (cm/s x 10^4) for man are ranging from 0.98 (PEG 238) to 3.39 
(PEG 634), for rat from 0.24 (PEG 238) to 1.04 (PEG 634) and correlate with the 
logP values (Moriguchi model) of -1.19 up to -3.49. Kinetic analysis of disposition 
parameters indicates higher initial volumes of distribution with higher molecular 
weight. Systemic availabilities for a p.o. dose increase along with molecular weight 
and lipophilicity from 40.9 % (PEG 238) to 72.4 (PEG 414), but decrease beyond 
414 down to 18.8 % (PEG 643).  
A decrease in the fraction absorbed and true Peff‘s appears to be the most 
reasonable explanation for the discontinuity of the correlation between in-silico 
Peff and in-vivo oral availability.   
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ACTIVATION OF MATRIPTASE-2 IN HEK CELLS IS A TRANS-
MECHANISM
Maurer, E., Stirnberg, M., Gütschow, M. 
Pharmazeutisches Institut, Universität Bonn, D-53121 Bonn, Germany 
Matriptase-2 is a recently identified member of the Type II Transmembrane Serine 
Protease (TTSP) family, an emerging class of cell surface proteases involved in 
tissue homeostasis and several human disorders.1
Matriptase-2 is predominantly expressed in the liver and recently the physiological 
role of matriptase-2 as a key regulator in iron homeostasis was identified.2,3 A 
correlation between mutations in the gene encoding matriptase-2 and iron-
refractory iron deficiency anemia (IRIDA) was found. Furthermore, it was 
demonstrated that a lack of matriptase-2 was linked to the inability to suppress 
expression of hepcidin, the systematic regulator of iron homeostasis. Matriptase-2 
downregulates high levels of hepcidin through proteolytic processing of 
hemojuvelin, a membrane-bound protein promoting hepcidin expression.  
To gain further insight into the activation of matriptase-2, we used HEK293 cells 
stably transfected with cDNA encoding human matriptase-2 and encoding the 
inactive variant of matriptase-2 in which the catalytic triad Ser-753 was exchanged 
for alanine (S753A).4 We could demonstrate that the cleavage of the zymogen to 
form the mature enzyme does not occur if the protease is mutated at the proteolytic 
site. This indicates that matriptase-2 activity is necessary for its own activation and 
that the enzyme undergoes an autocatalytic activation process.
To analyze whether the autoactivation process is catalyzed by the same (cis-
mechanism) or by another (trans-mechanism) matriptase-2 molecule, we co-
transfected HEK293 cells with two vectors, one expressing His-tagged wild type 
matriptase-2 and one the c-Myc-tagged inactive S753A matriptase-2 variant. 
Activation cleavage of the c-Myc-tagged inactive S753A mutant form was 
catalyzed by His-tagged wild type matriptase-2 suggesting a trans-mechanism in 
which matriptase-2 activates one another. 
Thus, our results show that activation of matriptase-2 is an autocatalytical process 
via a transactivation mechanism. 
1 Velasco et al. 2002, J. Biol. Chem. 277, 37637-37646 
2 Finberg et al. 2008 Nat. Genet. 40, 569-571 
3 Du et al. 2008, Science 320, 1088-1091 
4 Stirnberg et al. 2010, Biochem. J., in press 
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QUANTITATIVE DETERMINATION OF XANTHURENIC ACID IN 
ERYTHROCYTE LYSATES USING LC/ESI/MS/MS 
Völker, M.1, Kuehn, A.2, Pradel, G.2, Unger, M.1
1Institute of Pharmacy and Food Chemistry and 2Research Center for Infectious 
Diseases, University of Würzburg, Germany; 
The unicellular malaria pathogen Plasmodium falciparum is transmitted to its 
human host by blood feeding female mosquitoes of the genus Anopheles. Hence, 
development of the parasites in the mosquito represents an indispensable 
prerequisite for completion of the parasite’s life cycle. It starts with the uptake of 
erythrocytes containing mature male and female sexual precursor cells, the 
gametocytes, by the blood-feeding mosquito. In the mosquito midgut gametocytes 
are activated both by a drop in temperature and by presence of the mosquito-
derived molecule xanthurenic acid (XA). The activation of gametocytes leads to 
egress from the erythrocyte and the subsequent formation of micro- and 
macrogametes, which then undergo fertilization. It still remains unclear, which role 
XA plays during signal transduction leading to gametocyte activation. Here we 
report that XA interacts with red blood cells independent of infection and 
preliminary data suggest a transport of this molecule across the erythrocyte 
membrane. In order to investigate the factors involved in the erythrocytic uptake 
mechanism of XA, we measured XA concentrations in erythrocyte lysates after 
incubation of erythrocytes with different concentrations of XA with and without 
substrates of amino acid transporters. For this purpose, we developed a liquid 
chromatography tandem mass spectrometry method with electrospray ionization 
(LC/ESI/MS/MS) which allowed the precise and fast quantitative determination of 
XA and the internal standard kynurenic acid (KA) in erythrocyte lysates. Both XA 
and KA were measured in the positive ESI mode and linearity of the reversed 
phase LC/ESI/MS/MS method for XA was between 0.5 and 250 ng/ml.  
N COOH
OH
OH
N COOH
OH
Xanthurenic acid Kynurenic acid
C120
REVIEW AT A GLANCE: DIFFERENT APPROACHES TOWARDS 
PRECISE PROTEIN QUANTIFICATION 
Deng, X., Wätzig, H.
Pharmazeutische Chemie, TU Braunschweig  
Precise protein quantification is still challenging. Several approaches have been 
introduced during the last years, e.g. mass spectrometry (MS), gel electrophoresis 
(GE), capillary electrophoresis (CE), microfluidics. In general, a technical error of 
up to 20% is assumed. However, especially for quality control and for proteomic 
researches high precision is essential. We compare the most common techniques 
for protein analyses in term of reproducibility. In addition, the advantages and 
limitations of each method are presented. In recent publications, low percent 
relative standard deviations (RSD%s) of <3% were reported for protein 
quantification by MS. Moreover, by one-dimensional GE RSD%s of 1.5 - 3% were 
achieved under favourable circumstances. More studies have to be done to make 
precise protein quantification feasible.  
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A STUDY OF INFLUENCES ON PROTEIN PROPERTIES USING 
AFFINITY CAPILLARY ELECTROPHORESIS 
Redweik, S., Deng, X., Xu, Y., Wätzig, H. 
Pharmazeutische Chemie, TU Braunschweig 
Understanding the unique properties of proteins is essential. However, the 
knowledge about their physico-chemical properties and their real affecting size is 
still insufficient. Recently, findings that small proteins do not fit into large pores 
have been reported [1]. Their hydrodynamic radius can be measured by various 
methods, e.g. by Dynamic Light Scattering (DLS) or Atomic Force Microscopy 
(AFM) where similar values for the radius are achieved. Because this 
hydrodynamic radius is much smaller than the above mentioned pores there must 
be an expanded affecting size of the proteins. Therefore the influence and behavior 
of the solvent layers and of various reagents on protein properties have to be 
thoroughly discussed. Affinity Capillary Electrophoresis (ACE) was used to 
measure the influences of various reagents (e.g. different salts) on proteins. By 
varying the reagent concentration in the buffer solution a mobility shift can be 
observed as a result of complexation between the analyte and the protein. These 
changes in electrophoretic mobility can also be used to determine the binding 
constants of the reagents to the proteins. 
 [1] Edward Yeung, presentation on HPLC 2009 in Dresden    
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DRUG ANALYSIS IN THE PRESENCE OF MATRIX PROTEINS: 
VALIDATION OF A BLOOD-BRAIN BARRIER MODEL BY DIRECT-
INJECTION MICELLAR ELECTROKINETIC CHROMATOGRAPHY 
Sascha Kühne1, Christopher Untucht2, Michael Steinert2, Hermann Wätzig1
1Pharmazeutische Chemie, TU Braunschweig 2Mikrobiologie, TU Braunschweig 
Capillary electrophoresis (CE) as a well-suited analytical technique especially 
when proteins are involved has established in clinical laboratories for more than a 
decade. A micellar electrokinetic chromatography (MEKC) method with direct 
sample injection has been developed in order to characterize and validate a blood-
brain barrier (BBB) model by testing drug permeability. An aqueous stock solution 
of each drug (acetaminophen, caffeine, carbamazepine, cimetidine, indometacin 
and propranolol) was diluted with culture medium (Quantum 286, PAA Laborato-
ries, Pasching, Austria) to a final concentration of 0.1 mg/mL and transferred to the 
BBB model. After six hours, the samples were analyzed by CE without any further 
sample pre-treatment. All drugs are stable at the test conditions. Proteins from the 
culture medium did not impede the analysis, as the drug-protein interactions were 
reliably suppressed by high concentration of sodium dodecyl sulfate (200 mM) in 
the running buffer (borate buffer, 60 mM, pH 10.0). A standard fused-silica capil-
lary (ID: 50 μM, ltot: 50 cm, leff: 42 cm) has been cleaned by a mixture of equal 
parts of running buffer and isopropanol after each run. This rinsing reagent could 
very effectively remove adsorbed proteins from the capillary wall and avoid capil-
lary blocking, thus the capillary could be continuously used for more than a month. 
As the result of a careful optimization, a voltage of 30 kV was found to be the most 
suitable as it allows short analysis time as well as a sharp separation. The limits of 
detection were approximately 10 ng/mL.    
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HIGH PERFORMANCE SIZE EXCLUSION AND STRONG ANION 
EXCHANGE CHROMATOGRAPHY FOR PROTEIN ASSAYS 
Grotefend, S.1, Kaminski, L.1, Wätzig, H.1
1Pharmazeutische Chemie, TU Braunschweig 
The number of protein based pharmaceuticals, such as monoclonal antibodies 
(mab), increases steadily, since they were introduced as therapeutic substances. 
Undoubtedly, one main pillar of the quality control (QC) for these biologicals is an 
unfailing method for quantitative analysis of the API. Classic quantification 
methods for proteins (e.g. Bradford assay or gel electrophoresis) may be sufficient 
for bioanalytical assays but unfortunately they are inappropriate for QC purposes 
due to their low selectivity and low precision, respectively. Therefore intention of 
this work is to present two reliable and inexpensive alternatives. One of these is 
High Performance Size Exclusion Chromatography (HP-SEC / SE-HPLC). It will 
be shown that the application of the non-ideal SEC mode [1] not only allows for 
increased efficiency but also for precise quantification of the model proteins 
Ovalbumin and Myoglobin. The second method is Strong Anion Exchange (SAX). 
It allows for very fast separation and quantitation (approx. 5 min) of the model 
proteins Ovalbumin, Myoglobin and BSA. Both methods yield data of high 
precision (about 1% RSD each for retention times and peak areas) and can achieve 
low quantitation limits (< 15μg/ml for SAX and < 4μg/ml for SEC), depending on 
the used detector (two different UV detectors were used in these experiments). In 
the following, both methods will be compared in terms of precision, practicability, 
effort during sample and mobile phase preparation, selectivity, overall results and 
total analysis time (including post processing of raw data).     
[1] Kopaciewicz, W. and Regnier, F.E. Anal. Biochem. 126 (1982) 8 – 16 
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NANOLIQUID CHROMATOGRAPHY/MASS SPECTROMETRY OF 
NATIVE AND BIOTINYLATED GLYCANS ON A POROUS 
GRAPHITIZED CARBON-CHIP 
Bank, S.1, Kapková, P.1
1 Lehrstuhl für Pharmazeutische Chemie, Universität Würzburg 
About 50% of all proteins are supposed to be glycosylated and they seem to be 
involved in all kinds of cell processes. Depending on the structure, glycoproteins 
do not only participate in physiological activities. Moreover, they are associated 
with pathological pathways as well. Therefore, there is a great interest in 
identifying glycans, particularly, in changes in the glycan structure, which are 
presumed to occur at diseases like cancer, immune deficiencies, etc.  
Consequently the improvement of analytical methods and development of 
instrumentation in order to produce reliable and specific data about the protein 
glycosylation is very important. This is challenging due to both the high variety 
and complexity of sugar chains and small sample amounts.  
In this work, glycans from different glycoproteins have been analyzed by means of 
a nano-LC/Chip-mass spectrometry. 
Ovalbumin, ribonuclease from bovine pancreas (RNase B) and alpha-1-acid 
glycoprotein (AGP) were deglycosylated with PNGase F and extracted 
carbohydrates were derivatized with 2-AB (2-aminobenzamide) and BACH 
(biotinamidocaproyl hydrazide). Then, analysis was performed with a nano-
LC/ESI-ion trap system equipped with a chip cube (Agilent). Separation was 
acquired on a porous graphitized carbon chip with methanol and water as solvents.  
With ovalbumin, RNase B and AGP, all three types of N-glycans (hybrid, high-
mannose, complex) were analysed in native form and as 2-AB- and BACH- 
derivatives. In particular, the fragmentation behaviour upon MS/MS was observed. 
Through identifying the generated fragments of the sugar chains it is possible to 
draw conclusions about the original glycan structure. Especially, ring cleavages are 
of avail as they provide more specific structural information. Here, the number of 
these cleavages was increased by means of derivatization. Particularly, the BACH-
derivatization showed a high occurrence of ring fragments in comparison to the 
native and AB-derivatized carbohydrates. Implicating the capability of BACH to 
link with avidin/streptavidin, it is clearly a great tool for the analysis of unknown 
glycans. 
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VALIDATION OF A NEW HPLC-UV METHOD FOR THE 
SEPARATION OF METHIONINE AND ITS RELATED 
SUBSTANCES. 
Bäumert J., Holzgrabe U. 
Institute of Pharmacy and Food Chemistry, University of Wuerzburg, Am 
Hubland, 97074 Wuerzburg 
L-Methionine is used for pharmaceutical applications and DL-methionine 
for supplementation in animal food. Currently many HPLC methods are 
known to quantify methionine. Most of the methods work with a 
derivatization of the primary amino function. No selective method is 
available to detect the methionine, the L-methionine sulfone and the L-
methionine sulfoxide, the N-acetyl-methionine and the N-acetyl-methionyl-
methionine dipeptides in one run. The TLC method of the European 
Pharmacopoeia applies ninhydrine as derivatization reagent and the 
maximum limit for each impurity is set at 0.5% in L-methionine and 0.2% 
in DL-methionine batches. In this investigation a new and robust HPLC-UV 
method to separate methionine from its related substances has been 
developed and validated. The separation of the afore-mentioned impurities 
was achieved by means of a Phenomenex C12 Max-RP column using a 
mobile phase composed of aqueous 25mM heptane sulfonic sodium salt 
solution and acetonitrile = 85:15. The pH of the water phase was adjusted 
by phosphoric acid 85% to 2.0. Flow rate of the mobile phase was set at 1.5 
ml/min and the UV- spectrophotometer was set at 190 nm. The column was 
thermostated at 25 °C. Methionine and all impurities could be baseline 
separated. Good linearity for all analytes was achieved in the range of 
0.005% to 1%. The sum of impurities for all the examined batches was 
0.8%. Stability testing revealed that the solutions for the HPLC analysis 
have to be prepared freshly and protected from sunlight and heat. 
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TESTING OF ULTRAFILTRATION CELLS MADE OF 
POLYVINYLIDENE FLUORIDE FOR DETERMINATION OF PROTEIN 
BINDING OF QUATERNARY AND BISQUATERNARY COMPOUNDS  
Hörst, A.1, Albert, C.2, Holzgrabe, U.1 Bringmann, G.2
1 Lehrstuhl für Pharmazeutische Chemie, Universität Würzburg 2 Lehrstuhl für 
Organische Chemie, Universität Würzburg 
The extent of protein binding is one of the key parameters in both 
pharmacodynamics and pharmacokinetics. High protein binding extend the risk of 
drug interaction because of displacement of other drugs especially one with also a 
high protein binding and a low therapeutic index. Thus new developed drugs need 
to have a low protein binding. In our research group we use the continuous ultra 
filtration developed by Kinawi and Teller and latterly optimized by Heinze, Albert 
and Holzgrabe for his purpose. Since new developed quaternary and bisquaternary 
compounds as new antiinfectives couldn’t be measured by this method, further 
improvements were needed. As the tested compounds eluted too slow through the 
ultra filtration cell it was suggested that there is a strong binding of the compounds 
to the cell material poly(methyl methacrylate). To reduce the unspecific binding, 
surface coating and other cell materials were tried. Surface coating was not a 
suitable method because of damages to the cells by the coating chemicals. So 
polyflurated plastics as cell material were tested. Polytetrafluoroethylene showed 
good chemical indifference but the material was to supple so the cells wouldn’t last 
long. Finally polyvinylidene fluoride was found to be most suitable, concerning to 
its hardness and chemical indifference. Eventually the quaternary compound GB-
AP-05, which wasn’t measurable with poly(methyl methacrylate) cells, could be 
successfully tested by using the cells made of polyvinylidene fluoride. 
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TRIAMTERENE IN LIVER DYSFUNCTION: FAST ASSAY FOR 
HYDROXY METABOLITE-TO-DRUG RATIO IN PATIENT URINE BY 
CAPILLARY LC  
Tripolt, C., Schmid M.G., Plöschberger, K., Spahn-Langguth, H. 
Institute of Pharmaceutical Sciences, Karl-Franzens-University Graz, Austria 
As for caffeine and lidocaine a strong dependence of the ratio of hydroxyl 
metabolites to parent triamterene and the stage of liver disease was detected. With 
respect to its therapeutic use, triamterene is a potassium-sparing diuretic that is 
used for antihypertensive treatment. It acts through inhibition of the epithelial 
sodium channel (SCNN1) located at the luminal side of the collection tubule. 
Being a CYP1A2 substrate with no alternative clearance route triamterene is para-
hydroxylated and this is restricted to the liver. Hxdroxylation as rate-limiting step 
in triamterene kinetics in man is followed by a rapid sequential step, which is 
formation of the respective sulfate conjugate.   
In order to estimate liver function through triamterene clearance routinely as a 
contributional factor in liver differential diagnosis, availability of a quick, reliable, 
and cost-efficient procedure is essential. 
A suitable CLC-stationary phase was a 20 cm capillary with an inner diameter of 
200 μm and packed with RP-18 coated 5μ-particles. With a mobile phase 
consisting of acetonitrile/water pH3.2 containing dodecylamine (12/88, v/v) and 
delivered at a flow rate of 5 μl/min total analysis time was below 10 min. Capacity 
factors were 1.42 and 3.91 for triamterene and its major metabolite. Detection of 
the analytes in the eluate was via fluorescence measurement at 365/449 nm. With 
an injection volume of 80 nl (direct injection of urine supernatant) LOQ was 
appropriate for assaying triamterene and its major metabolite in patient urine. 
Elution order was reverse without dodecylamine addition. In this case the 
respective capacity factors were 4.90 and 2.54.  
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AGING OF DRUG PRODUCT MATRIX AS A POTENTIAL CAUSE OF 
MASS IMBALANCE 
Schulz, K.1,2, Oberdieck, U.1, Iffert, B.1, Weitschies, W.2
1 Bayer Schering Pharma AG, GDD, Global Pharmaceutical Development, 
Analytical Development PLIII, Berlin 
2 Department of Biopharmaceutics and Pharmaceutical Technology, Ernst Moritz 
Arndt University, Greifswald
An important quality feature of stability testing of drug products is mass balance 
[1]. One possible cause of mass imbalance is the cascading degradation of the drug 
substance, eventually leading to the formation of degradation products with 
concentrations below the limit of detection. The question whether the aging of the 
formulation matrix influences the recovery of substances in low concentrations and 
therefore the mass balance, has so far not been considered. However, this is of 
particular relevance in case of the detection of genotoxic substances in trace 
amounts. Complete recovery of these substances – as well as of any other relevant 
degradation product – is desirable at any time of the storage period. The objective 
of the present work was the investigation whether the aging of matrix simulated by 
various stress tests influences the recovery of genotoxic substances in trace 
amounts. The genotoxic substance 4-chloroaniline (PCA) was used as a model 
substance. In a first step, an analytical method was developed, allowing the 
identification of PCA in commercially available tablets with proguanil 
(Paludrine®), and the determination of PCA with low limits of detection and 
quantification (LOD and LOQ). A HPLC method was developed using an Ascentis 
Express C18 analytical column. The mobile phase consisted of acetonitrile and 
phosphate buffer (pH 7). For chromatographic separation a gradient was used. An 
ultraviolet spectrum, a fluorescence spectrum and a mass spectrum were performed 
to identify PCA. For PCA quantification, the HPLC method was coupled with a 
fluorescence detector, using external calibration. LOD and LOQ of PCA were 
found to be 0.003 μg/mL and 0.01 μg/mL, respectively.  
[1] R. Kirsch, Stabilität von Norethisteron® Tabletten unter Berücksichtigung der  
Massebilanz, Diss., Friedrich-Schiller-University, Jena, 2005 
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INFRARED THERMOMETRY IN CAPILLARY ELECTROPHORESIS 
Cianciulli, C.1, Wätzig, H.1
1Institut für Pharmazeutische Chemie, TU Braunschweig, Beethovenstr. 55, 
38106 Braunschweig, Deutschland 
Capillary electrophoresis (CE) is a well established and frequently used analysis 
technique in the development and quality control of pharmaceuticals.  
An unavoidable problem in CE is the generation of heat depending on the applied 
voltage and the resulting electric current flowing through the electrolyte. The 
arising temperature in a CE system has effects on the stability of migration times 
and peak areas.  
Infrared thermometry is used to monitor the Joule heating. The thermometer 
collects the temperature data of surface areas. So the temperature is measured on 
the outside of the capillary. The received data is compared to temperature data 
calculated with different methods by [1] and [2]. The data of the infrared 
thermometer has to be corrected because the used methods calculate the 
temperature inside the capillary. The results suggest that the temperature of a CE 
system should be monitored during laboratory routine. In addition, the maximal 
suitable power per meter is estimated.  
[1] Evenhuis, C. J.; Guijt, R. M.; Macka, M.; Marriott, P. J.; Haddad, P. R: 
Electrophoresis, 26, (2005), S. 4333–4344. 
[2] Knox, J. H.; McCormack, K. A.: Chramatographia, 38, (1994), 3/4, S. 
207–214. 
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BIODISTRIBUTION STUDIES ON GOLD COORDINATION 
COMPOUNDS BY TXRF SPECTROSCOPY 
Meyer A.a, Grotefend S.a, Gross A.b, Wätzig H.a, Ott I.a
aInstitute of Pharmaceutical Chemistry, Technische Universität Braunschweig, 
Beethovenstr. 55, 38106 Braunschweig, bBruker Nano GmbH,  
Schwarzschildstr. 12, 12489 Berlin 
X-ray fluorescence (XRF) appears when atoms are irradiated with short 
wavelength X-rays. Due to the fact that emitted fluorescence photons are 
characteristic in wavelength and energy, a specific elemental analysis and 
quantification using XRF as a non-destructive analytical technique is possible even 
in complex multielement matrices. The classical XRF is not suitable for trace 
element analysis in a cellular environment because of strong matrix effects. 
Technical modifications of the excitation mode established total reflection X-ray 
fluorescence (TXRF) spectroscopy as a new analytical technique initially applied 
to environmental research [1].  
As a promising alternative method for biodistribution studies we compared TXRF 
spectroscopy with the well established atomic absorption spectroscopy (AAS) 
aiming to identify advantages and disadvantages of both methods. For this purpose 
gold coordination compounds were measured in aqueous and biological 
environments and their biodistribution was evaluated. The current results of this 
ongoing project will be presented. 
[1] Elemental Analysis of Environmental Samples by Total Reflection X-Ray 
Fluorescence: a Review, R. Klockenkämper, A. von Bohlen, X-Ray Spectrometry 
25, (1996) 156 
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A FACILE NOVEL SYNTHESIS OF FINGOLIMOD ANALOGUES 
Zivkovic, A.1 and Stark, H.1
1 Johann Wolfgang Goethe University, Institute of Pharmaceutical Chemistry, 
ZAFES/LiFF/OSF/CMP, Frankfurt/Main,  
The role of sphingolipids in chemical biology as important modulators of diverse 
(patho)physiological functions has raised increased therapeutic interest. Within the 
sphingolipid pathways different important potential targets such as S1P receptor 
subtypes, sphingosine kinases, ceramide synthases are actually widely explored. 
Fingolimod (FTY720, Gilenia®) as parent prodrug compound for S1P receptor 
agonist is the most advanced drug in this group. 
Numerous related synthetic approaches for FTY720 have been described in 
literature and in patents, but in our hands none of those offered preparative 
approaches was practical enough for the synthesis of FTY720 or its derivatisation. 
For the development of FTY720 derivatives as a pharmacological tool its oxy-
analogue (R)-AAL can be taken as comparable lead structure. The goal of our 
approach was to provide easy access to the aromatic ether analogues to FTY720 
(O-FTY). 
We have developed a new efficient multigram synthesis of the oxy-FTY720 
analogue in four steps without any chromatographic separation and with overall 
yield of over 50%.1
This study was kindly supported by LOEWE Schwerpunkte LiFF and OSF. 
Literature:
[1] A. Zivkovic and H. Stark, Tetrahedron Letters 2010, 51, 3169-3171.  
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STRUCTURE-ACTIVITY RELATIONSHIP STUDIES ON 1-INDOL-1-
YL-PROPAN-2-ONES AS DUAL INHIBITORS OF CPLA2 AND FAAH 
Zahov, S., Hess, M., Schulze Elfringhoff, A., Lehr, M. 
Institute of Pharmaceutical and Medicinal Chemistry,  
University of Münster, Hittorfstrasse 58-62, D-48149 Münster 
 
In mammalian organism, derivatives of arachidonic acid play important roles as 
algesic and pro-inflammatory as well as analgesic and anti-inflammatory media-
tors. On the one hand, oxidation products of arachidonic acid such as prostaglandin 
E2 and leukotriene B4 formed via the arachidonic acid cascade are involved in the 
pathophysiology of pain and inflammation. On the other hand, the arachidonic acid 
amide anandamide generated via the endocannabinoid pathway has analgetic and 
anti-inflammatory properties. The key enzyme in the formation of oxidized deriva-
tives of arachidonic acid is cytosolic phospholipase A2 (cPLA2). An important 
enzyme in the endocannabinoid metabolism is fatty acid amide hydrolase (FAAH), 
which rapidly inactivates anandamide by cleavage to arachidonic acid and ethanol-
amine. Therefore, inhibitors of both cPLA2 and FAAH may represent new agents 
against pain and inflammation. 
 
  
 
 
 
 
1
 
Recently we have found that the indole-5-carboxylic acid derivative 1 is a dual in-
hibitor of cPLA2 and FAAH. In course of structure-activity relationship studies, 
the indole part of the molecule has been varied.[1] In further studies we replaced the 
carboxylic group of 1 by bioisosteric residues such as amide, sulfonamide and 
different heterocycles. The results of these structural variations of 1 on inhibit-tory 
potency against both enzymes are presented.   
 
Literature: 
[1] Forster, L.; Ludwig, J.; Kaptur, M.; Bovens, S.; Schulze Elfringhoff, A.; 
Holtfrerich, A.; Lehr, M. Bioorg . Med. Chem. 2010, 18, 945-952 
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A NOVEL PHARMACOLOGICAL TOOL: FLUORESCENT 
CELECOXIBDERIVATIVES 
Stark, H.1, Lill, A.1, Deckmann, K.2, Proschak, E.1, Schiffmann, S.2, Grösch, S.2
1 Goethe University, Institute of Pharmaceutical Chemistry, 
ZAFES/LiFF/OSF/CMP, Frankfurt/Main,  
2 Goethe University, Institute of Clinical Pharmacology, Frankfurt/Main 
Celecoxib, 4(5ptolyl3(trifluoromethyl)1Hpyrazol1yl)benzenesulfonamide, a 
cyclooxygenase-2 (COX-2) selective inhibitor, belongs to the class of non-steroidal 
anti-inflammatory drugs (NSAIDs). By inhibiting the COX-2 isoform only – 
celecoxib shows an IC50 value of 0.87 μM – the gastrointestinal side-effects of 
traditional NSAIDs are faded out. Despite this benefit of COX-2 inhibitors they 
still reveal serious side-effects on the cardiovascular system[1,2].
Beside the anti-inflammatory, analgesic and antipyretic effects, celecoxib also 
shows COX-dependent and COX-independent anti-carcinogenic effects, which 
actually are far from being understood.[2] Surprisingly the concentrations necessary 
for these effects are 20-times lower in in-vivo than in in-vitro assays, which is 
potentially due to celecoxib accumulation in distinct cell compartments.[2] With use 
of fluorescence-labeled celecoxib derivatives as novel pharmacological tools the 
accumulation hypothesis and the interaction partners of celecoxib within cancer 
cells should be studied and tested. 
Based on known structure-activity-relationships (SAR) and molecular docking-
experiments on celecoxib and related compounds, a set of different fluorescence-
labeled celecoxib derivatives was designed, synthesized and tested for activity.  
1-(4-Sulfamoylphenyl)-5-p-tolyl-1H-pyrazole-3-carboxylic acid was successfully 
coupled with dansylated linker to yield fluorescence-labeled celecoxib analogues 
with substitutions at the position of the former trifluoromethyl group. In addition to 
that, the fluorophore was connected with the former tolyl group via carboxamide 
and ether functionalities, respectively.  
Preliminary experiments with these novel pharmacological tools showed that they 
are able to pass the cell membrane and, upon excitation, can be visualized within 
the cell. Further data on cellular location are awaited. 
Acknowledgements: Kindly supported by LOEWE Schwerpunkte LiFF and OSF. 
Literature: 
[1] S. Grösch et al., J Natl Cancer Inst 2006, 98, 736.  
[2] I. Tegeder, G. Geisslinger, Naunyn-Schmiedeberg's Arch Pharmacol 2006, 373, 1. 
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AZA-ANALOGUES OF DIBENZEPINONES AS P38 MAP KINASE 
INHIBITORS
Fischer, S., Laufer, S.
Pharmazeutische Chemie, Universität Tübingen 
Inhibition of p38 MAP kinase is a valid approach for the treatment of inflammatory 
and autoimmune diseases. 
Prototype inhibitors of p38 MAP kinase like SB 203580 are well investigated lead 
compounds but often suffering from high toxicity and poor selectivity, making 
novel chemotypes necessary. 
Distinctly different templates are linear binders, e. g. benzophenones or 
ketopyrazoles. Starting from benzophenone-lead compounds (Ottosen et al., 2003) 
our hypothesis was to design more rigid structures by linking the two aromatic 
systems, which led us to substituted dibenzepinones. 
Although these compounds showed high potency in p38 enzyme assays, they are 
highly lipophilic and poorly soluble in aqueous media and may therefore suffer 
from low bioavailability. Our strategy was to improve aqueous solubility by using 
more hydrophilic scaffolds. Better physicochemical properties could be achieved 
by synthesis of aza-analogues of above-mentioned dibenzepinones compromising 
affinity to the enzyme.  
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5-LIPOXYGENASE INHIBITORS WITH THIAZOL-4-ONE SCAFFOLD 
Barzen, S.a, Rödl, C.a, Hofmann, B. a, Zivkovic, A. a, Schneider, G. a, Steinhilber, 
D. a , and Stark, H. a,
aJohann Wolfgang Goethe University, Institute of Pharmaceutical Chemistry, 
ZAFES/LiFF/OSF/CMP, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany. 
Lipoxygenases (LO) play a pivotal role in the metabolism of arachidonic acid (AA) 
with their catabolic pathway into leukotrienes (LT). One of the most important 
enzymes here is the 5-lipoxygenase (5-LO). Due to the key function  of LTs on 
inflammation1 and cancer2, the inhibition of their effects moved into the focus of 
several areas of research. At this moment, there are only two drugs admitted for 
therapy: Montelukast (Singulair®), an antagonist of CysLT1 receptors, and Zileuton 
(Zyflo®), a direct inhibitor of the 5-LO. Both drugs are admitted for the therapy of 
asthma bronchiale. Because of further medical need for alternative treatment 
options, the development of new direct inhibitors of the 5-LO is of permanent 
interest. By the inhibition of 5-LO the LT-formation is prevented on an early stage. 
Based on recently published lead stuctures3 we designed and synthesized new 
derivatives of compounds with a central thiazol-4-one-moiety as direct inhibitors 
of 5-LO. The thiazolone scaffold is substituted on its 2- and 5-positions as eastern 
and western part, respectively. The compounds could be prepared in an one-pot-
synthesis procedure from p-methoxybenzaldehyde, thioglycolic acid and 
differently substituted benzonitriles4. In these derivatives the western and the 
central part remained constant. The eastern part has been varied with different 
electron-releasing and -withdrawing moieties as well as with small and larger 
substituents of different steric and lipophilic properties. The results of the activity 
assays using a cell-free 5-LO assay and on whole cells (PMNL cells)3 showed 
highly comparable inhibitory potencies despite the large structural variations on the 
substituents. The IC50 values ranged from 0.09 to 0.65 μM in the cell-free assay 
and from 0.40 to 0.86 μM in the whole cell assay. It is concluded that large 
structural variations as substituents on the eastern part are accepted, but that they 
do not give great enhancement of inhibitory affinity at 5-LO.     
References:               Supported by LOEWE LiFF and LOEWE OSF funding grants. 
1Rådmark et al., TrendsBiochemSci 2007, 32, 332-41.        2Wang et al., Nat Rev Cancer 2010, 3, 181-193. 
3B. Hofmann et al., ChemMedChem 2008, 3, 1535-38.        4E.M. Zayed et al., Pharmazie 1985, 3, 194-7.
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pH-SENSITIVE CISPLATIN LIPOSOMES AS A TOOL FOR BYPASSING 
CHEMORESISTANCE IN OVARIAN CANCER CELLS 
Stölting, D.P., Krieger, M.L., Jaehde, U., Bendas, G.
Pharmaceutical Department, University of Bonn, D-53121 Bonn, Germany 
Cisplatin is a well-established cytostatic agent in the therapy of ovarian carcinoma. 
However, the therapeutic application and benefit of ciplatin is often restricted by 
the development of chemoresistance.  
A recent study reported on enhanced cisplatin uptake and cytotoxicity in resistant 
ovarian cancer cells by a liposomal formulation [1]. However, the intracellular 
release of the drug from the liposomes appeared to be a critical limitation. To 
further raise intracellular platinum levels, it is required to improve the mechanism 
of release. pH-sensitivity of liposomes by acid-labile bilayer composition is an 
already accepted approach [2]. 
The aim of this study was to prepare pH-sensitive cisplatin containing liposomes 
and to investigate their cytotoxicity in two sublines of ovarian cancer cells 
(A2780), sensitive and cisplatin-resistant ones. 
pH-sensitive liposomes were prepared from a DOPE/Chems (7/3) lipid 
composition. pH-sensitivity of these liposomes was confirmed by fluorescent 
marker release in dependence on pH. In order to induce an endocytotic uptake of 
the liposomes by transferrin-receptors, holotransferrin was coupled onto the 
terminal ends of a PEG anchor (1 mol%). 
The platinum uptake by both cell lines was analyzed by flameless AAS for 
different incubation times between 0.5 h and 24 h and related to total protein 
amounts. It was evident that platinum accumulated in both cell lines in a nearly 
similar extent, which exceeded the level of the free drug in the resistant cells 
clearly. However, the transferrin targeting was of minor importance for the drug 
uptake. The findings were correlated with cytotoxicity data based on the MTT-
assay at different time points (24 h, 48 h, 72 h). The comparison of the pH-
sensitive with conventional cisplatin liposomes or the free drug strongly 
underscores the potential of pH-sensitive liposomes to overcome platinum 
resistance.  
[1] Krieger ML. et al., Overcoming cisplatin resistance of ovarian cancer cells by 
targeted liposomes in vitro. Int J Pharm., 2010; 389: 10-17 
[2] Peschka-Süss R, Schubert R, Liposomes A Practical Approach, 2nd Edition, 
Oxford: Oxford University Press; 2003; 11: 305-318 
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GOLD(I) CARBENE COMPLEXES: A  CLASS OF COMPOUNDS WITH A 
HIGH BIOLOGICAL POTENTIAL 
Rubbiania R., Kitanovicb I., Alborziniab H., Canb S., Wolberc G., Wölflb S., Otta I. 
a) Institute of Pharmaceutical Chemistry, Technische Universität Braunschweig, 
Beethovenstr. 55, 38106 Braunschweig, Germany; b) Institut für Pharmazie und 
Molekulare Biotechnologie, Ruprecht-Karls-Universität Heidelberg, Im 
Neuenheimer Feld 364, 69120 Heidelberg, Germany c) Institute of Pharmacy, 
Freie Universität Berlin, Königin-Luise-Str. 2+4, 14195 Berlin, Germany  
r.rubbiani@tu-bs.de 
With the development of Auranofin the interest in the anticancer properties of gold 
complexes raised. However, remaining problems (such as the strong 
metabolization of Auranofin) did not allow a proper drug-design. Thioredoxin 
reductase (TrxR), an ubiquitary NADPH-dependent flavoenzyme, is nowadays 
considered as the main target for gold complexes. TrxR plays a central role in cell 
pathophysiology (proliferation, apoptosis, and metastasis) and is overexpressed in 
tumor cells. [1,2] Based on a molecular modelling study the synthesis of a series of 
disubstituted gold(I) carbene complexes and their intensive biological investigation 
was performed. The results indicated a strong activity on TrxR, selectivity against 
glutathione reductase (GR) and a remarkable stability against inactivation by 
glutathione. The target compounds 1a-4a (Fig.1) demonstrated interesting 
cytotoxic properties, induced apoptosis, dysregulated the cell metabolism, 
enhanced the formation of reactive oxygen species (ROS), reduced the oxygen 
consumption and altered the cell morphology.  
N
N
R
R
Au Cl 1a: R = methyl2a: R = ethyl
3a: R = benzyl
4a: R = diphenylmethyl
References                                                                                
1. S. Gromer et al., Med. Res. Rev. 2004, 24(1), 40-89
2. I. Ott.,Coord. Chem. Rev. 2009, 52(3), 763-770
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CYTOTOXICITY AND BIOLOGICAL ACTIVITY OF RHODIUM(III) 
AND IRIDIUM(III) COMPLEXES 
Geldmacher, Y.1,Rubbiani, R.2, Kitanovic, I.3, Wölfl, S.3, Ott I.2, Sheldrick W.S.1 
1Ruhr-Universität Bochum, Faculty of Chemistry and Biochemistry,  Department 
of Analytical Chemistry, Universitätsstr. 150, 44780 Bochum, Germany,  
2Technical University of Braunschweig, Department of Pharmaceutical Chemistry, 
Beethovenstr. 55, 38106 Braunschweig, Germany, 3 Ruprecht-Karls-Universität, 
Institute of Pharmacy and Molecular Biotechnology, , Im Neuenheimer Feld 364, 
69120 Heidelberg , Germany  
E-mail: Yvonne.Geldmacher@rub.de 
 
The rhodium(III) and iridium(III) complexes of the type [(C5Me5)MX(pp)]+ and 
[MX3(L)(pp)] with pp = phen, dpq, dppz, dppn and X = Cl, Br represent a new 
class of cytotoxic substances. Cytotoxicity and cellular uptake studies on the MCF-
7 and HT-29 cell lines have also been employed to establish relationships between 
the structure and the activity of mer- /fac- [MX3(L)(pp)] complexes (with L=H2O, 
CH3OH, 1-methylimidazole, DMSO; X=Cl, Br and M=Rh, Ir) [1,2]. 
 
One goal of our ongoing studies is to improve the cell selectivity and identify lead 
substances by varying the ligands L and pp in complexes [(5-
C5Me5)RhL(pp)](CF3SO3)n. It has previously been shown that there are significant 
differences between the cytotoxicities of Pt(II) complexes with methylated 1,10-
phenanthroline ligands [2]. We now report studies of the biological activity of [(5-
C5Me5)RhCl(pp)]CF3SO3 complexes containing methylated phenanthroline ligands 
and other substituted polypyridyl ligands. Measurements of the LDH release for 
lymphoma (BJAB) cells after 1h incubation with phen, 5,6-Me2phen and dppz 
complexes demonstrated that unspecific necrosis is negligible. Specific cell death 
apoptosis via DNA fragmentation was detected for BJAB cells after 72 h.  
References 
1. M.A. Scharwitz, I. Ott, Y. Geldmacher, R. Gust, W.S. Sheldrick,  Journal of 
Organometallic Chemistry, 2008, 693, 2299-2309.   
2. C.R. Brodie, J.G. Jollins, J.R. Aldrich-Wright; Dalton Trans, 2004, 1145.  
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SCHIFF BASE TRANSITION METAL COMPLEXES INDUCE STRONG 
ANTILEUKEMIA AND ANTILYMPHOMA EFFECTS  
Kircher, B.1, Hille, A.2, Schraffl, A.1, Schumacher, P.1, Ott, I.3, Gust, R.2
1 Immunbiologie und Stammzelllabor, Universitätsklinik für Innere Medizin V - 
Hämatologie & Onkologie, Medizinische Universität Innsbruck 2 Institut für 
Pharmazie, Freie Universität Berlin 3 Institut für Pharmazeutische Chemie, TU 
Braunschweig 
Schiff base transition metal complexes exert various biological effects including 
antifungal, antibacterial and even antitumor activities. Therefore, they are 
becoming more and more attractive lead structures for the design of cytostatics 
with a mode of action that differs from that of the frequently administered 
anticancer agent cisplatin. Data on antileukemia and antilymphoma effects of 
Schiff base transition metal complexes, however, are limited.
The activity of salophene (compound 1; N,N´-bis(salicylidene)-1,2-
phenylenediamine), its iron (II/III) and manganese (II/III) complexes as well as 
saldach (compound 2; rac-trans-N,N´-bis(salicylidene)-1,2-cyclohexanediamine) 
and its respective iron (II/III) complexes was evaluated against leukemia and non-
Hodgkin’s lymphoma cell lines.  
The free ligands (complexes 1 and 2) induced in all cell lines, if at all, only 
marginal, concentration-dependent cell growth-inhibitory effects, and did not 
trigger Cu/Zn superoxide dismutase (Cu/Zn SOD) release (an indirect marker for 
oxidative stress) or induce apoptosis. The Schiff base transition metal complexes 
[FeII(salophene)] and [FeIII(salophene)Cl]  blocked cellular growth, caused a strong 
release of Cu/Zn SOD and induced apoptosis. In contrast, the manganese analogs 
[MnII(salophene)] and [MnIII(salophene)OAc] inhibited cell growth, caused the 
programmed cell death only at higher concentrations and did not provoke release 
of Cu/Zn SOD in any of the cell lines. The ligand structure and regioisomery 
exerted a significant influence on the activity of the complexes. Methoxy-
substituted iron (III) salophene compounds induced even stronger effects on the 
cell lines than their unsubstituted counter parts. However, weaker cell growth-
inhibiting and cell death-promoting effects were observed when the salophene 
moiety of [FeII(salophene)] and [FeIII(salophene)Cl] was replaced with saldach.
In conclusion, Schiff base transition metal complexes exert strong inhibitory 
activities on human leukemia and lymphoma cells. 
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SYNTHESIS, CYTOTOXIC AND ANTIMICROBIAL ACTIVITIES OF 
HETEROCYCLIC TRANSITION METAL ION COMPLEXES 
Buczkowska, M.1, Lindequist, U2., Gdaniec, M3, Bednarski, P. J.1
1Pharmaceutical and Medicinal Chemistry, EMA University of Greifswald   
2Pharmaceutical Biology, EMA University of Greifswald 3Faculty of Chemistry, A. 
Mickiewicz University of Poznan, Poland 
The goal of this project was to explore the biological activities of Cu(II), Co(II), 
Zn(II) and Pt(II) complexes bearing chelating heterocyclic carboxylic ligands. 
Transition metal complexes were synthesized with 2-pyrazinecarboxylic acid, 
methyl-2-pyrazinecarboxylic acid, 2-picolinic acid, 4-imidazole-carboxylic acid, 
benzimidazole-2-carboxylic acid and 1-methylimidazole-2-carboxylic acid ligands 
(Fig. 1). The structures of the complexes were established by the IR, 1H-NMR,
195Pt-NMR, elemental analysis and some by X-ray crystal analyses. In search for 
the most stable structure, the energies of the cis and trans isomers of the 4-
imidazole-carboxylates have been studied by computational (DFT) methods. 
Structures of the ligands. 
The metal ion complexes were tested for their potential cytotoxic and antimicrobial 
activities. The cytotoxicity testing was done in a panel of human cancer cell lines 
on the 96 well microtiterplates using the crystal violet assay. The potency of 
compounds was estimated by the IC50 value in a panel of six cancer cell lines. 
Some platinum complexes showed promising cytotoxic activity. In the evaluation 
of antimicrobial activity the complexes were tested by using a modified agar 
diffusion method on five bacterial strains: S. aureus, B. subtilis, E. coli, P.
aeruginosa and C. maltosa. The evaluation of the activity was done by the 
measurement of the inhibition zones on the agar plates. Some of the Co (II) 
complexes gave inhibition zones of 19 mm or greater. The MIC values for the most 
active compounds have also been determined with the help of a microdilution test.
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DEVELOPMENT OF SIGMA-RECEPTOR BINDING HETEROCYCLIC 
DERIVATIVES WITH CYTOTOXIC ACTIVITY 
Korpis K.1), Weber F.2), Brune S.2), Wünsch B.2), Bednarski P.-J.1) 
1) Institute of Pharmacy, University of Greifswald, F.-L.-Jahn-Straße 17, 17487 
Greifswald, Germany 2) Institute of Pharmacy, University of Münster, 
Hittorfstraße 58-62, 48149 Münster, Germany 
 
Sigma receptors are present in peripheral organs and in the central nervous system. 
They have also been found in many cancer cell lines. It is known that they are 
over-expressed in certain tumor cell lines and that synthetic ligands to this receptor 
could play an important role in cancer diagnosis and therapy. The aim of this 
project is to determine the cytotoxic activity of new sigma receptor ligands with 
conformationally constrained piperazines and their flexible analogues.  
3 3
 
WMS 34-03 and WMS 34-04 
The synthesized heterocycles were tested for their growth inhibitory activities in a 
panel of five human tumor cell lines by using a microtiter assay based on the 
crystal violet method for adherent cells. Growth inhibition of cells in suspension 
was measured with the MTT method. The potency was characterized by the GI50 
value. WMS 34-03 and WMS 34-04 show promising cytotoxic activity with GI50 
values around 10 μM. These substances are being investigated for their ability to 
induce apoptosis. Selected compounds will also be characterized in metabolism 
studies. In addition, we analyzed for the 1 receptor in RPMI 8226 cells with 
Western blot analysis. This human multiple myeloma cell line, which is described 
to express 1 receptors in high density, is being used to conduct receptor binding 
assays, the results of which will be presented.    
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SYNTHESIS AND BIOLOGICAL ACTIVITY OF SPLITOMICIN ANA-
LOGS TARGETED AT Sirt1 
El Gaghlab, K.1, Schemies, J.2, Jung, M.2, Link, A.1
1Pharmazeut./Medizinische Chemie, Ernst-Moritz-Arndt-Universität Greifswald 
2Pharmazeutische Chemie, Albert-Ludwigs-Universität Freiburg 
Small molecules interfering with posttranslational modification of histones are of 
interest as tools to study epigenetic regulation of gene transcription. Known post-
translational modifications consist of protein phosphorylations, methylations, ace-
tylations and deactylations. Specifically, drugs that interfere with histone deacety-
lation could be useful to induce differentiation, growth arrest as well as apoptotic 
cell death in tumor cells. In addition, the “histone code” code that is based on mo-
lecular processing of histones by certain enzymes complements the genetic code 
and thus enables novel strategies for therapeutic intervention. Different classes of 
histone deacetylases have been described as key players in this context. Deacety-
lases that incorporate a divalent Zn atom in the active site can be targeted with 
hydroxamic acid warheads. Another class of histone deacetylases is known as Sir-
tuins some of which (S. cerevisiae Sir2) are for example inhibited by the lactone 
splitomicin (1) leading to telomeric silencing in yeast. However, splitomicin is only 
a micromolar inhibitor of yeast Sir2 and does not inhibit human subtypes and the 
lactone is prone to hydrolytic ring opening. In preliminary SAR-studies, analogs of 
lead 1 lacking this hydrolytically labile ring were described as inactive while the 
naphthalene moiety could successfully be replaced by smaller aromatic rings such 
as benzene in the fragment-like dihydrocoumarin 2. Here we report the synthesis 
and biological activity of a series of hydrolytically stable analogs of 1 and 2 such 
as compounds 3 and 4 with activity against Sirt1. These comparatively small com-
pounds characterized by high ligand efficiency are used as a starting point toward 
the development of specific inhibitors of human Sirt1-like histone deacetylases. 
1 2 3 4
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SYNTHESIS AND CYTOTOXICITY OF ADENINE ANALOGS AS 
FRAGMENTS AND LIGANDS FOR DRUG DESIGN STUDIES 
Kamper, C.1, Korpis, K.1, Bednarski, P. J.1, Link, A.1
1Pharmazeut./Medizinische Chemie, Ernst-Moritz-Arndt-Universität Greifswald  
The hydrogen-bonding capacity and versatile coordination ability of adenine to-
ward metal ions makes this fragment a privileged structure in medicinal chemistry. 
The former constitutes molecular recognition motifs crucial for correct DNA base-
pairing and stabilization of double-helical structure, while the latter not only is 
manifested on charge dissipation but also influences pKa of the exocyclic nitrogen. 
The five-membered imidazole ring harbored in the adenine framework makes this 
nucleobase also effective in biochemical catalysis, for instance in the ribosomal 
peptidyltransferase center. With this in mind, we have exploited additional adenine 
derived structures as fragment-like building blocks for bioactive compounds. To 
gain knowledge in the field of the versatile functional roles of the adenine frame-
work, we generated decorated adenines with substituents on the C2 and/or C6, 
position leaving the four imino nitrogen atoms unaltered. Since naturally occurring 
nucleobases permit versatile metal ion coordination, which is usually invoked for 
metal ion-nucleic acid interactions, these novel derivatives hold potential as ligands 
for the construction of new platinum derived complexes for anticancer therapy. 
These novel fragments might well be useful in the construction of drug-like mole-
cules and thus could be formed by metabolic processes. Herein we report the cyto-
toxicity of these molecules for the first time. 
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SYNTHESIS OF NEW NICOTINAMIDE-ANALOGUES AS POTENTIAL 
SIRTUIN INHIBITORS 
Schiedel, M.1, Jung, M.1  
1Institute of Pharmaceutical Sciences, Albert-Ludwigs-Universität Freiburg, 
Germany, http://jungm.de 
 
Sirtuins represent a specific NAD+-dependent class of histone deacetylases 
(HDACs). By using NAD+ as a cofactor, these enzymes cleave off the acetyl 
groups from the -amino group of lysines in histones and other proteins, e.g. p53, 
FOXO proteins, p300 or HIV tat. The human family of sirtuins consists of seven 
members, which are distributed to different cell compartments and involved in the 
regulation of various physiological processes like apoptosis, cell differentiation, 
metabolism, DNA recombination and HIV tat transactivation. Thus, sirtuin 
inhibitors are interesting potential drugs for drug discovery.[1] 
Besides the deacetylated lysines, the products of the catalytic reaction are 2`-O-
acetyl-adenosine diphosphate ribose and nicotinamide, which itself acts as a 
physiological sirtuin inhibitor. Thus, we chose nicotinamide as a lead structure for 
synthesis of new potential sirtuin inhibitors. 
 
Synthesis of 2,7-Naphthyridones[2] 
Quaternary N1-Alkylnicotinamides were treated with an alkaline solution of 
methylketones. After a nucleophilic addition of the deprotonated methylketone 
compound to the pyridinium salts in the 4-position, the 2,7-naphthyridones were 
formed by dehydrogenation. As an oxidant formic acid was used. The highly 
fluorescent products were either isolated as a dipolar ion out of the aqueous layer 
or its hydrochloride out of an ethanolic phase. 
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LESTAURTINIB  INHIBITS THE KINASE PRK1 IN VIVO 
Rumpf, T.1, Köhler, J.1 Erlenkamp, G.2, Metzger, E.3, Schüle, R.3, Sippl, W.2,
Jung, M.1
1Institute of Pharmaceutical Sciences, Albert-Ludwigs-University of Freiburg 
2Department of Pharmaceutical Chemistry, Martin-Lurther University of Halle-
Wittenberg
3Centre for Clinical Studies, Albert-Ludwigs-University of Freiburg 
Epigenetics is the study of changes in the protein expression caused by 
mechanisms other than the change of the underlying DNA sequence. These 
alterations in protein expression can be carried out by microRNA, DNA 
methylation and diverse histone modifications. In contrast to histone acetylation 
and methylation very little is known about histone phosphorylation. 
By now several kinases are known to play an important role in the regulation of 
gene expression. For androgen receptor signalling, PKC betaI and PRK1 have been 
shown to have crucial functions in activating gene transcription. 
Because of its activating role, PRK1 is considered to be a promising target for the 
treatment of prostate cancer.[1] Here we present a focussed library screening 
approach using known kinase inhibitors to identify PRK inhibitors. We identified 
the clinical candidate Lestaurtinib (see Figure 1) as a potent inhibitor of the 
epigenetic kinase PRK1. 
Figure 1: Chemical Structure of the PRK1-inhibitor Lestaurtinib 
[1] E. Metzger, N. Yin, M. Wissmann, N. Kunowska, K. Fischer, N. Friedrichs, D. 
Patnaik, J. M. Higgins, N. Potier, K. H. Scheidtmann, R. Buettner, R. Schule, Nat.
Cell. Biol. 2008, 10, 53-60. 
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INVESTIGATION OF THE INFLUENCE OF THE POSITIONS OF THE 
PHENOLIC HYDROXYL GROUPS IN 2,2´-BISBENZIMIDAZOLES 
CONCERNING THE EFFECT ON FLUORESCENT PROPERTIES 
Szymanowitz, K., Wellner, A., Gust, R. 
Institut für Pharmazie, Freie Universität Berlin 
Breast cancer is one of the most frequent cancers in women. About 60 percent of 
this tumor entity are hormone dependent, which means they contain estrogen 
receptors and require estradiol for growing. Therefore the differentiation between 
hormone dependent and hormone independent cancers plays an important role with 
regards to the individual therapy. Presently radioactive methods are used for 
diagnostic. In recent years promising fluorescent 1,1´-dialkyl-2,2´-bisbenz-
imidazole derivates have been synthesised in our group. These compounds shall be 
used for visualising the estrogen receptor in a non-radioactive method. In addition 
the influence of the positions of the phenolic hydroxyl groups in the benzimidazol 
rings have been investigated concerning the effect on absorption and fluorescent 
properties. Furthermore compounds with a potential (anti)estrogenic effect have 
been developed. 
All of these compounds meet the structural requirements to interact with estrogen 
receptors. Currently methods are set up to determine their binding quality to the 
estrogen receptors in whole cell assays and with isolated receptors. The 
(anti)estrogenic effect and the influence on the receptor density of these 
compounds are investigated in transactivation assays and western blots. 
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SYNTHESIS AND INVESTIGATION ON THE MODE OF ACTION OF 
(4R,5S)/(4S,5R)-2,4,5-TRIARYL-4,5-DIHYDRO-1H-IMIDAZOLES 
Elsner, S., Gust, R. 
Institut für Pharmazie, Freie Universität Berlin  
Almost 60 percent of mammary carcinoma are hormone dependent. The tumor 
cells contain estrogen receptors and require estradiol for proliferation. Selective 
estrogen receptor modulators (SERMs) are frequently used in tumor therapy 
because they have antiestrogenic effects in breast tissue but estrogenic effects in 
bones and the cardiovascular system. 
In recent years in our group were a lot of imidazole-derivatives synthesised which 
meet the structural requirement for interactions with estrogen receptors. The 
compounds are currently investigated for their effects in human hormone 
(in)dependent tumor cells. Compounds with aromatic hydroxyl groups reveal 
interaction with the estrogen receptor. In this context compounds with amino 
groups instead will be synthesised and analyzes in termes of estrogenic activity. 
It has been shown that derivatives with lipophilic substituents lack estrogenic 
activity but cause unlike hydroxylated compounds cytotoxic effects on testet tumor 
cells. Whether the cytotoxicity is caused by necrotic or apoptotic processes has to 
be resolved in LDH-release- and caspase-3-assays.  
Further compounds have to be synthesised for performing SAR studies which 
should reveal the essential structural elements for cytotoxic and (anti)estrogenic 
effects. For this purpose we are now establishing new methods of synthesis using a 
microwave. 
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IS THE CCN1 PATHWAY RELEVANT FOR INTEGRIN FUNCTION IN 
MELANOMA METASTASIS AND INTERFERENCE WITH HEPARIN? 
Schmitz, P.1, Schlesinger, M.1, Naggi, A.2, Torri, G.2, Casu, B.2, Bendas, G.1
1Department of Pharmacy, University Bonn, 53121 Bonn, Germany 
2“G.Ronzoni“ Institute, 20133 Milano, Italy 
The integrin VLA-4 (very late activation antigen-4) on the human melanoma cell 
line MV3 is crucial for cell adhesion in course of hematogenous metastasis. With 
respect to therapeutic interference in metastasis, heparin was found to inhibit MV3 
cell adhesion to VCAM-1 in vitro. Recent studies refer to structural requirements 
of heparin to reduce MV3 binding, but could not finally confirm the heparin 
binding to VLA-4, since several factors influence integrin signaling and activation. 
Recently, the activation of other integrins than VLA-4 on tumor cells was shown 
by binding to secreted cysteine-rich proteine 61 (Cyr61/CCN1) as a kind of 
autocrine stimulation. Since Cyr61 has binding ability to heparin, an indirect 
activity of heparin on VLA-4 via Cyr 61 can be assumed. 
To confirm direct binding of heparin to VLA-4, SAW biosensor studies were 
performed using a series of modified heparins and a VLA-4 containing MV3 
membrane preparation providing kinetic binding data. To further focus on the 
heparin binding pathway and Cyr61, the effects of exogenous added Cyr61 and the 
downregulation of Cyr61 in MV3 melanoma cells by shRNA technology were 
analysed. 
The kinetic binding data suggest a direct interaction between heparin and VLA-4. 
Binding affinities of fractionated heparin in the low micromolar range were 
attenuated by N-acetylation or size fractionation of heparin. Other modifications, 
such as partial desulfation or ring opening of the saccharides less affected the 
affinity or slightly increased binding. Preliminary data suggest a reduced binding 
of Cyr61-knockdown cells. The hypothesis of heparin interference on this pathway 
can be assumed and will be the matter of further investigations. 
However, our data provide evidence for a direct interference of heparin with 
VLA-4 mediated melanoma cell binding. This sheds light on the use of heparin in 
antimetastatic approaches. 
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SYNTHESIS OF PHARMACOLOGICAL INHIBITORS OF HSF-1/HSP70 
FOR THE TREATMENT OF MULTIPLE MYELOM 
Hartung, A.1, Holzgrabe, U.1 Chatterjee, M.2, Bargou, R.2
1Pharmazeutische Chemie, Uni Würzburg 2Medizinische Klinik und Poliklinik II, 
Uni Würzburg  
Since multiple myeloma (MM) is still a remediless disease, the development of 
novel drugs is urgently needed. The observation that heat shock proteins (HSP) are 
overexpressed in MM cells and that their genetically deactivation induces 
apoptosis of the cancer cells reveal HSPs as promising targets.[1] It was furthermore 
ascertained that knocking down HSF-1, which is an important transcriptional 
activator of HSP70 expression, similarly induces apoptosis.[2] However, efficient 
and selective inhibitors of HSF-1 or HSP70 are still not available.  
Derived from the known inhibitor emetine, several substituted quinolines and 
isoquinolines were synthesized and screened for their ability to inhibit the HSF-
mediated HSP70 induction. The first results revealed the tetrahydroisoquinole 
skeleton as a promising lead structure. Therefore several highly diverse 
tetrahydroisoquinolines have been synthesized to prove this concept and gain 
access to structure-activity relationship analysis. 
Literature:
[1] Chatterjee, M.; Jain, S.; Stuehmer, T.; Andrulis, M.; Ungethuem, U.; 
Kuban, R.-J.; Lorentz, H.; Bommert, K.; Topp, M.; Kraemer, D.; Mueller-
Hermelink, H. K.; Einsele, H.; Greiner, A.; Bargou, R. C., Blood 2007, 109
(2), 720-728. 
[2] Kim, S.-A.; Kwon, S.-M.; Yoon, J.-H.; Ahn, S.-G., International Journal 
of Oncology 2010, 36 (4), 867-872. 
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INDENO[1,2-B]INDOLE DERIVATIVES ARE COMPETITIVE 
INHIBITORS OF THE HUMAN PROTEIN KINASE CK2 
Hundsdörfer, C.1; Chapuis, A.3; Rollet, A.3; Bouaziz, Z.3; Le Borgne, M.3;
Hemmerling, H.-J.1; Götz, C.2; Jose, J.1
1Institute of Pharmaceutical and Medicinal Chemistry, HHU Düsseldorf 
2Medicinal Biochemistry and Molecular Biology, Saarland University  
3ISPB-Faculté de Pharmacie, Université Claude Bernard Lyon 1 
Protein kinases in general are thoroughly investigated drug targets and important 
targets for therapeutic intervention. Protein kinase CK2 is a ubiquitous 
serine/threonine kinase capable to phosphorylate a wide array of substrates in vitro. 
To date well over 300 potential physiological targets of CK2 have been identified, 
but it seems unlikely that the enzyme plays any role in the in vivo phosphorylation 
of casein, the protein from which its name originally derived. Beyond the 
importance of CK2 in the context of cell survival and cell proliferation, there is a 
large body of evidence that CK2 is involved in neoplastic transformation and 
cancer. In a number of different cancers, including those of the prostate, mammary 
gland, lung and others, abnormal high levels of CK2 have been observed. This 
suggests CK2 to be an attractive and promising target for anti-neoplastic 
therapeutics, but despite the growing evidence on CK2 participation in malignant 
transformation and cancer, only few inhibitors of the enzyme are available. In the 
present study, partially hydrogenated indeno[1,2-b]indoles were synthesized using 
a novel established protocol and after dehydrogenation, followed by oxidation a 
series of compounds were obtained [1] and tested for CK2 inhibition by the use of 
the recombinant human enzyme expressed in E. coli. Competitive inhibition was 
exemplarily demonstrated and new inhibitors with IC50 values in the nanomolar 
range were identified. 
[1] Hemmerling, H J, Götz, C, Jose, J (2008) Substituted indeno[1,2-b]indole 
derivatives as novel inhibitors of protein kinase CK2 and their use as 
tumour therapeutic agents, cytostatics and diagnostic aids. Patent
WO2008040547
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BENZOFURANONE TF INHIBITS PROTEIN KINASE CK2 AND 
SHOWS PRO-APOPTOTIC EFFECTS IN PROSTATE CANCER CELLS 
Gratz, A.1; Götz, C.2; Kuckländer, U.1; Jose, J.1 
1Institute of Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-
University, 40225 Düsseldorf, Germany,  
2Medicinal Biochemistry and Molecular Biology, Saarland University,  
66424 Homburg/Saar, Germany. 
 
Increased cellular CK2 activity was shown to contribute to the development and 
the maintenance of cancer. It is directly correlated to the dysregulation of many 
signal transduction pathways. Furthermore, there is strong evidence that elevated 
CK2 activity suppresses apoptosis and enhances cell proliferation. As a 
consequence the cell is predisposed to develop and maintain neoplastic diseases. 
Therefore, CK2 is considered a promising target for the development of anti-cancer 
drugs that reduce CK2 activity to a non-pathogenic level. 
To identify potential drug candidates, we developed a novel non-radiometric 
activity assay based on capillary electrophoresis using the recombinantly expressed 
human holoenzyme CK222 [1]. This assay allowed a library screening for CK2-
inhibiting compounds. By this means, we could identify the compound TF as a 
novel potent inhibitor with an IC50 value of 30 nM. Treatment of the prostate 
carcinoma cell line LNCaP with TF led to an inhibition of endogenous CK2 
activity and a decrease of cell viability measured by an MTT assay. Furthermore, 
we could demonstrate that incubation with TF induced apoptosis in these cancer 
cells. These effects were nearly identical to those obtained with the known 
inhibitor TBB used as a control. First results of a selectivity profiling with a TF-
concentration of 10 μM and 63 human protein kinases confirmed that TF is indeed 
an inhibitor with selectivity for CK2. 
 
 
[1] Gratz A, Götz C, Jose J (2010) A CE-based assay for human protein kinase 
CK2 activity measurement and inhibitor screening. Electrophoresis 31:634-40. 
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REPRESSION OF THE PROTO-ONCOGENE Pim-1 BY miR-33a 
Thomas M.1, Lange-Grünweller K.1, Weirauch U.2, Aigner A.2, Grünweller A.1 and 
Hartmann R.K.1
1Philipps-Universität Marburg, Institut für Pharmazeutische Chemie, Marbacher 
Weg 6, 35037 Marburg, Germany 
2Philipps-Universität Marburg, Institut für Pharmakologie und Toxikologie, Karl-
von-Frisch-Str. 1, 35043 Marburg, Germany 
MiRNAs are small ncRNAs that act as cellular regulators of development, 
proliferation, differentiation, apoptosis and stress response. So far, miRNAs are 
known to modulate gene expression in most species, including Homo sapiens.
In treatment of cancer, a miRNA-based strategy using miRNA mimics or anti-
microRNAs (AntimiRs) generates the ability to regulate a whole network of co-
interacting pathways. This could give the opportunity to modulate bio-pathologic 
features and disease outcomes. [1] 
Here we present the proto-oncogenic kinase Pim-1 to be the first cell cycle relevant 
target of miRNA 33a. We found that the erythroleukemia cell line K562 and the 
colon carcinoma cell line LS174T, which have high and moderate Pim-1 mRNA 
and protein levels, express low cellular miR-33a levels compared to other miRNAs 
like the oncogenic miR-17-5p or miR-20a. 
Within its 3'-UTR the Pim-1 kinase harbours a highly conserved binding site for 
miR-33a. We found that transfection of a miR-33a mimic leads to specific 
downregulation of Pim-1 at the mRNA and protein levels. Seed mutagenesis of the 
miR-33a target sequence in the 3'-UTR of Pim-1 demonstrated specificity of miR-
33a dependent regulation using a luciferase reporter assay. Moreover, transfection 
of the related miR-33b mimic has no effect on Pim-1 expression. The efficacy of 
the miR-33a dependent knockdown is not as strong but as persistent as obtained 
with selected Pim-1 specific siRNAs. RNAi-dependent downregulation of Pim-1 
inhibited proliferation in K562 and LS174T cells by arresting cells in G2/M phase 
of the cell cycle. Another cell cycle regulator, the kinase Cdk6, is not regulated by 
a miR-33a mimic although its priority to be targeted by miR-33a is ranked at 
higher position using the prediction tool TargetScan 5.1. 
[1]: Iorio MV, Croce CM (2009) MicroRNAs in Cancer: Small Molecules With a 
Huge Impact. J Clin Oncol 27: 5848-56 
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SYNTHESIS AND BIOLOGICAL EVALUATION OF SIMPLE 
PLATENSIMYCIN ANALOGUES 
Krauß, J., Bracher, F., Plesch, E. 
Department Pharmazie - Zentrum für Pharmaforschung, Ludwig-Maximilians-
Universität München, 81377 München 
 
The natural occurring antibiotic platensimycin (1) is an interesting lead structure 
for developing new antiinfectives due to its new mechanism of action, the 
inhibition of bacterial fatty acid biosynthesis. 
Since the total synthesis of platensimycin can be accomplished only by a multistep 
protocol, we intended to prepare simple analogues of this natural product, which 
still contain the functional groups that have previously been identified as being 
essential for binding to the target enzyme in fatty acid biosynthesis FabF/B (-
ketoacyl-(acyl-carrier-protein (ACP) synthase I/II). 
 
Essential residues for binding of platensimycin are the acylamino hydroxybenzoic 
acid structure, and the keto group and the cyclic ether in the aliphatic region. 
 
So our synthesis of the simple analogues focussed on conserving these elements. 
The synthesized analogues of platensimycin showed interesting antibiotic activities 
in an agar diffusion assay comparable to common antibiotics.  
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SYNTHESIS AND BIOLOGICAL EVALUATION OF BERBERINE 
DERIVATIVES 
Imming, P.1, Paul, A.1., Müller, C.2, Krauss, J.2, Bracher, F.2
1Pharmazeutische Chemie, Martin-Luther-Universität Halle-Wittenberg 
2Department Pharmazie, Ludwig-Maximilians-Universität München 
Isoquinoline alkaloids are distinguished by a bundle of activities, however all of 
them weak: antibacterial, antitumoral, anti-inflammatory, and antileishmanial [1-
4]. This renders them ideal leads for a SOSA approach (Selective optimization of 
side activities, [5]). 
We present the synthesis of isoquinolines with non-natural substitution pattern and 
test results for specific efficacy against bacteria, fungi, and human leukemic HL-60 
cells. 
Derivatives with a hydroxy group in position 9 (protoberberines of general 
formula, 1) were found to have the largest effect against the fungal species tested 
(Aspergillus niger, Hyphopichia burtonii), while the quaternary congener berberine 
exhibited only marginal activity. We suppose the protoberberines to inhibit 24-
sterolmethyltransferase (24-SMT) [6]. All compounds were weakly or not toxic 
against HL-60 cells. 
N
OH
O
R
9
1
References: 1. Iwasa, K. et al. (1996) Eur. J. Med. Chem. 31:469-478. 2. 
Kettmann, V. et al. (2004) Pharmazie 59:548-551. 3. Kuo, CL. et al. (2004) Cancer 
Lett. 203(2):127-137. 4. Vennerstrom, JL. et al. (1990) Antimicrob. Agents 
Chemother. 34:918-921 5. Wermuth, C. G. (2006) Drug Discov. Today 11:160-164 
6. Park, K-S. et al. (1999) J. Antimicrob. Chemother. 43:667-674 
C155
HAEMAGGLUTININ CLEAVING PROTEASES  
POSSIBLE TAGETS TO TREAT INFLUENZA INFEKTIONS 
Meyer, D.1, Sielaff, F.1, Böttcher-Friebertshäuser, E.2, Freuer, C.2, Garten, W.2,
Steinmetzer, T.1
1 Institute of Pharmaceutical Chemistry, Philipps University, Marburg 
2 Institute of Virology, Philipps University, Marburg 
Human Influenza viruses cause acute infection of the respiratory tract that affects 
millions of people during seasonal outbreaks every year. Recently, the outbreak of 
a swine origin H1N1 influenza virus for which there is no or little immunity in 
humans exacerbates the situation. Currently, only two drugs targeting the viral 
neuraminidase and the M2-channel protein inhibitor amantadine are approved for 
the treatment of influenza in the EU. Infectivity of influenza viruses strongly 
depends on correct cleavage of the haemagglutinin precursor HA0 by host cell 
proteases. All human pathogen HA precursors have a single arginine at the 
cleavage site. Recently, two membrane-bound trypsin-like serine proteases, 
TMPRSS2 (transmembrane protease serine S1 member 2; epitheliasin) and HAT 
(human airway trypsin-like protease or TMPRSS11D), localized in human airway 
epithelium, were identified, which activate HA and support replication of the 
viruses. Meanwhile we could demonstrate that HAT is proteolytically active on the 
cell surface, whereas TMPRSS2 cleaves HA0 within the cell. Both proteases are 
potential targets for the treatment of influenza. In contrast to HAT there is no 
commercial source for TMPRSS2. Therefore, we started our work with the 
expression, purification and activation of TMPRSS2 including their enzyme kinetic 
characterization. Among a series of substrate-analogue peptide mimetics 
containing a 4-amidino-benzylamide as P1 residue we could identify first leads, 
which inhibit TMPRSS2 and HAT in the nanomolar range. Although some of these 
analogues had similar potency in enzyme kinetic studies, we observed significant 
differences in their efficacy to inhibit virus propagation in TMPRSS2 or HAT 
expressing cell lines. 
C156
HIT VALIDATION FOR A FLUORIMETRIC SARS COV MAIN 
PROTEASE ASSAY  
Ludewig, S.1, Kossner, M.1 , Stempka, M.2, Kisker, C.3, Schirmeister, T.2 , 
Baumann, K.1
1Institut für Pharmazeutische Chemie, Technische Universität Braunschweig, 
2Institut für Pharmazie und Lebensmittelchemie, Universität Würzburg and 
3Rudolf-Virchow-Zentrum, DFG-Forschungszentrum für Experimentelle 
Biomedizin, Universität Würzburg 
Development of highly specific inhibitors for SARS CoV main protease which do 
not form a covalent bond with the protease and which do inhibit the protease in a 
competitive way is quite challenging. The determination of the potency and kinetic 
of potential inhibitors can be carried out by performing a fluorimetric enzymatic 
assay based on the principles of fluorescence resonance energy transfer (FRET). 
Mechanistically different effects other than inhibition, such as the inner filter effect 
or colloidal aggregation, can bias the measurement and may cause false positive 
results. Therefore a validated workflow is of utmost importance to prove the 
correct inhibitory potency. Simple methods to distinguish hits from false positives 
are proposed. Addition of Triton X-100 suppresses unspecific interactions between 
enzyme and inhibitor by forming colloidal aggregates. Moreover, with FRET 
assays the inner filter effect needs to be considered. It is caused amongst others by 
inhibitors which absorb light at the excitation or emission wavelength of the 
substrate and can be corrected by determining a correction factor dependent on the 
inhibitor concentration. Inhibitors binding covalently to the active site cysteine 
residue can be detected by the addition of dithiothreitol as an alternative thiol 
donor. If potential inhibitors still show activity after these tests, their kinetic 
characteristics need to be evaluated. Finally, the selectivity of the potential 
inhibitor should be checked against various different proteases. The 
aforementioned hit validation protocol will be exemplified with recently published 
SARS CoV MPro inhibitors. 
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BISQUATERNARY NAPHTHALIMIDES – NOVEL ACTIVE COMPOUNDS 
AGAINST PLASMODIA, TRYPANOSOMA AND STAPHYLOCCOCI 
Tischer, M.a, Menzel, T.b, Sologub, L.b, Pradel, G.b, Ohlsen, K.b, Holzgrabe, U.a
aInstitute of Pharmacy and Food Chemistry, University of Wuerzburg, Am Hubland, 
97094 Wuerzburg, Germany 
bInstitute of Molecular Infection Biology, University of Wuerzburg, Joseph-Schneider-
Straße 2 Bau D15, 97070 Wuerzburg, Germany 
Malaria is the world’s most prevalent tropical disease. The currently available drugs 
are showing increasing resistance and they are partially too expensive for of Africa. 
The situation of Trypanosoma ssp. is comparable. The bisquaternary bisnaphthalimides 
are a versatile class of compounds being active against Plasmodium falciparum1,
Trypanosoma brucei brucei2 and Staphylococcus strains3 in the low micromolar and 
nanomolar range of concentration. The qualitative analysis of the structure-activity 
relationships revealed the importance of a long methylene middle chain of at least 8 
methylene groups between the two bisquaternary naphthalimides or a monoquaternary 
naphthalimide consisting of a long alkyl chain attached to the positively charged 
nitrogen atom (for Plasmodia and Trypanosoma). As a singularity one 
bisnaphthalimide exhibits a high activity against several strains of Staphylococcus, 
especially multi-resistant strains. Radioactive labeling, surface plasmon resonance and 
gel retardation experiments revealed a direct and unspecific binding to the DNA of 
Staphylococci.  The cytotoxicity of these compounds studied here was evaluated and 
found to be very low. The structure activity relationships of cytotoxicity on the one 
hand and activity against Plasmodia, Trypanosoma and Staphyloccoci on the other 
hand are different. The mode of action in Plasmodia and Trypanosoma remains still to 
be elucidated. 
[1] Holzgrabe, U.; Antitrypanosomal activity of quarternary napthalimide derivatives; 
Bioorg. Med. Chem. Lett. 2007, 17, 1590-1593 
[2] Tischer, M.; The Bisnaphthalimides as New Active Lead Compounds against 
Plasmodium falciparum; Bioorg. Med Chem 2010, 18, 2987-3352 
[3] Menzel, T. M.; The novel bisquaternary bisnaphthalimide MT02 and its 
antibacterial mode of action against Stapylococcus aureus; Antimicrob. Agents 
Chemother. 2010, [submitted] 
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SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP OF 
NOVEL QUINOLONE-TYPE COMPOUNDS AGAINST TRYPANOSOMA 
BRUCEI 
Hiltensperger, G.1, Niedermeier, S.1, Stich, A.1, Holzgrabe, U.2 
1Institute of Pharmacy and Food Chemistry, University of Wuerzburg 2Medical 
Mission Institute 
 
Human african trypanosomiasis (HAT) is caused by infection with one of two 
parasites, which differ in their geographical range and etiopathology. While T.b.
gambiense HAT is primarily a human chronic disease and occurs in Western and 
Central Africa, T.b. rhodesiense HAT is primarily zoonotic with a huge animal 
reservoir and causes the acute form of sleeping sickness in Eastern and Southern 
Africa. Current estimations show that in the prevalence sub-Saharan area about 60 
million people are at risk and 50000 – 70000 cases occur annually1. Both forms of 
HAT show two clinical stages, whereas the first corresponds to the multiplication 
of the parasite in the blood and lymphatic system. After crossing the blood-brain 
barrier the trypanosoma attack the central nervous system and neurological 
symptomes appear. Without medical treatment, coma and finally death results. Due 
to a low number of available drugs which suffer from severe side effects, new and 
easily accessible active compounds are urgently needed. Therefore we synthesized 
a quinolone-type library and tested them against Trypanosoma brucei. The 4-oxo-
quinolone skeletons are build up using the Gould-Jacobs procedure with 
subsequent installation of the piperidine residue at C7 by nucleophilic aromatic 
substitution. The final step includes the amidation at C3 with different benzyl- and 
phenethylamines. The biological evaluation shows that the 4-oxo-quinolone-3-
carboxylates are inactive. The essential increase in activity is obtained by 
amidation at C3. Moreover the piperidine residue at C7 and longer alkyl chains at 
N1 lead to further enhancement. Compound 1, which exhibits an IC50 value of 0.78 
M, represents a promising lead structure for further structural modification. 
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1 E. M. Fèvre, B. v. Wissmann, S. C. Welburn, P. Lutumba, The Burden of Human 
African Trypanosomiasis, PloS.  Negl. Trop. Dis., 2008, 2 (12). 
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THE IMPORTANCE OF INHIBITING INFECTIVITY PROTEIN MIP FOR 
THE TREATMENT OF LEGIONELLOSIS 
Juli, C.1, Sippel, M.1, Thiele A.2, Weiwad M.2, Jäger, J.3, Steinert, M.3, Schweimer, 
K.4, Rösch, P.4, Sotriffer, C.A.1, Holzgrabe, U.1
1 Institute of Pharmacy, University of Würzburg, 2 Research Center for 
Enzymology of Protein Folding, Max-Planck Institute Halle, 3Institute of 
Microbiology, TU Braunschweig, 4 Department of Biopolymers, University of 
Bayreuth 
Legionella pneumophila is a Gram-negative aerobic pathogen causing two distinct 
forms of Legionellosis: Legionnaires’ disease, a severe pneumonia and Pontiac 
fever, a milder respiratory disease with symptoms resembling acute influenza. To 
date there is no efficient treatment for the severely progressing form with mortality 
rates of up to 20 %. [1] The bacteria occur in freshwater and are transmitted into 
human lungs i.e. alveolar macrophages [2] by inhaling Legionella-containing 
aerosols which can result from air condition systems, room air humidifiers, 
whirlpools or showers. In order to affect alveolar macrophages the bacteria have to 
cross epithelial cells and the extracellular matrix (ECM) of the lung tissue. This 
transmigration process is enabled by the macrophage-infectivity potentiator (Mip) 
protein which is arranged on the surface of the bacterium. Mip shows a peptidyl 
prolyl cis/tans isomerase activity and binds to collagen IV which is the prevalent 
collagen in the human lung. [3] In combination with another serine protease, Mip 
degrades ECM proteins and thereby allows the bacteria to cross the barrier. Hence, 
inhibiting Mip would hinder Legionella intrusion of macrophages and attenuate the 
infection.
Since no small-molecule inhibitor of Mip has been reported so far, the 
development of novel compounds against this target by means of computer-aided 
design, subsequent syntheses of selected molecules and their biological screening 
is the aim of this work. First pipecolic acid-type compounds have been already 
identified as “inhibitors” of Mip. 
[1] Ceymann et al: BMC Structural Biology 2008, 8: 17 
[2] Steinert et al: FEMS Microbiology Reviews 2002, 26: 149-162 
[3] Gelse et al: Advanced Drug Delivery Reviews 2003, 55:1531-1546 
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LOW MOLECULAR CHROMONE-BASED COMPOUNDS AS 
POTENTIAL DRUGS AGAINST MYCOBACTERIUM TUBERCULOSIS
Kesetovicova, D., Topf, C.,  Holzgrabe, U. 
Institut for Pharmacy and Food Chemistry, University of Wuerzburg 
 
According to WHO, one third of the worlds population is infected with TB and 
about 50 million people suffer from the drug-resistant form. Of particular concern 
is the development of multi-drug-resistant forms of the disease (MDR-TB), defined 
as forms resistant to two or more of the front line anti-TB agents1. 
 
Hence, drug resistance in Mycobacteria has become a serious medical problem. 
Thus, there is an urgent need of new drug candidates displaying selective mode of 
action. One of the well described selective targets in Mycobacteria is the type II 
fatty acid synthase (FAS) system, which differs significantly from the fatty acid 
biosynthesis pathway in eukaryotic cells. The key regulator of the FAS II enzyme 
system in Mycobacterium tuberculosis is the -ketoacyl-acyl carrier protein (ACP) 
synthase (KasA), which mediates the elongation of unsaturated fatty acid chains. 
ACP Synthase is inhibited by two natural products: thiolactomycin and cerulenin. 
Crystallographic data of the complex of KasA and thiolactomycin have been 
obtained recently2 and were used for a virtual screening of the modified ZINC 
database of ca. 2.9 million compounds. 
O
O
NH
O
Br
 
1
Among the structures found by virtual screening, chromone-moiety containing 
compound 1 was selected as a model structure of our study. Compound 1 
displaying the inhibition activity on KasA in low micromolar range (Kd 26 ± 7 μM) 
can be regarded as a hit in the early enzyme assay. A set of related compounds was 
synthetized and its KasA inhibitory activity evaluated.  
 
[1] TAACF Website: http://taacf.org/about-TB-background.htm 
[2] Luckner, S.R. et al., Structure 2009, 17 (7), 1004-13. 
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DEVELOPMENT OF NOVEL INHIBITORS OF KASA, A TARGET OF 
MYCOBACTERIUM TUBERCULOSIS
Topf, C.1, Kisker, C.2, Sotriffer, C. A.1, Holzgrabe, U.1 
1Institute of Pharmacy, University of Würzburg, 2Rudolf-Virchow-Center, 
University of Würzburg 
 
Fatty acid biosynthesis, the first step in membrane lipid biogenesis, is catalyzed in 
bacteria by a series of proteins which is termed the type II fatty acid synthase 
(FAS) system. As the difference to the multifunctional type I synthase found in 
eucaryotes is significant, there is a possibility to design inhibitors of the FAS II 
system as effective and selective antibiotics against mycobacteria. 
The enzyme of interest in our work is the -keto-acyl ACP synthase (KasA), an 
elongating enzyme in the FAS II system of Mycobacterium tuberculosis. The 
recently solved crystal structure of KasA in complex with the well-known inhibitor 
thiolactomycin (TLM)† provides important information about the binding pocket, 
essential protein-ligand interactions and the mechanism of inhibition. 
To identify novel lead structures a set of compounds has been retrieved by virtual 
screening of databases of commercially available compounds with a 
pharmacophore model based on the TLM binding mode. Subsequently, these 
compounds were docked into the KasA binding pocket to inspect the predicted 
binding modes, and the chemical accessibility of possible modifications was 
checked. Compounds with time-consuming synthesis were purchased, while more 
readily accessible substances from different chemical classes were synthesized and 
varied by altering the substitution pattern. Experimental testing of their inhibitory 
activity is currently in progress: The inhibitor-induced decrease of the intrinsic 
fluorescence of KasA is measured in a time-dependent manner in order to calculate 
Kd values.   
 
 
References: 
†Luckner, S. R. et al., Structure 2009, 17 (7), 1004-13. 
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SYNTHESIS, MOLECULAR MODELLING AND PHARMACOLOGY OF 
DUAL HISTAMINE H1/H4-ANTAGONISTS 
Wagner, E.1, Wittmann, H.-J.2 Elz, S.1, Strasser A.1
1Pharmazeutische Chemie, Uni Regensburg 2Fakultät für Chemie/Pharmazie, Uni 
Regensburg
Indole and benzimidazole piperazine carboxamides are known to be potent 
histamine H4-receptor antagonists [1]. The histamine H4-receptor is discussed to be 
involved in inflammation and regulation of the immune system [2], whereas 
Histamine H1-receptor antagonists like mepyramine, diphenhydramine and 
desloratidine are used for treatment of allergic diseases. New studies show that 
combined application of H1- and H4-antagonists in the acute murine asthma model 
exhibits synergistic inhibitory effects on eosinophil accumulation in the 
bronchoalveolar lavage fluid [3]. Thus, the design of dual H1/H4R-antagonists may 
result in a new class of drugs for therapy of type-I allergic diseases, like rhinitis 
and conjunctivitis. Therefore, we developed combined ligands with one H1- and 
one H4-pharmacophore, coupled by an alkyl spacer, as exemplary shown below. 
Competition binding assays were used to determine affinity of the new compounds 
at hH1R and hH4R. Most of the compounds showed affinity to both, hH1R and 
hH4R. However, in dependence of structure, large differences in affinities were 
observed. Molecular modelling studies were used to explain these differences on a 
molecular level. 
References:
[1] Venable et al. J. Med. Chem. 2005, 48, 8289-8298. 
[2] Thurmond et al. Nature Reviews Drug Discovery, 2008, 7, 41-53. 
[3] Deml et al. Mol. Pharmacol. 2009, 76, 1019-1030. 
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MOLECULAR MODELING STUDIES ON THE FLUOROPHILIC 
PROPERTIES OF THE S2 POCKET OF CATHEPSIN B 
Sisay, M. T.1,2, Frizler, M.2, Rodrigo, V.3, Fustero, S.3, Bajorath, J.1, Gütschow, M.2 
University of Bonn, 1Department of Life Science Informatics (BIT), 53113 Bonn, 
Germany, 2Pharmaceutical Institute, 53121 Bonn, Germany. 3Universidad de 
Valencia, Departamento de Química Orgánica, E-46100 Burjassot, Spain 
 
Cysteine proteases belonging to the papain-like subfamily are involved in 
important physiological processes such as antigen presentation, bone remodeling 
and apoptosis. Upregulation of these enzymes is implicated in autoimmune 
diseases, osteoporosis and cancer.1-3 Cathepsin B is a cysteine protease involved in 
tumor invasion and metastasis.3 It is also thought to play a role in the processing of 
the -amyloid precursor protein.4 Therefore, there is a considerable research focus 
on the design of new potent and selective inhibitors of cathepsin B.2 In this regard, 
molecular modeling studies can be used to get insights into the properties of the 
enzyme active site and the binding mode of known inhibitors. 
We will present our molecular modeling studies on the binding mode of chiral 
dipeptide-derived inhibitors5 with structural similarity to the cathepsin K inhibitor 
balicatib. 
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The compounds possess a ,-difluorinated cycloaliphatic moiety at the P2position. 
Our results provide information on the interaction of the fluorinated face of the 
inhibitors with the S2 pocket of the enzyme and let us conclude fluorophilic 
properties of the S2 pocket of cathepsin B. Such information can be used for the 
design of further potent and selective inhibitors. 
 
[1] Leung-Toung, R. et al., Curr. Med. Chem. 2002, 9, 979-1002. [2] Frizler, M. et
al., Curr. Top. Med. Chem. 2010, 10, 294322. [3] Mohamed, M. M. et al., Nat.
Rev. Cancer. 2006, 6, 764-775. [4] Klein, D. M. et al., J. Pharmacol. Exp. Ther. 
2009, 328, 813-821. [5] Fustero, S. et al., Chemistry 2008, 14, 7019-7029. 
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SYNTHESIS OF AMIDINES AS POTENT DDAH-1 INHIBITORS 
AND THEIR SELECTIVITY OVER ARGINASE AND NOS 
Lunk, I., Kotthaus, J.,Clement, B. 
Christian-Albrechts-University of Kiel, Department of Pharmaceutical and 
Medicinal Chemistry, Gutenbergstraße 76, D-24118 Kiel, Germany 
 
All three isoforms of NO-synthases (NOSs) are physiologically inhibited by 
endogenous N-methylated L-arginines. These compounds are degraded by 
dimethylarginine dimethylaminohydrolase (DDAH) to L-citrulline and 
(di)methylamine. Thus, Inhibition of DDAH activity would lead to 
increasing N-methylated L-arginine (NMMA, ADMA) levels, which could 
be another mechanism to indirectly affect nitric oxide (NO) formation. 
 
To date, three different classes of potent inhibitors are known: (1) 
pentafluorophenyl sulfonates, which are also inhibitors for the arginine 
deiminase;[1] (2) the most potent inhibitors are based on 
indolylthiobarbituric acid,[2] but their activity seems to be restricted to 
bacterial DDAH; and (3) L-arginine analogs whose best representatives are 
N-(2-methoxyethyl)-L-arginine and N-(1-iminobut-3-enyl)-L-ornithine.[3,4]  
 
Our approach was the development of amidine based L-arginine analogues 
as new inhibitors of DDAH-1 with selectivity over other enzymes especially 
NOS and arginase. These compounds were obtained by using Pinner 
synthesis.   
 
Additionally, we developed an AFMoC 3D QSAR model based on 
experimental pKi values of known hDDAH-1 inhibitors.[5] It will be used 
for further structure based optimization of the underlying compound classes.  
  
[1] P. Vallance et al., Chem Commun (Camb) 2005, 5563 
[2] B. Hartzoulakis et al., Bioorg Med Chem Lett 2007, 17, 3953 
[3]S. Rossiter et al., J Med Chem 2005, 48, 4670 
[4] J. Kotthaus et al., Bioorg Med Chem 2008, 16, 10205 
[5] H. Gohlke et al., J Med Chem 2002, 45, 4153 
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THE SEARCH FOR THE RIGHT POSE – A STRAIGHTFORWARD 
WORKFLOW FOR GSK-3 INHIBITORS 
Lemcke, T., Kruggel, S.
Institut für Pharmazie, Universität Hamburg, Bundesstraße 45, D-20146 
Hamburg, Germany
Binding mode prediction is a challenging problem in drug design. Because of the 
huge number of different docking programs available today, the choice of the most 
appropriate is difficult and many evaluations have been published.1 The focus was 
often on the enrichment in virtual screening protocols on the one hand. On the 
other hand approaches combining molecular dynamics (MD) with docking2
provide valuable results in predicting binding modes. As MD-simulations are 
computationally expensive, moreover challenging in their interpretation and may 
also introduce significant error and noise in docking results,3 we developed a 
straightforward workflow based on the combination of different docking programs, 
rescoring and complex minimization to identify native-like poses of protein kinase 
inhibitors. 
In a cross docking experiment of GSK-3 complexes, results obtained with the 
docking programs AutoDock4, FlexX5 and Fred6 were merged to account for 
different strengths and weaknesses of the respective programs. All poses were 
rescored with drugscoreX7 and a rmsd-based clustering was performed. Afterwards 
a complex minimization was accomplished with Szybki8 and the resulting 
complexes were again rescored. The workflow is described and its usefulness and 
limitations are discussed. It proofs valuable in identifying native-like poses of 
GSK-3 inhibitors and may therefore help identifying the correct binding mode of 
other protein kinase inhibitors without performing MD-simulations to account for 
receptor flexibility. 
1. Li, X. et al J Comp Chem 2010, 31, (11), 2109-2125. 
2. Nabuurs, S. B. et al J Med Chem 2007, 50, (26), 6507-6518. 
3. Armen, R. S. et al J Chem Theory Comp 2009, 5, (10), 2909-2923. 
4. Morris, G. M. et al J Comp Chem 1998, 19, (14), 1639-1662. 
5. Rarey, M. et al J Mol Biol 1996, 261, 470-489. 
6. Fred 2.2.5, OpenEye, Santa Fe, USA, www.eyesopen.com, 2009.
7. drugscoreX 0.48, G. Neudert, unpubl. test vers., pers. comm., 2010.
8. Szybki 1.3.4, OpenEye, Santa Fe, USA, www.eyesopen.com, 2009.
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BINDING MODE PREDICTION OF PFGSK-3 INHIBITORS WITH A 
THIENO[2,3-b]PYRIDINE SCAFFOLD 
Kruggel, S., Lemcke, T.
Institut für Pharmazie, Universität Hamburg, Bundesstraße 45, D-20146 
Hamburg, Germany
Even if the WHO states that the actual development gives cause for cautious 
optimism, malaria still remains a global emergency with estimated 243 million 
cases and 863 000 deaths in 2008 worldwide.1 Emerging development of resistance 
even against the WHO-recommended first-line therapy2 emphasizes the urgent 
need for new therapeutic concepts. Glycogen synthase kinase-3 of the malaria 
pathogen Plasmodium falciparum (PfGSK-3) was suggested as a potential target 
for antimalarial drugs in 20043 and a series of 
compounds with selectivity over the human 
analogue of PfGSK-3 was synthesized 
recently as part of a thesis.4
A crucial point in the further optimization 
will be the knowledge of the binding mode of 
the respective inhibitors. In the presented 
approach we used an extensive workflow for 
binding mode prediction to identify the most 
probable binding mode. The workflow 
combines docking into homology models of 
PfGSK-35, 6 with different docking programs, 
rescoring and complex minimization.7 The results will be presented here, they may 
help in understanding the structure activity relationships of existing inhibitors and 
give new impulses for further structural variations.  
1.  WHO, World Malaria Report 2009.
2.  WHO, Guidelines for the treatment of malaria - 2nd edition, 2010.
3.  Droucheau. E. et al Biochim. Biophys. Acta 2004, 1697, 181-196. 
4.  W Brandt. Neue Inhibitoren der Proteinkinasen PfGSK-3 und RET, 
Dissertation, TU Carolo-Wilhelmina Braunschweig, 2009.
5.  Kruggel, S.; Lemcke, T. Arch. Pharm. 2009, 342, (6), 327-332. 
6. Kruggel, S.; Lemcke, T. QSAR & Comb. Sci. 2009, 28, (8), 885-890. 
7. see related poster of Lemcke and Kruggel: The Search for the Right Pose
C167
THREE STEPS AHEAD? A COMPARISON OF STRUCTURE-BASED 
AND LIGAND-BASED VIRTUAL SCREENING METHODS 
Koelling, F.1, Baumann, K.1
1Pharmazeutische Chemie, TU Braunschweig  
Virtual Screening has become a standard technique in medicinal chemistry to 
screen huge purchasable or virtual compound libraries in silico for molecules 
showing activity at a certain biological target. Thus Virtual Screening affords the 
reduction of compound sets from millions to a few hundred substances, which can 
be tested with available biological assay capacities.  
As the amount of crystallographic data of proteins and co-crystallised inhibitors 
increases every year, structure based information supplies the medicinal chemist 
with striking information about a ligand binding to its target and may highlight the 
essential requirements a ligand needs for being an active molecule. If ligand–
receptor complex data are not available, working on a 3D crystal structure only, or, 
working on ligand data of known active substances are two promising alternatives. 
Here, three completely different virtual screening methods falling in three different 
categories are compared: LigandScout[1] a pharmacophore screening method that 
uses ligand-receptor complexes as input, FRED[2] a docking tool that uses receptor 
information only (i.e no co-crystallised ligand information is needed), and finally 
ROCS[3] that solely requires ligand information. 
The performance is evaluated in a retrospective screening on the FieldScreen[4]
dataset outlining strengths and weaknesses of each method for the scrutinized 
targets. This knowledge will help to design future prospective studies. 
References: 
[1] Ligandscout 3.0, inte:ligand, www.inteligand.com.
[2] ROCS,  openeye scientific software, www.eyesopen.com.
[3] FRED,  openeye scientific software, www.eyesopen.com.
[4] Cheeseright, T.J., Mackey, M.D., Melville, J.M., Vinter, J.G. FieldScreen: 
virtual screening using molecular fields. Application to the DUD data set. J. Chem. 
Inf. Model; 48, 2108-2117, 2008.  
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AZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR 
ANTAGONISTS 
Walter, M.1, Isensee, K.1, von Coburg, Y.1, Kottke, T.1, Ligneau, X.2, Camelin, J.-
C.2, Schwartz, J.-C.2, Stark, H.1
1Johann Wolfgang Goethe-Universität, Institut für Pharmazeutische Chemie 
2Bioprojet-Biotech, Frankreich 
Biogenic amines, such as histamine, play important roles as chemical mediators in 
human physiology.  Histamine mediates numerous central and peripheral effects 
via four known G protein-coupled receptor subtypes (hH1R-hH4R). Human 
histamine H3 receptors (hH3R) are acting as autoreceptors on synthesis and 
liberation of histamine as well as heteroreceptors on modulating the release of 
several other neurotransmitters (e.g., acetylcholine, dopamine, glutamate, 
noradrenalin, serotonin, GABA). Due to a distinct receptor expression pattern in 
the central nervous system (CNS) and their involvement in several neuronal 
functions, e.g., vigilance, attention and learning, the hH3R are attractive targets for 
the treatment of CNS disorders like schizophrenia, epilepsy, depression, 
Alzheimer’s disease, Parkinson’s disease and sleep disorders.1
Antagonist H3R ligands follow a general pharmacophore blueprint, containing a 
basic moiety, mostly a tertiary amine, linked by a spacer to a central core 
substituted by a variety of structural elements providing different physicochemical 
properties.2 In this investigation we focused on the variability of the core region by 
introducing polar heterocycles containing one to three nitrogen atoms (azoles) with 
different connecting moieties to the spacer. A diversity of structural motifs is used 
as substituents to optimize the receptor binding properties, which ranging from low 
nanomolar concentration to complete loss of affinity.  
We successfully introduced polar azole groups as new central core element in the 
hH3R antagonist pharmacophore and could establish a new structural class of hH3R
antagonists/inverse agonists showing the possibilities and limitations in structural 
variations on this central core element. 
References:  
1) Tiligada, E. et al., Expert Opin. Investig. Drugs. 2009, 18, 1519-31. 
2) Sander, K. et al., Bioorg. Med. Chem. Lett. 2010, 20, 1581-4.
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SYNTHESIS OF A FLUORESCENT ALLOSTERIC MODULATOR OF 
MUSCARINIC RECEPTORS  
Schmitz, J., Schmidt, I.,  Holzgrabe, U. 
Institute of Pharmacy and Food Chemistry, University of Würzburg, Am Hubland, 
97074 Würzburg, Germany 
Allosteric modulators of muscarinic receptors, such as W84 or naphmethonium, 
are established potent agents capable of selectively binding to the M2-subtype of 
the acetylcholine receptors M1-M5. They bind to a topographically different site 
than classical orthosteric ligands and are able to modulate the efficiency of 
orthosteric ligands by influencing both dissociation and association.1 The potency 
of allosteric modulators is determined indirectly by measurement of the inhibition 
of the dissociation of the orthosteric ligand N-methyl-scopolamine (NMS) or 
directly by use of a radiolabelled W84 derivative. Since fluorescent dye labelled 
allosteric modulators may help to directly characterize allosteric interactions and 
trace receptor trafficking by means of fluorescence correlation spectroscopy, the 
aim of this work was to synthesize a naphmethonium derivative which is suitable 
for a connection to the fluorescent dye Py-1. Therefore, several strategies to 
connect a primary amino group via an alkyl-spacer to naphmethonium were 
prosecuted. Finally, synthesis of a naphmethonium derivative via a chloride-
intermediate was successful. Subsequent conversion of this compound with Py-1 
which was synthesized according to the literature2 yielded the fluorescent 
naphmethonium derivative. 
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N N
+ N
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O
O
O
O
2 Br-
BF4-
spacer
naphmethonium mojety
Py-1 mojety
[1] Mohr, K.; Tränkle, C.; Kostenis, E.; Barocelli, E.; De Amici, M.; Holzgrabe, U. 
Br J Pharmacol 159 (2010), 997-1008. 
[2] Höfelschweiger, B. K. Dissertation (2005), Universität Regensburg. 
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BENZOTHIAZINONES – A NEW CLASS OF POTENT A1 ADENOSINE 
RECEPTOR ANTAGONISTS  
Schlenk, M., Paskaleva, M. , Iqbal, J. , Gäb, J. , Gütschow, M., Müller, C. E.
PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, 
Rheinische Friedrich-Wilhelms-Universität Bonn, Germany 
Several 3,1-benzothiazin-4-one derivatives originally synthesized as protease 
inhibitors were found to be potent antagonists at A1 adenosine receptors (ARs). 
We subsequently evaluated a larger series of compounds I and II with broad 
variation of the substitution pattern. The synthesized compounds were 
investigated in radioligand binding studies at rat A1, rat A2A, human A2B and 
human A3 receptors. Selected compounds were additionally examined in 
radioligand binding studies at human A1, human A2A, and rat A3 ARs in order to 
obtain information about potential species differences. The most potent 
compounds were further evaluated in adenylate cyclase and/or GTP shift assays. 
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       I        II 
The investigated benzothiazinone derivatives proved to be antagonists at adenosine 
receptors. Gü304 (II, R1 = Ph, R2 = H, R3 = H) was the most potent compound 
with a Ki value of 7.70 nM at rat and 65.5 nM at human A1 ARs. The compound 
also showed relatively high affinity for human A3 ARs (Ki = 30.4 nM). Some 
derivatives exhibited relatively high affinity for A2B receptors (Ki < 200 nM). In 
conclusion, we identified a novel chemical class of AR antagonists. The 
benzothiazinone scaffold was optimized towards high A1 affinity. It bears the 
potential for development of potent and selective antagonists for other AR subtypes 
as well, namely for A2B and A3 ARs.
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MULTITARGET APPROACH TOWARDS ALZHEIMER’S DISEASE 
BASED ON DUO DERIVATIVES 
Prinz, M.1, Alptuzun, V.2, Scheiber, J. 3, Fallarero, A.4, Holzgrabe, U. 1 
1Pharmacy, Uni Wuerzburg, 2Pharmacy, EGE University, Turkey, 3Roche, 
Penzberg, 4Pharmacy, University BioCity, Finland 
 
Based on DUO compounds, which are potent ditopic inhibitors of acetylcholin-
esterase (AChE) [1], but too long for the catalytic gorge, new compounds have 
been developed. Using roughly only one part of the molecule led to permanently 
positively charged molecules, which are not able to pass the blood-brain barrier 
(BBB) anymore [2]. Therefore the pyridinium ring was replaced by a piperidine 
ring whose nitrogen can be protonated. Modeling studies revealed that the loss of 
activity is due to the non-aromatic piperidine ring. Thus a “flat” pyridine 
hydrazone ring system was employed. These new lead compounds show satisfying 
inhibitory effects on AChE, as well as an activity on butylcholinesterase (BuChE) 
and seem to have inhibitory effects in ROS tests. Furthermore they inhibit the 
amyloid  fibril formation and lead to a disaggregation of preformed amyloid  
fibrils [3]. Even though the activity of these compounds has to be improved, they 
clearly show, that it is possible to develop multitarget molecules. New modeling 
studies point out a raised inhibitory effect on AChE elongating the hydrazone part 
or extending the conjugated system. Derivatives according to the modeling studies 
revealed a better inhibitory effect when the hydrazone part was elongated (eg 1), 
while extending the conjugated system shows only low improvements (eg 2). 
N
N
N N
N
NCl
Cl    
Eg. 1 (IC50 AChE 0.94±0.07μM)          Eg. 2 (IC50 AChE 0.063±0.009 μM) 
 
[1] P. Kapkova, N. Stiefl, U. Sürig, B. Engels, K. Baumann, U. Holzgrabe, Arch. 
Pharm. Med. Chem. 336, 523-540 (2003) 
[2] P. Kapkova, V. Alptüzün, P. Frey, E. Erciyas, U. Holzgrabe, Bioorg. Med. 
Chem. 14, 472-478 (2006) 
[3] V. Alptüzün, M. Prinz, V. Hörr, J. Scheiber, K. Radacki, A. Fallarero, P. 
Vuorela, B. Engels, H. Braunschweig, E. Erciyas, U. Holzgrabe, Bioorg. Med. 
Chem. 18, 2049-2059 (2010)
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CARBAMATES AS CNS-TARGETING BACLOFEN PRODRUGS: 
STUDIES WITH METHYL CARBAMATE 
Mosad,S.1, Eddiasty,I.1, Nieß, R.1, Abouzid, K.1, Hanafi, R.1, Abdel-Kader, R.1,
Spahn-Langguth, H.1,2,
1Faculty of Pharmacy & Biotechnology, German University in Cairo - GUC, New 
Cairo City, Egypt,  
2Institute of Pharmaceutical Sciences, Karl-Franzens-University, Graz, Austria  
Baclofen, a specific GABAB-receptor agonist, has successfully been used for deca-
des to treat spastic disorders. However, only intrathecal dosing provides direct bio-
phase access and yields effective CNS-levels, as indicated by the respective cere-
brospinal fluid concentrations. This implies that baclofen does not sufficiently per-
meate through the blood-brain-barrier.  
Since ester prodrugs of baclofen are not readily cleaved in vivo and were found to 
be subject to exsorptive transport, alternative prodrug concepts were evaluated. 
E.g., methyl 4-(tert-butoxycarbonyl amino) 3-(4chlorophenyl) butanoate (baclofen 
methyl carbamate) was synthesized and its solubility and log P were evaluated as 
bio-relevant parameters. Baclofen methyl carbamate was then tested vs. baclofen 
with respect to the obtainable target organ levels.  
Baclofen HCl as well as the methyl carbamate were dosed intraperitoneally to rats 
(baclofen dose: 1.0 mg/kg, carbamate dose, equimolar for direct comparability).  
Blood and brain samples were collected and the analytes quantified via RP-HPLC 
on an octadecylsilane stationary phase (gradient elution with pH2.6 0.1mM phos-
phate buffer/methanol mixtures; UV-eluate monitoring, 220 nm).  
It was found that the additional carbamate group in the baclofen methyl ester 
molecule had a significant influence, since the structural change was considerably 
decreasing the solubility in water and increasing the partitioning into lipophilic 
matrices. Maximum baclofen concentrations detected in brain tissue were almost 5-
times higher after carbamate dosage than after administration of baclofen itself. As 
opposed to parent baclofen the carbamate showed a rapid distribution into tissues 
after i.p. dosage.  In the blood compartment formation of baclofen was negligible. 
In the brain the prodrug was hydrolyzed to a remarkable extent, yet showing a 
delayed release profile for baclofen and reaching highest brain concentrations at a 
tmax of 3 hr. The possibility to simultaneously detect the respective ester via HPLC 
gave evidence that the methyl ester cleavage represents the first of two sequential 
metabolic steps regenerating baclofen in vivo. Hence, carbamate derivatives appear 
as very promising biolabile prodrugs for brain delivery of baclofen.  
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PYRIDINYL IMIDAZOLE COMPOUNDS AS SELECTIVE JNK3 
INHIBITORS
Klos, S., Bracht C., Laufer, S.
Pharmazeutische Chemie, Universität Tübingen 
The c-Jun terminal kinases (JNKs) are members of the mitogen activated protein 
(MAP) kinase family and regulate signal transduction in response to environmental 
stress. It is reported, that activation of JNK3 causes neurological damage and 
therefore JNK3 might be an interesting target for the treatment of neurological 
disorders.
Pyridinyl imidazoles are known as potent inhibitors of p38, which is a closely 
related MAP kinase family member differing at the ATP-binding site in only one 
amino acid at the gatekeeper region (Thr 106 vs. Met 146). The hydrophobic 
region II, a solvent exposed surface close to the ATP-site, is however less 
conserved.
By introduction of carboxylic acid moieties, targeting the hydrophobic region II, 
we obtained very potent inhibitors of JNK3 with high selectivity over p38.  
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SYNTHESIS OF ALLOSTERIC/ORTHOSTERIC HYBRID COMPOUNDS 
AS ANTAGONISTS FOR MUSCARINIC RECEPTORS 
Klöckner J.*, Kaufel D. #, Schmitz J.*, Mohr K.#, Holzgrabe U.* 
*Institute of Pharmacy and Food Chemistry, University of Würzburg, Am 
Hubland, 97074 Würzburg, Germany; 
#Institute of Pharmacy, Pharmacology and Toxicology, University of Bonn, 
Gerhard-Domagk-Str. 3, 53121 Bonn, Germany  
Among the five subtypes of muscarinic receptors the amino acid sequence of the 
orthosteric acetylcholine-binding site is highly conserved so that drugs that target 
the orthosteric site generally lack therapeutically relevant subtype selectivity.[1] 
However,  there is a second (allosteric) binding site that is less conserved among 
the different subtypes. Allosteric modulators that bind to this region have the 
ability to affect equilibrium binding of orthosteric agonists or antagonists.   
Fusion of appropriate building block of ligand of both binding sites was shown to 
yield a new class of highly selective and active muscarinic receptor agonists that 
combines allosteric subtype selectivity with orthosteric receptor activation.[2] In 
order to translate this concept directly to muscarinic receptor antagonists, the 
orthosteric agonistic building block, i.e. iperoxo, was replaced by the orthosteric 
antagonists atropine and scopolamine, respectively.  
Using [3H]N-methylscopolamine ([3H]NMS) as an orthosteric probe the binding 
affinities of the different compounds were determined at human receptors or 
mutant receptors, respectively, both being expressed in CHO cells. As the allosteric 
building blocks have highest affinity for the M2 receptor subtype and lowest for 
M5, binding affinity to these two subtypes was measured. The antagonist hybrid 
Naph6Atr displayed a relatively small but still significant M2/M5 subtype 
selectivity of 0.7 log units of affinity, whereas the antagonist atropine itself shows 
no appreciable selectivity. Additionally there is evidence that the appropriately 
designed antagonists also bind – in analogy to agonists – in a dualsteric mode at 
muscarinic receptors.  
The proof-of-principle is provided by this study, the M2/M5 selectivity has to be 
optimized in the future. The synthesis of corresponding derivatives is in progress.   
[1] De Amici et al. Med Res Rev. 2010, 30(3) 463-549 
[2] Antony et al. FASEB J 2009, 23(2) 442-450 
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“TRIVALENT” QUINAZOLINIMINES: HIGHLY POTENT AND 
SELECTIVE BUTYRYLCHOLINESTERASE INHIBITORS 
Chen, X. 1,2, Tikhonova, I. 2, Decker, M. 1,2 
1 Institut für Pharmazie, Universität Regensburg, Germany 2School of Pharmacy, 
Queen’s University Belfast, U. K. 
According to current research butyrylcholinesterase (BChE) compared to 
acetylcholinesterase (AChE) seems to represent an equally important target within 
the cholinergic system for treatment of cognition deficits in Alzheimer’s disease 
(AD). Tricyclic quinazolinimines have previously been identified as a novel 
structural template for cholinesterase (ChE) inhibitors. Homobivalent 
quinazolinimines bridged by alkylene spacers proved to be nanomolar inhibitors of 
both AChE and BChE. The degree of BChE selectivity was dependent on alicycle 
ring size. 
In this work, novel bivalent tricyclic quinazolinimines were synthesized: alicycle 
ring size, spacer length, and especially the chemical structure of the spacer 
(incorporating N-alkyl and N-acyl moieties) were systematically modified and 
investigated. Molecular modeling and docking procedures were applied to explain 
the data and probe the mid-gorge site of both ChEs.  
Intensive and systematic investigation into the different structural parameters with 
special regard to the spacer structure identified a compound with eight-atom 
spacer, eight-membered ring alicycles and a 4-methylpentanoyl moiety as the acyl 
part as a highly potent (IC50 = 3 nM) and selective inhibitor of BChE (>250-fold 
selectivity over AChE). Docking demonstrated the importance of the spacer 
structure on the compounds’ binding data characterizing them as “trivalent” 
inhibitors making use of the ChEs’ mid-gorge binding site. 
C176
2-AMINOTHIOPHEN-DERIVATIVES  
A NEW CLASS OF ANTAGONISTS OF THE GLUR6-RECEPTOR 
Briel, D.1, Rybak, A.1, Unverferth, K.2, Kronbach, C.2 
1University of  Leipzig, Faculty of  Biology, Pharmacy and Psychology  
2Biotie Therapies Corp., 01445 Radebeul 
 
Kainate receptors are interesting potential targets for the development of new anti-
epileptics. Among these receptors a special significance is ascribed to the kainate 
receptor subtype GluR6. This subtype is primarily expressed in the excitatoric 
pyramidal cells of the hippocampus. There are hints that the GluR6 and the GluR5 
subtype play an opposing role in the hippocampal activation. 
Compound 1 was our lead structure within the new class of thiophene derivatives 
with selective GluR6-antagonistic activity. Starting from 1 a number of compounds 
was synthesized and studied for their GluR5- und GluR6-inhibition in an in-vitro 
kainate-receptor  assay.  Thereby  the  structural  division  of  the  molecule  into  a 
hydrophobic (2: R3, R4) and a hydrophilic region (2: R1, NR2) was maintained. 
To get information  about  the  role  of  the  NR2-group  for the  receptor  binding 
the electron density and the H-donor properties of this molecular position were 
varied. The activities of the new derivatives were compared with that of compound 
1 (IC 50 = 0,75 M, GluR6 >100 M, GluR5 respectively). 
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N-ACETYL-5-ARYLALKOXYTRYPTAMINE ANALOGS: PROBING 
THE MELATONIN RECEPTORS TOWARDS MT1-SELECTIVITY  
Markl, Ch.1, Attia, M. I.1, Clafshenkel, B.2, Julius, J.2, Witt-Enderby, P. A.2,
Zlotos, D. P.3
1Pharmazeutische Chemie, Universität Würzburg 2School of Pharmacy, Duquesne 
University, Pittsburgh 3Pharmaceutical Chemistry, German University in Cairo 
The neurohormone melatonin (MLT, R = Me) exerts its physiological actions 
mostly via activation of  two  G-protein-coupled MT1 and MT2 receptors. An 
accurate characterization of MLT receptor-mediated functions requires MT1 and
MT2-selective ligands. While many series of MT2-selective agents are known, 
pronounced MT1-selectivity is still a challenge with only few examples reported up 
to date.1 The common structural feature of MT1-selective ligands is the presence of 
a bulky hydrophobic substituent in a position topologically equivalent to the MeO-
group of MLT. In order to probe the MLT receptors for MT1-selectivity, a series of 
MLT analogs obtained by the replacement of the ether methyl group with larger 
arylalkyl and aryloxyalkyl substituents was prepared. The most MT1-selective 
agents were substituted with a Ph(CH2)3 or a PhO(CH2)3 group. Both compounds 
displayed  higher MT1-affinity and selectivity than the most MT1-selective ligand 1
known up to date. 
1Zlotos, D. P.  Arch. Pharm. Chem. Life Sci. 2005, 338. 
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DIRECT FORMATION OF FUSED 1,3-THIAZINE-2,4-DITHIONES: 
OBSERVATION OF A CARBON DISULFIDE MEDIATED THIONATION  
Ottersbach, P.A. and Gütschow, M. 
Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der 
Immenburg 4, D-53121 Bonn, Germany 
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In the course of our investigations directed towards the synthesis of 3,1-
benzothiazines1 we explored a facile synthesis of 2H-3,1-benzothiazine-2,4(1H)-
dithiones (trithioisatoic anhydrides)2,3 or 2H-naphtho[2,3-d][1,3]thiazine-2,4(1H)-
dithione solely from anthranilic acids or 3-amino-2-naphthoic acid and carbon 
disulfide, performed at room temperature in 1,4-dioxane in the presence of Et3N.
Corresponding 2-alkylsulfanyl derivatives were obtained in one-pot reactions 
under the same conditions after addition of alkyl halides. The convenient 
procedures to directly form trithioisatoic anhydride derivatives proceed in 
moderate to excellent yields with fast and easy work up. 
The mechanism of the thiazine cyclization has been investigated with 13C-labeled 
carbon disulfide to reveal that carbon disulfide was incorporated into the 
heterocycle and additionally acted as a thionation reagent. The fact that carbon 
disulfide can facilitate a carbonyl oxygen-sulfur exchange is an almost unique 
observation until today.4
[1] Ottersbach, P. A. et al. Tetrahedron Lett. 2010, 51, 2727. [2] Wagner, G.; 
Rothe, L. Pharmazie 1971, 26, 271. [3] For the reactivity of trithioisatoic 
anhydrides see, for example, [a] Leistner, S. et al., Z. Chem. 1972, 12, 289. [b] 
Leistner S, et al. Monatsh. Chem. 1983, 114, 915. [4a] Polshettiwar, V.; Kaushik, 
M. P. J. Sulfur Chem. 2006, 27, 353. [b] Brillon, D. Sulfur Rep. 1992, 12, 297. 
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ENZYMATIC RESOLUTION OF AZO COMPOUNDS WITH 
QUATERNARY STEREOCENTERS 
Prechter, A.1, Dietz, F.2, Gröger, H.2, Heinrich, M.*,1 
1Pharmazeutische Chemie, FAU Erlangen-Nürnberg; 2Organische Chemie, FAU 
Erlangen-Nürnberg 
Only a few examples for the enzymatic resolution of compounds with quaternary 
stereocenters have so far been reported.[1] We have now developed a first two-step 
strategy to obtain enantiomerically enriched azo alcohols with quaternary carbon 
centers. Racemic azo compounds 1, which are accessible by a flexible 
methodology developed in our group,[2] were further converted to alcohols 2 by 
enzymatic resolution with an enantiomeric excess up to 87%. Further conversion to 
amino alcohols 3 and to amino acids 4 has been shown to be possible without 
significant loss of enantiomeric purity.[3]
In this pioneering approach radical and enzymatic methods have been successfully 
combined to open up a new synthetic access to a wide range of pharmaceutically 
relevant substances. 
[1]  a) S. Acherar, G. Audran, N. Vanthuyne, H. Monti, Tetrahedron:
Asymmetry 2003, 24132418; b) L. F. Solares, R. Brieva, M. Quirós, I. 
Llorente, M. Bayodb, V. Gotor, Tetrahedron: Asymmetry 2004, 341345.
[2]  a) M. R. Heinrich, O. Blank, S. Wölfel, Org. Lett. 2006, 8, 33233325; b) 
M. Heinrich, O. Blank, A. Wetzel, J. Org. Chem. 2007, 476484. 
[3] A. Prechter, F. Dietz, H. Gröger, M. R. Heinrich, patent application 2010.
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SYNTHESIS OF N- AND O-SULFONYLATED 5,6,7,8-TETRAHYDRO-
BENZO[4,5]THIENO[2,3-d]-PYRIMINDINE/QUINAZOLINE 
DERIVATIVES AND OBSERVATION OF A NO SULFONYL 
TRANSFER 
Mertens, M., Pietsch, M., Gütschow, M.
Pharmazeutisches Institut, Universität Bonn, D-53121 Bonn, Germany 
3-Phenylsulfonylquinazoline-2,4-diones were found as potent and covalently 
interacting inhibitors of chymotrypsin-type serine proteases.[1] The reactivity of 
their lactam carbonyl is increased by the electron-withdrawing arylsulfonyl group 
at the lactam nitrogen.[2] The direct conversion of the appropriate pyrimidine 
derivative with a sulfonyl chloride was considered to be the most convenient 
access to such compounds and was initially studied. Two possible products might 
be obtained in the course of this reaction due to the two nucleophilic sites (N-3 and 
O) of the pyrimidine ring. For the related alkylation of pyrimidine derivatives, an 
influence of the substituent in position 2 on the regioselectivity has been 
discussed.[3] We studied the regioselectivity of the direct sulfonylation of 1 and 
devised an alternative synthetic route to N-sulfonylated pyrimidinones 2.
Furthermore, a rearrangement was observed to produce 3 from 2. The underlying 
kinetics was monitored by HPLC. 
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[1] Fukami et al. Drug. Des. Discov. 2000, 17, 69-84. [2] Maruoka et al. Bioorg. 
Med. Chem. Lett. 2007, 17, 3435-3439. [3] Hori et al. Chem. Pharm. Bull. 1990,
38, 1286-1291.  
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NOVEL FLUOROETHYL-DERIVATIVES OF THEOPHYLLINE 
Schwan, G.1; Mährlein, M.1; Erdmann, S.1; Nieber, K.1; Briel, D.1
1Institut für Pharmazie, Universität Leipzig, Deutschland 
The xanthine derivatives theophylline, 7-(2-hydroxyethyl)-theophylline (etofylline) 
and 7-(2-chloroethyl)-theophylline (benaphylline) are well explored antagonists of 
adenosine receptors as well as unspecific inhibitors of PDE-enzyms. Based on 
these mechanisms theophylline and etofylline are commonly used therapeutics for 
airway diseases like COPD and asthma. 
We synthesized novel 7-fluoroethyl-derivatives of theophylline as electrosteres to 
etophylline respectively isosteres to benaphylline to complement the structure-
activity-relationships at adenosine receptors. Starting from theophylline, we 
alkylated using a variety of 2-fluoroethylhalides whereby the yield was decreased 
by increasing the number of fluorine atoms in the alkyl chain. Depending on the 
base, 7-(1-fluoro-2-iodo-vinyl)-theophylline was isolated as side product using 
2,2,2-trifluoro-1-iodethane undergoing an elimination of hydrogen fluoride. 
Cytotoxicity is investigated on human neuroblastoma-(SH-SY5Y), kidney-
(HEK293) and hepatocyte-(HEPG2) cell cultures using the MTT cell vitality assay 
and a lactate dehydrogenase assay. Until now there are no cytotoxic effects also 
after long-term incubation (48h) in the highest concentration (100 μM) detectable. 
The inhibition of adenosine receptors is temporally tested using binding assays. 
Furthermore, we expect activities on PDE-isoenzymes. 
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TRITYL RADICALS: SYNTHESIS AND ESR CHARACTERIZATION 
Müller, D., Metz, H., Mäder, K., Imming, P. 
Institut für Pharmazie, Martin-Luther-Universität Halle-Wittenberg 
Electron Spin Resonance (ESR, EPR) has been proposed for many years as a 
suitable tool for oxygen and pH measurement. [1] However, current limitations 
include low sensitivity due to broad lines of the probes, the superposition of several 
radical species with overlapping lines, non reliable performance and rapid signal 
loss. [2] Suitably substituted triarylmethyl radicals (TAM) would be ideal [3], but 
their use has been severely restricted by the very difficult synthetic accessibility. 
Using the example of the deuterated TAM 1, we present details of a synthetic 
procedure that addresses and solves major obstacles that were neglected hitherto 
[4], e.g. the preparation of the tetrathioarylether, the stability of the radical towards 
air, and factors influencing the shape and breadth of the ESR signal (solvent, 
conformation, concentration etc.).
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References: 1. Lurie, D. A. & Mäder, K. (2005) Adv. Drug Deliv. Rev. 57:1171-
1190. 2. Kempe, S., Metz, H. & Mäder, K. (2010) Eur. J. Pharm. Biopharm. 74:55-
66. 3. Andersson, S. et al. (1996) US Patent 5530140. 4. Dhimitruka, I. et al. 
(2010) Bioorg. Med Chem. Lett. 20:3946-3949. 
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ASSOCIATION OF ANGIOTENSIN II TYPE 2 (AT2) RECEPTOR GENE 
POLYMORPHISM -1332G/A WITH LEFT VENTRICULAR DYSFUNCTION IN A 
COHORT OF PATIENTS PRESENTING WITH CARDIOVASCULAR 
SYMPTOMS 
Ralf A. Benndorf1, Thomas Lutz2, Volker Rudolph3, Stephan Baldus3, Rainer H. Böger2
1 Clinical Pharmacy Unit, Institute of Pharmacology, Toxicology, and Clinical Pharmacy, 
University of Braunschweig, Germany 
2 Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology and 
Toxicology, University Medical Center Hamburg-Eppendorf, Germany 
3 Department of Cardiology, University Heart Center, Hamburg, Germany 
Background: The well-known biological functions of angiotensin II (Ang II), such as 
control of blood pressure, aldosterone secretion, vasoconstriction, and growth promotion, 
are elicited by activation of the ubiquitously expressed AT1 receptor. In contrast, the AT2 
receptor is only expressed at low levels in various tissues of the adult organism. 
Nevertheless, it is upregulated during cardiac and vascular injury and seems to 
counterbalance the effect of the AT1 receptor in these pathological conditions. The 
polymorphism -1332G/A (rs1403543) located in a branch-point site of the AT2 receptor 
gene has been associated with altered receptor expression and left ventricular hypertrophy. 
Objective: We assessed the association of the -1332G/A AT2 receptor gene polymorphism 
with left ventricular function in a cohort of patients presenting with cardiovascular 
symptoms at the University Medical Center Hamburg-Eppendorf between 2003 and 2005. 
Methods and Results: In 608 patients, we determined the -1332G/A polymorphism of the 
AT2 receptor gene and analysed its association with left ventricular function. Because of 
the X-chromosomal location of the AT2 receptor gene, heterozygous females were 
excluded from the analysis. Moreover, we collected follow-up data on mortality and 
cardiovascular complications, such as myocardial infarction, stroke, and revascularization 
during a mean of three years after inclusion of the patients. In cross-sectional analysis, the 
prevalence for reduced left ventricular function was elevated in patients carrying the -
1332A-allele [116 (47.2%) vs. 67 (34.9%); p=0.010]. In multivariate analysis adjusted for 
age, gender, BMI, hypertension, hypercholesterolemia, diabetes mellitus and nicotine 
abuse, the presence of the -1332A-allele was associated with reduced left ventricular 
function [OR 1.62 (95% CI 1.08-2.43; p=0.020)]. However, the gene variant was not 
associated with an increased incidence of mortality or cardiovascular complications in these 
patients. 
Conclusion: The -1332G/A polymorphism of the AT2 receptor gene is associated with a 
higher prevalence of left ventricular dysfunction, but not with mortality or cardiovascular 
complications in a cohort of patients presenting with cardiovascular symptoms. 
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INVESTIGATION OF ABSORPTION MODELS FOR NEVIRAPINE IN 
HEALTHY MALES TO SUPPORT MOTHER & NEWBORN DATA 
Frank, M.1, Van der Walt, JS.2,3, Kunz, A.4, Harms, G. 4 , Kloft, C.1
1Department of Clinical Pharmacy, Martin-Luther-Universitaet Halle-Wittenberg 
2Department of Pharmaceutical Biosciences, Uppsala University and 3Division of 
Clinical Pharmacology, University of Cape Town  
4Institute of Tropical Medicine, Charité-Universitaetsmedizin Berlin 
Objectives: To reduce the risk of HIV transmission from mother to child 
nevirapine (NVP) was given as prophylaxis in Uganda. 62 HIV positive pregnant 
women and newborns received a single oral dose of NVP. Population 
pharmacokinetic (PK) analysis was performed to characterise NVP PK in mothers 
and newborns. Due to sparse data situation rich data of NVP in healthy male 
volunteers were used to describe complex absorption processes of NVP. 
Methods: NVP-based prophylaxis consisted of 200 mg NVP tablets for women 
and healthy males and 2 mg/kg NVP syrup for newborns. 113 plasma samples of 
mothers and newborns as well as 95 breast milk samples were available for PK 
analysis of a combined model. 390 plasma samples of 26 volunteers were available 
to describe the PK of NVP in healthy males. Population PK analysis was 
performed using NONMEMTM. Appropriateness of model fit and performance was 
guided by various diagnostic tools. 
Results: Based on prior experiences for separate PK models [1] a combined 
population PK model for mothers and newborns was developed. First results 
suggest sufficient model performance. Due to the sparse data situation additional 
data of healthy males were used to describe complex absorption processes of NVP. 
A transit compartment model excelled zero-order and mixed-order absorption 
models. In a subsequent step, knowledge from population PK analysis of healthy 
males will be implemented in the combined PK model. 
Conclusion: Despite of the sparse data situation a first combined PK model for 
mothers and newborns was developed. Additional data of healthy males will be 
used to characterise the complex PK of NVP more adequately, especially the 
absorption process. The final PK model could guide dosing regimes for newborns 
to assist prevention strategies for HIV transmission from mother-to-child. 
References: [1] M. Frank et al. Population pharmacokinetic model development 
and evaluation after nevirapine administration to mothers and newborns. PAGE 18: 
1484 (2009). 
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DOXORUBICIN - STABILITY TESTING AND VALIDATION OF A 
HPLC-METHOD FOR A EUROPEAN PHASE II TRAIL IN CHILDREN 
Kontny, N.1, Krischke, M.2, Lanvers-Kaminsky, C.3, Schulze-Westhoff, P.3, Boos, 
J.3, Hempel, G.1
1Department of Pharmaceutical and Medical Chemistry – Clinical Pharmacy -, 
University of Muenster 2Center for clinical trials (ZKS), University Hospital 
Muenster 3Department of Paediatric Haematology and Oncology, University 
Children’s Hospital Muenster, Germany  
Background: Doxorubicin (Doxo) is a key component in the treatment of 
paediatric cancers. A better knowledge of the Doxo pharmacokinetics in children 
is needed because data on which to base current dosing regimens are limited. The 
EPOC consortium with participants from the UK, France, Germany and Italy 
conducts an investigator initiated trial (IIT) that aims to investigate the age-
dependency in the clearance of Doxo in children. Methods: IITs often cannot set 
as high quality standards as drug approval studies. In our HPLC-method for the 
quantification of Doxo and Doxorubicinol (Doxol) in human plasma, however, all 
working steps including the validation are performed in compliance to good 
clinical laboratory practise (GLCP) and the EMA´s “Guideline on Validation of 
Bioanalytical Methods”. Epirubicin is used as internal standard and analysis time 
is about 30 minutes. Applying a Purospher® STAR RP-18e column (Merck), a
gradient elution with water and acetonitrile, both with 0.1% formic acid, is used.
Results: To cover a concentration range from 5 to 1000 microgram per litre, we 
need only 100 microlitres of plasma to produce valid results. As required, the 
deviations between the mean accuracy values and the nominal values were less 
than 9% and less than 20% at the limit of determination. For precision the 
coefficients of variation did not deviate more than 11%. Dilution linearity, 
reproducibility and selectivity were demonstrated and we proved that there is no 
carry-over. Up to now, plasma samples and stock solutions are stable for 3 month; 
concentrations of stored samples did not decline more than 15% from 
concentrations of freshly prepared solutions. Future experiments are ongoing to 
investigate the long-term stability of Doxo and Doxol in plasma and stock 
solutions for one year. Furthermore, we plan to screen pre-analytical errors that 
can occur during sample collection. Conclusion: We managed to develop a 
GCLP-compliant method that requires only a small volume of blood. This allows 
us to get blood samples from very young children and, in addition to that, to draw 
blood by capillary blood sampling during Doxo infusion.  
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LEUKOPENIA IN CANCER PATIENTS RECEIVING HIGH-DOSE 
CHEMOTHERAPY AND MYELOSUPPORTIVE TREATMENT 
Nock, V.1,2, Lindauer, A.3, Jaehde, U.3, Kloft, C.1
1Martin-Luther-Universitaet Halle-Wittenberg, Dept. Clinical Pharmacy 
2and Graduate Research Training program PharMetrX, Halle, Germany 
3University of Bonn, Dept. Clinical Pharmacy, Bonn, Germany  
OBJECTIVES: Myelosuppression is one of the most important dose-limiting 
adverse events in many anticancer regimens. During a clinical study 19 patients 
received a combination therapy of carboplatin, etoposide and thiotepa/ifosfamid 
including peripheral blood stem cell retransfusion (PBSCT) and G-CSF treatment. 
The objective of the current data analysis was to describe the leukopenic effect in 
this regimen using pharmacokinetic/pharmacodynamic (PK/PD) modelling. 
METHODS: Individual pharmacokinetic profiles for the drugs were estimated and 
integrated into a PD model for myelosuppression [1] assuming an additive effect of 
the drugs on the proliferation rate of cells in bone-marrow (BM). Modelling and 
simulation activities were performed using NONMEMTM VI, statistical analyses 
using R 2.10. 
RESULTS: The median leukocyte count before therapy was 3.97x109 cells/L 
(range: 1.75-14.75x109 cells/L). Median nadir counts of 0.08 x109 cells/L (range 
0.02-0.14x109 cells/L) were reached after 236 h (±39 h), reflecting a grade 4 
leukopenia. Recovery to a leukocyte count above 3x109 cells/L (grade 1) was 
observed after a median time of 408 h (±75 h) for patients receiving PBSCT. PK 
parameter estimates for the drugs were in line with previous knowledge. The 
leukocyte time-course after nadir revealed a steep increase in concentration 
followed by a pronounced rebound after PBSCT. The mean maturation time of 
leukocytes in BM was 94.4 h for all patients except one, not receiving 
myelosupportive treatment. 
CONCLUSIONS: It was possible to integrate the generated individual PK profiles 
of the drugs in the PD model for leukopenia. Estimation of the PD parameters was 
precise although visual predictive checks (VPCs) suggest an improvement of the 
model by integration of the myelosupportive therapy in order to understand and 
manage this dose-limiting toxicity better and improve future chemotherapy. 
REFERENCES: [1] LE Friberg et al. Model of chemotherapy-induced 
myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713-
21 (2002) 
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LINEZOLID CONCENTRATIONS IN CYSTIC FIBROSIS PATIENTS: 
EVALUATION OF COMPETING PHARMACOKINETIC MODELS  
Schaeftlein, A.1,2, Keel, R.A.3, Kuti, J.L.3, Kloft, C.1
1Department of Clinical Pharmacy, Martin-Luther-Universitaet Halle-Wittenberg,  
 2 and Graduate Research Training program PharMetrX, Germany 3Ctr. for Anti-
Infective Res. and Dev., Hartford Hospital, Hartford , CT U.S.A.
Background: Linezolid, used for the treatment of serious infections, is thought to 
portray nonlinear pharmacokinetics (PK), whereby clearance decreases over 
time. This might be of clinical relevance for the special population of cystic 
fibrosis patients especially after multiple dosing. The objective of this 
analysis was to develop a PK model for this special population and compare 
the predictive performance with other suggested PK models. 
Methods: A linear classical two compartment model, a nonlinear, 
Michaelis-Menten model [1], a linear/nonlinear elimination mixture model 
[2] and a model with time-dependent inhibition [3] of linezolid were 
compared for describing and predicting the PK of 8 cystic fibrosis patients 
after 600 mg bid p.o. and i.v., single and multiple dose administration, in a 
cross-over design. All data analyses were performed using the nonlinear 
mixed-effect modelling approach (NONMEMTM). Model comparison was 
guided by the Akaike information criterion (AIC), goodness of fit (GOF) 
plots, and visual predictive checks (VPC). 
Results: (1) The patient linezolid data were best described by the time-
dependent inhibition model, based on the lowest AIC value (779) of all 
models (819-1080). (2) GOF plots showed that the Michaelis-Menten and 
the mixture model were less capable of describing the data compared to the 
other two models. (3) VPCs of the classical two compartment and time-
dependent inhibition model suggested that the latter better predicted the 
time-course in this population. 
Conclusion: The time-dependent inhibition model appeared to be most 
suitable to predict linezolid PK profiles of these cystic fibrosis patients. 
References: [1]. S. Swoboda et al. Eur J Clin Pharmacol, 66:291 (2010) [2]. 
AK. Meagher, A. Forrest et al. Antimicrob Agents Chemother, 47:548 
(2003) [3]. N. Plock et al. Drug Metab Dispos, 35:1816 (2007). 
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DEVELOPMENT AND EVALUATION OF INSTRUMENTS FOR HOME-
BASED MEDICATION REVIEWS  
Wüstmann, A.-F.1, Dipper, L.2, Fiß, T.3, Hoffmann, W.3, Kubiak, T.2, Ritter, C.A.1
Institutes of 1Pharmacy, Clinical Pharmacy, 2Psychology, and 3Community 
Medicine, Ernst-Moritz-Arndt-University of Greifswald 
OBJECTIVE: Patients with impaired mobility are a high-risk population for drug-
related problems (DRPs) such as adverse side effects or drug-drug interactions. 
They are, therefore, in urgent need of specialized pharmaceutical care provided by 
their community pharmacy. Standardized instruments are necessary to successfully 
conduct home-based medication reviews. METHOD: First, a questionnaire for 
home-based pharmacist-conducted medication reviews and a guide for detection 
and classification of DRPs in a structured approach were developed. Both were 
evaluated by six experts in a Delphi-like consensus approach. The questionnaire 
was further discussed in patient focus groups, while reliability of the guide was 
assessed by pharmacy students in their last year of education. RESULTS: By 
involving experts and patient focus groups standardized versions of questionnaire 
and guide were aimed for. In the first of a two-rounded Delphi-like consensus 
approach experts agreed at an average to 104.2, generally agreed to 8.5 and did not 
agree to 6.3 out of 119 aspects of a scoring list for the questionnaire. Concerning 
the guide, 167.6 out of 177 aspects were accepted, 2.7 generally accepted and 6.7 
not accepted. Reliability analysis revealed that in a constructed patient case 
carrying ten DRPs in a first round including 17 students, 3.3 +/-1.4 (range 1-6) 
DRPs were identified. In a second round with an improved version including 32 
students, 4.0 +/-1.5 (1-7) DRPs were detected. Interrater reliability was assessed 
among four groups of 5 students (3.6; 5.2; 3.2; 3.6 mean detected DRPs), and 
increasing group sizes of 2 (3.0) 5 (3.4), and 10 (4.0) students. In addition, a real 
patient case carrying two DRPs was assessed. Of all 35 students 28 (80%) detected 
both DRPs. Detection of both DRPs was also accomplished by 4/5 in 3 groups and 
3/5 in 1 group. Group size did not affect rating efficiency as 2/2, 4/5, and 9/10 
students identified both DRPs within the real patient. The Inter correlation 
coefficient (ICC) is 0.67. CONCLUSION: Both instruments are reliable to assess 
DRPs in home-based medication reviews of  patients with impaired mobility and 
can be implemented in prevalent models of pharmaceutical supply which are 
required to be established. 
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RANDOMIZED TRIAL COMPARING COMPLIANCE-MONITORING 
WITH ELECTRONIC OTCM-BLISTER PACKAGES AND MEMS®
Jekle, C.1, Krämer, I.1
1University Medical Center of the Johannes Gutenberg-University Mainz 
Background: The OtCM-system (Objective Therapy Compliance Measurement) is 
an innovative method for electronic compliance monitoring based on standard 
blister packages. So far MEMS® (Medication Event Monitoring System, Aardex, 
Switzerland), which works with conventional medicine bottles equipped with an 
electronic cap, represents the state-of-the-art technology for objective compliance 
measurement. Whenever the MEMS® cap is opened or a dosage form is taken from 
an OtCM-activated blister package, date and time are electronically documented. 
However, the quality of information gained is different. Each date/time 
combination retrieved from the OtCM-system correlates with removal of a single 
dose. In contrast the MEMS® cap openings can go along with removal of several 
doses at once or no dose. To verify the amount of actually removed doses the 
remaining medication is to be counted (pill count). The aim of this open, 
randomized, two-armed, prospective study was to compare both systems regarding 
quality of data, expenditure of time, functionality and practicability and to evaluate 
suitability and validity of the OtCM-system in clinical practice. 
Material and methods: The compliance measurement methods were compared in 
patients with potassium chloride replacement therapy over a four-week observation 
period. In parallel group design patients received Rekawan® retard capsules either 
in OtCM-activated blister packages or in MEMS® containers. At the end of the 
observation period patients were asked to fill out a questionnaire concerning the 
practicability of the respective system. Expenditure of time for preparation of the 
study medication and data analysis was documented. 
Results: 34 patients participated in the study over an average of 22 days. Taking- 
and dosing-compliance rates were similar in both groups. However, in the MEMS-
group the electronic data had to be substantiated by pill count and to be adapted 
when indicated. Functionality and practicability of the OtCM system were proven. 
Expenditure of time for preparation of medication and evaluation of data is less for 
the OtCM-system. 
Conclusion: OtCM-activated blister packages provide more reliable registration of 
medication removals and more valid information about dosing-compliance than the 
MEMS® caps. 
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POTENTIALLY INAPPROPRIATE MEDICATIONS – A GERMAN-IRISH 
COMPARISON IN THE RESIDENTIAL HOME CARE SETTING 
Kruse J.1, O’Sullivan D.2, Hempel G.1, O’Mahony D.3, Byrne S.2 
1Institute of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, 
Westfälische Wilhelms-Universität Münster, Germany  
2Pharmaceutical Care Research Group, School of Pharmacy, University College 
Cork, Cork, Ireland 
3School of Medicine, University College Cork and Department of Geriatric 
Medicine, Cork University Hospital, Cork Ireland  
 
Introduction: The prescribing of potentially inappropriate medications (PIMs) is a 
common problem. To determine the quality of inappropriate prescribing in the 
elderly ( 65 years) living in a residential home setting, a comparative study 
between two European countries (Germany and Ireland) using the STOPP 
screening tool was conducted. Methods: Prescriptions, diagnoses and biochemical 
data of residents from 4 nursing homes in the South of Ireland (n=127) were 
recorded. Corresponding to age and gender these data were matched with data from 
7 nursing homes in Münster (n=370). In total 115 matched pairs of residents were 
reviewed in using the STOPP screening tool to assess the prevalence of PIMs. 
Results: Each cohort consisted of 102 (88.7%) women and 13 men (11.3%), mean 
age 83.8 ± 7.4 years. A total of 1308 prescriptions were recorded in the Irish cohort 
(mean 11.8 ± 3.8), which corresponded to 1422 documented diagnoses (mean 11.4 
±4.0). The German cohort received a total of 1419 prescriptions (mean 12.2 ± 4.9), 
corresponding to 1232 diagnoses (mean 10.6 ± 4.3). The total number of PIMs 
detected in the Irish group was 267 (median 2, IQR 1-4). 87 Irish residents (75.7%) 
received at least one PIM. In the German cohort the total number of detected PIMs 
was 170 (median 1, IQR 0-2), while 76 residents (66.1 %) received at least one 
PIM. The amount of the criterion B7 (long-term use of long-acting 
benzodiazepines) was 14 (5.2%) in the Irish cohort. In the German cohort there 
was only 1 patient (0.6%), receiving a long-acting benzodiazepine, but in the 
German cohort the usage of Antipsychotics was higher. Conclusions: In both 
countries the prevalence of PIMs is high. A lower number of PIMs were identified 
in the German residential home setting. This might be due to a different prescribing 
practice in the two countries. The Irish cohort has a higher use of long-acting 
benzodiazepines, counted as PIMs. Antipsychotics, which were mostly not 
identified as PIMs, are more common in the German cohort. Further research has 
to be done to evaluate the reasons of these outcomes. 
K191
PAIN IN NURSING HOME RESIDENTS – CHALLENGES AND 
OPPORTUNITIES FOR APPROPRIATE THERAPY 
Kölzsch, M.1, Kopke, K.2, Ellert, S.2, Wulff, I.2, Kalinowski, S.2, Dräger, D.2,
Kreutz, R.1
1 Institute of Clinical Pharmacology and Toxicology, Charité - 
Universitätsmedizin Berlin 
2 Institute of Medical Sociology, Charité - Universitätsmedizin Berlin 
Background 
Pain is one of the most important syndromes in the elderly population, particularly 
in nursing home residents (NHR). Our aim was to evaluate pharmacotherapy of 
pain in nursing home residents in Berlin and Brandenburg, Germany. 
Methods
We conducted a study to interview NHR and to assess pain and pain medication. 
Quality of pain medication was assessed with the “Pain medication appropriateness 
scale“ (PMAS). In this scale, developed in 2006 in the US, pain control is 
classified on a percentage scale in which a score < 67% indicates poor pain control. 
Data on pain intensity, all medication prescribed to the subjects, and surgery 
procedures or injuries during the last 3 weeks were collected. 
Results 
Overall, 321 residents having pain or receiving scheduled pain medication were 
eligible for analysis. From these, 196 were able to report pain themselves during 
the interview, 98 NHR with cognitive impairment showed pain-associated 
behavior, and 27 individuals received scheduled pain medication but did not 
complain about pain. 
Scheduled analgesics were prescribed to 179 residents; the most frequently 
prescribed drugs were metamizol, fentanyl and tramadol. 
For the 321 residents the mean PMAS score was 49%. Overall, about 75% of all 
subjects had a PMAS score below 67%. Furthermore, two thirds of NHR with 
prescribed opioids according to WHO step 3 were not treated with laxatives for 
prophylaxis of constipation. 
Conclusion 
Our results demonstrate some problems in pain pharmacotherapy in NHR in 
Germany. These results should serve as a basis for practice guidelines aiming at 
eliminating these deficits to improve pain therapy in the elderly. 
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MULTIDISCIPLINARY INTERVENTION TO OPTIMISE TUMOR PAIN 
THERAPY AND SYSTEMATIC MONITORING OF ADVERSE EVENTS  
Bertsche, T.1, Askoxylakis, V.2, Habl, G.2, Tireford, A.3, Laidig, F.1, Kaltschmidt, 
J.1, Schmitt, S.P.W.1, Ghaderi, H.4, Zabel-du Bois, A.2, Milker-Zabel, S.2, Debus, 
J.2, Bardenheuer, H.J.4, Haefeli, W.E.1
1Clin. Pharmacol. & Pharmacoepid., Coop. Unit Clin. Pharmacy, Univ. Heidelberg; 
2Radiation Oncology, HD; 3Pharmacie, CHU Grenoble; 4Anaesthesiol., HD 
Introduction
A high fraction of tumor patients are not treated appropriately. Clinical pharmacists 
and computerised clinical decision support systems (CDSS) enhanced therapeutic 
outcomes in many areas. We aimed to assess (i) the impact of a multidisciplinary
intervention in tumor pain therapy based on a newly developed CDSS and (ii) the 
prevalence of analgesia-related adverse events (AEs) to identify additional fields 
that should be addressed by further interventions.
Patients and Methods
After ethical approval a two-step study was performed in consecutive tumor 
patients: (i) a prospective controlled study in two groups (control, intervention) to 
decrease guideline deviations in pain therapy (primary endpoint) by a pain 
management based on a CDSS, (ii) an observational study to identify analgesia-
related AEs by a daily monitoring procedure. Fisher’s-Exact-Test and Mann-
Whitney-U-Test were used as appropriate (significant with p<0.05). 
Results
(i) Out of 279 recommendations, 85% were fully accepted by the physicians. The 
number of patients with guideline deviations decreased from 37 to 7 (p<0.001, 
n=50 consecutive patients per group) and of those treated with co-analgesics 
increased from 23 to 33 (p=0.04). In the intervention group, median pain assessed 
by visual analogue scale decreased at rest from 3 (Q25%-Q75%: 2-5) on admission 
to 1.5 (1-2) at discharge (p<0.01) and during physical activity from 7 (5-9) to 2.5 
(1-5; p<0.001). (ii) In 106 consecutive patients 11% suffered from vomiting, 41% 
from nausea, and 36% from constipation. During their hospital stay 31% and 65% 
of all pain patients were not treated with an antiemetic or a laxative, respectively. 
Conclusion
A multidisciplinary intervention based on a newly developed CDSS ameliorates 
pain treatment. A high fraction of analgesia-related AEs and a high rate of patients 
not appropriately treated with antiemetics and laxatives indicated that supportive 
therapy should be addressed in further interventions (e.g. by an optimised CDSS).  
K193
MEDICATION ERRORS IN PEDIATRIC INPATIENTS: 
IDENTIFICATION AND PREVENTION BY A CLINICAL PHARMACIST 
Jaffan L., Gorny M., Läer S.
Department of Clinical Pharmacy and Pharmacotherapy. Heinrich-Heine-
University of Düsseldorf, Germany
Background Pharmacotherapy in children implies complex and individual 
treatment regimens. Processes of drug prescription or administration drugs in 
children give rise to medication errors. In order to increase safety in pediatric 
pharmacotherapy, susceptible domains for these medication errors have to be 
identified and ideally prevented to avoid harm. Methods During a 12-month period 
a clinical pharmacist was assigned to review medication order sheets twice a week 
and participated in medical rounds once a week on the pediatric ward for 
cardiology and pneumology at the university hospital of Duesseldorf. Due to 
ethical reasons, the medication errors were immediately discussed by the clinical 
pharmacist and the responsible physicians to avoid harm to the patients. Then, an 
intervention was made and the prescription was corrected. Medication errors were 
collected, number and types were determined, classified with a modified PCNE-
System1 and the severity of the medication errors according to the NCC MERP 
index2. Results The clinical pharmacist reviewed 413 patient charts with 2322 
prescriptions and 214 different drugs. Mean age of the patients was 6.5 years. Out 
of the 2322 prescriptions 393 medication errors were identified. The types of error 
classified with the PCNE-System1 were: “documentation” (363) and “therapy” 
(30). According to the severity, the errors could be classified as “potential errors” 
(44%), “errors which did not reach the patients” (48%), “errors reached patients 
without harm” (8%) and “errors need monitoring” (1%). Conclusion There are 
profound problems in the quality management of routine drug prescription in the 
hospital. Our analysis revealed that one out of six prescriptions needed to be 
corrected. According to the clinical pharmacist´s intervention, 92% of errors could 
be avoided.  
1 Pharmaceutical Care Network Europe. PCNE classification for drug-related problems: 
http://www.pcne.org/dokumenter/DRP/PCNE%20classification%20V5.01.pdf (accessed 30/06/2010).  
2 National Coordinating Council for Medication Error Reporting and Prevention. Index for Categorizing Medication Errors. 
http://www.nccmerp.org/medErrorCatIndex.html (accessed 30/06/2010). 
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MRP INHIBTORS INCREASE PLATINUM ACCUMULATION UPON 
EXPOSURE OF TUMOR CELLS TO OXALIPLATIN 
Mohn C. 1, Häcker H.-G. 2, Kalayda G.V. 1, Gütschow M. 2, Jaehde U. 1
1Clinical Pharmacy and 2Pharmaceutical Chemistry I, Institute of Pharmacy, 
University of Bonn, 53121 Bonn 
The mechanisms leading to oxaliplatin resistance resemble those of cisplatin 
resistance, including lower intracellular platinum accumulation, increased 
intracellular glutathione (GSH) levels and efflux via multidrug resistance-
associated proteins (MRP). To further elucidate the efflux mechanism of platinum 
complexes via MRP1 and MRP2, we investigated the effect of MRP inhibitors on 
platinum accumulation and determined intracellular GSH levels under various 
conditions.
Cells of the human ileocecal colorectal adenocarcinoma cell line HCT8 and its 
oxaliplatin-resistant variant HCT8ox were incubated with oxaliplatin (100 μM) and 
the GSH-depleting agent buthionine sulfoximine (BSO) as well as different 
concentrations of the MRP inhibitors Gü831 or indometacin. Intracellular platinum 
concentrations were determined using graphite furnace AAS. GSH was quantified 
after derivatisation with 2,3-Naphthalenedicarboxaldehyde using a microplate 
assay. Platinum and GSH concentration were related to the protein content 
determined by the bicinchoninic acid (BCA) assay. The effect of BSO on 
oxaliplatin cytotoxicity was assessed using the MTT assay. 
Coincubation of HCT8 and HCT8ox cells with oxaliplatin and indometacin or 
Gü83 led to an increased accumulation of platinum. The effect was shown to be 
concentration-dependent. The addition of oxaliplatin and/or Gü83, however, had 
no effect on the intracellular GSH content. Depletion of intracellular GSH levels by 
addition of BSO prior to oxaliplatin addition led only to a slight increase in 
oxaliplatin cytotoxicity and to no change in platinum accumulation. 
The observed increase of platinum accumulation indicates that MRP1 and/or 
MRP2 contribute to platinum efflux from the cells investigated and is not limited to 
resistant cells. The role of GSH still remains unclear. Further investigations are 
required to identify the chemical species transported.   
1Leyers S et al. Bioorg Med Chem Lett 2008; 18: 4761–3 
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CONTRIBUTION OF NA+/K+-ATPASE TO PLATINUM 
ACCUMULATION IN OVARIAN CARCINOMA CELLS 
Schneider, V.1, Kalayda, G.V.1, Jaehde, U.1
1 Institute of Pharmacy, Clinical Pharmacy, University of Bonn, D-53121 Bonn 
Cisplatin is one of the most effective drugs in the treatment of ovarian cancer. 
However, its therapeutic potential is limited by intrinsic or acquired resistance.  
A frequently observed mechanism of resistance is decreased cellular accumulation 
of cisplatin. In addition to passive diffusion, platinum uptake is also mediated by 
active or facilitated transport. One of the transporters assumed to be involved in the 
intracellular accumulation of cisplatin is Na+/K+-ATPase, which utilizes ATP 
hydrolysis as an energy source.  
In order to investigate the role of Na+/K+-ATPase in cisplatin uptake in the ovarian 
carcinoma cell line A2780 and its cisplatin-resistant variant A2780cis, we assessed 
the influence of ouabain, a specific Na+/K+-ATPase inhibitor, and oligomycin, a 
depletor of intracellular ATP levels, on platinum accumulation. 
Intracellular platinum concentrations (ng Pt/μg protein) were measured by flame-
less atomic absorption spectrometry (FAAS). The respective protein concentrations 
were measured with the bicinchoninic acid (BCA) protein assay. 
Pretreatment with different concentrations of ouabain for 1 hour led to a decreased 
platinum accumulation in the sensitive A2780 cell line up to 33.7 ± 8.8 % (mean ± 
SEM; n = 4). However, no influence of ouabain on platinum uptake was observed 
in the resistant A2780cis cells.
Additionally, we examined the accumulation of cisplatin in oligomycin-treated 
cells. Under the conditions of ATP deficiency, the intracellular platinum accu-
mulation after 60 minutes of incubation was significantly reduced to 53.9 ± 10.4 % 
and 72.7 ± 10.8 % (mean ± SEM; n = 5) in A2780 and A2780cis cells, 
respectively, compared to standard culture conditions. 
Our results indicate that cisplatin is to some extent taken up by energy-dependent 
processes in the sensitive A2780 cells, whereas cisplatin uptake in the resistant 
A2780cis cells seems to be less dependent on intracellular energy sources. In 
addition, Na+/K+-ATPase may be directly or indirectly involved in cisplatin uptake 
in A2780 cells in contrast to resistant cells. Interestingly, the ATP-depletor 
oligomycin reduced the accumulation of cisplatin to a higher extent compared to 
ouabain, indicating the existence of other energy-dependent processes beside 
Na+/K+-ATPase regulating cisplatin uptake. 
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PHARMACOKINETICS AND PHARMACODYNAMICS OF 
SUNITINIB AND SU12662 IN COLORECTAL CANCER PATIENTS  
Kanefendt, F.1, Lindauer, A.1, Kinzig, M.2, Strumberg, D.3, Scheulen, M.4, Mross, 
K.5, Fischer, R.6, Moritz, B.7, Sörgel, F.2, Jaehde, U.1
1Clinical Pharmacy, University of Bonn 2IBMP-Institute for Biomedical and 
Pharmaceutical Research, Nürnberg-Heroldsberg 3Marienhospital Herne, Department of 
Hematology and Oncology 4University Hospital of Essen, Department of Internal Medicine 
and Tumor Research 5Tumor Biology Center Freiburg, Department of Medical Oncology 
6University Hospital of Freiburg, Department of Gastroenterology 7CESAR-Central 
European Society for Anticancer Drug Research - EWIV, Vienna 
Background. Sunitinib has been shown to influence the plasma concentrations of 
various circulating proteins which can serve as biomarkers for its anti-angiogenic 
properties. In this study plasma concentrations of sunitinib, its active metabolite 
(SU12662) and three biomarkers were determined in patients with metastatic 
colorectal cancer patients within the clinical study C-II-005. A thorough 
understanding of the dose-concentration-effect relationship of sunitinib is a 
prerequisite for the development of a biomarker-guided treatment optimization 
strategy. 
Methods. Patients received 37.5 mg sunitinib daily in addition to FOLFIRI (n=17). 
Plasma concentrations of sunitinib and SU12662 were determined by LC-MS/MS 
and those of VEGF-A, sVEGFR-2, and sVEGFR-3 by immunoassays. Plasma 
concentrations and biomarker response were compared with a dataset previously 
obtained in 12 healthy volunteers (Lindauer et al. 2010).  
Results. After one day ‘on treatment’ no differences in the plasma concentrations 
of the active drug relative to the given dose were observed for both populations. 
Plasma concentrations of VEGF-A increased immediately after administration 
exhibiting a large inter-individual variability. Maximum response of the soluble 
receptor levels was observed at the end of each cycle with concentrations of 52-
94% (sVEGFR-2) and 32-96% (sVEFGR-3) of the respective baseline values. All 
biomarker levels returned to baseline after two weeks ‘off treatment’. 
Conclusion. Plasma concentrations of sunitinib and SU12662 as well as the 
observed changes in biomarker levels seemed to be comparable between the 
populations in relation to the duration of sunitinib treatment. The PK/PD models 
previously developed for healthy volunteers are currently adapted to describe 
concentration-effect relationships also in cancer patients.   
Reference. Lindauer A et al. Pharmacokinetic/pharmacodynamic modeling of biomarker 
response to sunitinib in healthy volunteers. Clin Pharmacol Ther 2010; 87:601-8
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HOMOCYSTEINE AS BIOMARKER IN A PK/PD MODEL OF 
METHOTREXATE IN YOUNG ALL PATIENTS 
Rühs, H.1, Panetta, J.C.2, Pui, C.H.2, Relling, M.V.2, Jaehde, U.1
1Department of Clinical Pharmacy, University of Bonn 2St. Jude Children’s 
Research Hospital, Memphis 
Objectives: Elevated homocysteine concentrations have been associated with 
neurotoxic symptoms upon chemotherapy with methotrexate (MTX). The aim of 
this study was to develop a PK/PD model based on plasma MTX and homocysteine 
concentrations measured in patients with acute lymphoblastic leukemia (ALL) as a 
basis for the development of improved dosing regimens with a lower risk of 
neurotoxicity. 
Methods: Based on methotrexate and homocysteine plasma concentration data 
from 388 ALL patients of the TOTAL XV study [1] a PK-PD model was built with 
NONMEM 7.1 using the FOCE interaction method. Several compartmental and 
indirect response models were investigated to describe the PK/PD relationship. 
Body size, age, sex and renal function were investigated as potential covariates on 
the model. 
Results: The PK of MTX could be described by a two-compartmental model, 
parameterized by CL, V1, Q and V2. Considering the wide range of age (1-18 
years) and the heterogeneous degree of maturation in the population an allometric 
scaling was included. Creatinine clearance was positively related to MTX CL 
(p < 0.001). The relationship between MTX and homocysteine concentrations 
could be described by fitting an indirect response model with impaired elimination 
of homocysteine. A lower elimination rate constant for homocysteine (kout) was 
positively associated with MTX concentrations (p < 0.001) using an inhibitory 
Emax model. 
Conclusions: Our semi-mechanistic PK-PD model describes the methotrexate and 
homocysteine concentrations of young ALL patients. The model is currently 
evaluated.
References: [1] Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste 
SC, Ribeiro RC, Rubnitz JE, Raimondi SC,Onciu M, Coustan-Smith E, Kun LE, 
Jeha S, Cheng C, Howard SC, Simmons V, Bayles A, Metzger ML,Boyett JM, 
Leung W, Handgretinger R, Downing JR, Evans WE, Relling MV. Treatment of 
childhood acutelymphoblastic leukemia without cranial irradiation. N Engl J Med 
360:2730-41, 2009.  
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IS THE INTAKE OF STANDARDISED GINKGO BILOBA EXTRACT 
ASSOCIATED WITH A BLEEDING RISK? 
Kellermann, A., Kloft, C.
1Department of Clinical Pharmacy, Martin-Luther-Universitaet Halle-Wittenberg 
Background: During Ginkgo biloba leaf extracts intake, there have been several 
case reports of unexpected bleeding. Despite several studies of very different 
quality and to provide a higher level of evidenence, a systematic review and meta-
analyses were undertaken to determine the effect of standardised Ginkgo biloba 
extract (GBE) on outcomes of haemostasis associated with risk of bleeding. 
Methods: The Medline, Embase, SciSearch and Cochrane CENTRAL databases 
were searched to identify all randomised controlled clinical trials measuring 
parameters of primary or secondary haemostasis. Inclusion criteria were p.o. 
standardised GBE medication for at least one week. For statistical analysis, the 
software RevMan® 5 (The Nordic Cochrane Centre, Copenhagen) version 2008 
was used. According to the type of continuous data three statistical methods were 
used: weighted mean difference (WMD), standardised mean difference (SMD) and 
generic inverse variance (GIV) [1].
Results: A total of 1979 adults (87% diseased patients), receiving GBE or placebo 
was investigated. Random-effects models of effects on baseline change or mean 
difference [95% CI] showed a positive effect of GBE on blood flow (reduced blood 
viscosity: WMD -1.03 mPa sec [-1.29;-0.78]), but no evidence of any effect on
thrombocyte aggregation and coagulation (ADP-induced thrombocyte aggregation: 
WMD -0.35 % [-15.16;+14.46], fibrinogen: GIV -1.32 mg/dL [-10.66;+8.01], PT: 
SMD 0.00 [-0.09;+0.09], PTT: WMD -0.42 sec [-0.92;+0.09]). Subgroup analyses 
revealed a statistically significant reduction in PTT for subgroups receiving high-
dose GBE of >240 mg/d (WMD -0.45 sec [-0.83;-0.08] and for studies only 
including patients vs. healthy volunteers (WMD -0.61 sec [-0.95;-0.27], 
respectively, both without being of clinical relevance. 
Conclusion: Based on these meta-analyses of outcomes of haemostasis, 
comparison between GBE treatment and placebo groups did not indicate a higher 
risk of bleeding associated with standardised Ginkgo biloba leaf extracts, 
ultimately contributing to an informed evaluation of (self-)medication for patients. 
References: [1] Higgins JPT, Green S. Cochrane Handbook for Systematic 
Reviews of Intervention. The Cochrane Collaboration 2008; Version 5.0.1.
Available from: URL: http://www.cochrane-handbook.org/, accessed Feb. 4, 2010. 
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DEVELOPMENT OF A MULTIPROFESSIONAL TUMOR THERAPY 
MANAGEMENT
Döhler N1, Krolop L1, Ringsdorf S1, Meier K2, Ko YD3, Kuhn W4, Jaehde U1
1Klinische Pharmazie, Universität Bonn 2Krankenhausapotheke Heidekreis-
Klinikum GmbH, Soltau 3Internistische Onkologie, Johanniter-Krankenhaus Bonn 
4Frauenklinik, Universitätsklinikum Bonn 
Introduction: Systemic cancer therapy is complex and associated with a high 
incidence of adverse drug events. The aim of the project is to define the role of 
physicians, pharmacists and nurses in a multiprofessional tumor therapy 
management model. 
Methods: Focus group meetings were held to identify different tasks as part of the 
multiprofessional tumor therapy management model. The modified Delphi 
technique was used to allocate these tasks to physicians, nurses and pharmacists by 
local cancer care teams. Physicians, nurses and pharmacists have been approached 
nationwide by the ’Deutsche Krebsgesellschaft’, Germany’s largest 
multiprofessional association in oncology, via an online questionnaire to assess the 
acceptance of the presented multiprofessional tumor therapy management model. 
Additionally the professions’ perceptions on benefits and problems of 
multiprofessional teamwork were explored.
Results: Two focus group meetings of six clinical pharmacists and one moderator 
identified 38 multiprofessional tumor therapy management tasks. Two Delphi 
rounds with 12 participants (five nurses, four physicians, three pharmacists 
working together in three different cancer care teams) allocated these tasks to the 
different professions. The results of the online questionnaire show that the proposal 
was found to be reasonable (79% agreement, 11% disagreement; n=344), practical 
(65% agreement, 15% disagreement; n=337), time-saving (60% agreement, 15% 
disagreement; n=333), quality-enhancing (67% agreement, 15% disagreement; 
n=338) and feasible (68% agreement, 10% disagreement; n=335).  
Conclusions: Our multiprofessional tumor therapy management model was 
generally accepted by the different professions. Moreover, problems and benefits 
of teamwork stated by the participants emphasized the need to (re)structure 
multiprofessional teamwork. Based on our model, more specialized models 
concerning e. g. medication adherence and supportive therapy strategies such as 
fatigue and nutrition can be developed and implemented according to the patient’s 
needs.
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ADVERSE DRUG EVENTS IN GERMAN NURSING HOMES 
Schröder, F.1, Bernard, S.2, Hanke, F.3, Schmiedl, S.2,  Jaehde, U.1, Thürmann, P.2
1Klinische Pharmazie, Pharmazeutisches Institut der Universität Bonn, 2Helios
Klinikum Wuppertal, Klinische Pharmakologie Private Universität 
Witten/Herdecke gGmbH,3GeroPharmCare GmbH, Köln  
Increasing age is frequently linked with multiple chronic diseases and 
polymedication. Furthermore, aging-related physiological changes may affect the 
pharmacokinetics and pharmacodynamics of administered drugs increasing the risk 
of adverse drug reactions. International studies show that drug-related problems are 
common in elderly care facilities leading to medical and economic consequences. 
However, no systematic study has been conducted in German nursing homes so far.  
In this prospectively designed cross-section analysis 2 clinical pharmacists 
surveyed the medical documentation of 789 nursing home residents in North Rhine 
Westphalia, Germany. Potential drug-related incidents were evaluated in 
cooperation with experts in clinical pharmacology and geriatrics to identify the 
presence, severity, and preventability of adverse drug events as well as the effects 
on the resident. This analysis is the first part of the study entitled “Drug Therapy 
Safety in Nursing Homes – cross-section analysis and feasibility of a 
multidisciplinary approach” which is funded by the Federal Ministry of Health 
(BMG) as part of the national campaign on “Medication safety (AMTS)”.  
In total, 102 adverse drug events were detected over a 30 day period of which   
62.7% (64) newly occurred during that period resulting in an overall rate of 8.11 
adverse drug events per 100 resident-months. 57.8% (37) out of the 64 events were 
judged preventable. Of all adverse events 30% were classified according to 
CTCAE as severe, disabling or life-threatening leading to a hospitalization rate of 
27.3%. Adverse drug reactions most commonly happened upon neurological/ 
psychiatric (36%) and cardiovascular (27%) medications as well as antiinfectives 
(12%).  Errors associated with adverse drug events occurred mainly at the stages of 
interdisciplinary communication, drug administration and monitoring in association 
with necessary dose adjustments.  
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A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL 
FOR HIGHDOSE LONGTERM INFUSION CARBOPLATIN 
Boven-Krohn, D.1, Hempel, G.1
1 Department of Pharmaceutical Chemistry – Clinical Pharmacy – University of 
Muenster, Germany 
Objectives: Carboplatin (CARBO) is a widely-used potent cytostatic drug for 
different malignancies in adults and children. Carboplatin is a lipophilic substance 
(-1,5 log Units) with a molecular weight of 373,26g/mol and a unbound-fraction of 
about 80% in Plasma. The main excretion route is via glomerular filtration. It’ s 
pharmacokinetic is well-characterized with a high interpatient variability 
depending on the individual renal clearance. Cytostatic action and inverse action 
(mainly thrombocytopenia) are strongly associated with the achieved Carboplatin-
Area under the curve (AUC). The aim of the current project was to evaluate a 
generic PBPK model for high-dose carboplatin to predict the individual systemic 
drug exposure.  
Methods: The simulations of carboplatin were performed by using the software 
PK SIM® and MoBi®(both BAYER TECHNOLOGY SERVICES, Leverkusen). 
The model was developed and evaluated by using concentration-time profiles from 
patients receiving highdose carboplatin (Eickhoff PhD Thesis 2000). The collective 
consists of 7 patients with ovarian cancer, with an age of 24 to 59 years. The aim 
AUC during this Carboplatin high-dose therapy was 8,2-12 (mg/ml*min) wich 
should be reached by a dosage of 361-985mg/m² given as a 24h long-term 
Infusion. The model was evaluated with data sets of a group of  4 individuals (age 
10,3-25,8 years) with different cancers (Eickhoff PhD Thesis 2000). They received 
doses from 1200mg- 4000mg Carboplatin (AUC 5,6-12 mg/ml*min) over a 96h 
long-term infusion.  
Results: The integration of an accumulation of the drug in the red blood cells 
(Mandal et al. 2004) and the individal adjustment of the clearance, optimized with 
the options of the MoBi® Software, lead to a good  correlation of the predicted 
with the observed data. The predictions of the pharmacokinetics in different age 
groups by the PBPK model were  in good agreement with observed data. The 
concentration-time-curves  (plasma and unbound CARBO) visualize the time-
dependent changes in the plasma-protein binding of the platinum species.
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A VALID METHOD FOR QUANTIFICATION OF CYTOKINES FROM 
MICRODIALYSATE CONTRIBUTING TO BIOMARKER PROFILING 
Kirbs, C.1, Simm, A.2, Wohlrab, J.3, Kloft, C.1 
1Department of Clinical Pharmacy, 2Department of Cardiothoracic Surgery, 
3Department of Dermatology and Venereology, Martin-Luther-Universitaet Halle-
Wittenberg  
 
Background: Cytokines (Mr 8-80 kDa) as immunomodulatory proteins are 
secreted by immune and tissue cells (e.g. fibroblasts) mediating all types of 
immune response such as inflammation, infection and allergic reactions. However, 
cytokine concentrations in plasma in most cases do not represent concentrations in 
irritated tissues. Microdialysis (MD) as a minimal invasive technique enables the 
determination of analytes in the interstitial fluid (ISF), i.e. at the site of 
inflammation. For quantification of cytokines in small sample volumes of 
microdialysate a reliable, valid bioanalytical assay was to be developed.  
Methods: Microdialysate was sampled from 4 healthy volunteers using CMA 66 
Linear MD Catheters (100 kDa cut-off), CMA 107 MD Pumps, CMA 106 Syringes 
and as MD perfusate Ringer’s solution (RS) or a mixture of RL and human 
albumin solution (HA) (ratio 9+1). These solutions were also investigated as proxy 
matrices for microdialysate due to its very limited availability. All matrices were 
spiked with same amounts of the four model cytokines interleukin 6, 8 and 10 (IL-
6, IL-8, IL-10) and tumour necrosis factor alpha (TNF-) and measured using 
BD™ Cytometric Bead Array (CBA) and BD FACSArray™ Bioanalyzer. 
Results: A robust, rapid flow cytometry (FCM) based multiplex assay was 
developed, allowing the simultaneous determination of IL-6, -8, -10 and TNF- 
from sample volumes of 25 μL in the concentration range of 6-6000 pg/mL (for 
higher concentrations dilution integrity was demonstrated). RL+HA (9+1) emerged 
as a suitable proxy matrix for microdialysate. Validation was performed meeting 
international requirements1, 2 (accuracy (%RE) and precision (%CV) 20%) and 
further in-house criteria.
Conclusion: The developed and validated method allows quantifying cytokines 
from microdialysate as a first step to facilitate MD investigations in healthy 
volunteers and patients. As future perspective, MD feasibility for the monitoring of 
cytokines as biomarkers for immune responses and therapy outcomes should next 
be demonstrated in pre- and clinical investigations. 
1Food and Drug Administration (FDA). Guidance for Industry. Bioanalytical 
Method Validation (2001), 2DeSilva, B., Smith, W.. Pharm Res. 20: 1885 (2003) 
K203
REPAIR OF TOPOISOMERASE II LPHA INDUCED DOUBLE 
STRAND BREAKS IS CELL-TYPE AND DRUG DEPENDENT 
Doerre, L., Schonn, I. Dartsch, D.C.
Clinical Pharmacy, Institute of Pharmacy, Hamburg University, Germany 
BACKGROUND: The induction of DNA double strand breaks (DSB) is the active 
principle of topoisomerase II alpha inhibitors that are commonly used in 
chemotherapy. Cells actively respond to such severe damage by triggering cell 
cycle checkpoints, DNA damage repair and bypass pathways and eventually the 
cell death machinery. Thus, the outcome of therapy depends on the nature of the 
DNA lesions and on cell-type specific abilities to initiate and complete these 
processes. Also, these processes contribute to interpatient variability of 
chemotherapeutic response. The ultimate goal of our investigations is therefore to 
determine if elements of the cellular DNA damage response qualify as markers to 
guide individualised cancer therapy. To this end, we asked whether and how DNA 
double strand break repair affects the sensitivity of three tumour cell lines of 
different origins towards topoisomerase II alpha inhibitors with different 
mechanism of actions, doxorubicin and etoposide. 
METHODS: The human intestinal cell lines CACO-2 and HT29 as well as the 
human acute monocytic leukaemia cell line THP-1 were exposed to etoposide and 
doxorubicin and subsequently maintained for defined periods of time in drug-free 
medium to allow DNA damage response. We assessed the time course of DNA 
damage (comet assay), clonogenicity (colony formation) as well as expression of 
proteins relevant to DNA repair (western blot and gene expression analysis).   
RESULTS: Although both drugs caused the same initial level of DSB in THP-1 
and CACO-2 cells, doxorubicin-induced DNA damage persisted whereas 
etoposide-induced strand breaks were rapidly repaired. Clonogenicity of CACO-2 
cells after treatment with doxorubicin or etoposide (0.5-50 μM/L) for 3 h 
correlated with their ability to repair DSB, which is in contrast to our results with 
HT29 cells where this correlation is missing. DNA damage response involved 
differential expression of proteins relevant to DNA repair. 
CONCLUSIONS: We assume that mechanisms and efficiency of DSB repair are 
dependent on the cell type and the DSB-inducing drug, because a direct correlation 
between DSB and cell death is present in some, but not in all cell type/drug 
combinations. The present, as well as previous results suggest that DSB induced by 
non-intercalating versus intercalating topoisomerase II alpha poisons are repaired 
by different mechanisms. 
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TRADITIONAL CHINESE MEDICINAL DRUGS INHIBITING BETA-
AMYLOID AGGREGATION IN C. ELEGANS
Link, P., Abbas, S., Wink, M.  
Institut für Pharmazie und Molekulare Biotechnologie, Universität Heidelberg 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder and the most common 
form of dementia. It mostly occurs in elderly people, which is a part of human 
population that is growing due to the improved living conditions and medical care. 
Therefore also the number of AD patients is growing. Although AD is an 
increasing social and health problem, there is no therapy available to cure this 
disease.  
Toxic beta-amyloid (A42) is one of the key proteins in the pathogenesis of AD. It 
is a cleavage product of amyloid precursor protein (APP). Aggregates of A42 build 
the core of the senile plaques, which are one of the morphological features found in 
the brains of AD patients. According to the amyloid cascade hypothesis, the 
accumulation and aggregation of A are the first events that lead to AD 
symptomatic.  
The aim of this study is to find new substances that could inhibit the aggregation of 
A42 and hence could be used to develop new drugs against AD. Drugs from 
traditional Chinese medicine (TCM) were chosen as a possible source for such 
substances. In TCM phytotherapy has an important role. Secondary metabolites of 
plants have many applications in the medicine due to their biological activities. The 
natural product galantamine, which inhibits the enzyme acetylcholine esterase, is 
already used in symptomatic therapy of AD.  
A transgenic strain of C. elegans – CL2006 – was used as a model organism. This 
strain expresses the human A42 peptide in its muscles, where it forms A42 
deposits similar to the senile plaques found in AD patients. Therefore it is a 
convenient model for studying the aggregation of A42 and molecular interactions 
associated with this process. The worms were treated with plant extracts and the 
effect on A42 deposits was assessed by microscopic evaluation.  
Several plant extracts decreased the number of plaques observed. These extracts 
were also studied for their antioxidative properties. Further work concerning the 
amelioration of A42 induced neurotoxicity, the active ingredients of the extracts 
and the clinical relevance of these substances still has to be done, but the first 
results of this study have pointed out some promising plants that are possibly 
useful in AD therapy. 
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ASPALATHUS LINEARIS DECREASES OXIDATIVE STRESS IN 
CAENORHABDITIS ELEGANS
Chen W., Wink M.
Institute of Pharmacy and Molecular Biotechnology, Heidelberg University 
Rooibos tea is a popular South African tea from Aspalathus linearis that is famous 
for its absence of stimulants such as caffeine and for its antioxidant polyphenolic 
compounds. Oxidative stress is linked to many aging diseases such as Alzheimer’s 
disease (AD) and diabetes. According to the antioxidant ability of rooibos, it is 
interesting to investigate rooibos as agent to reduce oxidative stress and for 
prevention of age-related diseases.  
In this study, we showed that rooibos has strong free radical scavenging activities, 
which was assured by DPPH and superoxide anion assays. Oxidative stress was 
induced in C. elegans by juglone. Pretreatment of C. elegans with rooibos extract 
yielded higher survival rates than in the not be treated control. Furthermore, we 
measured the intracellular H2O2-related level of reactive oxygen species (ROS) in 
C. elegans. The result shows that rooibos treatment reduced ROS level. We also 
used the transgenic TJ375 (hsp-16.2/GFP) strain that expresses the GFP reporter 
gene in the pharynx in response to the oxidative stress. We found that under the 
oxidative stress the density of the GFP expression in worms pretreated with 
rooibos extract is lower than that of worms without treatment. 
Those findings suggest that rooibos has beneficial effects by reducing oxidative 
stress. 
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THE ANTIMETASTATIC POTENTIAL OF NOVEL INDIRUBIN 
DERIVATIVES 
Christine Weber,1 Laurent Meijer,2 Angelika M. Vollmar,1
1 Department of Pharmacy, Pharmaceutical Biology, Center for Drug Research, 
Ludwig-Maximilians-University Munich, Germany, 2 CNRS Station Biologique de 
Roscoff, France 
In this current study, we are investigating the influence of 6-bromo-indirubin-
3’oxime (6BIO) and 7-bromo-indirubin-3’oxime (7BIO) on induction of apoptosis, 
cell proliferation, and anti-migratory effects in the well characterized pancreatic 
carcinoma L3.6pl and breast carcinoma Skbr3 tumor cell lines and characterize 
underlying mechanisms. 6BIO and 7BIO at doses of 10 μM were shown to 
significantly reduce the proliferation and viability as well as induce apoptosis in 
both cell lines. In addition, 6BIO, but not 7BIO, significantly reduced the 
migration of both cell lines, nearly halting them completely in the Skbr3 wound 
healing assay at sub-apoptotic doses (3 μM). Chemotaxis was dramatically 
disrupted and tumor cells significantly lost their ability to invade through 
membranes or MatrigelTM layers in response to chemoattractants. An increase of 
the phosphorylation site S785 of 1 integrin is seen upon 6BIO which has been 
linked to decreased motility of carcinoma cells Additionally adhesion of Skbr3 
tumor cells to fibronectin was reduced by 6BIO stimulation. The effects of 6BIO 
can be attributed to its reduction of the T308 phosphorylation site of Akt, most 
likely through its direct inhibition of PDK1, ultimately causing long term 
alterations to the actin cytoskeleton. Erk, FAK and Rac1 levels are unaffected, but 
cycling of these signaling molecules appears to be disrupted upon treatment. 
Finally 6BIO reduced the metabolic capabilities of Skbr3 spheroids at low doses, 
caused the dissolution of spheroid structures at higher doses and significantly 
blocked the migration of Skbr3 spheroids. Taken together, the results of this study 
strongly suggest that the indirubin derivative 6BIO operates by inhibiting different 
mechanisms in human tumor cells its exert their potent anti-tumor efficacy. 
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RFC AND OCT1/2 MRNA EXPRESSION IN UROTHELIAL AND NON-
UROTHELIAL BLADDER CARCINOMAS 
Spahn-Langguth, H.1, Mahran, L.G. 2, Abou-Aisha, K.M.2, Rady, M.H.2, Rohde, J.2,
Mostageer, M.2, El-Zeiry, M.2, Abdel Haleem, A.M. 2
1Institute of Pharmaceutical Sciences, Department of Pharmaceutical/Medicinal 
Chemistry, Karl-Franzens-University Graz, Austria  
2Department of Pharmacology and Toxicology, German University in Cairo – 
GUC, New Cairo City, Egypt  
Urinary bladder cancer (UBC) ranks ninth in worldwide cancer incidence. The 
spectrum of bladder tumours includes urothelial (transitional) cell carcinoma 
(TCC), and non-urothelial carcinoma (squamous cell carcinoma (SCC) and 
adenocarcinoma). The incidence of UBC varies over the world where TCC is more 
prevalent and well-studied. In Egypt, however, the pattern of UBC is unique in that 
both the transitional and squamous cell types prevail. At least 5% of all human 
genes are transporter-related. Most drug transporters belong to the SLC family of 
transporters which mediate uptake and chemosensitivity for anticancer drugs. The 
organic cation transporters (OCT1/SLC22A1 & OCT2/SLC22A2) and the reduced 
folate carrier (RFC/SLC19A1) are among the most important determinants of 
chemosensitivity to anticancer drugs. OCT1 and OCT2 transport cisplatin while 
RFC is the major entry route for anti-folates, whereby platinum-based agents and 
anti-folates are important components of the chemotherapeutic armamentarium for 
bladder cancer. Nevertheless, membrane transport of anti-cancer agents, by RFC or 
OCTs, is considered as limiting to antitumor activity. Quantification of RFC and 
OCT1/2 in mucosa of 39 untreated bladder cancer patients was performed using 
real-time quantitative PCR (RT-qPCR) using SYBR Green chemistry. OCT1 and 
RFC mRNA steady-state levels were found to be ~8.5fold and ~9fold higher, 
respectively, (N=39; P<0.0001) in the analyzed bladder tumor specimens relative 
to normal bladder RNA (commercial calibrator, Clonetech). RFC upregulation was 
strongly correlated with tumour type (p<0.05) and, hence, may be considered as a 
potential diagnostic marker for urothelial versus non-urothelial tumours. However, 
no significant difference was detected upon comparing OCT1 expression levels 
among the different tumor types. OCT1 and RFC mRNA levels were not 
associated with tumour grade or stage. OCT2 mRNA expression was not detected 
in any of the bladder cancer specimens utilized in this study. The results of this 
study implicate that both RFC and OCT1 (but not OCT2) may be considered as 
potential markers for predicting response to chemotherapy in bladder carcinomas.  
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THE INSULINOTROPIC EFFECT OF TEA, BUT NOT ITS K+ CHANNEL-
BLOCKING EFFECT, IS DEPENDENT ON GLUCOSE METABOLISM 
Belz, M., Willenborg, M., Ghaly, H., Panten, U., Rustenbeck, I. 
Institut für Pharmakologie und Toxikologie, TU Braunschweig 
Stimulators of insulin secretion depolarize the plasma membrane of the pancreatic 
B-cell by closure of ATP-dependent K+ channels. The consequence is the opening 
of voltage-dependent Ca2+ channels (VDCC) which finds its expression as action 
potential spiking. Action potentials are thus regarded as determinants of the Ca2+-
regulated exocytosis of insulin secretory granules. Tetraethylammonium (TEA) is 
known to increase the B-cell action potential amplitude by block of Kv channels 
and to increase insulin secretion. Paradoxically, we found that 10 mM TEA 
reduced the insulin secretion produced by a maximally effective concentration of 
the sulfonylurea glipizide by more than 50 %. In contrast, the insulinotropic effect 
of glipizide was enhanced by TEA when a basal glucose concentration was present. 
In the presence as well as in the absence of glucose glipizide produced a plateau 
depolarization with superimposed action potentials. Under both conditions, TEA 
increased the glipizide-induced action potential amplitude by about 50%. The 
action potential duration was only moderately increased, in contrast to the more 
than 20fold increase by the opener of L-type Ca2+ channels, Bay K8644. Under the 
same conditions, TEA transformed the plateau-like increase of the cytosolic free 
calcium concentration ([Ca2+]i) produced by glipizide into a further oscillatory 
increase. TEA did not negatively affect parameters of B-cell energy metabolism 
(NAD(P)H fluorescence and ATP/ADP- ratio). So there is a clear dissociation 
between electric and ionic events on one side and stimulation of secretion on the 
other side. Apparently, the above sequence of depolarization and Ca2+ influx via 
VDCC is insufficient to stimulate insulin secretion but additionally requires the 
presence of glucose as a beta cell nutrient to become effective.  
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ABC-TRANSPORTER MEDIATED INTERACTION POTENTIAL OF 
ETRAVIRINE 
Zembruski, N.C.L., Haefeli, W.E., Weiss, J. 
Department of Clinical Pharmacology and Pharmacoepidemiology, University of 
Heidelberg
Introduction: Etravirine is a novel next generation non-nucleoside reverse 
transcriptase inhibitor (NNRTI) for the treatment of HIV-1 infections having the 
advantage of a higher genetic barrier to resistance. ATP-binding cassette (ABC) - 
transporters are important drug efflux transporters that modulate safety and 
effectiveness of antiretroviral therapy and have the potential to mediate clinically 
relevant drug-drug interactions. To increase the understanding of the interaction 
potential of etravirine we investigated whether etravirine is a substrate, inhibitor, or 
inducer of important ABC-transporters.
Materials and Methods: We evaluated P-glycoprotein (P-gp/ABCB1) inhibitory 
potential by calcein assay in P388/dx and L-MDR1 cells. The inhibitory potential 
on breast cancer resistance protein (BCRP/ABCG2) was assessed by flow 
cytometric pheophorbide A efflux in MDCKII-BCRP cells. Substrate 
characteristics were evaluated by growth inhibition assay in MDCKII cells 
overexpressing human P-gp/ABCB1, BCRP/ABCG2, MRP1/ABCC1, 
MRP2/ABCC2, or MRP3/ABCC3. Induction of ABC-transporters was quantified 
by real-time RT-PCR in LS180 cells after four days of treatment.  
Results: Etravirine did not inhibit P-gp/ABCB1 in P388/dx and L-MDR1 cells up 
to the maximum concentration tested (10 μmol/L). In contrast, data demonstrate 
that etravirine is a potent inhibitor for BCRP/ABCG2 (IC50 1.0  ± 0.4 μmol/L). 
Growth inhibition assays suggest that etravirine is not transported by the ABC-
transporters investigated. At 1 μmol/L etravirine slightly induced expression of 
ABCB1 and ABCC3 and strongly increased expression of ABCG2 (about 3.5 fold).  
Conclusion: Our study indicates that drug transporter mediated interactions with 
etravirine might evolve particularly at the level of BCRP/ABCG2 for which 
etravirine is a strong inhibitor and inducer.   
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HOW 2B BOUND – NEW INSIGHTS INTO LIGAND RECOGNITION BY 
THE HUMAN ADENOSINE A2B RECEPTOR 
Thimm, D. T.1 Schiedel, A. C.1 Hochheiser, K.1 Hinz, S.1 Sherbiny, F. F.1,2 Maaß, 
A.2 Müller, C. E.1
1PharmaCenter Bonn, Pharmaceutical Chemistry I, University of Bonn, 53121 
Bonn, Germany 2Fraunhofer Institute for Algorithms and Scientific Computing 
SCAI, 53754 Sankt Augustin, Germany  
The human adenosine A2B receptor (hA2B) is one of the four G-protein coupled 
adenosine receptors. The hA2B receptor has been implicated to play a role e.g. in 
inflammation, neurodegenerative disorders and tumor growth. However, the 
receptor’s role in (patho)physiological processes is far from being completely 
understood. In part, this is due to the lack of highly potent and selective ligands, 
which are also desired because of their therapeutic potential. To gain deeper 
insights into the structure of the hA2B receptor’s binding pocket, and thus obtain 
more information for the design of the desired ligands, mutagenesis studies were 
performed. Ten amino acids, predicted by a computer-generated homology model 
to be in close proximity to the docked ligands, have been exchanged for alanine: 
Tyr10, Leu81, Asp159, Val169, Asn186, Met198, Trp247, Val250, Ser279 and 
His280. The receptor mutants were stably expressed in CHO cells using a retroviral 
vector. For the pharmacological characterization of these mutants cAMP 
accumulation assays and radioligand binding studies using the new antagonist 
radioligand [3H]PSB-603 were performed. While the Asp159, Val169 and Met198 
mutants showed similar pharmacological profiles as the wild type receptor, Tyr10 
seems to be involved in agonist, but not antagonist binding. Asn186 was found to 
be crucial for antagonist binding, but might even hamper agonist binding. Leu81, 
Val250 and His280 appear to be important for both antagonist and agonist binding. 
Trp247 and Ser279 are apparently not involved in antagonist binding, but appear to 
be crucial for binding of nucleosidic agonists. Using the data of these mutagenesis 
studies, the hA2B receptor model could be refined, facilitating the rational design of 
new potent and selective ligands of the hA2B receptor. 
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EFFECTS OF ORAL ANTIDIABETICS ON PROLIFERATION AND 
MIGRATION OF HUMAN CORONARY SMOOTH MUSCLE CELLS 
Hinze, A.V.1, 2; Rosero, N.1; Harst, A.1; Mayer, P.1; von Kügelgen, I.2 
1 Federal Institute for Drugs and Medical Devices, Bonn, Germany 
2 Department of Pharmacology and Toxicology, University of Bonn, Bonn,  
  Germany  
 
Objectives: Proliferation and migration processes of vascular smooth muscle cells 
play crucial roles in the progression of atherosclerosis, stenosis and restenosis after 
vascular intervention. Diabetes mellitus is known to be a major risk factor for the 
development of atherosclerosis. In our current study, we have therefore 
investigated the effects of oral antidiabetics on proliferation and migration of 
cultured human coronary artery smooth muscle cells (HCASMCs).  
Methods: The proliferation experiments were performed in serum-free medium for 
five days. Changes in impedance were determined online using the xCELLigence 
System. 24 h prior to the experiment, the medium was replaced by serum-free 
medium without any supplements. To study migration, HCASMC were seeded 
onto two-chamber-plates and the rate of migration was determined by measuring 
changes in impedance in the second chamber. Expression of early genes was 
determined by real-time RT-PCR. 
Results: Addition of the sulfonylurea glyburide (10 μM) caused a marked (49%) 
inhibition of proliferation. In the presence of diazoxide (0.1 μM), the inhibition 
was abolished. Rosiglitazone and pioglitazone (0.1 μM) also inhibited cell 
proliferation. The effects of these peroxisome proliferator-activated receptor 
(PPAR)
-agonists were blocked by the potent antagonist T0070907 (2-chloro-5-
nitro-N-4-pyridinyl-benzamide). The dipeptidyl-peptidase(DPP)-4 inhibitors 
vildagliptine and sitagliptine (0.1 μM) also caused a weak inhibition of cell growth. 
On PDGF (platelet-derived growth factor)-induced migration, glyburide had no 
significant effect, whereas pioglitazone produced a reduction by 63% and 
vildagliptine, sitagliptine and saxagliptine increased migration. All tested oral 
antidiabetics induced the expression of early genes (NR4A1, FOS, EGR1, EGR3). 
Conclusion: Closing of K(ATP)-channels by glyburide significantly inhibited the 
proliferation of cultured coronary smooth muscle cells, but had no effect on 
migration. PPAR
-agonists inhibited both proliferation and migration. In contrast, 
DPP-4 inhibitors caused a weak inhibition of proliferation and a strong increase in 
migration activity. The latter effect may contribute to progression of 
atherosclerosis.  
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PROMISCUOUS SIGNALING PATHWAY ACTIVATION BY 
OXOTREMORINE M VIA THE MUSCARINIC M2 ACETYLCHOLINE 
RECEPTOR IN PRIMARY CELLS 
Seemann W. 1, Wenzel D. 2, Sasse P. 2, Fleischmann B. 2 and Mohr K. 1
1Pharmacology & Toxicology, Institute of Pharmacy, University of Bonn 
2Institute of Physiology I, Life & Brain Center, University of Bonn 
The muscarinic acetylcholine receptor belongs to the superfamily of G protein-
coupled receptors (GPCRs). Stimulation of the M2 receptor by conventional 
agonists such as oxotremorine M is known to activate preferentially the Gi/o
pathway but also Gs pathway activation is detected, an effect called promisquous 
signaling. Until now, this has only been investigated under non-physiological 
conditions, i.e. in cells overexpressing the M2 receptor. To examine Gs pathway 
activation in primary cells, spontaneously beating murine embryonic atrial 
cardiomyocytes (CD1, d 14.5-16.5) were used. Beating ceased immediately upon 
superfusion with a supramaximal concentration of oxotremorine M, suggesting 
Gi/o-pathway activation; this effect could be almost completely reversed upon 
wash-out. In contrast, cardiomyocytes pretreated with the Gi/o protein inhibitor 
PTX (1000 ng/ml for 20 h) responded with an increase in beating rate by 23 ± 5% 
(means ± s.e.m., n=11) suggesting Gs-pathway activation. To further probe this 
concept, an allosteric/orthosteric receptor activator, “hybrid 1” (structure shown in 
[1]), was applied. This compound combines high potency receptor activation via 
the orthosteric site of the muscarinic M2 receptor with Gi signaling pathway 
selectivity. This is probably caused by the interaction with the allosteric receptor 
site. Hybrid 1 is devoid of Gs activation, even in cells overexpressing the M2
receptor [1]. The dualsteric agonist suppressed spontaneous beating of the 
embryonic atrial cardiomyocytes at supramaximal concentrations (which) but did 
not alter beating rate after PTX incubation. We conclude that promiscuous M2
receptor signaling is not restricted to cells with artificial M2 receptor 
overexpression, but rather a physiological signaling mechanism in intact primary 
cells. 
[1] Antony et al. (2009) FASEB J. 23: 442-450. 
Acknowledgement: The dualsteric agonist was kindly synthesized and provided by 
Prof. Dr. Ulrike Holzgrabe (Würzburg, Germany) and Prof. Dr. Marco De Amici 
(Milan, Italy). 
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GLUCOSE ACTS OSTEOTOXIC IN ESC DIFFERENTIATION BY 
ALTERATIONS IN THE WNT SIGNALING PATHWAY 
Dienelt, A.1,2, Nieber, K.2, zur Nieden, N.I.1,3 
1Fraunhofer Institute for Cell Therapy and Immunology, Department of Cell 
Therapy, Applied Stem Cell Technologies Unit, Leipzig, Germany 2University
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Diabetes has become a prevalent disease during the last decades. High blood 
glucose levels caused by this disease are known to affect bone regeneration and 
turnover. In addition to affecting bone formation in the adult, diabetes in pregnant 
women is also associated with a higher risk for the fetus to develop skeletal 
malformations. Since Wnt/beta-catenin (CatnB) signaling was shown before to 
play important roles in embryonic skeletogenesis, we hypothesized that 
hyperglycemia may alter bone formation through modulating CatnB activity.  
To mimic diabetic hyperglycaemia during embryonic development, we induced 
differentiation in murine embryonic stem cells (mESCs) in media containing either 
low (1.0 g/l) or high (4.5 g/l) concentrations of D-glucose. The formation of 
osteoblasts and osteoclasts, the two cell types found in the skeleton, were evaluated 
at distinct time points with cell type specific stainings, quantitative PCR and flow 
cytometry. As these cells are typically derived from the mesoderm, we also 
checked the expression of typical lineage markers for endo- and ectoderm. Using a 
LEF/TCF reporter ESC line, the nuclear activation of CatnB was investigated.  
Our results indicate that glucose acts as a developmental osteotoxicant in the 
mESC differentiation model. In particular, diminished osteoblast and osteoclast 
formation were found in high glucose concentrations, characterized by a 2.6fold 
decrease in bone specific marker expression. In addition, matrix calcification 
mediated by the bone forming osteoblast was over 100fold decreased in diabetic 
conditions. Beside the mesodermal bone cell formation also the development of the 
ectodermal lineage was decreased in hyperglycaemia (0.55fold), while the 
commitment of endodermal derived cells was more than 6fold enhanced. Wnt 
signaling was altered when cells were differentiated in high glucose and showed an 
accelerated TCF/ CatnB activity. Ultimately, our study gives first evidence that 
glucose influences skeletal differentiation of mESCs potentially by regulating 
nuclear CatnB activity. Since CatnB is regulated in early development, it may also 
affect the differentiation of other germ layers.  
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THE INSULINOTROPIC EFFECT OF FLUOROQUINOLONES: MORE 
THAN ONE MECHANISM OF ACTION INVOLVED 
Ghaly H, Hatlapatka K, Rustenbeck I 
Institute of Pharmacology, Toxicology and Clinical Pharmacy, University of 
Braunschweig, D-38106 Braunschweig, Germany
Several antimicrobial fluoroquinolones induce potentially life-threatening hypo-
glycaemias by stimulation of insulin secretion. The insulinotropic effect is 
generally explained by their ability to block KATP channels in pancreatic beta cells. 
However, using metabolically intact primary beta cells we have found that fluoro-
quinolone concentrations which were sufficient to strongly inhibit KATP channel 
activity in open cells were unable to significantly depolarize the beta cell plasma 
membrane. Supposing that an interference with mitochondrial energy metabolism 
was the reason we investigated the effects of gatifloxacin, ciprofloxacin and moxi-
floxacin on the NAD(P)H- and FAD-autofluorescence, the mitochondrial mem-
brane potential (Rhodamine 123-fluorescence) and adenine nucleotide content of 
isolated pancreatic islets or single beta cells. 20 mM glucose induced a NAD(P)H 
increase of 35 ± 9 % (n =6). This increase was abolished by 100 μM moxifloxacin 
(p < 0.01), whereas ciprofloxacin or gatifloxacin (100 μM each) did not induce sig-
nificant changes. The FAD-fluorescence decreased by 20 ± 5 % in response to 20 
mM glucose (n =4). This glucose-induced change was significantly diminished by 
moxifloxacin (decrease only by 8 ± 3%, p < 0.05) but not by ciprofloxacin or 
gatifloxacin.  Moxifloxacin, but not ciprofloxacin or gatifloxacin significantly re-
duced the normalized ATP/ADP ratio to 81.5% (p = 0.0014, n =7). The hyperpo-
larizing effect of 20 mM glucose was partially antagonized by moxifloxacin (p < 
0.05, n =4), but not ciprofloxacin or gatifloxacin. Conclusions: Apparently, fluoro-
quinolones interact with the respiratory chain and thereby inhibit the energy meta-
bolism of the pancreatic beta cell. The most marked effect is exerted by moxifloxa-
cin and may be sufficient to counteract the KATP channel blocking effect and/or its 
consequences for the release of insulin.  
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SAFFRON AND TRANS-CROCETIN INHIBIT THE ATP-INDUCED 
CALCIUM MOBILISATION IN RAT NEUROBLASTOMA CELLS 
Berger, F.1, Hensel A.2, Nieber, K.1
1Universität Leipzig, Institut für Pharmazie, Pharmakologie für 
Naturwissenschaftler, 2Universität Münster, Institut für pharmazeutische Biologie 
und Phytochemie 
Saffron, the dried stigmata of Crocus sativus L., is used in traditional medicine for 
a wide range of indications including cramps, asthma and depressive mood. Studies 
indicate a neuroprotective potential of saffron extract and several isolated 
compounds. The underlying mechanisms are not completely known. We found that 
an ethanolic saffron extract (CSE) and trans-crocetin, a carotinoid from saffron, act 
antagonistic on NMDA receptors. A current study showed, that trans-crocetin 
inhibited the ADP-induced platelet aggregation by decreasing intracellular Ca2+
release and extracellular Ca2+ influx [1]. Mechanisms or receptors which are 
involved were not characterised.  
In this study we examined the influence of CSE and trans-crocetin on the ATP-
induced increase of the intracellular calcium concentration ([Ca2+]i) in rat 
B104 neuroblastoma cells using a FURA-2-imaging system. The P2 receptor 
agonist ATP caused a concentration dependent (1 nM – 1 mM) increase of the 
[Ca2+]i with a transient peak descending to a short plateau phase with a maximum 
effect by 100 μM. The basal level of Ca2+ decreased in Ca2+-free medium 
containing 1 mM EGTA. The ATP (100 μM) induced Ca2+ peak was reduced and 
the plateau phase was removed under this conditions. This indicates that an initial 
release of Ca2+ from intracellular stores and an influx of extracellular Ca2+ are 
involved in the Ca2+ mobilisation.  
CSE (100 μg/ml) decreased the ATP-induced increase of the [Ca2+]i by 33.9  5.8 
%. The effect was concentration dependent (10-100 μg/ml) and still remained after 
a washout period of 15 min. Trans-crocetin 10 μM inhibited the ATP-induced 
increase of the [Ca2+]i by 26.1  2.8 %. The effect was also concentration 
dependent (1-50 μM) but not reversible after a washout period of 15 min. Further 
investigations are necessary to elucidate the involved mechanisms. 
[1] L. Yang et al. 2008 Involvement of Ca2+ in the inhibition by crocetin of platelet 
activity and thrombosis formation. J. Agric. Food Chem. 56:9429-9433
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FÖRSTER RESONANCE ENERGY TRANSFER BETWEEN 2´-MANT-
3´dGTP AND NITRIC OXIDE SENSITIVE GUANYLYL CYCLASE 
Busker, M., Haase, N., Haase, T., Kraehling, J. R., Linnenbaum, M., Oberle, S., 
Behrends, S. 
Pharmakologie, Toxikologie und Klinische Pharmazie, TU Braunschweig 
 
The heterodimeric enzyme NO sensitive guanylyl cyclase (NOsGC) catalyzes the 
conversion of GTP to the second messenger cGMP. Nitric oxide (NO) activates 
NOsGC by binding to its prosthetic heme group. (N-methyl)anthraniloyl-
substituted nucleotides (MANT-NTPs) are fluorescently labeled nucleotides that 
compete with GTP or ATP for binding to the substrate binding site of adenylyl and 
guanylyl cyclases (Gille et al., 2004). In the current work we use MANT-GTP 
derivatives and Förster resonance energy transfer (FRET) to probe the 
conformation of the active site of purified NOsGC under basal and NO-stimulated 
conditions. Using a spectrofluorometer purified NOsGC (3 μM) was excited at 
280 nm or 295 nm (tryptophan specific excitation) which led to emission with a 
maximum at 335 nm. This maximum decreased in the presence of 2’-MANT-
3’dGTP (3 μM) and a new peak with a maximum at 430 nm appeared. This 
indicates that tyrosine (Y) and tryptophan (W) residues serve as FRET donors, 
while 2’-MANT-3’dGTP acts as FRET acceptor. The FRET efficiency was 12.8 % 
for excitation at 280 nm and 6 % for the excitation at 295 nm. Therefore almost 
half of the total energy transfer at 280 nm excitation is caused by tryptophan 
residues even though the ratio of tryptophan to tyrosine is 5:37. Addition of the 
NO-donor DEA/NO increased FRET efficiency after excitation at 295 nm. This 
effect was absent for a mutant isoform of the 1 subunit which is also unresponsive 
to DEA/NO in guanylyl cyclase activity measurements. Based on these data we 
hypothesized that tryptophan residues come closer to the substrate binding site 
upon activation by NO leading to the observed increase in FRET efficiency. 
Tryptophan 669 of the rat 1 subunit is closest to the binding site of GTP as 
predicted by homology models. Site directed mutagenesis of this residue to alanine 
led to a decrease in FRET efficiency at 295 nm excitation from 6 % to 4.3 % for rat 
1 W669A. Addition of DEA/NO led to an increase in FRET efficiency as seen 
before for the wild type enzyme. Thus we were able to show that W669 is partly 
responsible for FRET, but is not responsible for the increase in FRET-efficiency 
after addition of DEA/NO. We are currently mutating tryptophan residue W22 in 
the heme NO binding (HNOB) domain of the 1 subunit to test whether this residue 
leads to the increase in FRET efficiency upon activation by NO. 
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CYTOTOXICAL AND PHARMACOLOGICAL EFFECTS OF NEW 
SELECTIVE PDE10A LIGANDS  
Erdmann, S.1, Schwan, G. 1, Scholz, S. 2, Briel, D. 1, Altenburger, R. 2, Nieber, K. 1
1 University Leipzig, Institute of Pharmacy, Talstraße 33, D-04103 Leipzig 
2 UFZ Helmholtz-Centre for Environmental Research, Department of Bioanalytical 
Ecotoxicology, Permoserstrasse 15, 04318 Leipzig, Germany 
Phosphodiesterases (PDEs) are essential regulators of cyclic nucleotide signaling 
with several physiological functions. Because of their therapeutic importance, PDE 
inhibitors became distinguished as therapeutic agents in the treatment of various 
diseases. Phosphodiesterase 10A (PDE10A) was recently identified as a cyclic 
nucleotide phosphodiesterase expressed primarily in dopaminoreceptive medium 
spiny neurons in the striatum. Inhibitors of the PDE10A may be interesting for the 
treatment of neurodegenerative and psychiatric disorders including Alzheimer’s 
disease, schizophrenia and depression. A novel approach for clinical diagnosis  are 
selective PDE10A ligands using as PET ligands. The aim of the present study was 
to establish cell-based assays to screen cytotoxic and pharmacological effects of 
fluoric substituted derivatives of a lead compound with high affinity and selectivity 
for the PDE10A. Cytotoxicity was investigate concentration- (1 nM-100 μM) and 
time- (12 h-48 h) dependently on human neuroblastoma-(SH-SY5Y), kidney-
(HEK293) and hepatocyte- (HEPG2) cell cultures using the cell vitality assay (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and a lactate 
dehydrogenase (LDH) assay. Pharmacological effects were determined using 
functional studies (calcium-imaging) and electrophysiological investigations 
(intracellular recordings). In vivo toxicity was investigated using the fish embryo 
toxicity test with zebra danio. The lead compound and the fluoric substituted 
derivatives had no effect in the MTT and LDH test after short term incubation (12 
h and 24 h), but reduced the cell viability and membrane integrity at high 
concentration (100 μM) after long term incubation (48 h). The lead compound 
showed no influence on the intracellular calcium concentration, whereas high 
concentrations (100 μM) of the fluoric substituted derivatives increased the 
intracellular calcium concentration. Electrophysiological investigations indicated 
no effect in membrane potential and input resistance of all tested compounds at 
100 μM. Using the in vivo test system an acute fish mortality was found after 48 h 
at 1μM (LC50= 0.1-1 μM). Our results indicate no toxic effect in concentration 
relevant for PET-ligands, but suggest a different pharmacological profile of the 
lead compound and fluoric substituted derivatives maybe by district binding 
characteristics to the PDE10A enzyme.  
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ANALYSIS OF HERBAL COMPONENTS CONTRIBUTING TO THE 
EFFECT OF STW 5 ON RAT COLON 
Herr, F.1, Voß, U.1, Kelber, O.2, Weiser, D.2, Nieber, K.1
Institut für Pharmazie, Universität Leipzig, 04013 Leipzig, Wissenschaftliche 
Abteilung, Steigerwald Arzneimittelwerk GmbH, 64295 Darmstadt 
STW 5 (Iberogast) is a fixed combination of nine herbal extracts used in the 
therapy of motility-related diseases of the gastrointestinal tract. Its main component 
is an aqueous-ethanolic fresh plant extract from Iberis amara (STW 6). As STW 5 
is a combination of herbal extracts, it seems reasonable to study the effects of its 
herbal components to evaluate the contribution to the effect of the fixed 
combination.  
Studies were conducted with isolated rat colon preparations. STW 5 and its 
components were tested to influence the basal tone and ACh (100 μM)-induced 
contractions using isometrical measurement. 
Comparable to ileum/ jejenum preparations STW 5 relaxed the basal tone and 
decreased the ACh-induced contractions in a concentration-dependent manner (64-
512 μg/ml). The study of the herbal components containing in STW 5 indicated 
that peppermint leaf (Menthae piperitae folium) had no effect on the basal tone but 
decreased in low concentration (9.7 μg/ml) the ACh-induced contractions whereas 
high concentrations (19.4-38.9 μg/ml) did not influence the contractions. STW 6 
(3-24.1 μg/ml) as well as chamomilla flowers (Matricariae flos, 14.5-116.3 μg/ml) 
and liquorice root (Liquiritiae radix, 10.6-84.9 μg/ml) had no effect neither on the 
basal tone nor on the ACh-induced contractions.  
Our results indicate that the components of STW 5 contribute differently to the 
spasmolytic and tonicising effects of STW 5 on rat colon preparations. 
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IN VITRO STUDY ON THE EFFECT OF AQUEOUS AND ETHANOLIC 
EXTRACTS OF STW 5 AND STW 6 ON RAT SMALL INTESTINE 
Hoser, S.1, Michael, S.1, Kelber, O.2, Weiser, D.2, Nieber, K.1
1Pharmakologie für Naturwissenschaftler, Universität Leipzig 
2Wissenschaftliche Abteilung, Steigerwald Arzneimittelwerk GmbH, Darmstadt 
STW 5 is a fixed combination of ethanolic extracts of nine different herbal 
constituents with a final ethanol concentration of 31 % V/V. Earlier data show an 
anti-inflammatory and spasmolytic effect of STW 5 in intestinal smooth muscle in 
vitro. In order to characterize further the effects of STW 5 and its main component 
STW 6 (Iberis amara) aqueous and ethanolic extracts were compared for their 
activity to influence the ACh-induced contraction using rat ileum/jejunum 
preparations. Lyophilisates of the herbal extracts were dissolved either in water or 
in ethanol (31 % V/V). In the absence of drugs ethanol (final concentration 
0.031 % V/V) did not influence the basal tone and the ACh (100 μM)-induced 
contraction when it was applied directly into the organ bath or after preincubation 
of the preparation with 0.031 % V/V ethanol for 30 minutes. STW 5 as aqueous or 
as ethanolic solution inhibited the ACh (100 μM)-induced contractions after 
application into the organ bath with no significant difference by 12.13.2 % and 
9.7 4.5 %, respectively. Under the same condition aqueous STW 6 was without 
effect on the ACh (100μM)-induced contractions whereas ethanolic STW 6 
increased the contractions by 13.93.5 %. TNBS (0.01 M) preincubation for 30 
minutes resulted in a declined ACh (100 μM) contractions. Using these 
preparations ethanol (0.031 % V/V) did not affect the reduced contraction. When 
aqueous or ethanolic extracts of STW 5 and STW 6 were applied to the TNBS 
preincubated preparations no differences were found in increasing the TNBS-
reduced ACh contractions (TNBS 33.74,1 %, STW 5 aq. 49.14.8 % eth. 
58.23.4 %, STW 6 aq. 65.76.7 % eth. 62.85.8 %). The results indicate that the 
solvent ethanol (1:100) did not influence the effects of STW 5 and STW 6 on 
intestinal contractility and, therefore, complement the electrophysiological 
investigations previously published(1). 
1) Storr et al. 2004, Digestion 70:257-264 
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NUCLEAR TRANSLOCATION OF HEME OXYGENASE UNDER 
CELLULAR STRESS CONDITIONS IS ISOFORM SPECIFIC  
Linnenbaum, M., Busker, M., Haase, N., Haase, T., Kraehling, J. R., Oberle, S., 
Behrends, S
Pharmakologie, Toxikologie und Klinische Pharmazie, TU Braunschweig 
Heme oxygenases (HO’s) are potential drug targets in cardiovascular disease. By 
catalyzing the degradation of the oxidant heme to biliverdin, carbon monoxide and 
iron, they have protective activities in the setting of inflammatory atherosclerotic 
diseases. There are two HO-isoforms: the inducible HO-1 and the constitutively 
expressed form HO-2. Besides the difference in expression no biochemical 
differences have been detected. The subcellular localization is also thought to be 
identical as both isoforms have a carboxy-terminal membrane anchor that interacts 
with the outer membrane of the endoplasmic reticulum. HO-1 is truncated at its 
carboxy-terminus and translocates to the nucleus after treatment with hemin or 
under hypoxic conditions (Lin et al, JBC 2007; 282: 20621-20633). It was the goal 
of the current study to compare the HO-isoforms with respect to subcellular 
localization and translocation under cellular stress conditions. 
Green fluorescent protein (GFP) was fused to the amino-terminus of HO-1 or  
HO-2 and the resulting fluorescent enzymes were expressed in human embryonic 
kidney (HEK 293) cells. Analysis using a confocal laser scanning microscope 
showed endoplasmic reticulum-localization for both isoforms. Deletion of the 
carboxy-terminal membrane anchor in these GFP-fusion proteins (HO-1 C 267 
and HO-2 C 289) led to a nuclear and homogenous cytosolic distribution for both 
isoforms. This implies that proteolytic cleavage of the carboxy-terminal membrane 
anchor after cellular stress conditions or other signal transduction events could also 
lead to nuclear translocation of HO-2. 
Exposure to hypoxia (3% O2) or hemin 100μM for 48h led to nuclear 
translocation and cytosolic redistribution of HO-1 but not HO-2. This implies that 
the signal transduction pathways that initiate nuclear translocation of HO-1 are at 
least in part specific for this isoform. It is thought that nuclear HO-1 can activate 
transcription factors and regulate its own expression (Lin et al, Free Radic Biol 
Med 2008; 44:847-855). We hypothesize that a similar nuclear translocation of 
HO-2 may be initiated by a distinct signal transduction pathway and that heme 
regulatory motifs (Cys-Pro-Phe), which are specific for HO-2 may play a role in 
this process.
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PATIENTS` PREFERENCES FOR WRITTEN INFORMATION ABOUT 
EFFECTS AND UNDESIRABLE SIDE EFFECTS OF DRUGS 
Mülders, V.1, Simic, D.2, Wilm, S.2, Schwappach, D.3, Thürmann, PA.1,4
1Department of Clinical Pharmacology, University of Witten/Herdecke, Germany, 
2Institute of General Practice and Family Medicine, University of 
Witten/Herdecke, 3Swiss Patient Safety Foundation, Zürich, Switzerland, 4Philipp 
Klee-Institute for Clinical Pharmacology, HELIOS Klinikum Wuppertal, Germany 
Package information leaflets (PILs) are often perceived as too long, deterrent and 
difficult to understand by patients. We thus investigated which information patients 
desire about their drugs and how this information should be presented. We 
conducted six focus groups with n = 5-7 patients each with diabetes, arterial 
hypertension and hypercholesterolemia to elicit their wishes for written drug 
information. From the interview data, attributes (e.g., prevalence of side effects) 
and their corresponding levels (e.g., graphical versus numerical presentation of 
prevalence) were derived by content analysis in a multidisciplinary team including 
patients. Focus groups revealed that PILs cause emotional responses such as 
anxiety, uncertainty or dissatisfaction in patients resulting in a broad spectrum of 
reactions, ranging from seeking for help to non-compliance. Patients demand 
readable, attractive and short PILs written in simple language with an accentuation 
of important information by colour or typeface. Six attributes, four relating to 
content of drug information leaflets and two relating to presentation of information, 
were identified to be of great importance for patients.  
These findings were used in a stated-preference task (discrete choice experiment) 
in 1000 people aged 50 years and above. 16 scenarios were developed, paired in 
binary choices and presented to respondents in order to identify the relative 
importance of each attribute. Patients preferred coloured over black-white leaflets, 
the provision of a brief summary and general health tips, but no visual presentation 
of quantification of side effects and no information about what to do in case of side 
effects. Patients` preferences were dependent on age and education. The elderly 
preferred less information. Furthermore, they wished more often information in 
case of side effects, declaration of all side effects and more rarely a brief summary 
than the younger. Patients with a higher level of education valued the declaration 
of all side effects and the declaration of information in case of side effects higher 
than patients with a lower level of education.  
These attributes will be tested in a subsequent randomised controlled trial.  
Funded by the Federal Ministry of Education and Research (01GX0751) 
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DETECTION OF THE ADENINE RECEPTOR IN HUMAN AND RAT 
NEURONAL AND NON-NEURONAL CELLS 
Nieber, K., Siegert, F. and Bloßfeld, M.  
Institut für Pharmazie, Universität Leipzig 
Adenine was identified to be an endogenous ligand of a G-protein coupled receptor 
in rats. There is evidence for its protective effects on neuronal cells. A mouse 
ortholog but not a human ortholog was described [1]. Preliminary radioligand 
binding studies using a human neuronal cell line suggest the existence of a human 
ortholog. The aim of the present study was to detect the adenine receptor on human 
and rat neuronal as well as non-neuronal cell lines. Human THP-1 and SH-SY5Y 
cells were used, whereas for rats NR8383 and B104 cells were investigated. The 
influence of adenine (10 μM to 1 mM) on cell viability and cell death was 
determined after 12 and 36 hours of incubation using the MTT and LDH test. In rat 
cells the receptor mRNA was detected via qualitative RT-PCR. Adenine increased 
the cell viability of THP-1 and SH-SY5Y cells in a concentration dependent 
manner, up to 132.98.7 % and 127.817.1 %, respectively. In contrast the cell 
viability of rat NR8383 and B104 cells was decreased to 81.96.8 % and 
88.47.8 %, respectively after 36 hrs of incubation with 500 μM adenine. 
PSB-08162 was described as an adenine receptor antagonist [2]. In our 
experiments it antagonized the effect of adenine in all cell types. Interestingly, 
PSB-08162 itself reduced the cell viability. In a concentration of 100 μM it 
decreased the cell viability after 36 hrs in SH-SY5Y and B104 to 80.86.9 % and 
84.714.2 %, respectively. Additionally, an interaction between the adenine and 
the adenosine A1 receptor was shown on rat but not on human cells. Our results 
indicate that the adenine receptor is expressed on neuronal and non-neuronal cells 
from both species. The studies represent for the first time the pharmacological 
evidence of an adenine receptor in human cells. The pharmacological analysis 
pointed to a partial agonism of PSB-08162 on human and rat cell lines. 
[1] Von Kügelgen I, Schiedel AC, Hoffmann K, Alsdorf BBA, Abdelrahman A, Müller CE. Cloning 
and functional expression of a novel Gi protein-coupled receptor for adenine from mouse brain. 
Mol Pharmacol 2008;73:469-477 
[2] Personal information from Prof. C.E. Müller, Institute of Pharmacy, University of Bonn 
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A NOVEL TOOL FOR PROBING THE ACTIVE STATE OF 
MUSCARINIC ACETYLCOLINE RECEPTORS 
Schrage, R.1, Klöckner, J.2, De Amici, M.3, Tränkle, C.1, Holzgrabe, U.2, Mohr, K.1
1Pharmacology and Toxicology Section, Institute of Pharmacy, University of 
Bonn; 2Institute of Pharmaceutical Chemistry, University of Würzburg; 
3Department of Pharmaceutical Sciences, University of Milan, Italy 
G protein-coupled receptors (GPCRs) are among the most promising targets for 
drugs and are therefore in the focus of academic and industrial research. In recent 
years, increasing evidence for major conformational changes between the active 
and the inactive receptor states of proteins has emerged [1]. However, in 
radioligand binding studies receptors are most commonly investigated by probing 
the protein with orthosteric antagonists instead of agonists because antagonist 
affinity (KD) is often more than 100-fold higher than that of agonists. 
The oxotremorine-like agonist iperoxo is distinguished by an extremely high 
potency to affect muscarinic acetylcholine receptors [2]. We prepared the N-
desmethyl-derivative of iperoxo for commercial radiolabelling with 
[3H]methyliodide.  [3H]iperoxo was used in  binding experiments with CHO Flp-
In™ cells overexpressing the human muscarinic acetylcholine receptor of the M2
(hM2) subtype in both, membrane homogenates (10 mM HEPES, 10 mM MgCl2,
100 mM NaCl, pH 7.4, 30 °C) and living cells (Hanks’ balanced salt solution with 
20 mM HEPES).  
In homologous competition binding experiments conducted with membrane 
homogenates [3H]iperoxo labels both, a high affinity compartment  (pKD = 10), 
which is likely to represent a G protein-coupled receptor population (20 %), and a 
low affinity compartment, which might reflect an uncoupled receptor fraction. In 
living cells [3H]iperoxo binding is monophasic and its affinity is reduced but still 
rather high  (pKD = 8.7), suggesting that the majority of receptors is not coupled 
with G proteins due to a high intracellular level of guanylnucleotides.  
In summary, the high affinity of this novel radioagonist enables to investigate 
interaction with muscarinic acetylcholine receptors in living cells and may thus 
provide unique insight into the receptor biology of active-state GPCRs. 
[1] Rosenbaum DM et al. (2009). Nature 459: 356-363  
[2] Dallanoce C et al. (1999). Bioorg. Med. Chem. 7: 1539–1547 
Support of the DFG is gratefully acknowledged (HO 1368/12-1 MO/2-1). 
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GPR17- STILL AN ORPHAN RECEPTOR 
Stumpf, A.1, Spinrath, A.2, Müller, C. E.3, Mohr, K.1, Kostenis, E.2 
1Pharmacology and Toxicology Section, Institute of Pharmacy, 2Section 
Molecular-, Cellular-, and Pharmacobiology, Institute of Pharmaceutical Biology, 
3Pharmaceutical Chemistry I, Institute of Pharmacy, University of Bonn 
 
GPR17, an orphan G protein-coupled receptor, was described as a molecular target 
for uracil nucleotides such as UDP, UDP-galactose and UDP-glucose as well as for 
cysteinyl-leukotrienes [1]. However, in 2009, Maekawa et al. [2] postulated that 
GPR17 is a ligand-independent, negative regulator for the cysteinyl-leukotriene 1 
receptor. 
We used 1321N1 astrocytoma cells stably transfected with GPR17 in several 
different functional assays to probe for activation of GPR17 by uracil nucleotides. 
We measured GPR17-induced signaling on the level of G protein activation using 
[35S]GTP
S binding assays, of intracellular messenger using fluorimetric Ca2+-
measurements, and whole cell response using real-time measurement of dynamic 
mass redistribution (DMR; Epic® system). None of these functional assays showed 
a specific GPR17 activation by the above-mentioned nucleotide agonists. However, 
GPR17 is activated by a small molecule agonist demonstrating a ligand-dependent 
signaling.  
We conclude that GPR17 is probably still an orphan receptor whose endogenous 
ligand remains to be identified. 
We thank Corning® Life Sciences for their support on the Epic® system. 
A. St. is member of the NRW International Graduate School BIOTECH-Pharma. 
A. Sp. is member of the DFG-funded GRK 677. 
[1] Ciana, P., Fumagalli, M., Trincavelli, L. et al. (2006) EMBO J 25:4615-4627 
[2] Maekawa, A., Balestrieri, B., Austen, K. et al. (2009) Proc Natl Acad Sci USA 
106:11685-11690 
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MECHANISMS OF LPS-INDUCED PROLIFERATION OF BEAS-2B 
CELLS AND EFFECTS OF GINGER COMPOUNDS ON LPS-PROVOKED 
IL-8 SECRETION 
Timmel, J.1, Verspohl, E.J.1  
1Department of Pharmacology, Institute of Pharmaceutical and Medicinal 
Chemistry, University of Muenster 
 
OBJECTIVE: We recently demonstrated the proliferative effect of 
lipopolysaccharides (LPS) on BEAS-2B cells, a human bronchial epithelial cell 
line. Proliferation is an important aspect of airway remodelling in inflammatory 
bronchial diseases like asthma. The aim of the present study was to elucidate the 
intracellular signalling pathways leading to increased proliferation. Furthermore, 
several compounds of Zingiber officinale (ginger) were tested with regard to their 
effect on LPS-induced secretion of the pro-inflammatory chemokine Interleukin 8, 
which is increased in plasma of asthmatic patients. In traditional medicine, ginger 
is used as an anti-inflammatory drug. 
MATERIALS AND METHODS: Increased DNA synthesis, i.e. cell proliferation, 
was measured by an [3H]-thymidine assay. Cells were stimulated with 
lipopolysaccharides from P. aeruginosa in the presence or absence of specific 
inhibitors of intracellular signalling. IL-8 secretion of LPS-stimulated BEAS-2B 
cells was measured by ELISA (R&D Systems). 
RESULTS: Lipopolysaccharides induce increased cell proliferation in BEAS-2B 
cells; the effect is diminished by the tyrosine kinase inhibitor Genistein, the JNK 
inhibitor SP 600125 and the p38 inhibitor SB 202190, but not by the ERK1/2 
inhibitor PD 98059. The increased IL-8 secretion of BEAS-2B cells stimulated 
with LPS is attenuated by volatile ginger oil, the monoterpenoid -Pinene and the 
sesquiterpenoid ar-Curcumene, but not by Citral, -Phellandrene or the pungent 
constituent [6]-Gingerol and its artificial metabolite [6]-Shogaol. 
CONCLUSION: The LPS-induced proliferation of BEAS-2B cells is partly 
mediated by JNK and p38, but not ERK1/2 MAPK, and tyrosine kinases. The 
volatile oil from Zingiber officinale and only some of its compounds show anti-
inflammatory effects in LPS-stimulated BEAS-2B cells. 
 
P226
EFFECT OF FREE FATTY ACIDS, LIPOPOLYSACCHARIDES AND 
BISPHENOL-A ON CYTOKINE SECRETION FROM INS-1 CELLS 
van Oppen J. N.1, Verspohl E. J.1
1Dept. Pharmacology, Institute of Medicinal Chemistry, Westfaelische Wilhelms 
University, Münster, Germany 
An elevated Free Fatty Acid (FFA) supply augments glucose stimulated insulin 
secretion. (GSIS) and chronic exposure of saturated FFA, particularly in 
association with elevated blood glucose levels, can reduce insulin biosynthesis, 
insulin secretion and induce beta-cell apoptosis. Bisphenol-A (BPA) is a 
component of plastics that line food and beverage containers. It can leach from 
products in contact with food and can be detected in urine samples. In vitro studies 
demonstrated effects of BPA on adipocytes differentiation and glucose transport. It 
is the aim of this study to show the impact on producing relevant immunological 
effects in INS-1 cells, a rat pancreatic cell line. INS-1 cells were exposed to FFA (4 
μg/ml), LPS (0.4 μg/ml) and BPA (10 μg/ml) for 4 and 12 hours. The secretion of 
cytokines and chemokines was qualitatively measured by a Proteome Profiler® 
Array Kit (R&D Systems, ARY 008). Interleukin 6 (IL-6) production was 
quantified by ELISA (R&D Systems, Quantikine IL-6) after incubating cells for 24 
hours with various concentrations of BPA in the presence or absence of estrogen. 
There is a binding affinity of BPA for the nuclear receptors ER-alpha, ER-beta and 
the classical/non-classical membrane estrogen receptors as well as the G-Protein-
coupled receptor (GPR-30). The existence of the Interleukin-17-Receptor (IL-17-
R) was demonstrated by using Western-Blot. The Proteome Profiler showed an up-
regulation ICAM-1, IL-3, -4, IP-10, MIP-1 after FFA (4 μg/ml) exposure for 4 
hours; LPS (0.4 μg/ml)/4 hours: ICAM-1, IFN-, IL-1, -4, -6, -10, MIP-1;
combination of FFA (4 μg/ml) and LPS (0.4 μg/ml): ICAM-1, IFN-, IL-1, -2, -3, -
4, -6, -10, -13, -17 and TNF-. A 24 h incubation of BPA (10 μg/ml) induced the 
release of ICAM-1, IFN-, IL-4, -6, -10, and -13. An up-regulation (30.5%) of pro-
inflammatory IL-6 secretion was observed. The combination of BPA (10 μg/ml) 
and estrogen (10 μg/ml) demonstrated an increase of IL-6 secretion up to 42.9%; 
the effect of BPA and estrogen was additive. The results implicate that FFA, LPS 
and BPA trigger secretion of pro-inflammatory and anti-inflammatory cytokines in 
insulin secreting cells.
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EFFECTS OF STW 5 AND STW 6 ON RAT ILEAL AND COLONIC 
PREPARATIONS: A COMPARATIVE STUDY 
Voß, U.1, Michael, S.2, Kelber, O.3, Weiser, D.3, Nieber, K.1
1Institut für Pharmazie, Universität Leipzig, 04013 Leipzig, 2Löwen-Apotheke-
Waldheim, 04736 Waldheim, 3Wissenschaftliche Abteilung, Steigerwald 
Arzneimittelwerk GmbH, 64295 Darmstadt 
The multi-herbal drug STW 5 (Iberogast) is successfully used for the treatment of 
gastro-intestinal disorders, like functional dyspesia or irritable bowel syndrome. It 
is a fixed combination of nine plant extract with Iberis amara (STW 6) as its main 
component.  
In this study the influence of STW 5 and STW 6 on tonus and on acetylcholine 
(ACh)-induced contractions was examined in-vitro to analyze region specific 
differences of the phytomedicine. We used 1-1.5 cm long untreated and inflamed 
ileum and colon preparations of male Wistar rats. The inflammation was induced 
by intraluminal installation of 2,4,6-trinitrobenzene sulfonic acid (TNBS, 10 mM). 
STW 5 (128-512 μg/ml) concentration dependently reduced the tonus and 
decreased ACh-induced contractions of untreated ileal and colonic preparations. 
STW 6 in equivalent concentrations (3-24,1 μg/ml) neither affects tonus nor 
contractility. TNBS-induced inflammation leads to a significant reduction of ACh-
induced contractions. Co-incubation with STW 5 (512 μg/ml) and STW 6 (24,1 
μg/ml) partially normalized the TNBS-induced decrease in ACh-induced 
contractions of ileum preparations. In inflamed colon segments only the co-
incubation with STW 6 (24,1 μg/ml) enhanced the ACh-induced contractions, 
while STW 5 (512 μg/ml) had no effect. 
In conclusion, STW 5 influences intestinal motility and tonus, whereas STW 6 
does not contribute to these effects. In TNBS-inflamed ileum preparations STW 5 
as well as STW 6 normalized the reduced ACh-induced contractions, while in 
colon preparations STW 6 but not STW 5 is effective. Our study confirm region 
specific efficacy of STW 5 and its main component STW 6. 
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EFFECT OF A2B ADENOSINE RECEPTORS ON RAT TRACHEA TONUS 
AND ON CILIARY BEAT FREQUENCY 
Walaschewski, R., Verspohl, E. J. 
Abteilung Pharmakologie, Institut für Pharmazeutische und Medizinische 
Chemie, Westfälische Wilhelms-Universität Münster  
It was shown that the activation of A2B adenosine receptors induces a relaxing 
effect on the musculus trachealis of guinea pigs, while activation of the A1
adenosine receptor mediates a contraction.The nonselective adenosine receptor 
agonist adenosine-5'-N-ethylcarboxamide (NECA) produces a relaxing but no 
contracting effect, although it has a higher affinity for the A1 than the A2B
adenosine receptor. The aim was to identify the relevance of A1 and A2B receptors 
by using NECA, the selective A2B receptor agonist BAY 60-6583 and the A2B
receptor antagonist PSB-1115 on rat trachea contraction and on CBF (ciliary beat 
frequency). NECA (1.3 and 4.3 μM) induced a contraction (+25.39 % and +61.01 
%, respectively) of a trachea precontracted by carbachol. This effect was mediated 
by A1 receptors, since the selective A1 adenosine receptor agonist N6-
Cyclohexyladenosin (CHA, 1 μM) mimicked this effect (+18.02 %). The effect 
vanished after repeated administrations of NECA (desensitisation) and even a 
relaxing effect was found by 4.3 μM (-25,86 %). This relaxing effect could be 
blocked by 5.3 μM PSB-1115 (-6.70 %). BAY 60-6583 was not effective probably 
due to solubility problems. BAY 60-6583 led to a significant increase of CBF by 
12.14 %, which was neutralized by PSB-1115 (5.3 μM). This study shows, that the 
relaxation on the rat musculus trachealis depends on the activation of the A2B
adenosine receptor, whereas the activation of the A1 adenosine receptor leads to a 
contraction. A2B adenosine receptors are involved in CBF modulation. 
We thank Dr. T. Krahn, Bayer Schering Pharma AG, for providing BAY 60-6583 
and Prof. Dr. C. E. Müller, Pharmazeutische Chemie I, Rheinische Friedrich-
Wilhelms-Universität Bonn, for supplying PSB-1115.    
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Traditional plant remedies against fever – potential modern phytotherapeu-
tics?
N. Schuster1, S. Anagnostou2
1,2 Institut für Geschichte der Pharmazie, Philipps-Universität Marburg 
Throughout the ages only the symptom “fever”, but not the true etiological causes 
of the diseases were known. So long before modern pathogenesis and antibiotics 
changed our understanding of illnesses many different pathological conditions and 
even full groups of illnesses were called fever. For centuries plants represented the 
major part of the traditional materia medica and many were used against fever of 
different origin. A screening of medicinal plants used against fever for centuries 
and analyzing possible effects as treatment against respective types of fever may 
give precious hints for special efficacies of the used plants or even their constitu-
ents, for example antipyretic, antibiotic or antiviral properties. In this context it is 
especially important to understand and evaluate the use of the plants on the base of 
the contemporary, medical-pharmaceutical paradigm. 
In the early modern time, for example, particularly plants which contained bitter 
substances were used against fever. Bitter substances are known to activate the 
digestion and in those days fever was often understood as a digestion procedure 
which helps the body to deposit of harmful substances and to restore the balance of 
the bodily humors. Furthermore bitter plants were described as being “cold” and 
seemed therefore right to heal a warm condition such as fever. A representative for 
those bitter plants used as febrifuge is centaury (Centaurium erythraea), also known 
as “the fever herb”. Dioscurides (1st century) was the first who described its appli-
cation against fever and named it “Febrifuga”. The authors of the “Kräuterbücher” 
such as Hieronymus Bock (1498–1554) praised it as remedy against fever as well 
and in the 19th century centaury was even used as a cheap alternative for the China 
bark (Cinchona sp.). In 1991 researchers from Turkey actually proved antipyretic 
and anti-inflammatory effects of an extract of centaury in animals.  
Purpose of our work is to prove the continuous use of traditional herbs against fev-
er from the early modern time to today and suggest selected plants for further in-
vestigations concerning constituents with antipyretic and antiinfective activity.  
Literature:
BERKAN, Tayfun u.a.: Antiinflammatory, analgesic, and antipyretic effects of an aqueous extract 
of Erythraea centaurium. In: Planta medica 57 (1991 ) Heft 1 , 34–37. 
BOCK, Hieronymus: Kreütterbuch. Straßburg 1595, S. 51r.
KÜLKEN, Thomas: Fieberkonzepte in der Geschichte der Medizin. Heidelberg 1985.
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PLANT REMEDIES FOR THE TREATMENT OF WOUNDS FROM 
EARLY MODERN TIME TO THE PRESENT 
Müller, J., Anagnostou, S., Friedrich, C.
Institut für Geschichte der Pharmazie, Philipps-Universität Marburg.  
Plant remedies for the treatment of wounds look back on a long tradition in 
pharmacy. The empirical use for often hundreds of years can be interpreted as an 
indication for a potential effect on the wound-healing process. Many of these plants 
fell in oblivion or have experienced a different application. Discovering or 
rediscovering such plants can be interesting for the development of modern 
phytotherapeutics for wound treatment. In historical sources of the early modern 
time like herbals, pharmacopoeias and pharmaco-botanical works far more than 
hundred herbal medications for wound treatment are mentioned. After the 
screening of these plants, the medico-pharmaceutical tradition of selected 
medicinal plants will be analyzed to investigate their stringent application as 
wound healing agents from early modern time to the present. In combination with 
the latest scientific data concerning their constituents and efficacy their possible 
potential for modern wound treatment will be evaluated. 
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HERBARIUM SIEGESBECKIANUM  
Pötz, A.1
1Geschichte der Naturwissenschaften, Pharmaziegeschichte, TU Braunschweig  
On Lorenz Heister`s recommendation the german physician Johann Georg 
Siegesbeck (1686-1755), who founded his career as a botanist in Helmstedt, 
became director of the Medical Garden of Saint Petersburg in 1735. He is well 
known due to his hassle with Carl von Linné. While establishing his ideas of 
classifying plants after their sexual organs Linné has been attacked by Siegesbeck. 
He negated this concept as well for religious as for botanical reasons. The religious 
aspect of this conflict mainly defines the perception of Siegesbeck in history of 
science ever since. In 1747 he was excluded from The Saint Petersburg Academy 
of Sciences for political reasons and returned to Germany to work at Seehausen as 
a physician.  
This poster should highlight the botanical significance of Siegesbeck through his 
work on the herbarium. His private herbarium came to the Herzog August 
Bibliothek at Wolfenbüttel and is still stored there today. The circumstances for 
this transfer to Wolfenbüttel are not known. It contains approximately 1.500 dried 
specimen in fifteen volumes. Most of the plants are named in pre-linnéan 
nomenclature and listed in alphabetical order in an added index. The sheets with 
the glued samples are not fixed to the book and granted Siegesbeck the flexibility 
to change the order of his herbarium. This order still remains predominantly. A 
remarkable amount of plants originates from Siegesbeck’s period in Russia and led 
the Herzog August Bibliothek to date the herbarium to 1735. 
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REFORMS OF THE PHARMACEUTICAL SYSTEM SHOWN BY THE 
EXAMPLE OF THE FORMER RHINE PROVINCE (1791-1875) 
Landgraf, S.
Abteilung für Geschichte der Naturwissenschaften mit Schwerpunkt 
Pharmaziegeschichte 
TU Braunschweig 
The causes for competitive conflicts between doctors and non-legitimised healers 
are manifold. What fuelled the conflict at the beginning of the 19th was the 
occupation by the French. When French Patent Law of 1791 was introduced the 
ancient battle about the division of the pharmaceutical market was sparked off 
again. In the ensuing Prussian reform efforts, they maintained the subordinated 
concept of French Patent Law. Especially against the background of tough 
financial conditions, there was a noticeable increase in outside pressures to reform 
the pharmaceutical market with respect to the efficiency and costs of therapeutic 
agents. This is how popular medicine made its official arrival on the remedy scene. 
Patent laws and privileges existed to protect inventors; at the same time 
government regulations had to be established to protect the general public from the 
numerous inventions. The side effects of widespread quackery trade on the so 
called salus aegroti in turn, influenced the pharmaceutical needs as a regulative 
factor.
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Fachgruppensymposien
FÖRDERUNG DER KOOPERATION VON ARZT UND APOTHEKER 
ALS THEMA DES NEUEN AKTIONSPLANS DES 
BUNDESMINISTERIUMS FÜR GESUNDHEIT  ZUR VERBESSERUNG 
DER ARZNEIMITTELTHERAPIESICHERHEIT (AMTS) 
Dr. Amin-Farid Aly 
Arzneimittelkommission der deutschen Ärzteschaft 
Der Sachverständigenrat zur Begutachtung der Entwicklung im Gesundheitswesen 
hat mit seinem Sondergutachten 2009 zum Thema „Generationenspezifische 
Gesundheitsversorgung in einer Gesellschaft des längeren Lebens“ ausdrücklich 
darauf hingewiesen, dass in Zukunft in der Arzneimittelversorgung die 
interdisziplinäre Zusammenarbeit zwischen Ärzteschaft und Apothekerschaft an 
Bedeutung gewinnen wird. Als wesentliches Ziel wird in diesem Zusammenhang 
„die Förderung von Therapiesicherheit und bestimmungsgemäßem Gebrauch“ von 
Arzneimitteln genannt. Trotz vielfältiger punktueller Erfahrungen in der Praxis ist 
eine zwischen Ärzteschaft und Apothekerschaft abgestimmte gemeinsame Position 
zur Verantwortung der jeweiligen Bereiche und ihrer Zusammenarbeit zur 
Verbesserung
der AMTS bislang nicht formuliert worden.  
Der Aktionsplan AMTS 2010 – 2012 nimmt die Zusammenarbeit zwischen 
Apothekern und Ärzten im Bereich AMTS als ein zentrales Thema auf. In der 
Koordinierungsgruppe die für die Umsetzung und Weiterentwicklung des 
Aktionsplan AMTS verantwortlich ist, sind sowohl Ärzte als auch Apotheker 
vertreten. Daher sollen hier Vorschläge für eine Optimierung der Zusammenarbeit 
zwischen von Ärzteschaft und Apothekerschaft zur Verbesserung der AMTS 
erarbeitet werden.  
Der Vortrag benennt Felder der Zusammenarbeit zwischen Apothekern und Ärzten 
und zeigt erste Vorstellungen einer möglichen Zusammenarbeit hinsichtlich der 
Arzneimitteltherapiesicherheit. 
F1-1
ZUKUNFT eMEDIKATION. WIE IT DIE PHARMAZEUTISCHE 
BETREUUNG UNTERSTÜTZEN KANN 
Dr. Stefan Schwenzer 
ID Berlin 
Die durchgehende EDV-gestützte Begleitung und Unterstützung der 
Medikationsprozesse sowohl in der ambulanten als auch in der stationären 
Versorgung (kurz eMedikation) ist trotz einzelner Rückschläge (eGK) dabei sich 
als fester Bestandteil der Arzneimittelversorgung zu etablieren. Auch die 
pharmazeutische Betreuung wird in Zukunft fester Bestandteil innovativer 
Versorgungskonzepte sein. Dabei wird sich ein Augenmerk auf eine strukturierte 
Erfassung und Bewertung der Patientenmedikation richten. Hierbei sollten neben 
der Medikation möglichst viele Begleitparameter, wie z.B. Alter, Allergien, 
Diagnosen und Laborwerte berücksichtigt werden. Moderne Softwaresysteme 
sollen die Bewertung dieser komplexen Zusammenhänge unterstützen und dabei 
Apotheker und Ärzte mit Informationen versorgen, die über eine einfache 
Interaktionsprüfung deutlich hinausgehen.  
Hier haben Softwarehersteller in den letzten Jahren die Entwicklung deutlich 
vorangetrieben. Die Kombination moderner IT-Technologien mit semantischer und 
regelbasierter Wissensanalyse wird inzwischen erfolgreich in der Routine 
eingesetzt. Dieses unterstützt sowohl eine strukturierte Medikationsdokumentation, 
als auch die Prüfung der Medikation im Kontext von Diagnosen und Labordaten. 
Der Einsatz von Services und Webkomponenten ermöglicht dabei die Entwicklung 
skalierbarer und modularer Lösungen, die sich für eine integrierte Nutzung in der 
sektorenübergreifenden Versorgung und pharmazeutischen Betreuung anbieten. 
F1-2
ERSCHLIEßUNG VON SICHERHEITS- UND WIRTSCHAFTLICHKEITSRE-
SERVEN DURCH DIE DOKUMENTATION ARZNEIMITTELBEZOGENER 
PROBLEME 
Prof. Dr. Marion Schaefer 
Institut für Klinische Pharmakologie, Invalidenstrasse 115, 10115 Berlin  
Durch das Erkennen, Vorbeugen und Lösen arzneimittelbezogener Probleme in der 
Arztpraxis, im Klinik- und Heimalltag aber vor allem bei der Abgabe von Medikamenten in 
der Apotheke werden die Arzneimitteltherapiesicherheit und die Therapieeffizienz erhöht 
und mögliche Folgekosten gesenkt. Dies ist durch zahlreiche Betreuungsstudien im Sinne 
einer  leitliniengerechten Versorgung belegt worden.  Erkannte arzneimittelbezogene Prob-
leme können mit Hilfe einer standardisierten Klassifikationssystems softwaregestützt do-
kumentiert werden, wodurch eine patientenindividuelle und arzneimittelspezifische Rück-
verfolgung, Interaktion und Vermeidung möglich wird. Damit wird auch einer Forderung 
der WHO entsprochen, die nicht nur die Erfassung unerwünschter Arzneimittelwirkungen 
sondern auch aller anderen arzneimittelbezogenen Probleme fordert. 
Eine systematische und möglichst lückenlose Dokumentation der Arzneimittelanwendung 
schafft für den Patienten eine individuelle Datenbasis, mit der die Sicherheit der Arzneimit-
teltherapie erhöht und die Nachhaltigkeit der ärztlich veranlassten Therapie unterstützt 
werden kann.  
Sachlogisch ergeben sich kostenrelevante Nutzenkomponenten einer Arzneimitteldoku-
mentation aus folgenden Einzelschritten, bei denen grundsätzlich  auf die gespeicherte 
Medikationshistorie zurückgegriffen werden muß: 
- Berücksichtigung bestehender Kontraindikationen (Allergien, Begleiterkrankungen etc.) 
- Vermeidung versehentlicher Fehlverordnungen durch Abgleich mit zuvor verordneten 
Arzneimitteln, einschliesslich unzweckmässiger Stärken und Darreichungsformen 
- Erkennung und Überprüfung von Doppelverordnungen 
- Einschätzung der Patientencompliance über die Abstände der Rezepteinlösung 
- Überprüfung der individuellen Dosierung (soweit angegeben oder vom Patienten er-
fragbar) 
- Erkennung und Vermeidung schwerwiegender Interaktionen mit klinischen Konseque-
zen
- Aufnahme von AM-Unverträglichkeiten, die zum Medikationsabbruch geführt haben, 
als  Patientenmerkmal, um eine künftige Wiederverordnung zu vermeiden. 
Durch die Klassifizierung arzneimittelbezogener Probleme wird die Kooperation der Heil-
berufler erleichtert und kann besser auf therapierelevante Schwerpunkte fokussiert werden. 
Durch einen entsprechenden Dokumentationsstandard für arzneimittelbezogene Probleme 
soll eine weitere Verbesserung der Arzneimitteltherapiesicherheit bei gleichzeitiger Er-
schließung von Wirtschaftlichkeitsreserven, etwa durch gezielte Förderung der Compliance 
erreicht werden. 
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TRACING CHEATERS IN SPORTS –  
MASS SPECTROMETRY IN ANTI-DOPING RESEARCH 
Parr, M.K.
Center for Preventive Doping Research, Institute of Biochemistry,  
German Sport University Cologne 
In sports the (mis-)use of drugs is regulated by the World Anti-Doping Agency 
(WADA). Its list of prohibited substances classifies the use of several classes of 
substances and prohibited methods in sports as doping (Tab. 1). The analyses in 
doping control are mainly performed utilizing GC-MS(/MS), LC-MS/MS and 
isotope ratio mass spectrometry (IRMS). 
Current research mainly focuses on the identification of metabolites suitable for 
elongated detection of classical doping agents, the discrimination between 
endogenously produced and synthetic congeners, the detection of new performance 
enhancing substances and the identification of their metabolites. This also includes 
the characterization of new designer steroids that are marketed as dietary 
supplements. Additionally the manipulation of doping control samples is detectable 
by the help of mass spectrometric techniques. 
Tab 1: Classes of prohibited substances and methods in sports  
Anabolic
Agents
Peptide Hormones, 
Growth Factors 
and and related 
Substances
Beta-2
Agonists
Hormone 
Antagonists and 
Modulators 
Diuretics
and other 
Masking
Agents
Stimulants Narcotics Cannabinoids Glucocorticoids  
Enhancement 
of Oxygen 
Transfer 
Chemical and 
Physical 
Manipulation 
Gene Doping Alcohol *) Beta-
Blockers *)
*) only prohibited in particular sports 
F2-1
PREPARATION OF MONOLITHIC COLUMNS FOR LC-MS/MS 
ANALYSIS OF PROTEINS AND DRUGS
Sproß, Jens, Sinz, Andrea
Abteilung Pharmazeutische Chemie und Bioanalytik, Institut für Pharmazie, 
Martin-Luther-Universität Halle-Wittenberg, Wolfgang-Langenbeck-Str.4, D-
06120 Halle/Saale 
During the past few years monolithic supports have been used for an 
increasing variety of applications. The examples for applications of 
monoliths presented show that the chromatographic performance of 
bioreactors and affinity media prepared from monolithic media is superior 
compared to that of conventional particle-based systems. The ease of 
fabrication and modification combined with a long life time of the prepared 
columns and their potential to be used in fully automated analytical systems 
make them attractive tools for yet an increasing number of applications. 
F2-3
CE IN PHARMACEUTICAL ANALYSIS – APPLICATION TO DRUG 
IMPURITY PROFILING 
Scriba, G. K. E.
Pharmaceutical/Medicinal Chemistry, Friedrich Schiller University Jena 
CE has been recognized as a suitable technique for the determination of the 
stereoisomeric purity as well as for the analysis of related substances of drugs, for 
the determination of organic and inorganic counterions, for the analysis of peptides 
and proteins, etc. [1]. This is also reflected by the fact that CE has been included as 
a general monograph in the European Pharmacopoeia as well as the United States 
Pharmacopeia several years ago. The technique is applied in several monographs 
of the pharmacopeias for drug identification and/or tests. 
Traditionally, the stereoisomeric composition of a drug is determined by optical 
rotation which is not very accurate. Thus, current research efforts aim at the 
development of new CE methods for the determination of the stereoisomer 
composition of drugs. The studies include methods for the simultaneous 
determination of related substances of the drugs besides the stereoisomers. Such 
analyses are typically performed in separate tests in the pharmacopeias. Examples 
for the method development in cyclodextrin-mediated separations in EKC and 
MEEKC will be discussed. 
[1] Capillary Electrophoresis Methods for Pharmaceutical Analysis, S. Ahuja, M. 
I. Jimidar, eds., Elsevier, Amsterdam, The Netherlands 2008. 
F2-4
CAPILLARY ELECTROPHORESIS (CE) AND FRET AS TOOLS FOR 
TESTING INHIBITORS OF HUMAN PROTEINKINASE CK2 
Jose, J.1, Gratz, A.1, Götz, C.2
1Pharmazeutische und Chemie, Heinrich-Heine-Universität, Düsseldorf 
2Medizinische Biochemie, Universitätsklinikum Homburg.  
Protein kinase CK2 is of increasing impact as a target for treating neoplastic 
diseases. Upregulated CK2-activity can be found in a variety of tumors. 
Until now, the common in vitro assay to quantify compound-driven CK2-
inhibition needs the use of radioactive isotopes. We present two novel CK2-
inhibition assays that could complete or even replace the standard 
radiometric assay. 
The first assay is based on Förster-resonance-energy-transfer (FRET) 
between the donor-fluorophor EDANS and the acceptor DABCYL within 
the CK2 substrate peptide [DABCYL]-RRRDDDSDDD-[EDANS]. This 
peptide possesses an elastase cleavage site adjacent to the phosphate-
acceptor serine. The non-phosphorylated peptide can be cleaved by elastase 
and consequently FRET is hampered. Upon phosphorylation the elastase 
recognition site within the peptide is masked, cannot be cleaved and FRET 
is retained. The degree of phosphorylation is measured as donor-
fluorescence intensity that develops during the loss of FRET. Thus 
fluorescence intensity is inversely correlated with CK2-activity.
The second assay is based on a direct product quantification of a CK2-
reaction by capillary electrophoresis. The acquisition of a phosphate moiety 
leads to a difference in electric charge between substrate and product and 
enables their electrophoretic separation (“mobility-shift”). Quantification is 
performed by calculating the area of the product peptide peaks, recorded by 
UV-absorption. The IC50-values of Emodin and TBB that were determined 
by this assay showed a good agreement with published data [1]. 
Subsequently, new inhibitors of human CK2 with IC50 values in the 
nanomolar range could be identified.  
[1] Gratz A, Götz C, Jose J (2010) Electrophoresis 31:634-40.  
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A YEAR CPOE - PRACTICAL EXPERIENCES AND PERSPECTIVES 
FROM A CLINICAL PHARMACIST 
Keiner, D.
Zentralapotheke, SRH Zentralklinikum Suhl gGmbH 
Objectives: The use of electronic prescription software increases drug safety in 
hospital. However, the implementation rate of CPOE in german hospitals is less 
than 3 percent. Prescription errors occur often at cost-intensive drugs. 
Setting: Since December 2008, the hospital uses Rp-Doc® first in the heart-lung 
vascular center (HLG, 4 wards, 144 beds). Experience with process design as well 
as clinical and pharmaceutical aspects are presented. 
Results: Drug profiles of 50 patients were evaluated. The average number of 
inpatient prescribed drugs was 7,2 ± 3,28 (1-16). In 82% of the patients was 
considered a polymedication (more than 4 drugs) and in 32% a renal insufficiency 
(GFR <50 ml/min). The investment in the HLG-center of 41 T € standing drug-cost 
savings of 71 T € (about 15%) against.  
Conclusions: The introduction of CPOE leads to a modification of workflows. 
Each change/enter of pharmacy or nursing needs the physician release. Patient 
safety and quality indicators can be improved. In addition, economic aspects such 
as cost unit accounting and supplementary reimbursement (Zusatzentgelt) control 
can be implemented easily. 
F4-1
SAFETY OF PHARMACOTHERAPY ON THE INTERFACE BETWEEN 
OUTPATIENT AND INPATIENT TREATMENT 
Nowak, K. 
Hospital pharmacy/Department of clinical pharmacy, Diakonie Hospital kd, Bad 
Kreuznach, FRG 
Abstract: 
Healthcare in FRG primarily takes place on two strictly separated sections, the 
outpatient and inpatient treatment. Whenever patients with long-term medications 
(e.g. chronic diseases) need an inpatient treatment in the hospital, a lot of problems 
and questions in the context of medication occur on this interface, because in 
German hospitals exist mainly clearly drug formularies and standardised drug 
therapies. This is the result of cooperation between hospital pharmacists and 
physicians in the formulary committee. However in the outpatient section drug 
therapies are only rudimentarily standardised and a plenty of proprietary medicinal 
products in FRG are available. Unfortunately the existing rebate-contracts between 
generic manufacturers and statutory insurance companies (GKV) increase the 
complexity in this sector. 
Now for over 15 years, the clinical pharmacist’s daily task in our hospital is to 
ensure the safety of pharmacotherapy when patients with chronic medication enter 
the surgical wards. Directly on bed-side or in patients chart the previous 
(individual) outpatient medication is checked and proved. In particular, the 
plausibility, correct dosage, drug-drug-interaction and specific contraindications 
are clarified. Recommendations for a drug conversion to our formulary medication 
and standardised drug therapies are given and are highly accepted by the 
physicians. 
Most recently, the reason for the actual hospital admission (initial diagnosis) is 
matched with published and documented adverse effects of the previous 
medication, because sometimes direct or hidden drug adverse effects induce 
hospital admission.  
In this presentation our daily realisation and really happened practical examples are 
shown.
F4-2
CLINICAL-PHARMACEUTICAL INTERVENTION STUDIES TO 
OPTIMISE PATIENT SAFETY IN DRUG THERAPY IN HOSPITAL 
SETTINGS 
Bertsche, T.1,2 
1Cooperation Unit Clinical Pharmacy, University of Heidelberg; 2Department of 
Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg 
Objectives 
Drug-related problems (DRP) are frequent in hospitals. Particularly, they occur in 
prescription and administration and lead to death, prolonged hospital stay, and 
severe adverse drug reactions (ADRs). Different reasons, such as knowledge 
deficits, account for DRPs. In a setting of limited resources, however, intervention 
strategies to improve patient safety have to be prioritised to the most frequent and 
severe DRPs and have to be tailored to the causes. 
Participants and methods 
At a university hospital, we identified DRPs in routine care by instructed monitors 
(clinical pharmacists) and assessed knowledge deficits by a questionnaire survey. 
DRPs were classified according to their prevalence, potential risk, and reasons for 
their occurrence using a decision-matrix model. Tailored interventions such as 
teaching sessions, clinical pharmacist interventions, and newly developed clinical 
decision support systems were implemented in hospital settings including e.g. 
intensive care units, paediatric wards, or cancer patients. Relative risk reduction, p-
values, and total numbers (control and intervention group) are presented. 
Results 
In drug administration, we identified physico-chemical incompatibilities and drug 
administration by gastric tube as most prevalent DRPs (n=1376 processes). DRP 
prevalence decreased by 59% (p=0.003, incompatibilities, adult ICU patients, 
n=1108 drug pairs) and by 94% (p<0.001, gastric tube administration in children, 
n=1164 processes). In a follow-up analysis these effects were sustainable. In drug 
prescription, guideline adherence in pain treatment for cancer patients increased by 
81% (p<0.001, n=100 patients), ADRs caused by drug interactions decreased by 
43% (p=0.001, n=265 patients) and excessive dosing in patients with renal 
insufficiency by 51% (p<0.001, n=68). 
Conclusions 
Tailored interventions in routine care by clinical pharmacists based on teaching 
sessions and newly developed electronic systems decreased rates of DRPs and 
DRP-related ADRs. 
F4-3
MEDICATION SAFETY – HOW DO NURSES CONTRIBUTE?  
Mahler, C.1
1University Hospital Heidelberg, Department of General Practice and Health 
Service Research  
Background
In Germany several people are involved in the medication process, which starts 
with the prescription and ends after the drug reaches the place of drug metabolism 
with the monitoring process. Health professionals involved in the process are 
nearly always the physician (prescription), the pharmacist (dispenser) and/or 
nurses; however non health professionals (patients) are also always involved as 
well as family members sometimes. Good communication is necessary between all 
persons involved to assure medication safety, as poor communication is associated 
with medication-related errors and adverse effects. Nurses are usually called on as 
soon as patients are not capable of managing certain steps within the whole 
medication process – this applies both to the hospital and the primary care setting. 
Especially within the long-term care of patients with chronic diseases nurses are 
often integrated and challenged.  
Questions  
1. For which tasks within the medication process do nurses in Germany take over 
responsibility?  
2. How do nurses contribute to medication safety? 
Answers 
Within the hospital setting the nurses’ main focus of attention is to survey 
administration, dispensation of medicines as well as to observe medication effects 
and side effects in order to reduce medication related problems and medication 
errors. Employing specially trained pain and/or wound nurses ensures medication 
(and patient) safety.  
In the primary care setting nurses support patient self management, by identifying 
problems in coping with (complex) medication regimens in everyday life, by 
supporting patients to manage these and by developing individual medication 
routines. This raises adherence and hence medication safety. 
Nurses often take over communication about medication related issues at the 
interface between patient, family members and other health professionals and 
therefore contribute to medication safety. To ensure medication safety a team 
approach, including all involved health professionals, is necessary. 
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MEDICATION SAFETY OF ELDERLY PATIENTS IN NURSING 
HOMES 
Jaehde, U. 1, Hanke, F. 2 
1Institute of Pharmacy, Clinical Pharmacy, Universität Bonn, 2GeroPharmCare 
GmbH, Köln  
The multimorbidity of elderly patients often leads to polymedication. Therefore, 
these patients are at particular risk to suffer from drug-related problems such as 
adverse drug events. Studies have shown that the incidence of adverse drug events 
is particularly high in long-term care facilities leading to severe consequences such 
as hospitalization and death (Gurwitz et al. 2005).
In a prospectively designed cross-section analysis in North Rhine-Westfalia funded 
by the Federal Ministry of Health (BMG) two clinical pharmacists surveyed the 
documentation of 789 nursing home residents and interviewed the nurses regarding 
symptoms observed in the previous month. The incidence of adverse drug events 
was found to be 8.11 per 100 resident-months with a preventability rate of 57.8%. 
The majority of adverse drug events were caused by CNS and cardiovascular drugs 
(Schröder et al., this conference).
Based on these data, a structured intervention was planned by a multiprofessional 
panel of experts consisting of clinical pharmacologists, clinical pharmacists, 
general practitioners, nurses, and geriatricians. The intervention comprised five 
measures: (1) intensive seminars for nurses and pharmacists, (2) advanced training 
for the prescribing general practitioners, (3) the implementation of a reminder card 
summarizing high-risk drugs and monitoring issues, (4) the formation of 
medication safety teams in each nursing home consisting of a nurse and a 
pharmacist, and (5) structured documentation and communication regarding 
individual drug therapy. The intervention has recently been implemented in four 
nursing homes in North Rhine-Westphalia. 
In conclusion, incidence and severity of adverse drug events indicate serious 
deficiencies in the health care of elderly patients living in nursing homes. 
Medication safety-enhancing interventions have the potential to improve the health 
status of the residents and to reduce costs, e.g. by avoiding unnecessary falls and 
hospitalization. The developed intervention is easy to implement and may serve as 
a model for German nursing homes.
Reference: 
Gurwitz et al. Am J Med. 2005;118:251-8 
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DATA DRIVEN QUALITY IMPROVEMENT IN PRIMARY CARE 
(DQIP): USING ROUTINE DATA TO IMPROVE THE QUALITY AND 
SAFETY OF PRESCRIBING IN PRIMARY CARE 
Tobias Dreischulte 
Background
A number of systematic reviews have demonstrated that approximately 4-5% of all 
unplanned hospital admissions are caused by preventable adverse drug events, of 
which more than half have been attributed to errors in medication prescribing and 
monitoring. The ‘DQIP’ study is a five year research programme which aims to 
develop and test a complex intervention to improve the quality and safety of 
prescribing in UK primary care. A central component of this intervention is the 
analysis (audit) and feedback of providers’ achievements against quality and safety 
indicators based on morbidity linked prescribing data, which has become routinely 
available as a by-product of novel contractual arrangements between the UK 
National Health Service (NHS) and general medical practitioners (GPs).   
Methods
The design and evaluation of the ‘DQIP’ intervention follows the Medical 
Research Council’s (MRC) guidance and uses a mix of quantitative and qualitative 
research methods in six studies divided into two phases. In phase 1 potential 
quality and safety improvement targets (primary outcomes) are determined (study 
1) and tested (study 2), intervention components are piloted (study 3) and options 
for embedding the intervention into the wider health care environment are explored 
(study 4). Phase 2 includes the conduct of a cluster randomised trial in two Scottish 
health boards (study 5) and a parallel process evaluation (study 6) in order to 
understand how the intervention mediates effectiveness.  
Results 
The findings of the completed study 1 will be reported, where a broad set of 
prescribing quality and safety indicators was developed and prioritised based on 
literature review and expert consensus. Instruments of data feedback that are 
currently undergoing pilot testing will be presented.  
Discussion and conclusion 
Opportunities, limitations and methodological challenges of using indicators of 
prescribing quality and safety in the context of quality judgement, quality 
improvement and as outcome measures in quality improvement research will be 
discussed. 
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MORE THAN GOOD PRICES - PATIENT SAFETY IN DRUG THERAPY 
WITHIN A LARGE COLLABORATION OF COMMUNITY 
PHARMACIES 
Schwalbe, O.1, Braun, C.1, Simons, S.2, Jaehde, U.1
1Institute of Pharmacy, Clinical Pharmacy, Universität Bonn 2Apotheke am 
Stadttor, Neuenrade 
Background: Since the 1990s especially professional bodies proclaimed a change 
of the pharmacy profession from product centeredness towards patient orientation. 
Patient centeredness has been associated with the term “pharmaceutical care” and 
the introduction of the subject “Clinical Pharmacy” into the pharmacy state 
curriculum. Nevertheless, change towards pharmaceutical care in pharmacies has 
been slow and not sustainable, e.g. due to limited resources and lack of 
reimbursement. Notwithstanding, pharmacies might relevantly promote patient 
safety in drug therapy. So far, data characterising the impact of pharmacies’ 
everyday activities on patient safety in drug therapy have been scarce.  
Objectives: To identify a research framework to sustainably establish and evaluate 
new patient oriented services which promote patient safety in drug therapy. 
Setting & Methods: Pharmacies in Germany belonging to the pharmacy 
collaboration “LINDA Apotheken” were included in this project. We employed 
quantitative (online survey, register) as well as qualitative (semi-structured 
interviews, observation) research methods.  
Results: Action research was identified as a suitable framework. It is a democratic 
and participant oriented approach. It consists of the following steps constituting the 
so called “action research cycle”: plan, act, observe and reflect. The first cycle 
dealt with an online survey (response rate: 30%, 398 out of 1320) on patient 
oriented services in pharmacies and decision-making about the prospective project: 
It showed that 98% of all pharmacies use an automated drug-drug interaction 
(DDI) check. Furthermore, ca. 50% of all pharmacies had some form of 
documentation of their DDI management. The second cycle, which is ongoing, 
deals with a pilot study in nine pharmacies investigating the feasibility of an 
electronic documentation system for the management of DDIs.  
Conclusions: Action research might be a promising way towards sustainably 
establishing and evaluating patient oriented services in community pharmacies, 
which increase patient safety in drug therapy. First data collected from the 
participating pharmacies demonstrated a promising basis for the establishment of 
such services. 
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IN-VITRO MODELS FOR CONGENITAL KERATINIZATION 
DISORDERS 
Hennies, H.C.1, Torres, S.1, Casper, R.1, Weindl, G.2, Ackermann, K.2, Küchler, 
S.2, Oji, V.3, Traupe, H.3, Schäfer-Korting, M.2, Eckl, K.M.1
1Dermatogenetics, Cologne Center for Genomics, Universität zu Köln 2Institute of 
Pharmacy (Pharmacology and Toxicology), Freie Universität Berlin 3Department
of Dermatology, University Hospital of Münster 
Hereditary keratinization disorders are a clinically and genetically heterogeneous 
group of skin diseases. They are characterized by abnormalities in terminal 
keratinocyte differentiation. Clinical features include marked keratosis, more or 
less intense scaling of the skin, either generalized or localized, and mild to 
extensive erythema. A disturbed epidermal barrier function is often seen, which 
may lead to secondary signs such as increased trans-epidermal water loss and 
imbalances in nutrition but also severe eczema and allergies.  
To investigate the epidermal barrier function and to assess novel therapeutics we 
have developed 3D full-thickness human skin models that mimic congenital 
ichthyosis, a rare and severe keratinization disorder. The model consists of an 
underlying dermal equivalent and a fully stratified, perfectly organized epidermal 
part with a well established basement membrane zone and all keratinocyte layers. 
The model has been validated using reference substances for reconstructed skin. 
We have employed the model for the characterization of an autosomal recessive 
skin disorder, the peeling skin disease. It is characterized by lifelong patchy 
peeling of the skin and severe erythroderma, associated with pruritus and atopy. 
The analysis of the epidermal permeation in models generated with patient 
keratinocytes clearly demonstrated an impairment of the epidermal barrier 
function, which is supposed to underlie the atopic phenotype in the patients. The 
models are now being used to investigate the abilities, effects, and toxicity of new 
drugs for therapeutic approaches specifically designed for genetic cornification 
disorders. The enhancement of epidermal penetration using nanoparticles was 
assessed in the in-vitro models with a model dye loaded onto the particles. Our 
animal-free model is the first human artificial skin model suitable for the 
characterization of epidermal barrier functional defects caused by monogenic 
disorders. It shows a high reproducibility of barrier properties and can be used 
more generally for the analysis of drugs as well as toxic substances.  
F6-1
Fachgruppensymposien
http://www.digibib.tu-bs.de/?docid=00038117 24/02/2011
IN VITRO WOUND HEALING MODELS 
Küchler S1, Wolf NB1, Schäfer-Korting M1
1Institut für Pharmazie (Pharmakologie/Toxikologie), FU Berlin, Berlin 
To monitor the healing process of wounded skin several in vitro methods 
are already described in the literature. Hereby, wounds were induced by 
deep scratching using a mesh or scalpel, punch biopsies or freeze damage. 
However, these procedures appear problematic with respect to reproducible 
wound sizes. To overcome this problem a new in vitro model for the 
investigation of wound healing has been established using a reconstructed 
full thickness skin model and a laser wounding procedure. Furthermore, its 
suitability for monitoring wound healing process was determined by testing 
the new approach of accelerating wound healing by the means of topically 
applied opioids.  
The laser wounds were induced with a CO2-Laser aiming for an almost 
complete destruction of irradiated epidermis without morphological 
alterations of the dermis and well defined wound margins. After method 
establishment healing process was investigated applying morphine solutions 
or morphine loaded nanoparticulate carrier systems onto the centre of the 
wounds. After a healing period of 4 days, skin models were analyzed using 
haematoxylin-eosin staining procedure. 
Histological evaluation of the healing process revealed that morphine 
induced keratinocyte proliferation and migration from the margins and from 
the few remaining viable keratinocytes on the wound ground. Subsequently 
the wound ground was almost completely covered by a new epithelium 
which was not the case for the negative control. Moreover, semi-
quantification of the thickness of the regenerated epidermis revealed a 
significantly thicker epidermis in those wounds treated with morphine 
solution compared to the control. Thus, morphine effects in the standardized 
laser-wounds are well in accordance with other publications showing the 
acceleration of wound healing by the means of topically applied opioids. 
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IN VITRO INFECTION MODELS OF LOCALIZED CANDIDA 
INFECTIONS
Weindl, G.1
1Institut für Pharmazie (Pharmakologie und Toxikologie), Freie Universität Berlin 
Basic research on the biology and immunology of microbial infection requires 
appropriate model systems. Due to the complexity of the processes, most studies 
involve animal testing. Besides ethical concerns, these models are not always 
representative of infections in humans, which holds true particularly for the human 
pathogenic fungus Candida albicans. In vitro models that closely parallel the in 
vivo situation and allow studies of relevant physiologic functions are thus highly 
desirable. 
Possible alternatives, especially for localized infections, are provided by models 
using in vitro reconstituted human epithelium or epidermis. In recent years, these 
model systems have been successfully established to evaluate the effectiveness of 
topical anti-infectives, to characterize the role of fungal virulence factors, and to 
study the immune responses during localized C. albicans infections. Early studies 
focused on the consequence of gene disruption in C. albicans on pathogenicity and 
the epithelial cytokine pattern. Most recently, these models have been 
supplemented with immune cells such as lymphocytes and polymorphonuclear 
leukocytes to study their role during the course of infection and to characterize the 
interaction between the skin barrier and accessory immune cells. Using the in vitro 
model, it has been demonstrated that an immunological crosstalk between C.
albicans–infected oral epithelium and polymorphonuclear leukocytes induced an 
immune cell-mediated upregulation of epithelial Toll like receptor 4, a member of 
an important receptor family which plays a critical role in innate immune 
recognition of pathogens. The increased receptor expression was directly 
responsible for protecting the mucosal surface from fungal invasion and cell injury. 
These studies will help us to get insights into the complex mechanisms by which 
appropriate innate and acquired immune responses are initiated and to identify 
factors that contribute to an increased susceptibility to Candida infection in 
patients.
Although any conclusion from these models for an in vivo infection has to be made 
with caution, the available systems reflect more and more the physiological 
situation found in vivo, thereby providing a valid matrix to model the events under 
controlled experimental conditions. In addition, such model systems can also be 
used to study infections with other fungi or bacteria. 
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NEUE ERKENNTNISSE ZUR MOLEKULAREN UND 
MORPHOLOGISCHEN STRUKTUR DES STRATUM CORNEUM  
Neubert, R. 
Institut für Pharmazie, Martin-Luther-Universität Halle-Wittenberg 
Im Vortrag werden zunächst die morphologischen Strukturelemente des Stratum 
corneum (SC), die Desmosomen und die „hakenähnlichen“ Strukturen der 
Corneocyten vorgestellt, die den Raum für die hochgeordneten SC-Lipide schaffen. 
Danach werden neue Ergebnisse hinsichtlich des Einflusses der einzelnen SC-
Lipide auf die molekulare Architektur der SC- Bilayer gezeigt. Die Resultate 
wurden mit der Neutronenstreuung erhalten.  
Im Mittelpunkt dabei stehen die Ceramide und es wird der Einfluss der 
kurzkettigen Ceramide CER [AP] und CER [NP] den Aufbau der SC-
Doppelschichten präsentiert. Es wird zunächst der Einfluss des hydrophilsten 
Ceramids des CER [AP] auf die Barrierefunktion des SC vorgestellt und gezeigt, 
dass dieses Ceramid essentiell für die Barrierefunktion des SC zu sein scheint. 
Neue Ergebnisse der Arbeitsgruppe von Lars Norlen zeigen, dass im SC 
asymmetrische Doppelschichten vorliegen, da die kurzkettigen Ceramide 
unterschiedlich lange Alkylketten aufweisen.  Die asymmetrischen 
Doppelschichten bestehen aus einer 45 nm-Doppelschicht, in der sich 
hauptsächlich Cholesterolmoleküle befinden, und einer 65 nm-Doppelschicht, in 
der sich die freien Fettsäuren befinden. Dabei scheint das CER [NP] in der 
gestreckten Konformation eine Schlüsselrolle zu spielen. Die Resultate von Norlen 
konnten unter Verwendung von deuterierter Lignocerinsäure und deuteriertem 
Cholesterol mit Neutronenstreuung bestätigt werden. 
Außerdem wird gezeigt, wie sich Moleküle, die Penetration erhöhen (Enhancer), 
wie zum Beispiel Ölsäure und flüssige, synthetische Wachse, in die 
Doppelschichten der SC-Lipide einordnen. 
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IN-VITRO METHODS TO DETERMINE THE DERMAL ABSORPTION. 
WHAT THEY CAN – WHERE ARE THEIR LIMITS? 
Schäfer, U. F.
Biopharmazie und Pharmazeutische Technologie, Universität des Saarlandes, 
Campus, Geb. A41, 66123 Saarbrücken 
In-vitro methods to determine dermal absorption play an important role in product 
development in the field of pharmaceutics as well as cosmetics. In addition there is 
an increasing demand of such methods with respect to safety data of chemicals as 
recommended by the EU REACH program. In principle two different types of me-
thods are used: Penetration models address the distribution of substances under 
investigation within the different skin layers. Whereas permeation models deter-
mine the diffusion of substances through the skin or selected skin layers (1). 
Different experimental setups for penetration studies will be presented and espe-
cially the different methods of skin segmentation will be shown. Moreover, possi-
bilities of errors concerning penetration experiments will be displayed and their 
influence on the results will be discussed. As prototype for permeation experiments 
the well known Franz diffusion cell will be presented and the impact of the mem-
brane used, e.g. full thickness skin, heat separated epidermis and bio-engineered 
skin constructs, on the results will be reviewed. In summary for both experimental 
set-ups the calculated parameters will be discussed concerning their comparability 
and the level of predictability. 
(1) Hahn T., Schäfer U.F., Lehr C-M., SOFW-Journal, 136, 28-40 (2010) 
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PENETRATION AND STORAGE OF NANOPARTICLES IN THE SKIN
Lademann, J., Richter, H., Sterry, W., Patzelt, A. 
Charité – Universitätsmedizin Berlin, Clinic for Dermatology, Department of 
Experimental and Applied Physiology (CCP), Berlin 
The requirements on nanoparticles in cosmetics and medicine are very different in 
most cases. One the one hand, nanoparticles such as TiO2 and ZnO, which are 
widely applied in sunscreens, should be localised on the skin surface in the upper 
cell layers of the stratum corneum, while during drug delivery they should 
penetrate the skin barrier in order to reach the target structures in living cells. The 
Charité utilises various methods to investigate the penetration and storage of 
nanoparticles in the skin, with hair follicles being in the focus of attention. Ideally 
suited as target structures for drug delivery, hair follicles are surrounded by a dense 
network of blood vessels and characterized by a high concentration of both stem 
and dendritic cells. 
Investigations of nanoparticles of different size and materials showed that particles 
of circa 600 nm in diameter penetrate into the hair follicles particularly efficiently 
and can be stored there for up to 10 days. Thus, the retention time in the hair 
follicle is almost one order of magnitude longer than in the stratum corneum. The 
excellent penetration of these particles is due to the surface structure of the skin. 
The dandruff has a mean thickness of circa 600 nm and forms a “zigzag” structure 
on the hair surface. Obviously, this makes the moving hair acting like some sort of 
a gear pump and stimulates the transport process. The investigations did not show, 
however, that any particles with diameters between 40 nm and 1μm penetrated 
from the hair follicle into living tissue if the barrier was intact. This is plausible as 
the hair follicle, too, has a barrier structure of its own. Only in the event of artificial 
barrier damage a penetration of nanoparticles of 40 nm in diameter into living 
tissue structures could be observed. Consequently, a penetration through the intact 
skin barrier can be excluded for the investigated particle systems. But nanoparticles 
are also well suited to delivering drugs into the hair follicles for subsequent release. 
All in all a toxicological evaluation of nanoparticles must primarily be made with 
respect to their chemical composition. Only secondarily it is to be examined if the 
specific structure of the systems leads to new, possibly hazardous properties.  
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DERMATOLOGICAL VEHICLES – CLASSICAL AND INNOVATIVE 
FORMULATION CONCEPTS 
Daniels, R.
Pharmazeutische Technologie, Eberhard Karls Universität Tübingen 
The efficacy, tolerability, and application properties of dermatological products are 
clearly related to the type of base used. Interactions between the vehicle, the skin, 
and the drug affect the rate of release of the active moiety and the therapeutic 
activity of the drug product.  
The so called vehicle effect may be only a simple physical effect, e.g. cooling. In 
dependence on their composition, dermatological vehicles can, moreover, 
intensively interact with the skin and thus affect either positively or negatively the 
skin barrier function. 
On diseased skin the acuity of the disease determines predominantly which type of 
vehicle should be used. Exceptions occur when special conditions of the site of 
application have to be considered, e.g. hairy skin regions. 
To meet these multifaceted needs, a surprisingly large number of different vehicles 
are used in dermal therapy. Consequently, most dermatological drug substances, 
e.g. corticosteroids, are commercially available in different hydrophilic and 
lipophilic vehicles. If this is not the case, extemporaneous prescriptions may fill an 
existing therapeutic gap. 
All this is necessary because the proper choice of the vehicle, whether it is 
hydrophilic or lipophilic, as well as its water, lipid, and emulsifier content allows 
to individualize and optimize dermal treatment. 
The majority of products make use of classical dermatological vehicles, e.g. 
hydrophilic ointment or wool alcohol ointment, and variations thereof. 
However, innovative formulation concepts with improved efficiency and 
tolerability are beginning to emerge. Frequently, the development of a new vehicle 
aims to enhance drug penetration. Moreover, cosmetic and usage criteria, e.g. 
absorption, spreadability, and skin feel, influence increasingly the development of 
new products. Although these parameters are primarily not responsible for the 
effectiveness of a drug product they largely affect patient compliance during long 
term therapy. Betulin stabilized emulsions (Betulsions) represent solid stabilized 
w/o emulsions which require an absolute minimum of ingredients because the 
active moiety acts simultaneously as a stabilizer. Foams are not only cosmetically 
elegant formulations they also allow for an almost touchless application, which 
might be extremely favorable for wound treatment. 
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FORMULATION FOR THE TREATMENT OF SOLAR DAMAGES 
Müller-Goymann, C.C., Grüning, N., van Hemelrijck, C.
Pharmazeutische Technologie, TU Braunschweig  
Solar damages resulting from insufficient protection against UV irradiation during 
the individual’s lifetime are expressed as actinic keratosis or even worse basal cell 
carcinoma (BCC) and squamous cell carcinoma (SCC). One therapy option is the 
photodynamic therapy (PDT) involving three key components: a photosensitizer, 
light of an appropriate wavelength and oxygen within the tissue. As a photosen-
sitizer precursor 5-aminolevulinic acid (ALA) is applied on the skin, has to be 
taken up by the cells and converted into protoporphyrin IX as the active photo-
sensitizer. Since ALA permeation through the skin is slow and rather incomplete 
due to ALA’s hydrophilic properties, light exposure needs several hours 
subsequent to ALA application before being performed. The challenge was to 
develop a semisolid formulation with sufficient and fast permeation across the 
lipophilic barrier of the skin, the stratum corneum. 
The developed semisolid liquid crystalline formulation consists of poloxamer 407, 
dimethyl isosorbide, isopropylic alcohol, propylene glycol dicaprate/dicaprylate 
and water. A predominantly higher permeation coefficient of 5-ALA across human 
SC was obtained from this formulation when compared to commonly used bases 
from the German Pharmacopoeia, such as Basiscreme DAC (increase by factor 7.4) 
and water containing hydrophilic ointment (increase by factor 19.4). Further 
permeation studies revealed a synergistic effect of all components leading to more 
than an additive effect on 5-ALA permeation enhancement.  
Rheological measurements showed a reversible gelification upon heating. At 
refrigerator temperature the system was in the liquid state, at 12.7 °C it became a 
gel.
By means of differential calorimetry (DSC) strong interactions between the 
formulation and stratum corneum lipid structure could be detected. The results 
agree with the findings of the permeation results and explain an increased 
permeability of the stratum corneum. This increase in permeability would allow for 
a reduction of drug concentration and a shorter application - light exposure interval 
offering better compliance of the patients. 
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Plesch, E.   C154 
Plitzko, B.   C112 
Plöger, M.   T011 
Plöschberger, K.   C128 
Pohl, U.   H‐3(n.v.) 
Pohlmann, A.R.   T052 
Pötz, A.   G232 
Pradel, G.   C120, C158 
Prechter, A.   C180 
Preisitsch, M.   B089, B1‐1 
Preu, L.   C4‐4 
Prinz, M.   C172 
Probst, K.   B1‐2 
Probst, S.   T014 
Proschak, E.   C134 
Puhlmann, E.   B089 
Pui, C.H.   K198 
Rades, T.   Pl‐06 
Radespiel, R.   Key1‐1, Key1‐2 
Rady, M.   P208 
Raith, K.   F3‐6(n.v.) 
Rammensee, H.G.   P1‐2 
Rauh, D.   Key6‐1 
Recanatini, M.   C6‐3 
Redweik, S.   C122 
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Reichl, S.   T009, T080, T081, 
T082, T084, T086 
Reichling, J.   B091 
Reichmann, D.   C112, C113 
Rein, H.   T067, T069 
Reintjes, T.   T3‐4 
Reitz, E.   T5‐2 
Relling, M.V.   K198 
Remmler, C.   C113 
Richter, H.   F8‐3 
Richter, K.   B092 
Richter, W.   K1‐4 
Riedel, F.   F7‐2(n.v.) 
Ringsdorf, S.   K200 
Rischer, M.   T012 
Ritter, C.A.   K1‐1, K189, Key5‐2 
Rödl, C.   C136 
Rodrigo, V.   C164 
Rogge, A.   P2‐4 
Rohde, J.   P208 
Rohe, A.   C115 
Rollet, A.   C151 
Rösch, P.   C160 
Rose, C.   T015 
Rosero, N.   P212 
Rossi, A.   P2‐3 
Rossi, M.   T1‐3 
Roßricker, T.   F3‐3(n.v.) 
Rubbiani, R.   C138, C139, C4‐4 
Rudolph, V.   K184 
Ruef, P.   K1‐2 
Rüger, R.   T036 
Rühs, H.   K198 
Rumpf, T.   C146 
Rustenbeck, I.   P209, P215, 
P2‐1, P2‐2 
Rüttinger, H.H.   C115 
Rybak, A.   C177 
Sadler, P.J.   C4‐3 
Saenger, M.   T2‐4 
Sakmann, A.   T074, T076 
Salazar, J.   T041 
Saljé, K.   P3‐2 
Samanta, A.   Key2‐1 
Sänger, S.   T019 
Saniocki, I.   T074 
Sass, G.   P5‐4 
Sasse, P.   P213 
Sautebin, L.   P2‐3 
Savic, S.   T049 
Schächtele, C.   C4‐4 
Schädlich, A.   T004, T015 
Schaeflein, L.   P1‐4 
Schäfer, M.   F1‐3 
Schäfer, U.F.   F8‐2, T052, 
T056, T4‐2 
Schäfer‐Korting, M.   F6‐1, 
F6‐2, P3‐4 
Schaffran, T.   T034 
Schäftlein, A.   K188 
Schänzer, W.   P3‐3 
Scheiber, J.   C172, Key3‐2 
Scheicher, B.   C118 
Schemies, J.   C143 
Scheulen, M.   K197 
Schiedel, A.C.   C6‐1, P211 
Schiedel, M.   C145 
Schiemann, S.   B104, B105, 
C3‐1 
Schiffmann, S.   C134 
Schilling, M.   T008 
Schirmeister, T.   C157 
Schlager, H.   K1‐4 
Schlenk, M.   C171 
Schlesinger, M.   C149, C2‐3 
Schmelzer, C.E.H.   B088 
Schmerwitz, U.K.   P5‐4 
Schmid, M.G.   C128 
Schmidberger, H.   T2‐4 
Schmidt, I.   C170 
Schmidt, M.   C115 
Schmiedl, S.   K201 
Schmitt, C.P.   K1‐2 
Schmitt, S.P.W.   K193 
Schmitz, J.   C170, C175 
Schmitz, P.   C149 
Schmolke, H.   T028, T1‐4 
Schneider, G.   C136 
Schneider, H.   T085 
Schneider, M.   T060 
Schneider, M.   C110 
Schneider, T.   C3‐1 
Schneider, V.   C4‐1, K196 
Schoenitz, M.   T1‐2 
Scholl, S.   Key1‐1, Key1‐3, T1‐2 
Scholz, S.   P218 
Schon, I.   K204 
Schrader, J.   T024 
Schraffl, A.   C140 
Schrage, R.   P224 
Schraitle, R.   F7‐3(n.v.) 
Schrappe, M.   F5‐5(n.v.) 
Schröder, F.   K201 
Schröder, T.   C3‐4 
Schubert, R.   T021, T024, 
T034, T037, T038, T070, 
T071 
Schubert‐Zsilavecz, M.   C5‐4 
Schuldt, A.   T029 
Schüle, R.   C146 
Schulz, K.   C129 
Schulze Elfringhoff, A.   C133 
Schulze‐Westhoff, P.   K186 
Schulz‐Siegmund, M.   T085, 
T3‐3 
Schumacher, P.   C140 
Schumacher, S.   C109 
Schur, J.   Key1‐3, T029 
Schuster, N.   G230 
Schütte, K.   Key4‐3 
Schwalbe, O.   F5‐4 
Schwan, G.   C182, P218 
Schwanck, B.   B106 
Schwappach, D.   P222 
Schwartz, J.C.   C169 
Schweimer, K.   C160 
Schwenzer, S.   F1‐2 
Scriba, G.K.E.   F2‐4 
Seebald, K.   K1‐2 
Seemann, W.   P213 
Segura, R.   T1‐3 
Seibt, B.F.   C6‐1 
Selge, T.   Key4‐3 
Selzer, D.   T056 
Seufert, J.   Pl‐08 
Shegokar, R.   T017, T042 
Sheldrick, W.S.   C139 
Sherbiny, F.F.   C6‐1, P211 
Siegert, F.   P223 
Siegmund, W.   P3‐1, P3‐2 
Sielaff, F.   C156 
Sierck, G.   C113 
Simic, D.   P222 
Simm, A.   K203 
Simon, S.   T038 
Simons, S.   F5‐4 
Sinz, A.   C3‐4, C5‐1, F2‐3 
Sippel, M.   C160 
Sippl, W.   C115, C146, Key3‐1 
Sisay, M.T.   C164 
Sluszniak, M.   T3‐2 
Sologub, L.   C158 
Sommer, B.   T031 
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Sörgel, F.   K197 
Sotriffer, C.A.   C160, C162 
Spahn‐Langguth, H.   C118, 
C128, C173, P208 
Spalthoff, V.   T043 
Speikamp   F2‐8(n.v.) 
Spinrath, A.   P225 
Sproß, J.   C5‐1, F2‐3 
Stange, E.   P4‐3 
Stark, H.   C132, C134, C136, 
C169 
Stasch, J.P.   Pl‐12 
Steckel, H.   T055, T057, T058, 
T066 
Steffen, C.   F7‐1(n.v.) 
Steffens, K.J.   T062 
Stein, J.   F7‐4(n.v.) 
Steinbach, A.   T027 
Steinert, M.   C123, C160 
Steinhilber, D.   C136 
Steinmetzer, T.   C156 
Stempka, M.   C157 
Sterry, W.   F8‐3 
Stich, A.   C159 
Stiesch, M.   T005, T3‐2 
Stirnberg, M.   C119, C1‐3 
Stoltenberg, I.   T075 
Stölting, D.P.   C137 
Strasdat, B.   T007 
Strasser, A.   C163, C6‐2 
Strauß, B.   Key2‐1 
Strauß, O.   T006 
Strumberg, D.   K197 
Stumpf, A.   P225 
Süss, R.   T027, T033, T034 
Syrowatka, F.   T072 
Szymanowitz, K.   C147 
Tahrani, A.   B1‐3 
Takacs, L.   P5‐3 
Taupitz, T.   T5‐4 
Tawab, M.   C5‐4 
Telsnig, D.   C5‐3 
Teßmar, J.   Pl‐13, T006, T3‐4 
Thiele, A.   C160 
Thimm, D.T.   P211 
Thom, K.   T044 
Thomas, M.   C153, Key2‐3 
Thommes, M.   T065, T5‐2 
Thömmes, S.   C108 
Thürmann, P.A.   K201, P222 
Tiegs, G.   P5‐4 
Tikhonova, I.G.   C176 
Timmel, J.   P226 
Tireford, A.   K193 
Tischer, M.   C158 
Tolle, N.   C4‐4 
Tong, L.   T023, T032 
Topf, C.   C161, C162 
Torres, S.   F6‐1 
Torri, G.   C149 
Totzke, F.   C4‐4, P5‐4 
Traiser, C.   K1‐2 
Tränkle, C.   P224 
Traupe, H.   F6‐1 
Tripolt, C.   C128 
Trows, S.   T059 
Tscheka, C.   T060 
Unger, M.   C120, P1‐4 
Untucht, C.   C123 
Unverferth, K.   C177 
Vainio, U.   T032 
van den Berg, N.   K1‐1 
van der Walt, J.S.   K185 
van Hemelrijck, C.   F8‐5 
van Oppen, J.N.   P227 
Vereb, G.   P5‐3 
Verpoorte, E.   T031 
Verspohl, E.J.   P226, P227, 
P229 
Verstraelen, J.   T086 
Vielle, C.   F3‐1(n.v.) 
Vila‐Planas, J.   T031 
Vinson, B.R.   P1‐2 
Völker, M.   C120, P1‐4 
Völker, T.   C107 
Vollmar, A.M.   P207, P5‐3, 
P5‐4 
von Coburg, Y.   C169 
von Kügelgen, I.   P212 
von Storp, B.   T011 
von Woedtke, T.   C2‐4 
Vordenbäumen, S.   C110 
Vorstheim, P.   Key7‐1 
Voß, U.   P219, P228 
Wacker, G.   H‐1(n.v.) 
Wadie, W.   P1‐1 
Wagenseil, L.   T057 
Wagner, E.   C163 
Wahl, B.   C111 
Wahl, M.A.   T5‐3 
Wahrig, B.   H‐2(n.v.) 
Walaschewski, R.   P229 
Walter, M.   C169 
Wang, H.   Key4‐2 
Wätzig, H.   C121, C122, C123, 
C124, C130, C131, 
F2‐8(n.v.), T009 
Weber, C.   P207 
Weber, F.   C142 
Weindl, G.   F6‐1, F6‐4, P3‐4 
Weirauch, U.   C153, Key2‐3 
Weiser, D.   P1‐1, P1‐2, P1‐3, 
P219, P220, P228 
Weiss, J.   P210 
Weitensteiner, S.B.   P5‐3 
Weitschies, W.   C129, T044, 
T061, T077 
Weiwad, M.   C160 
Wellner, A.   C147 
Weltmann, K.D.   C2‐4 
Wende, K.   B089, B090 
Wening, K.   T068 
Wentzlaff, M.   T061 
Wenzel, D.   P213 
Werth, R.   C4‐2 
Werz, O.   C5‐4, P2‐3, P2‐4 
Westendorf, A.F.   C4‐3 
Westmeier, R.   T059 
Wieland, G.D.   T036 
Wilke, C.   C2‐4 
Wilke, S.   Key4‐3 
Willenborg, M.   P209 
Wilm, S.   P222 
Wilson, I.D.   Pl‐02 
Windhagen, H.   T3‐2 
Wink, M.   B091, B1‐3, P205, 
P206 
Winkel, A.   T002, T005, T3‐2 
Winter, G.   T043 
Winz, M.   Key2‐1 
Witt‐Enderby, P.A.   C178 
Wittmann, H.J.   C163, C6‐2 
Wittstock, U.   B093, B094 
Wöhl‐Bruhn, S.   T002, T008 
Wohlrab, J.   B088, K203 
Wolber, G.   C138, Key3‐3 
Wolf, N.   F6‐2 
Wölfl, S.   C138, C139 
Wölk, C.   C116, C117 
Wray, V.   B089, B1‐1 
Wu, B.   C114 
Wulff, I.   K192 
Wulle, S.   H‐4(n.v.) 
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Wunder, A.   C3‐2 
Wundrack, A.   F3‐4(n.v.) 
Wünsch, B.   C1‐4, C142 
Wurster, E.C.   T2‐4 
Wüstmann, A.F.   K189 
Xu, Y.   C122 
Yang, K.W.   T036 
Ye, H.C.   Key4‐2 
Zabel‐du Bois, A.   K193 
Zadeh, S.   Key1‐2 
Zahler, S.   P5‐3, P5‐4 
Zahov, S.   C133 
Zainuddin, E.   B089, B1‐1 
Zembruski, N.C.L.   P210 
Zerzankova, L.   C4‐3 
Zivkovic, A.   C132, C136 
Zlotos, D.P.   C178 
Zodi, R.   B098 
Zügel, S.   P1‐3 
zur Nieden, N.I.   P214 
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Wir freuen uns auf Ihren Anruf!
Sie erreichen uns 24 Stunden 
täglich an 365 Tagen im Jahr. 
Tel. 0800 - 422 55 85
(gebührenfrei innerhalb Deutschlands) 
www.tk-online.de
Nutzen Sie die Vorteile 
von Deutschlands 
bester Krankenkasse.
Wir wechseln!
Überzeugen Sie sich von hervor-
ragenden Leis tungen, wie zum 
Beispiel:
Ständig erreichbare Ärzte 
am TK-FamilienTelefon
Erstklassige Wahltarife für 
eine spürbare Beitragssenkung
Mit dem TK-Klinikführer 
ganz einfach eine geeignete 
Klinik finden
Wechseln Sie zum Testsieger. 
Jetzt.
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
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